<SEC-DOCUMENT>0001104659-22-076904.txt : 20220701
<SEC-HEADER>0001104659-22-076904.hdr.sgml : 20220701
<ACCEPTANCE-DATETIME>20220701170505
ACCESSION NUMBER:		0001104659-22-076904
CONFORMED SUBMISSION TYPE:	10-12B/A
PUBLIC DOCUMENT COUNT:		27
FILED AS OF DATE:		20220701
DATE AS OF CHANGE:		20220701

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ProMIS Neurosciences Inc.
		CENTRAL INDEX KEY:			0001374339
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		10-12B/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41429
		FILM NUMBER:		221062229

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 200, 1920 YONGE STREET
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M4S 3E2
		BUSINESS PHONE:		416-847-6898

	MAIL ADDRESS:	
		STREET 1:		SUITE 200, 1920 YONGE STREET
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M4S 3E2

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMORFIX LIFE SCIENCES LTD
		DATE OF NAME CHANGE:	20060831
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-12B/A
<SEQUENCE>1
<FILENAME>tm229830d8_1012ba.htm
<DESCRIPTION>10-12B/A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: center; width: 100%"><DIV STYLE="text-align: center; font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B>&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE
COMMISSION</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDMENT NO. 2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>to</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM&nbsp;10</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>GENERAL FORM&nbsp;FOR
REGISTRATION OF SECURITIES</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO SECTION&nbsp;12(b)&nbsp;OR
12(g)&nbsp;OF</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE SECURITIES EXCHANGE
ACT OF 1934</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROMIS NEUROSCIENCES
INC.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Exact name of registrant
as specified in its charter)</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Canada</B></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>98-0647155</B></FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: center; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(State&nbsp;or&nbsp;other&nbsp;jurisdiction&nbsp;of</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>incorporation&nbsp;or&nbsp;organization)</B></P></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(I.R.S.&nbsp;employer</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>identification&nbsp;no.)</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Suite&nbsp;200, 1920
Yonge Street</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Toronto, Ontario</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>M4S 3E2</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Address of principal
executive offices and zip code)</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>416-847-6898</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Registrant&#8217;s telephone
number, including area code)</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Securities to be registered
pursuant to Section&nbsp;12(b)&nbsp;of the Act:</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Common Shares</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Title of class)</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Securities to be registered
pursuant to Section&nbsp;12(g)&nbsp;of the Act:</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>None</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Title of class)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221;
and &#8220;emerging growth company&#8221; in Rule&nbsp;12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; width: 19%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
    <TD STYLE="text-align: justify; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 52%"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD>
    <TD STYLE="text-align: justify; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 23%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated&nbsp;filer</FONT></TD>
    <TD STYLE="text-align: right; width: 4%"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#120;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging&nbsp;growth&nbsp;company
    </FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financing accounting standards provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act.&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="fulla_005"></A><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: left"><A HREF="#fulla_001">Implications of Being an
    Emerging Growth Company</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><A HREF="#fulla_001">ii</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#v_001">Smaller Reporting Company Status</A></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><A HREF="#fulla_001">ii</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#fulla_002">Use of Names</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_002">ii</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#fulla_003">Currency</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_003">ii</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#fulla_004">Trademarks, Trade Names and Service Marks</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_004">ii</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#fulla_006">Disclosure Regarding Forward-Looking
    Statements</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_006">iii</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#fulla_007">Risk Factors Summary</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_007">iv</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#b_2">Glossary of Key Terms and Definitions</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_004">vi</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#b_3">ITEM 1. BUSINESS</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#b_3">1</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#d_001">ITEM 1A. RISK FACTORS</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#d_001">37</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#g_001">ITEM 2. FINANCIAL INFORMATION</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#g_001">90</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#g_003">ITEM 3. PROPERTIES</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#g_003">98</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#g_004">ITEM 4. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
    OWNERS AND MANAGEMENT</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#g_004">98</A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 90%"><A HREF="#g_005">ITEM 5. DIRECTORS AND EXECUTIVE
    OFFICERS</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 10%"><A HREF="#g_005">99</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>


<TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 90%"><A HREF="#h2">ITEM 6. EXECUTIVE COMPENSATION</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 10%"><A HREF="#h2">106</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#h3">ITEM 7. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS,
    AND DIRECTOR INDEPENDENCE</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#h3">113</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase; font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#fulla_015">ITEM 8. <FONT STYLE="text-transform: uppercase">Legal
    Proceedings</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_015">115</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#fulla_017">ITEM 9. MARKET PRICE OF AND DIVIDENDS
    ON THE REGISTRANT&#8217;S COMMON EQUITY AND RELATED SHAREHOLDER MATTERS</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_017">115</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#fulla_022">ITEM 10. RECENT SALES OF UNREGISTERED
    SECURITIES</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_022">116</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#fulla_024">ITEM 11. DESCRIPTION OF THE REGISTRANT&#8217;S
    SECURITIES TO BE REGISTERED</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_024">119</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#fulla_025">ITEM 12. INDEMNIFICATION OF DIRECTORS
    AND OFFICERS</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_025">120</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#fulla_026">ITEM 13. FINANCIAL STATEMENTS AND SUPPLEMENTARY
    DATA</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_026">122</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#fulla_027">ITEM 14. CHANGES IN AND DISAGREEMENTS
    WITH AUDITORS ON ACCOUNTING AND FINANCIAL DISCLOSURE</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_027">122</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#fulla_028">ITEM 15. FINANCIAL STATEMENTS AND EXHIBITS</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_028">F-1</A></TD></TR>
  </TABLE>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="fulla_001"></A>Implications
of Being an Emerging Growth Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a company with less than $1.07&nbsp;billion
in revenue during our most recently completed fiscal year, we qualify as an &#8220;emerging growth company&#8221; as defined in Section&nbsp;2(a)&nbsp;of
the Securities Act of 1933, as amended, which we refer to as the &#8220;<B>Securities Act</B>,&#8221; as modified by the Jumpstart Our
Business Startups Act of 2012, or the &#8220;<B>JOBS Act</B>.&#8221; As an emerging growth company, we may take advantage of specified
reduced disclosure and other exemptions from requirements that are otherwise applicable to public companies that are not emerging growth
companies. These provisions include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Reduced
                                            disclosure about our executive compensation arrangements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Exemptions
                                            from non-binding shareholder advisory votes on executive compensation or golden parachute
                                            arrangements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Our
                                            election under Section&nbsp;107(b)&nbsp;of the JOBS Act to delay adoption of new or revised
                                            accounting standards with different effective dates for public and private companies until
                                            those standards would otherwise apply to private companies; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Exemption
                                            from the auditor attestation requirement in the assessment of our internal control over financial
                                            reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may take advantage of these exemptions for
up to five years or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company
if we have more than $1.07&nbsp;billion in annual revenues as of the end of a fiscal year, if we are deemed to be a large-accelerated
filer under the rules&nbsp;of the Securities and Exchange Commission (the &#8220;<B>SEC</B>&#8221;) or if we issue more than $1.0&nbsp;billion
of non-convertible debt over a three-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on the information contained
in this document or to which we have referred you. We have not authorized anyone to provide you with information that is different. You
should assume that the information contained in this document is accurate as of the date of this Registration Statement, as amended (the
 &ldquo;<B>Registration Statement</B>&rdquo;), only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once this Registration Statement becomes effective
(the &#8220;<B>Effective Date</B>&#8221;), we will become subject to the reporting requirements of Section&nbsp;13(a)&nbsp;under Securities
Exchange Act of 1934, as amended (the &#8220;<B>Exchange Act</B>&#8221;) and will be required to file annual reports on Form&nbsp;10-K,
quarterly reports on Form&nbsp;10-Q and current reports on Form&nbsp;8-K, and we will be required to comply with all other obligations
of the Exchange Act applicable to issuers filing registration statements pursuant to Section&nbsp;12(b)&nbsp;of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-transform: uppercase; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="text-transform: uppercase"><B><A NAME="v_001"></A>Smaller
Reporting Company Status</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is a &ldquo;smaller reporting company&rdquo;
as defined in Exchange Act Rule&nbsp;12b-2. As a result, the Company is eligible to take advantage of certain reduced disclosure and other
requirements that are otherwise applicable to public companies including, but not limited to, not being subject to the auditor attestation
requirements of Section&nbsp;404(b)&nbsp;of the Sarbanes-Oxley Act of 2002. The Company will remain a smaller reporting company until
the last day of the fiscal year in which (1)&nbsp;the aggregate worldwide market value of its common shares held by non-affiliates equaled
or exceeded $250 million as of the prior June&nbsp;30th, or (2)&nbsp;its annual revenues equaled or exceeded $100 million during such
completed fiscal year and the aggregate worldwide market value of its common shares held by non-affiliates equaled or exceeded $700 million
as of the prior June&nbsp;30<SUP>th</SUP>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-transform: uppercase; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="fulla_002"></A>Use
of Names</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this Registration Statement, unless the context
otherwise requires, the terms &#8220;<B>we</B>,&#8221; &#8220;<B>us</B>,&#8221; &#8220;<B>our</B>,&#8221; &#8220;<B>Company</B>&#8221;
or &#8220;<B>ProMIS</B>&#8221; refer to ProMIS Neurosciences Inc., together with its wholly-owned subsidiary, ProMIS Neurosciences (US)
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-transform: uppercase; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="fulla_003"></A>Currency</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise indicated, all references to
 &#8220;$&#8221; or &#8220;US$&#8221; in this Registration Statement refer to United States dollars, and all references to &#8220;C$&#8221;
refer to Canadian dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-transform: uppercase; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="fulla_004"></A>Trademarks,
Trade Names and Service Marks</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Registration Statement contains certain
trademarks which are protected under applicable intellectual property laws and are the Company&#8217;s property. Solely for convenience,
the Company&#8217;s trademarks and trade names referred to in this Registration Statement may appear without the &reg; or &#8482; symbol,
but such references are not intended to indicate, in any way, that the Company will not assert, to the fullest extent under applicable
law, its rights to these trademarks and trade names.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="fulla_006"></A>Disclosure
Regarding Forward-Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Registration Statement contains statements
that we believe are, or may be considered to be, &#8220;forward-looking statements.&#8221; Forward-looking statements are neither historical
facts nor assurances of future performance. Instead, they are based on current beliefs, expectations or assumptions regarding the future
of the business, future plans and strategies, operational results and other future conditions of the Company. All statements other than
statements of historical fact included in this Registration Statement regarding the prospects of our industry or our prospects, plans,
financial position or business strategy may constitute forward-looking statements. In addition, forward-looking statements generally
can be identified by the use of forward-looking words such as &#8220;plans,&#8221; &#8220;expects&#8221; or &#8220;does not expect,&#8221;
 &#8220;is expected,&#8221; &#8220;look forward to,&#8221; &#8220;budget,&#8221; &#8220;scheduled,&#8221; &#8220;estimates,&#8221; &#8220;forecasts,&#8221;
 &#8220;will continue,&#8221; &#8220;intends,&#8221; &#8220;the intent of,&#8221; &#8220;have the potential,&#8221; &#8220;anticipates,&#8221;
 &#8220;does not anticipate,&#8221; &#8220;believes,&#8221; &#8220;should,&#8221; &#8220;should not,&#8221; or variations of such words
and phrases that indicate that certain actions, events or results &#8220;may,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;might,&#8221;
or &#8220;will,&#8221; &#8220;be taken,&#8221; &#8220;occur,&#8221; or &#8220;be achieved,&#8221; or the negative of these terms or variations
of them or similar terms. Furthermore, forward-looking statements may be included in various filings that we make with the SEC or press
releases or oral statements made by or with the approval of one of our authorized executive officers. Although we believe that the expectations
reflected in these forward-looking statements are reasonable, we cannot assure you that these expectations will prove to be correct.
These forward-looking statements are subject to certain known and unknown risks and uncertainties, as well as assumptions that could
cause actual results to differ materially from those reflected in these forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that
predictions, forecasts, projections and other forward-looking statements will not be achieved. We caution readers not to place undue
reliance on these statements as a number of important factors could cause the actual results to differ materially from the beliefs, plans,
objectives, expectations, anticipations, estimates and intentions expressed in such forward-looking statements. Risks, uncertainties
and other factors which may cause the actual results, performance or achievements of the Company, as applicable, to be materially different
from any future results, performance or achievements expressed or implied by such forward-looking information and statements include,
but are not limited to, the risks described under the heading &#8220;<I>Risk Factors Summary</I>&#8221; and in Item 1A&#8212;&#8220;<I>Risk
Factors</I>&#8221; in this </FONT>Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Readers
are cautioned not to place undue reliance on any forward-looking statements contained in this </FONT>Registration Statement, which reflect
management&#8217;s opinions only as of the date hereof. Except as required by law, we undertake no obligation to revise or publicly release
the results of any revision to any forward-looking statements. You are advised, however, to consult any additional disclosures we make
in our reports to the SEC. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf
are expressly qualified in their entirety by the cautionary statements contained in this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="fulla_007"></A><FONT STYLE="text-transform: uppercase"><B>Risk
Factors Summary</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investing in our securities involves risks.
You should carefully consider the risks described in Item 1A&mdash;&ldquo;<I>Risk Factors</I>&rdquo; beginning on page&nbsp;37 before
deciding to invest in our securities. If any of these risks actually occurs, our business, financial condition and results of operations
would likely be materially adversely affected. In such case, the trading price of our securities would likely decline, and you may lose
all or part of your investment. Set forth below is a summary of the  risks we face:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to the COVID-19 Pandemic</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Our
                                            business and operations have and may be further adversely affected by the evolving and ongoing
                                            COVID-19 global pandemic.</P></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                       </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">The
                                            ongoing COVID-19 pandemic may negatively impact the availability of scientific staff, physicians
                                            and other healthcare professionals, which may negatively impact our business, financial condition
                                            and results of operations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to the Development of Our Product
Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Our
                                            product candidates are still in the early stages of development and there is significant
                                            uncertainty that any such products will actually be developed.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                            </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">We
                                            have concentrated a portion of our research and development efforts on the treatment of AD,
                                            a field that has seen very limited success in drug development.</P></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                             </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Our
                                            business is heavily dependent on the successful development, regulatory approval and commercialization
                                            of PMN310 and any future product candidates that we may develop or acquire, including PMN442
                                            and PMN267.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Our
                                            approach to the potential treatment of AD is based on a novel therapeutic approach, which
                                            exposes us to unforeseen risks.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                 </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We
                                            may not successfully expand our pipeline of product candidates, including by pursuing additional
                                            indications for PMN310 or by in-licensing or acquiring additional product candidates for
                                            other diseases.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                      </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Nonclinical
                                            and clinical drug development involves a lengthy, expensive and uncertain process. The results
                                            of nonclinical studies and early clinical trials are not always predictive of future results.
                                            PMN310 or any other product candidate that we advance into clinical trials may not achieve
                                            favorable results in later clinical trials, if any, or receive marketing approval.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                            </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Clinical
                                            failure can occur at any stage of clinical development and we have never completed a clinical
                                            trial or submitted NDA, BLA, or marketing authorization application, or MAA.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                      </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We
                                            may incur additional costs or experience delays in completing, or ultimately be unable to
                                            complete, the development and commercialization of our product candidates.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                          </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Adverse
                                            side effects, properties or other safety risks associated with PMN310, PMN442, PMN267 or
                                            any future product candidates could delay or preclude approval, cause us to suspend or discontinue
                                            clinical trials, abandon further development, limit the commercial profile of an approved
                                            label or result in significant negative consequences following marketing approval, if any.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We
                                            may experience delays or difficulties in the enrollment and retention of patients in clinical
                                            trials, which could delay or prevent our receipt of necessary regulatory approvals.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Interim,
                                            &#8220;top-line&#8221; and preliminary results from our clinical trials that we announce
                                            or publish from time to time may change as more data become available and is subject to audit
                                            and verification procedures that could result in material changes in the final data.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                    </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We
                                            cannot be certain that PMN310, PMN442, PMN267 or any of our future product candidates will
                                            receive regulatory approval, and without regulatory approval we will not be able to market
                                            our product candidates.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                    </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Our
                                            lead product candidate, PMN310, is being developed for the treatment of AD, a disease that
                                            has seen limited success in drug development.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                              </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">We
                                            may in the future conduct clinical trials for our product candidates outside the U.S., and
                                            the FDA, EMA and other foreign regulatory authorities may not accept data from such trials.</P></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                         </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We
                                            may not be successful in our efforts to build a pipeline of additional product candidates.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                                                                                                                       </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">If
                                            we do not achieve our projected development goals in the time frames we announce and expect,
                                            the commercialization of our products may be delayed.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                         </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We
                                            may develop PMN310, PMN442, PMN267 and future product candidates for use in combination with
                                            other therapies, which could expose us to additional regulatory risks.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                          </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Changes
                                            in methods of product candidate manufacturing or formulation may result in additional costs
                                            or delay.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to the Commercialization of
Our Product Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Successful
                                            commercialization of our products, if approved, will depend on a number of factors and we
                                            cannot guarantee that we will be able to successfully commercialize our products.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                    </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">The
                                            market opportunities for PMN310, PMN442, PMN267, and future product candidates, if approved,
                                            may be smaller than we anticipate.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Even
                                            if our current or future product candidates obtain regulatory approval, they may fail to
                                            achieve the broad degree of adoption and use by physicians, patients, hospitals, healthcare
                                            payors and others in the medical community necessary for commercial success.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                 </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Our
                                            product candidates have never been manufactured on a commercial scale, and there are risks
                                            associated with scaling up manufacturing to commercial scale. In particular, we will need
                                            to develop a larger scale manufacturing process that is more efficient and cost-effective
                                            to commercialize our potential products, which may not be successful.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                 </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">The
                                            successful commercialization of our product candidates will depend in part on the extent
                                            to which governmental authorities and health insurers establish adequate coverage, reimbursement
                                            levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement
                                            for our product candidates, if approved, could limit our ability to market those drugs and
                                            decrease our ability to generate revenue.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                       </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">We
                                            currently have no sales organization. If we are unable to establish sales capabilities on
                                            our own or through third parties, we may not be able to market and sell our product candidates
                                            effectively in the U.S. and foreign jurisdictions, if approved, or generate product revenue.</P></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Financial Position and
Capital Needs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We
                                            will require additional financing to achieve our goals, and a failure to obtain this necessary
                                            capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce
                                            or terminate our development programs, commercialization efforts or other operations.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                      </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We
                                            have no product candidates approved for commercial sale, we have never generated any revenue
                                            from sales and we may never be profitable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Dependence on Third Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We
                                            will rely on third parties to supply components, research, develop, test, and manufacture
                                            our product candidates and market, if approved. The loss of any of these third party relationships
                                            or the failure of any of them to meet their obligations to us could affect our ability to
                                            develop and obtain approval of our product candidates in a timely manner.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We
                                            intend to rely on contract research organizations, or CROs, and other third parties to conduct,
                                            supervise and monitor a significant portion of our research and nonclinical testing and clinical
                                            trials for our product candidates, and if those third parties do not successfully carry out
                                            their contractual duties, comply with regulatory requirements or otherwise perform satisfactorily,
                                            we may not be able to obtain regulatory approval or commercialize product candidates, or
                                            such approval or commercialization may be delayed, and our business may be substantially
                                            harmed.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                       </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">If
                                            any of our third-party manufacturers encounter difficulties in production of PMN310, PMN442,
                                            PMN267 or any future product candidate we develop, or fail to meet rigorously enforced regulatory
                                            standards, our ability to provide supply of our product candidates for clinical trials or,
                                            if approved, for commercial sale could be delayed or stopped, or we may be unable to maintain
                                            a commercially viable cost structure.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                               </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We
                                            will likely seek collaborations with third parties for the development or commercialization
                                            of our product candidates. If those collaborations are not successful, we may not be able
                                            to capitalize on the market potential of those product candidates, including PMN310, PMN442,
                                            and PMN267.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">If
                                            we are unable to obtain and maintain sufficient intellectual property protection for our
                                            product candidates, and other proprietary technologies we develop, or if the scope of the
                                            intellectual property protection obtained is not sufficiently broad, our competitors could
                                            develop and commercialize products similar or identical to ours, and our ability to successfully
                                            commercialize our product candidates, and other proprietary technologies if approved, may
                                            be adversely affected.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                        </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Patent
                                            terms may be inadequate to protect our competitive position on our product candidates for
                                            an adequate amount of time.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                         </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">If
                                            we do not obtain patent term extension for our product candidates our business may be materially
                                            harmed.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                                                                                                                                     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">If
                                            we fail to comply with our obligations in the agreements under which we license intellectual
                                            property rights from third parties, or otherwise experience disruptions to our business relationships
                                            with our licensors, we could lose license rights that are important to our business.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Obtaining
                                            and maintaining our patent protection depends on compliance with various procedural, document
                                            submission, fee payment and other requirements imposed by governmental patent agencies, and
                                            our patent protection could be reduced or eliminated for non-compliance with these requirements.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Changes
                                            in U.S. patent law could diminish the value of patents in general, thereby impairing our
                                            ability to protect our product candidates.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                            </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We
                                            may not be able to protect our intellectual property rights throughout the world.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                                                                                                              </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We
                                            may become subject to claims challenging the inventorship or ownership of our patents and
                                            other intellectual property.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                   </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We
                                            may not be successful in obtaining or maintaining necessary rights to product components
                                            and processes for our development pipeline through in-licenses.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                           </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Third-party
                                            claims alleging intellectual property infringement may prevent or delay our drug discovery
                                            and development efforts.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We
                                            may be subject to claims that we have wrongfully hired an employee from a competitor or that
                                            we or our employees have wrongfully used or disclosed alleged confidential information or
                                            trade secrets of their former employers.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                      </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We
                                            may be involved in lawsuits to protect or enforce our patents or the patents of our licensors,
                                            which could be expensive, time-consuming, and unsuccessful. Further, our issued patents could
                                            be found invalid or unenforceable if challenged in court, and we may incur substantial costs
                                            as a result of litigation or other proceedings relating to patent and other intellectual
                                            property rights.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                          </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Because
                                            of the expense and uncertainty of litigation, we may not be in a position to enforce our
                                            intellectual property rights against third parties.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">If
                                            we are unable to protect the confidentiality of our trade secrets, our business and competitive
                                            position would be harmed. Our reliance on third parties requires us to share our trade secrets,
                                            which increases the possibility that a competitor will discover them or that our trade secrets
                                            will be misappropriated or disclosed.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                            </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">If
                                            our trademarks and trade names are not adequately protected, then we may not be able to build
                                            name recognition in our markets of interest and our business may be adversely affected.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                            </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Any
                                            collaboration arrangements that we may enter into in the future may not be successful, which
                                            could adversely affect our ability to develop and commercialize our future products.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                        </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Intellectual
                                            property discovered through government funded programs may be subject to federal regulations
                                            such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for
                                            U.S.-based companies. Compliance with such regulations may limit our exclusive rights and
                                            limit our ability to contract with non-U.S. manufacturers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Legal and Regulatory Compliance
Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD>
<TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
<TD STYLE="text-align: justify">Our relationships with customers, healthcare providers, including physicians, and third-party payors
are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and other healthcare laws
and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Even
                                            if we obtain regulatory approval for PMN310, PMN442, PMN267 or any future product candidates,
                                            they will remain subject to ongoing regulatory oversight, which may result in significant
                                            additional expense.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Failure
                                            to comply with health and data protection laws and regulations could lead to government enforcement
                                            actions and civil or criminal penalties, private litigation or adverse publicity and could
                                            negatively affect our operating results and business.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                   </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Even
                                            if we obtain FDA or EMA approval any of our product candidates in the U.S. or European Union,
                                            we may never obtain approval for or commercialize any of them in any other jurisdiction,
                                            which would limit our ability to realize their full market potential.</P></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                   </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Healthcare
                                            legislative or regulatory reform measures may have a negative impact on our business and
                                            results of operations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Our
                                            business activities may be subject to the FCPA and similar anti-bribery and anti-corruption
                                            laws.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                                                                                                                               </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Our
                                            employees, independent contractors, consultants, commercial partners and vendors may engage
                                            in misconduct or other improper activities, including noncompliance with regulatory standards
                                            and requirements and insider trading, which could significantly harm our business.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                            </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Our
                                            insurance policies are expensive and only protect us from some business risks, which will
                                            leave us exposed to significant uninsured liabilities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="b_1"></A>Risks Related to Our Business
and Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We
                                            face significant competition in an environment of rapid technological and scientific change,
                                            and there is a possibility that our competitors may achieve regulatory approval before us
                                            or develop therapies that are safer or more effective than ours.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Ownership of Our Common Shares
and Our Status as a U.S. Public Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Investment
                                            in the Company&#8217;s Common Shares is speculative, involves risk, and there is no guarantee
                                            of a return.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                      </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">If
                                            equity research analysts do not publish research or reports, or publish unfavorable research
                                            or reports, about us, our business or our market, our share price and trading volume could
                                            decline.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                 </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Concentration
                                            of ownership of our Common Shares among our existing executive officers, directors and principal
                                            shareholders may prevent new investors from influencing significant corporate decisions.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
                                            constating documents permit us to issue an unlimited amount of additional Common Shares or
                                            Preferred Shares, which may prevent a third-party takeover or cause our shareholders to experience
                                            dilution in the future.</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                        </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Anti-takeover
                                            provisions in our governing documents and under Canadian Law could prevent or delay transactions
                                            that shareholders may favor.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">The
                                            rights of our shareholders may differ from the rights typically offered to shareholders of
                                            a U.S. corporation and these differences may make our Common Shares less attractive to investors.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                    </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">If
                                            we fail to attract and retain senior management and key scientific personnel, our business
                                            may be materially and adversely affected.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">If
                                            product liability lawsuits are brought against us, we may incur substantial liabilities and
                                            may be required to limit commercialization of our current or future product candidates.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                          </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We
                                            may explore strategic collaborations that may never materialize or may fail.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                                                                                                         </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We
                                            are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221;
                                            and, as a result of the reduced disclosure and governance requirements applicable to emerging
                                            growth companies and smaller reporting companies, our Common Shares may be less attractive
                                            to investors.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We
                                            have never paid dividends on our capital shares and we do not intend to pay dividends for
                                            the foreseeable future. Consequently, any gains from an investment in our Common Shares will
                                            likely depend on whether the price of our Common Shares increases.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                         </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We
                                            are subject to the continued listing criteria of the TSX and our failure to satisfy these
                                            criteria may result in a delisting of our Common Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We
                                            cannot assure you that our Common Shares will become listed on Nasdaq and, if listed, our
                                            failure to meet Nasdaq&rsquo;s continued listing requirements could result in a delisting
                                            of our Common Shares.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Our
                                            internal controls over financial reporting may not be effective, which could have a material
                                            and adverse effect on our business.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                                                                                                                                                              </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The
                                            elimination of monetary liability against our directors, officers, and employees under Canadian
                                            law and the existence of indemnification rights for our obligations to our directors, officers,
                                            and employees may result in substantial expenditures by us and may discourage lawsuits against
                                            our directors, officers, and employees.</P></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">There
                                            may be difficulty in enforcing judgments and effecting service of process on directors and
                                            officers that are not citizens of the U.S.</P></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                        </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">If
                                            we are characterized as a passive foreign investment company, U.S. Holders may be subject
                                            to adverse U.S. federal income tax consequences.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We
                                            will incur increased costs and demands upon management as a result of being a public company.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                                                                                                                          </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Comprehensive
                                            tax reform legislation could adversely affect our business and financial condition.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                                                                                                                           </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Our
                                            business and operations would suffer in the event of computer system failures, cyberattacks
                                            or a deficiency in our cybersecurity or a natural disaster.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Disruptions
                                            at the FDA, the SEC and other government agencies caused by funding shortages or global health
                                            concerns could hinder their ability to hire and retain key leadership and other personnel,
                                            prevent new products and services from being developed or commercialized in a timely manner
                                            or otherwise prevent those agencies from performing normal business functions on which the
                                            operation of our business may rely, which could negatively impact our business.</P></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                             </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Unfavorable
                                            global economic conditions could adversely affect our business, financial condition or results
                                            of operations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="b_2"></A>Glossary
of Key Terms and Definitions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this Registration Statement, unless otherwise
indicated or the context otherwise requires, the following terms shall have the indicated meanings. Words importing the singular include
the plural and vice versa and words importing any gender include all genders. A reference to an agreement means the agreement as it may
be amended, supplemented or restated from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>A&#946;</B>&#8221; means Amyloid beta,
an extracellular brain protein whose toxic misfolded form is implicated as a root cause of AD;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>A&#946;O</B>&#8221; means Amyloid beta
oligomers; misfolded A&#946;O are widely considered a root cause of AD;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>AChE</B>&#8221; means Acetylcholinesterase;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>AD</B>&#8221; means Alzheimer&#8217;s
disease;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>aducanumab</B>&#8221; means Biogen&#8217;s
monoclonal antibody targeting amyloid beta;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>ALS</B>&#8221; means amyotrophic lateral
sclerosis;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>a-syn</B>&#8221; means alpha-synuclein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Biogen</B>&rdquo; means Biogen Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>Board</B>&#8221; means the board of
directors of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>CBCA</B>&#8221; means the <I>Canada
Business Corporations Act</I>, R.S.C. 1985, c. C-44, and the regulations made under that enactment, as amended;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>CBD</B>&#8221; means corticobasal degeneration;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>CEO</B>&#8221; means Chief Executive
Officer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>CFO</B>&#8221; means Chief Financial
Officer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>CMMS</B>&#8221; means Centers for Medicare
and Medicaid Services;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&ldquo;<B>CMO</B>&rdquo; means Chief Medical Officer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vi<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Collective Coordinates</B>&rdquo; means
an algorithmic method which employs protein molecular dynamics to predict novel therapeutic targets in AD and other neurodegenerative
diseases; and is complementary to ProMIS&rsquo; predictive algorithm technology;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>Common Shares</B>&#8221; means the
common shares in the capital of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>Company</B>&#8221; or &#8220;<B>ProMIS</B>&#8221;
means ProMIS Neurosciences Inc., incorporated pursuant to the CBCA on January&nbsp;23, 2004 under number 4203801;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>CPT</B>&#8221; means the Current Procedural
Terminology code;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>CSO</B>&#8221; means Chief Scientific
Officer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>DLB</B>&#8221; means Dementia with
Lewy bodies;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>DSEs</B>&#8221; means disease specific
epitopes on the molecular surface of misfolded proteins;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>DSU</B>&#8221; refers to a deferred
share unit awarded under the DSU Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>DSU Plan</B>&#8221; means the deferred
share unit plan for non-employee directors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>EMA</B>&rdquo; means the European Medicines
Agency;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>FDA</B>&#8221; means the U.S. Food
and Drug Administration;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>FTLD</B>&#8221; means frontotemporal
lobar degeneration;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B>GLP</B>&rdquo; means Good Laboratory Practices;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>GMP</B>&#8221; means Good Manufacturing
Practices;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>HD</B>&#8221; means Huntington&#8217;s
disease;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>LATE</B>&#8221; means limbic-predominant
age-related TDP-43 encephalopathy;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>LBD</B>&#8221; means Lewy body dementia,
a severe form of Parkinson&#8217;s disease;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>mAb</B>&#8221; means monoclonal antibody;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>management</B>&#8221; means all members
of the Board as well as the senior executive officers of ProMIS;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>MCI</B>&#8221; means mild cognitive
impairment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>MSA</B>&#8221; means Multiple System
Atrophy;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<B>Nasdaq</B>&#8221;
means the </FONT>Nasdaq Stock Market;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>PD</B>&#8221; means Parkinson&#8217;s
disease;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>PMN310</B>&#8221; means a mAb targeting
toxic prion-like forms of A&#946;O, and designated as the Company&#8217;s first lead product candidate for development in AD;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>PMN442</B>&rdquo; means a mAb targeting
toxic prion-like forms of a-syn and designated as the Company&rsquo;s second lead product candidate for development in MSA;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>PMN267</B>&rdquo; means a mAb targeting
toxic prion-like forms of TDP-43 and designated as the Company&rsquo;s third lead product candidate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>Preferred Shares</B>&#8221; means preferred
shares in the authorized capital of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>ProMIS USA</B>&#8221; means ProMIS
Neurosciences (US),&nbsp;Inc., a subsidiary corporation of ProMIS, which subsidiary was incorporated on January&nbsp;14, 2016 pursuant
to the General Corporation Law of the State of Delaware;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>PSP</B>&#8221; means progressive supranuclear
palsy;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>RACK1&rdquo; </B>means receptor of
activated protein C kinase 1;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B>Stock Option</B>&rdquo; means option granted under the terms
of the Company&rsquo;s Stock Option Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>Stock Option Plan</B>&#8221; means
the Company&#8217;s incentive stock option plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>SOD1</B>&#8221; means superoxide dismustase
1;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>TDP-43</B>&#8221; means TAR-DNA binding
protein 43;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>TSX</B>&#8221; means the Toronto Stock
Exchange and any successor thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>UBC</B>&#8221; means the University
of British Columbia, Vancouver, British Columbia, Canada;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>UHN</B>&rdquo; means University Health
Network, Toronto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>USPTO</B>&#8221; means the U.S. Patent
Trademark Office; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>U.S.</B>&#8221; and &#8220;<B>USA</B>&#8221;
means the United States of America, its territories, any State of the United States and the District of Columbia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->viii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="b_3"></A>ITEM
1. BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="b_4"></A>Corporate Structure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Name, Address and Incorporation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ProMIS Neurosciences Inc. was incorporated on
January&nbsp;23, 2004 under the name 4203801 Canada Inc. pursuant to the CBCA. The Company changed its name to Amorfix Life Sciences
Ltd. on August&nbsp;24, 2004 and to ProMIS Neurosciences Inc. effective July&nbsp;8, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 21, 2022, the directors of the Company
authorized a reverse share split of the issued and outstanding Common Shares in a ratio of 60:1, effective June 28, 2022 (the &ldquo;<B>Reverse
Share Split</B>&rdquo;). All information included in this Registration Statement has been adjusted to reflect the Reverse Share Split.
Unless otherwise stated herein, all share and per share numbers relating to the Company&rsquo;s Common Shares prior to the effectiveness
of the Reverse Share Split&nbsp;have been adjusted to give effect to the Reverse Share Split, including the financial statements and notes
thereto. See &ldquo;<I>Description of the Registrant&rsquo;s Securities to be Registered</I>&rdquo; on page 119 for more information
about our Common Shares. The Company&rsquo;s Common Shares are listed on the TSX under the symbol, &ldquo;PMN.&rdquo; The Company&rsquo;s
Common Shares also trade on the OTCQB Venture Market in the U.S. under the symbol, &ldquo;ARFXD.&rdquo; The Company has also submitted
an application for listing of its Common Shares on the Nasdaq under the symbol &ldquo;PMN.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our head office is located at 1920 Yonge Street,
Suite&nbsp;200, Toronto, Ontario, Canada M4S 3E2 and our registered and records office is located at 1055 West Georgia Street, Vancouver,
British Columbia, Canada V6E 4N7. Our telephone number is (416) 847-6898 and our website address is www.promisneurosciences.com. The
information provided on our website is not part of this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Intercorporate Relationships</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ProMIS has one wholly-owned U.S. subsidiary,
ProMIS Neurosciences (US) Inc. (&#8220;<B>ProMIS USA</B>&#8221;), which was incorporated in Delaware on January&nbsp;14, 2016. ProMIS
USA has had no material activities to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="b_5"></A>Business of the Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>General</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ProMIS is applying its patented technology
platform to build a portfolio of antibody therapies, therapeutic vaccines, and other antibody-based therapies in neurodegenerative diseases
and other misfolded protein diseases, which may include AD, MSA, ALS, PD, LBD, FTLD, PSP, CBD, and schizophrenia. These diseases share
a common biologic cause &#8211; misfolded versions of proteins, that otherwise perform a normal function. The misfolded versions kill
neurons and produce disease. ProMIS&#8217; technology platform is an example of the advances in drug discovery enabled by computational
power, <I>in silico</I> discovery, and/or artificial intelligence. We believe this platform provides a potential advantage by selectively
targeting the toxic misfolded proteins with therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>ProMIS&#8217; Platform Technology</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ProMIS&#8217; scientific foundation is centered
on the growing knowledge base relating to diseases characterized by the presence of abnormal, misfolded proteins. Genetic and experimental
research in the neuroscience community has demonstrated that propagating, neurotoxic, misfolded proteins (also referred to as prion-like
particles or toxic soluble oligomers) are fundamental drivers of multiple neurodegenerative diseases, including AD, MSA, and ALS. ProMIS&#8217;
platform technology allows for the identification of conformational epitopes that become exposed on toxic, misfolded forms of a given
protein but are not present on the properly folded form of the same protein. Such DSEs can then be used to generate therapeutic antibody
candidates that selectively target toxic forms of the protein without interfering with essential functions of the healthy protein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company first licensed the exclusive rights
to the ProMIS<SUP>TM</SUP> target identification technology from UBC to predict novel DSEs on the molecular surface of misfolded proteins.
ProMIS<SUP>TM</SUP> is an &#8220;in silico&#8221; rational selection approach that can be applied to any protein where the normal folding
structure is at least partially known. The Company also acquired a worldwide license from UBC to &#8220;Collective Coordinates&#8221;,
a method to predict novel therapeutic targets in AD and other neurodegenerative diseases. Developed principally by the Company&#8217;s
former Chief Physics Officer, Steven Plotkin, PhD, the Collective Coordinates method is a computational algorithm employing protein molecular
dynamics simulations, and is complementary to the ProMIS<SUP>TM</SUP> predictive algorithm technology. The addition of Collective Coordinates
to its computational discovery platform gave ProMIS a unique, proprietary and robust engine to predict DSEs on the molecular surface
of misfolded proteins. The amino acid sequence of the toxic, misfolded form and the healthy, properly folded form of a target protein
are exactly the same but the two differ in their shape, or conformation. The ProMIS platform offers the ability to identify targets unique
to the toxic, misfolded form. These conformational epitopes are used to immunize mice or rabbits to generate selective mAbs that can
attack the disease-causing form of the protein without interfering with the healthy form of the same protein. The mAbs raised in animals
are humanized (the critical binding regions are inserted into a human antibody framework) for potential use in patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"></P>

<!-- Field: Page; Sequence: 10; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our Pipeline</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are developing a pipeline of antibodies aimed
at selectively targeting misfolded toxic forms of proteins that drive neurodegenerative diseases without interfering with the essential
functions of the same properly folded proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm229830d4_1012b-img01.jpg" ALT="" STYLE="height: 135px; width: 624px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP> The Company plans to investigate additional synucleinopathies,
including PD and DLB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">* Arrows denote the stage of each program</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>ADDITIONAL DEVELOPMENT PROGRAMS</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tm229830d4_1012b-img02.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>1</SUP> Initial indication</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>*</SUP> Arrows denote the stage of each
program</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>ProMIS&rsquo; Objectives for 2022</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s priorities for 2022 fall into the following four
key areas:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Continue
                                            to progress PMN310 antibody lead program for AD</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Continue
                                            to progress PMN442 antibody for MSA</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: left">Continue
                                            to progress PMN267 antibody for ALS</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Use
                                            of the ProMIS proprietary platform to support portfolio expansion</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>PRODUCT CANDIDATES</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Development of a Therapy for the Treatment
of AD</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>AD Overview</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AD, a progressive neurodegenerative disease,
is the most common type of dementia, accounting for approximately 60-80% of all dementia cases. Early symptoms of AD include recent memory
loss, as well as apathy and depression. As the disease progresses inexorably, language deterioration, impaired ability to mentally manipulate
visual information, poor judgment, confusion, restlessness, and profound mood swings develop. Eventually AD destroys cognition, personality,
and the ability to function. The early symptoms of AD, especially at the inaugural stage of MCI, are often missed because they are frequently
and mistakenly taken for &#8216;natural signs of ageing&#8217;. In 2020, current reports conclude that 50% of primary care physicians
believe the medical profession is not prepared to meet the expected increase in demands the projected rise in AD and dementia cases will
create.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During
                                            2020, it was estimated there were 5.8 million Americans living with AD and that number is
                                            projected to rise to 14 million by 2050. In the U.S., one in three seniors dies of AD or
                                            another dementia, which kills more people than breast cancer and prostate cancer combined.
                                            AD is the sixth leading cause of death in the U.S., according to the Alzheimer&rsquo;s Association.
                                            In 2020, AD and other dementias cost the U.S. $305 billion and those costs are projected
                                            to rise to $1.1 trillion by 2050. It is reported that 16 million Americans are unpaid caregivers,
                                            who in 2020 provided 18.6 billion hours of support, valued at $244 billion, to people with
                                            AD and other dementias.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Among
                                            people aged 70 with AD, 61% die before age 80, or twice the death rate (30%) of those without
                                            AD. Deaths from AD, as recorded on death certificates, have increased 146% over the last
                                            two decades. In the U.S. and Canada combined, an estimated 6.3 million people have AD currently,
                                            9.5 million have MCI, and 42.3 million have evidence of potential pathology with no symptoms.
                                            In the U.S., AD costs the health system $305 billion, and that number is projected to grow
                                            to $1.1 trillion by 2050 if there are no advances in treatment and prevention.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Historically, a major challenge in AD has been
diagnosis. Twenty years ago, diagnosis of AD could only be confirmed by autopsy. Two years ago, consensus guidelines were developed that
established new diagnostic criteria &#8211; A/T/N. The methods used were based on sophisticated approaches to brain imaging: amyloid
positron emission tomography (&#8220;<B>PET</B>&#8221;) scans measuring amyloid plaque as a proxy for pathology, tau PET scans measuring
tau tangles as a proxy for pathology, and cortical magnetic resonance imaging (&#8220;<B>MRI</B>&#8221;) measuring the thickness of the
frontal cortex of the brain as a measure of neurodegeneration. Each of these tests costs thousands of dollars, affordable perhaps to
diagnose patients for a clinical trial, but not practical for screening millions of people who might be at risk or have pre-symptomatic
AD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are now blood-based biomarkers (diagnostic
assays) that can provide information that correlates with expensive A/T/N imaging so that it is possible to detect and monitor AD neuropathology
in blood. Two measures have been scientifically validated: NfL, which measures the rate of neuronal loss, and phosphorylated tau which
measures the level of toxic, misfolded tau. Blood levels of these have been shown to correlate with brain imaging measures, as well as
disease status or progression. These advances have implications for ProMIS&#8217; strategy. Better diagnostics can facilitate more efficient
clinical trials, both in terms of identifying potential subjects for the trial and also detecting a potential treatment effect in early,
small trials. Secondly, the ability to diagnose disease prior to symptoms raises the possibility of preventive treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According
                                            to the World Alzheimer Report 2015, the current dementia market comprises two product categories,
                                            namely, AChE inhibitors and N-methyl-D-aspartate receptor antagonists. AChE inhibitors dominate
                                            the market. The overall market is dominated by four leading brands &ndash; Aricept, Namenda,
                                            Exelon and Ebixa. Aricept, whose active ingredient is an AChE inhibitor, holds the largest
                                            market share. The U.S. was the largest market for AD drugs in 2019, accounting for approximately
                                            35% of total worldwide AD pharmaceutical sales in that year.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Although
there is no current scientific or general consensus on the causation of AD or method of action to treat AD, evidence from some genetic
and preclinical studies suggests a causative role for A</FONT><FONT STYLE="font-family: Symbol">b</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">in
the pathogenesis of AD. We believe results of published genetic studies support a direct link between increased levels of A</FONT><FONT STYLE="font-family: Symbol">b
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">and disease susceptibility. Research suggests that genetic mutations
in the A</FONT><FONT STYLE="font-family: Symbol">b</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">precursor protein (APP)
and in the presenilin 1 and 2 genes responsible for familial forms of early onset AD all result in increased production of A</FONT><FONT STYLE="font-family: Symbol">b
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">and A</FONT><FONT STYLE="font-family: Symbol">b</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">aggregates
(<I>Citron et al, 1992; Borchelt et al, 1996</I>). Some Down Syndrome patients with three copies of the APP gene on chromosome 21 also
have elevated levels of APP and A</FONT><FONT STYLE="font-family: Symbol">b</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">deposits
and have developed AD at a premature age (<I>Podlisny et al, 1987</I>). Along the same lines, the APOE4 allele which has been linked
to an increased risk of late onset AD is associated with increased A</FONT><FONT STYLE="font-family: Symbol">b</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">deposit
while the APOE2 allele linked to a decreased risk is associated with decreased A</FONT><FONT STYLE="font-family: Symbol">b</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">levels
(<I>Holtzman et al, 2012</I>). Finally, the only known protective mutation against AD is found in the APP gene and research suggests
that this leads to a reduction in the formation of A</FONT><FONT STYLE="font-family: Symbol">b</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">(<I>Jonsson
et al, 2012</I>). In a preclinical study, it was reported that intracerebral injection of A</FONT><FONT STYLE="font-family: Symbol">b</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">-containing
brain extracts from human AD patients into susceptible mice induced cerebral amyloidosis and associated pathology. Depletion of A</FONT><FONT STYLE="font-family: Symbol">b
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">from the extracts reversed this activity supporting a link between A</FONT><FONT STYLE="font-family: Symbol">b
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">and disease induction (<I>Meyer-Luehmann et al, 2006</I>).</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">While
the presence of A</FONT><FONT STYLE="font-family: Symbol">b</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">plaque is
a distinguishing feature of AD, there is a growing body of scientific evidence that the synaptic loss and neurodegenerative spread of
AD is primarily mediated by soluble oligomers of misfolded A</FONT><FONT STYLE="font-family: Symbol">b</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">rather
than plaque (<I>Cleary et al, 2004; Jin et al, 2011</I>). Reports from several groups indicate that plaque burden correlates poorly with
memory impairment (<I>Cleary et al, 2004; Ferreira et al, 2015</I>) and insoluble A</FONT><FONT STYLE="font-family: Symbol">b</FONT>
<FONT STYLE="font-family: Times New Roman, Times, Serif">fibrils show little or no demonstrable toxicity <I>in vitro</I> or <I>in vivo
</I>(<I>Balducci et al, 2010; Shankar et al, 2008</I>). In contrast, a significant correlation between disease severity and levels of
soluble A</FONT><FONT STYLE="font-family: Symbol">b</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">in the central nervous
system was reported by Lue et al (<I>Lue et al, 1999</I>), and the direct neurotoxicity of soluble A</FONT><FONT STYLE="font-family: Symbol">b
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">oligomers was demonstrated in neuronal cultures in vitro by separate
groups (<I>Lauren et al, 2009; Jin et al, 2011</I>). In published reports using rodent models, the injection of soluble oligomeric A</FONT><FONT STYLE="font-family: Symbol">b,
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">but not soluble monomers or plaque, was shown to induce synaptic damage
and cognitive dysfunction (<I>Cleary et al, 2005; Hong et al, 2016).</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
convergence of evidence from multiple studies suggests that the progressive nature of AD arises from the formation and spread of a prion-like
subset of misfolded oligomers of A</FONT><FONT STYLE="font-family: Symbol">b</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">that
adopt a </FONT><FONT STYLE="font-family: Symbol">b-</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">sheet-rich conformation
transmissible to native A</FONT><FONT STYLE="font-family: Symbol">b</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">in
a template-like manner. The self-propagation of these prion-like oligomers follows the stereotypical progression of AD with initial involvement
of the enthorhinal cortex followed by spreading to the hippocampus and neocortex as described by Khan et al (<I>Khan et al, 2014</I>).
The prion-like spread of A</FONT><FONT STYLE="font-family: Symbol">b</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">oligomers
has been well-documented in animal models by different groups following the injection of purified oligomers or brain extracts from AD
patients or diseased animals (<I>Cleary et al, 2005; Meyer-Luehmann et al, 2006; Watts et al, 2014; Hong et al, 2016</I>). There is also
<I>in vitro</I> evidence that such misfolded &ldquo;A</FONT><FONT STYLE="font-family: Symbol">b</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">prions&rdquo;
from AD brain can catalyze the misfolding and hyperphosphorylation of tau, another protein involved in the pathogenesis of AD as reported
by Jin et al (<I>Jin et al, 2011</I>). Targeting of A</FONT><FONT STYLE="font-family: Symbol">b</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">oligomers
therefore represents an attractive strategy to inhibit progression of the neurodegenerative A</FONT><FONT STYLE="font-family: Symbol">b</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">-Tau
cascade (<I>Choi et al, 2015; Khan et al, 2014</I>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>PMN310</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProMIS&rsquo;
                                            lead therapeutic program is PMN310, a mAb designed to treat AD by selectively targeting the
                                            toxic misfolded form of A&beta;. Based on the understanding of A</FONT><FONT STYLE="font-family: Symbol; font-size: 10pt">b
                                            </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">biology
                                            described above, PMN310 was designed to be more selective for the toxic oligomer of amyloid
                                            than aducanumab, Biogen&rsquo;s anti-A&beta; antibody, and BAN 2401, currently being co-developed
                                            by Eisai Co. and Biogen. Both aducanumab and BAN2401 bind oligomers, but also plaque. This
                                            off-target binding of plaque frequently leads to a side effect, ARIA-E, and potentially limits
                                            the benefit of aducanumab and BAN2401 by both limiting the highest dose that can be safely
                                            administered and by &ldquo;wasting&rdquo; a substantial portion of the administered antibody
                                            which binds plaque, reducing what is available to neutralize the toxic oligomers.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Although
                                            there is no current scientific or general consensus on the causation of AD or method of action
                                            to treat AD, the purported importance of targeting toxic oligomers is supported by recent
                                            results of clinical trials, conducted by third parties, with therapeutic mAbs targeting A</FONT><FONT STYLE="font-family: Symbol">b</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">.
                                            Antibodies that bind A&beta; monomers (bapineuzumab, solanezumab, crenezumab) did not show
                                            efficacy, suggesting that high selectivity for low abundance toxic A&beta;O is desirable
                                            to prevent mAbs from being consumed by unproductive binding to non-pathogenic, abundant monomers
                                            (target distraction). Other antibodies with reduced binding to monomers and more selectivity
                                            for aggregated A&beta; produced more promising results, including aducanumab which received
                                            accelerated approval from the FDA, and BAN2401 and donanemab which showed evidence of a cognitive
                                            benefit in Phase 2 trials. However, treatment with all of these antibodies was associated
                                            with the dose-limiting adverse events of ARIA-E (brain edema) and ARIA-H (microhemorrhages)
                                            correlated with binding to insoluble deposits of A</FONT><FONT STYLE="font-family: Symbol">b
                                            </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">in the vasculature and plaque.
                                            We believe that a selective, oligomer-specific antibody that does not bind monomers or plaque
                                            would circumvent these issues and potentially provide an improved product profile. In March
                                            2022, we presented results of our analysis of the binding response of other A&beta;-directed
                                            antibodies (aducanumab, BAN2401, donanemab, crenezumab, solanezumab). All antibodies showed
                                            some binding signal to toxic amyloid beta oligomers from human brain extracts but target
                                            distraction by monomers abolished or reduced binding. Only the antibodies that retained binding
                                            to oligomers (aducanumab, donanemab and BAN2401) without distraction by monomers, have shown
                                            improvement on cognitive endpoints in previous clinical trials. In our analysis, PMN310 avoided
                                            monomer target distraction, with the smallest percent inhibition of binding to brain oligomers
                                            when compared to other A&beta;-directed antibodies. We believe this data supports the therapeutic
                                            potential of PMN310.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Using
                                            the ProMIS platform, six different conformational epitopes were identified as potential targets
                                            exposed on toxic A&beta;O but not A&beta; monomers or plaque. MAbs raised against these epitopes
                                            displayed selectivity for A&beta; oligomers vs monomers and inhibited A&beta;O toxicity and
                                            propagation <I>in vitro</I>. In January&nbsp;2017, the Company designated the PMN310 antibody
                                            (binds conformational epitope 301) as its first lead candidate for development in AD. As
                                            described in our published preclinical studies (Gibbs et. al., 2019), PMN310 displayed the
                                            desired selective profile with binding to synthetic A&beta;O and little or no binding to
                                            A&beta; monomers as determined by surface plasmon resonance (SPR), and no detectable binding
                                            to plaque or vascular deposits in AD brain sections as determined by immunohistochemistry
                                            (IHC). In SPR studies with cadaveric brain tissue from individuals with AD, PMN310 also showed
                                            binding to brain fractions indicating that PMN310 can potentially recognize toxic A&beta;O
                                            species present in the brain. <I>In vitro</I>, PMN310 inhibited A&beta;O propagation in a
                                            thioflavin-T (ThT) based assay measuring the formation of A&beta; aggregates with a beta-sheet
                                            structure over time (Fig. 1). PMN310 also reduced the killing of primary mouse neurons by
                                            toxic A&beta;O in culture (Fig.1). <I>In vivo</I>, the activity of murine PMN310 was tested
                                            in two different models. In one model conducted at SynAging (Vandoeuvre-les-Nancy, France),
                                            PMN310 and a preparation of toxic A&beta;O were co-delivered (mAb:A&beta;O ratio of 1.6)
                                            by intracerebroventricular (ICV) injection into male, 3-month old, wild-type C57Bl6/J mouse
                                            to determine whether PMN310 might improve cognitive performance and molecular markers in
                                            this model of A&beta;O-induced neurotoxicity. Treatment groups consisted of day 0 ICV injection
                                            of vehicle alone, A&beta;O alone, vehicle with PMN310 or A&beta;O with PMN310, and contained
                                            12 mice per group to achieve statistical significance. Cognitive performance was assessed
                                            on days 7-8 using the novel object recognition (NOR) assay. Mice were sacrificed and perfused
                                            on day 10, the hippocampus was isolated and levels of synaptic (PSD-95, SNAP25) and inflammation
                                            (TNF-</FONT><FONT STYLE="font-family: Symbol">a</FONT>) markers were measured by ELISA in
                                            hippocampal homogenates from individual mice. A<FONT STYLE="font-family: Symbol">b</FONT>O-injected
                                            mice failed to recognize a new object and displayed a discrimination index of 0 or less.
                                            Co-injection of PMN310 with the toxic oligomers prevented this cognitive deficit. As expected,
                                            ICV injection of PMN310 alone had no effect (Fig. 2). The cognitive deficit induced by ICV
                                            injection of A<FONT STYLE="font-family: Symbol">b</FONT>O was associated with inflammation
                                            and synaptic damage in the hippocampus, a region important in the development of memory.
                                            Hippocampal homogenates from A<FONT STYLE="font-family: Symbol">b</FONT>O-treated mice displayed
                                            an increase in levels of TNF-<FONT STYLE="font-family: Symbol">a</FONT> and decreases in
                                            PSD-95 and SNAP25. Partial protection from these changes was observed in mice co-injected
                                            with A<FONT STYLE="font-family: Symbol">b</FONT>O and PMN310.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 43%">Figure 1A</TD>
  <TD STYLE="padding-left: 1.625in; text-align: justify; width: 57%">1B</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><IMG SRC="tm229830d4_1012b-img03.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fig. 1. Inhibition of aggregation propagation
<I>in vitro</I> (thioflavin-based assay) (A)&nbsp;and inhibition of A&#946;O toxicity for primary mouse neurons <I>in vitro</I> (B).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tm229830d4_1012b-img04.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fig.
                                            2. Administration of PMN310 to mice prevented the loss of short-term memory formation caused
                                            by toxic A&beta;O.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">*p&lt;0.05 vs Vehicle, <SUP>#</SUP>p&lt;0.05
vs A&beta;O. Discrimination index = (time exploring new object &ndash; time exploring familiar object)/total exploration time.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
a second <I>in vivo</I> model conducted at reMYND (Leuven, Belgium), the potential effect of treatment with murine PMN310 (mouse IgG2a)
was tested in the transgenic (Tg) hAPP[V717I] mouse model of AD. Characterization of the model indicates that these hAPP-Tg mice display
spontaneous, progressive accumulation of A</FONT><FONT STYLE="font-family: Symbol">b</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">in
the brain, eventually resulting in amyloid plaques around 10-11 months of age. In the pre-plaque stage of the pathology, there is a clear
cognitive and long-term synaptic potentiation (LTP) deficit in these mice suggesting that impairment is caused by soluble toxic species
such as A</FONT><FONT STYLE="font-family: Symbol">b</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">O rather than plaque.
The aim of the study was to assess the impact of 7 weekly doses of PMN310 administered intraperitoneally (i.p.) at 30 mg/kg to female
mice, beginning at 5.0 months of age. Experimental groups consisted of hAPP-Tg mice treated with vehicle or PMN310, and non-Tg, age-matched
littermates treated with vehicle as a control, with 17 mice per group to achieve statistical significance. Spatial learning and memory
performance were assessed using the Morris Water Maze task at 6.4 months of age (after 7 doses of antibody) which measures the ability
of mice to learn and remember the location of a hidden platform in a pool of water. Compared to non-Tg littermates, the hAPP-Tg mice
were significantly impaired and showed an increase in both escape latency (time required to find the hidden platform, p=0.0024) and the
search path or distance traveled to reach the platform (p=0.0047). Treatment of hAPP-Tg mice with PMN310 significantly improved these
outcomes with a decrease in escape latency (p=0.0187) and search path (p=0.0071) (Fig. 3).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tm229830d4_1012b-img05.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fig. 3. Systemic administration of PMN310 provides
a cognitive benefit in a mouse model of AD (hAPP[V717I] Tg mice)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As described in our publication (Gibbs et
al, 2019), PMN310 brain exposure and kinetics after systemic i.p. administration were assessed in mice. In one study conducted by ProMIS,
aged 15-17 month old wild type littermates of APP/PS1 mice, received a single 30 mg/kg i.p. injection of humanized PMN310 (n=4), aducanumab
(n=3) or PBS as a negative control (n=2). Levels of human IgG present in the plasma and perfused brains were measured 24 h later by ELISA.
Equivalent amounts of PMN310 and aducanumab were detected in plasma and brain demonstrating a comparable degree of CNS penetrance (p=0.28)
in the range of ~0.3%. As expected, no human IgG was detected in mice injected with PBS alone. Additionally, a study was conducted by
ProMIS in aged (13-17 months old) transgenic APP/PS1 mice in order to assess the time course of CNS exposure to PMN310. Plasma and brain
levels of human IgG were measured by ELISA on days 1, 7, 14 and 21 after i.p. administration of 30 mg/kg PMN310 (n=4-6 per time point).
In spite of declining plasma levels (p=0.0016 for day 1 vs day 7, p&lt;0.0001 for day 1 vs days 14 and 21), CNS levels of PMN310 were
detectable out to the study endpoint at day 21 (no significant difference in brain levels at the different time points). These results
suggest that PMN310 is comparable to other therapeutic mAbs and is similarly able to cross the blood-brain barrier to reach its target.
The Company believes that the greater selectivity of PMN310 for A&beta;O may result in greater neutralization of this disease-causing
species (no target distraction) and may potentially be better tolerated (allowing for higher doses) due to a reduced risk of the ARIA
adverse events that have been reported associated with plaque-binding antibodies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has conducted a non-GLP study
in Cynomolgus monkeys. The study was conducted in two phases. In Phase A, one pair of animals (Group 1) were administered a single dose
of PMN310 at a dose of 100 mg/kg by IV bolus injection and tolerability and toxicokinetics were assessed for 5 weeks. In Phase B, eight
animals were separated into 4 groups (Groups 2-5) and administered 2 doses of drug on Day 1 and 7. The 4 groups were administered 0 mg/kg,
100 mg/kg, 400 mg/kg, and 1200 mg/kg via a 75 minute IV infusion at each of the 2 dosing occasions. PMN310 was very well tolerated. No
adverse events were found in any parameters across all animals and all doses. No PMN310-related clinical signs were observed throughout
the study. Body weight, food consumption, and clinical pathology parameters were unaffected by PMN310 administration at any dose level.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company successfully humanized PMN310
in a human IgG1 framework. Producer cell line development is progressing using Selexis' proprietary and high performance SURE<I>technology
</I>Platform. Cell banks and drug product candidate will be generated in partnership with KBI. An Investigational New Drug Application
(&ldquo;<B>IND</B>&rdquo;) for Phase 1 testing of PMN310 is planned for 2022. In April 2022, we submitted a Type B Pre-IND meeting package.
FDA&rsquo;s written feedback on the proposed preclinical and clinical strategy to support submission of the IND was received in May 2022,
and the Company remains on track for an anticipated IND submission for PMN310 in 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Development of a Therapy for the Treatment
of MSA</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>MSA Overview</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">MSA
                                            is a rare neurodegenerative disease with an estimated prevalence of 3.4-4.9 cases per 100,000
                                            population. MSA is characterized by rapidly progressive autonomic failure and motor symptoms
                                            with predominant parkinsonian features (MSA-P) or dominant cerebellar features (MSA-C). There
                                            is no effective treatment and the mean survival from the onset of symptoms is 6-10 years.
                                            Histologically, the disease is characterized by a-syn aggregates in the cytoplasm of oligodendrocytes
                                            and, to a lesser extent, in neurons and other glial cells. The causative role of a-syn aggregates
                                            in MSA pathogenesis is supported by experimental evidence showing that a-syn aggregates from
                                            MSA brain homogenates propagate in a prion-like manner <I>in vitro</I> and <I>in vivo</I>,
                                            and cause MSA-like neurodegeneration in mice. The characteristics of MSA, although devastating
                                            for the patients, present several advantages for clinical testing: disease progression is
                                            rapid allowing for earlier detection of therapeutic potential; high levels of NfL in serum
                                            represent a potential biomarker for inhibition of neuronal damage; and no placebo effects
                                            have been observed in clinical trials to date. Even though MSA is a rare disease, recruitment
                                            is facilitated by the unmet need and existence of a global MSA Registry (GLOMAR), along with
                                            supporting organizations.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>PMN442</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research
                                            discussed in the literature indicates that misfolded toxic a-syn is a primary driver of disease.
                                            Multiple studies indicate that pathogenic aggregates of a-syn can propagate from cell to
                                            cell in a prion-like manner causing progressive neuronal damage and disease symptoms. In
                                            order to target pathogenic a-syn without interfering with normal a-syn, the ProMIS platform
                                            was used to generate several mAbs against predicted conformational epitopes of misfolded,
                                            toxic a-syn. The peptide epitopes possessed <I>in vitro</I> seeding activity for a-syn monomers
                                            as determined in a ThT-based assay measuring the formation of a-syn aggregates over time.
                                            mAbs raised against these epitopes showed the ability to selectively bind the pathogenic
                                            forms of a-syn (toxic oligomers and small soluble fibrils) but not the normal forms of a-syn
                                            (monomers, physiologic tetramers) that play important functional roles in the brain (Fig.
                                            4). <I>In vitro</I> studies showed that the ProMIS mAbs were able to protect rat dopaminergic
                                            neurons (neurons that are destroyed in PD) against toxic a-syn oligomers (Fig. 5). In separate
                                            assays, the mAbs also neutralized the seeding activity of a-syn soluble fibrils (Fig. 6)
                                            which is involved in the cell to cell propagation of disease. Importantly, the mAbs recognize
                                            toxic species of a-syn present in brain homogenates from patients with synucleinopathies
                                            (Fig. 7). Taken together, the results support the potential for using these antibodies to
                                            selectively target and protect against a-syn pathogenic species in patients with synucleinopathies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tm229830d4_1012b-img06.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fig.
4. Selectivity of mAbs for pathogenic species of a-syn. The binding response of a representative mAb to various concentrations of a</FONT>-syn
monomers, toxic oligomers and soluble fibrils (sonicated PFFs) measured in a Millipore immunoassay. Mean <U>+</U> SD of triplicates shown
with the calculated lower limit of quantitation (LLOQ) for each species.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tm229830d4_1012b-img07.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fig. 5. Protection against neurotoxicity. mAb
inhibition of oligomer toxicity for dopaminergic neurons. Cultures of primary rat dopaminergic neurons were exposed to toxic a-syn oligomers
with or without mAbs. Survival is expressed as the percentage of viable neurons compared to a control culture with vehicle only (CTL).
Results shown are the mean <U>+</U> SEM of 6 replicate cultures. BDNF was used as a positive control. # p = 0.0004 vs. CTL, *p <U>&lt;
</U>0.002 vs. a-synO, **p <U>&lt;</U> 0.003 vs. a-synO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm229830d4_1012b-img08.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fig. 6. Inhibition of seeding activity. mAb inhibition
of the recruitment of endogenous rat a-syn into phosphorylated aggregates. Cultures of primary rat hippocampal neurons were exposed to
soluble human a-syn preformed fibrils (PFF) with or without mAbs. CTL = neurons incubated with vehicle alone. Results are expressed as
a percentage of the phosphorylated rat a-syn staining area with PFF alone and show the mean <U>+</U> SEM of 6 replicate cultures. *p&lt;0.02
vs PFF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 7</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="tm229830d4_1012b-img09.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fig.7.
Binding to native pathogenic a-syn species in patient brain extract. The binding response of immobilized mAbs to a</FONT>-syn in brain
extract from DLB (A)&nbsp;and MSA (B)&nbsp;patients was measured by SPR. A pan a-syn reactive antibody and mouse IgG1 (mIgG1) were used
as controls. Results shown are the mean <U>+</U> SEM of two (A)&nbsp;or four (B)&nbsp;independent studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Using the ProMIS platform, several conformational
epitopes were identified as likely to become exposed on misfolded, pathogenic forms of a-syn (toxic oligomers and soluble seeding fibrils).
MAbs were raised against these epitopes and were tested for the desired binding profile and ability to protect neurons against toxic
a-syn species <I>in vitro</I>. Multiple mAbs were screened and PMN442 emerged as the lead candidate for this program with the desired
characteristics. PMN442 showed robust binding to a-syn oligomers and seeding fibrils, with negligible binding to a-syn monomers and physiologic
tetramers which are required for normal neuronal function. PMN442 also reacted with native toxic a-syn present in brain homogenates from
individuals with MSA and DLB. In addition, PMN442 did not stain dense deposits of a-syn in Lewy bodies and Lewy dendrites in brain sections
from diseased individuals. Although characteristic of disease, Lewy bodies/Lewy dendrites are not believed to be a major driver of toxicity
and can actually act as a sink, diverting antibodies away from the pathogenic species (oligomers and seeding fibrils).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In activity assays, PMN442 protected rat dopaminergic
neurons against killing by a-syn toxic oligomers. PMN442 also inhibited the processes involved in the cell-to-cell propagation of a-syn
aggregates: it reduced the uptake of human a-syn seeding fibrils by neurons and the subsequent formation of intracellular aggregates,
as well as the recruitment of endogenous normal a-syn into those aggregates. These results support the potential of PMN442 to selectively
target and protect against a-syn pathogenic species in patients with MSA and other synucleinopathies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Development of a Therapy for the Treatment
of ALS</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>ALS Overview</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ALS, commonly known as Lou Gehrig&#8217;s Disease,
is a progressive neurodegenerative disease that causes muscle weakness, paralysis and, ultimately, respiratory failure. ALS attacks randomly,
occurs throughout the world with no racial, ethnic or socioeconomic boundaries. Most people with ALS only live two to five years after
their first signs of disease. It is estimated there are currently 30,000 people in North America and 450,000 people worldwide, suffering
from ALS, with approximately 5,000 new cases arising in North America annually. Patients with ALS present symptoms such as progressive
weakness, muscle atrophy and spasticity. These neurodegenerative and neuromuscular symptoms arise due to the ultimate degeneration of
motor neurons in the spinal cord, the brain stem and in the brain cortex. Incurable and usually fatal within five years, ALS gradually
robs a patient of the ability to walk, talk and breathe. Currently, there is no confirmatory test for ALS and many people go undiagnosed
at early phases of the disease. Approximately two-thirds of those afflicted by ALS are currently undergoing some form of symptomatic
treatment. There are no therapies approved that halt or significantly slow progression.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The biological mechanisms that cause ALS are
only partially understood. There are scientific research results indicating that toxic, misfolded forms of TDP-43 are believed to play
an important role in the development of ALS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>PMN267</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Misfolded, aggregated TDP-43 forming inside neurons
has been implicated in the pathogenesis of ALS, FTLD and LATE through direct toxicity, loss of function of normal TDP-43, induction of
misfolding of other neuronal proteins, and prion-like, cell-to-cell propagation of disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Experimentally, misfolded aggregates of TDP-43
are toxic to neural cells, and the prion-like propagation of TDP-43 aggregates has been demonstrated in cell culture and animal models.
Importantly, misfolded TDP-43 has been found to induce the misfolding of other proteins into pathogenic aggregates (e.g., SOD1, nuclear
pore proteins and transport proteins, DISC1), such that targeting misfolded TDP-43 potentially represents an opportunity to not only
neutralize TDP-43 pathology but also interrupt this pathogenic interactome.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Identification
                                            of epitopes present on misfolded TDP-43 through the ProMIS discovery platform allowed for
                                            the generation of high affinity antibodies (Fig. 8) showing selective recognition of misfolded
                                            cytoplasmic aggregates of TDP-43 with no detectable interaction with normal TDP-43 which
                                            is located in the nucleus and is important for normal cell function (Fig. 9). The antibodies
                                            also recognized and stained pathogenic TDP-43 aggregates in spinal cord sections from ALS
                                            patients and brain sections from FTLD patients (immunohistochemistry) indicating that they
                                            have the potential to target disease-causing TDP-43 in these patients. <I>In vitro</I> data
                                            showed that such antibodies can inhibit the cell to cell transmission of misfolded TDP-43
                                            in the extracellular space thereby offering the potential to inhibit spreading of pathology
                                            (Fig. 10).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 8</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="tm229830d4_1012b-img10.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fig. 8. High affinity mAbs. In SPR studies, serial
dilutions of test mAbs were flowed over the target epitope immobilized on sensorchips to assess the binding kinetics and affinity. Binding
curves were fitted to a Langmuir 1:1 interaction model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 9</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm229830d4_1012b-img11.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fig. 9. Selective binding of mAb to misfolded,
cytoplasmic aggregates of TDP-43. Staining of HEK293 cells transfected with mutant TDP-43 shows cytoplasmic aggregates of misfolded TDP-43
(red). Staining of the same cells with a PMN mAb (green) shows co-localization with TDP-43 aggregates with no staining of endogenous,
normal TDP-43 in the nucleus (nuclei stained blue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 10</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="tm229830d4_1012b-img12.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fig. 10. Inhibition of cell-to-cell transmission
of misfolded TDP-43 by mAbs. Supernatant from HEK293 cells transfected with misfolding mutant TDP-43 was incubated with test antibodies
and added to na&iuml;ve recipient cells to assess transmission of misfolding TDP-43 (HA-tagged). Compared to a mouse IgG1 negative control
(mIgG1), several mAbs inhibited transmission to recipient cells as determined by a reduction in the density of the HA band on a Western
blot of recipient cell lysate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intrabody
                                            versions of the TDP-43 antibodies were also generated. Intrabodies (from intracellular and
                                            antibody) are expressed from within the cell and were designed to target intracellular aggregates
                                            of TDP-43. Testing indicated that intrabodies expressed inside HEK293 cells associated selectively
                                            with pathogenic aggregates of TDP-43 in the cytoplasm (Fig. 11) and promoted degradation
                                            of the aggregates without affecting normal TDP-43 function or harming the cells (Fig. 12).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 11</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="tm229830d4_1012b-img13.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fig. 11. Co-localization of intrabody with misfolded,
cytoplasmic aggregates of TDP-43. Staining of HEK293 cells co-transfected with mutant TDP-43 (green) and plasmid encoding a PMN intrabody
(red) shows co-localization of the two. There was no interaction of the intrabody with endogenous, normal TDP-43 in the nucleus (nuclei
stained blue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 12</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm229830d4_1012b-img14.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fig. 12. Clearance of TDP-43 aggregates by intrabody.
Transfection of HEK293 cells with a ProMIS intrabody results in degradation of HA-tagged mutant TDP-43 (dNLS) aggregates as measured
by reduction in the density of the HA band on a Western blot of cell lysate compared to an empty vector (EV) control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These results support the potential for using
these mAbs to selectively target and protect against pathogenic TDP-43. We believe the antibodies could be used to interfere with the
cell to cell spread of misfolded aggregates of TDP-43 in the extracellular space while intrabody constructs delivered inside the cells
via gene therapy vectors could be used to degrade intracellular aggregates and prevent further propagation (concept illustrated in Fig.
13).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 13</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="tm229830d4_1012b-img15.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Using the ProMIS platform several epitopes were
identified as likely to become exposed on misfolded, pathogenic forms of TDP-43, but not on the properly folded, functional protein. MAbs
were raised against these epitopes and tested for selective reactivity with misfolded TDP-43 aggregates and protective activity. Screening
of multiple mAbs yielded PMN267 as the lead candidate exhibiting the desired properties. PMN267 bound its target epitope with high affinity
in the 10E-11M range. In a cell system, PMN267 showed selective recognition of misfolded, cytoplasmic TDP-43 aggregates and no detectable
interaction with endogenous normal TDP-43 in the nucleus. Similarly, PMN267 did not react with TDP-43 in stress granules which are important
in protection against oxidative stress. PMN267 also showed binding to exosomes derived from the brains of deceased FTLD individuals. Systemic
IP delivery of PMN267 was tested in a transgenic mouse model of ALS/FTLD. In this model, doxycycline-regulated expression of human &#8710;NLS-TDP-43
is under control of the neurofilament heavy chain promoter such that progression of disease is driven by intracellular expression of aggregating
 &#8710;NLS-TDP-43 in all neurons, with little or no contribution of cell to cell spread of aggregates. In this aggressive model, a trend
for improvement was observed with PMN267 treatment (30 mg/kg/week for 9 weeks) in the majority of motor function read-outs evaluated,
including hind limb clasping, hind limb paralysis, grill test of agility, paw coordination, and footfall pattern. We believe the results
suggest evidence of protection against motor function deficits by systemic, extracellular delivery of PMN267. A separate <I>in vivo</I>
study in a transgenic mouse model expressing wild type human TDP-43 is ongoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An intrabody version of PMN267 (single chain antibody
sequence encoded into a plasmid) expressed from within cells showed co-localization with cytoplasmic aggregates of TDP-43 and no detectable
binding to normal, nuclear TDP-43. Expression of the intrabody promoted degradation of misfolded TDP-43 aggregates in the HEK293 cell
system by approximately 58% (Fig. 12). <I>In vitro</I> studies were also performed in collaboration with Dr. Gene Yeo at University of
California, San Diego using iPSC-derived motor neurons from ALS patients, the cell type predominantly affected in ALS. In these studies,
neurons transduced with vectorized PMN267 intrabody or a control protein (luciferase) were subjected to prolonged stress by puromycin-induced
suppression of protein synthesis for 24 hours, giving rise to TDP-43 aggregates that persisted after another 24 hours of recovery. Neurons
expressing PMN267 intrabody compared to control protein showed a 30-60% reduction in the amount of stress-induced TDP-43 aggregates as
quantitated by high-content imaging. The Company believes that the observed selectivity of PMN267 for misfolded TDP-43 and avoidance of
normal TDP-43 has the potential to allow for inhibition of disease without compromising essential TDP-43 function. Intrabody development
would involve collaboration with a partner with gene therapy expertise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>DEVELOPMENT PROGRAMS</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Expansion to Include Other Neurodegenerative
and Misfolded Protein Diseases</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ProMIS discovery platform is also being
applied to other toxic proteins that drive neurodegenerative and other misfolded protein diseases including a-syn in PD and LBD, tau
in AD, FTLD, PSP, and CBD, RACK1 in ALS and HD, SOD1 in ALS and DISC1 in schizophrenia. Under disease conditions, misfolding of these
proteins leads to the formation of toxic aggregates inside brain cells that are capable of spreading damage by propagating from cell-to-cell.
Disease-associated conformational epitopes identified through ProMIS&#8217; computational platform can be used to potentially generate
therapeutic antibodies or potentially form the basis for the development of vaccines. The Discovery phase of the process comprises 2
distinct stages: 1) computational modeling to predict and construct conformational peptide epitopes present on the misfolded, toxic form
of a protein, followed by either immunization with the peptide epitopes to generate antibodies/intrabodies, or incorporation of the peptide
antigen into a therapeutic vaccine, 2) screening and validation of multiple candidates <I>in vitro</I> and <I>in vivo</I> to select a
lead for preclinical development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Alpha-synuclein</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Evidence from genomic analysis, cell culture,
and <I>in vivo</I> studies points to a-syn as a major driver of PD and other synucleinopathies. A large body of data suggests that soluble
aggregates (oligomers, soluble fibrils) are the most toxic form of a-syn and can spread pathology from neuron to neuron. In contrast,
a-syn monomers and physiological tetramers are non-toxic and are required for normal neuronal function.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In an attempt to develop a potential therapy,
the ProMIS computational platform was used to identify epitopes that are selectively exposed on toxic misfolded species of a-syn, in
a conformation that distinguishes it from that of monomers, physiological tetramers and insoluble fibrils (Lewy body/Lewy neurites).
The analyses suggest that immunization with these conformational epitopes led to the generation of mAbs that selectively bind the toxic
forms of a-syn as determined by several methods (surface plasmon resonance, immunohistochemistry and dot blot analysis).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PD is a progressive neurodegenerative disorder
characterized by loss of dopaminergic neurons located in the midbrain and the presence of intraneuronal inclusions (Lewy bodies/Lewy
neurites) consisting mainly of aggregates of a-syn. Accumulation of insoluble a-syn fibrils in the brain is also observed in LBD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PD is the second most common neurodegenerative
disorder after AD. It is estimated there are over 10 million patients diagnosed worldwide and up to 10 million total subjects with PD,
including undiagnosed individuals. The prevalence of PD increases with age, affecting approximately 1.1% of the population over the age
of 60. Currently, the Parkinson&#8217;s Foundation Prevalence Project estimates 930,000 people in the U.S. live with PD, and this number
is expected to rise to 1.2 million by 2030. As global life expectancy increases, so will the burden of PD. It is estimated that the global
number of people with PD will grow by 88% between 2020 and 2040.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Global Data estimates that drug sales for PD
will, according to the U.S. National Institute of Environmental Health Sciences, grow from 2020 to 2027 by approximately 11.3% to reach
$4.76 billion across the seven largest markets by 2027. Over the seven year forecast period, the market is expected to grow driven by
the launch of late-stage pipeline products and growth of the PD population. North America dominates the PD market. Nearly 1 million people
in the U.S. are living with PD with the average age of onset being 60 and the prevalence of PD in the population increases from 1% at
age 60 (5 &#8211; 10% of whom had early onset from age 50) to 4% at age 80. It is predicted by the U.S. National Institute of Health
that by 2030, due to the aging population in the U.S., approximately 1.2 million people will be suffering from PD. The Asia Pacific market
is also expected to record significant growth in this market, centered on China, Japan and India.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Scientific studies indicate that toxic oligomers
and small soluble fibrils, derived from naturally occurring a-syn, are the root cause of disease development and progression in PD. Recent
findings suggest that physiological a-syn tetramers inhibit aggregation and must be preserved for normal a-syn homeostasis. We believe
a potential therapy will require antibodies selective for the toxic forms of a-syn oligomers and/or small soluble fibrils, while avoiding
physiologic forms of a-syn. Selectivity for only the toxic forms of a-syn represents the essential feature of a successful antibody therapy,
for it is critical that treatment not hinder normal forms of a-syn that play an important functional role in the brain. Traditional methods
are unable to generate antibodies with adequate precision to selectively target these neurotoxic forms of a-syn. ProMIS is using its
proprietary technology platform for discovering and developing antibodies that can uniquely and precisely target these specific toxic
forms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Current treatments center on the management of
dopamine levels in the brain, with levodopa-based therapies remaining the standard of care in the PD market for the past 50 years. These
therapies provide initial relief of symptoms at a low annual cost of therapy, with Sinemet (carbidopa/levodopa, Merck Sharp&nbsp;&amp;
Dohme) and Madopar (benserazide/levodopa, Roche) being the two most popular branded drugs. However, dopamine replacement or dopamine
agonist (bromocriptine) therapies only provide temporary symptomatic relief, are associated with debilitating long-term side effects
and do not affect the underlying neurodegeneration and progression of disease related to toxic forms of a-syn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Tau</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Propagation
of misfolded, pathogenic aggregates of tau has also been implicated in AD and other tauopathies such as PSP, CBD, and FTLD-tau. The ProMIS
platform was therefore used to identify epitopes and raise mAbs against pathogenic forms of tau (toxic oligomers and small soluble fibrils).
A set of mAbs has been generated that preferentially bind pathogenic tau aggregates as opposed to physiologic tau monomers. </FONT>The
Company believes that selectivity of antibodies for tau pathogenic species, as opposed to pan-tau reactivity (binding to all forms of
tau), is needed both in order to preserve normal tau function and to minimize the diversion of active antibody from the target through
unproductive binding to more abundant non-toxic forms of tau. In binding assays, the ProMIS mAbs recognized toxic species of tau in brain
homogenates from individuals with AD (Fig. 14) indicating that the mAbs can recognize toxic tau species present in the brain. In activity
assays, the mAbs were able to inhibit the seeding activity of AD brain homogenate resulting in decreased induction of tau aggregation
in a cell system. (Fig. 15). These results suggest that these mAbs may be useful in targeting pathogenic tau in AD and potentially other
tauopathies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, mAbs against additional epitopes are
being generated and screened. The next steps will entail selecting the candidates for <I>in vivo</I> testing and eventual selection of
additional product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Figure 14</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm229830d4_1012b-img16.jpg" ALT="" STYLE="height: 260px; width: 381px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fig.
14. Binding to native pathogenic tau species in the brain extracts of individuals with AD.</FONT> The binding response of a representative
immobilized mAb to tau in brain extract from 3 different individuals with AD was measured by SPR. Mouse IgG1 (muIgG1) was used as a negative
control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 15</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="tm229830d4_1012b-img17.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fig.
15. Inhibition of seeding activity of AD brain homogenate.</FONT> Brain homogenate +/- mAbs was transduced into Biosensor cells with
Lipofectamine 200. FRET signal was measured 48 hours later by flow cytometry. Results are expressed as Normalized Integrated FRET density
defined as the percent of FRET positive cells multiplied by the Median Fluorescence Intensity of those FRET positive cells and normalized
to cells treated with IgG.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The immediate goal for the ProMIS extended therapeutic
portfolio is to achieve further scientific characterization and validation of one or more of these programs. Based on results of this
evaluation the most promising program or programs will be advanced in development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>SOD1</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Misfolded SOD1 is abundant in both familial (FALS)
and sporadic (SALS) forms of ALS but is not found in samples from normal controls or patients with other neurodegenerative disorders<I>.
</I>Misfolding of SOD1 can be induced by mutations (FALS) or other factors such as oxidative stress and interaction with misfolded TDP-43,
as mentioned above. Like TDP-43, misfolded SOD1 aggregates are toxic and have the ability to propagate from cell to cell causing spreading
of disease. In order to target pathogenic SOD1 in ALS, the ProMIS platform was used to successfully generate mAbs against different regions
of SOD1 predicted to be exposed in misfolded SOD1 but inaccessible in the normal, properly folded protein. These antibodies were shown
to bind misfolded SOD1 in spinal cord homogenates from both FALS and SALS patients, with no recognition of normal SOD1 in control normal
spinal cord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In <I>in vitro</I> assays, ProMIS mAbs inhibited
the cell to cell propagation of misfolded SOD1 while administration of mAb in a mouse model of ALS significantly prolonged survival of
the animals. These results support the potential use of such mAbs to selectively target and protect against pathogenic SOD1 in ALS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, mAbs against additional epitopes are
being generated for screening. The next steps will entail additional <I>in vitro</I> and <I>in vivo</I> studies for eventual selection
of a lead(s)&nbsp;for development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>RACK1</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RACK1 is a core ribosomal protein of the eukaryotic
small (40S) ribosomal subunit. It is a scaffold protein that interacts with several other proteins thereby regulating a variety of signaling
pathways critical for cell proliferation, transcription and protein synthesis. It is essential for proper neuronal function. In ALS,
our own findings and those of others indicate that misfolded RACK1 co-localizes in cytoplasmic aggregates in motor neurons of the spinal
cord suggesting an involvement in disease. Indeed, in a cell system, mutant TDP-43 has been reported to suppress global protein synthesis
by co-aggregating with RACK1 on polyribosomes, a finding that we have reproduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To investigate RACK1 as a potential target for
ALS and HD, ProMIS explored the impact of RACK1 knock-down (KD) <I>in vitro </I>and <I>in vivo</I> (i.e., what happens in the absence
of RACK1). In a cell system, as expected, RACK1 was observed to co-aggregate with misfolded mutant TDP-43 in the cytoplasm. Knock-down
of RACK1 expression resulted in disaggregation of cytoplasmic TDP-43 and even relocation to the nucleus (normal location) in some of
the cells (Fig. 16). The disaggregation was accompanied by a reversal of the suppression of protein synthesis by mutant TDP-43 (Fig.
17).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Figure 16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="tm229830d4_1012b-img18.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fig.
16. Disaggregation of mutant TDP-43. RACK1 (red) normally co-localizes with mutant TDP-43 aggregates in the cytoplasm (green) in the
top panels. With RACK1 KD (bottom panels), TDP-43 disaggregates and localizes in the nucleus in some of the cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 17</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm229830d4_1012b-img19.jpg" ALT=""></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fig.
17. Reversal of protein synthesis suppression. Protein synthesis (red) is suppressed in cells expressing aggregated mutant TDP-43 (green)
in the top panels. RACK1 KD (bottom panels) disaggregates TDP-43 and restores protein synthesis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In fruit fly studies, genetic KD of RACK1 in
retinal neurons protected against neurodegeneration caused by overexpression of TDP-43 (Fig. 18)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm229830d4_1012b-img20.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fig.
18. Protection against neuronal degeneration. </FONT>Fruit flies overexpressing human TDP-43 in retinal neurons show degeneration (loss
of ommatidia pointed by arrow). TDP-43 pathology is prevented by RACK1 KD in these flies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Results from the literature and ProMIS&#8217;
proof of concept data using RACK1 KD support intracellular targeting of RACK1 as a potential therapeutic approach for ALS and HD. Knock-down
of RACK1 is non-selective (all forms knocked-down) and may not be well-tolerated in humans. We are therefore using the ProMIS platform
to identify epitopes present on misfolded RACK1 and generate antibodies selective for pathogenic, aggregated RACK1. Such antibodies can
then be converted into intrabodies with the goal of targeting intracellular, misfolded RACK1 while preserving normal cell function.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ProMIS has so far generated 5 mAbs with the desired
selectivity (representative example in Fig. 19) and intrabody versions have been generated for testing. Next steps involve generation
and screening of additional antibodies, followed by <I>in vitro</I> and <I>in vivo</I> studies for the eventual selection of a candidate(s)&nbsp;for
development. Development of intrabodies will be best executed in collaboration with a partner offering gene therapy expertise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 19</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tm229830d4_1012b-img21.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fig.
19. Selectivity for misfolded RACK1 in aggregates. </FONT>Representative mAb showing co-localization of staining (green) with RACK1 in
TDP-43 aggregates (yellow) but not normal diffuse RACK1 elsewhere in the cytoplasm (purple).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Schizophrenia</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>DISC1</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Protein misfolding and proteostasis have been
found to play a role in neurodevelopment disease. DISC1, a candidate for misfolding protein in schizophrenia was first identified in
a Scottish family with an autosomal dominant neurodevelopmental syndrome including schizophrenia, which was found to be due to a balanced
translocation of part of the C-terminus of a gene subsequently named &#8220;disrupted in schizophrenia&#8221;. DISC1 is an important
hub protein participating in neurogenesis, mitochondrial transport and dynamics in dendrites, cytoskeletal function, and protein translation
in adults, especially at the synapse and under conditions of oxidative stress. DISC1 has also been deemed a scaffold protein, and it
is possible that proteins of this class are inherently more susceptible to misfolding and aggregation, which is generally associated
with both loss-of-function and toxic gain-of-function. However, a true scaffold protein can change its conformation and that of its interactors,
and no current evidence exists that the extensive interactome/regulome of DISC1 undergoes conformational change. However, we believe
that DISC1 can change conformation in disease, as exemplified by decreased detergent solubility in brains of individuals dying with schizophrenia
or psychotic mood disorders and the induced co-aggregation of DISC1 by TDP-43<SUP>+</SUP> inclusions in human frontotemporal dementia.
Missense and frameshift mutations in DISC1 have been identified that are linked to familial schizophrenia (R37W, L607F, 4bd deletion
extreme 3' end of exon 12), but the role of these mutations has been disputed, and there is no GWAS signal for DISC1 that is statistically
significant. However, many variants in interactors of DISC1 show significant association with schizophrenia and cognitive decline. DISC1
itself can oligomerize, which may be associated with toxic gain-of-function as well as loss-of function.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Application of the ProMIS platform to DISC1 and
its interactome offers the potential to generate selective antibodies to probe the pathobiology of DISC1, gain insight into the biology
of schizophrenia and potentially intervene therapeutically. Epitopes predicted to be presented on misfolded DISC1 have been identified
and will be used to generate mAbs for further studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Future directions</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Treatment of neurodegenerative diseases driven
by misfolded protein aggregates that exist both extracellularly and intracellularly could potentially benefit from therapeutic modalities
that complement our antibody/intrabody approach. We are therefore exploring antisense oligonucleotide (ASO) therapeutic approaches with
Dr. Michelle Hastings, Professor and Director of the Center for Genetic Diseases at the Rosalind Franklin University of Medicine and
Science, and we are exploring a protein degradation strategy (PROTACS) for ALS <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
Dr. Justin Yerbury, Professorial Fellow at the School of Chemistry and Molecular Bioscience at the University of Wollongong in Australia.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Alzheimer&#8217;s Vaccine Program</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The recent development of blood-based biomarkers
for neurodegeneration allows for increased screening to potentially diagnose and identify individuals at risk of developing AD. A vaccine
capable of inducing an effective antibody response against A&#946;O could therefore be administered prophylactically to at-risk individuals
to potentially prevent development of symptomatic disease; and the vaccine could be given therapeutically to individuals living with
a diagnosis of AD to potentially inhibit disease progression. ProMIS initiated a program to construct and test a multivalent peptide
vaccine candidate for AD containing conformational epitopes identified by the ProMIS platform. The demonstrated ability of these conformational
epitopes to induce mAbs with selectivity and protective activity against A&#946;O (see above) supports their potential as vaccine candidates.
In addition, the Company believes that a multivalent vaccine containing several B cell epitopes has the potential to maximize &#8220;coverage&#8221;
by immunizing simultaneously against multiple epitopes that can be expressed at variable levels on A&#946;O.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that the same peptide antigens that
generate a mAb infusion therapy can be used to create a therapeutic vaccine. The goal of a therapeutic vaccine is to spur the human immune
system to generate antibodies that neutralize toxic oligomers, just as the infusion antibodies will hopefully do. The advantage is that
a single course of therapy, usually an initial vaccination followed by a booster, can potentially provide years of therapeutic benefit,
eliminating the need for frequent costly infusions. The disadvantage of a vaccine approach is that there is no opportunity to improve
or refine the antibodies created by the patient&#8217;s immune system. With infusion antibodies, the final drug candidate may have gone
through a significant amount of refinement and optimization. With therapeutic vaccines, the treatment is only as good as the peptide
antigens on which it is based.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In studies conducted by third parties, a first
generation vaccine consisting of aggregated human A&#946; protein with QS1 adjuvant induced antibody production in AD patients but elicited
meningoencephalitis (brain inflammation) and had to be discontinued for safety reasons. Subsequent studies indicated that T helper (&ldquo;<B>Th</B>&rdquo;)
cell epitopes in the A&#946; vaccine gave rise to a pro-inflammatory Th1-type response against the same A&#946; epitopes in the brain<I>)</I>.
The Company believes it can avoid this issue with a vaccine candidate consisting of its A&#946;O B cell epitopes (no A&#946; Th epitopes)
conjugated to keyhole limpet hemocyanin (KLH) as a carrier protein. KLH has been used in humans and provides Th cell epitopes that are
needed to help the development of an antibody response by B cells. Since KLH is a foreign protein not present in human brain, immunization
is expected to result in an antibody response against A&#946;O without a potentially detrimental Th cell inflammatory response (Fig.
20). This premise is supported by initial preclinical studies conducted in collaboration with the University of Saskatchewan&#8217;s
Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac), a global leader in vaccine research and development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
these studies, 5-6 week old Balb/c mice (n=6/group) received 2 intramuscular (IM) injections (days 0 and 28) of a vaccine candidate construct
containing ProMIS&#8217; A&#946;O 301 peptide epitope linked to KLH and formulated with different adjuvants. Analysis of serum samples
collected on day 0 and after 1 or 2 vaccinations on days 28 and 48 showed induction of a robust antibody response against the A&#946;O
epitope as measured by ELISA (Fig. 21). ELISPOT analysis of spleen cells (immune cells) collected from immunized mice as the end of the
study on day 48 showed a lack of Th cell cytokine production in response to stimulation with the A&#946;O epitope thereby indicating
that the peptide only contains a B cell epitope. As expected, T cell help was provided by the carrier protein and stimulation with KLH
gave rise to the production of Th cytokines. These results support the premise that a vaccine consisting of A&#946;O-restricted conformational
B cell epitopes conjugated to KLH for T cell help may successfully induce a protective antibody response against A&#946;O without eliciting
a potentially inflammatory A</FONT><FONT STYLE="font-family: Symbol">b</FONT>- directed Th response. Characterization of immune sera
from the mice showed selective binding to A&beta;O compared to A&beta; monomers as determined by SPR, and no detectable binding to plaque
in brain sections from AD patients as determined by IHC. Optimization of adjuvant formulation and dosing regimen and evaluation of a
multivalent construct are ongoing, to be followed by <I>in vivo</I> studies of protective activity in AD mouse models.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 20</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tm229830d4_1012b-img22.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fig. 20. Illustration of vaccine concept</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 21</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tm229830d4_1012b-img23.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fig.
21. Induction of robust antibody response against A&#946;O epitope</FONT>. Titers of IgG antibodies against the 301 peptide epitope were
measured by ELISA. Values for individual mice at baseline and on days 28 and 48 post-immunization are shown.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Using the ProMIS discovery platform, our aim
is to devise a safe and effective vaccine to induce a specific immune response against toxic A&#946;Os. We have identified a set of six
different peptide epitopes selectively exposed on toxic A&#946;Os. Immunization of mice with each of these individual epitopes produced
mAbs that selectively bind A&#946;Os, not monomers or fibrils. The immediate goals for this program are to create and evaluate a multivalent
AD vaccine comprised of several ProMIS peptide antigens associated with toxic misfolded A&#946;<B><I>.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, ProMIS CSO Neil Cashman, through
UBC, has applied for a grant which, if awarded, would provide funding to initiate the development of a therapeutic vaccine targeting
misfolded a-syn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ProMIS&#8217; Technology Platform and Intellectual
Property Portfolio</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The basis of ProMIS&rsquo;
proprietary technology platform is the ability to identify small regions of toxic proteins, including their specific shape or &ldquo;conformation&rdquo;
that are displayed only on the toxic forms of that protein. We have developed patented methods and know-how combining biology and physics,
to identify these small regions of proteins which can be the targets for antibodies. When displayed on the toxic protein, these small
regions are known as &ldquo;epitopes&rdquo;. ProMIS makes copies of these epitopes, in a precisely defined shape. These drug development
tools are called peptide antigens and we believe they are the key to our ability to create antibody therapies, vaccines, and diagnostics.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ProMIS computational platform consists of two proprietary patented algorithms, the ProMIS</FONT><SUP>TM</SUP> and Collective Coordinates
algorithms. Both are molecular dynamics algorithms which combine physics and biology to simulate the folding, or misfolding of proteins.
The ProMIS<SUP>TM</SUP> algorithm was our first to be developed. Collective Coordinates was developed after the ProMIS<SUP>TM</SUP> algorithm
and is the more powerful algorithm for prediction/determination of conformational epitopes. ProMIS has successfully applied these computational
algorithms to several misfolded protein categories, looking for epitopes exposed only on a misfolded toxic form which can be used as
an antigen to generate an antibody.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peptide
antigens are the key to creating selective antibodies that target toxic misfolded proteins, like our lead therapeutic antibody candidate
(PMN310 for AD). PMN310 was created using a peptide antigen that we correctly predicted to be exposed only on toxic A</FONT>&#946;Os,
not the monomeric or plaque forms of A&#946;. ProMIS has generated a portfolio of over 20 peptide antigens that have led to selective
antibodies against toxic misfolded forms of A&#946; for AD, a-syn for MSA and PD, tau for AD, FTLD, PSP, and CBD, TDP-43 and SOD1 for
ALS, RACK1 for ALS and HD, and DISC1 for schizophrenia. Those peptide antigens, and the corresponding selective antibodies, represent
proprietary reagents that potentially can be used to create proprietary diagnostic tests in neurodegenerative diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finally, peptide antigens are also a potential
key to making vaccines. Therapeutic vaccines are designed to treat a disease by causing the patient&#8217;s immune system to make antibodies
(or T-Cells, in some areas like cancer) that neutralize the toxic disease driver. The potential advantage of a therapeutic vaccine, if
effective, is that a single course of therapy might provide benefit for many years, not requiring frequent, expensive and inconvenient
infusions. In preventive therapy, we believe such an approach may be particularly valuable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Overview of ProMIS&#8217; Intellectual
Property (IP) Portfolio</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ProMIS IP program consists of a three
layered strategy. The first layer of protection comprises two computational algorithms, ProMIS<SUP>TM </SUP>and Collective Coordinates,
obtained under worldwide exclusive license from the UBC. These algorithms are used to predict the specific site and shape (conformation)
of epitopes on misfolded proteins implicated in the development of neurodegenerative diseases and on other complex proteins. PCT applications
for these disease specific epitopes have been submitted and comprise the second layer of IP protection. Finally, the third layer of protection
consists of the composition of matter for the antibodies targeting these disease related epitopes, including use(s)&nbsp;thereof. A summary
of the ProMIS patent portfolio as of June 4, 2022 is shown in Appendix A hereto.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Prior Joint Venture Agreements with BC Neuroimmunology Lab Inc.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July&nbsp;2020, the Company entered into two
collaborative agreements with BC Neuroimmunology Lab Inc. (<B>&ldquo;BCNI&rdquo;</B>): the Neurodegen Collaboration and the COVID-19
Collaboration (collectively, the &ldquo;<B>BCNI Collaborations</B>&rdquo;). The Company and BCNI entered into the Neurodegen Collaboration
to develop and offer highly accurate and objective tests for detection, diagnosis and monitoring of AD. The Company and BCNI entered
into the COVID-19 Collaboration to provide a service of highly sensitive and specific serological assays for the detection and characterization
of antibodies to the SARS-CoV-2 virus that is responsible for COVID-19. Each of the BCNI Collaborations generally provided for an even
split among the Company and BCNI with respect to, among other things, funding, capital expenditures, working capital needs or operating
losses, ownership, investment decisions, and cash surpluses. The BCNI Collaborations were both terminated in December 2021 and are no
longer material to the Company&rsquo;s business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The foregoing
description of the BCNI Collaborations are qualified in their entirety by reference to the COVID-19 Collaboration and the Neurodegen
Collaboration joint venture agreements, which are attached hereto as Exhibits 10.1 and 10.2, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>License Agreements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>License Agreement with the University of British
Columbia</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
February 4, 2009, ProMIS (under its previous name, Amofix Life Sciences Ltd.) entered into an exclusive license agreement with UBC in
which ProMIS gained exclusive worldwide rights to develop and commercialize intellectual property rights belonging to UBC, based on its
technology relating to misfolded proteins. Such agreement was amended and restated effective October 6, 2015 (as amended and restated,
the &ldquo;<B>UBC License Agreement</B>&rdquo;). The UBC License Agreement expires on a product by product and country by country basis
upon the expiration of ProMIS&rsquo; obligation to pay royalties to UBC under the terms thereof (unless terminated earlier pursuant to
the terms of the UBC License Agreement). The Company&rsquo;s obligation to pay royalties under the UBC License Agreement expires upon
the longer of the life of the Patents (as defined in the UBC License Agreement), including those identified in Schedule A thereto (as
amended from time to time), and ten years following the First Commercial Sale of a Product (as those terms are defined in the UBC License
Agreement) in any country. Since the Company has not made commercial sales under the UBC License Agreement to date, the UBC License Agreement
is currently expected to expire no earlier than March 5, 2027. However, this date may be adjusted upon the Company&rsquo;s First Commercial
Sale of a Product or upon an amendment to Schedule A to the UBC License Agreement to add additional patents. The UBC License Agreement
may also be terminated by UBC, at its option, upon the occurrence of certain events including, but not limited to, our insolvency, winding
up, liquidation or other termination of existence. ProMIS also has the right, in its sole discretion, to terminate the UBC License Agreement
upon written notice to UBC. The UBC License Agreement calls for certain customary payments such as an annual license fee and payment
to UBC of a low to high single digit royalty on revenues. As of March 31, 2022, the Company has paid a total of C$175,000 to UBC pursuant
to the terms of the UBC License Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The foregoing
description of the UBC License Agreement is qualified in its entirety by reference to the UBC License Agreement, which is attached hereto
as Exhibit 10.4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>License Agreement with the University Health
Network</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 4, 2006, ProMIS (under its previous
name, Amorfix Life Sciences Ltd.) entered into a license agreement with UHN in which ProMIS obtained an exclusive license to UHN&rsquo;s
ownership rights in SOD1 exposed dimer interface antibody, which was coinvented by Neil Cashman while employed at the University of Toronto
and certain employees of UHN (the <B>&ldquo;Original UHN License Agreement</B>). The parties to the Original UHN License Agreement entered
into amendments on July 13, 2006 and July 11, 2007 (together with the Original UHN License Agreement, the &ldquo;<B>Amended UHN License
Agreement</B>&rdquo;). The Amended UHN License Agreement was amended and restated on November 4, 2013 (together with the Amended UHN
License Agreement, the &ldquo;<B>UHN License Agreement</B>&rdquo;). Except as otherwise provided in the UHN License Agreement or as mutually
agreed to by the parties, the UHN License Agreement expires upon expiration of the last patent issued on any of the technology under
the UHN License Agreement. The Company currently expects the UHN License Agreement to expire no earlier than April 29, 2041. The UHN
License Agreement may be terminated upon the occurrence of certain events, including upon the Company&rsquo;s voluntary petition in bankruptcy
or insolvency, the Company&rsquo;s consent to an involuntary petition in bankruptcy or if a receiving order is given against us, or upon
the appointment of a receiver by a court of competent jurisdiction. The UHN License Agreement may also be terminated at the discretion
of UHN upon a material breach of the UHN License Agreement by the Company, subject to a period to cure such breach. The Company and UHN
may also agree to mutually terminate the UHN License Agreement. The UHN License Agreement calls for certain customary payments such as
milestone payments, buyout payments and payment to UHN between a half of a percent to a low single digit royalty on revenues. The aggregate
amount of all potential milestone and buyout payments under the UHN License Agreement (excluding royalty payments) is $3,325,000 and,
as of March 31, 2022, the Company has paid a total of C$19,815 to UHN pursuant to the terms of the UHN License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The foregoing
description of the UHN License Agreement is qualified in its entirety by reference to the UHN License Agreement, which is attached hereto
as Exhibits 10.7, 10.7.1, 10.7.2 and 10.7.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to those developments discussed elsewhere
in this Registration Statement, the following is a summary of the significant developments of the Company that have occurred since March&nbsp;2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March&nbsp;24, 2020, ProMIS announced that
it had received approval from the TSX to amend the exercise price of an aggregate of 736,375 outstanding common share purchase warrants
(excluding common share purchase warrants held by Insiders) (the &ldquo;<B>Repriced Warrants</B>&rdquo;). The exercise price of the Repriced
Warrants was amended to $7.80 per share, effective April&nbsp;8, 2020 until May&nbsp;22, 2020. At the end of such period, the Repriced
Warrants reverted to their original exercise price. All other terms of the Repriced Warrants remain unchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September&nbsp;22, 2020, the Company announced </FONT>the resignation of Anthony Giovinazzo from the Board. It also announced the initiation
of a program to construct and test a multivalent peptide vaccine for AD. The critical first steps in vaccine development will be carried
out by VIDO-InterVac, a global leader in vaccine research and development based on the campus of the University of Saskatchewan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 29, 2020, Dr.&nbsp;David Wishart,
Distinguished University Professor in the Departments of Biological Sciences and Computing Science at the University of Alberta, was
appointed to the Scientific Advisory Board. Dr.&nbsp;Wishart has studied protein folding and misfolding for more than 30 years using
a combination of computational and experimental approaches. The experimental approaches include NMR spectroscopy, circular dichroism,
fluorescence spectroscopy, electron microscopy, protein engineering and molecular biology. The computational methods include molecular
dynamics, agent-based modeling, bioinformatics and machine learning. Dr.&nbsp;Wishart has been with the University of Alberta since 1995.
He also holds adjunct appointments with the Faculty of Pharmaceutical Sciences and the Department of Pathology and Laboratory Medicine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January&nbsp;1, 2021, James Kupiec resigned as Chief Medical Officer
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February&nbsp;1, 2021, Johannes Roth resigned from the </FONT>Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March&nbsp;22, 2021, ProMIS completed a
US$7M (C$8.75) private placement of convertible unsecured debentures (the &ldquo;<B>Debentures</B>&rdquo;). The Debentures are convertible
into Common Shares at the option of the holder at a conversion price of US$6.00 per share and accrue interest at 1% per annum, which
is payable annually. At the Company&rsquo;s election, accrued interest may be paid in cash or Common Shares (such number of shares determined
by dividing the interest due by the 5-day volume-weighted average trading price, or &ldquo;VWAP,&rdquo; of the Common Shares).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Debentures will mature on March&nbsp;22, 2026. Prior to the maturity date, the Company may force conversion of the Debentures at the
conversion price upon raising US$50</FONT> million in equity and/or debt cumulatively. On the maturity date, the Company may redeem the
outstanding principal amount of the Debentures in either cash or Common Shares (at the then 5-day VWAP less a 10% discount) or a combination
thereof at its election. Amounts redeemed in Common Shares on the maturity date are subject to prior TSX acceptance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
investors were granted a right to participate, on a pro rata basis, in subsequent </FONT>Company offerings of equity securities for cash
consideration pursuant to a public offering or a private placement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May&nbsp;12, 2021, ProMIS appointed Dr.&nbsp;Rudolph Tanzi, as
Chair of its Scientific Advisory Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May&nbsp;13, 2021, ProMIS appointed Neil Warma to the </FONT>Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May&nbsp;21, 2021, the Company announced the
initiation of producer cell line development for PMN310, which is the first step in the manufacturing of antibody therapeutics. This
program will be carried out by Selexis, SA, using Selexis&rsquo; proprietary SUREtechnology Platform&trade;. PMN310, is a humanized mAb
that binds with high affinity and selectivity to toxic oligomers of A&beta; (a recognized root cause of AD).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May&nbsp;27, 2021, ProMIS appointed Dr.&nbsp;David
Wishart as Chief Physics Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August&nbsp;25, 2021, ProMIS completed
a public offering of 2,096,354 units at a price of $9.60 per unit for gross proceeds of $20,125,000. Each unit consisted of one common
share and one-quarter purchase warrant. Each warrant entitles the holder thereof to purchase one common share at an exercise price of
$12.60 per share at any time for five years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September&nbsp;1, 2021, ProMIS appointed Josh
Mandel-Brehm to the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September&nbsp;22, 2021, ProMIS appointed
Maggie Shafmaster to the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October&nbsp;22, 2021, ProMIS appointed Gavin
Malenfant as Chief Operating Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October&nbsp;22, 2021, Dr.&nbsp;Elliot Goldstein
resigned from his role as Chief Executive Officer and President of ProMIS and Eugene Williams accepted the role of Chairman and Chief
Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December&nbsp;1, 2021, we held our special
meeting of shareholders where our shareholders voted and approved the share consolidation resolution, which authorizes the Board, at
any time before July&nbsp;1, 2023, to consolidate our Common Shares <FONT STYLE="background-color: white">within a range from a ratio
of thirty pre-consolidation common shares to one post consolidation common share up to a ratio of sixty pre-consolidation common shares
for one post-consolidated common share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January&nbsp;18, 2022, ProMIS appointed Dr.&nbsp;Carsten
Korth to its Scientific Advisory Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 27, 2022, ProMIS appointed Dr. Cheryl
Wellington to its Scientific Advisory Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 3, 2022, ProMIS appointed Drs. Guy
Rouleau and Alain Dagher to its Scientific Advisory Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 19, 2022, ProMIS appointed Dr. Larry
Altstiel as Chief Medical Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 11, 2022, ProMIS appointed Maggie Shafmaster
to serve as lead independent director of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 12, 2022, Shareholders of the Company
approved an amendment of the Company&rsquo;s bylaws to increase its quorum requirement for shareholder meetings to 33 1/3% of shares
outstanding. Additionally, the Company&rsquo;s shareholder rights plan agreement dated as of January 22, 2016 and amended and extended
as of May 15, 2019 between the Company and Computershare Trust Company of Canada as rights agent expired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 17, 2022, the Company amended and
restated the Debentures (the &ldquo;<B>Amended and Restated Debentures</B>&rdquo;) to amend the conversion feature of the
Debentures. Previously, the Debentures were convertible into Common Shares at the option of the holder at any time and from time to
time at a conversion price of $6.00. Following the amendment, the Amended and Restated Debentures became convertible into Series 1
Preferred Shares (the &ldquo;<B>Series 1 Preferred Shares</B>&rdquo;) at the option of the holder at any time and from time to time
at a conversion price of $6.00. No other terms of the Debentures were amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 17, 2022, the directors of the
Company authorized the creation of the Series 1 Preferred Shares and the filing of an amendment to the Articles of Incorporation of
the Company, as amended (the &ldquo;<B>articles</B>&rdquo;), to designate the Series 1 Preferred Shares, which was filed with
Corporations Canada on even date thereof . During the period of June 17, 2022 to June 19, 2022, the Company also received notices of
conversion from the holders of the Amended and Restated Debentures, requesting conversions in the aggregate of $7 million,
representing the entirety of the outstanding balance thereof. In satisfaction of the notices of conversion, the Company issued, in
the aggregate, 70,000,000 Series 1 Preferred Shares to the Amended and Restated Debenture holders in accordance with the terms of
the Amended and Restated Debentures and made cash payments to settle accrued interest through the conversion dates in the amount of
$17,069. A copy of the press release announcing the conversion is attached hereto as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 21, 2022, the directors of the
Company authorized the Reverse Share Split effective June 28, 2022. On the same date, the directors also authorized and filed with Corporations Canada an
amendment to the articles to in connection with the Reverse Share Split.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Industry Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Markets</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ProMIS is applying its patented technology
platform to build a portfolio of antibody therapies, therapeutic vaccines, and other antibody based therapies in neurodegenerative diseases
and other misfolded protein diseases, which may include AD, MSA, ALS, PD, LBD, FTLD, PSP, CBD, and schizophrenia. These diseases share
a common biologic cause &#8211; misfolded versions of proteins, that otherwise perform a normal function, kill neurons and produce disease.
ProMIS&#8217; technology platform is an example of the advances in drug discovery enabled by computational power, <I>in silico</I> discovery,
and artificial intelligence. We believe this platform provides a potential advantage by selectively targeting the toxic misfolded proteins
with therapeutics or detecting them with diagnostics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Marketing Plans and Milestones</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because ProMIS&#8217; technology potentially
has many human and animal applications for both diagnostic and therapeutic uses, its development, marketing and commercial launch schedule
must be planned in relation to its available resources. ProMIS intends to out-license the marketing and sales of its product applications
to major international healthcare firms for commercial exploitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Government Regulations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulatory Approval and Certification</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All commercial applications of ProMIS&#8217;
technology will be subject to substantial regulation and certification in the jurisdictions in which ProMIS or its strategic partners
intend to sell its therapeutic products. The initial markets for ProMIS&#8217; product candidates are the U.S. and because the Canadian
healthcare (diagnostic and therapeutic) market-place is regulated in a similar manner as in the U.S., ProMIS intends to conform its regulatory
and certification scheme to the more rigorous standards imposed by the FDA. Some countries throughout the world provide reciprocal approval
based upon the receipt by an innovator of an FDA approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Human Therapeutic Products</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ProMIS&#8217; human therapeutic product applications
will also be subject to rigorous preclinical and clinical testing and other approval procedures by the FDA and similar regulatory agencies
in other countries. First, preclinical testing of human therapeutics is conducted on animals in the laboratory to evaluate the potential
efficacy, safety and toxicity of a pharmaceutical product candidate. The results of these studies, along with a GMP compliant manufacturing
dossier are submitted to the FDA as part of an IND. An IND automatically becomes effective 30&nbsp;days after receipt by the FDA, unless
the FDA, within the 30-day time period, notifies the applicant of safety concerns or questions related to one or more proposed clinical
trials and places the trial on a clinical hold. Typically, the clinical evaluation process involves three phases. In Phase 1, clinical
trials are conducted with a small number of healthy human subjects, or in some diseases in patients to determine the early safety profile,
the pattern of therapeutic drug distribution and metabolism. The total number of subjects included in Phase 1 clinical trials varies
but is generally in the range of 20 to 80. In Phase 2, clinical trials are conducted with groups of patients afflicted with a specific
disease to determine preliminary evidence of efficacy, the optimal dosages, and more extensive evidence of safety. Phase 2 clinical trials
are typically controlled and conducted in a limited population, usually involving no more than several hundred subjects. In Phase 3,
large scale, statistically-driven multi-center, well-controlled clinical trials are conducted with patients afflicted with a target disease
in order to provide enough data to demonstrate the efficacy and safety required by the FDA. Phase 3 clinical trials usually involve several
hundred to several thousand subjects. In most, though not all, cases, the FDA requires two adequate and well-controlled Phase 3 clinical
trials to support approval of a drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Data from clinical trials conducted outside the
U.S. may be accepted by the FDA subject to certain conditions. For example, the clinical trial must be conducted in accordance with Good
Clinical Practices (&ldquo;<B>GCP</B>&rdquo;) requirements and/or the FDA must be able to validate the data from the clinical trial through
an onsite inspection if it deems such inspection necessary. Where data from foreign clinical trials are intended to serve as the sole
basis for marketing approval in the U.S., the FDA will not approve the application on the basis of foreign data alone unless those data
are considered applicable to the U.S. patient population and U.S. medical practice, the clinical trials were performed by clinical investigators
of recognized competence, and the data is considered valid without the need for an on-site inspection by the FDA or, if the FDA considers
such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Marketing Approval</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assuming successful completion of the required
clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s
chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of a New Drug Application
(&#8220;<B>NDA</B>&#8221;) or Biologics License Application (&#8220;<B>BLA</B>&#8221;) requesting approval to market the product for
one or more indications. In most cases, the submission of an NDA or BLA is subject to a substantial application user fee. Under the Prescription
Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of&#8201;&#8220;filing&#8221;
of a standard NDA or BLA, for a new molecular entity to review and act on the submission. This review typically takes twelve months from
the date the NDA or BLA is submitted to FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA conducts a preliminary review of all
NDAs or BLAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently
complete to permit substantive review. The FDA may request additional information rather than accept an NDA or BLA for filing. In this
event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before
the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews
an NDA or BLA to determine, among other things, whether the drug or biologic is safe and effective and whether the facility in which
it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality, and
purity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA may refer an application for a novel
drug or biologic to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific
experts, which reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions.
The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before approving an NDA or BLA, the FDA typically
will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines
that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to ensure consistent production
of the product within required specifications. Additionally, before approving an NDA or BLA, the FDA may inspect one or more clinical
trial sites to assure compliance with current good clinical practice, or cGCP, requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After evaluating the NDA or BLA and all related
information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and
clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter
generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA or BLA and may require
additional clinical or preclinical testing in order for FDA to reconsider the application. Even with submission of this additional information,
the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions
have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial
marketing of the drug with specific prescribing information for specific indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if the FDA approves a product, it may limit
the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling,
require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#8217;s or biologic&#8217;s
safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions,
including distribution and use restrictions or other risk management mechanisms under a Risk Evaluation and Mitigation Strategy, or REMS,
which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of
a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved
product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements
and FDA review and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Expedited Development and Review Programs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA maintains several programs intended to
facilitate and expedite development and review of new drugs or biologics to address unmet medical needs in the treatment of serious or
life-threatening diseases or conditions. These programs include Fast Track designation, Breakthrough Therapy designation, Priority Review
and Accelerated Approval, and the purpose of these programs is to either expedite the development or review of important new drugs to
get them to patients more quickly than standard FDA review timelines typically permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A drug is eligible for Fast Track designation
if it is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address unmet medical
needs for such disease or condition. Fast Track designation provides increased opportunities for sponsor interactions with the FDA during
preclinical and clinical development, in addition to the potential for rolling review once a marketing application is filed. Rolling
review means that the agency may review portions of the marketing application before the sponsor submits the complete application. In
addition, a drug may be eligible for Breakthrough Therapy designation if it is intended to treat a serious or life-threatening disease
or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies
on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough
Therapy designation provides all the features of Fast Track designation in addition to intensive guidance on an efficient drug development
program, and FDA organizational commitment to expedited development, including involvement of senior managers and experienced review
staff in a cross-disciplinary review, where appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any product submitted to the FDA for approval,
including a product with Fast Track or Breakthrough Therapy designation, may also be eligible for additional FDA programs intended to
expedite the review and approval process, including Priority Review designation and Accelerated Approval. A product is eligible for Priority
Review designation, once an NDA or BLA is submitted, if the drug that is the subject of the marketing application has the potential to
provide a significant improvement in safety or effectiveness in the treatment, diagnosis or prevention of a serious disease or condition.
Under priority review, the FDA&#8217;s goal date to take action on the marketing application is six months compared to ten months for
a standard review. Products are eligible for Accelerated Approval if they can be shown for a serious or life-threatening condition and
to have an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or an effect on an intermediate clinical
endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, which is reasonably likely to predict an
effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the
condition and the availability or lack of alternative treatments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accelerated Approval is usually contingent on
a sponsor&#8217;s agreement to conduct additional post-approval studies to verify and describe the product&#8217;s clinical benefit.
The FDA may withdraw approval of a drug or an indication approved under Accelerated Approval if, for example, the confirmatory trial
fails to verify the predicted clinical benefit of the product, other evidence demonstrates that the product is not shown to be safe and
effective under conditions of use, or required post-approval studies are not conducted with due diligence. In addition, the FDA generally
requires, as a condition for Accelerated Approval, that all advertising and promotional materials intended for dissemination or publication
within 120 days of marketing approval be submitted to the agency for review during the pre-approval review period. After the 120-day
period has passed, all advertising and promotional materials must be submitted at least 30 days prior to the intended time of initial
dissemination or publication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if a product qualifies for one or more of
these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA
review or approval may not be shortened. Furthermore, Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated
Approval do not change the scientific or medical standards for approval or the quality of evidence necessary to support approval, though
they may expedite the development or review process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Post-Approval Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Drugs or biologics manufactured or distributed
pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements
relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse
experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling
claims are subject to prior FDA review and approval. There are continuing, annual user fee requirements for any marketed products and
the establishments where such products are manufactured, as well as new application fees for supplemental applications with clinical
data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA may impose a number of post-approval
requirements as a condition of approval of an NDA or BLA. For example, the FDA may require post-marketing testing, including Phase 4
clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, drug and biologic manufacturers
and other entities involved in the manufacture and distribution of approved drugs or biologics are required to register their establishments
with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance
with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being
implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting
and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers
must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once an approval of a drug or biologic is granted,
the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after
the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated
severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions
to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks;
or imposition of distribution or other restrictions under a REMS program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA strictly regulates marketing, labeling,
advertising and promotion of products that are placed on the market. Drugs or biologics may be promoted only for the approved indications
and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting
the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant
liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In many foreign countries, drugs and biologics
are subject to regulatory requirements in addition to and sometimes different than the U.S. requirements described herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Companion Diagnostics</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA defines <I>in vitro</I>, or IVD, companion
diagnostic device as an <I>in vitro</I> diagnostic device that provides essential information for the safe and effective use of a corresponding
therapeutic product. The use of an IVD companion diagnostic device with a therapeutic product is stipulated in the instructions for use
in the labeling of both the diagnostic device and the corresponding therapeutic product, including the label. Applications for an IVD
companion diagnostic device and its corresponding therapeutic product will be reviewed and approved according to applicable regulatory
requirements. The IVD companion diagnostic device application will be reviewed and approved or cleared under the device authorities of
the Federal Food, Drug, and Cosmetic Act (&#8220;<B>FD&amp;C Act</B>&#8221;) and relevant medical device regulations; the therapeutic
product application will be reviewed and approved under section 505 of the FD&amp;C Act (i.e., drug products) or section 351 of the Public
Health Service Act (i.e., biological products) and relevant drug and biological product regulations. The FDA intends to review each IVD
companion diagnostic device submission within the context of, or in conjunction with, its corresponding therapeutic product, and FDA
review of the IVD companion diagnostic device and the therapeutic product will be carried out collaboratively among relevant FDA offices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ideally, a therapeutic product and its corresponding
IVD companion diagnostic device should be developed contemporaneously, with the clinical performance and clinical significance of the
IVD companion diagnostic device established using data from the clinical development program of the corresponding therapeutic product.
Some of our current and future product development candidates may depend upon co-development of accurate genetic and potentially other
IVDs. Thus, we will likely need to comply with both FDA drug and medical device regulations. This adds additional cost and complexity
to our development programs. The availability of IVD companion diagnostics can allow more efficient development programs and more appropriate
use of products in the marketplace with more predictable outcomes for patients and higher value medicines. Ultimately FDA approval of
the IVD will be required to allow approval of some of our products. However, technical difficulties or other issues could delay or disrupt
the development of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>U.S. Healthcare Fraud and Abuse Laws and
Compliance Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to various federal and state laws
targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our proposed sales and marketing programs
for drugs and biologics. In addition, we may be subject to patient privacy regulation by both the federal government and the states in
which we conduct our business. The laws that may affect such operations include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 95%">the
                                            federal Anti-Kickback Statute is a criminal statute which prohibits, among other things,
                                            persons from soliciting, receiving, offering or paying remuneration, directly or indirectly,
                                            in cash or in kind, to induce or reward, or in return for, either the referral of an individual
                                            for, or the purchase, order or recommendation of, an item or service reimbursable under a
                                            federal healthcare program, such as the Medicare and Medicaid programs. The term &#8220;remuneration&#8221;
                                            has been broadly interpreted to include anything of value;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 95%">federal
                                            false claims and civil monetary penalties laws, including the federal civil False Claims
                                            Act, which prohibits anyone from, among other things, knowingly presenting, or causing to
                                            be presented, for payment to federal programs (including Medicare and Medicaid) claims for
                                            items or services that are false or fraudulent;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 95%">provisions
                                            of federal Health Insurance Portability and Accountability Act of 1996 (&#8220;<B>HIPAA</B>&#8221;),
                                            which created federal criminal statutes that prohibit, among other things, knowingly and
                                            willfully executing a scheme to defraud any healthcare benefit program or making false statements
                                            in connection with the delivery of or payment for healthcare benefits, items or services.
                                            In addition, HIPAA, as amended by the Health Information Technology for Economic and Clinical
                                            Health Act of 2009 (&#8220;<B>HITECH</B>&#8221;) and its implementing regulations, impose
                                            certain requirements relating to the privacy, security and transmission of individually identifiable
                                            health information;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 95%"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">the
                                            federal Physician Payments Sunshine Act requirements, under the Patient Protection and Affordable
                                            Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or
                                            collectively the Affordable Care Act, which require manufacturers of certain drugs and biologics
                                            to track and report to CMMS payments and other transfers of value they make to U.S. physicians
                                            and teaching hospitals as well as physician ownership and investment interests in the manufacturer;
                                            and</P></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 95%">the
                                            Foreign Corrupt Practices Act of 1977 (&#8220;<B>FCPA</B>&#8221;) which prohibits U.S. businesses
                                            and their representatives from offering to pay, paying, promising to pay or authorizing the
                                            payment of money or anything of value to a foreign official in order to influence any act
                                            or decision of the foreign official in his or her official capacity or to secure any other
                                            improper advantage in order to obtain or retain business.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Environmental Regulation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may also be subject to foreign and
local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control
and disposal of hazardous or potentially hazardous substances. There can be no assurance that the Company will not incur significant
costs to comply with laws and regulations in the future or that such laws or regulations will not have a material adverse effect upon
the Company&#8217;s business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Pricing and Reimbursement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Precision therapeutic products and their accompanying
companion diagnostic are largely paid for based on third party payor reimbursement. In the U.S., concurrent with approval for commercialization
of such therapeutic products by the FDA, each therapeutic product is assigned a product code, and its associated companion diagnostic
assigned a similar code, or CPT. Each product code and CPT is then assigned a reimbursement level by the CMMS. Third party insurance
payors typically establish a specific fee to be paid for each code submitted. Third party payor reimbursement policies are generally
determined with reference to the reimbursement for CPT codes for Medicare patients which themselves are determined on a national basis
by CMMS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In recent years, Congress has considered reductions
in Medicare reimbursement levels for drugs administered by physicians. CMMS, the agency that administers the Medicare and Medicaid programs,
also has authority to revise reimbursement rates and to implement coverage restrictions for some drugs. Cost reduction initiatives and
changes in coverage implemented through legislation or regulation could decrease utilization of and reimbursement for any approved products.
While Medicare regulations apply only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy
and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from federal
legislation or regulation may result in a similar reduction in payments from private payors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the state level, legislatures have increasingly
passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement
constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some
cases, designed to encourage importation from other countries and bulk purchasing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Parallel to this regulatory reimbursement scheme
in the U.S., other countries also regulate reimbursement similar to the U.S. Therefore, it is important that ProMIS establish for its
human diagnostic and therapeutic products reimbursement schemes, which provide ultimate financial payment for ProMIS&#8217; products
consistent with its business plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Healthcare Reform Measures</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The U.S. and many foreign jurisdictions have
enacted or proposed legislative and regulatory changes affecting the healthcare system. The U.S. government, state legislatures and foreign
governments also have shown significant interest in implementing cost-containment programs to limit the growth of government-paid healthcare
costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription
drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Affordable Care Act substantially changed
the way healthcare is financed by both governmental and private insurers, and significantly impacts the pharmaceutical industry. The
Affordable Care Act is intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance
remedies against healthcare fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose
new taxes and fees on pharmaceutical and medical device manufacturers, and impose additional health policy reforms. Among other things,
the Affordable Care Act expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum
Medicaid rebate for both branded and generic drugs, expanded the 340B program, and revised the definition of average manufacturer price
(&#8220;<B>AMP</B>&#8221;), which could increase the amount of Medicaid drug rebates manufacturers are required to pay to states. The
legislation also extended Medicaid drug rebates, previously due only on fee-for-service Medicaid utilization, to include the utilization
of Medicaid managed care organizations as well and created an alternative rebate formula for certain new formulations of certain existing
products that is intended to increase the number of rebates due on those drugs. On February&nbsp;1, 2016, CMMS issued final regulations
to implement the changes to the Medicaid Drug Rebate program under the Affordable Care Act. These regulations became effective on April&nbsp;1,
2016. Since that time, there have been significant ongoing efforts to modify or eliminate the Affordable Care Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Affordable Care Act has been subject to challenges
in the courts. On December&nbsp;14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in
its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. On December&nbsp;18, 2019, the Fifth Circuit U.S.
Court of Appeals held that the individual mandate is unconstitutional and remanded the case to the Texas District Court to reconsider
its earlier invalidation of the entire Affordable Care Act. An appeal was taken to the U.S. Supreme Court. On June&nbsp;17, 2021, the
U.S. Supreme Court ruled that the plaintiffs lacked standing to challenge the law as they had not alleged personal injury traceable to
the allegedly unlawful conduct.&nbsp; As a result, the U.S. Supreme Court did not rule&nbsp;on the constitutionality of the Affordable
Care Act or any of its provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other legislative changes have been proposed
and adopted since passage of the Affordable Care Act. The Budget Control Act of 2011, among other things, created the Joint Select Committee
on Deficit Reduction to recommend proposals in spending reductions to Congress. The Joint Select Committee did not achieve its targeted
deficit reduction of an amount greater than $1.2 trillion for the fiscal years 2012 through 2021, triggering the legislation&#8217;s
automatic reductions to several government programs. These reductions included aggregate reductions to Medicare payments to healthcare
providers of up to 2.0% per fiscal year. The Bipartisan Budget Act of 2018 retained the federal budget &#8220;sequestration&#8221; Medicare
payment reductions of 2%, and extended it through 2027 unless congressional action is taken, and also increased labeler responsibility
for prescription costs in the Medicare Part&nbsp;D coverage gap. On January&nbsp;2, 2013, the American Taxpayer Relief Act was signed
into law, which, among other things, reduced Medicare payments to several types of providers, including hospitals, imaging centers and
cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from
three to five years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further legislative and regulatory changes under
the Affordable Care Act remain possible, although the Biden Administration has signaled that it plans to build on the Affordable Care
Act and expand the number of people who are eligible for subsidies under it. President Biden indicated that he intends to use executive
orders to undo changes to the Affordable Care Act made by the Trump administration and would advocate for legislation to build on the
Affordable Care Act. It is unknown what form any such changes or any law would take, and how or whether it may affect our business in
the future. We expect that changes or additions to the Affordable Care Act, the Medicare and Medicaid programs, allowing the federal
government to directly negotiate drug prices and changes stemming from other healthcare reform measures, especially with regard to healthcare
access, financing or other legislation in individual states, could have a material adverse effect on the healthcare industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect that additional federal, state and
foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments
will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products,
if approved, or additional pricing pressures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulation Outside of the U.S.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to regulations in the U.S., we may
be subject to a variety of regulations in foreign jurisdictions that govern, among other things, clinical trials and any commercial sales
and distribution of our products, if approved, either directly or through our distribution partners. Whether or not we obtain FDA approval
for a product candidate, we must obtain the requisite approvals from regulatory authorities in foreign jurisdictions prior to the commencement
of clinical trials or marketing and sale of the product in those countries. The foreign regulatory approval process and the time required
to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Some
foreign jurisdictions have a drug product approval process similar to that in the U.S., which requires the submission of a clinical trial
application much like the IND prior to the commencement of clinical studies. Regulatory approval in one country or jurisdiction does
not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may
negatively impact the regulatory process in others. Moreover, some nations may not accept clinical studies performed for U.S. approval
to support approval in their countries or require that additional studies be performed on natives of their countries. In addition, in
certain foreign markets, the pricing of drug products is subject to government control and reimbursement may in some cases be unavailable
or insufficient. We face the risk that the resulting prices would be insufficient to generate an acceptable return to us or any future
partner of ours. If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines,
suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Commercial Marketing Plans and Strategies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ProMIS does not intend to market its therapeutic
products and companion diagnostics it develops that require extensive distribution channels. Instead, ProMIS intends to license to, or
enter into strategic alliances with, larger pharmaceutical entities that are equipped to manufacture and/or market ProMIS&#8217; products
through their distribution networks. ProMIS may license some or all of its patent rights to more than one company to achieve the fullest
development, marketing and distribution of its products. To this end ProMIS intends to continue to develop and improve its proprietary
technologies and to expand the applications of its technologies in the healthcare markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Generate Product Revenues</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues, if any, from its precision therapeutics
pipeline and companion diagnostics are expected to be generated from research funding, license fees, milestone payments, co-development
funding, and royalties from partnerships to be completed by ProMIS with selected third-party, multi-national health care firms. As of
the date of this form, ProMIS has not generated any significant product revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Develop Collaborative Customer-Funded Commercialization
Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to increase market exposure of its products
and to capitalize on a partner&#8217;s clinical development competencies, market position, and distribution capabilities, ProMIS intends
to develop its projects with collaborative commercial partners who will fund further product development projects incorporating ProMIS&#8217;
technology. These collaborative arrangements typically will provide for a jointly funded development project and contemplate a licensing
arrangement (which may be entered into at the same time as the development project or at a later date) under which, if a project is commercialized
by the collaborative partner, ProMIS would potentially receive license fees, royalty payments from product sales and manufacturing revenue.
ProMIS believes that such arrangements with major commercial partners will serve to validate its proprietary technologies in human healthcare
areas and thereby assist ProMIS in attracting additional licensing arrangements on favorable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Enhance Out-licensing of ProMIS Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Where practical, ProMIS will outsource its product
manufacturing and has explored and will continue to evaluate the possibility of entering into strategic manufacturing alliances with
appropriate third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Human Healthcare Products Competition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ProMIS will compete with many large and small
pharmaceutical companies that are developing and/or marketing therapeutic compounds for AD, ALS and/or PD. Many large pharmaceutical
companies and smaller biotechnology companies maintain well-funded research departments concentrating on therapeutic approaches to neurodegenerative
diseases. ProMIS expects substantial competition from these companies as they develop different and/or novel approaches to the treatment
of these diseases. Some of these approaches may directly compete with the technology that ProMIS is currently developing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If approved, PMN310 will compete with therapies
currently approved for the treatment of patients with AD, which have primarily been developed to treat the symptoms of AD rather than
the underlying cause of the disease, such as memantine and cholinesterase inhibitors. PMN310 may also compete with one or more potentially
disease-modifying therapeutics that target A&beta; or amyloid plaques. Biogen&rsquo;s aducanumab was approved by the FDA in June&nbsp;2021
under the accelerated approval pathway, which allows for earlier approval of drugs that treat serious conditions, and that fill an unmet
medical need based on a surrogate endpoint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Eisai has disclosed that the pivotal trial program
for Lecanemab will conclude in September of 2022. If successful, it may be the next approved anti-amyloid therapy. In many therapeutic
categories, after initial approvals validate a general mechanistic approach, competitive dynamics are driven by relative safety, efficacy,
convenience, and cost effectiveness. We expect this will be the case in the anti-amyloid immunotherapy category</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other companies known to be developing therapies
with A&beta;/amyloid plaque-related targets include Alzheon,&nbsp;Inc., Alzinova AB, Chugai Pharmaceutical Co. Ltd., Cognition Therapeutics,&nbsp;Inc.,
Eisai Co.,&nbsp;Ltd., Eli Lilly and Company, Grifols, S.A., KalGene Pharmaceuticals,&nbsp;Inc., Neurimmune AG, Novartis AG, Acumen Pharmaceuticals
Inc., Prothena Biosciences,&nbsp;Inc., Roche Holding AG (including Genentech, its wholly owned subsidiary) and Wren Therapeutics,&nbsp;Inc.
Additionally, PMN310, if approved, may also compete with other potential therapies intended to address underlying causes of AD that are
being developed by several companies, including AbbVie Inc., AC Immune SA, Alector,&nbsp;Inc., Anavex Life Sciences Corp., Annovis Bio,&nbsp;Inc.,
Athira Pharma,&nbsp;Inc., Biohaven Pharmaceuticals,&nbsp;Inc., Cassava Sciences,&nbsp;Inc., Cortexyme,&nbsp;Inc., Denali Therapeutics,&nbsp;Inc.,
Johnson&nbsp;&amp; Johnson (including Janssen, its wholly-owned subsidiary) and Takeda Pharmaceutical Co. Ltd. Some of these competitors
are developing therapies that either seek to block the aggregation of amyloid oligomers (for example, Alzheon, Inc.), or mitigate the
toxicity of amyloid oligomers (for example, Cognition Therapeutics, Inc.). These and other therapies may end up being used as complementary
therapies in clinical practice, in addition to antibodies targeting aggregated amyloid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the intense competitive environment that is
the human pharmaceutical industry, those companies that complete clinical trials, obtain regulatory approval and commercialize their
therapeutic products first may enjoy competitive advantages. ProMIS believes that it will develop compounds with characteristics that
may enable them, if fully developed, to have a market impact. A number of major human pharmaceutical companies have significant programs
to develop drugs for the treatment of neurodegenerative disease. These companies include Eisai/Pfizer, Novartis, Merck, Genentech, Lilly,
Biogen, Amgen and Johnson&nbsp;&amp; Johnson.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Proprietary Protection</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ProMIS has acquired the rights to certain proprietary
discovery platforms for the identification of proteins involved in misfolding diseases embodied in various national and international
patent applications. ProMIS has also filed international patent applications related to immunotherapy targeting toxic forms of SOD1 and
TDP-43 for ALS, toxic oligomers of A&#946; for AD and toxic aggregates for a-syn for PD to further protect its intellectual property
rights related to its therapeutic programs. In addition, the Company has obtained proprietary rights to two computational algorithms
(ProMIS<SUP>TM</SUP> and Collective Coordinates) for identification of DSEs in protein misfolding diseases as well as predicted DSEs
against multiple disease targets. ProMIS intends to aggressively protect the commercial applications for diagnostic, therapeutic and
prophylactic applications of these discoveries. In addition, ProMIS has developed know-how, which it may elect to keep as trade secrets
and not publicly disclose in patent applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employees<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP></SUP></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ProMIS seeks to hire qualified scientists
and key employees as needed. As of June 30, 2022, the Company had seven total employees, consisting of six full-time employees and one
part-time employee. The remainder of the scientists and key personnel had consulting agreements with ProMIS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="d_001"></A>ITEM
1A. RISK FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following specific factors could materially adversely affect the Company and should be considered when deciding whether to make an investment
in the Company. The risks and uncertainties described in this </FONT>Registration Statement and the information incorporated by reference
herein are those we currently believe to be material, but they are not the only ones we face. Additionally, investors should not interpret
the disclosure of a risk to imply that the risk has not already materialized. If any of the following risks, or any other risks and uncertainties
that we have not identified or that we currently consider not to be material, actually occur or become material risks, our business,
prospects, financial condition, results of operations and cash flows, and consequently the price of the Common Shares could be materially
and adversely affected. In all these cases, the trading price of our securities could decline, and prospective investors could lose all
or part of their investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investors should carefully consider the risk
factors set out below and consider all other information contained herein and in the Company&#8217;s other public filings before making
an investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to the COVID-19 Pandemic</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our business and operations have and may
be further adversely affected by the evolving and ongoing COVID-19 global pandemic.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business and operations have and may be further
adversely affected by the effects of the recent and evolving COVID-19 virus, and the efforts to mitigate it, which was declared a global
pandemic by the World Health Organization in March&nbsp;2020. The COVID-19 pandemic has resulted in travel and other restrictions in
order to reduce the spread of the disease, including public health directives and orders in the U.S. and the European Union that, among
other things and for various periods of time, directed individuals to shelter at their places of residence, directed businesses and governmental
agencies to cease non-essential operations at physical locations, prohibited certain non-essential gatherings and events and ordered
cessation of non-essential travel. For example, in April 2020, the COVID-19 pandemic caused us to close one of our labs for several months
in order to comply with local and federal mandates aimed at preventing the further spread of the virus. Future remote work policies and
similar government orders or other restrictions on the conduct of business operations related to the COVID-19 pandemic may negatively
impact productivity and may disrupt our ongoing research and development activities and our clinical programs and timelines, the magnitude
of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business
in the ordinary course. Further, such orders also may impact the availability or cost of materials, which would disrupt our supply chain
and manufacturing efforts and could affect our ability to conduct ongoing and planned clinical trials and preparatory activities. We
have also experienced preclinical supply chain disruptions, including increased prices and reduced availability of manufacturing materials
and supplies related to our IND-enabling work as well as for non-human primates for our nonclinical studies, as a result of the COVID-19
pandemic. Additionally, business interruptions to external parties, such as academic institutions or potential pharmaceutical collaborators,
caused by the COVID-19 pandemic may impact our ability to progress or effectively partner our programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The spread of COVID-19, which has caused a broad
impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, COVID-19
may be difficult to assess or predict, the continued widespread pandemic could result in significant disruption of global financial markets,
reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market
correction resulting from the spread of COVID-19 could materially affect our business and the value of our Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The global COVID-19 pandemic continues to rapidly
evolve. The extent to which the COVID-19 pandemic impacts our business and operations, including our clinical development and regulatory
efforts, will depend on future developments that are highly uncertain and cannot be predicted with confidence as of the filing of this
Registration Statement, such as the ultimate geographic spread of the disease, the duration of the outbreak, the duration and effect
of business disruptions and the short-term effects and ultimate effectiveness of travel restrictions, quarantines, social distancing
requirements and business closures in the U.S. and other countries to contain and treat the disease. Accordingly, we do not yet know
the full extent of potential delays or impacts on our business, our clinical and regulatory activities, healthcare systems or the global
economy as a whole. However, these impacts could adversely affect our business, financial condition, results of operations and growth
prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, to the extent the ongoing COVID-19
pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other risks
and uncertainties described in this &#8220;<I>Risk Factors</I>&#8221; section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The ongoing COVID-19 pandemic may negatively
impact the availability of scientific staff, physicians and other healthcare professionals, which may negatively impact our business,
financial condition and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on the availability of scientific staff,
physicians and other healthcare professionals to provide testing services. If scientific staff, physicians and other healthcare professionals
were unable or unwilling to provide these services in the future due to any reason including infection due to COVID-19, this would cause
interruptions in our business until mitigated accordingly. As such, vacancies and disabilities relating to our current staff may cause
interruptions in our business and result in lower revenues.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we expand our operations, we may encounter
difficulty in securing the necessary professional scientific, medical and skilled support staff to support our expanding operations,
which may adversely affect our business, financial condition and results of operations. Additionally, we follow posted health guidelines,
as and when posted, to protect the health of our employees and decrease the potential impact of serious illness, including COVID- 19,
on our operations. However, should an employee of, or visitor to, our offices or research and development facilities become infected
with COVID-19, it could place our workforce at risk, which could result in the disruption or suspension of operations at our facilities.
Such a suspension in operations could also be mandated by governmental authorities in response to the COVID-19 pandemic. This would negatively
impact our operations which could adversely impact our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="fulla_029"></A><B>Risks Related to the
Development of Our Product Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our product candidates are still in the
early stages of development and there is significant uncertainty that any such products will actually be developed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our product candidates are at an early stage
of development. Significant additional investment in research and development, product validation, technology transfer to manufacturing,
production scale-up, manufacturing, clinical testing, and regulatory submissions of such product candidates is required prior to commercialization.
There can be no assurance that any such product candidates will actually be developed and, if developed, will be approved. The development
and regulatory processes may require access to rare biofluid and tissue samples from people and animals which may not be available to
us in sufficient amounts or in a timely fashion to allow us to complete the development or receive regulatory approval of any product
candidate or process. A commitment of substantial time and resources is required to conduct research and clinical trials if we are to
complete the development of any product candidate. It is not known whether any of these product or process candidates will meet applicable
health regulatory standards and obtain required regulatory approvals, or whether such products, if approved, can be produced in commercial
quantities at reasonable costs and be successfully marketed, or if our investment in any such products will be recovered through sales
or royalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect to incur substantial capital expenditures
in connection with the development of our product candidates. If we fail to successfully develop and sell all or any of our product candidates,
then we will not earn any return on our investment in these future products, which will adversely affect our results of operations and
could adversely affect the market price of the Common Shares. Our success in developing and selling new products will depend upon multiple
factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 95%">our
                                            ability to develop safe and effective products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 95%">our
                                            serology assays and vaccines achieving the desired sensitivity for antibody-based immunity
                                            and immune response, as applicable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 95%">acceptance
                                            of the product by the medical community and by patients and third-party payors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 95%">inherent
                                            development risks, such as the product proving to be unsafe or unreliable, or not having
                                            the anticipated effectiveness; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 95%">our
                                            ability to develop repeatable processes to manufacture new products in sufficient quantities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of these factors cannot be overcome, we
may not be able to develop and introduce our products in a timely or cost-effective manner, which could adversely affect our future growth
and results of operations. Our failure to develop and obtain approval of our product candidates could adversely affect the market price
of the Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have concentrated a portion of our research
and development efforts on the treatment of AD, a field that has seen very limited success in drug development.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have focused our research and development
efforts on developing effective treatments for AD. Collectively, efforts by pharmaceutical companies in the field of AD have seen very
limited successes in drug development. There are few approved products available for patients with AD. Only one disease-modifying therapeutic
option has been approved by the FDA. Biogen&#8217;s Aduhelm (aducanumab), a mAb administered via infusion, received accelerated approval
from the FDA on June&nbsp;7, 2021. We cannot be certain that our approach will lead to the development of approvable or marketable products.
With the exception of Aduhelm, the only drugs approved by the FDA to treat patients with AD address the symptoms of the disease. Since
2003, over 500 clinical studies have been completed and only Aduhelm has been approved by the FDA, compared to a success rate of 50%
to 80% for all other drug candidates. As a result, the FDA has a limited set of products to rely on in evaluating PMN310. This could
result in a longer than expected regulatory review process, increased expected development costs or the delay or prevention of commercialization
of PMN310 for the treatment of AD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our business is heavily dependent on the
successful development, regulatory approval and commercialization of PMN310 and any future product candidates that we may develop or
acquire, including PMN442 and PMN267.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently have no products approved for sale,
and our lead product candidate is in early stages of development. The success of our business, including our ability to finance our company
and generate revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of
our product candidates and, in particular, the advancement of PMN310. However, given our stage of development, it may be many&nbsp;years,
if we succeed at all, before we have demonstrated the safety and efficacy of a product candidate sufficient to warrant approval for commercialization.
We cannot be certain that our product candidates will receive regulatory approval or be successfully commercialized even if we receive
regulatory approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The clinical and commercial success of PMN310
and any future product candidates that we may develop or acquire will depend on a number of factors, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                            ability to raise any additional required capital on acceptable terms, or at all;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                            ability to complete an IND enabling studies and successfully submit INDs or comparable applications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">timely
                                            completion of our preclinical studies and clinical trials, which may be significantly slower
                                            or cost more than we currently anticipate and will depend substantially upon the performance
                                            of third-party contractors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">delays
                                            or difficulties in enrolling and retaining patients in our clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">whether
                                            we are required by the FDA or similar foreign regulatory agencies to conduct additional clinical
                                            trials or other studies beyond those planned to support the approval and commercialization
                                            of our product candidates or any future product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">acceptance
                                            of our proposed indications and primary endpoint assessments relating to the proposed indications
                                            of our product candidates by the FDA and similar foreign regulatory authorities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                            ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities
                                            the safety, efficacy and acceptable risk to benefit profile of our product candidates or
                                            any future product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            prevalence, duration and severity of potential side effects or other safety issues experienced
                                            with our product candidates or future approved products, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">achieving
                                            and maintaining, and, where applicable, ensuring that our third-party contractors achieve
                                            and maintain, compliance with our contractual obligations and with all regulatory requirements
                                            applicable to our product candidates or any future product candidates or approved products,
                                            if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            ability of third parties with whom we contract to manufacture adequate clinical trial and
                                            commercial supplies of our product candidates or any future product candidates remain in
                                            good standing with regulatory agencies and develop, validate and maintain commercially viable
                                            manufacturing processes that are compliant with cGMPs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            convenience of our treatment or dosing regimen;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory
                                            authorities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">acceptance
                                            by physicians, payors and patients of the benefits, safety and efficacy of our product candidates
                                            or any future product candidates, if approved, including relative to alternative and competing
                                            treatments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            willingness of physicians, operators of clinics and patients to utilize or adopt any of our
                                            product candidates or any future product candidates, if approved;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                            ability to achieve sufficient market acceptance, coverage and adequate reimbursement from
                                            third-party payors and adequate market share and revenue for any approved products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            COVID-19 pandemic, which may result in clinical site closures, delays to patient enrollment,
                                            patients discontinuing their treatment or follow up visits or changes to trial protocols;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                            ability to successfully develop a commercial strategy and thereafter commercialize our product
                                            candidates or any future product candidates in the U.S. and internationally, if approved
                                            for</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">marketing,
                                            reimbursement, sale and distribution in such countries and territories, whether alone or
                                            in collaboration with others;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">patient
                                            demand for our product candidates, if approved, including patients&#8217; willingness to
                                            pay out-of-pocket for any approved products in the absence of coverage and/or adequate reimbursement
                                            from third-party payors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                            ability to establish and enforce intellectual property rights in and to our product candidates
                                            or any future product candidates; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                            ability to avoid third-party patent interference, intellectual property challenges or intellectual
                                            property infringement claims.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the FDA or other regulatory agencies
may not agree with our clinical development plan and require that we conduct additional clinical trials to support our regulatory submissions.
We have not yet conducted an end of Phase&nbsp;2 meeting with the FDA to discuss the registration pathway for PMN310, and our current
clinical development plans for PMN310 in AD may change as a result of future interactions with the FDA. For example, the FDA may not
accept the results of the ongoing PMN310 clinical trials and may require that we conduct additional trials, including more than one pivotal
trial, in order to gain approval in AD. Furthermore, any approval of PMN310 for AD may be limited to PMN310 in combination with the existing
standard of care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These factors, many of which are beyond our control,
could cause us to experience significant delays or an inability to obtain regulatory approvals or commercialize our product candidates.
Even if regulatory approvals are obtained, we may never be able to successfully commercialize any of our product candidates. Accordingly,
we cannot provide assurances that we will be able to generate sufficient revenue through the sale of our product candidates or any future
product candidates to continue our business or achieve profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our approach to the potential treatment
of AD is based on a novel therapeutic approach, which exposes us to unforeseen risks.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no current scientific or general consensus
on the causation of AD or method of action to treat AD. We have discovered and are developing PMN310, a humanized antibody that selectively
targets A&#946;O, or A&#946;Os, to treat AD. Our approach is based on research on A&#946;Os, globular assemblies of the A&#946; peptide
that are distinct from other forms of amyloid. A&#946;Os have gained scientific acceptance as primary toxins involved in the initiation
and propagation of AD pathology. Based on the results of our nonclinical studies to date, we believe PMN310 is different from current
and prior clinical-stage anti-amyloid drugs and product candidates based on its selectivity for A&#946;Os. We believe that this is a
novel mechanism which has the potential to provide more favorable outcomes, as compared to approved therapies and product candidates
in development and may potentially slow disease progression. However, we may ultimately discover that PMN310 does not possess properties
required for therapeutic effectiveness. We have no evidence regarding the efficacy, safety or tolerability of PMN310 in humans. We may
spend substantial funds attempting to develop PMN310 or other product candidates and never succeed in doing so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The market for any products that we successfully
develop, if any, will also depend on the cost of the product. We do not yet have sufficient information to reliably estimate what it
would cost to commercially manufacture PMN310, if approved, and the actual cost to manufacture PMN310 or any drug we develop in the future
could materially and adversely affect the commercial viability of the drug. We may also find that the manufacture of our product candidates
is more difficult than anticipated, resulting in an inability to produce a sufficient amount of our product candidates for our clinical
trials or, if approved, commercial supply. If we do not successfully develop PMN310 or any other drug we develop with drug product cannot
be reliably and economically manufactured at scale, we will not become profitable, which would materially and adversely affect the value
of our Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not successfully expand our pipeline
of product candidates, including by pursuing additional indications for PMN310 or by in-licensing or acquiring additional product candidates
for other diseases.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A key element of our strategy is to build and
expand our pipeline of product candidates, including by developing PMN310 for the treatment AD, and by identifying other product candidates.
In addition, we may in-license or acquire additional product candidates for other diseases. We may not be able to identify or develop
additional product candidates that are safe, tolerable and effective. Even if we are successful in continuing to build our pipeline,
the potential product candidates that we identify, in-license or acquire may not be suitable for clinical development. For example, our
research methodology may be unsuccessful in identifying potential drug candidates or those we identify may be shown to have harmful side
effects or other characteristics that make them unmarketable or unlikely to receive regulatory approval. We cannot guarantee that we
will be successful in identifying additional potential drug candidates, or that we will be able to successfully identify and in-license
new and valuable product candidates from other parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Nonclinical and clinical drug development
involves a lengthy, expensive and uncertain process. The results of nonclinical studies and early clinical trials are not always predictive
of future results. PMN310 or any other product candidate that we advance into clinical trials may not achieve favorable results in later
clinical trials, if any, or receive marketing approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The research and development of product candidates
is extremely risky. Only a small percentage of product candidates that enter the development process ever receive marketing approval.
Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete nonclinical development
and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing
is expensive and can take many years to complete, and its outcome is inherently uncertain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The results of nonclinical studies and early
clinical trials are not necessarily predictive of future results and PMN310, or any other product candidate that we may develop, may
not be further developed or have favorable results in later studies or trials. Clinical trial failure may result from a multitude of
factors including, but not limited to, flaws in study design, dose selection, placebo effect, patient enrollment criteria and failure
to demonstrate favorable safety or efficacy traits. As such, failure in clinical trials can occur at any stage of testing. A number of
companies in the pharmaceutical industry have suffered setbacks in the advancement of their product candidates into later-stage clinical
trials due to lack of efficacy or adverse safety profiles, notwithstanding results in earlier nonclinical studies or clinical trials.
In addition, the results of clinical trials in one set of patients or disease indications may not be predictive of those obtained in
another. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the
same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size
and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of
dropout among clinical trial participants. A number of companies in the pharmaceutical industry have suffered significant setbacks in
advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials.
This is particularly true in AD, where failure rates historically are higher than in most other disease areas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of negative or inconclusive results,
we may decide, or regulatory authorities may require us, to conduct additional clinical trials or nonclinical studies. In addition, data
obtained from clinical trials and nonclinical studies is susceptible to varying interpretations, and regulatory authorities may not interpret
our data as favorably as we do, which may further delay, limit or prevent development efforts, clinical trials or marketing approval.
Furthermore, as more competing product candidates within a particular class of drugs proceed through clinical development to regulatory
review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are unable to complete nonclinical studies
or clinical trials of PMN310 or future product candidates, due to safety concerns or otherwise, or if the results of these trials are
not sufficient to convince regulatory authorities of their safety or efficacy, we will not be able to obtain marketing approval for commercialization
on a timely basis or at all. Even if we are able to obtain marketing approval for PMN310 or any future product candidates, those approvals
may be for indications or dose levels that deviate from our desired approach or may contain other limitations that would adversely affect
our ability to generate revenue from sales of those product candidates. Moreover, if we are not able to differentiate our product candidate
against other approved product candidates within the same class of drugs, or if any of the other circumstances described above occur,
our business would be harmed and our ability to generate revenue from that class of drugs would be severely impaired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Clinical failure can occur at any stage
of clinical development and we have never completed a clinical trial or submitted NDA, BLA, or marketing authorization application, or
MAA.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are early in our development efforts for PMN310,
and will need to successfully complete our ongoing and planned clinical trials, including pivotal clinical trials, in order to obtain
FDA approval to market PMN310 or any other product candidate we seek to develop. Carrying out clinical trials and the submission of a
successful BLA is a complicated process. Although members of our team have significant experience in clinical development of drugs through
regulatory approval, as an organization, we have just begun conducting our first clinical trial, we have no experience in conducting
any clinical trials, we have limited experience in preparing regulatory submissions and we have not previously submitted a BLA for any
product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we have had limited interactions
with the FDA and cannot be certain how many clinical trials of PMN310 will be required or how such trials should be designed. Consequently,
we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to BLA submission
and approval of PMN310 or any other product candidate. We may require more time and incur greater costs than our competitors and may
not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our
planned clinical trials, could prevent us from or delay us in commercializing PMN310 or any future product candidates we may develop,
and failure to successfully complete any of these activities in a timely manner could have a material adverse impact on our business
and financial performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may incur additional costs or experience
delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may experience numerous unforeseen events
during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our
product candidates, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">regulatory
                                            authorities,&nbsp;Institutional Review Boards, or IRBs, or Ethics Committees, or ECs, may
                                            not authorize us or our investigators to commence a clinical trial or conduct a clinical
                                            trial at a prospective trial site or we may fail to reach a consensus with regulatory authorities
                                            on trial design;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">regulatory
                                            authorities in jurisdictions in which we seek to conduct clinical trials may differ from
                                            each other on our trial design, and it may be difficult or impossible to satisfy all such
                                            authorities with one approach;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">we
                                            may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts
                                            or clinical trial protocols with prospective trial sites, the terms of which can be subject
                                            to extensive negotiation and may vary significantly among different contract research organizations,
                                            or CROs, and trial sites;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">we
                                            may be unable to add or be delayed in adding a sufficient number of clinical trial sites
                                            and obtaining IRB or independent EC approval at each clinical trial site;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">clinical
                                            trials of our product candidates may fail to show safety or efficacy or otherwise produce
                                            negative or inconclusive results, and we may decide, or regulatory authorities may require
                                            us, to conduct additional clinical trials or abandon drug development programs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the
                                            number of patients required for clinical trials of our product candidates may be larger than
                                            we anticipate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">enrollment
                                            in our clinical trials may be slower than we anticipate or participants may drop out of these
                                            clinical trials at a higher rate than we anticipate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>difficulties
                                            in having subjects complete a clinical trial or returning for post-treatment follow-up;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>changes
                                            to clinical trial protocols;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                            third-party contractors, including clinical investigators, contract manufacturers and vendors
                                            may fail to comply with applicable regulatory requirements, lose their licenses or permits,
                                            or otherwise fail, or lose the ability to, meet their contractual obligations to us in a
                                            timely manner, or at all;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">we
                                            might have to suspend or terminate clinical trials of our product candidates for various
                                            reasons, including a finding that the participants are being exposed to unacceptable health
                                            risks;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">regulatory
                                            authorities or IRBs may require that we or our investigators suspend or terminate clinical
                                            research for various reasons, including noncompliance with regulatory requirements, a finding
                                            that our product candidates have undesirable side effects or other unexpected characteristics,
                                            or that the participants are being exposed to unacceptable health risks;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            cost of clinical trials of our product candidates may be greater than we anticipate, and
                                            we may lack adequate funding to continue one or more clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            supply or quality of our product candidates or other materials necessary to conduct clinical
                                            trials of our product candidates may be insufficient or inadequate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>clinical
                                            trial sites may deviate from clinical trial protocol or drop out of a clinical trial; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">occurrence
                                            of serious adverse events in trials of the same class of agents conducted by other companies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Adverse side effects, properties or other
safety risks associated with PMN310, PMN442, PMN267 or any future product candidates could delay or preclude approval, cause us to suspend
or discontinue clinical trials, abandon further development, limit the commercial profile of an approved label or result in significant
negative consequences following marketing approval, if any.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As is the case with pharmaceuticals generally,
it is possible that there may be side effects and adverse events associated with the use of PMN310, PMN442, PMN267 or any future product
candidates we may develop. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects
or unexpected characteristics as the clinical trials progress to greater exposures and a larger number of patients. Undesirable side
effects caused by, or unexpected or unacceptable characteristics associated with, PMN310, PMN442, PMN267 or any future product candidates
we may develop, could result in the delay, suspension or termination of clinical trials by us, the FDA or other regulatory authorities,
or IRBs for a number of reasons. We may also elect to limit their development to more narrow uses or subpopulations in which the undesirable
side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit
the commercial expectations for such product candidate if approved. If we elect or are required to further delay, suspend or terminate
any clinical trial of any product candidates we may develop, the commercial prospects of such product candidates will be harmed and our
ability to generate drug revenues from any such product candidates will be delayed or eliminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is possible that, as we test our product candidates
in clinical trials, or as the use of a product candidate becomes more widespread if it receives regulatory approval, we may identify
additional adverse events that were not identified or not considered significant in our earlier trials. If such side effects become later
known in development or upon approval, if any, such findings may harm our business, financial condition, results of operations and prospects
significantly. If we or others later identify undesirable side effects, a number of potentially significant negative consequences could
result, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>regulatory
                                            authorities may withdraw, suspend or limit approval of a product candidate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>we
                                            may be required to recall a drug or change the way such drug is administered to patients;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">regulatory
                                            authorities may require additional warnings or statements in the labeling, such as a boxed
                                            warning or a contraindication or issue safety alerts, press releases or other communications
                                            containing warnings or other safety information about the product candidate, for example,
                                            field alerts to physicians and pharmacies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">regulatory
                                            authorities may require us to implement a REMS to ensure that the benefits of the drug outweigh
                                            its risks, which could include medication guides, physician communication plans, or elements
                                            to assure safe use, such as restricted distribution methods, patient registries and other
                                            risk minimization tools;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">we
                                            may be required to change the way a drug is distributed or administered, conduct additional
                                            clinical trials or be required to conduct additional post-marketing studies or surveillance;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>we
                                            may be subject to regulatory investigations and government enforcement actions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>we
                                            may decide to remove such product candidates from the market;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>we
                                            could be sued and held liable for harm caused to patients;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>sales
                                            of the drug may decrease significantly or become less competitive; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>our
                                            reputation may suffer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any of these events could prevent us from achieving
or maintaining market acceptance of a product candidate, if approved, and could significantly harm our business, financial condition,
results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may experience delays or difficulties
in the enrollment and retention of patients in clinical trials, which could delay or prevent our receipt of necessary regulatory approvals.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Successful and timely completion of clinical
trials will require that we enroll a sufficient number of patients. Patient enrollment, a significant factor in the timing of clinical
trials, is affected by many factors, including the size and nature of the patient population and competition for patients eligible for
our clinical trials with competitors which may have ongoing clinical trials for product candidates that are under development to treat
the same indications as one or more of our product candidates or approved products for the conditions for which we are developing our
product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trials may be subject to delays as a result of
patient enrollment taking longer than anticipated or patient withdrawal. We may not be able to initiate or continue clinical trials for
our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials
as required by the FDA, EMA or foreign regulatory authorities. We cannot predict how successful we will be at enrolling subjects in future
clinical trials. Subject enrollment is affected by other factors including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the
                                            severity and difficulty of diagnosing the disease under investigation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the
                                            eligibility and exclusion criteria for the trial in question;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the
                                            size of the patient population and process for identifying patients;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>our
                                            ability to recruit clinical trial investigators with the appropriate competencies and experience;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the
                                            design of the trial protocol;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the
                                            perceived risks and benefits of the product candidate in the trial, including relating to
                                            cell therapy approaches;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            availability of competing commercially available therapies and other competing therapeutic
                                            candidates&#8217; clinical trials for the disease or condition under investigation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the
                                            willingness of patients to be enrolled in our clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the
                                            efforts to facilitate timely enrollment in clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">potential
                                            disruptions caused by the COVID-19 pandemic, including difficulties in initiating clinical
                                            sites, enrolling and retaining participants, diversion of healthcare resources away from
                                            clinical trials, travel or quarantine policies that may be implemented, and other factors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the
                                            patient referral practices of physicians;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the
                                            ability to monitor patients adequately during and after treatment; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the
                                            proximity and availability of clinical trial sites for prospective patients.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our inability to enroll a sufficient number of
patients for clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether.
Enrollment delays in these clinical trials may result in increased development costs for our product candidates, which would cause the
value of our company to decline and limit our ability to obtain additional financing. Furthermore, we expect to rely on CROs and clinical
trial sites to ensure the proper and timely conduct of our clinical trials and we will have limited influence over their performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, even if we are able to enroll a
sufficient number of patients for our clinical trials, we may have difficulty maintaining enrollment of such patients in our clinical
trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Interim, &#8220;top-line&#8221; and preliminary
results from our clinical trials that we announce or publish from time to time may change as more data become available and is subject
to audit and verification procedures that could result in material changes in the final data.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, we may publish interim, top-line
or preliminary results from our clinical trials. Interim results from clinical trials that we may complete are subject to the risk that
one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary
or top-line results also remain subject to audit and verification procedures that may result in the final data being materially different
from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the
final data are reported. Differences between preliminary, top-line or interim data and final data could significantly harm our business
prospects and may cause the trading price of our Common Shares to fluctuate significantly. We also make assumptions, estimations, calculations
and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate
all data. As a result, the top-line results that we report may differ from future results of the same studies, or different conclusions
or considerations may qualify such results, once additional data have been received and fully evaluated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, others, including regulatory agencies
may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance
of data differently, which could impact the value of the particular development program, the approvability or commercialization of the
particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding
a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we
determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose
may ultimately be deemed meaningful by you or others with respect to future decisions, conclusions, views, activities or otherwise regarding
a particular product candidate or our business. If the interim, top-line or preliminary data that we report differ from actual results,
or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize,
product candidates may be harmed, which could significantly harm our business prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We cannot be certain that PMN310, PMN442,
PMN267 or any of our future product candidates will receive regulatory approval, and without regulatory approval we will not be able
to market our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently have no product candidates approved
for sale and we cannot guarantee that we will ever have marketable product candidates. Our ability to generate revenue related to sales
of PMN310, PMN442, and PMN267, if ever, will depend on the successful development and regulatory approval of such product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The development of a product candidate and its
approval and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval,
advertising, promotion, sale, distribution, import and export are subject to extensive regulation by the FDA, the EMA and regulatory
authorities in other countries, with regulations differing from country to country. We are not permitted to market our product candidates
in the U.S., Europe or other countries until we receive approval of a BLA from the FDA or MAA from the EMA, respectively. We have not
submitted any marketing applications for any product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BLAs and MAAs, and other foreign equivalents
must include extensive nonclinical and clinical data and supporting information to establish the product candidate&#8217;s safety and
effectiveness for each desired indication. BLAs and MAAs must also include significant information regarding the chemistry, manufacturing
and controls for the drug. Obtaining approval of a BLA or a MAA is a lengthy, expensive and uncertain process, and we may not be successful
in obtaining approval. The FDA and the EMA review processes can take years to complete and approval is never guaranteed. If we submit
a BLA to the FDA, the FDA must decide whether to accept or reject the submission for filing. We cannot be certain that any submissions
will be accepted for filing and review by the FDA. Regulators of other jurisdictions, such as the EMA, have their own procedures for
approval of product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if a drug is approved, the FDA or the EMA,
or other foreign equivalent, as the case may be, may limit the indications for which the drug may be marketed, require extensive warnings
on the drug labeling or require expensive and time-consuming clinical trials or reporting as conditions of approval. Regulatory authorities
in countries outside of the U.S. and Europe also have requirements for approval of product candidates with which we must comply prior
with marketing in those countries. Obtaining regulatory approval for marketing of a product candidate in one country does not ensure
that we will be able to obtain regulatory approval in any other country. In addition, delays in approvals or rejections of marketing
applications in the U.S., Europe or other countries may be based upon many factors, including regulatory requests for additional analyses,
reports, data, nonclinical studies and clinical trials, regulatory questions regarding different interpretations of data and results,
changes in regulatory policy during the period of drug development and the emergence of new information regarding PMN310, PMN442, PMN267
or other product candidates we may develop in the future. Also, regulatory approval for any of our product candidates may be withdrawn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before we submit a BLA to the FDA or a MAA to
the EMA for a product candidate, we will be required to successfully complete our clinical trials. The FDA generally requires two pivotal
clinical trials to support approval. In addition, we must scale up manufacturing and complete other standard nonclinical and clinical
studies. We cannot predict whether clinical trials will be successful or whether regulators will agree with our conclusions regarding
the nonclinical studies and the clinical trials we conduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our lead product candidate, PMN310, is
being developed for the treatment of AD, a disease that has seen limited success in drug development.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Efforts by biopharmaceutical and pharmaceutical
companies in treating AD have seen limited success in drug development. Only one disease-modifying therapeutic option has been approved
by the FDA. Biogen&rsquo;s Aduhelm, a mAb administered via infusion, received accelerated approval from the FDA on June 7, 2021. We cannot
be certain that our oral, small-molecule approach will lead to the development of approvable or marketable products. With the exception
of Aduhelm, the only drugs approved by the FDA to treat patients with AD address the symptoms of the disease. Since 2003, over 500 clinical
studies have been completed and only Aduhelm has been approved by the FDA. As a result, the FDA has a limited set of products to rely
on in evaluating PMN310. This could result in a longer than expected regulatory review process, increased expected development costs
or the delay or prevention of commercialization of PMN310 for the treatment of AD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the significant uncertainty
related to insurance coverage and reimbursement of all newly-approved products, there is greater uncertainty for products approved for
the treatment of AD.&nbsp; For example, the yearly wholesale acquisition out of pocket cost of the maintenance dose of Aduhelm was $28,200.
The CMMS issued a draft determination that proposes to cover the cost of anti-amyloid monoclonal antibodies, including Aduhelm,&nbsp;only
in the context of clinical trials approved by CMMS or by the National Institutes of Health. They include only randomized controlled trials
conducted in hospital-based outpatient settings, and require patient diversity reflecting that of the U.S. population diagnosed with
AD. &nbsp;In April 2022, the CMMS confirmed this determination and announced that it would deny routine payment for Aduhelm and finalized
a strict policy to require patients to enroll in clinical trials for the government to cover the drug. Biogen announced on May 3, 2022
that it was taking steps that effectively ended its marketing of Aduhelm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may in the future conduct clinical trials
for our product candidates outside the U.S., and the FDA, EMA and other foreign regulatory authorities may not accept data from such
trials.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may in the future choose to conduct one or
more of our clinical trials outside the U.S., including in Europe. The acceptance of study data from clinical trials conducted outside
the U.S. or another jurisdiction by the FDA, EMA or applicable foreign regulatory authorities may be subject to certain conditions or
may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval
in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i)&nbsp;the data are applicable
to the U.S. population and U.S. medical practice; and (ii)&nbsp;the trials were performed by clinical investigators of recognized competence
and pursuant to cGCP, regulations. Additionally, the FDA&rsquo;s clinical trial requirements, including sufficient size of patient populations
and statistical powering, must be met. Many foreign regulatory bodies have similar approval requirements. In addition, such foreign trials
would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance
that the FDA, EMA or any other foreign regulatory authority will accept data from trials conducted outside of the U.S. or the applicable
jurisdiction. If the FDA, EMA or any applicable foreign regulatory authority does not accept such data, it would result in the need for
additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product
candidates not receiving approval or clearance for commercialization in the applicable jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be successful in our efforts
to build a pipeline of additional product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may not be able to identify and successfully
develop new product candidates. Even if we are successful in building our product pipeline, the potential product candidates that we
identify may not be suitable for clinical development or, if deemed suitable for clinical development, successful in any clinical trials.
For example, product candidates may be shown to have harmful side effects or other characteristics that indicate that they are unlikely
to be successfully developed, much less receive marketing approval and achieve market acceptance. If we do not successfully develop and
commercialize product candidates, we will not be able to obtain product revenue in future periods, which would result in significant
harm to our financial position and adversely affect our share price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we do not achieve our projected development
goals in the time frames we announce and expect, the commercialization of our products may be delayed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, we may estimate the timing
of the accomplishment of various scientific, clinical, regulatory, manufacturing and other product development goals, which we sometimes
refer to as milestones. These milestones may include the commencement or completion of nonclinical studies and clinical trials and the
submission of regulatory filings, including BLA submissions. From time to time, we may publicly announce the expected timing of some
of these milestones. All of these milestones are, and will be, based on a variety of assumptions. The actual timing of these milestones
can vary significantly compared to our estimates, in some cases for reasons beyond our control. We may experience numerous unforeseen
events during, or as a result of, any future clinical trials that we conduct that could delay or prevent our ability to receive marketing
approval or commercialize our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may develop PMN310, PMN442, PMN267 and
future product candidates for use in combination with other therapies, which could expose us to additional regulatory risks.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may develop PMN310, PMN442, PMN267 and future
product candidates for use in combination with one or more other approved therapies for the disease state being studied. Even if any
product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies,
we would continue to be subject to the risk that the FDA, EMA or comparable foreign regulatory authorities could revoke approval of the
therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these
existing therapies. This could result in our own products being removed from the market or being less successful commercially.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, we will not be able to market and sell
any product candidate we develop in combination with an unapproved therapy for a combination indication if that unapproved therapy does
not ultimately obtain marketing approval either alone or in combination with our product. In addition, unapproved therapies face the
same risks described with respect to our product candidates currently in development, including the potential for serious adverse effects,
delay in their clinical trials and lack of FDA approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Changes in methods of product candidate
manufacturing or formulation may result in additional costs or delay.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As product candidates proceed through nonclinical
studies to late-stage clinical trials towards potential approval and commercialization, it is common that various aspects of the development
program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and product characteristics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Such changes carry the risk that they will not
achieve our intended objectives. Any such changes could cause our product candidates to perform differently and affect the results of
planned clinical trials or other future clinical trials conducted with the materials manufactured using altered processes. Such changes
may also require additional testing, FDA notification approval. This could delay completion of clinical trials, require the conduct of
bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product
candidates and jeopardize our ability to commence sales and generate revenue. In addition, we may be required to make significant changes
to our upstream and downstream processes across our pipeline, which could delay the development of our future product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to the Commercialization of
Our Product Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Successful commercialization of our products,
if approved, will depend on a number of factors and we cannot guarantee that we will be able to successfully commercialize our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Successful commercialization of our products,
if at all, will depend on a number of factors, including our ability to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">raise
                                            sufficient capital to fund future commercialization efforts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">build
                                            a commercial team and supporting organizational infrastructure;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">obtain
                                            necessary licenses, on commercially reasonable terms, for certain offerings the Company may
                                            contemplate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">establish
                                            partnerships and alliances with third parties to secure commercial capabilities that we may
                                            not wish to build;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">market
                                            and distribute our products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">distinguish
                                            our products from others available on the market;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">obtain
                                            any necessary regulatory approvals for our facilities, products and processes;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">gain
                                            reimbursement by third-party payors, such as private health insurers, managed-health organizations,
                                            and state-sponsored health insurance plans for each jurisdiction in which our products are
                                            offered;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">educate
                                            physicians and change physician behavior to secure clinical adoption of our products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">promote
                                            awareness of our products to increase market penetration; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">publish
                                            in peer-reviewed journals.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no assurance that we will be successful
in these areas. Any failure or delay in such areas could have a material adverse impact on our business, financial condition, results
of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The market opportunities for PMN310, PMN442,
PMN267, and future product candidates, if approved, may be smaller than we anticipate.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect to seek approval for product candidates
for various neurodegenerative diseases and other misfolded protein diseases. Our estimates of market potential have been derived from
a variety of sources, including scientific literature, patient foundations and market research and may prove to be incorrect. Even if
we obtain significant market share for our product candidates after FDA approval, the potential target populations may be too small to
consistently generate revenue, and we may never achieve profitability without obtaining marketing approval for additional indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if our current or future product candidates
obtain regulatory approval, they may fail to achieve the broad degree of adoption and use by physicians, patients, hospitals, healthcare
payors and others in the medical community necessary for commercial success.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if one or more of our product candidates
receive FDA or other regulatory approvals, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare
payors and others in the medical community. Most of our product candidates target mechanisms for which there are limited or no currently
approved products, which may result in slower adoption by physicians, patients and payors. If our product candidates do not achieve an
adequate level of acceptance, we may not generate significant product revenue and we may not become profitable. The degree of market
acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            clinical indications for which the product is approved and patient demand for approved products
                                            that treat those indications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            safety and efficacy of our product as compared to other available therapies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            availability of coverage and adequate reimbursement from governmental healthcare plans or
                                            third party payors for any of our product candidates that may be approved;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">acceptance
                                            by physicians, operators of clinics and patients of the product as a safe and effective treatment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">physician
                                            and patient willingness to adopt a new therapy over other available therapies to treat approved
                                            indications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">overcoming
                                            any biases physicians or patients may have toward particular therapies for the treatment
                                            of approved indications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">proper
                                            training and administration of our product candidates by physicians and medical staff;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">public
                                            misperception regarding the use of our therapies, if approved for commercial sale;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">patient
                                            satisfaction with the results and administration of our product candidates and overall treatment
                                            experience, including, for example, the convenience of any dosing regimen;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            cost of treatment with our product candidates in relation to alternative treatments and reimbursement
                                            levels, if any, and willingness to pay for the product, if approved, on the part of insurance
                                            companies and other third-party payors, physicians and patients;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            revenue and profitability that our products may offer a physician as compared to alternative
                                            therapies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">limitations
                                            or warnings contained in the FDA-approved labeling for our products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">any
                                            FDA requirement to undertake a REMS;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            effectiveness of our sales, marketing and distribution efforts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">adverse
                                            publicity about our products or favorable publicity about competitive products; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">potential
                                            product liability claims.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot assure you that our current or future
product candidates, if approved, will achieve broad market acceptance among physicians, patients, healthcare payors and others in the
medical community. Even if we receive regulatory approval to market any of our product candidates, we cannot assure you that any such
product candidate will be more effective than other commercially available alternatives or successfully commercialized. Any approval
we may obtain could be for indications or patient populations that are not as broad as intended or desired or may require labeling that
includes significant use or distribution restrictions or safety warnings. We may also be required to perform additional or unanticipated
clinical trials to obtain approval or be subject to additional post-marketing testing requirements to maintain approval. In addition,
regulatory authorities may withdraw their approval of a product or impose restrictions on its distribution, such as in the form of a
REMS. Any failure by our product candidates that obtain regulatory approval to achieve market acceptance or commercial success would
adversely affect our reputation, ability to raise additional capital, financial condition, results of operations and business prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our product candidates have never been
manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale. In particular,
we will need to develop a larger scale manufacturing process that is more efficient and cost-effective to commercialize our potential
products, which may not be successful.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our product candidates have never been manufactured
on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale including, among others, cost
overruns, potential problems with process scale-up, process reproducibility, stability issues, lot consistency and timely availability
of raw materials. There is no assurance that our third-party manufacturers will be successful in establishing a larger-scale commercial
manufacturing process for our product candidates which achieves our objectives for manufacturing capacity and cost of goods. In addition,
there is no assurance that any third-party manufacturers will be able to manufacture our product candidates to specifications acceptable
to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch
of such products or to meet potential future demand. Our failure to properly or adequately scale up manufacturing for commercial scale
would adversely affect our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The successful commercialization of our
product candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage,
reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates,
if approved, could limit our ability to market those drugs and decrease our ability to generate revenue.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The availability and adequacy of coverage and
reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors
are essential for most patients to be able to afford prescription medications such as our product candidates, if approved. Our ability
to achieve acceptable levels of coverage and reimbursement for products by governmental authorities, private health insurers and other
organizations will have an effect on our ability to successfully commercialize our product candidates. Even if we obtain coverage for
our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments
that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the U.S., the European Union or elsewhere
will be available for our product candidates or any product that we may develop, and any reimbursement that may become available may
be decreased or eliminated in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Third-party payors increasingly are challenging
prices charged for biopharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement
for particular drugs or biologics when an equivalent generic drug, biosimilar or a less expensive therapy is available. It is possible
that a third-party payor may consider our product candidates as substitutable and only offer to reimburse patients for the cost of the
less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing
of existing third-party therapeutics may limit the amounts we will be able to charge for our product candidates. These payors may deny
or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too
low to enable us to realize an appropriate return on our investment in our product candidates. If reimbursement is not available or is
available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain
a satisfactory financial return on our investment in the development of product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is significant uncertainty related to the
insurance coverage and reimbursement of newly-approved products. In the U.S., third-party payors, and governmental healthcare plans,
such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be
covered. The Medicare and Medicaid programs increasingly are used as models in the U.S. for how private payors and other governmental
payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of
coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. We cannot
predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No uniform policy for coverage and reimbursement
for products exists among third-party payors in the U.S. Therefore, coverage and reimbursement for products can differ significantly
from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us
to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage
and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules&nbsp;and regulations regarding
reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules&nbsp;and regulations are likely.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Outside the U.S., international operations are
generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment
initiatives in Europe and other foreign jurisdictions have and will continue to put pressure on the pricing and usage of our product
candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health
systems. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional
foreign price controls or other changes in pricing regulation could restrict the amounts that we are able to charge for our product candidates.
Accordingly, in markets outside the U.S., the reimbursement for our product candidates may be reduced compared with the U.S. and may
be insufficient to generate commercially-reasonable revenue and profits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moreover, increasing efforts by governmental
and third-party payors in the U.S. and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and
the level of reimbursement for newly approved products, and, as a result, they may not cover or provide adequate payment for our product
candidates. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed
health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on
healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense.
As a result, increasingly high barriers are being erected to the entry of new products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We currently have no sales organization.
If we are unable to establish sales capabilities on our own or through third parties, we may not be able to market and sell our product
candidates effectively in the U.S. and foreign jurisdictions, if approved, or generate product revenue. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently do not have a marketing or sales
organization. &nbsp;In order to commercialize our product candidates in the U.S. and foreign jurisdictions, if approved, we intend to
make arrangements with third parties to perform these services, and we may not be successful in doing so. If we are unable to enter into
such arrangements on acceptable terms or at all, we may not be able to successfully commercialize our product candidates, if approved.
 &nbsp;If we are not successful in commercializing our product candidates or any future product candidates, if approved, either on our
own or through arrangements with third parties, we may not be able to generate any product revenue and we would incur significant additional
losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Financial Position and
Capital Needs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will require additional financing to
achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay,
limit, reduce or terminate our development programs, commercialization efforts or other operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The development of biopharmaceutical therapeutic
candidates is capital-intensive. We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct
our ongoing and planned preclinical studies of our development programs, initiate clinical trials for our therapeutic candidates and
seek regulatory approval for our current therapeutic candidates and any future therapeutic candidates we may develop. If we obtain regulatory
approval for any of our therapeutic candidates, we also expect to incur significant commercialization expenses related to product manufacturing,
marketing, sales and distribution. Because the outcome of any preclinical study or clinical trial is highly uncertain, we cannot reasonably
estimate the actual amounts necessary to successfully complete the development and commercialization of our therapeutic candidates. Furthermore,
following the effectiveness of this Registration Statement, we expect to incur additional costs associated with operating as a public
company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. We had working
capital of $13.0 million as of March 31, 2022. Although we expect available funds will be sufficient to fund our operating expenses for
at least 12 months from the date this Registration Statement is issued, we will require substantial additional funds for further research
and development, planned clinical testing, regulatory approvals, establishment of manufacturing capabilities and, if necessary, the marketing
and sale of our products. Our ability to raise additional financing and maintain operations in the future could be at substantial risk
and there can be no assurance that additional funding or partnerships will be available on acceptable terms that would foster successful
commercialization of our products. Failing to raise capital when needed or on attractive terms could force us to delay, reduce or eliminate
our research and development programs or any future commercialization efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may attempt to raise additional funds for
these purposes through public or private equity or debt financing, collaborations with other biopharmaceutical companies and/or from
other sources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have no product candidates approved
for commercial sale, we have never generated any revenue from sales and we may never be profitable.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have no product candidates approved for
sale, have never generated any revenue from sales, have never been profitable and do not expect to be profitable in the foreseeable future.
To date, we have not recorded any revenues from the sale of biopharmaceutical products. As at March 31, 2022, we had a deficit of $64.3
million. The cumulative deficit incurred from when we changed our name and focus in July&nbsp;2015, through March&nbsp;31, 2021 was $34.3
million. We expect to incur additional losses during the periods of research and development, clinical testing, and application for regulatory
approval of its product candidates. We also expect to incur losses unless and until such time as payments from corporate collaborations,
product sales and/or royalty payments generate sufficient revenues to fund its continuing operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, we have devoted most of our financial
resources to research and development of PMN310, including our nonclinical development activities of PMN310, and corporate overhead.
We expect that it will be several years, if ever, before we have a product candidate approved and ready for commercialization. We expect
to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our development of, and
seek regulatory approvals for, PMN310 and any other product candidate we may develop in the future, prepare for and begin the commercialization
of any approved product candidates and add infrastructure and personnel to support our drug development efforts and operations as a public
company. We anticipate that any such losses could be significant for the next several years. These net losses and negative cash flows
have had, and will continue to have, an adverse effect on our shareholders&#8217; equity and working capital. Further, these net losses
may fluctuate significantly from quarter-to-quarter or year-to-year. To become and remain profitable, we must develop and eventually
commercialize PMN310 or another drug with significant revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may never succeed in developing a commercial
drug and, even if we succeed in commercializing one or more product candidates, we may never generate revenues that are large enough
to achieve profitability. In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown
challenges. Because of these numerous risks and uncertainties, we are unable to accurately predict the timing or amount of increased
expenses or when, or if, we will be able to generate revenues or achieve profitability. If we do achieve profitability, we may not be
able to sustain or increase profitability on a quarterly or annual basis, and we will continue to incur substantial research and development
costs and other expenditures to develop and market additional product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Dependence on Third Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will rely on third parties to supply
components, research, develop, test, and manufacture our product candidates and market, if approved. The loss of any of these third party
relationships or the failure of any of them to meet their obligations to us could affect our ability to develop and obtain approval of
our product candidates in a timely manner.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
</FONT>activities will require us to enter into various arrangements with corporate and academic collaborators, licensors, licensees
and others for the research, development, clinical testing, manufacturing, marketing and commercialization of our products. We intend
to attract corporate partners and enter into additional research collaborations. There can be no assurance, however, that we will be
able to establish such additional collaborations on favorable terms, if at all, or that our current or future collaborations will be
successful. Failure to attract commercial partners for our products may result in substantial clinical testing, manufacturing and commercialization
costs prior to realizing any revenue from product sales or result in delays or program discontinuance if funds are not available in sufficient
quantities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Should any collaborative partner fail to develop,
manufacture, or successfully commercialize any product to which we have rights, or any partner&#8217;s product to which we will have
rights, our business may be adversely affected. Failure of a collaborative partner to continue to participate in any particular program
could delay or halt the development or commercialization of products generated from such program. In addition, there can be no assurance
that the collaborative partners will not pursue other technologies or develop alternative products either alone or in collaboration with
others, including our competitors, as a means for developing treatments for the diseases targeted by our programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, we will hold licenses for certain
technologies and there can be no assurance that these licenses will not be terminated, or that they will be renewed on acceptable conditions.
We intend to negotiate additional licenses in respect of technologies developed by other companies and academic institutions. Terms of
license agreements to be negotiated may include, <I>inter alia</I>, a requirement to make milestone payments, which may be substantial.
We will also be obligated to make royalty payments on the sales, if any, of products resulting from licensed technology and, in some
instances, may be responsible for the costs of filing and prosecuting patent applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We intend to rely on contract research
organizations, or CROs, and other third parties to conduct, supervise and monitor a significant portion of our research and nonclinical
testing and clinical trials for our product candidates, and if those third parties do not successfully carry out their contractual duties,
comply with regulatory requirements or otherwise perform satisfactorily, we may not be able to obtain regulatory approval or commercialize
product candidates, or such approval or commercialization may be delayed, and our business may be substantially harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to engage CROs and other third parties
to conduct our planned nonclinical studies or clinical trials, and to monitor and manage data. We expect to continue to rely on third
parties, including clinical data management organizations, medical institutions and clinical investigators, in the future. Any of these
third parties may terminate their engagements with us, some in the event of an uncured material breach and some at any time for convenience.
If any of our relationships with these third parties terminate, we may not be able to timely enter into arrangements with alternative
third parties or to do so on commercially reasonable terms, if at all. Switching or adding CROs involves substantial cost and requires
management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur,
which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our
relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays
or challenges will not have a material adverse impact on our business, financial condition and prospects. Further, the performance of
our CROs and other third parties conducting our trials may also be interrupted by the ongoing COVID-19 pandemic, including due to travel
or quarantine policies, heightened exposure of a CRO or clinical site or other vendor staff who are healthcare providers to COVID-19
or prioritization of resources toward the pandemic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, any third parties conducting our
clinical trials will not be our employees, and, except for remedies available to us under our agreements with such third parties, we
cannot control whether or not they devote sufficient time and resources to our clinical programs. If these third parties do not successfully
carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy
of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for
other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or
successfully commercialize our product candidates. Consequently, our results of operations and the commercial prospects for our product
candidates would be harmed, our costs could increase substantially and our ability to generate revenue could be delayed significantly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on these parties for execution of our
nonclinical studies and clinical trials and generally do not control their activities. Our reliance on these third parties for research
and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example,
we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational
plan and protocols for the trial. Moreover, the FDA requires us to comply with Good Clinical Practices, or GCPs, which are standards
for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate
and that the rights, integrity and confidentiality of trial participants are protected. If we or any of our CROs or other third parties,
including trial sites, fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable
and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our
marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine
that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product produced
under cGMPs conditions. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the
regulatory approval process, or may result in fines, adverse publicity and civil and criminal sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also are required to register certain ongoing
clinical trials and post the results of certain completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within
specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, principal investigators for our
clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such
services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that
a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation
of the trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility
of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications
by the FDA and may ultimately lead to the denial of marketing approval for PMN310 or any other product candidate we develop.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also expect to rely on other third parties
to store and distribute product supplies for our clinical trials. Any performance failure on the part of our distributors could delay
clinical development or marketing approval of our product candidates or commercialization of our products, producing additional losses
and depriving us of potential revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If any of our third-party manufacturers
encounter difficulties in production of PMN310, PMN442, PMN267 or any future product candidate we develop, or fail to meet rigorously
enforced regulatory standards, our ability to provide supply of our product candidates for clinical trials or, if approved, for commercial
sale could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The processes involved in manufacturing PMN310,
PMN442, PMN267 and any other product candidate we may develop are highly-regulated and subject to multiple risks. As product candidates
are developed through nonclinical studies to late-stage clinical trials towards approval and commercialization, it is common that various
aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize processes and results.
Such changes carry the risk that they will not achieve these intended objectives, and any of these changes could cause our product candidates
to perform differently and affect the results of planned clinical trials or other future clinical trials. When changes are made to the
manufacturing process, we may be required to provide preclinical and clinical data showing the comparable identity, strength, quality,
purity or potency of the products before and after such changes. If microbial, viral or other contaminations are discovered at the facilities
of our third-party manufacturers, such facilities may need to be closed for an extended period of time to investigate and remedy the
contamination, which could delay clinical trials and adversely harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to conduct clinical trials of our product
candidates, or supply commercial product candidates, if approved, we will need to manufacture them in both small and large quantities.
We currently rely on third parties to manufacture our product candidates, and our manufacturing partners will have to modify and scale-up
the manufacturing process when we transition to commercialization of our product candidates, if approved. Our manufacturing partners
may be unable to successfully modify or scale-up the manufacturing capacity for any of our product candidates in a timely or cost-effective
manner, or at all. In addition, quality issues may arise during scale-up activities. If our manufacturing partners are unable to successfully
scale-up the manufacture of our product candidates in sufficient quality and quantity, the development, testing and clinical trials of
that product candidate may be delayed or become infeasible, and regulatory approval or commercial launch of any resulting product may
be delayed or not obtained, which could significantly harm our business. In addition, building internal manufacturing capacity would
carry significant risks in terms of being able to plan, design and execute on a complex project to build manufacturing facilities in
a timely and cost-efficient manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the manufacturing process for any
product candidates that we may develop will be subject to FDA, EMA and foreign regulatory requirements, and continuous oversight, and
we will need to contract with manufacturers who can meet all applicable FDA, EMA and foreign regulatory authority requirements, including
complying with cGMPs on an ongoing basis. If we or our third-party manufacturers are unable to reliably produce product candidates in
accordance with the requirements of the FDA, EMA or other regulatory authorities, we may not obtain or maintain the approvals we need
to commercialize such product candidates. Even if we obtain regulatory approval for any of our product candidates, there is no assurance
that either we or our third party contract manufacturers will be able to manufacture the approved product in accordance with the requirements
of the FDA, EMA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch
of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical trials, require bridging
clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates,
impair commercialization efforts, increase our cost of goods and have an adverse effect on our business, financial condition, results
of operations and growth prospects. Significant non-compliance could also result in the imposition of sanctions, including warning or
untitled letters, fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product
candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions
and criminal prosecutions, any of which could damage our reputation and our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will likely seek collaborations with
third parties for the development or commercialization of our product candidates. If those collaborations are not successful, we may
not be able to capitalize on the market potential of those product candidates, including PMN310, PMN442, and PMN267.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We
                                            will likely seek third-party collaborators for the commercialization of PMN310, PMN442, and
                                            PMN267 and any of our future product candidates, in the U.S. and may enter into collaboration
                                            agreements for the development and commercialization of any of our product candidates outside
                                            the U.S. In the U.S., commercialization partners are likely to include large biotechnology
                                            or pharmaceutical companies. Our likely collaborators outside the U.S. would most likely
                                            include regional and national pharmaceutical companies and biotechnology companies. If we
                                            enter into such arrangements with any third parties, we will likely have limited control
                                            over the amount and timing of resources that our collaborators dedicate to the development
                                            or commercialization of our product candidates. Our ability to generate revenue from these
                                            arrangements will depend on our collaborators&rsquo; abilities to successfully perform the
                                            functions assigned to them in these arrangements.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Collaborations involving our product candidates
would pose the following risks to us:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>collaborators
                                            have significant discretion in determining the efforts and resources that they will apply
                                            to these collaborations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>collaborators
                                            may not perform their obligations as expected;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">collaborators
                                            may not pursue development and commercialization of any product candidates that achieve regulatory
                                            approval or may elect not to continue or renew development or commercialization programs
                                            based on clinical trial results, changes in the collaborators&#8217; strategic focus or available
                                            funding, or external factors, such as an acquisition, that divert resources or create competing
                                            priorities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">collaborators
                                            may delay clinical trials, provide insufficient funding for a clinical trial program, stop
                                            a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or
                                            require a new formulation of a product candidate for clinical testing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">collaborators
                                            could independently develop, or develop with third parties, products that compete directly
                                            or indirectly with our product candidates if the collaborators believe that competitive products
                                            are more likely to be successfully developed or can be commercialized under terms that are
                                            more economically attractive than ours;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>we could grant
                                            exclusive rights to our collaborators that would prevent us from collaborating with others;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">product
                                            candidates discovered in collaboration with us may be viewed by our collaborators as competitive
                                            with their own product candidates or drugs, which may cause collaborators to cease to devote
                                            resources to the commercialization of our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a
                                            collaborator with marketing and distribution rights to one or more of our product candidates
                                            that achieve regulatory approval may not commit sufficient resources to the marketing and
                                            distribution of such products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">disagreements
                                            with collaborators, including disagreements over proprietary rights, contract interpretation
                                            or the preferred course of development, might cause delays or termination of the research,
                                            development or commercialization of product candidates, might lead to additional responsibilities
                                            for us with respect to product candidates, or might result in litigation or arbitration,
                                            any of which would be time-consuming and expensive;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">collaborators
                                            may not properly maintain or defend our or their intellectual property rights or may use
                                            our or their proprietary information in such a way as to invite litigation that could jeopardize
                                            or invalidate such intellectual property or proprietary information or expose us to potential
                                            litigation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>collaborators
                                            may infringe the intellectual property rights of third parties, which may expose us to litigation
                                            and potential liability; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">collaborations
                                            may be terminated for the convenience of the collaborator and, if terminated, we could be
                                            required to raise additional capital to pursue further development or commercialization of
                                            the applicable product candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Collaboration agreements may not lead to development
or commercialization of product candidates in the most efficient manner or at all. If any future collaborator of ours were to be involved
in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed,
diminished or terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We
face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for any collaboration will
depend, among other things, upon our assessment of the collaborator&rsquo;s resources and expertise, the terms and conditions of the
proposed collaboration and the proposed collaborator&rsquo;s evaluation of a number of factors. Those factors may include the design
or results of clinical trials, the likelihood of approval by the FDA, EMA or similar regulatory authorities outside the U.S., the potential
market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients,
the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there
is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator
may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and
whether such a collaboration could be more attractive than the one with us for our product candidate. Collaborations are complex and
time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large
pharmaceutical companies that have resulted in a reduced number of potential future collaborators.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may not be able to negotiate additional collaborations
on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product
candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization
or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization
activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own,
we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient
funds, we may not be able to further develop our product candidates or bring them to market and generate revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to obtain and maintain</I></B></FONT><B><I> sufficient intellectual property protection for our product candidates, and
other proprietary technologies we develop, or if the scope of the intellectual property protection obtained is not sufficiently broad,
our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize
our product candidates, and other proprietary technologies if approved, may be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our commercial success will depend in part on
our ability to obtain and maintain a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual
property related to our product candidates, and other proprietary technologies we develop. If we are unable to obtain or maintain patent
protection with respect to our product candidates, and other proprietary technologies we may develop, our business, financial condition,
results of operations, and prospects could be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 67 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The
                                            patent position of biotechnology and pharmaceutical companies is highly uncertain and involves
                                            complex legal, scientific, and factual questions and has been the subject of frequent litigation
                                            in recent years. As a result, the issuance, scope, validity, enforceability, and commercial
                                            value of our patent rights are highly uncertain. Our patent applications may not result in
                                            patents being issued that protect our product candidates and other proprietary technologies
                                            we may develop or that effectively prevent others from commercializing competitive technologies
                                            and products. Further, no consistent policy regarding the breadth of claims allowed in pharmaceutical
                                            patents has emerged to date in the U.S. or in many jurisdictions outside of the U.S. Changes
                                            in either the patent laws or interpretations of patent laws in the U.S. and other countries
                                            may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth
                                            of claims that may be enforced in the patents that may be issued from the applications we
                                            may own or license from third parties. Further, if any patents we obtain or license are deemed
                                            invalid and unenforceable, our ability to commercialize or license our technology could be
                                            adversely affected.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The patent application process is subject to
numerous risks and uncertainties, and there can be no assurance that we or any of our actual or potential future collaborators will be
successful in protecting our product candidates and other proprietary technologies and their uses by obtaining, defending and enforcing
patents. These risks and uncertainties include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">the
                                            USPTO and various foreign governmental patent agencies require compliance with a number of
                                            procedural, documentary, fee payment and other provisions during the patent process, the
                                            noncompliance with which can result in abandonment or lapse of a patent or patent application,
                                            and partial or complete loss of patent rights in the relevant jurisdiction;</P>
</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>patent applications
                                            may not result in any patents being issued;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">issued
                                            patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable,
                                            or may otherwise not provide any competitive advantage;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                            competitors, many of whom have substantially greater resources than we do and many of whom
                                            have made significant investments in competing technologies, may seek or may have already
                                            obtained patents that will limit, interfere with, or eliminate our ability to make, use and
                                            sell our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">other
                                            parties may have designed around our claims or developed technologies that may be related
                                            or competitive to ours, may have filed or may file patent applications and may have received
                                            or may receive patents that overlap or conflict with our patent applications and/or patents,
                                            either by claiming the same composition of matter, methods or formulations or by claiming
                                            subject matter that could dominate our patent position;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any
                                            successful opposition to any patents owned by or licensed to us could deprive us of rights
                                            necessary for the practice of our technologies or the successful commercialization of any
                                            product candidate that we may develop;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">because
                                            patent applications in the U.S. and most other countries are confidential for a period of
                                            time after filing, we cannot be certain that we or our licensors were the first to file any
                                            patent application related to our product candidates and other proprietary technologies and
                                            their uses;</P>
</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">an
                                            interference proceeding can be provoked by a third party or instituted by the USPTO to determine
                                            who was the first to invent any of the subject matter covered by the patent claims of any
                                            application with an effective filing date before March&nbsp;16, 2013;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"></P>

<!-- Field: Page; Sequence: 68 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: red">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">there
                                            may be significant pressure on the U.S. government and international governmental bodies
                                            to limit the scope of patent protection both inside and outside the U.S. for disease treatments
                                            that prove successful, as a matter of public policy regarding worldwide health concerns;
                                            and</P>
</TD></TR></TABLE>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">countries
                                            other than the U.S. may have patent laws less favorable to patentees than those upheld by
                                            U.S. courts, allowing foreign competitors a better opportunity to create, develop, and market
                                            competing product candidates in those countries.</P>
</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The
                                            patent prosecution process is expensive, time-consuming, and complex, and we may not be able
                                            to file, prosecute, or maintain all necessary or desirable patent applications at a reasonable
                                            cost or in a timely manner. It is also possible that we will fail to identify patentable
                                            aspects of our research and development output before it is too late to obtain patent protection.
                                            Although we enter into non-disclosure and confidentiality agreements with parties who have
                                            access to patentable aspects of our research and development output, such as our employees,
                                            corporate collaborators, outside scientific collaborators, CROs, contract manufacturers,
                                            consultants, advisors and other third parties, any of these parties may breach such agreements
                                            and disclose such output before a patent application is filed, thereby jeopardizing our ability
                                            to seek patent protection for such output. In addition, our ability to obtain and maintain
                                            valid and enforceable patents depends on whether the differences between our inventions and
                                            the prior art allow our inventions to be patentable over the prior art. Furthermore, publications
                                            of discoveries in the scientific literature often lag behind the actual discoveries, and
                                            patent applications in the U.S. and other jurisdictions are typically not published until
                                            18 months after filing, or in some cases not at all.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The degree of future protection for our proprietary
rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain
or keep our competitive advantage. If we do not adequately protect our intellectual property and proprietary technology, competitors
may be able to use our product candidates and other proprietary technologies and erode or negate any competitive advantage we may have,
which could have a material adverse effect on our financial condition and results of operations. For example:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">others
                                            may be able to make compounds that are similar to our product candidates but that are not
                                            covered by the claims of our patents;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we
                                            might not have been the first to file patent applications for these inventions;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">others
                                            may independently develop similar or alternative technologies or duplicate any of our technologies;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any
                                            patents that we obtain may not provide us with any competitive advantages;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we
                                            may not develop additional proprietary technologies that are patentable;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                            competitors might conduct research and development activities in countries where we do not
                                            have patent rights or where patent protection is weak and then use the information learned
                                            from such activities to develop competitive products for sale in our major commercial markets;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we
                                            cannot ensure that we will be able to successfully commercialize our product candidates on
                                            a substantial scale, if approved, before the relevant patents that we own or license expire;
                                            or</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            patents of others may have an adverse effect on our business.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Others have filed, and in the future are likely
to file, patent applications covering products and technologies that are similar, identical or competitive to ours or important to our
business. We cannot be certain that any patent application owned by a third party will not have priority over patent applications filed
or in-licensed by us, or that we or our licensors will not be involved in interference, opposition or invalidity proceedings before U.S.
or non-U.S. patent offices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 69 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We
                                            cannot be certain that claims in an issued patent covering our product candidates will be
                                            considered patentable by the USPTO, courts in the U.S., or by patent offices and courts in
                                            foreign countries. Furthermore, the laws of some foreign countries do not protect proprietary
                                            rights to the same extent or in the same manner as the laws of the U.S. As a result, we may
                                            encounter significant problems in protecting and defending our intellectual property internationally.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The
                                            strength of patents in the biotechnology and pharmaceutical fields involves complex legal
                                            and scientific questions and can be uncertain. Patent applications that we file or in-license
                                            may fail to result in issued patents with claims that cover our product candidates in the
                                            U.S. or in foreign countries. Even if such patents do successfully issue, third parties may
                                            challenge the ownership, validity, enforceability, or scope thereof, which may result in
                                            such patents being narrowed, invalidated, or held unenforceable. Any successful opposition
                                            to our patents could deprive us of exclusive rights necessary for the successful commercialization
                                            of our product candidates. Furthermore, even if they are unchallenged, our patents may not
                                            adequately protect our intellectual property, provide exclusivity for our product candidates
                                            or prevent others from designing around our claims. If the breadth or strength of protection
                                            provided by our patents with respect to our product candidates is threatened, it could dissuade
                                            companies from collaborating with us to develop, or threaten our ability to commercialize
                                            our product candidates.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For U.S. patent applications in which claims
are entitled to a priority date before March&nbsp;16, 2013, an interference proceeding can be provoked by a third party or instituted
by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our patents or patent
applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights from the
prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms.
Our participation in an interference proceeding may fail and, even if successful, may result in substantial costs and distract our management
and other employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For U.S. patent applications containing a claim
not entitled to priority before March&nbsp;16, 2013, there is greater level of uncertainty in the patent law. In September&nbsp;2011,
the Leahy-Smith America Invents Act, or America Invents Act, was signed into law. The America Invents Act includes a number of significant
changes to U.S. patent law, including provisions that affect the way patent applications will be prosecuted and may also affect patent
litigation. The USPTO is developing regulations and procedures to govern the administration of the America Invents Act, and many of the
substantive changes to patent law associated with the America Invents Act, and in particular, the &#8220;first to file&#8221; provisions,
were enacted on March&nbsp;16, 2013. This will require us to be cognizant going forward of the time from invention to filing of a patent
application and be diligent in filing patent applications, but circumstances could prevent us from promptly filing patent applications
on our inventions. It remains unclear what impact the America Invents Act will have on the operation of our business. As such, the America
Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of patent applications and
the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Patent terms may be inadequate to protect
our competitive position on our product candidates for an adequate amount of time.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The
                                            term of any individual patent depends on applicable law in the country where the patent is
                                            granted. In the U.S., provided all maintenance fees are timely paid, a patent generally has
                                            a term of 20 years from its application filing date or earliest claimed non-provisional filing
                                            date. Extensions may be available under certain circumstances, but the life of a patent and,
                                            correspondingly, the protection it affords is limited. When the terms of all patents covering
                                            our product candidates expire, our business may become subject to competition from competitive
                                            products, including biosimilar version of our products.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 70 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our product candidates are protected by certain
patents, which expire at varying times. We cannot be certain that we will file and, if filed, obtain patent protection for our product
candidates beyond our rights in our current patent portfolio. If we are unable to obtain additional patent protection on our product
candidates, our primary protection from biosimilar market entries will be limited to regulatory biologic exclusivity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we do not obtain patent term extension
for our product candidates our business may be materially harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depending upon the timing, duration, and specifics
of any FDA marketing approval of our product candidates, one or more of patents issuing from U.S. patent applications that we file or
license may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984,
or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term, or PTE, of up to five years as compensation for
patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond
a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug,
a method for using it or a method for manufacturing it may be extended. Similar patent term restoration provisions to compensate for
commercialization delay caused by regulatory review are also available in certain foreign jurisdictions, such as in Europe under Supplemental
Protection Certificate, or SPC. If we encounter delays in our development efforts, including our future clinical trials, the period of
time during which we could market our product candidates under patent protection would be reduced. Additionally, we may not receive an
extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents, or otherwise fail to
satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we
request. If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request,
the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval
of competing products following our patent expiration, and our revenue could be reduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to comply with our obligations
in the agreements under which we license intellectual property rights from third parties, or otherwise experience disruptions to our
business relationships with our licensors, we could lose license rights that are important to our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Licensing of intellectual property rights is
of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and
our licensors regarding intellectual property rights subject to a license agreement, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            scope of rights granted under the license agreement and other interpretation-related issues;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">whether
                                            and the extent to which our technology and processes infringe on intellectual property rights
                                            of the licensor that are not subject to the license agreement;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                            right to sublicense intellectual property rights to third parties under collaborative development
                                            relationships;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                            diligence obligations with respect to the use of the licensed technology in relation to our
                                            development and commercialization of our product candidates, and what activities satisfy
                                            those diligence obligations; and</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            ownership of inventions and know-how resulting from the joint creation or use of intellectual
                                            property by our licensors and us and our partners.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If disputes over intellectual property rights
that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms and/or to secure
our rights to the licensed intellectual property, our business, results of operations, financial condition, and prospects may be adversely
affected. We may enter into additional licenses in the future and if we fail to comply with obligations under those agreements, we could
suffer adverse consequences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 71 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Obtaining and maintaining our patent protection
depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent
agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The USPTO and various foreign governmental patent
agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent process.
Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on any issued patents and/or applications are
due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patents and/or applications. We have
systems in place to remind us to pay these fees, and we employ outside counsel to pay these fees due to foreign patent agencies. While
an inadvertent lapse may sometimes be cured by payment of a late fee or by other means in accordance with the applicable rules, there
are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or
complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market with
similar or identical products or technology earlier than should otherwise have been the case, which would have a material adverse effect
on our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Changes in U.S. patent law could diminish
the value of patents in general, thereby impairing our ability to protect our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As
                                            is the case with other biotechnology and pharmaceutical companies, our success is heavily
                                            dependent on intellectual property, particularly on obtaining and enforcing patents. Our
                                            patent rights may be affected by developments or uncertainty in U.S. or foreign patent statutes,
                                            patent case law, USPTO rules&nbsp;and regulations or the rules&nbsp;and regulations of foreign
                                            patent offices. Obtaining and enforcing patents in the biotechnology and pharmaceutical industry
                                            involve both technological and legal complexity, and is therefore costly, time-consuming
                                            and inherently uncertain. In addition, the U.S. may, at any time, enact changes to U.S. patent
                                            law and regulations, including by legislation, by regulatory rule-making, or by judicial
                                            precedent, that adversely affect the scope of patent protection available and weaken the
                                            rights of patent owners to obtain patents, enforce patent infringement and obtain injunctions
                                            and/or damages. For example, the scope of patentable subject matter under 35 U.S.C. 101 has
                                            evolved significantly over the past several years as the Court of Appeals for the Federal
                                            Circuit and the Supreme Court issued various opinions, and the USPTO modified its guidance
                                            for practitioners on multiple occasions. Other countries may likewise enact changes to their
                                            patent laws in ways that adversely diminish the scope of patent protection and weaken the
                                            rights of patent owners to obtain patents, enforce patent infringement, and obtain injunctions
                                            and/or damages.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further,
                                            the U.S. and other governments may, at any time, enact changes to law and regulation that
                                            create new avenues for challenging the validity of issued patents. For example, the America
                                            Invents Act created new administrative post-grant proceedings, including post-grant review,
                                            <I>inter partes</I> review, and derivation proceedings that allow third parties to challenge
                                            the validity of issued patents. This applies to all of our U.S. patents, even those issued
                                            before March&nbsp;16, 2013. Because of a lower evidentiary standard in USPTO proceedings
                                            compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent
                                            claim, a third party could potentially provide evidence in a USPTO proceeding sufficient
                                            for the USPTO to hold a claim invalid even though the same evidence would be insufficient
                                            to invalidate the claim if first presented in a district court action. In addition to increasing
                                            uncertainty with regard to our ability to obtain patents in the future, this combination
                                            of events has created uncertainty with respect to the value of patents, once obtained. Depending
                                            on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations
                                            governing patents could change in unpredictable ways that could weaken our ability to obtain
                                            new patents or to enforce our existing patents and patents that we might obtain in the future.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 72 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to protect our intellectual
property rights throughout the world.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patents
                                            are of national or regional effect. Filing, prosecuting, and defending patents on our product
                                            candidates, and other proprietary technologies we develop in all countries throughout the
                                            world would be prohibitively expensive. In addition, the laws of some foreign countries do
                                            not protect intellectual property rights in the same manner and to the same extent as laws
                                            in the U.S. Consequently, we may not be able to prevent third parties from practicing our
                                            inventions in all countries outside the U.S. Competitors may use our technologies in jurisdictions
                                            where we have not obtained patent protection to develop their own products and further, may
                                            export otherwise infringing products to territories where we have patent protection, but
                                            enforcement of such patent protection is not as strong as that in the U.S. These products
                                            may compete with our products and our patents or other intellectual property rights may not
                                            be effective or sufficient to prevent them from competing.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The
                                            requirements for patentability may differ in certain countries. For example, unlike other
                                            countries, China has a heightened requirement for patentability, and specifically requires
                                            a detailed description of medical uses of a claimed drug. In India, unlike the U.S., there
                                            is no link between regulatory approval for a drug and its patent status. In addition to India,
                                            certain countries in Europe and developing countries, including China, have compulsory licensing
                                            laws under which a patent owner may be compelled to grant licenses to third parties. In addition,
                                            some countries limit the enforceability of patents against government agencies or government
                                            contractors.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In those countries, we may have limited remedies
if patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of those
patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce intellectual property rights around
the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many companies have encountered significant problems
in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly
certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly
those relating to biotechnology or pharmaceutical products, which could make it difficult for us to stop the infringement of our patents
or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign
jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our
patents at risk of being invalidated or interpreted narrowly, and could provoke third parties to assert claims against us. We may not
prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly,
our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage
from the intellectual property that we develop or license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may become subject to claims challenging
the inventorship or ownership of our patents and other intellectual property.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may be subject to claims that former employees
(including former employees of our licensors), collaborators or other third parties have an interest in our patents rights, trade secrets,
or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result
in the patents issuing thereon being unenforceable. For example, we may have inventorship disputes arise from conflicting views regarding
the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the
development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates
or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other
claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of
our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose
valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome
could have a material adverse effect on our business, financial condition, results of operations and prospects. Even if we are successful
in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 73 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be successful in obtaining or
maintaining necessary rights to product components and processes for our development pipeline through in-licenses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presently we have intellectual property rights
to our product candidates through a license from the UBC. We also have an intellectual property license through a license with UHN, and,
if this agreement remains in place, we could be required to pay a low single digit royalty on revenues to UHN and a low to high single
digit royalty on revenues to UBC in the future. Because our program may require the use of additional proprietary rights held by third
parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights.
In addition, our product candidates may require specific formulations to work effectively and efficiently and these rights may be held
by others. We may be unable to acquire or in-license, on reasonable terms, proprietary rights related to any compositions, formulations,
methods of use, processes or other intellectual property rights from third parties that we identify as being necessary for our product
candidates. Even if we are able to obtain a license to such proprietary rights, it may be non-exclusive, thereby giving our competitors
access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop
or license replacement technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Where we obtain licenses from or collaborate
with third parties, we may not have the right to control the preparation, filing, and prosecution of patent applications, or to maintain
or enforce the patents, covering technology that we license from third parties, or such activities, if controlled by us, may require
the input of such third parties. If any of our licensors or collaboration partners fail to prosecute, maintain and enforce such patents
and patent applications in a manner consistent with the best interests of our business, including by payment of all applicable fees for
patents covering our product candidates, we could lose our rights to the intellectual property or our exclusivity with respect to those
rights, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent
competitors from making, using and selling competing products. In addition, even where we have the right to control patent prosecution
of patents and patent applications we have licensed from third parties, we may still be adversely affected or prejudiced by actions or
inactions of our licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution.
We may also require the cooperation of our licensors and collaborators to enforce any licensed patent rights, and such cooperation may
not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests
of our business, or in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents
or any patents that may issue from such application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moreover, we will likely have obligations under
our current or future licenses, including making royalty and milestone payments, and any failure to satisfy those obligations could give
our licensor the right to terminate the license. Termination of a necessary license, or expiration of licensed patents or patent applications,
could have a material adverse impact on our business. Our business would suffer if any such licenses terminate, if the licensors fail
to abide by the terms of the license, if the licensors fail to enforce licensed patents against infringing third parties, if the licensed
patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable
terms. Furthermore, if any licenses terminate, or if the underlying patents fail to provide the intended exclusivity, competitors or
other third parties may gain the freedom to seek regulatory approval of, and to market, products identical or similar to ours. Moreover,
our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims,
regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights. In addition, while we cannot currently
determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant.
The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully
develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve
or maintain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The licensing and acquisition of third-party
proprietary rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also
be pursuing strategies to license or acquire third-party proprietary rights that we may consider necessary or attractive in order to
commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources
and greater clinical development and commercialization capabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 74 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For example, we have collaborated and may in
the future collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under written
agreements with these institutions. Typically, these institutions provide us with an option to negotiate an exclusive license to any
of the institution&#8217;s proprietary rights in technology resulting from the collaboration. Regardless of such option to negotiate
a license, we may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are
unable to do so, the institution may offer, on an exclusive basis, their proprietary rights to other parties, potentially blocking our
ability to pursue our program. In addition, disputes may arise under our existing or future license agreements with these institutions
or with other counterparties which may, among other things, lead to the termination or renegotiation of these agreements, or otherwise
require us to incur significant financial obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, companies that perceive us to be
a competitor may be unwilling to assign or license rights to us, either on reasonable terms, or at all. We also may be unable to license
or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment, or
at all. If we are unable to successfully obtain rights to required third-party intellectual property rights on commercially reasonable
terms, our ability to commercialize our products, and our business, financial condition, and prospects for growth, could suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Third-party claims alleging intellectual
property infringement may prevent or delay our drug discovery and development efforts.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our
                                            success depends in part on our avoiding infringement of the patents and proprietary rights
                                            of third parties. There is a substantial amount of litigation, both within and outside the
                                            U.S., involving patents and other intellectual property rights in the biotechnology and pharmaceutical
                                            industries, as well as administrative proceedings for challenging patents, including <I>inter
                                            partes</I> review, interference and reexamination proceedings before the USPTO, or oppositions
                                            and other comparable proceedings in foreign jurisdictions. The America Invents Act introduced
                                            new procedures including <I>inter partes</I> review and post grant review. The implementation
                                            of these procedures brings uncertainty to the possibility of challenges to our patents in
                                            the future and the outcome of such challenges. Numerous U.S. and foreign issued patents and
                                            pending patent applications, which are owned by third parties, exist in the fields in which
                                            we are developing our product candidates. As the biotechnology and pharmaceutical industries
                                            expand and more patents are issued, the risk increases that our activities related to our
                                            product candidates may give rise to claims of infringement of the patent rights of others.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The pharmaceutical and biotechnology industries
have produced a proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various
types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not
always uniform. We cannot assure you that any of our current or future product candidates will not infringe existing or future patents.
We may not be aware of patents that have already issued that a third party might assert are infringed by one of our current or future
product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Third parties may assert that we are employing
their proprietary technology without authorization. There may be third-party patents of which we are currently unaware with claims to
materials, compositions, formulations, methods of manufacture or methods for treatment related to our product candidates, or the use
or manufacture of our product candidates. Because patent applications can take many years to issue and may be confidential for 18 months
or more after filing, there may be currently pending third-party patent applications which may later result in issued patents that our
product candidates, and other proprietary technologies may infringe, or which such third parties claim are infringed by the use of our
technologies. Parties making claims against us for infringement or misappropriation of their intellectual property rights may seek and
obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product
candidates. Defense of these claims, regardless of their merit, could involve substantial expenses and could be a substantial diversion
of management and other employee resources from our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 75 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we collaborate with third parties in the development
of technology in the future, our collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary
information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information
or expose us to litigation or potential liability. Further, collaborators may infringe the intellectual property rights of third parties,
which may expose us to litigation and potential liability. In the future, we may agree to indemnify our commercial collaborators against
certain intellectual property infringement claims brought by third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any claims of patent infringement asserted by
third parties would be time-consuming and could:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">result
                                            in costly litigation;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">divert
                                            the time and attention of our technical personnel and management;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">cause
                                            development delays;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">prevent
                                            us from commercializing our product candidates until the asserted patent expires or is finally
                                            held invalid, unenforceable, or not infringed in a court of law;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">require
                                            us to develop non-infringing technology, which may not be possible on a cost-effective basis;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">require
                                            us to pay damages to the party whose intellectual property rights we may be found to be infringing,
                                            which may include treble damages if we are found to have been willfully infringing such intellectual
                                            property;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">require
                                            us to pay the attorney&#8217;s fees and costs of litigation to the party whose intellectual
                                            property rights we may be found to be willfully infringing; and/or</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">require
                                            us to enter into royalty or license agreements, which may not be available on commercially
                                            reasonable terms, or at all.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If
                                            we are sued for patent infringement, we would need to demonstrate that our products or methods
                                            either do not infringe the patent claims of the relevant patent or that the patent claims
                                            are invalid or unenforceable, and we may not be able to do either. Proving invalidity or
                                            unenforceability is difficult. For example, in the U.S., proving invalidity before federal
                                            courts requires a showing of clear and convincing evidence to overcome the presumption of
                                            validity enjoyed by issued patents. Even if we are successful in these proceedings, we may
                                            incur substantial costs and divert management&rsquo;s time and attention in pursuing these
                                            proceedings, which could have a material adverse effect on us. If we are unable to avoid
                                            infringing the patent rights of others, we may be required to seek a license, which may not
                                            be available, defend an infringement action or challenge the validity or enforceability of
                                            the patents in court. Patent litigation is costly and time-consuming. We may not have sufficient
                                            resources to bring these actions to a successful conclusion. In addition, if we do not obtain
                                            a license, develop or obtain non-infringing technology, fail to defend an infringement action
                                            successfully or have infringed patents declared invalid or unenforceable, we may incur substantial
                                            monetary damages, encounter significant delays in bringing our product candidates to market
                                            and be precluded from developing, manufacturing or selling our product candidates.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We
                                            do not always conduct independent reviews of pending patent applications of and patents issued
                                            to third parties. We cannot be certain that any of our or our licensors&rsquo; patent searches
                                            or analyses, including but not limited to the identification of relevant patents, analysis
                                            of the scope of relevant patent claims or determination of the expiration of relevant patents,
                                            are complete or thorough, nor can we be certain that we have identified each and every third-party
                                            patent and pending application in the U.S., Europe and elsewhere that is relevant to or necessary
                                            for the commercialization of our product candidates in any jurisdiction, because:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">some
                                            patent applications in the U.S. may be maintained in secrecy until the patents are issued;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">patent
                                            applications in the U.S. and elsewhere can be pending for many years before issuance, or
                                            unintentionally abandoned patents or applications can be revived;</P>
</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 76 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">pending
                                            patent applications that have been published can, subject to certain limitations, be later
                                            amended in a manner that could cover our technologies, our product candidates or their uses;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">identification
                                            of third-party patent rights that may be relevant to our technology is difficult because
                                            patent searching is imperfect due to differences in terminology among patents, incomplete
                                            databases, and the difficulty in assessing the meaning of patent claims;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">patent
                                            applications in the U.S. are typically not published until 18 months after the priority date;
                                            and</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">publications
                                            in the scientific literature often lag behind actual discoveries.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore,
                                            the scope of a patent claim is determined by an interpretation of the law, the written disclosure
                                            in a patent and the patent&rsquo;s prosecution history and can involve other factors such
                                            as expert opinion. Our interpretation of the relevance or the scope of claims in a patent
                                            or a pending application may be incorrect, which may negatively impact our ability to market
                                            our products. Further, we may incorrectly determine that our technologies or product candidates
                                            are not covered by a third party patent or may incorrectly predict whether a third party&rsquo;s
                                            pending patent application will issue with claims of relevant scope. Our determination of
                                            the expiration date of any patent in the U.S. or internationally that we consider relevant
                                            may be incorrect, which may negatively impact our ability to develop and market our products
                                            or product candidates.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our
                                            competitors may have filed, and may in the future file, patent applications covering technology
                                            similar to ours, and others may have or obtain patents or proprietary rights that could limit
                                            our ability to make, use, sell, offer for sale or import our product candidates or future
                                            products or impair our competitive position. Numerous third-party U.S. and foreign issued
                                            patents and pending patent applications exist in the fields in which we are developing product
                                            candidates. There may be third-party patents or patent applications with claims to materials,
                                            formulations, methods of manufacture or methods for treatment related to the use or manufacture
                                            of our product candidates. Any such patent application may have priority over one of our
                                            patent applications, which could further require us to obtain rights to issued patents covering
                                            such technologies. If another party has filed a U.S. patent application on inventions similar
                                            to ours, we may have to participate in an interference proceeding declared by the USPTO to
                                            determine priority of invention in the U.S. The costs of these proceedings could be substantial,
                                            and it is possible that such efforts would be unsuccessful if, unbeknownst to us, the other
                                            party had independently arrived at the same or similar invention prior to our own invention,
                                            resulting in a loss of our U.S. patent position with respect to such inventions. Other countries
                                            have similar laws that permit secrecy of patent applications and may be entitled to priority
                                            over our applications in such jurisdictions.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of our competitors may be able to sustain
the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any
uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to
raise the funds necessary to continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a third party prevails in a patent infringement
lawsuit against us, we may have to stop making and selling the infringing product, pay substantial damages, including treble damages
and attorneys&#8217; fees if we are found to be willfully infringing a third party&#8217;s patents, obtain one or more licenses from
third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot predict whether any such license would
be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation,
we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may
fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further
develop and commercialize our product candidates, which could harm our business significantly. Even if we were able to obtain a license,
the rights may be nonexclusive, which may give our competitors access to the same intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 77 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be subject to claims that we have
wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information
or trade secrets of their former employers.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As is common in the biotechnology and pharmaceutical
industries, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates,
and other proprietary technologies. Many of these consultants, and many of our employees, were previously employed at, or may have previously
provided or may be currently providing consulting services to, other pharmaceutical companies including our competitors or potential
competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade
secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to
defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual
property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims,
litigation could result in substantial costs and be a distraction to our management team and other employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be involved in lawsuits to protect
or enforce our patents or the patents of our licensors, which could be expensive, time-consuming, and unsuccessful. Further, our issued
patents could be found invalid or unenforceable if challenged in court, and we may incur substantial costs as a result of litigation
or other proceedings relating to patent and other intellectual property rights.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Third
                                            parties including competitors may infringe, misappropriate or otherwise violate our patents,
                                            patents that may issue to us in the future, or the patents of our licensors that are licensed
                                            to us. To counter infringement or unauthorized use, we may need to or choose to file infringement
                                            claims, which can be expensive and time-consuming. We may not be able to prevent, alone or
                                            with our licensors, infringement, misappropriation, or other violation of our intellectual
                                            property, particularly in countries where the laws may not protect those rights as fully
                                            as in the U.S., or if we require, but do not receive, the consent or cooperation of our licensors
                                            to enforce such intellectual property.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If
                                            we choose to go to court to stop another party from using the inventions claimed in our patents,
                                            that individual or company has the right to ask the court to rule&nbsp;that such patents
                                            are invalid, unenforceable, or should not be enforced against that third party for any number
                                            of reasons. In patent litigation in the U.S., defendant counterclaims alleging invalidity
                                            and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged
                                            failure to meet any of several statutory requirements for patentability, including lack of
                                            novelty, obviousness, lack of written description, indefiniteness, or non-enablement. Grounds
                                            for an unenforceability assertion could include an allegation that someone connected with
                                            prosecution of the patent withheld relevant information from the USPTO or made a misleading
                                            statement during prosecution, i.e., committed inequitable conduct. Third parties may also
                                            raise similar claims before the USPTO, even outside the context of litigation. Similar mechanisms
                                            for challenging the validity and enforceability of a patent exist in foreign patent offices
                                            and courts and may result in the revocation, cancellation, or amendment of any foreign patents
                                            we or our licensors hold now or in the future. The outcome following legal assertions of
                                            invalidity and unenforceability is unpredictable, and prior art could render our patents
                                            or those of our licensors invalid. If a defendant were to prevail on a legal assertion of
                                            invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the
                                            patent protection on such product candidate. Such a loss of patent protection would have
                                            a material adverse impact on our business.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interference or derivation proceedings provoked
by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our
patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology
or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer
us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to
the same technology. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial
costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material
adverse effect on our ability to raise the funds necessary to conduct our future clinical trials, continue our research programs, license
necessary technology from third parties, or enter into development or manufacturing partnerships that would help us bring our product
candidates to market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 78 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may not have sufficient financial or other
resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation
or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation
and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace. Even if resolved
in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses
and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements
of the results of hearings, motions, or other interim proceedings or developments and if securities analysts or investors perceive these
results to be negative, it could have a substantial adverse effect on the price of our Common Shares. Such litigation or proceedings
could substantially increase our operating losses and reduce the resources available for development activities or any future sales,
marketing, or distribution activities. Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of
litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ability to enforce our patent rights depends
on our ability to establish standing in a court of competent jurisdiction. Whether a patent holder or licensee of a patent has standing
can be uncertain and the considerations complex. However, if a licensor is required to be joined, and they are unwilling to do so, we
may be unable to proceed with an infringement action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ability to enforce our patent rights depends
on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components or methods that are
used in connection with their products and services. Moreover, it may be difficult or impossible to obtain evidence of infringement in
a competitor&#8217;s or potential competitor&#8217;s product or service. We may not prevail in any lawsuits that we initiate and the
damages or other remedies awarded if we were to prevail may not be commercially meaningful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Because of the expense and uncertainty
of litigation, we may not be in a position to enforce our intellectual property rights against third parties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because of the expense and uncertainty of litigation,
we may conclude that even if a third party is infringing our issued patent or patents that may issue from patent applications or other
intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best
interest of our company or our shareholders. In such cases, we may decide that the more prudent course of action is to simply monitor
the situation or initiate or seek some other non-litigious action or solution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are unable to protect the confidentiality
of our trade secrets, our business and competitive position would be harmed. Our reliance on third parties requires us to share our trade
secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on trade secrets to protect our proprietary
technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult
to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored
researchers, and/or other advisors, and inventions agreements with employees, consultants, and advisors, to protect our trade secrets
and other proprietary information. In addition to contractual measures, we try to protect the confidential nature of our proprietary
information using commonly accepted physical and technological security measures. Despite these efforts, we cannot provide any assurances
that all such agreements have been duly executed, and these agreements may not effectively prevent disclosure of confidential information
and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently
discover our trade secrets and proprietary information. For example, the FDA, as part of its Transparency Initiative, is currently considering
whether to make additional information publicly available on a routine basis, including information that we may consider to be trade
secrets or other proprietary information, and it is not clear at the present time how the FDA&#8217;s disclosure policies may change
in the future, if at all. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary
rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, such security measures may not provide
adequate protection for our proprietary information, for example, in the case of misappropriation of a trade secret by an employee, consultant,
customer, or third party with authorized access. Our security measures may not prevent an employee, consultant or customer from misappropriating
our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy
to protect our interests fully. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have
taken to protect our proprietary technologies will be effective. Unauthorized parties may also attempt to copy or reverse engineer certain
aspects of our products that we consider proprietary. Even though we use commonly accepted security measures, the criteria for protection
of trade secrets can vary among different jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Enforcing
                                            a claim that a party illegally disclosed or misappropriated a trade secret is difficult,
                                            expensive and time-consuming, and the outcome is unpredictable. In addition, some courts
                                            inside and outside the U.S. are less willing or unwilling to protect trade secrets. Moreover,
                                            third parties may still obtain this information or may come upon this or similar information
                                            independently, and we would have no right to prevent them from using that technology or information
                                            to compete with us. Trade secrets will over time be disseminated within the industry through
                                            independent development, the publication of journal articles, and the movement of personnel
                                            skilled in the art from company to company or academic to industry scientific positions.
                                            Though our agreements with third parties typically restrict the ability of our advisors,
                                            employees, collaborators, licensors, suppliers, third-party contractors, and/or consultants
                                            to publish data potentially relating to our trade secrets, our agreements may contain certain
                                            limited publication rights. If any of our trade secrets were to be lawfully obtained or independently
                                            developed by a competitor, we would have no right to prevent such competitor from using that
                                            technology or information to compete with us, which could harm our competitive position.
                                            Because from time to time we expect to rely on third parties in the development, manufacture,
                                            and distribution of our products and provision of our services, we must, at times, share
                                            trade secrets with them. Despite employing the contractual and other security precautions
                                            described above, the need to share trade secrets increases the risk that such trade secrets
                                            become known by our competitors, are inadvertently incorporated into the technology of others,
                                            or are disclosed or used in violation of these agreements. If any of these events occurs
                                            or if we otherwise lose protection for our trade secrets, the value of this information may
                                            be greatly reduced and our competitive position would be harmed. If we do not apply for patent
                                            protection prior to such publication or if we cannot otherwise maintain the confidentiality
                                            of our proprietary technology and other confidential information, then our ability to obtain
                                            patent protection or to protect our trade secret information may be jeopardized.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If our trademarks and trade names are not
adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely
affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our trademarks or trade names, once registered,
may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect
our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our
markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build
brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims
brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade
names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be
able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties,
such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach
of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill
associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade
names, trade secrets, domain names, copyrights, or other intellectual property may be ineffective and could result in substantial costs
and diversion of resources and could adversely affect our financial condition or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moreover,
                                            any names we may propose to use with our product candidates in the U.S. must be approved
                                            by the FDA, regardless of whether we have registered it, or applied to register it, as a
                                            trademark. The FDA typically conducts a review of proposed product names, including an evaluation
                                            of potential for confusion with other product names. If the FDA (or an equivalent administrative
                                            body in a foreign jurisdiction) objects to any of our proposed proprietary product names,
                                            it may be required to expend significant additional resources in an effort to identify a
                                            suitable substitute name that would qualify under applicable trademark laws, not infringe
                                            the existing rights of third parties, and be acceptable to the FDA. Similar requirements
                                            exist in Europe. Furthermore, in many countries, owning and maintaining a trademark registration
                                            may not provide an adequate defense against a subsequent infringement claim asserted by the
                                            owner of a senior trademark. At times, competitors or other third parties may adopt trade
                                            names or trademarks similar to ours, thereby impeding our ability to build brand identity
                                            and possibly leading to market confusion. In addition, there could be potential trade name
                                            or trademark infringement claims brought by owners of other registered trademarks or trademarks
                                            that incorporate variations of our registered or unregistered trademarks or trade names.
                                            If we assert trademark infringement claims, a court may determine that the marks we have
                                            asserted are invalid or unenforceable, or that the party against whom we have asserted trademark
                                            infringement has superior rights to the marks in question. In this case, we could ultimately
                                            be forced to cease use of such trademarks.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Any collaboration arrangements that we
may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our future
products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any future collaborations that we enter into
may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators.
Collaborations are subject to numerous risks, which may include that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">collaborators
                                            have significant discretion in determining the efforts and resources that they will apply
                                            to collaborations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">collaborators
                                            may not pursue development and commercialization of our products or may elect not to continue
                                            or renew development or commercialization programs based on trial or test results, changes
                                            in their strategic focus due to the acquisition of competitive products, availability of
                                            funding, or other external factors, such as a business combination that diverts resources
                                            or creates competing priorities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">collaborators
                                            could independently develop, or develop with third parties, products that compete directly
                                            or indirectly with our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a
                                            collaborator with marketing, manufacturing, and distribution rights to one or more products
                                            may not commit sufficient resources to or otherwise not perform satisfactorily in carrying
                                            out these activities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we
                                            could grant exclusive rights to our collaborators that would prevent us from collaborating
                                            with others;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">collaborators
                                            may not properly maintain or defend our intellectual property rights or may use our intellectual
                                            property or proprietary information in a way that gives rise to actual or threatened litigation
                                            that could jeopardize or invalidate our intellectual property or proprietary information
                                            or expose us to potential liability;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">disputes
                                            may arise between us and a collaborator that causes the delay or termination of the research,
                                            development, or commercialization of our current or future products or that results in costly
                                            litigation or arbitration that diverts management attention and resources;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 81 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">collaborations
                                            may be terminated, and, if terminated, may result in a need for additional capital to pursue
                                            further development or commercialization of the applicable current or future products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">collaborators
                                            may own or co-own intellectual property covering our products that results from our collaborating
                                            with them, and in such cases, we would not have the exclusive right to develop or commercialize
                                            such intellectual property; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a
                                            collaborator&#8217;s sales and marketing activities or other operations may not be in compliance
                                            with applicable laws resulting in civil or criminal proceedings.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Intellectual property discovered through
government funded programs may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements
and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract
with non-U.S. manufacturers.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As
                                            of the date of this Registration Statement, neither our patents nor our product candidates
                                            are subject to march-in rights. However, some of our future patents may be generated through
                                            the use of U.S. government funding, and we may acquire or license in the future intellectual
                                            property rights that have been generated through the use of U.S. government funding or grants.
                                            Pursuant to the Bayh-Dole Act of 1980, the U.S. government has certain rights in inventions
                                            developed with government funding. These U.S. government rights include a non-exclusive,
                                            non-transferable, irrevocable worldwide license to use inventions for any governmental purpose.
                                            In addition, the U.S. government has the right, under certain limited circumstances, to require
                                            us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions
                                            to a third party if it determines that: (1)&nbsp;adequate steps have not been taken to commercialize
                                            the invention; (2)&nbsp;government action is necessary to meet public health or safety needs;
                                            or (3)&nbsp;government action is necessary to meet requirements for public use under federal
                                            regulations (also referred to as &ldquo;march-in rights&rdquo;). If the U.S.&nbsp;government
                                            exercised its march-in rights in our future intellectual property rights that are generated
                                            through the use of U.S. government funding or grants, we could be forced to license or sublicense
                                            intellectual property developed by us or that we license on terms unfavorable to us, and
                                            there can be no assurance that we would receive compensation from the U.S. government for
                                            the exercise of such rights. The U.S. government also has the right to take title to these
                                            inventions if the grant recipient fails to disclose the invention to the government or fails
                                            to file an application to register the intellectual property within specified time limits.
                                            Intellectual property generated under a government funded program is also subject to certain
                                            reporting requirements, compliance with which may require us to expend substantial resources.
                                            In addition, the U.S. government requires that any products embodying any of these inventions
                                            or produced through the use of any of these inventions be manufactured substantially in the
                                            U.S. This preference for U.S. industry may be waived by the federal agency that provided
                                            the funding if the owner or assignee of the intellectual property can show that reasonable
                                            but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees
                                            that would be likely to manufacture substantially in the U.S. or that under the circumstances
                                            domestic manufacture is not commercially feasible. This preference for U.S. industry may
                                            limit our ability to contract with non-U.S. product manufacturers for products covered by
                                            such intellectual property.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Legal and Regulatory Compliance
Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our relationships with customers, healthcare
providers, including physicians, and third-party payors are subject, directly or indirectly, to federal and state healthcare fraud and
abuse laws, false claims laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with
such laws, we could face substantial penalties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Healthcare
                                            providers, including physicians, and third-party payors in the U.S. and elsewhere will play
                                            a primary role in the recommendation and prescription of any product candidates for which
                                            we obtain marketing approval. Our current and future arrangements with healthcare professionals,
                                            principal investigators, consultants, customers and third- party payors subject us to various
                                            federal and state fraud and abuse laws and other healthcare laws, including, without limitation,
                                            the federal Anti-Kickback Statute, the federal civil and criminal false claims laws and the
                                            law commonly referred to as the Physician Payments Sunshine Act and regulations promulgated
                                            under such laws. These laws will impact, among other things, our clinical research, proposed
                                            sales, marketing and educational programs, and other interactions with healthcare professionals.
                                            In addition, we may be subject to patient privacy laws by both the federal government and
                                            the states in which we conduct or may conduct our business. The laws that will affect our
                                            operations include, but are not limited to:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 82 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            federal Anti-Kickback Statute, which prohibits, among other things, individuals or entities
                                            from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including
                                            any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in
                                            kind in return for, or to induce, either the referral of an individual, or the purchase,
                                            lease, order or arrangement for or recommendation of the purchase, lease, order or arrangement
                                            for any good, facility, item or service for which payment may be made, in whole or in part,
                                            under a federal healthcare program, such as the Medicare and Medicaid programs. The term
                                            &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. Although
                                            there are a number of statutory exceptions and regulatory safe harbors protecting some common
                                            activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices
                                            that involve remuneration that may be alleged to be intended to induce prescribing, purchases
                                            or recommendations may be subject to scrutiny if they do not qualify for an exception or
                                            safe harbor. A person does not need to have actual knowledge of this statute or specific
                                            intent to violate it in order to have committed a violation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            federal civil and criminal false claims laws, including, without limitation, the federal
                                            False Claims Act, which can be enforced by private citizens through civil whistleblower or
                                            qui tam actions, and civil monetary penalty laws which prohibit, among other things, individuals
                                            or entities from knowingly presenting, or causing to be presented, claims for payment or
                                            approval from the federal government, including Medicare, Medicaid and other government payors,
                                            that are false or fraudulent or knowingly making, using or causing to be made or used a false
                                            record or statement material to a false or fraudulent claim or to avoid, decrease or conceal
                                            an obligation to pay money to the federal government. A claim includes &#8220;any request
                                            or demand&#8221; for money or property presented to the U.S. federal government. Several
                                            pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly
                                            providing free product to customers with the expectation that the customers would bill federal
                                            programs for the product. Other companies have been prosecuted for causing false claims to
                                            be submitted because of the companies&#8217; marketing of products for unapproved, and thus
                                            non-reimbursable, uses. In addition, the government may assert that a claim including items
                                            or services resulting from a violation of the federal Anti-Kickback Statute constitutes a
                                            false or fraudulent claim for purposes of the federal False Claims Act;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">HIPAA
                                            which created additional federal criminal statutes which prohibit, among other things, a
                                            person from knowingly and willfully executing, or attempting to execute, a scheme to defraud
                                            any healthcare benefit program, including private third-party payors and knowingly and willfully
                                            falsifying, concealing or covering up a material fact or making any materially false, fictitious
                                            or fraudulent statement in connection with the delivery of or payment for healthcare benefits,
                                            items or services. Similar to the federal Anti-Kickback Statute, a person or entity does
                                            not need to have actual knowledge of the statute or specific intent to violate it in order
                                            to have committed a violation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">the
                                            federal transparency laws, including the federal Physician Payments Sunshine Act, which requires
                                            certain manufacturers of drugs, medical devices, biologicals and medical supplies for which
                                            payment is available under Medicare, Medicaid or the State Children&rsquo;s Health Insurance
                                            Program, with specific exceptions, to report annually to the CMMS, information related to:
                                            (i)&nbsp;payments or other &ldquo;transfers of value&rsquo;&rsquo; made to physicians (defined
                                            to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals,
                                            and (ii)&nbsp;ownership and investment interests held by physicians and their immediate family
                                            members. Effective January&nbsp;1, 2022, these reporting obligations extended to include
                                            transfers of value made during the previous year to physician assistants, nurse practitioners,
                                            clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists
                                            and certified nurse midwives; and</P>
</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">analogous
                                            state and foreign laws and regulations; state laws that require manufacturers to report information
                                            related to payments and other transfers of value to physicians and other healthcare providers,
                                            marketing expenditures or drug pricing; state laws that require pharmaceutical companies
                                            to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the
                                            relevant compliance guidance promulgated by the federal government, or that otherwise restrict
                                            payments that may be made to healthcare providers; and state and local laws that require
                                            the registration of pharmaceutical sales representatives.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 83 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because of the breadth of these laws and the
narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities could
be subject to challenge under one or more of such laws. It is possible that governmental authorities will conclude that our business
practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare
laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that
may apply to us, we may be subject to significant penalties, including, without limitation, civil, criminal and administrative penalties,
damages, fines, disgorgement, imprisonment, exclusion from participating in federal and state funded healthcare programs, such as Medicare
and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement
to resolve allegations of non-compliance with these laws, contractual damages, diminished profits and future earnings, reputational harm
and the curtailment or restructuring of our operations, any of which could harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The risk of our being found in violation of these
laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their
provisions are open to a variety of interpretations. Efforts to ensure that our business arrangements with third parties will comply
with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even
if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention
from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems
to comply with multiple jurisdictions with different compliance and reporting requirements increases the possibility that a healthcare
company may run afoul of one or more of the requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if we obtain regulatory approval for
PMN310, PMN442, PMN267 or any future product candidates, they will remain subject to ongoing regulatory oversight, which may result in
significant additional expense.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even
                                            if we obtain any regulatory approval for PMN310, PMN442 and PMN267 or any future product
                                            candidates, such product candidates will be subject to ongoing regulatory requirements applicable
                                            to research, development, testing, manufacturing, labeling, packaging, storage, advertising,
                                            promoting, sampling, record-keeping and submission of safety and other post-market information,
                                            among other things. Any regulatory approvals that we receive for PMN310, PMN442, PMN267 or
                                            any future product candidates may also be subject to Risk Evaluation and Mitigation Strategy,
                                            or REMS, limitations on the approved indicated uses for which the drug may be marketed or
                                            to the conditions of approval or requirements that we conduct potentially costly post-marketing
                                            testing and surveillance studies, including Phase 4 trials and surveillance to monitor the
                                            quality, safety and efficacy of the drug. An unsuccessful post-marketing study or failure
                                            to complete such a study could result in the withdrawal of marketing approval. We will further
                                            be required to immediately report any serious and unexpected adverse events and certain quality
                                            or production problems with our products to regulatory authorities along with other periodic
                                            reports. Any new legislation addressing drug safety issues could result in delays in product
                                            development or commercialization, or increased costs to assure compliance. We cannot predict
                                            the likelihood, nature or extent of government regulation that may arise from future legislation
                                            or administrative action, either in the U.S. or abroad. If we are slow or unable to adapt
                                            to changes in existing requirements or the adoption of new requirements or policies, or if
                                            we are not able to maintain regulatory compliance, we may lose any marketing approval that
                                            we may have obtained and we may not achieve or sustain profitability.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, drug manufacturers are subject to
payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP
requirements and adherence to commitments made in the BLA or foreign marketing application. If we, or a regulatory authority, discover
previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility
where the product is manufactured or if a regulatory authority disagrees with the promotion, marketing or labeling of that drug, a regulatory
authority may impose restrictions relative to that drug, the manufacturing facility or us, including requesting a recall or requiring
withdrawal of the drug from the market or suspension of manufacturing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 84 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we fail to comply with applicable regulatory
requirements following approval of a product candidate, a regulatory authority may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">issue
                                            a Form&nbsp;483, an untitled letter or warning letter asserting that we are in violation
                                            of the law;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">seek
                                            an injunction or impose administrative, civil or criminal penalties or monetary fines;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">issue
                                            a safety alert, Dear Healthcare Provider letter, press release or other communication containing
                                            warnings or safety information about the product;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">mandate
                                            corrections to promotional materials and labeling or issuance of corrective information;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">suspend
                                            or withdraw regulatory approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">suspend
                                            any ongoing clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">refuse
                                            to approve a pending marketing application or supplement to an approved application or comparable
                                            foreign marketing application (or any supplements thereto) submitted by us or our strategic
                                            partners;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">restrict
                                            the marketing or manufacturing of the drug;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">seize
                                            or detain the drug or otherwise require the withdrawal of the drug from the market;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">refuse
                                            to permit the import or export of products or product candidates; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">refuse
                                            to allow us to enter into supply contracts, including government contracts.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any government investigation of alleged violations
of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of
any event or penalty described above may inhibit our ability to commercialize a product candidate, if approved, and harm our business,
financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Failure to comply with health and data
protection laws and regulations could lead to government enforcement actions and civil or criminal penalties, private litigation or adverse
publicity and could negatively affect our operating results and business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to or affected by federal, state
and foreign data protection laws and regulations which address privacy and data security. In the U.S., numerous federal and state laws
and regulations, including HIPAA, as amended by HITECH, state data breach notification laws, state health information privacy laws and
federal and state consumer protection laws, including Section&nbsp;5 of the Federal Trade Commission Act, which govern the collection,
use, disclosure and protection of health-related and other personal information, may apply to our operations and the operations of any
future collaborators. In addition, we may obtain health information from third parties, including research institutions from which we
obtain clinical trial data that are subject to privacy and security requirements under HIPAA, as amended by HITECH, and other privacy
and data security laws. Depending on the facts and circumstances, we could be subject to significant administrative, civil and criminal
penalties if we obtain, use or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner
that is not authorized or permitted by HIPAA. Further, various states have implemented similar privacy laws and regulations. For example,
California also recently enacted the California Consumer Privacy Act of 2018, or CCPA. The CCPA gives California residents expanded rights
to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about
how their personal information is used. The CCPA also provides for civil penalties for violations, as well as a private right of action
for data breaches that is expected to increase data breach litigation. The CCPA went into effect on January&nbsp;1, 2020 and grants the
California Attorney General the power to bring enforcement actions for violations beginning July&nbsp;1, 2020. The CCPA has been amended
from time to time, and it remains unclear what, if any, further modifications will be made to this legislation or how it will be interpreted.
As currently written, the CCPA may impact our business activities and as a result may increase our compliance costs and potential liability.
Many similar privacy laws have been proposed at the federal level and in other states.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 85 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign data protection laws, including Regulation&nbsp;2016/679,
known as the General Data Protection Regulation, or GDPR, may also apply to health-related and other personal information data subjects
in the EU or the United Kingdom, or UK. The GDPR went into effect on May&nbsp;25, 2018. Companies that must comply with the GDPR face
increased compliance obligations and risk, including robust regulatory enforcement of data protection requirements as well as potential
fines for noncompliance of up to &#8364;20&nbsp;million or 4% of annual global revenue of the noncompliance company, whichever is greater.
The GDPR imposes numerous requirements for the collection, use, storage and disclosure of personal information of EU or UK data subjects,
including requirements relating to providing notice to and obtaining consent from data subjects, personal data breach notification, cross-border
transfers of personal information, and honoring and providing for the rights of EU or UK individuals in relation to their personal information,
including the right to access, correct and delete their data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compliance with U.S. and foreign data protection
laws and regulations could require us to take on more onerous obligations in our contracts, require us to engage in costly compliance
exercises, restrict our ability to collect, use and disclose data, or in some cases, impact our or our partners&#8217; or suppliers&#8217;
ability to operate in certain jurisdictions. Failure to comply with U.S. and foreign data protection laws and regulations could result
in government investigations and/or enforcement actions, fines, civil or criminal penalties, private litigation or adverse publicity
and could negatively affect our operating results and business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moreover, clinical trial subjects about whom
we or any of our potential collaborators obtain information, as well as the providers who share this information with us, may contractually
limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply
with data protection laws or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming
to defend and could result in adverse publicity that could materially and adversely affect our business, financial condition, results
of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if we obtain FDA or EMA approval any
of our product candidates in the U.S. or European Union, we may never obtain approval for or commercialize any of them in any other jurisdiction,
which would limit our ability to realize their full market potential.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to market any products in any particular
jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a&nbsp;country-by-country&nbsp;basis
regarding safety and efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approval by the FDA in the U.S. or the EMA in
the European Union does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain
approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in
one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee
regulatory approval in any other country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approval processes vary among countries and can
involve additional product testing and validation and additional administrative review periods. In many jurisdictions outside the U.S.,
a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price
that we intend to charge for our products is also subject to approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 86 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Seeking foreign regulatory approval could result
in difficulties and increased costs for us and require additional nonclinical studies or clinical trials, which could be costly and time
consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products
in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets,
and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements
in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed,
our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Healthcare legislative or regulatory reform
measures may have a negative impact on our business and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The U.S. and many foreign jurisdictions have
enacted or proposed legislative and regulatory changes affecting the healthcare system. The U.S. government, state legislatures and foreign
governments also have shown significant interest in implementing cost-containment programs to limit the growth of government-paid healthcare
costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription
drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Affordable Care Act substantially changed
the way healthcare is financed by both governmental and private insurers, and significantly impacts the pharmaceutical industry. The
Affordable Care Act is intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance
remedies against healthcare fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose
new taxes and fees on pharmaceutical and medical device manufacturers, and impose additional health policy reforms. Among other things,
the Affordable Care Act expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum
Medicaid rebate for both branded and generic drugs, expanded the 340B program, and revised the definition of AMP, which could increase
the amount of Medicaid drug rebates manufacturers are required to pay to states. The legislation also extended Medicaid drug rebates,
previously due only on fee-for-service Medicaid utilization, to include the utilization of Medicaid managed care organizations as well
and created an alternative rebate formula for certain new formulations of certain existing products that is intended to increase the
number of rebates due on those drugs. On February&nbsp;1, 2016, CMMS issued final regulations to implement the changes to the Medicaid
Drug Rebate program under the Affordable Care Act. These regulations became effective on April&nbsp;1, 2016. Since that time, there have
been significant ongoing efforts to modify or eliminate the Affordable Care Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Affordable Care Act has been subject to challenges
in the courts. On December&nbsp;14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in
its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. On December&nbsp;18, 2019, the Fifth Circuit U.S.
Court of Appeals held that the individual mandate is unconstitutional and remanded the case to the Texas District Court to reconsider
its earlier invalidation of the entire Affordable Care Act. An appeal was taken to the U.S. Supreme Court. On June&nbsp;17, 2021, the
U.S. Supreme Court ruled that the plaintiffs lacked standing to challenge the law as they had not alleged personal injury traceable to
the allegedly unlawful conduct.&nbsp; As a result, the U.S. Supreme Court did not rule&nbsp;on the constitutionality of the Affordable
Care Act or any of its provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other legislative changes have been proposed
and adopted since passage of the Affordable Care Act and we expect that additional federal, state and foreign healthcare reform measures
will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products
and services, which could result in limited coverage and reimbursement and reduced demand for our product candidates, if approved, or
additional pricing pressures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 87 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our business activities may be subject
to the FCPA and similar anti-bribery and anti-corruption laws.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business activities may be subject to the
FCPA, U.S. domestic bribery statutes, and similar anti-bribery or anti-corruption laws, regulations or rules&nbsp;of other countries
in which we may operate, including the U.K. Bribery Act of 2010. The FCPA generally prohibits offering, promising, giving, or authorizing
others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action,
or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and
fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our
business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments.
Additionally, in many other countries, hospitals are owned and operated by the government, and doctors and other hospital employees would
be considered foreign officials under the FCPA. There is no certainty that all of our employees, agents, contractors or those of our
affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations
of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down
of our facilities, implementation of compliance programs and prohibitions on the conduct of our business. Any such violations could include
prohibitions on our ability to offer our product candidates in one or more countries and could materially damage our reputation, our
brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results
and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our employees, independent contractors,
consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory
standards and requirements and insider trading, which could significantly harm our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are exposed to the risk of fraud or other
misconduct by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could
include intentional failures to comply with the regulations of the FDA and non-U.S. regulators, provide accurate information to the FDA
and non-U.S. regulators, comply with health care fraud and abuse laws and regulations in the U.S. and abroad, report financial information
or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health
care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other
abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion,
sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use
of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation.
It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity
may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other
actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us,
those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our insurance policies are expensive and
only protect us from some business risks, which will leave us exposed to significant uninsured liabilities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not carry insurance for all categories
of risk that our business may encounter. Some of the policies we currently maintain include general liability, products liability and
directors&#8217; and officers&#8217; insurance. We do not know, however, if we will be able to maintain insurance with adequate levels
of coverage. Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product
liability claims could prevent or inhibit the commercialization of PMN310 or any other product candidate. Any significant uninsured liability
may require us to pay substantial amounts, which would adversely affect our financial position and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="fulla_008"></A>Risks Related to Our
Business and Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We face significant competition in an environment
of rapid technological and scientific change, and there is a possibility that our competitors may achieve regulatory approval before
us or develop therapies that are safer or more effective than ours.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The development and commercialization of new
drugs is highly competitive. Moreover, the AD field is characterized by strong competition and a strong emphasis on intellectual property.
We may face competition with respect to any product candidates that we seek to develop or commercialize in the future from major pharmaceutical
companies, specialty pharmaceutical companies and biotechnology companies worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 88 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Potential competitors also include academic institutions,
government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative
arrangements for research, development, manufacturing and commercialization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
approved, PMN310 will compete with therapies currently approved for the treatment of patients with AD, which have primarily been developed
to treat the symptoms of AD rather than the underlying cause of the disease, such as memantine and cholinesterase inhibitors. PMN310
may also compete with one or more potentially disease-modifying therapeutics that target A</FONT>&#946; or amyloid plaques. Biogen&#8217;s
aducanumab was approved by the FDA in June&nbsp;2021 under the accelerated approval pathway, which allows for earlier approval of drugs
that treat serious conditions, and that fill an unmet medical need based on a surrogate endpoint. Regulatory approval of aducanumab is
pending in Europe and Japan. Other companies known to be developing therapies with A&#946;/amyloid plaque-related targets include Alzheon,&nbsp;Inc.,
Alzinova AB, Chugai Pharmaceutical Co. Ltd., Cognition Therapeutics,&nbsp;Inc., Eisai Co.,&nbsp;Ltd., Eli Lilly and Company, Grifols,
S.A., KalGene Pharmaceuticals,&nbsp;Inc., Neurimmune AG, Novartis AG, Acumen Pharmaceuticals Inc., Prothena Biosciences,&nbsp;Inc., Roche
Holding AG (including Genentech, its wholly owned subsidiary) and Wren Therapeutics,&nbsp;Inc. Additionally, PMN310, if approved, may
also compete with other potential therapies intended to address underlying causes of AD that are being developed by several companies,
including AbbVie Inc., AC Immune SA, Alector,&nbsp;Inc., Anavex Life Sciences Corp., Annovis Bio,&nbsp;Inc., Athira Pharma,&nbsp;Inc.,
Biohaven Pharmaceuticals,&nbsp;Inc., Cassava Sciences,&nbsp;Inc., Cortexyme,&nbsp;Inc., Denali Therapeutics,&nbsp;Inc., Johnson&nbsp;&amp;
Johnson (including Janssen, its wholly-owned subsidiary) and Takeda Pharmaceutical Co. Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many of our current or potential competitors,
either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development,
manufacturing, nonclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved product candidates
than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated
among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly
through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining
qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as
well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated
if our competitors develop and commercialize product candidates that are safer, more effective, have fewer or less severe side effects,
are more convenient, or are less expensive than any product candidates that we may develop. Furthermore, currently approved product candidates
could be discovered to have application for treatment of AD, which could give such product candidates significant regulatory and market
timing advantages over any of our product candidates. Our competitors also may obtain FDA, EMA or other regulatory approval for their
product candidates more rapidly than we may obtain approval for ours from the FDA, which could result in our competitors establishing
a strong market position before we are able to enter the market. Additionally, product candidates or technologies developed by our competitors
may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates
we may develop against competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our competitors market product candidates
that are more effective, safer or less expensive than our product candidates, if approved, or that reach the market sooner than our product
candidates, we may not achieve commercial success. In addition, the pharmaceutical industry is characterized by rapid technological change.
If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or product
candidates developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 89 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Ownership of Our Common Shares
and Our Status as a U.S. Public Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Investment in the Company&rsquo;s Common
Shares is speculative, involves risk, and there is no guarantee of a return.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no guarantee that the Common Shares
will earn any positive return in the short term or long term. A holding of Common Shares is speculative and involves a high degree of
risk and should be undertaken only by holders whose financial resources are sufficient to enable them to assume such risks and who have
no need for immediate liquidity in their investment. A holding of Common Shares is appropriate only for holders who have the capacity
to absorb a loss of some or all of their holdings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our
market, our </I></B></FONT><B><I>share price and trading volume could decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The trading market for our Common Shares will
be influenced by the research and reports that equity research analysts publish about us and our business. As a newly public company,
we anticipate having only limited research coverage by equity research analysts. Equity research analysts may elect not to provide research
coverage of our Common Shares, and such lack of research coverage may adversely affect the market price of our Common Shares. In the
event we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included
in their reports. The price of our shares could decline if one or more equity research analysts downgrade our shares or issue other unfavorable
commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly,
demand for our shares could decrease, which in turn could cause our shares price or trading volume to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Concentration of ownership of our Common
Shares among our existing executive officers, directors and principal shareholders may prevent new investors from influencing significant
corporate decisions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on their shareholdings as of June 29,
2022, our directors, executive officers and beneficial owners of greater than 5% of our outstanding shares and their respective affiliates
will beneficially own, in the aggregate, approximately 28.16% of our outstanding Common Shares. As a result, these persons, acting together,
would be able to significantly influence all matters requiring shareholder approval, including the election and removal of directors,
any merger, consolidation, sale of all or substantially all of our assets or other significant corporate transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of these persons or entities may have interests
different than yours. For example, because many of these shareholders purchased their shares at prices substantially below the estimated
public offering price and have held their shares for a longer period, they may be more interested in selling our Company to an acquirer
rather than other investors, or they may want us to pursue strategies that deviate from the interests of other shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our constating documents permit us to issue
an unlimited amount of additional Common Shares or Preferred Shares, which may prevent a third-party takeover or cause our shareholders
to experience dilution in the future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">Our
constating documents authorize us to issue an unlimited&nbsp;number of Common Shares and an unlimited&nbsp;number of&nbsp;Preferred Shares.
Our Board has the authority to cause us to issue additional Common Shares and Preferred Shares and to determine the special rights and
restrictions of the shares of one or more series of our Preferred Shares, each without consent of our shareholders. The issuance of any
such securities may result in a reduction of the book value or market price of our Common Shares. Given the fact that we have not achieved
profitability or generated positive cash flow historically, and we operate in a capital-intensive industry with significant working capital
requirements, we may be required to issue additional Common Shares or other securities that are dilutive to existing shareholders&nbsp;in
the future in order to continue our operations. Our efforts to fund our intended business plan may result in dilution to existing shareholders.
Further, any such issuances could result in a change of control or a reduction in the market price for our Common Shares. Additionally,
the rights of the holders of Common Shares&nbsp;will be subject to, and may be adversely affected by, the rights of holders of any Preferred
Shares that may be issued in the future. For example, Preferred Shares typically rank senior to Common Shares as to dividend rights,
liquidation preference or both and may be convertible into Common Shares. Lastly, our ability to issue Preferred Shares could make it
more difficult for a third-party to acquire a majority of our outstanding voting shares, particularly in the event we issue Preferred
Shares with special voting rights, the effect of which may be to deprive our shareholders of a control premium that might otherwise be
realized in connection with an acquisition of us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Anti-takeover provisions in our governing
documents and under Canadian Law could prevent or delay transactions that shareholders may favor.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions of our governing documents and the
CBCA may discourage, delay or prevent a merger or acquisition that shareholders may consider favorable, including transactions in which
shareholders might otherwise receive a premium for their Common Shares, and may also frustrate or prevent any attempt by shareholders
to change the direction or management. For example, these provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">require
                                            a 66 <SUP>2</SUP>/3% majority of shareholder votes cast in favor of a resolution to effect
                                            various amendments to the Articles of Incorporation of the Company, as amended (the &#8220;<B>articles</B>&#8221;);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">require
                                            that in the event of shareholders of the Company vote via written resolution, that such resolution
                                            must be signed by all shareholders of the Company entitled to vote on that resolution;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">establish
                                            advance notice requirements for nominations for election to the Board at any annual or special
                                            meeting of shareholders of the Company; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
transaction in which a third party seeks to acquire our voting securities or equity securities that would result in the acquiror holding
greater than 20% of the securities of that class may be governed by Multilateral Instrument 62-104&#8212;<I>Take-Over Bids and Issuer
Bids </I>(the &quot;<B>Takeover Bid Rules</B>&quot;) promulgated by the Canadian Securities Administrators. The &quot;General Principles&quot;
of the Takeover Bid Rules&nbsp;and certain important aspects of the Takeover Bid Rules&nbsp;are described more fully in the section entitled
 &quot;<I>Description of the Registrant&#8217;s Securities to be Registered</I>&quot; on page&nbsp;119.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 90 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The rights of our shareholders may differ
from the rights typically offered to shareholders of a U.S. corporation and these differences may make our Common Shares less attractive
to investors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are incorporated under the federal laws
of Canada, and, therefore, certain of the rights of holders of our shares are governed by Canadian law, including the provisions of the
CBCA, and by our articles. These rights differ in certain respects from the rights of shareholders in typical U.S. corporations and these
differences may make our Common Shares less attractive to investors. The principal differences are described in the section entitled
 &quot;<I>Description of the Registrant&rsquo;s Securities to be Registered</I>&quot; on page 119.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to attract and retain senior
management and key scientific personnel, our business may be materially and adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our success depends in part on our continued
ability to attract, retain and motivate highly qualified management and clinical and scientific personnel. We are highly dependent upon
members of our senior management, particularly our CEO, Eugene Williams, as well as our senior scientists and other members of our management
team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, initiation
or completion of our planned clinical trials or the commercialization of our product candidates or any future product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Competition for qualified personnel in the biopharmaceutical
field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need
to hire additional personnel as we expand our clinical development and if we initiate commercial activities. We may not be able to attract
and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be
subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information,
or that their former employers own their research output.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If product liability lawsuits are brought
against us, we may incur substantial liabilities and may be required to limit commercialization of our current or future product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We face an inherent risk of product liability
as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For
example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing,
manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design,
a failure to warn of dangers inherent in the product, negligence, strict liability and breach of warranty. Claims could also be asserted
under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial
liabilities or be required to limit commercialization of our product candidates. Even a successful defense would require significant
financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 91 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">decreased
                                            demand for our current or future product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">injury
                                            to our reputation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">withdrawal
                                            of clinical trial participants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">costs
                                            to defend the related litigation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">diversion
                                            of management&#8217;s time and our resources;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">substantial
                                            monetary awards to trial participants or patients;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">regulatory
                                            investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">loss
                                            of revenue; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            inability to commercialize our current or any future product candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are unable to obtain and maintain sufficient
product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims, the commercialization
of our current or any future product candidates we develop could be inhibited or prevented. We currently carry product liability insurance
covering our clinical trials. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment
or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance
coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for
which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage
limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient funds to pay such amounts.
Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us
against losses. If and when we obtain approval for marketing any of our product candidates, we intend to expand our insurance coverage
to include the sale of such product candidate; however, we may be unable to obtain this liability insurance on commercially reasonable
terms or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may explore strategic collaborations
that may never materialize or may fail.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may attempt to broaden the global reach of
our platform by selectively collaborating with leading therapeutic companies and other organizations. As a result, we may periodically
explore a variety of possible additional strategic collaborations in an effort to gain access to additional product candidates or resources.
At the current time, we cannot predict what form such a strategic collaboration might take. In the event we do form such collaborations,
we intend to retain significant economic and commercial rights to our programs in key geographic areas that are core to our long-term
strategy. We are likely to face significant competition in seeking appropriate strategic collaborators, and strategic collaborations
can be complicated and time consuming to negotiate and document. We may not be able to negotiate strategic collaborations on acceptable
terms, or at all. We are unable to predict when, if ever, we will enter into any additional strategic collaborations because of the numerous
risks and uncertainties associated with establishing them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are an &#8220;emerging growth company&#8221;
and a &#8220;smaller reporting company&#8221; and, as a result of the reduced disclosure and governance requirements applicable to emerging
growth companies and smaller reporting companies, our Common Shares may be less attractive to investors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an &#8220;emerging growth company&#8221;
as defined in the JOBS Act and we intend to take advantage of some of the exemptions from reporting requirements that are applicable
to other public companies that are not emerging growth companies, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>not being required
                                            to comply with the auditor attestation requirements in the assessment of our internal control
                                            over financial reporting;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">not
                                            being required to comply with any requirement that may be adopted by the Public Company Accounting
                                            Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s
                                            report providing additional information about the audit and the financial statements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">reduced
                                            disclosure obligations regarding executive compensation in our periodic reports, proxy statements
                                            and registration statements; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">not
                                            being required to hold a nonbinding advisory vote on executive compensation and shareholder
                                            approval of any golden parachute payments not previously approved.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot predict if investors will find our
Common Shares less attractive because we will rely on these exemptions. If some investors find our Common Shares less attractive as a
result, there may be a less active trading market for our Common Shares and our share price may be more volatile. We may take advantage
of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the
earlier of the last day of the fiscal year (i)&nbsp;following the fifth anniversary of the closing of our initial public offering, (ii)&nbsp;in
which we have total annual gross revenue of at least $1.07&nbsp;billion, or (iii)&nbsp;in which we are deemed to be a large accelerated
filer, which means the market value of our Common Shares that are held by non-affiliates exceeds $700&nbsp;million as of the prior June&nbsp;30th,
and the date on which we have issued more than $1.0&nbsp;billion in non-convertible debt during the prior three-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the JOBS Act, emerging growth companies
can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected
to take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced
disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject
to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies,
which may make comparison of our financials to those of other public companies more difficult. As a result of these elections, the information
that we provide in this Registration Statement may be different than the information you may receive from other public companies in which
you hold equity interests. In addition, it is possible that some investors will find our Common Shares less attractive as a result of
these elections, which may result in a less active trading market for our Common Shares and higher volatility in our share price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are also a &#8220;smaller reporting company&#8221;
as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company.
We may take advantage of certain of the scaled disclosures available to smaller reporting companies until the fiscal year following the
determination that our voting and non-voting Common Shares held by non-affiliates is more than $250&nbsp;million measured on the last
business day of our second fiscal quarter, or our annual revenues are more than $100&nbsp;million during the most recently completed
fiscal year and our voting and non-voting Common Shares held by non-affiliates is more than $700&nbsp;million measured on the last business
day of our second fiscal quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have never paid dividends on our capital
shares and we do not intend to pay dividends for the foreseeable future. Consequently, any gains from an investment in our Common Shares
will likely depend on whether the price of our Common Shares increases.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never declared or paid any dividends
on our Common Shares and do not intend to pay any dividends in the foreseeable future. We anticipate that we will retain all of our future
earnings for use in the operation of our business and for general corporate purposes. Any determination to pay dividends in the future
will be at the discretion of our Board. Accordingly, investors must rely on sales of their Common Shares after price appreciation, which
may never occur, as the only way to realize any future gains on their investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are subject to the continued listing
criteria of the TSX and our failure to satisfy these criteria may result in a delisting of our Common Shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Common Shares are currently listed on the
TSX. In order to maintain our listing on TSX, we must maintain certain financial and share distribution targets, including maintaining
a minimum number of public shareholders. In addition to objective standards, the TSX may delist the securities of any issuer if, in its
opinion, an issuer&rsquo;s financial condition and/or operating results appear unsatisfactory, if it appears that the extent of public
distribution or the aggregate market value of a security has become so reduced as to make continued listing on the TSX inadvisable, if
the issuer sells or disposes of principal operating assets or ceases to be an operating company, if an issuer fails to comply with the
listing requirements of TSX, or if any other event occurs or any condition exists which makes continued listing on the TSX, in the opinion
of the TSX, inadvisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the TSX delists our Common Shares, investors
may face material adverse consequences, including, but not limited to, a lack of trading market for the Common Shares, reduced liquidity,
decreased analyst coverage of the Company, and an inability for us to obtain additional financing to fund our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We cannot assure you that our Common Shares
will become listed on Nasdaq and, if listed, our failure to meet Nasdaq&rsquo;s continued listing requirements could result in a delisting
of our Common Shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although we have submitted an application
to list our Common Shares on Nasdaq, we cannot assure you that we will be able to meet the initial listing standards, including the minimum
per share price and minimum capitalization requirements, or that we will be able to maintain a listing of our Common Shares on any such
trading venue. For example, we effected the Reverse Share Split to meet Nasdaq&rsquo;s minimum per share requirement for initially listing
our shares on Nasdaq. However, the effect of the Reverse Share Split on the market price of our Common Shares cannot be predicted with
certainty, and it is possible that the market price of our Common Shares following the Reverse Share Split will not be in compliance
with the minimum bid price requirement to maintain listing on Nasdaq. If, after listing, we fail to satisfy any of Nasdaq&rsquo;s continued
listing requirements, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps
to delist our Common Shares. Such a delisting would likely have a negative effect on the price of our Common Shares and would impair
your ability to sell or purchase our Common Shares when you wish to do so. In the event of a delisting, we can provide no assurance that
any action taken by us to restore compliance with listing requirements would allow our Common Shares to become listed again, stabilize
the market price or improve the liquidity of our Common Shares, prevent our Common Shares from dropping below the required minimum bid
price or prevent future non-compliance with Nasdaq listing requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our internal controls over financial reporting
may not be effective, which could have a material and adverse effect on our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is subject to reporting and other
obligations under applicable Canadian securities laws and rules&nbsp;of any stock exchange on which the Common Shares are listed, including
NI 52-109, and upon effectiveness of this Registration Statement, will be subject to U.S. securities reporting and regulatory requirements.
These reporting and other obligations place significant demands on our management, administrative, operational and accounting resources.
If we are unable to accomplish any such necessary objectives in a timely and effective manner, our ability to comply with our financial
reporting obligations and other rules&nbsp;applicable to reporting issuers could be impaired. Moreover, any failure to maintain effective
internal controls could cause us to fail to satisfy our reporting obligations or result in material misstatements in our financial statements.
If we cannot provide reliable financial reports or prevent fraud, our reputation and operating results could be materially adversely
affected, which could also cause investors to lose confidence in our reported financial information, which could result in a reduction
in the trading price of the Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not expect that its disclosure
controls and procedures and internal controls over financial reporting will prevent all error or fraud. A control system, no matter how
well-designed and implemented, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be
met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls
must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide
absolute assurance that all control issues within an organization are detected. The inherent limitations include the realities that judgments
in decision making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Controls can also be circumvented
by individual acts of certain persons, by collusion of two or more people or by management override of the controls. Due to the inherent
limitations in a control system, misstatements due to error or fraud may occur and may not be detected in a timely manner or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 94 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The elimination of monetary liability against
our directors, officers, and employees under Canadian law and the existence of indemnification rights for our obligations to our directors,
officers, and employees may result in substantial expenditures by us and may discourage lawsuits against our directors, officers, and
employees.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
by-laws </FONT>provide that, subject to the CBCA, we may indemnify a director or officer or a former director or officer or a corporation
of which the we are or were a shareholder or creditor and their heirs and legal representatives of such person against all costs, charges,
and expenses including and amount to be paid to settle an action or satisfy a judgment, reasonably incurred in respect of any civil,
criminal or administrative action or proceeding to which they are made a party by reason of being or having been a director or officer
of us or a director or officer of any such corporation. Each director and officer upon being elected and appointed shall be deemed to
have contracted with us on the terms of this indemnity. The failure of a director or officer to comply with the provisions of the CBCA
or the articles or the by-laws shall not invalidate any indemnity to which they are entitled under the by-laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may also have contractual indemnification
obligations under any future employment agreements with our officers or agreements entered into with our directors. The foregoing indemnification
obligations could result in us incurring substantial expenditures to cover the cost of settlement or damage awards against directors
and officers, which we may be unable to recoup. These provisions and the resulting costs may also discourage us from bringing a lawsuit
against directors and officers for breaches of their fiduciary duties, and may similarly discourage the filing of derivative litigation
by our shareholders against our directors and officers even though such actions, if successful, might otherwise benefit us and our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There may be difficulty in enforcing judgments
and effecting service of process on directors and officers that are not citizens of the U.S.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are incorporated under the CBCA and some of
our directors and officers reside outside of the U.S., in Canada. Consequently, it may not be possible for an investor to effect service
of process within the U.S. on us or those persons. Furthermore, it may not be possible for an investor to enforce judgments obtained
in U.S. courts based upon the civil liability provisions of U.S. federal securities laws or other laws of the U.S. against us or those
persons. There is doubt as to the enforceability, in original actions in Canadian courts, of liabilities based upon U.S. federal securities
laws and as to the enforceability in Canadian courts of judgments of U.S. courts obtained in actions based upon the civil liability provisions
of the U.S. federal securities laws. Therefore, it may not be possible to enforce those actions against us and certain of our directors
and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are characterized as a passive foreign
investment company (&#8220;PFIC&#8221;), U.S. Holders may be subject to adverse U.S. federal income tax consequences.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on our current operations, income, assets
and certain estimates and projections, including as to the relative values of our assets, including goodwill, which is based on the expected
price of our Common Shares, we were not a PFIC for the 2021 taxable year and do not expect to be a PFIC for the 2022 taxable year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, we must make an annual determination
as to whether we are a PFIC based on the types of income we earn and the types and value of our assets from time to time, all of which
are subject to change. Therefore, we cannot assure you that we will not be a PFIC for our current taxable year or any future taxable
year. A non-U.S. corporation generally will be considered a PFIC for any taxable year if either (1)&nbsp;at least 75% of its gross income
is passive income or (2)&nbsp;at least 50% of the value of its assets (based on an average of the quarterly values of the assets during
a taxable year) is attributable to assets that produce or are held for the production of passive income. The market value of our assets
may be determined in large part by the market price of the Common Shares, which is likely to fluctuate. In addition, the composition
of our income and assets will be affected by how, and how quickly, we use any cash that we raise. If we were to be treated as a PFIC
for any taxable year during which you hold Common Shares, certain adverse U.S. federal income tax consequences could apply to U.S. Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of this discussion, a &ldquo;U.S.
Holder&rdquo; is a holder who, for U.S. federal income tax purposes, is a beneficial owner of Common Shares, and who is: (i)&nbsp;an
individual who is a citizen or individual resident of U.S.; (ii)&nbsp;a corporation, or other entity taxable as a corporation, created
or organized in or under the laws of the U.S., any state therein or the District of Columbia; (iii)&nbsp;an estate the income of which
is subject to U.S. federal income taxation regardless of its source; or (iv)&nbsp;a trust if (1)&nbsp;a U.S. court is able to exercise
primary supervision over the administration of the trust and one or more U.S. persons have authority to control all substantial decisions
of the trust or (2)&nbsp;the trust has a valid election in effect to be treated as a U.S. person under applicable U.S. Treasury Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 95 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will incur increased costs and demands
upon management as a result of being a public company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a public company listed in the U.S., we will
incur significant additional legal, accounting and other costs. These additional costs could negatively affect our financial results.
In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented
by the SEC and Nasdaq, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations
and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance
is provided by regulatory and governing bodies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to invest resources to comply with
evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion
of management&#8217;s time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts
to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against
us and our business may be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Failure to comply with these rules&nbsp;might
also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might
be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The
impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our Board, on committees
of our Board or as members of senior management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Comprehensive tax reform legislation could
adversely affect our business and financial condition.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The rules dealing with U.S. federal, state and
local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service
and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders
of our Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additional changes to U.S. federal income tax
law are currently being contemplated, and future changes in tax laws could have a material adverse effect on our business, cash flow,
financial condition or results of operations. It cannot be predicted whether, when, in what form, or with what effective dates, new tax
laws may be enacted, or regulations and rulings may be enacted, promulgated or issued under existing or new tax laws, which could result
in an increase in our or our stockholders&rsquo; tax liability or require changes in the manner in which we operate in order to minimize
or mitigate any adverse effects of changes in tax law or in the interpretation thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 96 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our business and operations would suffer
in the event of computer system failures, cyberattacks or a deficiency in our cybersecurity or a natural disaster.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Despite the implementation of security measures,
our internal computer systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses, malware,
natural disasters, terrorism, war, telecommunication and electrical failures, cyberattacks or cyber-intrusions over the Internet, attachments
to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a security breach
or disruption, particularly through cyberattacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists,
has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased.
If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development
programs. For example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our
regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption
or security breach was to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary
information, we could incur material legal claims and liability and damage to our reputation, and the further development of our product
candidates could be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Disruptions at the FDA, the SEC and other
government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership
and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent
those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact
our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ability of the FDA to review and approve
new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key
personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have
fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations
may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid
and unpredictable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Disruptions at the FDA and other agencies may
also slow the time necessary for new drugs or biologics to be reviewed and approved by necessary government agencies, which would adversely
affect our business. For example, over the last several years, including most recently from December&nbsp;22, 2018 to January&nbsp;25,
2019, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough
critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly
impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on
our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FDA and regulatory authorities outside the U.S.
may adopt policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities. In response
to the COVID-19 pandemic, on March&nbsp;10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing
facilities and products while local, national and international conditions warrant. On March&nbsp;18, 2020, the FDA announced its intention
to temporarily postpone routine surveillance inspections of domestic manufacturing facilities and provided guidance regarding the conduct
of clinical trials, which the FDA continues to update. As of June&nbsp;23, 2020, the FDA noted it was continuing to ensure timely reviews
of applications for medical products during the COVID-19 pandemic in line with its user fee performance goals and conducting mission
critical domestic and foreign inspections to ensure compliance of manufacturing facilities with FDA quality standards. As of July&nbsp;2020,
utilizing a rating system to assist in determining when and where it is safest to conduct such inspections based on data about the virus&rsquo;
trajectory in a given state and locality and the rules&nbsp;and guidelines that are put in place by state and local governments, FDA
is either continuing to, on a case-by-case basis, conduct only mission critical inspections, or, where possible to do so safely, resuming
prioritized domestic inspections, which generally include pre-approval inspections. Foreign pre-approval inspections that are not deemed
mission-critical remain postponed, while those deemed mission-critical will be considered for inspection on a case-by-case basis. FDA
will use similar data to inform resumption of prioritized operations abroad as it becomes feasible and advisable to do so. The FDA may
not be able to maintain this pace and delays or setbacks are possible in the future. Should FDA determine that an inspection is necessary
for approval, and an inspection cannot be completed during the review cycle due to restrictions on travel, FDA has stated that it generally
intends to issue a complete response letter. Further, if there is inadequate information to make a determination on the acceptability
of a facility, FDA may defer action on the application until an inspection can be completed. Additionally, regulatory authorities outside
the U.S. may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their
regulatory activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 97 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a prolonged government shutdown occurs, or
if global health concerns prevent the FDA or other regulatory authorities from conducting business as usual or conducting inspections,
reviews or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory
submissions, which could have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Unfavorable global economic conditions
could adversely affect our business, financial condition or results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our results of operations could be adversely
affected by general conditions in the global economy and in the global financial markets. Portions of our future clinical trials may
be conducted outside of the U.S. and unfavorable economic conditions resulting in the weakening of the U.S. dollar would make those clinical
trials more costly to operate. Furthermore, a severe or prolonged economic downturn, including a recession or depression resulting from
the current COVID-19 pandemic or other public health crises, weather catastrophe, acts of terrorism, war (such as the military conflict
between Russia and Ukraine), threats of terrorist attacks or war, political disruption or other events outside of our control could result
in a variety of risks to our business, including, among other things, weakened demand for our product candidates or any future product
candidates, if approved, and our ability to raise additional capital when needed on acceptable terms, if at all. Any of the foregoing
could seriously harm our business, and we cannot anticipate all of the ways in which the political or economic climate and financial
market conditions could seriously harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 98 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="g_001"></A><FONT STYLE="text-transform: uppercase"><B>ITEM
2. FINANCIAL INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="g_002"></A>MANAGEMENT'S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS<SUP></SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>All references in this management&rsquo;s
discussion and analysis of financial condition and results of operations, or MD&amp;A, to the &ldquo;Company&rdquo;,
 &ldquo;ProMIS&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo;, or &ldquo;our&rdquo; refer to ProMIS Neurosciences Inc., unless otherwise
indicated or the context requires otherwise. The following MD&amp;A is prepared as of July 1, 2022 for the year ended December 31,
2021 and 2020 and for the three months ended March 31, 2022 and 2021 and should be read in conjunction with the audited consolidated
financial statements for the year ended December 31, 2021 and 2020 and the unaudited condensed consolidated interim financial
statements for the three months ended March 31, 2022 and 2021 (collectively, the &ldquo;<B>Financial Statements</B>&rdquo;), which
have been prepared by management in accordance with United States generally accepted accounting principles (&ldquo;<B>U.S.
GAAP</B>&rdquo;) as issued by the Financial Accounting Standards Board (&ldquo;<B>FASB</B>&rdquo;). All dollar amounts refer to
United States dollars, except as stated otherwise. Unless otherwise stated herein, all share and per share numbers relating to the
Company&rsquo;s Common Shares prior to the effectiveness of the Reverse Share Split&nbsp;have been adjusted to give effect to the
Reverse Share Split.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are applying our patented technology platform
to build a portfolio of antibody therapies, therapeutic vaccines, and other antibody-based therapies in neurodegenerative diseases and
other misfolded diseases, including AD, MSA, and ALS. The Company also plans to investigate additional synucleinopathies, including PD,
DLB, FTLD, PSP, CBD and schizophrenia. These diseases share a common biologic cause &ndash; misfolded versions of proteins, that otherwise
perform a normal function, become toxic and kill neurons, resulting in disease. ProMIS&rsquo; technology platform is an example of the
advances in drug discovery enabled by computational power, in silico discovery, and/or artificial intelligence. We believe this platform
provides a potential advantage in selectively targeting the toxic misfolded proteins with therapeutics or detecting them with diagnostics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are developing a pipeline of antibodies aimed
at selectively targeting misfolded toxic forms of proteins that drive neurodegenerative diseases without interfering with the essential
functions of the same properly folded proteins. Our product candidates are PMN310, PMN442, and PMN267. Our lead product candidate is
PMN310, a monoclonal antibody designed to treat AD by selectively targeting the toxic misfolded form of A&beta;. In light of research
suggesting that misfolded toxic a-syn is a primary driver of disease, our second lead product candidate, PMN442, shows robust binding
to a-syn oligomers and seeding fibrils in preclinical studies, with negligible binding to a-syn monomers and physiologic tetramers which
are required for normal neuronal function. PMN267 is our third lead product candidate, which has been shown in preclinical studies to
selectively recognize misfolded, cytoplasmic TDP-43 aggregates without interacting with endogenous normal TDP-43. TDP-43 is believed
to play an important role in the development of ALS. We also have a number of development programs as discussed in the Business section
of this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are incorporated under the CBCA and located
at 1920 Yonge Street, Toronto, Ontario. We are traded on the TSX under the symbol PMN and on the OTCQB Venture Market under the symbol
ARFXD. We have a wholly-owned U.S. subsidiary, ProMIS USA, which was incorporated in January 2016 in the State of Delaware. ProMIS USA
has had no activity and has no financial impact on our Financial Statements. Since our inception, we have devoted substantially all of
our resources to developing our platform technologies, building our intellectual property portfolio, business planning, raising capital
and providing general and administrative support for these operations. We have principally financed our operations through private placements
of common shares and warrants and convertible debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have incurred significant operating losses
since inception. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development
and eventual commercialization of our product candidates and any future product candidates. Our net losses were $9.8&nbsp;million and
$4.3&nbsp;million for the years ended December&nbsp;31, 2021 and December 31, 2020, respectively, and were $2.1 million and $6.1 million
for the three months ended March 31, 2022 and 2021, respectively. As of December&nbsp;31, 2021 and March 31, 2022, we had an accumulated
deficit of $62.2 million and $64.3 million, respectively. We expect to continue to incur net losses for the foreseeable future and expect
our research and development expenses, general and administrative expenses and capital expenditures to increase. In particular, we expect
our expenses to increase as we continue our development of, and seek regulatory approvals for, our product candidates, as well as initiate
clinical trials, hire additional personnel, pay fees to outside consultants, lawyers and accountants, and incur other increased costs
associated with being a public company. In addition, if we obtain marketing approval for any product candidates, we expect to incur significant
commercialization expenses related to product manufacturing, marketing, sales and distribution. We may also incur expenses in connection
with the in-licensing or acquisition of additional product candidates. Furthermore, upon the effectiveness of this Registration Statement,
we expect to incur additional costs associated with operating as a public company in the United States, including significant legal,
accounting, investor relations, compliance and other expenses that we did not incur as a public Canadian company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">As a result, we will need substantial
additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant
revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings, or other capital
sources, which may include collaborations with other companies or other strategic transactions. We may be unable to raise additional
funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter
into such agreements as and when needed, we may have to significantly delay, reduce or eliminate the development and commercialization
of one or more of our product candidates or delay our pursuit of potential in-licenses or acquisitions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 99 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Because of the numerous risks
and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or
if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable.
If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations
at planned levels and be forced to reduce or terminate our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect that our cash of $13.8&nbsp;million
as of March 31, 2022, will be sufficient to fund the Company&rsquo;s operating expenses for at least 12 months from the date this Registration
Statement is issued. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital
resources sooner than we expect. See &ldquo;<I>Liquidity and Capital Resources</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Components of Operating Results</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Revenue </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">We have not generated any revenue
since our inception and do not expect to generate any revenue from the sale of our products in the near future, if at all. If our product
candidates are successful and result in marketing approval or if we enter into collaboration or license agreements with third parties,
we may generate revenue in the future from a combination of product sales or payments from such collaboration or license agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Operating Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Research and Development Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Research and development expenses
consist primarily of costs incurred in connection with the development and research of our platform technologies, as well as unrelated
discovery program expenses. We expense research and development costs in the periods in which they are incurred. These expenses include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">employee-related
                                            expenses, including salaries, related benefits and share-based compensation expense, for
                                            employees engaged in research and development activities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">external
                                            research and development expenses incurred under arrangements with third parties, such as
                                            contract research organizations or CROs, and consultants;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            cost of acquiring, developing, and manufacturing clinical study materials; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">costs
                                            associated with preclinical and clinical activities and regulatory operations.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 44.75pt 0pt 0.75in; text-align: justify; text-indent: -19.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">We enter into consulting, research,
and other agreements with commercial entities, researchers, universities, and others for the provision of goods and services. Such arrangements
are generally cancelable upon reasonable notice and payment of costs incurred. Costs are considered incurred based on an evaluation of
the progress to completion of specific tasks under each contract using information and data provided by the respective vendors, including
our clinical sites. These costs consist of direct and indirect costs associated with our platform technologies, as well as fees paid
to various entities that perform certain research on our behalf. Depending upon the timing of payments to the service providers, we recognize
prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses are based on management&#8217;s estimates
of the work performed under service agreements, milestones achieved, and experience with similar contracts. We monitor each of these
factors and adjust estimates accordingly. See &#8220;<I>Item 1A. Risk Factors</I>&#8221; in this document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Research and development activities
account for a significant portion of our operating expenses. We expect our research and development expenses to increase substantially
for the foreseeable future as we continue to implement our business strategy, which includes advancing our platform technologies through
clinical development as well as other product candidates into clinical development, expanding our research and development efforts, including
hiring additional personnel to support our research efforts, our clinical and product development efforts, and seeking regulatory approvals
for our product candidates that successfully complete clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<!-- Field: Split-Segment; Name: 1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">We use our personnel and infrastructure
resources across multiple research and development programs directed toward identifying and developing product candidates. Our direct
research and development expenses consist primarily of external costs, including fees paid to consultants, contractors and CROs in connection
with our development activities and the cost of acquiring, developing, and manufacturing clinical study materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">General and administrative expenses
consist primarily of personnel costs including salary, bonus, employee-benefits and share-based compensation, costs incurred in development
and protection of intellectual property, professional service fees, and other general overhead and facility costs, (including rent) depreciation
and amortization. We expect our general and administrative expenses to increase substantially for the foreseeable future as we increase
our administrative function to support the growth of the business and its continued research and development activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Other (Expense) Income</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Other (expense) income consists primarily of interest expense on our
Debentures and changes in the fair value of our financial instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal">Result of Operations</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Years Ended December 31, 2021 and 2020</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes our results of
operations for the periods presented:</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Years Ended December 31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2021</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2020</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Change</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Operating expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 61%; padding-left: 0.25in"><FONT STYLE="font-size: 10pt">Research and development</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">4,627,386</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">2,224,650</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">2,402,736</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt; padding-left: 0.25in"><FONT STYLE="font-size: 10pt">General and administrative</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">3,663,707</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">2,026,957</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,636,750</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 27pt"><FONT STYLE="font-size: 10pt">Total operating expenses</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">8,291,093</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">4,251,607</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">4,039,486</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Loss from operations</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(8,291,093</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(4,251,607</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4,039,486</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Other (expense)/income</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(1,499,013</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,327</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,500,340</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 27pt"><FONT STYLE="font-size: 10pt">Net loss</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(9,790,106</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(4,250,280</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">5,539,826</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Research and Development Expenses</I></B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table summarizes
the period-over-period changes in research and development expenses for the periods presented:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Years Ended December 31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2021</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2020</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Change</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 61%"><FONT STYLE="font-size: 10pt">Direct research and development expenses by program</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">PMN310</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,654,430</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">530,015</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,124,415</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">ALS</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">376,656</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">19,193</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">357,463</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Platform and other programs</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">346,655</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">176,173</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">170,482</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Indirect research and development expenses:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Personnel related expense, including share-based compensation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">741,121</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,358,575</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(617,454</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Consulting expense</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">462,699</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">129,013</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">333,686</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Other operating costs</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">45,825</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">11,681</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">34,144</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total research and development expenses</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">4,627,386</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">2,224,650</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">2,402,736</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses increased by
$2.4 million, or 108%, for the year ended December 31, 2021 compared to the year ended December 31, 2020. This increase is attributable
to a $2.7 million increase in direct research and development expenses related to a $2.1 million increase in spending on our lead program,
PMN310, largely attributable to $1.8 million of expenses on pre-clinical preparation costs and $0.3 million on external research costs,
a $0.4 million expenses on external research costs on ALS portfolio projects and a $0.2 million increase in spending on our platform
technology and other projects. The $0.3 million increase in consulting expense relates to various consultants advising on the preparation
of the IND and design of preclinical and clinical trials. The increases were partially offset by a decrease of $0.6 million in personnel
related expenses due to a reduction in management compensation and the attrition of contracted staff.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 101 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>General and Administrative Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table summarizes
the period-over-period changes in general and administrative expenses for the periods presented:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Years Ended
    December 31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font: 10pt Times New Roman, Times, Serif; text-align: left">Personnel related, including share-based compensation</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">966,125</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">736,529</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">229,596</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Professional and consulting fees</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,203,685</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">973,979</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,229,706</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Patent expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">438,935</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">256,126</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">182,809</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Facility-related and other</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">54,962</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">60,323</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,361</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total general and administrative expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,663,707</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,026,957</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,636,750</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses increased
by $1.6 million, or 81%, for the year ended December 31, 2021 compared to the year ended December 31, 2020. The increase in professional
and consulting fees was primarily due to $0.6 million from the expensing of share issue costs associated with the August 2021 financing,
one-time costs of $0.4 million related to a potential listing on a stock exchange in the United States, which such listing is not assured,
increased consulting fees of $0.4 million and an increase in foreign exchange losses of $0.2 million, offset by a decrease of $0.3 million
in investor relations expenses due to decreased investor relations activities. Patent fees increased by $0.3 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Other Expense/Income</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other expense increased by $1.5 million for the
year ended December 31, 2021 compared to the year ended December 31, 2020. The increase was primarily due to $0.4 million of interest
expense incurred on the Debentures and $1.1 million due to the change in fair value of financial instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Three Months Ended March 31, 2022 and 2021</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes our results
of operations for the periods presented:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Three
    Months Ended March 31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2021</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Change</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Operating expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; width: 61%; padding-left: 0.25in"><FONT STYLE="font-size: 10pt">Research and development</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">1,902,832</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">219,592</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">1,683,240</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; padding-left: 0.25in"><FONT STYLE="font-size: 10pt">General and administrative</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">2,035,686</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">348,377</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,687,309</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 27pt"><FONT STYLE="font-size: 10pt">Total operating expenses</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">3,938,518</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">567,969</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">3,370,549</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Loss from operations</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(3,938,518</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(567,969</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(3,370,549</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Other income/(expense)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,843,673</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(5,541,342</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(7,385,015</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 27pt"><FONT STYLE="font-size: 10pt">Net loss</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(2,094,845</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(6,109,311</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">4,014,466</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Research and Development Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table summarizes
the period-over-period changes in research and development expenses for the periods presented:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Three
    Months Ended March 31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2021</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Change</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 61%"><FONT STYLE="font-size: 10pt">Direct research and development expenses by program</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">PMN310</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">998,296</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">28,162</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">970,134</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">ALS</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">110,404</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">28,924</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">81,480</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Platform and other programs</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">114,353</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">79,072</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">35,281</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Indirect research and development expenses:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Personnel related expense, including share-based compensation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">452,768</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">56,609</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">396,159</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Consulting expense</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">208,828</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10,551</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">198,277</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Other operating costs</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">18,183</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">16,274</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,909</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total research and development expenses</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">1,902,832</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">219,592</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">1,683,240</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses increased
by $1.7 million, or 768%, for the three months ended March 31, 2022 compared to the three months ended March 31, 2021. This increase
is attributable to a $1.1 million increase in direct research and development expenses related to a $1.0 million increase in spending
on our lead program, PMN310, largely attributable to $0.5 million of expenses on pre-clinical preparation costs and $0.5 million on external
research costs, $0.1 million in external research costs on ALS portfolio projects and a $0.1 million increase on our platform technology
and other projects. The $0.2 million increase in consulting expense relates to various consultants advising on the preparation of the
IND and design of preclinical and clinical trials. The increase of $0.4 million in personnel related expenses relates to the engagement
of full-time and additional management personnel.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 102; Options: NewSection; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>General and Administrative Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table summarizes
the period-over-period changes in general and administrative expenses for the periods presented:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Three
    Months Ended March 31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2021</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Change</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 61%"><FONT STYLE="font-size: 10pt">Personnel related, including share-based compensation</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">478,026</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">179,500</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">298,526</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Professional and consulting fees</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,406,685</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">158,969</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,247,716</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Patent expense</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">115,592</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">42,386</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">73,206</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Facility-related and other</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">35,383</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(32,478)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">67,861</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total general and administrative expenses</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">2,035,686</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">348,377</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">1,687,309</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses increased
by $1.7 million, or 484%, for the three months ended March 31, 2022 compared to the three months ended March 31, 2021. The increase in
professional and consulting fees included $0.8 million of one-time fees incurred in relation to the filing of this Registration Statement
and increased consulting fees of $0.1 million and legal fees of $0.1 million, and an increase in investor relations expenses of $0.2
million. Additional drivers included an increase in salaries, recruiting and other personnel related expenses of $0.3 million and patent
fees of $0.1 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Other Expense/Income</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other expense decreased by $7.4 million for
the three months ended March 31, 2022 compared to the three months ended March 31, 2021. The decrease was primarily due to $2.0 million
gain due to the change in fair value of financial instruments in the three months ended March 31, 2022 compared to a $5.5 million loss
in the three months ended March 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Liquidity and Capital Resources</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Sources of Liquidity</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a development stage company as we have
had minimal recurring revenues to date and do not expect to have significant revenues until we are able to sell a product candidate after
obtaining applicable regulatory approvals or we establish collaborations that provide funding, such as licensing fees, milestone payments,
royalties, research funding or otherwise. Operations have been financed since inception, through the sale of equity and debt securities
and the conversion of common share purchase warrants and share options. Our objectives, when managing capital, are to ensure there are
sufficient funds available to carry out our research, development and eventual commercialization programs. When we have excess funds,
we manage our liquidity risk by investing in highly liquid corporate and government bonds with staggered maturities to provide regular
cash flow for current operations. We do not hold any asset-backed commercial paper and our cash is not subject to any external restrictions.
We also manage liquidity risk by frequently monitoring actual and projected cash flows. The Board reviews and approves the Company&rsquo;s
operating and capital budgets, as well as any material transactions not in the ordinary course of business. The majority of our accounts
payable and accrued liabilities have maturities of less than three months. We are dependent on our ability to generate revenues from
our products or secure additional financing in order to continue our research and development activities and meet our ongoing obligations.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 103; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2020, we announced we had received
approval from the TSX to amend the exercise price of an aggregate of 736,375 outstanding warrants. The exercise price of the warrants
repriced was C$7.80 per share, effective April 8, 2020 and expiring on May 22, 2020. The warrants repriced ranged in exercise prices
of C$17.10 to C$28.80. At the end of the warrant repricing period, all unexercised warrants reverted to the original exercise price. All
other terms of the warrants remained unchanged. There was a total of 736,375 warrants repriced and of the repriced warrants, 158,871
were exercised during the repricing period ended May 22, 2020, for total proceeds of $0.9 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2020, we closed on a special warrant financing (&quot;<B>Special
Warrants</B>&quot;). We issued 270,326 Special Warrants for gross proceeds of $1.5 million ($1.3 million, net of issuance costs). Each
Special Warrant is exercisable, without payment of any additional consideration by the holder, into one common share and one transferable
common share warrant (&ldquo;<B>Warrant</B>&rdquo;). Each Warrant entitles the holder to acquire one common share at an exercise price
at C$12.00 per warrant share for a period of 60 months until November 4, 2025. Each Special Warrant will automatically convert at the
earlier of the date that is (i) the third business day after a receipt for a final prospectus qualifying the distribution of the shares
and warrants issuable upon the conversion of the Special Warrants and (ii) four months and one day after the issue date of the Special
Warrants. In March 2021, the Special Warrants automatically converted into 270,326 Common Shares and 270,326 Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2021, we completed a $7.0 million
private placement the Debentures. The Debentures are convertible into common shares at the option of the holder at a conversion price
of $6.00 and accrue interest at 1% per annum, which is payable annually. At the Company&rsquo;s election, accrued interest may be paid
in cash or common shares (such number of shares determined by dividing the interest due by the five-day VWAP of the common shares. The
Debentures mature on March 22, 2026. Prior to the maturity date, the Company is entitled to convert of the Debentures at the conversion
price upon raising an aggregate of $50 million in equity and/or debt. On the maturity date, the Company may redeem the outstanding principal
amount of the Debentures in either cash or common shares (at the then five-day VWAP less a 10% discount) or a combination thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2021, we announced the closing of
a public offering of 2,096,354 common share units at a price of $9.60 per Common Share unit for gross proceeds of $20.1 million. Each
common share unit consisted of one Common Share and one-quarter common share purchase warrant. Each whole warrant entitles the holder
thereof to purchase one common share at an exercise price of $12.60 per share at any time for five years. The warrants contain an acceleration
clause allowing the Company to accelerate the expiry date of the warrants to 30 days following a time period during which the common
share VWAP exceeds a TSX trading price of $37.80 for ten consecutive trading days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We incurred a net loss of $9.8 million and
$2.1 million for the year ended December 31, 2021 and three months ended March 31, 2022, respectively, and reported an accumulated deficit
of $62.2 million and $64.3 million, respectively. We expect available funds will be sufficient to fund our operating expenses for at least 12 months from the date this Registration Statement is issued. However, additional funding will be necessary to fund future research, pre-clinical and clinical activities. We will
seek additional funding through public financings, debt financings, collaboration agreements, strategic alliances and licensing agreements.
Although we have been successful in raising capital in the past, there is no assurance of success in obtaining such additional financing
on terms acceptable to us, if at all, and there is no assurance that we will be able to enter into collaborations or other arrangements.
If we are unable to obtain funding, it could force us to delay, reduce or eliminate research and development programs and product portfolio
expansion or commercialization efforts. These potential delays, reductions and eliminations could adversely affect future business prospects,
and the ability to continue operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cash Flows</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">The following table summarizes
our sources and uses of cash for the periods presented:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Years
    Ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font: 10pt Times New Roman, Times, Serif; text-align: left">Net cash used in operating activities</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">(9,305,383</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,232,532</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">(6,072,851</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net cash provided by (used in) investing activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">94,618</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(83,089</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">177,707</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net cash provided by financing activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">25,522,801</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,864,918</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22,657,883</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Effect of exchange rates on cash</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(175,018</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(24,235</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(150,783</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 13.7pt">Net increase
    (decrease) in cash</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">16,137,018</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(474,938</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">16,611,956</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Three
    Months Ended March 31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2021</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 74%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash used in operating activities</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,366,768</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(752,615</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash provided by (used in) investing activities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,057</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,058</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash provided by financing activities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,875,184</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect of exchange rates
    on cash</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">179,131</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54,175</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 13.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    increase (decrease) in cash</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,189,694</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,178,802</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><I>Cash
Flows from Operating Activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash used in operating activities was $9.3
million for the year ended December 31, 2021, <FONT STYLE="background-color: white">which consisted of a net loss of $9.8 million, partially
offset by $2.0&nbsp;million in non-cash charges and a net change of $1.6&nbsp;million in our net operating assets and liabilities. The
non-cash charges primarily consisted of the change in fair value of financial instruments of $1.1 million, share-based compensation of
$0.5 million and $0.4 million for amortization of debt discount</FONT>. Changes in cash flows related to operating assets and liabilities
primarily consisted of a $1.4 million decrease in deferred compensation for management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"></P>

<!-- Field: Page; Sequence: 104; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash used in operating activities was $3.2 million
for the year ended December 31, 2020, <FONT STYLE="background-color: white">which consisted of a net loss of $4.3 million, partially
offset by $0.4&nbsp;million in non-cash charges and a net change of $0.7&nbsp;million in our net operating assets and liabilities. The
non-cash charges primarily consisted of share-based compensation of $0.4 million</FONT>. Changes in cash flows related to operating assets
and liabilities primarily consisted of a $0.6 million increase in deferred compensation for management.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash used in operating activities was $3.4
million for the three months ended March 31, 2022, <FONT STYLE="background-color: white">which consisted of a net loss of $2.1 million,
increased by $1.8&nbsp;million in non-cash charges and offset by a net change of $0.5&nbsp;million in our net operating assets and liabilities.
The non-cash charges primarily consisted of the change in fair value of financial instruments of $2.0 million, share-based compensation
of $0.1 million and $0.1 million for amortization of debt discount</FONT>. Changes in cash flows related to operating assets and liabilities
primarily consisted of a $0.1 million decrease in prepaid expenses and other current assets and an increase of $0.4 million of accounts
payable and accrued liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash used in operating activities was $0.8
million for the three months ended March 31, 2021, <FONT STYLE="background-color: white">which consisted of a net loss of $6.1 million,
partially offset by $5.7&nbsp;million in non-cash charges and increased by a net change of $0.4&nbsp;million in our net operating assets
and liabilities. The non-cash charges primarily consisted of the change in fair value of financial instruments of $5.5 million and share-based
compensation of $0.1 million</FONT>. Changes in cash flows related to operating assets and liabilities primarily consisted of a $0.2
million increase in prepaid expenses and other current assets.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><I>Cash
Flows from Investing Activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash provided by investing activities was
$0.1 million for the year ended December 31, 2021, <FONT STYLE="background-color: white">which related primarily to the proceeds from
the sale of property and equipment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash used in investing activities was $0.1 million
for the year ended December 31, 2020, <FONT STYLE="background-color: white">which related primarily to purchases of property and equipment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash used in investing activities was nominal
for the three months ended March 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cash provided by investing activities was
nominal for the three months ended March 31, 2021, <FONT STYLE="background-color: white">which related to the investment in a Joint Venture
which was terminated during the year ended December 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><I>Cash
Flows from Financing Activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash provided by financing activities was $25.5
million for the year ended December 31, 2021, <FONT STYLE="background-color: white">which consisted of $18.6 million of proceeds from
the issuance of common share units and $6.9 million of proceeds from the issuance of the Debentures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash provided by financing activities was $2.9
million for the year ended December 31, 2020, <FONT STYLE="background-color: white">which consisted of $1.6 million of proceeds from
the issuance of common shares related to the exercise of warrants and $1.3 million of proceeds from the issuance of the Special Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">There
was no cash used in or provided by financing activities during the three months ended March 31, 2022.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white">Cash
provided by financing activities was $6.9 million for the three months ended March 31, 2021, which consisted of proceeds from convertible
debt.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white"></FONT>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify">Critical Accounting Policies and
Estimates</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our MD&amp;A is based on our Financial Statements,
which have been prepared in accordance with U.S GAAP and on a basis consistent with those accounting principles followed by us and disclosed
in Note 2 to our audited consolidated financial statements for the year ended December 31, 2021. The preparation of these Financial Statements
in conformity with U.S. GAAP requires our management to make certain judgments and estimates that affect the reported amounts of assets
and liabilities and the disclosure of contingent assets and liabilities at the date of the Financial Statements, as well as the reported
expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that
we believe are reasonable under the circumstances, the results of which form the basis for making judgement about the carrying value
of assets and liabilities that are not readily apparent from other sources. Significant estimates and judgments include, but are not
limited to, accrual for research and development expenses, the valuation of share-based compensation and the valuation of
warrant liabilities and embedded derivative liabilities. Accordingly, actual results may differ from these judgments and estimates under different assumptions or conditions
and any such difference may be material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that the following critical accounting
estimates discussed below are most important to understanding our historical and future performance, as these estimates relate to the
more significant areas involving management&rsquo;s judgments and estimates. Other than as described in Note 2 of our unaudited interim
condensed consolidated financial statements included herein, there have been no material changes to our critical accounting estimates
since December 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; background-color: white"><I>The COVID-19
Pandemic</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We anticipate that the COVID-19 pandemic may
have an impact on the development timelines of our programs. Estimates and assumptions about future events and their effects cannot be
determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, we
are not aware of any specific event or circumstance that would require the update of our estimates, assumptions and judgments. These
estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements
as soon as they become known. Actual results could differ from those estimates and any such differences may be material to our financial
statements.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; background-color: white"><I>Share-based
Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Share-based compensation expense
related to share awards granted to employees, directors and non-employees is recognized based on the grant-date estimated fair values
of the awards using the Black&nbsp;Scholes option pricing model (&quot;<B>Black Scholes</B>&quot;). The value is recognized as expense
ratably over the requisite service period, which is generally the vesting term of the award. We adjust the expense for actual forfeitures
as they occur. Share based compensation expense is classified in the accompanying consolidated statements of operations and comprehensive
loss based on the function to which the related services are provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Black-Scholes requires a number
of assumptions, of which the most significant are expected volatility, expected option term (the time from the grant date until the options
are exercised or expire) and risk-free rate. Expected volatility is determined using the historical volatility for the Company. The risk-free
interest rate is based on the yield of Canadian government bonds with a remaining term equal to the expected life of the option. Expected
dividend yield is zero because we have never paid cash dividends on common shares, and we do not expect to pay any cash dividends in
the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white"><I>Embedded
Derivatives</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2021, the Company completed a $7.0
million private placement of Debentures (see Note 10 to our audited consolidated financial statements).&nbsp; The Debentures contained
certain embedded features that were assessed for derivative accounting pursuant to ASC 815.&nbsp; &nbsp;Pursuant to ASC 815, we accounted
for the conversion feature as derivative liability and recorded the embedded conversion feature at fair value and adjust the instrument
to fair value at each reporting with the difference recorded in earnings.&nbsp; The conversion feature was initially measured and at
each reporting period using a scenario-based valuation method using a Monte Carlo model. Significant estimates are required to determine
expected volatility and risk-free interest rate. The Company determines these assumptions mainly by reference to historical experience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 105; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recently Issued Accounting Pronouncements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A description of recently issued accounting
pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our audited consolidated
financial statements appearing at the end of this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="background-color: white"><B>QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">In the normal course of business,
we are exposed to a number of financial risks that can affect our operating performance. These risks are credit risk, liquidity risk
and market risk. Our overall risk management program and prudent business practices seek to minimize any potential adverse effects on
the Company&#8217;s financial performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Credit Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject
the Company to a significant concentration of credit risk consist primarily of cash and short-term investments. We manage our exposure
to credit losses by placing our cash with accredited financial institutions, which at times, may exceed federally insured limits, and
when we have excess funds, such funds are invested in high-quality government and corporate issuers with low credit risk. Cash held is
not subject to any external restrictions. As of the year ended December 31, 2021 and three months ended March 31, 2022, a hypothetical
10% relative change in interest rates would not have a material impact on our Financial Statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0"><B><I>Liquidity Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Our exposure to liquidity risk
is dependent on purchasing obligations and raising funds to meet commitments and sustain operations. We are a pre-revenue development
stage company, and we rely on external fundraising to support our operations. We also manage liquidity risk by continuously monitoring
actual and projected cash flows. Our Board reviews and approves the Company&#8217;s operating budget, as well as any material transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0"><B><I>Foreign Currency Exchange Risk </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are exposed to foreign exchange risk on
our US dollar denominated cash and US dollar denominated liabilities. As of December 31, 2021, we held USD $17.7 million of cash and
prepaid expenses and USD $12.1 million of accounts payable, accrued liabilities, convertible debt, derivative and warrant liability.
A 10% change in the USD exchange rate on the December 31, 2021 balances would impact net loss by $0.6 million. As of March 31, 2022,
we held USD $13.7 million of cash and prepaid expenses and USD $10.3 million of accounts payable, accrued liabilities, convertible debt,
derivative and warrant liability. A 10% change in the USD exchange rate on the March 31, 2022 balances would impact net loss by $0.4
million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Inflation Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inflation generally affects us by increasing
our cost of labor, outside consultants and CROs. We do not believe that inflation had a material effect on our business, financial
condition or results of operations during the years ended December&nbsp;31, 2021 or 2020 and the three months ended March 31, 2022 or
2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 106; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="g_003"></A>ITEM
3. PROPERTIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not own or lease any material
properties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="g_004"></A><FONT STYLE="text-transform: uppercase"><B>ITEM
4. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the expected
beneficial ownership of the Company&rsquo;s Common Shares as of June 29, 2022 for (i)&nbsp;each member of the Board, (ii)&nbsp;each named
executive officer (as defined below), (iii)&nbsp;each person known to the Company to be the beneficial owner of more than 5% of the Company&rsquo;s
securities and (iv)&nbsp;the members of the Board and the executive officers of the Company as a group. Beneficial ownership is determined
according to the rules&nbsp;of the SEC. Generally, a person has beneficial ownership of a security if the person possesses sole or shared
voting or investment power of that security, including any securities of which a person has the right to acquire beneficial ownership
within 60 days. Information with respect to beneficial owners of more than 5% of the Company&rsquo;s securities is based on completed
questionnaires and related information provided by such beneficial owners as of June 29, 2022. Except as indicated, all shares of the
Company&rsquo;s securities will be owned directly, and the person or entity listed as the beneficial owner has sole voting and investment
power. Unless otherwise indicated, the address of all listed shareholders is 1920 Yonge Street, Suite&nbsp;200, Toronto, Ontario, M4S
3E2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    and Position of Beneficial Owner</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount
    and Nature of Beneficial<BR>
    Ownership<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percent
    of<BR>
    Class</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors and Executive
    Officers</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 57%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eugene Williams,
    Chairman&nbsp;&amp; Chief Executive Officer</FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">298,356</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.06</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel Geffken, Chief
    Financial Officer</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,477</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(3)</SUP></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elliot Goldstein, Former
    CEO &amp; President</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">263,840</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(4)</SUP></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.60</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neil Cashman, Chief
    Scientific Officer&nbsp;&amp; Director</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">238,596</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(5)</SUP></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.25</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Madge
    &ldquo;Maggie&rdquo; K. Shafmaster, Lead Independent Director</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,333</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(6)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;*</FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William Wyman, Director</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">90,264</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(7)</SUP></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.25</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick Kirwin, Director</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">89,096</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(8)</SUP></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.23</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard Gregory, Director</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,667</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(9)</SUP></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Josh Mandel-Brehm, Director</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,771</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(10)</SUP></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neil K. Warma, Director</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,333</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(11)</SUP></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;*</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    directors and executive officers as a group (11 people)<SUP>(12)</SUP></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">809,021</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(13)</SUP></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.63</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&gt;5%
    Shareholders</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    19 Investments LLC</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">757,813</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(14)</SUP></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.78</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Crocker
    Mountain LLC</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">576,042</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(15)</SUP></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.75</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">* Represents less than 1%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Notes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    purposes of this table, beneficial ownership has been determined in accordance with the provisions of Rule 13d-3 of the Exchange
    Act, under which, in general, a person is deemed to be the beneficial owner of a security if he or she has or shares the power to
    vote or direct the voting of the security or the power to dispose of or direct the disposition of the security, or if he or she has
    the right to acquire beneficial ownership of the security within 60 days. Except as otherwise indicated, each director or executive
    officer has sole voting and investment power with respect to the shares shown, and none of such shares are pledged.</FONT></TD></TR>
  </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 107; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes 138,726 Common Shares underlying options and 7,899 Common
    Shares underlying warrants. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes 14,583 Common Shares underlying options and 1,042 Common
    Shares underlying warrants, which are held by Danforth Advisors LLC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes 132,476 Common Shares underlying options and 7,899 Common
    Shares underlying warrants.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes 122,060 Common Shares underlying options, 11,806 Common
    Shares underlying warrants and 1,062 Common Shares underlying DSUs. Also includes 1,617 common shares held by Rosemary Cashman, his
    spouse.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Represents Common Shares underlying options.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes 20,000 Common Shares underlying options and 7,326 Common
    Shares underlying warrants.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(8)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes 3,333 Common Shares underlying warrants, 16,667 Common
    Shares underlying options,&nbsp;22,332 Common Shares held by Patrick D. Kirwin Professional Corporation and 2,383 Common Shares held
    by Patrick Kirwin in a Tax Free Savings Account. Mr.&nbsp;Kirwin exercises the power to vote or direct the voting or the power to
    dispose or direct disposition of such securities. Also includes 5,732 Common Shares and 667 Common Shares underlying warrants held
    by Mrs. Jeananne Kirwin, Mr. Kirwin&rsquo;s spouse. &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(9)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Represents Common Shares underlying options.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(10)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Represents Common Shares underlying options.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(11)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Represents Common Shares underlying options.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(12)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes all current company Executive Officers and Directors (see <I>Item 5 &ndash; Directors and Executive Officers</I>), which excludes Mr. Goldstein but includes Gavin Malenfant and Larry Altstiel.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(13)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes 383,269 Common Shares underlying options, 32,073 shares
    underlying warrants, and 1,062 shares underlying DSUs.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(14)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes 500,000 Series 1 Preferred Shares, which are convertible
    into Common Shares on a 1:1 basis, and 257,813 Common Shares underlying units, which units include 206,250 Common Shares and 51,563
    Common Shares underlying warrants.&nbsp;&nbsp;Michael Gordon has sole voting and dispositive power over the Common Shares held by
    Title 19 Investments LLC.&nbsp;&nbsp;The address of Title 19 Investments LLC is c/o JDJFOS, P.O. Box 962049, Boston, MA 02196.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(15)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes 150,000 Series 1 Preferred Shares, which are convertible
    into Common Shares on a 1:1 basis, and 85,208 Common Shares underlying warrants. Jeremy Sclar has sole voting and dispositive power
    over the Common Shares held by Crocker Mountain LLC. &nbsp;The address of Crocker Mountain LLC is 33 Boylston Street, Ste. 3000,
    Chestnut Hill, MA 02467.&nbsp;&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="g_005"></A>ITEM
5. DIRECTORS AND EXECUTIVE OFFICERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the individuals
who we anticipate will be the directors and executive officers of the Company as of the filing of this Registration Statement and their
respective positions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; width: 33%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eugene
    Williams</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 8%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 55%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman&nbsp;&amp;
    Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel
    Geffken</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gavin
    Malenfant</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Operating Officer</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neil
    Cashman</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Scientific Officer&nbsp;&amp; Director</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Larry
    Altstiel</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Medical Officer</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maggie
    Shafmaster</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lead
    Independent Director</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
    Wyman</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick
    Kirwin</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard
    Gregory</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Josh
    Mandel-Brehm</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neil
    Warma</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 108; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="fulla_009"></A>Director and Executive
Officer Biographies</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Eugene Williams, Chairman&nbsp;&amp; CEO</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Williams has served as Chairman and
CEO of the Company since October&nbsp;2021. Prior thereto, Mr.&nbsp;Williams served as Executive Chairman of the Company since July&nbsp;2015.
Prior thereto, Mr.&nbsp;Williams served as Chairman and Chief Executive Officer of Akashi (f/k/a DART Therapeutics,&nbsp;Inc.) from June&nbsp;2010
to January&nbsp;2014. Previously Mr.&nbsp;Williams was a senior executive at Genzyme, where he had broad management responsibilities
in drug development, commercialization, and licensing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Williams graduated from Harvard College
with an Artium Baccalaureus degree in Economics and earned a Master of Business Administration from Harvard Business School.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Daniel Geffken, CFO</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Geffken has served as CFO of the Company
since March&nbsp;2017. He is a co-founder of Danforth Advisors LLC since June&nbsp;2011, and has served as Managing Director. Mr.&nbsp;Geffken
has served on the board of directors of a number of public companies, including Windtree Therapeutics,&nbsp;Inc. since 2019, Arcturus
Therapeutics,&nbsp;Inc. from November&nbsp;2017 to May&nbsp;2018, and Alcobra Pharmaceuticals Inc. from May&nbsp;2013 to November&nbsp;2017.
Mr.&nbsp;Geffken has served on the board of directors of Elicio Therapeutics, a private company, since 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Geffken earned a Bachelor of Science
degree from the University of Pennsylvania and a Master of Business Administration from Harvard Business School.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Gavin Malenfant, COO</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Malenfant has served as Chief Operating
Officer of the Company since October&nbsp;2021.&nbsp; Prior to joining ProMIS, Mr. Malenfant operated his own consulting business for
series A companies. &nbsp;Mr. Malenfant&rsquo;s experience is backed by nearly twenty-years with Genzyme, leading the rare disease program
management organization and head of operations for research and development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.&nbsp;Malenfant
earned a Bachelor of Science degree in Biology from the University of Massachusetts at Boston</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Neil Cashman, CSO&nbsp;&amp; Director</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr.&nbsp;Cashman has served as CSO and as
a director of the Company since May&nbsp;2004 and June&nbsp;2010, respectively. Dr.&nbsp;Cashman has served as a Professor at the UBC
since July&nbsp;2005 and became Professor Emeritus as of February&nbsp;1, 2022. He has also served as the Canada Research Chair in Neurodegeneration
and Protein Misfolding Diseases at UBC from 2005 to 2019. He is also director of the ALS Clinic at Vancouver General Hospital since July&nbsp;2005.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr.&nbsp;Cashman earned a Bachelor of Arts degree
in Physics from Bowdoin College and a Medical Degree from the University of Massachusetts Medical School. Dr.&nbsp;Cashman served his
residency in neurology with the University of Chicago Hospitals&nbsp;&amp; Clinics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Larry Altstiel, CMO</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Altstiel has served as CMO of the Company
since April 2022. Dr. Altstiel has decades of medical expertise in neurodegenerative diseases and experience in the pharmaceutical industry.
Since 2017, Dr. Altstiel has served as part-time Chief Medical Officer of Pinteon Therapeutics Inc. From 2014 to 2017, he served as a
director and scientific advisor of Neurotrope, Inc. (n/k/a Synaptogenix Inc. (NASDAQ: SNPX).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Altstiel earned a Bachelor of Science
degree in Chemistry from the University of Illinois, a Ph.D. in Virology from the Rockefeller University and a Medical Degree from the
University of Miami.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Madge &ldquo;Maggie&rdquo; Shafmaster,
Lead Independent Director</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr.&nbsp;Shafmaster has served as a director
of the Company since September&nbsp;2021 and as lead independent director of the Company since May 2022. Dr.&nbsp;Shafmaster has over
25 years of experience providing intellectual property advice to the biotechnology and pharmaceutical industries. Since 2014, Dr.&nbsp;Shafmaster
has served as an independent intellectual property consultant to the biotech and pharma industries. Prior to this, she served from 2011
to 2014 as Vice President, Chief Patent Counsel for Sanofi Pasteur and from 2007 to 2011 as Senior Vice President, Chief Patent Counsel
for Genzyme Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 109; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr.&nbsp;Shafmaster earned her Ph.D. in Molecular
Biology and Virology from Cornell University Graduate School of Medical Sciences, a Juris Doctor from New York Law School and a Bachelor
of Arts in Biology from the University of California Santa Cruz.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>William Wyman, Director</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Wyman has served as a director of the
Company since March&nbsp;2014. In 1984, Mr.&nbsp;Wyman co-founded Oliver Wyman&nbsp;&amp; Co., a general management consulting firm.
Since his retirement from the firm in 1995, Mr.&nbsp;Wyman has served as a director and advisor to nearly two dozen public and private
companies in the finance and technology industries. Mr.&nbsp;Wyman has also served as a consultant and owner of Wyman Consulting Associates
since 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Wyman has been a member of the board
of trustees of Dartmouth Hitchcock Medical Center, Mary Hitchcock Hospital and the Dartmouth Hitchcock Clinic, and currently serves on
the Board Joint Development Committee. He is currently a member of the Board of Trustees of New England College. He served as a director
of Allston Trading, LLC, a trading firm, since 2008, and as a member of the board of advisors of several private equity firms since 1995.
He has also served on the National Academy of Sciences' committee on health equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Wyman earned his Bachelor of Arts degree
in Economics from Colgate University and his Master of Business Administration from the Harvard Business School.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Patrick Kirwin, Director</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Kirwin has served as a director of the
Company since June&nbsp;2015. Mr.&nbsp;Kirwin is senior partner at the law firm Kirwin LLP. Mr.&nbsp;Kirwin earned a Bachelor of Arts
degree in Economics from the University of Alberta and a Juris Doctor from the University of Toronto Law School.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Richard Gregory, Director</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr.&nbsp;Gregory has served as a director of
the Company since October&nbsp;2016. He has served as Executive Vice President and Chief Scientific Officer of ImmunoGen,&nbsp;Inc. from
2015 to 2019. Dr.&nbsp;Gregory has been a Fellow of the American Institute for Medical and Biological Engineering since 2015. He has
served on the board of directors of Homology Medicines,&nbsp;Inc. and Cambridge Therapeutic Technologies since 2015 and March&nbsp;2021,
respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr.&nbsp;Gregory earned a Bachelor of Science
degree in Biochemistry from Virginia Polytechnic Institute and State University (Virginia Tech) and a Ph.D. in Biochemistry from the
University of Massachusetts Amherst.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Josh Mandel-Brehm, Director</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Mandel-Brehm has served as a director
of the Company since September&nbsp;2021. Mr.&nbsp;Mandel-Brehm has served as President and Chief Executive Officer of CAMP4 Therapeutics
Corporation since May&nbsp;2017 and as entrepreneur partner with Polaris Partners. Prior to May&nbsp;2017, Mr.&nbsp;Mandel-Brehm served
in business development for Biogen Corporation from May&nbsp;2013 to May&nbsp;2017. He has also been a founder and board member for Vico
Therapeutics B.V. since October&nbsp;2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Mandel-Brehm earned a Bachelor of Arts
degree in Biology from Washington University in St. Louis and a Master of Business Administration from the University of Michigan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 110; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Neil K. Warma, Director</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Warma has served as a director of the
Company since May&nbsp;2021.&nbsp;Mr.&nbsp;Warma has been a healthcare entrepreneur for over 25 years having managed and advised numerous
biotechnology and pharmaceutical companies across the globe. Mr.&nbsp;Warma has served as the General Manager of I-Mab Biopharma U.S.,
a publicly-traded global biopharmaceutical company since September&nbsp;2019.&nbsp; Mr.&nbsp;Warma was founder and from 2018 to 2019
served as CEO of Biohealth Care, LLC, which provided advisory services to the healthcare industry. Previously, Mr.&nbsp;Warma was President
and CEO and a member of the board of directors of Opexa Therapeutics,&nbsp;Inc., a publicly-traded biopharmaceutical company from 2008
to 2017.&nbsp;He was President, CEO and Director of Viron Therapeutics from 2004 to 2007 and prior to that held several senior positions
at Novartis AG in Basel, Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Warma has served as a director for Genexine
Ltd.,&nbsp;a public company, and Biotechnology Innovation Organization since March&nbsp;2021 and November&nbsp;2020, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Warma earned a Bachelor of Science degree
in Neuroscience from the University of Toronto and a Master of Business Administration from York University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Significant Employee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Johanne Kaplan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr.&nbsp;Kaplan has served as the Company&#8217;s
Chief Development Officer (&#8220;<B>CDO</B>&#8221;) since 2016, assuming the role in a full-time capacity on January&nbsp;1, 2022. Prior
to taking on the CDO role full-time, Dr.&nbsp;Kaplan also served as Chief Scientific Officer at Shepherd Therapeutics from 2016 to 2021
and as Chief Scientific Officer at Epiva Biosciences from 2015 to 2016. Before joining the Company, Dr.&nbsp;Kaplan held increasing positions
of responsibility at Sanofi Genzyme, from 1992 through 2015, most recently serving as Vice President of Research at Sanofi Genzyme from
2005 until her retirement in 2015. As Vice President of Neuroimmunology Research, she led the contribution of the Genzyme science team
supporting the approval of Lemtrada (alemtuzumab) and Aubagio (teriflunomide) for the treatment of relapsing-remitting multiple sclerosis.
She also established partnerships for the development of novel therapies for neuroinflammatory disorders. Prior to joining Genzyme, Dr.&nbsp;Kaplan
was an Associate Immunopathologist at SmithKline Beecham where she established an immunotoxicology program. Her work has resulted in
over 70 scientific publications and multiple patents. Dr.&nbsp;Kaplan holds a PhD in Microbiology&nbsp;&amp; Immunology from McGill University
in Montreal, Canada and conducted post-doctoral studies at the Albert Einstein College of Medicine in New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While Dr.&nbsp;Kaplan does not serve in a policy-making
function for the Company and is therefore not an executive officer for U.S. securities law purposes, her scientific background and experience
play an important role in the Company&rsquo;s operations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="fulla_010"></A><B>Board Committees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: White">
    <TD STYLE="border: Black 1pt solid; vertical-align: bottom; width: 25%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Member</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; width: 14%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Independent</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; vertical-align: bottom; width: 12%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Audit</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; vertical-align: bottom; width: 31%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
    Governance and <BR>
    Nominating</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eugene
    Williams</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neil
    Cashman</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maggie
    Shafmaster</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
    Wyman</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick
    Kirwin</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard
    Gregory</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD></TR>

<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; width: 25%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Josh
    Mandel-Brehm</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; width: 14%; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; width: 12%">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; width: 31%; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neil
    Warma</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 111; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Audit Committee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The audit committee of the Board (the &#8220;<B>Audit
Committee</B>&#8221;) assists the Company&#8217;s Board in fulfilling its oversight responsibilities relating to financial accounting
and reporting process and internal controls for the Company and ensuring the adequacy and effectiveness of the Company&#8217;s risk management
programs. The Audit Committee reviews the financial reports and other financial information provided by the Company to regulatory authorities
and its shareholders, as well as reviews the Company&#8217;s system of internal controls regarding finance and accounting, including
auditing, accounting and financial reporting processes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Composition of the Audit Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of filing of this Registration
Statement, the following are the members of the Audit Committee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left; width: 33%">Name&nbsp;of&nbsp;Member</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 31%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Independent<SUP>(1)</SUP></B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 30%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financially&nbsp;Literate<SUP>(2)</SUP></B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">William Wyman</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Patrick Kirwin</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Neil Warma</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A member of the Audit Committee
    is independent if he or she has no direct or indirect &#8216;material relationship&#8217; with the Company. A material relationship
    is a relationship which could, in the view of the Company&#8217;s Board, reasonably interfere with the exercise of a member&#8217;s
    independent judgment. Any executive officer of the Company is deemed to have a material relationship with the Company. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A member of the Audit Committee
    is financially literate if he or she has the ability to read and understand a set of financial statements that present a breadth
    and level of complexity of accounting issues that are generally comparable to the breadth and complexity of the issues that can reasonably
    be expected to be raised by the Company&#8217;s financial statements. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Relevant Education and Experience</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each member of the Audit Committee has experience
relevant to his or her responsibilities as an Audit Committee member. See Item 5&#8212;&#8220;<I>Directors and Executive Officers</I>&#8221;
for a description of the education and experience of each Audit Committee member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Audit Committee Oversight</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At no time since the commencement of the Company&#8217;s
most recently completed financial year were any audit committee recommendations to nominate or compensate an external auditor not adopted
by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Audit Committee Charter</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board has adopted a written charter for the
Audit Committee, which sets out the Audit Committee&#8217;s responsibilities. The Audit Committee performs a number of roles including
(i)&nbsp;assisting directors to meet their oversight responsibilities, (ii)&nbsp;enhancing communication between directors and the external
auditors; (iii)&nbsp;ensuring the independence of the external auditors; (iv)&nbsp;increasing the credibility and objectivity of financial
reports; and (v)&nbsp;strengthening the role of the directors by facilitating in-depth discussions among directors, management and the
external auditor. The Audit Committee has been delegated responsibility for: (i)&nbsp;the Company&#8217;s internal audit function; (ii)&nbsp;the
integrity of our consolidated financial statements and accounting and financial processes and the audits of our consolidated financial
statements; (iii)&nbsp;compliance with legal and regulatory requirements; (iv)&nbsp;the&nbsp;external auditors&#8217; qualifications
and independence; (v)&nbsp;the work and performance of financial management and external auditors; and (vi)&nbsp;the&nbsp;system of disclosure
controls and procedures and system of internal controls regarding finance, accounting, legal compliance and risk management established
by management and the Board. The Audit Committee has unrestricted access to all books and records of the Company and may request any
information as it may deem appropriate. It also has the authority to retain and compensate special legal, accounting, financial and other
consultants or experts in the performance of its duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 112; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Corporate Governance and Nominating Committee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporate Governance and Nominating Committee
of the Board assists the Board in fulfilling its oversight responsibilities relating to the corporate governance of the Company and the
size, structure, and membership of the Board and its committees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Composition of the Corporate Governance and
Nominating Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this Registration Statement,
the following are the members of the Corporate Governance and Nominating Committee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; width: 84%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name&nbsp;of&nbsp;Member</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 13%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Independent<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Josh Mandel-Brehm</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maggie Shafmaster</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neil Warma</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)&nbsp;</FONT>A
member of the Corporate Governance and Nominating Committee is independent if he or she has no direct or indirect &#8216;material relationship&#8217;
with the Company. A material relationship is a relationship which could, in the view of the Company&#8217;s Board, reasonably interfere
with the exercise of a member&#8217;s independent judgment. Any executive officer of the Company is deemed to have a material relationship
with the Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Corporate Governance and Nominating Committee
Charter</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board has adopted a written charter for the
Corporate Governance and Nominating Committee, which sets out the Corporate Governance and Nominating Committee&#8217;s responsibilities.
The Corporate Governance and Nominating Committee has been delegated responsibility for: i) reviewing the appropriate skills and characteristics
required of Board members in the context of the current make-up of the Board; and ii) assess the Board&#8217;s compliance with laws and
policies relating to the independence of certain Board members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Compensation Committee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Compensation Committee of the Board assists
the Board in fulfilling its oversight responsibilities relating to the recruitment, compensation, evaluation and retention of senior
management and other key employees, and in particular the CEO, with the skills and expertise needed to enable the Company to achieve
its goals and strategies at competitive compensation and with appropriate performance incentives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Composition of the Compensation Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this Registration Statement,
the following are the members of the Compensation Committee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; width: 84%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name&nbsp;of&nbsp;Member</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 13%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Independent<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard Gregory</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neil Warma</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William Wyman</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)&nbsp;</FONT>A
member of the Compensation Committee is independent if he or she has no direct or indirect &#8216;material relationship&#8217; with the
Company. A material relationship is a relationship which could, in the view of the Company&#8217;s Board, reasonably interfere with the
exercise of a member&#8217;s independent judgment. Any executive officer of the Company is deemed to have a material relationship with
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Compensation Committee Charter</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board has adopted a written charter for the
Compensation Committee, which sets out the Compensation Committee&#8217;s responsibilities. The Compensation Committee has been delegated
responsibility for reviewing: i) compensation policies and guidelines for supervisory and management personnel of the Company; ii) corporate
benefits, bonuses and other incentives, including share options and restricted share awards; iii) corporate goals and objectives relevant
to chief executive officer compensation; iv) non-chief executive officer and director compensation, incentive compensation plans and
equity-based plans; v) the competitiveness and appropriateness of the Company&#8217;s policies relating to the compensation of executive
officers; and vi) any material changes or trends in human resources policy, procedure, compensation and benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 113; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="fulla_011"></A>Board Qualifications
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that each of the members of
our Board has the experience, qualifications, attributes and skills that make him or her suitable to serve as our director, in light
of our highly regulated business and complex operations. See Item 5&#8212;&#8221;<I>Directors and Executive
Officers</I>&#8221; for a description of the education and experience of each director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Eugene Williams&#8217;s specific qualifications,
experience, skills and expertise include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 4%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experience
                                            as Chairman and CEO of the Company and in other executive leadership capacities in the pharmaceutical
                                            and biotechnology industries. </FONT></P>
                                                         <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    deep understanding of entrepreneurship, of drug development and of the pharmaceutical and biotechnology industries. </FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
    strategy. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neil Cashman&#8217;s specific qualifications,
experience, skills and expertise include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 4%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical and biotechnology
    industry and academic expertise in protein misfolding, neurodegeneration, and neurological clinical care. </FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experience
    as CSO. </FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previous
    history on the Company&#8217;s Board.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Maggie Shafmaster&#8217;s specific qualifications,
experience, skills and expertise include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 4%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experience
    providing intellectual property advice to the biotechnology and pharmaceutical industries.&nbsp;&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extensive
    business experience in various executive level roles.</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
    strategy.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">William Wyman&#8217;s specific qualifications,
experience, skills and expertise include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 4%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previous
    history on the Company&#8217;s Board.</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extensive
    business experience in various executive and board level roles.</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    and management experience.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patrick Kirwin&#8217;s specific qualifications,
experience, skills and expertise include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previous
    history on the Company&#8217;s Board.</FONT></TD></TR>
  <TR>
    <TD STYLE="width: 4%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Knowledge
    of past and current business strategies.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 114; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Richard Gregory&#8217;s specific qualifications,
experience, skills and expertise include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extensive
    business experience in various executive and board level roles.</FONT></TD></TR>
  <TR>
    <TD STYLE="width: 4%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
    and biotechnology industry knowledge. </FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
    governance. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Josh Mandel-Brehm&#8217;s specific qualifications,
experience, skills and expertise include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extensive
    business experience in various executive level roles in the biotechnology industry. </FONT></TD></TR>
  <TR>
    <TD STYLE="width: 4%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    deep understanding of entrepreneurship and of the biotechnology industry. </FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
    Strategy. </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neil K. Warma&#8217;s specific qualifications,
experience, skills and expertise include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experience
    in executive level roles in the pharmaceutical and biotechnology industries. </FONT></TD></TR>
  <TR>
    <TD STYLE="width: 4%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    and management experience.</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    deep understanding of entrepreneurship and of the pharmaceutical and biotechnology industries. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board believes these qualifications bring
a broad set of complementary experience to the Board&#8217;s discharge of its responsibilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="h1"></A><B>Conflicts of Interest&#8212;Board
Leadership Structure and Risk Oversight</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Conflicts of interest may arise as a result of
the directors and officers of the Company also holding positions as directors or officers of other companies. Some of the individuals
that are directors and officers of the Company have been and will continue to be engaged in the identification and evaluation of assets,
businesses and companies on their own behalf and on behalf of other companies, and situations may arise where the directors and officers
of the Company will be in direct competition with the Company. Conflicts, if any, will be subject to the procedures and remedies provided
under the Company&#8217;s Code of Business Conduct and Ethics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="h2"></A><B>ITEM
6. EXECUTIVE COMPENSATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following discussion describes the significant
elements of the compensation of each person who served as the Company&rsquo;s Chief Executive Officer (&ldquo;<B>CEO</B>&rdquo;) during
2021 and two most highly compensated executive officers (collectively, the &ldquo;<B>named executive officers</B>&rdquo; or &ldquo;<B>NEOs</B>&rdquo;).
As at December&nbsp;31, 2021, the NEOs of the Company were Eugene Williams (Executive Chairman&nbsp;&amp; CEO), Elliot Goldstein (former
CEO and President), Daniel Geffken (CFO) and Neil Cashman (CSO).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s policy with respect to compensation
of the named executive officers and other officers of the Company is based upon the principles that total compensation must: (1)&nbsp;be
competitive in order to help attract and retain the talent needed to lead and grow the Company&#8217;s business; (2)&nbsp;provide a strong
incentive for executives and key employees to work towards the achievement of the Company&#8217;s goals; and (3)&nbsp;ensure that the
interests of management and the Company&#8217;s shareholders are aligned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 115; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When determining the compensation of its executive
officers, the Compensation Committee considers: (i)&nbsp;recruiting and retaining executives critical to the success of the Company and
the enhancement of shareholder value; (ii)&nbsp;providing fair and competitive compensation compared to the remuneration paid by other
reporting issuers similarly placed within the same business as the Company; (iii)&nbsp;balancing the interests of management and the
Company&#8217;s shareholders; and (iv)&nbsp;rewarding performance, both on an individual basis and with respect to operations in general.
In order to achieve these objectives, the compensation paid to the Company&#8217;s executive officers consists of two components: (i)&nbsp;base
salary; and (ii)&nbsp;long-term equity incentives in the form of share options. In making compensation determinations, external sources
are consulted when deemed necessary by the Compensation Committee. The members of the Compensation Committee are disclosed under Item
5 of this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The total compensation paid to each of the named
executive officers of the Company consists of a base salary or consulting fee and share options to reward and retain NEOs. Total compensation
paid to each NEO reflects the executive&#8217;s overall experience, responsibility and time committed to the organization. The goal of
the Company is to pay base salary compensation to retain the NEOs in the range of industry peers, while maintaining the overall goal
that total compensation should include variable and long-term components as well.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to the CEO&#8217;s compensation
in particular, the CEO&#8217;s base salary is determined after considering the salary levels of other executives with similar responsibilities
and experience. The CEO&#8217;s base salary is compared to salary levels of comparable executives at a variety of companies, with particular
emphasis on biotechnology companies with similar market capitalizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options are granted by the Board to employees,
executive officers, including the named executive officers, and directors pursuant to the Company&#8217;s Stock Option Plan. The purpose
of the Stock Option Plan is to attract, retain and motivate these individuals and create incentives for them to contribute toward the
long-term goals of the Company. Moreover, the Stock Option Plan aims to align the interests of participants with the Company&#8217;s
Shareholders through opportunities of increased equity-based ownership in the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board may also grant DSUs to senior officers,
including any named executive officers, under the Company&rsquo;s DSU Plan, which provides an alternative form of compensation to satisfy
annual and special bonuses payable to senior officers. The number of DSUs granted is determined by dividing the applicable bonus amount
by the fair market value of the Common Shares as at the last trading day before calculation in accordance with TSX policies. Recipients
of DSUs cannot exercise their DSUs until such time as they cease to be a senior officer at which time they may elect to receive one Common
Share for each whole DSU they hold at the time they cease to be eligible to participate in the DSU Share Unit Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Approach to Risk</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board understands that compensation practices
can have unintended risk consequences. The Compensation Committee continually reviews the Company&#8217;s compensation policies to identify
any practice that might encourage an employee to expose the Company to unacceptable risk. At the present time, the Compensation Committee
is satisfied that the current executive compensation program does not encourage the Company&#8217;s executive officers, including the
NEOs, to expose the Company to inappropriate risk. The Board takes a conservative approach to executive compensation, rewarding individuals
for the success of the Company once that success has been demonstrated and encouraging them to continue that success through the grant
of long-term incentive awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 116; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Hedging Policy</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no specific requirements to prevent
an NEO or director from purchasing financial instruments including, for greater certainty, prepaid variable forward contracts, equity
swaps, collars, or units of exchange funds that are designed to hedge or offset a decrease in market value of equity securities granted
as compensation or held, directly or indirectly, by the NEO or director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Summary Compensation Table for 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth all compensation
paid to or earned by the named executive officers of the Company in the last fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Name
    and<BR> Principal Position</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Year</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Salary<BR>
    ($)<SUP>(1)</SUP></B></FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option<BR>
    Awards<BR> ($)<SUP>(2)</SUP></B></FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All
    Other<BR> Compensation<BR> ($)<SUP>(3)</SUP></B></FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Total
    <BR> ($)</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left; width: 38%"><FONT STYLE="font-size: 10pt">Eugene
    Williams <BR><I>Executive Chairman&nbsp;&amp; CEO</I></FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 7%; text-align: center"><FONT STYLE="font-size: 10pt">2021</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">360,000</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 10%; text-align: right">&mdash;</TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;21,057</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">381,057</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: middle; font: italic 7pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">Elliot
                                            Goldstein</FONT></P> <P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt"><I>Former
                                            CEO&nbsp;&amp; President<SUP>(4)</SUP></I></FONT></P></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">2021</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">50,000</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">12,677</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">62,677</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Daniel Geffken <BR><I>Chief Financial
    Officer</I></FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">2021</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">71,670</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">97,200</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">168,870</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Neil Cashman <BR><I>Chief Scientific
    Officer</I></FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">2021</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">79,017</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">79,017</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)&nbsp;The
amounts reported in the Salary column reflect payments made pursuant to various consulting agreements. </FONT>In addition, during 2021
the named executive officers were paid salary that had been accrued for service in prior years but not paid in those prior years, as
follows: Eugene Williams, $257,677; Elliot Goldstein, $257,677.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)&nbsp;The amounts reported in the Option
Awards column reflects aggregate grant date fair value computed in accordance with ASC Topic 718, Compensation&mdash;Stock Compensation.
These amounts reflect our calculation of the value of these awards at the grant date and do not necessarily correspond to the actual
value that may ultimately be realized by the named executive officer. Please refer to Note 13 of the Notes to the Audited Consolidated
Financial Statements for additional information regarding share based compensation. Option Awards granted in 2021 with respect to Mr.&nbsp;Geffken&rsquo;s
service were granted to Danforth Advisors, LLC. Mr.&nbsp;Geffken serves as Managing Director of such entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)&nbsp;Amounts reported in the All Other Compensation
column reflect payments made to Mr.&nbsp;Williams and Dr.&nbsp;Goldstein for health insurance costs. The amount reported for Mr.&nbsp;Geffken
reflects payments made to Danforth Advisors, LLC as a retainer for Mr.&nbsp;Geffken&#8217;s services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4)&nbsp;Dr.&nbsp;Goldstein ceased serving as
CEO of the Company on June 30, 2021 and ceased serving as President and a director on December&nbsp;31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 117; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Consulting and Employment Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Eugene
Williams</I></B></FONT>. The Chairman and CEO services provided by Mr.&nbsp;Williams to the Company were historically provided pursuant
to a consulting agreement entered into between the Company and Virtua, LLC dated June&nbsp;29, 2015 (the &ldquo;<B>Virtua Consulting Agreement</B>&rdquo;).
Pursuant to the terms of the Virtua Consulting Agreement, Mr.&nbsp;Williams was appointed Executive Chair of the Company beginning on
the date of the Virtua Consulting Agreement and continuing until either party provides notice of its intent to terminate the Virtua Consulting
Agreement for any reason, at any time, upon 30 days&rsquo; written notice, which was able to be waived by either party, upon 15 days written
notice in the event of a breach by either party, or on the written agreement of both parties. Subject to adjustment by the Board, the
Company agreed to pay Virtua, LLC a $30,000 fixed fee per month, with $10,000 of that monthly fee to be allocated for services provided
by Mr.&nbsp;Williams, plus reimbursement for reasonable expenses. The Virtua Consulting Agreement also provided for the grant of options
to Mr.&nbsp;Williams under the Company&rsquo;s Stock Option Plan equal to five percent of the shares issued and outstanding immediately
following the completion or termination of the private placement offering announced by the Company on May&nbsp;22, 2015. Such options
expire 10 years following their grant date and entitle Mr.&nbsp;Williams to acquire shares at the market price on the grant date, with
one quarter of such options immediately vesting and the balance vesting in equal installments on the last day of each month for 36 months,
except, in the event of a change of control or in the case where there is a termination without good reason, on the occurrence of which
the entire balance shall vest immediately. In the event the Virtua Consulting Agreement is terminated other than for a change of control
or where there is a termination without good reason, unvested options were to cease vesting as of such termination date. The foregoing
description is qualified in its entirety by reference to the Virtua Consulting Agreement, which is included as Exhibit&nbsp;10.11 hereto
and incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December&nbsp;21, 2021, the Company extended
to Mr.&nbsp;Williams an offer of employment (the &ldquo;<B>Williams Offer Letter</B>&rdquo;) to serve as the Company&rsquo;s CEO beginning
January&nbsp;1, 2022. Pursuant to the terms of the of the Williams Offer Letter, Mr.&nbsp;Williams&rsquo; compensation for service as
the Company&rsquo;s CEO is set at $480,000 and Mr. Williams is eligible to participate in any and all bonus and benefit programs that
the Company makes available to its employees. In addition, Mr.&nbsp;Williams was awarded 50,000 share options on February 10, 2022 priced
at $8.40, vesting 1/48<SUP>th </SUP>monthly over a four-year period, with the options expiring on February 10, 2032. Upon termination,
all vested options will be exercisable at any time during the twelve months following termination. In the event of termination of Mr.&nbsp;Williams&rsquo;
employment by the Company without cause, by Mr.&nbsp;Williams with good reason, or termination by way of a change in control, then upon
Mr.&nbsp;Williams&rsquo; execution of a release of claims, Mr.&nbsp;Williams is entitled to an aggregate amount equivalent to eighteen
months of his then-current base salary The Williams Offer Letter supersedes all prior agreements regarding Mr.&nbsp;Williams&rsquo; services
to and compensation from the Company, including the Williams Consulting Agreement. The foregoing description is qualified in its entirety
by reference to the Williams Offer Letter, which is included as Exhibit&nbsp;10.36.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Elliot
Goldstein</I></B></FONT>. Dr.&nbsp;Goldstein was party to a consulting agreement with the Company dated April&nbsp;1, 2021 for CEO consulting
services (the &ldquo;<B>Goldstein Consulting Agreement&rdquo;</B>). Under the Goldstein Consulting Agreement, Dr.&nbsp;Goldstein agreed
to provide the Company CEO consulting services for a six month period in exchange for a monthly payment of $5,000, subject to increases
as approved by the Board. Dr. Goldstein entered into a second consulting agreement dated October 1, 2021 for President consulting services
(the &ldquo;<B>Second Goldstein Consulting Agreement</B>&rdquo;, and together with the Goldstein Consulting Agreement, the &ldquo;<B>Goldstein
Consulting Agreements</B>&rdquo;). Under the Second Goldstein Consulting Agreement, Dr. Goldstein agreed to provide the Company President
consulting services until September 30, 2022 in exchange for a monthly payment of $10,000 plus reasonable expenses incurred in connection
with such services. Prior to entry into the Goldstein Consulting Agreements, Mr.&nbsp;Goldstein provided services to the Company under
the Virtua Consulting Agreement. Pursuant to the terms of the Virtua Consulting Agreement, Mr.&nbsp;Goldstein was appointed Chief Executive
Officer of the Company beginning on the date of the agreement and continuing until either party provides notice of its intent to terminate
the agreement for any reason, at any time, upon 30 days&rsquo; written notice, which was able to be waived by either party, upon 15 days
written notice in the event of a breach by either party, or on the written agreement of both parties. The Company agreed to pay Virtua,
LLC a $30,000 fixed fee per month, with $20,000 of that monthly fee to be allocated for services provided by Mr.&nbsp;Goldstein, plus
reimbursement for reasonable expenses. The foregoing descriptions are qualified in their entirety by reference to the Goldstein Consulting
Agreement, the Second Goldstein Consulting Agreement and Virtua Consulting Agreement, which are included as Exhibits 10.8, 10.8.1 and
10.11 hereto and incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"></P>

<!-- Field: Page; Sequence: 118; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Daniel Geffken</I></B>. The CFO services
provided by Mr.&nbsp;Geffken are provided pursuant to a consulting agreement entered into between the Company and Danforth Advisors,
LLC dated October&nbsp;17, 2016, and as amended from time-to-time (the &ldquo;<B>Danforth Consulting Agreement</B>&rdquo;). Under the
Danforth Consulting Agreement, Mr.&nbsp;Geffken agreed to provide the Company the customary services of a CFO at an hourly rate of $325
for a one year term. On March&nbsp;27, 2017, the Danforth Consulting Agreement was amended to provide for services based on a $5,000
monthly retainer, subject to a 4% annual increase, plus expenses. The Danforth Consulting Agreement was subsequently amended on December&nbsp;12,
2017 to extend the term for an additional year and on August&nbsp;31, 2018 to extend the term for an additional year. The Danforth Consulting
Agreement was further amended on November&nbsp;10, 2021 to extend the term of the consulting agreement through October&nbsp;29, 2024
and to set Mr.&nbsp;Geffken&rsquo;s compensation at a fixed monthly fee of $15,000. The Danforth Consulting Agreement provides for an
extension of terms by the mutual agreement of the parties and that either party may terminate the agreement upon sixty days prior written
notice to the other, or 30 days in the case of termination for cause. The Corporation also issued 8,333 stock options to Danforth Advisors,
LLC, which will vest as follows: 25% vested immediately upon the grant of options and the balance will vest in equal installments over
36 months. The foregoing description is qualified in its entirety by reference to the Danforth Consulting Agreement and the amendments
thereto, which are included as Exhibits 10.12 and 10.12.1, 10.12.2, 10.12.3 and 10.12.4 hereto and incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Neil
Cashman</I></B></FONT>. Dr.&nbsp;Cashman is party to a consulting and advisory agreement with the Company dated March&nbsp;1, 2005 (the
 &#8220;<B>Cashman Consulting Agreement</B>&#8221;) for CSO consulting services. The Cashman Consulting Agreement provides that it shall
remain in effect until terminated by either party, with the Company agreeing to provide Dr.&nbsp;Cashman six month&#8217;s written notice
and Dr.&nbsp;Cashman agreeing to provide the Company thirty day&#8217;s written notice. In return for the CSO services, the Company agreed
to pay Dr.&nbsp;Cashman a monthly consulting fee of $5,000, plus expenses, subject to adjustment as approved by the Board. Effective
March 1, 2017, the monthly consulting fee payable to the CSO was&nbsp;increased to CDN$9,000 per month pursuant to a Board authorized
resolution. The foregoing description is qualified in its entirety by reference to the Cashman Consulting Agreement, which is included
as Exhibit&nbsp;10.10 hereto and incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Outstanding Equity Awards Table for 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth outstanding equity
awards for the named executive officers of the Company at fiscal 2021 year end.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Option Awards</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Stock Awards<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number&nbsp;of<BR>
    Securities<BR>
    Underlying<BR>
    Unexercised<BR>
    Options&nbsp;(#)<BR>
    Exercisable</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number&nbsp;of<BR>
    Securities<BR>
    Underlying<BR>
    Unexercised<BR>
    Options&nbsp;(#)<BR>
    Unexercisable</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Equity <BR>
    Incentive <BR>
    Plan Awards: <BR>
    Number of <BR>
    Securities <BR>
    Underlying <BR>
    Unexercised <BR>
    Unearned <BR>
    Options<BR>
    (#)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Option<BR>
    Exercise<BR>
    Price<BR>
    ($)<SUP>(2)</SUP></B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Option<BR>
    Expiration<BR>
    Date</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number of<BR>
    shares or <BR>
    units of<BR>
    stock<BR>
    that<BR>
    have not<BR>
    vested<BR>
    (#)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Market<BR>
    value of<BR>
    shares or<BR>
    units of <BR>
    stock<BR>
    that<BR>
    have not<BR>
    vested <BR>
    (US$)<SUP>(3)</SUP></B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Equity<BR>
    incentive<BR>
    plan<BR>
    awards:<BR>
    number of<BR>
    unearned<BR>
    shares,<BR>
    units <BR>
    or other<BR>
    rights that <BR>
    have not<BR>
    vested <BR>
    (#)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Equity<BR>
    incentive plan<BR>
    awards:<BR>
    market or<BR>
    payout value<BR>
    of unearned<BR>
    shares,<BR>
    units <BR>
    or other<BR>
    rights that <BR>
    have not<BR>
    vested <BR>
    ($)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 11%; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Eugene
    Williams</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 0%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 18%"><FONT STYLE="font-size: 10pt">78,821 Common Shares</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 0%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 10%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 10%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 7%; text-align: right"><FONT STYLE="font-size: 10pt">1.914</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><SUP>(4)</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 7%; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">7/6/2025</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 5%; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 5%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 5%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 5%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">36,988 Common Shares</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">3.078</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><SUP>(5)</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">7/31/2025</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">16,666 Common Shares</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">22.242</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><SUP>(6)</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">3/29/2028</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Elliot Goldstein</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">78,821 Common Shares</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">1.914</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><SUP>(4)</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">7/6/2025</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">36,988 Common Shares</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">3.078</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><SUP>(5)</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">7/31/2025</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">16,666 Common Shares</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">22.242</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><SUP>(6)</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">3/29/2028</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Daniel Geffken<SUP>(7)</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">8,333 Common Shares</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">8.5188</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><SUP>(8)</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">3/1/2027</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">8,333 Common Shares</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">7,638 Common Shares</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">8.5188</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><SUP>(9)</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">11/12/2031</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Neil Cashman</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">78,821 &nbsp;Common Shares</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">1.914</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><SUP>(4)</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">7/6/2025</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">258</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">25.80</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">36,988 &nbsp;Common Shares</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">3.078</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><SUP>(5)</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">7/31/2025</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">332</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">33.23</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">471</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">47.15</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"></P>

<!-- Field: Page; Sequence: 119; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)&nbsp;The Company&#8217;s only share-based
awards are DSUs (other than options) that have been granted under the DSU Plan. DSUs only vest in full upon separation from service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)&nbsp;Pursuant to the Company&rsquo;s Stock
Option Plan, the option exercise price is granted in Canadian dollars. This presentation has been converted into U.S. dollars using the
Bank of Canada daily exchange rate for December 31, 2021, which was US$1.00 to C$1.2678.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) The value of the unvested share-based
awards was calculated based on the closing price of the Company&rsquo;s Common Shares on the TSX on December&nbsp;30, 2021, which was
C$7.80 (US$6.00). The Bank of Canada exchange rate as of December&nbsp;30, 2021 was US$1.00 to C$1.2678.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4)&nbsp;The option was granted on July&nbsp;6,
2015 with an exercise price of C$2.43. The option vested &frac14; immediately with balance having vested ratably over 36 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5)&nbsp;The option was granted on July&nbsp;31,
2015 with an exercise price of C$3.90. The option vested &frac14; immediately with balance having vested ratably over 36 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6)&nbsp;The option was granted on March&nbsp;29,
2018 with an exercise price of C$21.84. The option vested &frac14; immediately with balance having vested ratably over 36 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7)&nbsp;Options are held by Danforth Advisors,
LLC. Mr.&nbsp;Geffken serves as Managing Director of such entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8)&nbsp;The option was granted on March&nbsp;1,
2017 with an exercise price of C$10.80. The option vested 1/5 immediately with balance having vested ratably over 36 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(9)&nbsp;The option was granted on November&nbsp;12,
2021 with an exercise price of C$10.80. The option vests ratably over 12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Retirement Benefit Plans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not have any retirement benefit
plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Termination and Change in Control Benefits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not offer a formal plan providing
for any termination or change in control benefits. For information about change in control benefits for Messrs.&nbsp;Williams and Malenfant,
see &#8220;<I>Consulting and Employment Agreements</I>&#8221; above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>DIRECTOR
COMPENSATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&nbsp;31, 2021, the Company had
eight directors, two of whom were also employees: Eugene Williams (Chairman and CEO) and Neil Cashman (CSO). The remaining six directors
were considered independent directors at such time, namely Richard Gregory, Patrick Kirwin, Josh Mandel-Brehm, Maggie Shafmaster, Neil
K. Warma and William Wyman.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Directors who hold positions as executive officers
with the Company do not receive additional compensation for their service as directors. Mr.&nbsp;Williams and Dr.&nbsp;Cashman did not
receive any additional compensation for their services as directors during the year ended December&nbsp;31, 2021. For a description of
the compensation paid to Mr.&nbsp;Williams and Dr.&nbsp;Cashman, see&nbsp;<I>&#8220;Summary Compensation Table for 2021</I>,<I>&#8221;</I>&nbsp;above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each member of the Company&#8217;s Board is entitled
to reimbursement for reasonable travel and other expenses incurred in connection with attending Board meetings and meetings for any committee
on which he or she serves.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 120; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Compensation of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The form and amount of director compensation
is reviewed annually and as deemed advisable by the Compensation Committee, which shall make recommendations to the Board based on such
review. The Compensation Committee reviews director compensation on an annual basis to ensure that the Company offers director compensation
that is: (i)&nbsp;commensurate with the efforts the Company expects from existing Board members; (ii)&nbsp;competitive in the Company&#8217;s
industry in order that the Company might attract the best possible candidates to assist the Company and its shareholders in a fiduciary
capacity; and (iii)&nbsp;aligned with shareholder interests as the Company grows. The Board retains the ultimate authority to determine
the form and amount of director compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Director Compensation for 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth all compensation
paid to or earned by each director of the Company during fiscal year 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT><SUP>(1)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Fees&nbsp;Earned</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>or<BR>
                                            Paid&nbsp;in&nbsp;Cash<BR> ($)</B></FONT><B><SUP>(2)</SUP></B></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Option<BR>
                                            Awards</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>($)<SUP>(3)</SUP></B></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total&nbsp;($)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 61%; text-align: justify">Richard Gregory</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">30,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">67,269</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">107,269</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Patrick Kirwin</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">67,269</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">107,269</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Josh Mandel-Brehm</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13,333</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">83,297</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">96,630</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Maggie Shafmaster</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">51,182</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">61,182</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Neil Warma</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">25,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">74,302</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">99,302</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">William Wyman</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">67,269</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">107,269</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Johannes
    Roth<SUP>(4)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(1)</SUP></FONT>&nbsp;Mr.&nbsp;Williams,
Dr.&nbsp;Cashman and Dr.&nbsp;Goldstein, who served as executive officers during 2021, did not receive any compensation for their Board
service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(2)</SUP></FONT>&nbsp;Cash
fees paid to non-employee directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>(3)</SUP>&nbsp;The amounts reported in
the Option Awards column reflects aggregate grant date fair value computed in accordance with ASC Topic 718, Compensation&mdash;Stock
Compensation. These amounts reflect our calculation of the value of these awards at the grant date and do not necessarily correspond
to the actual value that may ultimately be realized by the director. Please refer to Note 13 of the Notes to the Audited Consolidated
Financial Statements for additional information regarding share based compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(4)</SUP></FONT>&nbsp;Mr.&nbsp;Roth
resigned from the Board on February&nbsp;1, 2021 and did not receive any compensation for his service in 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Compensation Committee Interlocks and Insider
Participation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See Item 7 &#8212; &#8220;<I>Certain Relationships
and Related Transactions and Director Independence</I>&#8221; for further details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None of the Company&#8217;s executive officers
served as a member of the compensation committee (or other Board committee performing equivalent functions or, in the absence of any
such committee, the entire Board) of another entity, one of whose executive officers served as a director of the Company or on the Compensation
Committee, during the fiscal year ended December&nbsp;31, 2021. None of the Company&#8217;s executive officers served as a director of
another entity, one of whose executive officers served on the Compensation Committee, during the fiscal year ended December&nbsp;31,
2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 121; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="h3"></A><B>ITEM
7. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND<BR>
DIRECTOR INDEPENDENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="fulla_012"></A>Related Party Transactions<SUP></SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the Company, a related party transaction
includes any transaction or proposed transaction in which:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            Company is or will be a participant;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            aggregate amount involved exceeds $17,000 (approximately 1% of the Company&#8217;s average
                                            assets for the last two fiscal years) in any fiscal year; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">any
                                            related party has or will have a direct or indirect material interest.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Related parties include any person who is or
was (since the beginning of the last fiscal year, even if such person does not presently serve in that role) an executive officer or
director of the Company, any shareholder beneficially owning more than 5% of any class of the Company&#8217;s voting securities or an
immediate family member of any such persons. Immediate family member means any child, stepchild, parent, stepparent, spouse, sibling,
mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, sister-in-law, and any person (other than a tenant or employee)
sharing the household of such person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee is charged with oversight
over related party transactions entered into by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 122; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="fulla_013"></A>Company Transactions
with Related Parties </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into related party transactions
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Neil
Cashman</I></B></FONT>. Dr.&nbsp;Cashman is a Professor of Neurology with UBC. Please see Item 1 &#8212; &#8220;<I>Business</I>&#8221;
for more information regarding the Company&#8217;s relationship with UBC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Eugene
Williams</I></B></FONT><I>. </I>Payments for Mr. William&rsquo;s services were pursuant to a consulting agreement with Virtua, LLC. Virtua,
LLC&#8217;s sole line of business was providing management services to the Company. Details regarding the consulting agreement are set
forth in Item 6 &#8211; &#8220;<I>Executive Compensation</I>.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Daniel Geffken</I></B>.
Mr.&nbsp;Geffken serves as Managing Director of Danforth Advisors, LLC. Payments for CFO services provided to the Company by Mr.&nbsp;Geffken
are made to Danforth Advisors, LLC. For the years ended 2021, 2020 and 2019, the Company paid $326,619.75, $232,083.40 and $227,755.74,
respectively, to Danforth Advisors, LLC for services provided pursuant to a consulting agreement. From January 1, 2022 to June 30 2022,
the Company has paid $284,589.65 to Danforth Advisors, LLC for services provided pursuant to the same consulting agreement. Additionally,
on March 1, 2017 and November 12, 2021, the Company granted 8,333 and 8,333 share options, respectively, to Danforth Advisors, LLC pursuant
to the same agreement. For additional information regarding this agreement and the amounts paid for Mr.&nbsp;Geffken&rsquo;s services,
see Item 6 &ndash; &ldquo;<I>Executive Compensation</I>.&rdquo;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Elliot
Goldstein</I></B></FONT>. Dr.&nbsp;Goldstein previously served as CEO and President of the Company. Payments for Dr.&nbsp;Goldstein&#8217;s
services were pursuant to a consulting agreement with Virtua, LLC. Virtua, LLC&rsquo;s sole line of business was providing management
services to the Company. Details regarding the consulting agreement are set forth in Item 6 &#8211; <I>&#8220;Executive Compensation.&#8221;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Gavin
Malenfant</I></B></FONT>. Mr.&nbsp;Malenfant was paid $41,300 as a consultant in 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please see Item 6 &#8212;
 &#8220;<I>Executive Compensation</I>&#8221; for details regarding executive and director compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="fulla_014"></A><B>Director Independence</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of this Registration Statement,
the independence of our directors is determined under the corporate governance rules&nbsp;of the Nasdaq. The independence rules&nbsp;of
Nasdaq include a series of objective tests, including that an &#8220;independent&#8221; person will not be employed by us and will not
be engaged in various types of business dealings with us. In addition, the Board is required to make a subjective determination as to
each person that no material relationship exists with the Company either directly or as a partner, shareholder or officer of an organization
that has a relationship with the Company. It has been determined by the Board that six of our directors that we expect to be on the Board
as of the Effective Date are independent persons under the independence rules&nbsp;of the Nasdaq: Richard Gregory, Patrick Kirwin, Josh
Mandel-Brehm, Maggie Shafmaster, Neil K. Warma and William Wyman.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 123; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="fulla_015"></A><B>ITEM
8. Legal Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="fulla_016"></A>Legal Proceedings<SUP></SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At present, to the Company&#8217;s knowledge,
there are no material pending legal proceedings or regulatory actions to which the Company is or was a party to or of which any of its
property is or was the subject of, and no such proceedings or actions are known by the Company to be contemplated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="fulla_017"></A>ITEM
9. MARKET PRICE OF AND DIVIDENDS ON THE REGISTRANT&#8217;S COMMON EQUITY<BR>
AND RELATED SHAREHOLDER MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="fulla_018"></A><B>Trading Price and
Volume</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Shares of the Company are traded on
the TSX under the symbol &ldquo;PMN.&rdquo; The following table sets forth trading information for the Common Shares for the periods indicated,
as quoted on the TSX, and gives effect to the Reverse Share Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Period</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Low&nbsp;Trading&nbsp;<BR>
    Price<BR>
    (C$)</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>High
    Trading <BR>
    Price<BR>
    (C$)</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Year Ending December 31, 2022</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 74%; text-align: justify"><FONT STYLE="font-size: 10pt">First Quarter (through March 31, 2022)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">7.20</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">9.90</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Second Quarter (through June 30, 2022)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8.30</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8.10</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Year Ending December&nbsp;31, 2021</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Fourth Quarter (December&nbsp;30, 2021)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7.20</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12.00</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Third Quarter (September&nbsp;30, 2021)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10.50</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">16.20</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Second Quarter (June&nbsp;30, 2021)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">9.90</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">16.50</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">First Quarter (March&nbsp;31, 2021)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4.80</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13.50</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Year Ending December&nbsp;31, 2020</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Fourth Quarter (December&nbsp;31, 2020)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4.80</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10.20</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Third Quarter (September&nbsp;30, 2020)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7.80</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">14.10</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Second Quarter (June&nbsp;30, 2020)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7.20</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">18.60</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">First Quarter (March&nbsp;31, 2020)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6.00</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13.80</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Shares of the Company are also
traded on the OTCQB Venture Market under the symbol &#8220;ARFXD.&#8221; The following table sets forth trading information for the Common
Shares for the periods indicated, as quoted on the OTCQB, and gives effect to the Reverse Share Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Period</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Low&nbsp;Trading&nbsp;<BR>
    Price<BR>
    ($)</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>High Trading</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Price<BR> ($)</B></FONT></P></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Year Ending December 31, 2022</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: justify"><FONT STYLE="font-size: 10pt">First Quarter (through March 31, 2022)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">6.00</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">6.34</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Second Quarter (through June 30, 2022)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6.36</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6.49</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Year Ending December&nbsp;31, 2021</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Fourth Quarter (December&nbsp;31, 2021)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6.00</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6.91</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Third Quarter (September&nbsp;30, 2021)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8.48</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8.83</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Second Quarter (June&nbsp;30, 2021)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">9.85</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10.46</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">First Quarter (March&nbsp;31, 2021)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">9.82</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10.80</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Year Ending December&nbsp;31, 2020</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Fourth Quarter (December&nbsp;31, 2020)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3.76</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5.24</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Third Quarter (September&nbsp;30, 2020)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6.32</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6.45</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Second Quarter (June&nbsp;30, 2020)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">9.42</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">9.78</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">First Quarter (March&nbsp;31, 2020)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5.52</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5.64</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 124; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="fulla_019"></A><B>Shareholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2022, there were 123 holders
of record of our Common Shares.</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="fulla_020"></A>Dividends</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no restrictions in the Company&#8217;s
articles, by-laws or elsewhere, which would prevent the Company from paying dividends. No dividends have been declared or paid on the
Common Shares in the last five fiscal years, and it is not expected that dividends will be declared or paid in the immediate or foreseeable
future. Consequently, to date there have been no distributions made by the Company. The policy of the Board is to reinvest all available
funds in operations. The Board will reassess this policy from time to time. Any decision to pay dividends on the Common Shares will be
made by the Board based on the assessment of, among other factors, earnings, capital requirements and the operating and financial condition
of Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="fulla_021"></A><B>Equity Compensation
Plans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth securities
authorized for issuance under the Stock Option Plan and the DSU Plan as of December&nbsp;31, 2021. Figures below are presented on an
as-converted basis and give effect to the Reverse Share Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="12" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Equity
    Compensation Plan Information</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Plan Category</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number
    of<BR>
    securities<BR>
    to be issued upon<BR>
    exercise of<BR>
    outstanding options,<BR>
    warrants and rights</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Weighted-average<BR>
    exercise price of<BR>
    outstanding options,<BR>
    warrants and rights</B><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number
    of securities<BR>
    remaining available<BR>
    for future issuance<BR>
    under equity<BR>
    compensation plans</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 39%; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Equity compensation plans approved by security holders<SUP>(</SUP></B><SUP>1)</SUP></FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 17%; text-align: right"><FONT STYLE="font-size: 10pt">739,099</FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: justify"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 17%; text-align: right"><FONT STYLE="font-size: 10pt">8.40</FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 18%; text-align: right"><FONT STYLE="font-size: 10pt">287,233</FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Equity compensation plans not approved by security holders</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&mdash;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">739,099</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8.40</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">287,233</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)&nbsp;The total number of Common Shares that
may be reserved and available for issuance under the Stock Option Plan shall not exceed the number of Common Shares equal to twenty percent
(20%) of the total issued and outstanding Common Shares from time to time less any Common Shares reserved for issuance under the DSU
Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">(2) The weighted-average exercise price reported herein does not take
into account the DSUs awarded under the DSU Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="fulla_022"></A><FONT STYLE="text-transform: uppercase"><B>ITEM
10. RECENT SALES OF UNREGISTERED SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following information represents securities
sold by the Company within the past three years through June 30, 2022 &lrm;which were not registered under the Securities Act. Included
are new issues, securities issued in exchange for &lrm;property, services or other securities and new &lrm;securities resulting from
the modification of outstanding securities. The Company sold all of the securities listed below pursuant &lrm;to the exemption from registration
provided by Section&nbsp;4(a)(2)&nbsp;of the Securities Act, or Regulation D or Regulation S &lrm;promulgated thereunder. The information
presented below with respect to securities sold or granted and the exercise price of certain securities has been adjusted to account
for the Reverse Share Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>2019</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January&nbsp;2, 2019, the Company granted
16,667 Stock Options with an exercise price per Stock Option of C$15.00 to certain directors, executives and employees. No consideration
was received by the Company for the issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January&nbsp;22, 2019, the Company completed
a private placement of 159,333 units at C$13.80 per unit, for gross proceeds of C$2,198,800. Each unit consisted of one Common Share
and one Common Share purchase warrant. Each warrant entitles the holder to purchase one Common Share at an exercise price of C$28.80
each at any time for five years following closing of the private placement, subject to earlier expiry upon 30 days&rsquo; notice if,
at any time after four months from closing (until January&nbsp;23, 2024), the 20-day VWAP of Common Shares is greater than C$60.00, and
ProMIS may accelerate the expiry of the Warrants by issuing a press release announcing the reduced term and expiry not less than 30 days
after the publication date of such press release. In connection with the offering, the Company also issued a total of 2,742 finder&rsquo;s
warrants equal to 7% of the number of units sold to purchasers introduced by such finders. The finder&rsquo;s warrants have the same
term as the offering warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 125; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March&nbsp;15, 2019, the Company issued
4,167 Common Shares at a price per share of C$18.00 for total aggregate consideration of C$75,000 upon the exercise of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March&nbsp;26, 2019, the Company issued
1,458 Common Shares at a price per share of C$12.00 for total aggregate consideration of C$17,500 upon the exercise of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June&nbsp;2019, the Company closed a private
placement, consisting of 78,000 Units at C$15.00 for gross proceeds of C$1,170,000. Each Unit consisted of one Common Share and one warrant,
with each warrant entitling the holder thereof to purchase one Common Share at an exercise price of C$21.00 per Common Share at any time
for five years (until June&nbsp;26, 2024) following the closing of the private placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September&nbsp;19, 2019, the Company granted
4,167 Stock Options with a price per Stock Option of C$13.80 to certain directors, executives and employees. No consideration was received
by the Company for the issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December&nbsp;31, 2019, the Company completed
a private placement of 233,361 Units at C$12.00 per Common Share for total gross proceeds of C$2,800,333, issued in two tranches completed
on November 15 and December 31, 2019. Each Unit consisted of one Common Share and one warrant, with each warrant entitling the holder
thereof to purchase one Common Share at an exercise price of C$21.00 per Common Share at any time up to five years following closing
of the private placement. In connection with the offering, the Company also issued a total of 2,707 finder&rsquo;s warrants equal to
7% of the number of units sold to purchasers introduced by such finders. The finder&rsquo;s warrants have the same term as the offering
warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>2020</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February&nbsp;25, 2020, the Company reported
a total of 79,838 of the Common Share purchase warrants issued on February&nbsp;10 and February&nbsp;21, 2017 in a non-brokered private
placement were exercised at a price of C$12.00 per Common Share for gross proceeds of C$958,051, which warrants expired on February&nbsp;21,
2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February&nbsp;28, 2020, the Company granted
6,667 Stock Options with an exercise price per Stock Option of C$12.00 to certain directors, executives and employees. No consideration
was received by the Company for the issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March&nbsp;24, 2020, the Company announced
that it had received TSX approval to reprice to C$7.80 each, in aggregate, 736,376 outstanding warrants issued between August&nbsp;9,
2017 and December&nbsp;30, 2019, all expiring 5 years from the original date of issuance. The warrant repricing period was effective
from April&nbsp;8, 2020 to May&nbsp;22, 2020. In April&nbsp;and May&nbsp;2020, the Company received gross proceed of C$1,239,195 from
the exercise of 158,871 warrants from the warrant repricing program. At the end of the warrant repricing period, the warrants reverted
to the original exercise price. All other terms of the warrants remain unchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April&nbsp;15, 2020, the Company granted
2,500 Stock Options with an exercise price per Stock Option of C$9.00 to certain directors, executives and employees. No consideration
was received by the Company for the issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October&nbsp;23, 2020, the Company proceeded
with a private placement offering (the &ldquo;<B>SW Offering</B>&rdquo;) of 279,613 special warrants (&ldquo;<B>Special Warrant</B>&rdquo;)
at a price of C$7.20 per Special Warrant, for aggregate gross proceeds of up to C$3,000,000. The SW Offering closed in two tranches:
the first in the amount of 230,326 Special Warrants closed on November 5, 2020 raising gross proceeds of $1,658,349.72; and the second
in the amount of 40,000 Special Warrants closed on November 16, 2020, raising gross proceeds of $288,000 (the November 5 and 16, 2020
closings collectively, the &ldquo;<B>Closing</B>&rdquo;). Each Special Warrant is exercisable without payment of any additional consideration
by the holder, into one unit (&ldquo;<B>Special Unit</B>&rdquo;), with each Special Unit consisting of one Common Share and one transferable
Common Share purchase warrant (&ldquo;<B>Unit Warrant</B>&rdquo;). Each Unit Warrant entitles the holder thereof to acquire one Common
Share (&ldquo;<B>Unit Warrant Share</B>&rdquo;) at an exercise price of C$12.00 per Unit Warrant Share for a period of 60 months after
the Closing, subject to acceleration of the expiry date described as follows. If at any time after the expiry of the four-month hold
period applicable to the Unit Warrants, the twenty-day VWAP of the Common Shares on the TSX, or such other exchange on which the Common
Shares may be listed, is greater than C$36.00, the Company may deliver a notice to the holders of Unit Warrants accelerating the expiry
date to a date that is not less than 30 days following the date of such notice. In connection with Offering, the Company issued 8,120
compensation warrants (&ldquo;<B>Compensation Warrants</B>&rdquo;) on November 5, 2020 and an additional 1,167 Compensation Warrants
on November 16, 2020 for a total of 9,287 Compensation Warrants. The Compensation Warrants have the same terms as the Unit Warrants,
except that the compensation warrants were immediately issued on November 5 and 16, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Special Warrants will be deemed to be automatically
exercised at 1:00 p.m. PT (the &ldquo;<B>Deemed Exercise Time</B>&rdquo;) on the earlier of the date (the &ldquo;<B>Conversion Date</B>&rdquo;)
that is (i) the third business day after a receipt for a final prospectus qualifying the distribution of the shares and Unit Warrants
issuable upon the conversion of the Special Warrants and (ii) 4 months and one day after the issue date of the Special Warrants. The
Special Warrants will be deemed to have been exercised, delivered and surrendered by the holder thereof immediately prior to the Deemed
Exercise Time without any further action on the part of the holder. The Company filed a preliminary short form prospectus dated November
26, 2020 to qualify the distribution of certain Units Warrants upon deemed conversion of the Special Warrants. However, the Special Warrants
automatically converted on March 5, 2021 and March 17, 2021, as applicable, during the review process. The Corporation therefore did
not file a final short form prospectus and a final receipt was not issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 126; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>2021</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 5 and 17, 2021, the Special Warrants
issued by the Company in the SW Offering automatically converted, without payment of any additional consideration by the holder of the
Special Warrants, into Special Units of the Company consisting of one Common Share and one Unit Warrant, pursuant to the terms of the
Special Warrant. Upon the conversion of the Special Warrants, the holders of the Special Warrants were issued a total of 279,613 Common
Shares and 279,613 Unit Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March, 22, 2021, the Company completed
a private placement for gross proceeds of $7 million by debentures convertible into Common Shares, at the option of the debenture holder,
at $6.00 per Common Share and accrue interest at 1% per annum, which is payable annually. Interest may be paid in cash or in Common Shares,
at the option of ProMIS (such number of Common Shares area to be determined by dividing the interest due by the 5-day VWAP of the Common
Shares). The Debentures mature on March 22, 2026, and ProMIS has the option, prior to the maturity date, to force conversion of the Debentures
at the conversion price upon raising $50 million in equity and/or debt cumulatively. At maturity ProMIS may redeem the outstanding principal
amount of the Debentures in either cash or Common Shares at the then current 5-day VWAP less a 10% discount, or at its election, a combination
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March&nbsp;30, 2021, the Company granted
25,000 Stock Options with an exercise price per Stock Option of C$10.20 to certain directors, executives and employees. No consideration
was received by the Company for the issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May&nbsp;14, 2021, the Company granted
12,500 Stock Options with an exercise price per Stock Option of C$10.80 to certain directors, executives and employees. No consideration
was received by the Company for the issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June&nbsp;30, 2021, the Company granted
833 Stock Options with an exercise price per Stock Option of C$12.60 to certain directors, executives and employees. No consideration
was received by the Company for the issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June&nbsp;30, 2021, the Company granted
40,625 Stock Options with an exercise price per Stock Option of C$18.00 to certain directors, executives and employees. No consideration
was received by the Company for the issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August&nbsp;12, 2021, the Company granted
1,667 Stock Options with an exercise price per Stock Option of C$14.4 to certain directors, executives and employees. No consideration
was received by the Company for the issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August&nbsp;25, 2021, the Company completed
a public offering of 2,096,354 units at a price of $9.60 for gross proceeds of $20,125,000 and the issuance of 146,745 compensation warrants
with a strike price of $9.60. Each unit consisted of one Common Share and one-quarter purchase warrant. Each purchase warrant entitles
the holder thereof to purchase one common share at an exercise price of $12.60 per share at any time for five years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September&nbsp;1, 2021, the Company granted
8,333 Stock Options with an exercise price per Stock Option of C$12.60 to certain directors, executives and employees. No consideration
was received by the Company for the issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September&nbsp;22, 2021, the Company granted
58,333 Stock Options with an exercise price per Stock Option of C$11.40 to certain directors, executives and employees. No consideration
was received by the Company for the issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November&nbsp;12, 2021, the Company granted
8,333 Stock Options with an exercise price per Stock Option of C$10.80 to certain directors, executives and employees. No consideration
was received by the Company for the issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December&nbsp;9, 2021, the Company granted
41,667 Stock Options with an exercise price per Stock Option of C$8.40 to certain directors, executives and employees. No consideration
was received by the Company for the issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>2022<SUP></SUP></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 10, 2022, the Company granted
112,500 Stock Options with an exercise price per Stock Option of C$8.40 to certain directors, advisors, executives and employees. No
consideration was received by the Company for this issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 14, 2022, the Company granted
8,333 Stock Options with an exercise price per Stock Option of C$8.40 to certain employees. No consideration was received by the Company
for this issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 14, 2022, the Company granted 30,833
Stock Options with an exercise price per Stock Option of C$7.20 to a certain employee. No consideration was received by the Company for
this issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Between June 17, 2022 and June 19, 2022,
in satisfaction of the notices of conversion received from the holders of the Amended and Restated Debentures, the Company issued,
in the aggregate, 70,000,000 Series 1 Preferred Shares to the Amended and Restated Debenture holders in accordance with the terms of
the Amended and Restated Debentures and made cash payments to settle accrued interest through the conversion dates in the amount of
$17,069. At the holder&rsquo;s option, the Amended and Restated Debentures are convertible into Common Shares after giving effect to
any capital reorganization of the Company, resulting in 1,166,666 Common Shares reserved for issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 127; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="fulla_024"></A>ITEM
11. DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES TO BE REGISTERED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Description of the Company&#8217;s Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Registration Statement relates to the
Company&rsquo;s Common Shares. The Company is authorized to issue an unlimited number of Common Shares, of which there are 7,195,526
Common Shares issued and outstanding as of June 30, 2022, an unlimited number of Preferred Shares, and 70,000,000 Series 1 Preferred
Shares, all of which are issued and outstanding as of June 30, 2022. The following description may not be complete and is subject to,
and qualified in its entirety by reference to, the terms and provisions of our articles and by-laws, as amended (the &ldquo;<B>Constating
Documents</B>&rdquo;), which are included as exhibits to this Registration Statement<FONT STYLE="text-transform: uppercase">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2022, the Common Shares collectively
represent 86% of our total issued and outstanding shares and 100% of the voting power attached to all of our issued and outstanding shares.
The Company refers to its Common Shares as &ldquo;shares.&rdquo;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Common Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Voting Rights</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of Common Shares shall be entitled
to receive notice of all meetings of shareholders, and to attend, vote and speak at such meetings, except those meetings at which only
holders of another specified class or series of shares of the Company are entitled to vote separately as a class or series. A quorum
for a meeting of Shareholders shall be two shareholders, or two proxyholders representing shareholders, or any combination thereof, holding
not less than thirty-three and one-third percent (33 1/3%) of the issued shares entitled to be voted at the meeting. On all matters upon
which holders of shares are entitled to vote, each Common Share is entitled to one vote per Common Share. Unless a different majority
is required by law or the Constating Documents, resolutions to be approved by holders of shares require approval by a simple majority
of the total number of votes of all shares cast at a meeting of Shareholders at which a quorum is present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Dividend Rights</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no restrictions in the Company&#8217;s
articles or elsewhere, which would prevent the Company from paying dividends. No dividends have been declared or paid on the Common Shares
of the Company in the last five fiscal years, and it is not expected that dividends will be declared or paid in the immediate or foreseeable
future. Consequently, to date there have been no distributions made by the Company. The policy of the Board is to reinvest all available
funds in operations. The Board will reassess this policy from time to time. Any decision to pay dividends on the Common Shares of the
Company will be made by the Board based on the assessment of, among other factors, earnings, capital requirements and the operating and
financial condition of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Liquidation Rights</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of the liquidation, dissolution
or winding-up of the Company or any other distribution of the Company&#8217;s assets for the purpose of winding up the Company&#8217;s
affairs, after the payment of dividends declared but unpaid, the holders of Common Shares shall be entitled <I>pari passu</I> to receive
any remaining property of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Pre-emptive and Redemption Rights</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of Common Shares do not have any pre-emptive
or redemption rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 128; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<!-- Field: Split-Segment; Name: 1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Preferred Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Preferred Shares of the Company may
be issued in one or more series and the directors are authorized to fix the number of Preferred Shares in each series and to
determine the designation, rights, privileges, restrictions and conditions attached to the Preferred Shares of each series.
Preferred Shares rank on parity with the Common Shares with respect to the payment of dividends unless one or more series of
Preferred Shares are entitled to cumulative dividends. Preferred Shares also rank on parity with the Preferred Shares of every other
series and are entitled to a priority over any other class of shares ranking junior to the Preferred Shares, and all series of
Preferred Shares participate ratably with respect to the distribution of assets upon the liquidation, dissolution or winding-up of
the Company. The Series 1 Preferred Shares are the Company&rsquo;s only series of Preferred Shares outstanding as of June 30, 2022
and are convertible, at the option of the holder thereof, at any time and from time to time, into 1,166,666 fully paid
non-assessable Common Shares. Such Series 1 Preferred Shares are not being registered by this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="fulla_025"></A><B>ITEM
12. INDEMNIFICATION OF DIRECTORS AND OFFICERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indemnification of our officers and our directors
is subject to the provisions of the CBCA, principally section 124 of the CBCA, which provides as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Indemnification</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)&nbsp;A corporation may indemnify a director
or officer of the corporation, a former director or officer of the corporation or another individual who acts or acted at the corporation&#8217;s
request as a director or officer, or an individual acting in a similar capacity, of another entity, against all costs, charges and expenses,
including an amount paid to settle an action or satisfy a judgment, reasonably incurred by the individual in respect of any civil, criminal,
administrative, investigative or other proceeding in which the individual is involved because of that association with the corporation
or other entity</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Advance of Costs</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)&nbsp;A corporation may advance moneys to
a director, officer or other individual for the costs, charges and expenses of a proceeding referred to above in subsection (1). The
individual shall repay the moneys if the individual does not fulfil the conditions of subsection (3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Limitation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)&nbsp;A corporation may not indemnify an individual
under subsection (1)&nbsp;unless the individual:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;acted
honestly and in good faith with a view to the best interests of the corporation, or, as the case may be, to the best interests of the
other entity for which the individual acted as director or officer or in a similar capacity at the corporation&#8217;s request; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
the case of a criminal or administrative action or proceeding that is enforced by a monetary penalty, the individual had reasonable grounds
for believing that the individual&#8217;s conduct was lawful.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 129; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Indemnification in Derivative Actions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)&nbsp;</FONT>A
corporation may with the approval of a court, indemnify an individual referred to in subsection (1), or advance moneys under subsection
(2), in respect of an action by or on behalf of the corporation or other entity to procure a judgment in its favor, to which the individual
is made a party because of the individual&#8217;s association with the corporation or other entity as described in subsection (1)&nbsp;against
all costs, charges and expenses reasonably incurred by the individual in connection with such action, if the individual fulfils the conditions
set out in subsection (3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Right to Indemnity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)&nbsp;</FONT>Despite
subsection (1), an individual referred to in that subsection is entitled to indemnity from the corporation in respect of all costs, charges
and expenses reasonably incurred by the individual in connection with the defense of any civil, criminal, administrative, investigative
or other proceeding to which the individual is subject because of the individual&#8217;s association with the corporation or other entity
as described in subsection (1), if the individual seeking indemnity:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;was
not judged by the court or other competent authority to have committed any fault or omitted to do anything that the individual ought
to have done; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;fulfils
the conditions set out in subsection (3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Insurance</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)&nbsp;</FONT>A
corporation may purchase and maintain insurance for the benefit of an individual referred to in subsection (1)&nbsp;against any liability
incurred by the individual:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
the individual&#8217;s capacity as a director or officer of the corporation; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
the individual&#8217;s capacity as a director or officer, or similar capacity, of another entity, if the individual acts or acted in
that capacity at the corporation&#8217;s request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Application to Court</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)&nbsp;</FONT>A
corporation, an individual or an entity referred to in subsection (1)&nbsp;may apply to a court for an order approving an indemnity under
this section and the court may so order and make any further order that it sees fit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Notice to Director</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8)&nbsp;An applicant under subsection (7)&nbsp;shall
give the Director notice of the application and the Director is entitled to appear and be heard in person or by counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 130; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Other Notice</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(9)&nbsp;On an application under subsection (7)&nbsp;the
court may order notice to be given to any interested person and the person is entitled to appear and be heard in person or by counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our by-laws provide subject to the CBCA, we may
indemnify a director or officer or a former director or officer or a corporation of which we are or were or shareholder or creditor and
their heirs and legal representatives of such person against all costs, charges, and expenses including and amount to be paid to settle
an action or satisfy a judgment, reasonably incurred in respect of any civil, criminal or administrative action or proceeding to which
they are made a party by reason of being or having been a director or officer of us or a director or officer of any such corporation.
Each director and officer of on being elected and appointed shall be deemed to have contracted with us on the terms of this indemnity.
The failure of a director or officer to comply with the provisions of the CBCA, the articles or the by-laws shall not invalidate any
indemnity to which they are entitled under our by-laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have entered into indemnification agreements
or employment agreements containing indemnification provisions with certain of our executive officers and our directors. See &ldquo;<I>Consulting
and Employment Agreements</I>&rdquo; above for more information about our employment agreements. Under these indemnification provisions,
an indemnified person is entitled, subject to the terms and conditions thereof, to the right of indemnification by the Company for certain
expenses to the fullest extent permitted by applicable law. We believe that these indemnification agreements are necessary to attract
and retain qualified individuals to serve as directors and executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors may cause us to purchase and maintain
insurance for the benefit of any person who is or was serving as a director, officer, employee or agent of us or as a director, officer,
employee or agent of any corporation of which we are or were a shareholder and their heirs or personal representatives against any liability
incurred as a director, officer, employee or agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have an insurance policy covering our directors
and officers, within the limits and subject to the limitations of the policy, with respect to certain liabilities arising out of claims
based on acts or omissions in their capacities as directors or officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="fulla_026"></A><B>ITEM
13. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The financial statements required to be included in this Registration
Statement are included in Item 15 and begin on page F-1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="fulla_027"></A>ITEM
14. CHANGES IN AND DISAGREEMENTS WITH AUDITORS ON ACCOUNTING AND FINANCIAL DISCLOSURE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December&nbsp;10, 2021, the Company engaged
Baker Tilly US, LLP (&ldquo;<B>Baker Tilly</B>&rdquo;) to perform an audit (the &ldquo;<B>U.S. Audit</B>&rdquo;) in accordance with the
standards of the Public Company Accounting Oversight Board of the Company&rsquo;s financial statements prepared in conformity with accounting
principles generally accepted in the U.S. for its fiscal years ended December&nbsp;31, 2020 and 2021, which financial statements are
included in this Registration Statement. Baker Tilly&rsquo;s engagement was recommended to the Company&rsquo;s Board by the Audit Committee
and approved by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to engaging Baker Tilly to conduct the
U.S. Audit, the Company had not consulted Baker Tilly regarding the application of accounting principles to a specified transaction,
either completed or proposed, or the type of audit opinion that might be rendered on the Company&#8217;s financial statements, nor did
the Company consult with Baker Tilly regarding any matter that was either the subject of a disagreement (as defined in paragraph (a)(1)(iv)&nbsp;of
Item 304 of Regulation S-K) or a reportable event (as described in paragraph (a)(1)(v)&nbsp;of Item 304 of Regulation S-K).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of filing of this Registration
Statement, PricewaterhouseCoopers LLP remains engaged as the Company&#8217;s independent auditor in Canada. PricewaterhouseCoopers LLP
has served as the Company&#8217;s auditors since 2004 and has conducted its most recent audits under Canadian Auditing Standards of the
Company&#8217;s financial statements prepared in accordance with International Financial Reporting Standards. In connection with the
effectiveness of this Registration Statement, if and when such effectiveness may occur, the Company anticipates that it will request
PricewaterhouseCoopers LLP to resign as its auditor.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 131; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="fulla_028"></A>ITEM
15. FINANCIAL STATEMENTS AND EXHIBITS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Years Ended December 31, 2021 and 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Index to Audited Consolidated
Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; margin-bottom: 5.75pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 88%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 12%"><B>Page</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Audited Consolidated Financial Statements</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#ss1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent
    Registered Public Accounting Firm</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="#ss1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#ss2"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="#ss2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#ss3"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Operations
    and Comprehensive Loss</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="#ss3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#ss4"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Changes
    in Shareholders&rsquo; Equity (Deficit)</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="#ss4"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#ss5"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="#ss5"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#ss6"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="#ss6"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</FONT></A></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Three Months Ended March 31, 2022 and 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Index to Unaudited Condensed Consolidated
Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 90%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Page</B>&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt"><B>Unaudited Condensed Consolidated Financial Statements</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#y_001"><FONT STYLE="font-size: 10pt">Condensed Consolidated Balance Sheets</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="#y_001"><FONT STYLE="font-size: 10pt">F-26</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><A HREF="#y_002"><FONT STYLE="font-size: 10pt">Condensed Consolidated Statements of Operations and Comprehensive Loss</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="#y_002"><FONT STYLE="font-size: 10pt">F-27</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#y_003"><FONT STYLE="font-size: 10pt">Condensed Consolidated Statements of Changes in Shareholders&rsquo; Equity (Deficit)</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="#y_003"><FONT STYLE="font-size: 10pt">F-28</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><A HREF="#y_004"><FONT STYLE="font-size: 10pt">Condensed Consolidated Statements of Cash Flows</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="#y_004"><FONT STYLE="font-size: 10pt">F-29</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#y_005"><FONT STYLE="font-size: 10pt">Notes to Condensed Consolidated Financial Statements</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="#y_005"><FONT STYLE="font-size: 10pt">F-30</FONT></A></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 132; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="ss1"></A>REPORT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Shareholders and Board of Directors of ProMIS Neurosciences
Inc. and Subsidiary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Opinion on the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated balance sheets of ProMIS Neurosciences Inc. and Subsidiary (the &ldquo;Company&rdquo;) as of December 31, 2021 and 2020,
and the related consolidated statements of operations and comprehensive loss, changes in shareholders&rsquo; equity (deficit),
and cash flows for each of the two years in the period ended December 31, 2021, and the related notes (collectively referred to as the
 &ldquo;consolidated financial statements&rdquo;). In our opinion, the consolidated financial statements present fairly,
in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and
its cash flows for each of the two years in the period ended December 31, 2021, in conformity with accounting principles generally accepted
in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These consolidated financial statements
are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting
Oversight Board (United States) (&ldquo;PCAOB&rdquo;) and are required to be independent with respect to the Company in accordance with
the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with
the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required
to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required
to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness
of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures
to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe
that our audits provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Baker Tilly US, LLP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&rsquo;s auditor since 2021.</P></TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tewksbury, Massachusetts</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">April 4, 2022, except for the effects of the reverse share split described
in Note 2, as to which the date is June 30, 2022</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="ss2"></A> Consolidated
Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in US dollars, except share and
per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December&nbsp;31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2021</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2020</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assets</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current assets:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 74%; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,943,905</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">806,887</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term investments</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33,248</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,963</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and
    other current assets</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">737,316</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">133,022</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total current assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,714,469</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">972,872</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,671</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">78,111</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets, net</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,614</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,637</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other assets</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,353</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total assets</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,746,754</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,085,973</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liabilities and Shareholders' Equity (Deficit)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current liabilities:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">408,981</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">437,441</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued liabilities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">520,093</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46,201</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    compensation</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,398,989</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current liabilities</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">929,074</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,882,631</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible debt, net of issuance costs and debt
    discount</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,906,057</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative liability</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,379,878</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant liability</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,871,687</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total liabilities</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,086,696</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,882,631</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments and contingencies (Note 16)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders' equity (deficit):</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Common shares, no par value,
                                  unlimited shares authorized, 7,195,526 and 4,828,846 shares issued and outstanding as of December&nbsp;31,
                                  2021 and 2020, respectively</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional paid-in capital</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68,039,178</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51,655,168</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated other comprehensive
    loss</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(187,919</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(50,731</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    deficit</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(62,191,201</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(52,401,095</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total shareholders'
    equity (deficit)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,660,058</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(796,658</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total liabilities
    and shareholders' &nbsp;equity (deficit)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,746,754</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,085,973</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="ss3"></A> Consolidated
Statements of Operations and Comprehensive Loss</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in US dollars, except share and
per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Years Ended December&nbsp;31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Research and development</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">4,627,386</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,224,650</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 9pt">General and administrative</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,663,707</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,026,957</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total operating
    expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,291,093</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,251,607</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss from operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(8,291,093</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,251,607</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of financial instruments</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,095,636</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest expense on convertible debt</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(416,286</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,909</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,327</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(9,790,106</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,250,280</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Other comprehensive loss</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Foreign currency
    translation adjustment</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(137,188</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(72,803</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Comprehensive loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(9,927,294</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,323,083</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss per share, basic and diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1.69</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.89</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Weighted-average shares outstanding
    of common shares, basic and diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,785,617</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,759,997</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="ss4"></A> Consolidated Statements
of Changes in Shareholders&#8217; Equity (Deficit)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in US dollars, except share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Common Shares</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Shares</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Additional <BR>
    Paid-in <BR>
    Capital</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Accumulated <BR>
    Other <BR>
    Comprehensive <BR>
    Income (Loss)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Accumulated <BR>
    Deficit</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="white-space: nowrap; width: 28%"><FONT STYLE="font-size: 10pt">Balance, January&nbsp;1, 2020</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">4,590,138</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">48,435,848</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">22,072</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">(48,150,815</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">307,105</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Exercise of warrants</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">238,708</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">1,608,090</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">1,608,090</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Issuance of special warrants - net of issuance costs of $226,703</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">1,256,828</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">1,256,828</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Share-based compensation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">354,402</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">354,402</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Foreign currency translation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">(72,803</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">(72,803</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Net loss</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(4,250,280</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(4,250,280</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Balance, December&nbsp;31, 2020</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">4,828,846</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">51,655,168</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">(50,731</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">(52,401,095</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">(796,658</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Conversion of special warrants</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">270,326</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Issuance of common shares, net of issuance costs of $1,665,099</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">2,096,354</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">15,868,381</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">15,868,381</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Share-based compensation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">515,629</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">515,629</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Foreign currency translation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">(137,188</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">(137,188</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Net loss</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(9,790,106</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(9,790,106</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Balance, December&nbsp;31, 2021</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">7,195,526</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">68,039,178</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(187,919</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(62,191,201</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">5,660,058</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these consolidated financial statements.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="ss5"></A> Consolidated
Statements of Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in US dollars)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years Ended December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Cash flows from operating activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; font-size: 10pt; text-align: left">Net loss</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(9,790,106</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(4,250,280</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Share-based compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">515,629</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">354,402</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Foreign currency exchange loss</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">85,066</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Change in fair value of derivative liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,936,191</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Change in fair value of warrant liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(840,555</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Depreciation of property and equipment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">40,576</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,726</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Gain on sale of property and equipment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(59,157</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Amortization of debt discount and issuance costs</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">366,018</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Amortization of intangible assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,249</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,955</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Changes in operating assets and liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Prepaid expenses and other current assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(600,635</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">113,017</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Accounts payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(31,654</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">68,933</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Accrued liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">471,463</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(115,978</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Deferred compensation</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,403,468</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">585,693</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 27pt">Net cash used in operating activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(9,305,383</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3,232,532</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Cash flows from investing activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Purchase of short-term investments</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(33,102</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(31,220</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Maturity of short-term investment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">33,069</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">31,064</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Proceeds from sale of property and equipment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">98,335</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Purchase of property and equipment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(6,044</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(80,705</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other investing activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,360</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,228</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 27pt">Net cash provided by (used in) investing activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">94,618</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(83,089</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Cash flows from financing activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Proceeds from convertible debt</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,915,199</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Proceeds from issuance of common share units, net of issuance costs</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">15,868,381</P></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Proceeds from issuance of warrants</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,739,221</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Proceeds from issuance of common shares from exercise of warrants</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,608,090</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Proceeds from issuance of Special Warrants - net of issuance costs</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,256,828</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 27pt">Net cash provided by financing activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">25,522,801</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,864,918</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Effect of exchange rates on cash</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(175,018</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(24,235</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Net increase (decrease) in cash</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">16,137,018</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(474,938</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Cash at beginning of year</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">806,887</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,281,825</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Cash at end of year</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">16,943,905</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">806,887</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Noncash financing activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Issuance of compensation warrants in consideration of issuance costs</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">957,947</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">29,618</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Fair value adjustment for modification of warrants</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">85,005</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="ss6"></A>Notes to Consolidated
Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in US dollars, except share and
per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD><TD STYLE="text-align: justify"><B>DESCRIPTION
                                            OF BUSINESS</B></TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Business Description</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">ProMIS Neurosciences&nbsp;Inc.
(the &ldquo;<B>Company</B>&rdquo; or &ldquo;<B>ProMIS</B>&rdquo;) is applying its patented technology platform to build a portfolio
of antibody therapies, therapeutic vaccines, and other antibody-based therapies in neurodegenerative diseases and other misfolded
protein diseases, including Alzheimer&rsquo;s disease multiple system atrophy, and amyotrophic lateral sclerosis. The Company also
plans to investigate additional synucleinopathies, including Parkinson&rsquo;s disease and dementia with Lewy bodies, frontotemporal
lobar degeneration, progressive supranuclear palsy, corticobasal degeneration and schizophrenia. These diseases share a common
biologic cause &ndash; misfolded versions of proteins that otherwise perform a normal function, become toxic and kill neurons,
resulting in disease. ProMIS&rsquo; technology platform is an example of the advances in drug discovery enabled by computational
power, in silico discovery, and/or artificial intelligence. ProMIS believes this platform provides a potential advantage by
selectively targeting the toxic misfolded proteins with therapeutics or detecting them with diagnostics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company was incorporated on
January 23, 2004 under the Canada Business Corporations Act and is located at 1920 Yonge Street, Toronto, Ontario. The Company&rsquo;s
common shares are traded on the Toronto Stock Exchange (&ldquo;<B>TSX</B>&rdquo;) under the symbol PMN and on the OTCQB Venture Market
under the symbol ARFXD. The Company has a wholly-owned U.S. subsidiary, ProMIS Neurosciences (US) Inc. (&ldquo;<B>ProMIS USA</B>&rdquo;),
which was incorporated in January&nbsp;2016 in the State of Delaware. As of December 31, 2021, ProMIS USA has had no activity and has
no financial impact on the Company&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The success of the Company is dependent
on obtaining the necessary regulatory approvals of its product candidates, marketing its products and achieving profitable operations.
The continuation of the research and development activities and the commercialization of its products, if approved, are dependent on
the Company&#8217;s ability to successfully complete these activities and to obtain additional financing through a combination of financing
activities and operations. It is not possible to predict either the outcome of future research and development or commercialization programs,
or the Company&#8217;s ability to fund these programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>COVID-19</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Impacts resulting from the COVID-19
pandemic have resulted in a widespread health crisis that has already adversely affected the economies and financial markets of many
countries around the world. The international response to the spread of COVID-19 has led to significant restrictions on travel; temporary
business closures; quarantines; global stock market and financial market volatility; a general reduction in consumer activity; operating,
supply chain and project development delays and disruptions; and declining trade and market sentiment; all of which have and could further
affect the world economy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The extent to which the novel coronavirus
may impact the Company&#8217;s business, preclinical research and development activities will depend on future developments which are
highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, travel restrictions and social distancing
in Canada, the United States and other countries, business closures or business disruptions and the effectiveness of actions taken by
governments around the globe to contain and treat the disease. International scientific conferences at which the Company has been invited
to present have been postponed, cancelled or will be held online instead, which diminishes exposure and the opportunity to meet with
collaborators and potential partners. These scientific conferences have started to be held in person with an option to attend online.
Vendors performing work for the Company have remained open, although they have indicated that their timelines are now somewhat longer.
The current global uncertainty and its effect on the local and global economies may also have an adverse effect on the Company&#8217;s
ability to secure additional financing to continue its research and development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 138; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Liquidity Risk</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The accompanying consolidated
financial statements were prepared on a going concern basis, which assumes that the Company will continue its operations for the foreseeable
future and will be able to realize its assets and discharge its liabilities in the normal course of business. To date, the Company has
not generated revenues from its activities. The Company had a net loss of $9,790,106, for the year ended December&nbsp;31, 2021 and an
accumulated deficit of $62,191,201 as of December&nbsp;31, 2021. Available funds are expected to be sufficient to fund the Company&rsquo;s
operating expenses for at least 12 months from the date the consolidated financial statements are issued. However, additional
funding will be necessary to fund future research, pre-clinical and clinical activities. The Company will seek additional funding through
public financings, debt financings, collaboration agreements, strategic alliances and licensing agreements. Although the Company has
been successful in raising capital in the past, there is no assurance of success in obtaining such additional financing on terms acceptable
to us, if at all, and there is no assurance that the Company will be able to enter into collaborations or other arrangements. If the
Company is unable to obtain funding, it could force delays, reduce or eliminate research and development programs, product portfolio
expansion or commercialization efforts, which could adversely affect future business prospects, and the ability to continue operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company may continue to incur net
losses for at least the next several years as the Company advances its product candidates. The Company is actively pursuing additional
financing to further develop certain of the Company&#8217;s scientific initiatives, but there is no assurance these initiatives will
be successful, timely or sufficient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>2.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>BASIS
                                            OF PRESENTATION AND Summary of Significant Accounting Policies</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Basis of Presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The accompanying consolidated
financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&ldquo;<B>GAAP</B>&rdquo;).
Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards
Codification (&ldquo;<B>ASC</B>&rdquo;) and as amended by Accounting Standards Updates (&ldquo;<B>ASU</B>&rdquo;) of the Financial Accounting
Standards Board (&ldquo;<B>FASB</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On June 21, 2022, the directors
of the Company authorized a reverse share split of the issued and outstanding Common Shares in a ratio of 60:1, effective June 28, 2022
(the &ldquo;<B>Reverse Share Split</B>&rdquo;). All information included in these consolidated financial statements has been adjusted,
on a retrospective basis, to reflect the Reverse Share Split, unless otherwise stated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Principles of Consolidation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The accompanying consolidated
financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions
have been eliminated in consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Use of Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The preparation of consolidated
financial statements in conformity with GAAP requires management to make certain estimates, judgements and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions
made in the accompanying consolidated financial statements include, but are not limited to, the valuation of intangible assets,
accrual for research and development expenses, the valuation of share-based compensation and the valuation of warrants, and the valuation
of warrant liabilities and embedded derivative liabilities. Actual results could differ from those estimates, and such differences could
be material to the consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 139; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Segment Information</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Operating segments are identified as
components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision
maker (&ldquo;<B>CODM</B>&rdquo;), or decision-making group, in making decisions on how to allocate resources and assess performance.
The Company has one operating segment and its Chief Executive Officer and Executive Chairman of the Board of Directors collectively serve
as the CODM. Substantially all of the Company&#8217;s assets are located in Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Foreign Currency</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Comprehensive loss is defined as a
change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. The reporting currency
of the Company is the United States dollar (&ldquo;<B>US$</B>&rdquo;) and the functional currency of the Company is the Canadian dollar
(&ldquo;<B>C$</B>&rdquo;). The assets and liabilities of the Company are translated to US$ at exchange rates in effect at the balance
sheet date. All income statement accounts are translated at average exchange rates. Resulting foreign currency translation adjustments
are recorded directly in accumulated other comprehensive income (loss) as a separate component of shareholders&rsquo; equity (deficit).
Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional
currency are included in general and administrative expenses in the accompanying consolidated statements of operations and comprehensive
loss when realized and are not material for the years ended December 31, 2021 and 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; color: #231f20"><B>Cash and Cash Equivalents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company considers all highly liquid
investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of December&nbsp;31,
2021 and 2020 the Company had no cash equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Short-term Investments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Short-term investments consist of guaranteed
certificates of deposit with a maturity greater than 90 days and up to one year at the time of purchase. Accordingly, all short-term
investments are classified as current assets in the accompanying consolidated balance sheets. The short-term investment is being held
as collateral for the Company&rsquo;s credit cards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Concentration of Credit Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Financial instruments that potentially
subject the Company to a significant concentration of credit risk consist of cash and short-term investments. Cash is deposited in checking
and money market accounts at accredited financial institutions, which at times, may exceed federally insured limits. The short-term investment
is deposited in a guaranteed certificate of deposit with an accredited financial institution that guarantees 100% of the original amount
invested. Management believes that these financial institutions are financially sound, and, accordingly, minimal credit risk exists with
respect to these high-quality financial institutions. As of December&nbsp;31, 2021, the Company has not experienced any losses on its
cash or short-term investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 140; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Fair Value Measurements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">FASB ASC 820, <I>Fair Value Measurements
and Disclosures, </I>(<B>&ldquo;ASC 820&rdquo;</B>) defines fair value as the price that would be received to sell an asset or paid to
transfer a liability in an orderly transaction between market participants at the measurement date. Valuation techniques used to measure
fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried
at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, as established by
ASC 820, of which the first two are considered observable and the last is considered unobservable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Level
                                            1 &#8211; Observable inputs, such as unadjusted, quoted prices in active markets for identical
                                            assets or liabilities at the measurement date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Level
                                            2 &#8211; Inputs (other than Level 1 quoted prices) are either directly or indirectly observable
                                            inputs for similar assets or liabilities. These include quoted prices in active markets for
                                            similar assets or liabilities, quoted prices in markets that are not active for identical
                                            or similar assets or liabilities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Level
                                            3 &#8211; Unobservable inputs that are supported by little or no market activity and that
                                            are significant to the fair value of the assets or liabilities, including pricing models,
                                            discounted cash flow methodologies and similar techniques.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">To the extent that the valuation is
based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment.
Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level
3. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair
value measurement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in">The Company&rsquo;s warrant liability
and embedded derivative liability were classified as Level 3 financial instruments for the year ended December 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The carrying amounts of prepaid and
other current assets, short-term investments, accounts payable, and accrued expenses are generally considered to be representative of
their fair value based on the short-term nature of these financial instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Impairment of Long-Lived Assets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company evaluates its long-lived
assets, which consist of property and equipment and definite-lived intangible assets, for impairment whenever events or changes in circumstances
indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by
a comparison of the carrying amount of an asset to the estimated future undiscounted net cash flows expected to be generated by the asset.
If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount
of the asset exceeds the fair value of the asset. No impairments have been identified as of December&nbsp;31, 2021 and 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 141; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Property and Equipment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Property and equipment, net are stated
at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life
of each asset. Laboratory and equipment are depreciated over two to five years. Computer equipment is depreciated over two to three years.
Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accompanying consolidated
balance sheets and any resulting gain or loss is included in loss from operations in the accompanying consolidated statements of operations
and comprehensive loss. Expenditures for repairs and maintenance are expensed as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Intangible Assets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Definite-lived intangible assets are
stated at cost less accumulated amortization and any accumulated impairment losses. An intangible asset&rsquo;s carrying amount is assessed
for impairment whenever there is an indication that the asset may be impaired. The Company&rsquo;s definite-lived intangible assets consist
of acquired rights and patents. Intangible assets are amortized on a straight-line basis over the lesser of the life of the intangible
asset or its estimated useful life, which is 15 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Derivative Liability</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company evaluates its convertible
debt, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to
be separately accounted for in accordance with FASB ASC Topic 815, <I>Derivatives and Hedging </I>and Topic 480, <I>Distinguishing Liabilities
from Equity</I>. The result of this accounting treatment is that the fair value of the embedded derivative, if required to be bifurcated,
is marked-to-market at each balance sheet date and recorded as a liability. The change in fair value is recorded in the accompanying
consolidated statements of operations and comprehensive loss as a component of other income or expense. Upon conversion or exercise of
a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Collaboration Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company may enter into collaboration
arrangements with pharmaceutical and biotechnology partners. The Company analyzes its collaboration arrangements to assess whether they
are within the scope of FASB ASC 808, <I>Collaborative Arrangements, </I>(<B>&ldquo;ASC 808&rdquo;</B>), to determine whether such arrangements
involve joint operating activities performed by the parties that are both active participants in the activities and exposed to significant
risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement
based on changes in responsibilities of all parties in the arrangement. ASC 808 does not provide guidance on the recognition of consideration
exchanged or accounting for the obligations that may arise between parties. The Company concluded that ASC Topic 730, <I>Research and
Development, </I>should be applied by analogy to payments between parties during the development activities of its collaboration arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>General and Administrative</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">General and administrative expenses
consist primarily of personnel costs including salary, bonus, employee-benefits and share-based compensation, costs incurred in development
and protection of intellectual property, professional service fees, and other general overhead and facility costs, including rent, depreciation
and amortization, which relate to the Company&rsquo;s general and administrative functions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Research and Development Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Research and development expenses consist
primarily of costs incurred in connection with the development and research of the Company&rsquo;s platform technology, as well as discovery
program expenses. The Company expenses research and development costs as incurred. These expenses include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">employee-related
                                            expenses, including salaries, related benefits and share-based compensation expense, for
                                            employees engaged in research and development functions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 142; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">external
                                            research and development expenses incurred under arrangements with third parties, such as
                                            contract research organizations (&ldquo;<B>CROs</B>&rdquo;), and consultants;</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">the
                                            cost of acquiring, developing, and manufacturing clinical study materials; and</P></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Costs
                                            associated with preclinical and clinical activities and regulatory operations.</P></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Prepaid and Accrued Research and Development Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Substantial portions of the Company&rsquo;s
pre-clinical trials are performed by third-party laboratories, medical centers, CROs and other vendors. These vendors generally bill
monthly for services performed, or bill based upon milestone achievement. For preclinical studies, the Company accrues expenses based
upon estimated percentage of work completed and the remaining contract milestones. At times, the Company is obligated to make upfront
payments upon execution of research and development agreements. Upfront payments, including nonrefundable amounts, for goods or services
that will be used or rendered for future research and development activities are capitalized as prepaid expenses until such goods are
delivered or the related services are performed. The Company estimates the period over which such services will be performed based on
the terms of the agreements as well as the level of effort to be expended in each period. Sometimes the actual timing of performance
or the level of effort varies from the estimate, and if that does occur, the Company will adjust the amounts recorded accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Patent Costs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">All patent-related costs incurred in
connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the
expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying consolidated statements of operations
and comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company issues warrants on its
common shares in connection with financings as well as for compensation of intermediaries and advisors. The Company accounts for warrants
as either equity instruments or as liabilities depending on the specific terms of the warrant agreements in accordance with FASB ASC
Topic 815, <I>Derivatives and Hedging </I>and Topic 480, <I>Distinguishing Liabilities from Equity</I>. When classified as equity, warrants
are recorded within additional paid-in-capital. Warrants identified as meeting the definition of a derivative are recognized as a liability
and treated in accordance with the derivative liability accounting policy described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Debt Issuance Costs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Debt issuance costs are specifically identifiable costs
associated with issuance of a new debt instrument. Debt issuance costs are reported on the consolidated balance sheet as a direct deduction
from the face amount of the related debt. Debt issuance costs are amortized to interest expense over the term of the related debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Share-based Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Share-based compensation expense related
to share awards granted to employees, directors and non-employees is recognized based on the grant-date estimated fair values of the
awards using the Black- Scholes option pricing model (&ldquo;<B>Black-Scholes</B>&rdquo;). The value is recognized as expense ratably
over the requisite service period, which is generally the vesting term of the award. The Company adjusts the expense for actual forfeitures
as they occur. Share based compensation expense is classified in the accompanying consolidated statements of operations and comprehensive
loss based on the function to which the related services are provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 143; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Black Scholes requires a number of
assumptions, of which the most significant are expected volatility, expected option term (the time from the grant date until the options
are exercised or expire) and risk-free rate. Expected volatility is determined using the historical volatility for the Company. The risk-free
interest rate is based on the yield of Canadian government bonds with a remaining term equal to the expected life of the option. Expected
dividend yield is zero because the Company has never paid cash dividends on common shares and the Company does not expect to pay cash
dividends in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Income Taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company is a taxable entity under
the Income Tax Act (Canada). Deferred income tax assets and liabilities are determined based on differences between the financial statement
carrying amounts and the respective income tax bases of assets and liabilities, measured using substantively enacted income tax rates
and laws that are expected to be in effect when the differences are expected to reverse. Deferred tax assets are recognized to the extent
it is more likely than not that taxable income will be available against which the deferred tax asset can be utilized. Deferred tax assets
are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company follows the provisions
of ASC 740-10, <I>Uncertainty in Income Taxes</I> (&ldquo;<B>ASC 740-10</B>&rdquo;). The Company has not recognized a liability as a
result of the implementation of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not
been provided since there is no unrecognized benefit since the date of adoption. The Company has not recognized interest expense or penalties
as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize interest accrued
related to unrecognized tax benefits in interest expense and penalties in operating expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Basic and Diluted Net Loss Per Share</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Basic net loss per common share is
computed by dividing net loss by the weighted-average number of common shares outstanding during each period. Diluted net loss per share
of common shares includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, share
options and warrants, which would result in the issuance of incremental shares of common shares. For diluted net loss per share, the
weighted-average number of common shares is the same for basic net loss per share due to the fact that when a net loss exists, dilutive
securities are not included in the calculation as the impact is anti-dilutive. For all periods presented, basic and diluted net loss
per share are the same, as any additional share equivalents would be anti-dilutive. As the Company has reported a net loss for all periods
presented, diluted net loss per common share is the same as basic net loss per common share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 144; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Emerging Growth Company Status</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company is an Emerging Growth
Company, as defined in Section&nbsp;2(a)&nbsp;of the Securities Act of 1933, as modified by the Jumpstart Our Business Startups Act of
2012 (&ldquo;<B>JOBS&nbsp;Act</B>&rdquo;). Under the JOBS&nbsp;Act, emerging growth companies can delay adopting new or revised accounting
standards issued subsequent to the enactment of the JOBS&nbsp;Act, until such time as those standards apply to private companies. The
Company has elected to use this extended transition period for complying with new or revised accounting standards that have different
effective dates for public and private companies until the earlier of the date that it (i)&nbsp;is no longer an emerging growth company
or (ii)&nbsp;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS&nbsp;Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements
as of public company effective dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Recently Issued Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In February&nbsp;2016, the FASB
issued ASU No.&nbsp;2016-02, <I>Leases</I> (&ldquo;<B>Topic 842</B>&rdquo;), which requires lessees to recognize the following for all
leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee&rsquo;s obligation to
make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents
the lessee&rsquo;s right to use, or control the use of, a specified asset for the lease term. In July&nbsp;2018, the FASB issued ASU
2018-11, <I>Leases </I>(&ldquo;<B>Topic 842</B>&rdquo;) <I>Targeted Improvements</I>, to amend certain aspects of Topic 842. These amendments
provide entities with an additional (and optional) transition method to adopt Topic 842. Under this transition method, an entity initially
applies the transition requirements in Topic 842 at that Topic&rsquo;s effective date with the effects of initially applying Topic 842
recognized as a cumulative effect adjustment to the opening balance of retained earnings (or other components of equity or net assets,
as appropriate) in the period of adoption. On April&nbsp;8, 2020, the FASB changed the effective date of this standard applicable to
the Company as an emerging growth company to January&nbsp;1, 2022. The Company is currently evaluating the potential impact of adopting
this standard on its consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In December 2019, the FASB issued
ASU No 2019-12, <I>Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</I> (&ldquo;<B>Topic 740</B>&rdquo;), as part
of its simplification initiative to reduce the cost and complexity in accounting for income taxes. The amendments in ASU 2019-12 removes
certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim
period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also amends other aspects of the guidance
to help simplify and promote consistent application of GAAP. The guidance is effective for interim and annual periods beginning after
December 15, 2020, with early adoption permitted. For emerging growth companies, the standard is effective for fiscal years beginning
after December 15, 2021. The Company is currently evaluating the potential impact adopting ASU 2019-12 will have on the Company&rsquo;s consolidated financial statements and related disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In August&nbsp;2020, the FASB issued
ASU No.&nbsp;2020-06, <I>Debt&mdash;Debt with Conversion and Other Options (</I>&ldquo;<B>Subtopic 470-20</B>&rdquo;<I>) and Derivatives
and Hedging Contracts in Entity s Own Equity (</I>&ldquo;<B>Subtopic 815-40</B>&rdquo;<I>): Accounting for Convertible Instruments and
Contracts in an Entity&rsquo;s Own Equity</I>. ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number
of accounting models for convertible debt instruments and convertible preferred shares. Limiting the accounting models results in fewer
embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments
that continue to be subject to separation models are (i)&nbsp;those with embedded conversion features that are not clearly and closely
related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative
accounting and (ii)&nbsp;convertible debt instruments issued with substantial premiums for which the premiums are recorded as additional
paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity&rsquo;s own equity
to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective for the Company for fiscal years beginning
after December&nbsp;15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December&nbsp;15, 2020, including
interim periods within those fiscal years. The Company is currently evaluating the potential impact adopting ASU 2020-06 will have on
the Company&rsquo;s consolidated financial statements and related disclosures.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 145; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><B>3.</B></TD><TD><B>FAIR VALUE MEASUREMENTS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following are the major categories
of assets measured at fair value on a recurring basis as of December 31, 2021 and 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 94%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">As of
    December&nbsp;31, 2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Level 1</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Level 2</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Level 3</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 13.7pt">Short-term
    investments</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">33,248</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">33,248</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 27.35pt">Total assets
    measured at fair value</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">33,248</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">33,248</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;Liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 13.7pt">Derivative liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,379,878</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,379,878</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 13.7pt">Warrant liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,871,687</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,871,687</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 27.35pt">Total liabilities
    measured at fair value</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,251,565</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,251,565</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 94%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">As of
    December&nbsp;31, 2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Level 1</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Level 2</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Level 3</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 13.7pt">Short-term
    investments</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">32,963</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">32,963</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 27.35pt">Total assets
    measured at fair value</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">32,963</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">32,963</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No transfers between levels have occurred in either
reporting period presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><B>4.</B></TD><TD><B>PREPAID EXPENSES AND OTHER CURRENT ASSETS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Prepaid expenses and other current assets consist of the
following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 94%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">Upfront research payments</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">554,878</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">30,714</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Goods and services tax receivable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48,690</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,286</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Insurance</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">32,853</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">27,335</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Dues and subscriptions</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16,863</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Consultants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">69,915</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13,929</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">License fee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">19,754</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&mdash;</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Deposits</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,839</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,818</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Miscellaneous</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,387</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,077</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current
    assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">737,316</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">133,022</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 146; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><B>5.</B></TD><TD><B>PROPERTY AND EQUIPMENT</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Property and equipment, net, consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 94%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">Laboratory equipment</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">66,403</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">151,114</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Computer equipment</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">17,657</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11,498</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total property and equipment</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">84,060</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">162,612</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(79,389</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(84,501</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Property and equipment, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,671</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">78,111</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Depreciation expense was $40,576 and
$6,726 for the years ended December&nbsp;31, 2021 and 2020, respectively. The Company recognized a gain on the sale of property and equipment
of $59,157 for the year ended December 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>6.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>Intangible
                                            assets</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company has intangible assets consisting
of acquired rights and patents with finite lives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In March&nbsp;2012, the Company acquired
rights to a certain patented technology that it had licensed from its Chief Scientific Officer for C$100,000. The Company is amortizing
this asset over its expected useful life of 15 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 94%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">Intangible assets</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">79,015</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">78,417</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less: accumulated amortization</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(51,401</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(45,780</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Intangible assets, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">27,614</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">32,637</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Amortization expense was $5,249 and
$4,955 for the years ended December&nbsp;31, 2021 and 2020, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December&nbsp;31, 2021, the estimated
expected amortization expense related to the Company&rsquo;s intangible assets for each year through the year ended 2026 is $5,272 and,
thereafter totals $1,254.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>7.</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>ACCRUED LIABILITIES</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Accrued liabilities consist of the
following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 94%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-size: 10pt">Legal</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">171,777</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Accounting</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">123,026</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">29,446</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Project work completed</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">106,845</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,736</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Accrued interest</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">54,398</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Annual meeting</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">21,479</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">21,671</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Other</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">42,568</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(17,652</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Accrued liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">520,093</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">46,201</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><B>8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></B></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>DEFERRED
    COMPENSATION</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company deferred cash payment of
management compensation for the Executive Chairman. Chief Executive Officer, Chief Scientific Officer, Chief Medical Officer and Chief
Development Officer at December&nbsp;31, 2020, in the amount of $1,398,989. As of December&nbsp;31, 2021, all deferred compensation to
management was paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 147; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><B>9.</B></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><B>Collaboration
                                            agreements</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In July&nbsp;2020, the Company entered into two collaborative
agreements (&ldquo;<B>BCNI Collaborations</B>&rdquo;) with BC Neuroimmunology Lab Inc. (<B>&ldquo;BCNI&rdquo;</B>) as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Neurodegenerative Diseases </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company and BCNI (&ldquo;<B>Neurodegen
Collaboration</B>&rdquo;) agreed to develop and offer highly accurate and objective tests for detection, diagnosis and monitoring of
AD. The operation will first offer existing blood-based assays for NfL and P-tau181. Further assays will be added, potentially incorporating
the Company&rsquo;s proprietary peptide antigens and tests for additional neurodegenerative diseases. The agreement was accounted for
as a collaboration arrangement. Beginning in October&nbsp;2020, each party contributed up to Canadian C$12,500 each month to cover operating
costs up to the time that the operation becomes cashflow positive. The Company and BCNI acquired laboratory equipment that they jointly
control. The Company contributed $19,973 and $115,900 during 2021 and 2020, respectively, of which $19,973 and $9,655 were recorded in
research and development expenses in 2021 and 2020, respectively, in the accompanying consolidated statements of operations and comprehensive
loss and $106,245 is reflected in property and equipment, net, in the accompanying consolidated balance sheets in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Covid-19</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company and BCNI (&ldquo;<B>Covid-19
Collaboration</B>&rdquo;) agreed to provide the service of highly sensitive and specific serological assays for the detection and characterization
of antibodies to the SARS-CoV-2 virus that is responsible for COVID-19. The Company and BCNI agreed to create an independent entity for
the Covid-19 Collaboration to be established in 2021. The Company acquired 50% ownership interest in the future entity for $2,353. The
Company recorded its investment in the future entity using the equity method of accounting and is reflected in other assets in the accompanying
consolidated balance sheets. The Company is responsible for the funding of all operating expenses, with prior notification of the planned
expenditures, to bring the assay through approval. The agreement was accounted for as a collaboration arrangement for the year ended
December 31, 2020. The Company contributed $10,306 during 2020, which was recorded as research and development expense in 2020 on the
accompanying consolidated statements of operations and comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In January&nbsp;2021,&nbsp;Covid-19
Collaboration became an independent entity. The Company and BCNI each owned 50% of the Covid-19 Collaboration. In February&nbsp;2021,
the Company funded C$25,000 of expenses, which would be paid back out of the profits, if any. As the Covid-19 Collaboration became an
independent entity the Company accounted for it using the equity method. For the year ended December 31, 2021, the Company funded $77,549
of expenses. The Company recognized a pro-rata share of losses for the full amount of its investment in the Covid-19 Collaboration of
$2,353 for the year ended December 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In December&nbsp;2021, The BCNI Collaborations
were terminated. The Covid-19 Collaboration redeemed the shares purchased by the Company for an aggregated redemption price of $2,353.
A payment to the Company of C$128,000, which included the share redemption payment, and for the portion of the equipment purchased and
related expenses incurred by the Company in relation to the Neurodegen Collaboration, was received by the Company on December&nbsp;21,
2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>10.</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>CONVERTIBLE DEBT</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In March&nbsp;2021, the Company
completed a $7.0 million private placement of convertible debentures (the &ldquo;Debentures&rdquo;). The Company allocated $3,567,442
of proceeds to the Debenture. The Company incurred $48,220 of issuance costs in connection with the private placement of which $24,575
was allocated to the Debentures and amortized over the life of the Debenture. The Debentures are convertible into common shares at the
option of the holder at any time and from time to time at a conversion price of $6.00 and accrue interest at 1% per annum, which is payable
annually. At the Company&rsquo;s election, accrued interest may be paid in cash or common shares (such number of shares determined by
dividing the interest due by the 5-day volume-weighted average price (&ldquo;<B>VWAP</B>&rdquo;) of the common shares). The Debentures
mature on March&nbsp;22, 2026. Prior to the maturity date, the Company is entitled to convert the Debentures at the conversion price
upon raising an aggregate of $50 million in equity and/or debt. On the maturity date, the Company may redeem the outstanding principal
amount of the Debentures in either cash or common shares (at the then 5-day VWAP less a 10% discount) or a combination thereof. The Company
recognized $366,000 of interest expense relating to the amortization of the debt discount related to the derivative liability and issuance
costs allocated to the Debentures as of December 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The conversion feature has been
recognized as a derivative liability recorded as a discount to the Debenture, adjusted to fair value each reporting period and being
recorded in the consolidated statements of operations and comprehensive loss. The derivative liability has been valued at $3,432,558
at issuance date using a scenario-based valuation method using a Monte Carlo model, volatility of 101.43%, a risk-free interest rate
of 0.15% and a selected debt yield of 15.96%. The derivative liability at December 31, 2021 has been valued at $5,379,878 using a scenario-based
valuation method using a Monte Carlo simulation model, volatility of 95.95%, a risk-free interest rate of 1.15% and a selected debt yield
of 15.96%. The total liability of the Debenture and the derivative liability at December 31, 2021 was $9,285,935. The portion of issuance
costs allocated to the conversion feature of $23,645 were expensed when incurred in 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December
    31, 2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2020</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;$</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 86%; font: 10pt Times New Roman, Times, Serif; text-align: left">Derivative liability at issuance</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">3,432,558</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of the derivative liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,936,191</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Foreign exchange loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11,129</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 9pt">Balance at December 31, 2021</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,379,878</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>11.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>COMMON
                                            SHARES</B></FONT></TD>
</TR></TABLE>
<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company has authorized an unlimited
number of both common and preferred shares. As of December 31, 2021 and 2020, the Company has 7,195,526 and 4,828,846 issued and outstanding
common shares and no preferred shares as of December&nbsp;31, 2021 and 2020, respectively. The common shares have no par value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Common shares reserved for future issuance
consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>December&nbsp;31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2021</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2020</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 64%"><FONT STYLE="font-size: 10pt">Warrants</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: right"><FONT STYLE="font-size: 10pt">1,560,588</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: right"><FONT STYLE="font-size: 10pt">619,429</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Convertible debt</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,166,667</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Special Warrants</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">540,653</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Options issued and outstanding under stock option plan</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">738,037</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">646,195</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Deferred share units</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,061</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,061</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Common shares available for grant under stock option plan</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">281,798</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">173,120</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total common shares reserved for future issuance</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">3,748,151</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">1,980,458</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 148; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The rights of the common shares are
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Voting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">Subject to any special voting rights
or restrictions, holders of common shares entitled to vote shall have one vote per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Dividends</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company&rsquo;s board of directors
may from time to time declare and authorize payment of dividends, if any, as they may deem advisable and need not give notice of such
declaration to any shareholder. Subject to the rights of common shareholders, if any, holding shares with specific rights as to dividends,
all dividends on common shares shall be declared and paid according to the number of such shares held and paid in Canadian dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Liquidation Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In the event of the liquidation, dissolution
or winding-up of the Company or any other distribution of the Company&rsquo;s assets for the purpose of winding up the Company&rsquo;s
affairs, after the payment of dividends declared but unpaid, the holders of Common Shares shall be entitled <I>pari passu</I> to receive
any remaining property of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Equity Transactions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In August&nbsp;2021, the Company
announced the closing of a public offering of 2,096,354 common share units at a price of US$9.60 per unit for gross proceeds of $20,125,000.
The Company incurred $3,067,604 of share issuance costs in conjunction with the public offering. Each common share unit (&ldquo;<B>Unit</B>&rdquo;)
consisted of one common share and one-quarter common share warrant. Each whole warrant entitles the holder thereof to purchase one quarter
common share at an exercise price of $12.60 per share at any time for five years. The warrants contain an acceleration clause allowing
the Company to accelerate the expiry date of the warrants to 30 days following a time period during which the common share VWAP exceeds
a TSX trading price of $37.80 for ten consecutive trading days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company determined the allocation
of the US$9.60 Unit issue price to the common shares and the one-quarter common share purchase warrants based on the relative fair values
of the warrants, with the residual charged to equity. The common shares were allocated gross proceeds of $15,868,381 and share issue
costs of $1,665,099. The common share warrants are accounted for as a warrant liability since the exercise price is in US$ while the
Company&rsquo;s functional currency is C$. The initial balance was calculated using the assumptions below resulting an allocation of
gross proceeds of $2,739,221. Due to the existence of the acceleration option, the Company determined it was appropriate to fair value
the warrants using a Monte Carlo Simulation model (&ldquo;<B>Monte Carlo</B>&rdquo;). The common shares issued were allocated a price
of US$8.28 per share and the quarter common share purchase warrants were allocated a price of US$1.32. Assumptions used to determine
the value of the common share warrants were: an average risk-free interest rate of 0.84%; annual volatility of 95.6%; and expected life
of 5.0 years. The issuance costs allocated to the warrants based on the relative fair values of the warrants, amounted to $444,558 and
were charged to general and administrative expense in the consolidated statements of operations and comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2021, the fair value
of the warrants was calculated using the Monte Carlo model with the following parameters: risk free interest rate of 1.21%; annual volatility
of 93.6%; and expected life of 4.7 years. The balance at December 31, 2021 was $1,871,687.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December
    31,<BR> 2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2020</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&mdash;</P><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 83%; font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant liability at issuance</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,739,221</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of the warrant liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(840,555</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Foreign exchange gain</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(26,979</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 9pt">&nbsp;Balance at December 31, 2021</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,871,687</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Related to the sale of the Units, the Company paid certain
intermediaries $1,408,750 and issued 146,744 compensation warrants. The compensation warrants are exercisable at any time for five years
at an exercise price of USD$9.60 and do not have an acceleration clause. The compensation warrants have been issued as consideration
for services provided by the intermediaries. The Company used a Black Scholes calculation to determine the fair value of the compensation
warrants at the issuance date. The fair value of $957,947 was recorded to additional paid-in capital. Significant assumption used in
the Black Scholes calculation included risk free interest rate of 1.21%; historical volatility of 95.6%; and a 5.0 year expiry.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 149; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Warrants</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During February&nbsp;2020, 79,837
warrants were exercised for total proceeds of $713,818 and 57,515 warrants expired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During March&nbsp;2020, the Company
announced a repricing of various warrants to an exercise price of C$7.80, effective April&nbsp;8, 2020 and expiring on May&nbsp;22, 2020.
The warrants repriced ranged in exercise prices of C$17.10 to C$28.80. At the end of the warrant repricing period, all unexercised warrants
revert to the original exercise price. All other terms of the warrants shall remain unchanged. A total of 736,375 warrants were repriced,
and, of the repriced warrants, 158,871 were exercised during the repricing period ending on May&nbsp;22, 2020, for total proceeds of
$894,272. In connection with the repricing, the Company recorded a fair value adjustment on the date of the modification of $85,005,
which was treated as transaction costs and recorded to additional paid in capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In November&nbsp;2020, the Company
closed on a special warrant financing (<B>&ldquo;Special Warrants&rdquo;</B>). The Company issued 270,326 Special Warrants, resulting
in proceeds of $1,483,531 ($1,256,828, net of issuance costs). Each Special Warrant is exercisable, without payment of any additional
consideration by the holder, into one common share and one transferrable common share warrant (<B>&ldquo;Warrants&rdquo;</B>). Each Warrant
entitles the holder to acquire one common share at an exercise price at C$12.00 per warrant share for 60 months until November&nbsp;2025.
Each Special Warrant will automatically convert at the earlier of the date that is (i)&nbsp;the third business day after a receipt for
a final prospectus qualifying the distribution of the shares and warrants issuable upon the conversion of the Special Warrants and (ii)&nbsp;four
months and one day after the issue date of the Special Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Related to the special warrant financing,
the Company compensated certain intermediaries cash fees equal to 7% of the gross proceeds totaling $53,929 and issued 9,286 warrants,
which have the same terms as the Warrants.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In March&nbsp;2021, the Special
Warrants issued by the Company in connection with the November&nbsp;2020 financing, automatically converted into 270,326 common shares
and 270,326 Warrants.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As at December&nbsp;31, 2021, outstanding
common share warrants and exercise prices denominated in C$ unless otherwise noted, related to unit offerings are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exercise<BR>
    Price $</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number of <BR>
    Warrants</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Expiry date</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 31%; text-align: right"><FONT STYLE="font-size: 10pt">18.00</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 31%; text-align: right"><FONT STYLE="font-size: 10pt">81,009</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 33%; text-align: right"><FONT STYLE="font-size: 10pt">August&nbsp;2022</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">17.10</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">21,083</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">August&nbsp;2022</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">28.80</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100,073</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">April&nbsp;2023</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">28.80</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">139,659</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">January&nbsp;2024</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">18.00</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">68,334</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">June&nbsp;2024</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">18.00</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">150,818</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">November&nbsp;2024</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">18.00</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">49,167</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">December&nbsp;2024</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12.00</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">279,613</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">November&nbsp;2025</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">USD12.60</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">524,088</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">August 2026</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">USD9.60</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">146,744</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">August 2026</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">1,560,588</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 150; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><B>13.</B></TD><TD><B>SHARE-BASED COMPENSATION</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>2007 Stock Option Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company maintains the 2007 Stock
Option Plan (<B>&ldquo;2007 Option Plan&rdquo;</B>). In June&nbsp;2015, the 2007 Option Plan was amended from a fixed option plan to
a rolling share option plan pursuant to which the Company is authorized to grant options of up to 20% of its issued and outstanding common
shares. Share options granted vest at various rates and have a term not exceeding ten years. As of December&nbsp;31, 2021 and 2020, the
Company had 280,375 and 173,119 options, respectively, available for grant under the 2007 Option Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following table summarizes the
activity of the share options under the 2007 Option Plan for the years ended December&nbsp;31, 2021 and 2020. All amounts are denominated
in C$, except year and share amounts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number of<BR>
    Share Options</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Weighted Average<BR>
    Exercise<BR>
    Price Per<BR>
 Share</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Weighted<BR>
 Average<BR>
    Remaining<BR>
    Contractual<BR>
    Term (years)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Aggregate<BR>
    Intrinsic<BR>
    Value</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 48%"><FONT STYLE="font-size: 10pt">Outstanding as of January&nbsp;1, 2020</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">638,729</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">7.80</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">5.7</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">2,855,797</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">9,166</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">11.40</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Forfeited</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(1,700</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">16.80</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Outstanding as of December&nbsp;31, 2020</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">646,195</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7.80</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4.8</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,155,145</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">197,291</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12.00</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Forfeited</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(104,166</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">14.40</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Expired</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(1,283</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">18.00</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Outstanding as of December&nbsp;31, 2021</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">738,037</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 10pt">8.40</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 10pt">5.1</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">2,231,293</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Vested and exercisable as of December&nbsp;31, 2021</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">642,238</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 10pt">7.80</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 10pt">4.4</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">2,220,043</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The aggregate intrinsic value of options
outstanding, exercisable, and vested and exercisable is calculated as the difference between the exercise price of the underlying options,
and the fair value of the Company&#8217;s common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During the years ended December&nbsp;31,
2021 and 2020, the Company granted share options with a grant date fair value of C$1,225,433 and C$78,347, respectively. During the years
ended December&nbsp;31, 2021 and 2020, there were no options exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 151; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The fair value of the share options
granted was estimated using Black Scholes with the following assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Year Ended December&nbsp;31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2021</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2020</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9.35pt; text-indent: -9.35pt"><FONT STYLE="font-size: 10pt">Weighted average fair value of common shares</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">C$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6.00</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">C$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8.40</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 74%; padding-left: 9.35pt; text-indent: -9.35pt"><FONT STYLE="font-size: 10pt">Expected volatility</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">92</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">105.0</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9.35pt; text-indent: -9.35pt"><FONT STYLE="font-size: 10pt">Risk-free interest rate</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.95</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.90</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9.35pt; text-indent: -9.35pt"><FONT STYLE="font-size: 10pt">Expected dividend yield</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9.35pt; text-indent: -9.35pt"><FONT STYLE="font-size: 10pt">Expected term (years)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4.5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5.5</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Expected volatility is based on historical
volatility of our shares over the expected life of the option, as our options are not readily tradable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>DSU Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company has a deferred share
unit plan (&ldquo;<B>DSU Plan</B>&rdquo;) for senior officers. Under the DSU Plan, rights to the Company&rsquo;s common shares may be
awarded on a deferred payment basis up to a maximum of 16,666 common share units. Each common share unit will fully vest upon cessation
of employment with the Company and then can be redeemed for one common share of the Company by the unitholder. The Company has 1,061
units outstanding as of December&nbsp;31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">S<B>hare-based Payment Expense</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following table summarizes total
share-based compensation included in the Company&#8217;s accompanying consolidated statements of operations and comprehensive loss:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 94%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Year Ended
    December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">144,905</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">267,525</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">General and administrative</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">370,724</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">86,877</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total share-based compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">515,629</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">354,402</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December&nbsp;31, 2021, there
was $572,959 of unrecognized share-based compensation related to options outstanding, which were expected to be recognized over weighted-average
remaining service period of 2.7 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>14.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><B>Income
                                            taxes</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2021 and 2020,
the net deferred tax assets have not been recognized in the accompanying consolidated financial statements. A valuation allowance
is recognized to reduce the deferred tax asset as it is more likely than not that a tax benefit will not be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The following are the significant components of the Company&rsquo;s
deferred taxes as of December&nbsp;31:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Non-capital losses carried forward</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right">11,640,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right">8,981,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development expenditures</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,421,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,230,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Investment tax credits</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,201,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,078,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Tax value of technology rights and property and equipment
    in excess of accounting basis</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">287,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">293,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Unrealized foreign exchange loss on convertible debt</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">12,000</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&mdash;</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Share issue costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">550,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">138,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total deferred income tax assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18,111,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,720,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Valuation allowance</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(18,111,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(14,720,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net deferred
    income tax assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 152; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December&nbsp;31, 2021, the Company
has available research and development expenditure credits for income tax purposes of approximately $12,911,000, which may be carried
forward without expiration to reduce future taxable income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December&nbsp;31, 2021, the Company
has non-capital income tax loss carry-forwards of approximately $43,936,000 available to reduce future income for income tax purposes.
The income tax loss carry-forwards have expiry dates between the years 2026 and 2042.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December&nbsp;31, 2021, the Company
has approximately $2,890,000 of non-refundable investment tax credits available to offset future income taxes. The non-refundable investment
tax credits have expiry dates between 2025 and 2035.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">A reconciliation of the combined federal
and provincial statutory income tax rate applied to the net loss for the year to the income tax recovery as of December&nbsp;31 is as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -7.9pt; padding-left: 7.9pt">Basic
    combined Canadian statutory income tax rate</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">26.5</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">26.5</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -7.9pt; padding-left: 7.9pt">Income tax recovery
    based on statutory rate</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,457,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,126,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -7.9pt; padding-left: 7.9pt">Permanent differences</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">396,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">94,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -7.9pt; padding-left: 7.9pt">Share issue costs
    recorded, net of equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(443,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(61,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -7.9pt; padding-left: 7.9pt">Unrecognized
    benefit of current year tax losses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,504,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,093,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; text-indent: -8pt; padding-left: 8pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company does not expect a significant
change in the amount of unrecognized tax benefits over the next 12 months. However, any adjustments arising from certain ongoing examinations
by tax authorities could alter the timing or amount of taxable income or deductions and these adjustments could differ from the amount
accrued. The Company&rsquo;s federal and provincial income tax returns files for all years remain subject to examination by the taxation
authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>15.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>Related
                                            party transactions</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During the years ended December&nbsp;31,
2021 and 2020, the Company paid $322,639 and $231,354, respectively, for consulting services to a firm specializing in finance and strategic
support for life science companies. The Chief Financial Officer of the Company is a managing director of the consulting firm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">In April&nbsp;2016, the Company entered
into a three-year, collaborative research agreement (&ldquo;<B>CRA</B>&rdquo;) with the University of British Columbia (&ldquo;<B>UBC</B>&rdquo;)
and the Vancouver Coastal Health Authority in the amount of C$787,500, with the Company&rsquo;s Chief Scientific Officer, as principal
investigator at the UBC. In March&nbsp;2018, the CRA was amended and funding was increased to C$892,500 over three years. In July&nbsp;2018,
the total funding commitment to UBC increased to C$1,130,000 over the period of the agreement. In February&nbsp;2019, the CRA was amended,
and funding was increased to C$2,130,000 for an additional two-year period. In September&nbsp;2019, the CRA was amended, and funding
was increased to C$2,630,000 for an additional one- year period. In November 2021, the CRA was amended for an additional grant of C$800,000
effective January 1, 2022, for the 2022 calendar year for total funding of C$3,430,000. During the years ended December&nbsp;31, 2021
and 2020, the Company incurred costs of $393,341 and $353,253, respectively, and are included in research and development expenses in
the accompanying consolidated statements of operations and comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 153; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During the years ended December&nbsp;31,
2021 and 2020, the Company paid $413,555 and $666,096, respectively, for management services to a company owned by the Company&rsquo;s
Chief Executive Officer and Executive Chairman for services rendered. The Company also reimbursed at cost the rental of an office, which
is used by the Company. During the years ended December&nbsp;31, 2021 and 2020, the Company incurred rental expense of $1,034 and $27,093,
respectively, and are included in general and administrative expenses in the accompanying consolidated statements of operations and comprehensive
loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>16.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>Commitments
                                            and contingencies</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Research, Development and License
Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company enters into research, development
and license agreements with various parties in the ordinary course of business where the Company receives research services and rights
to proprietary technologies. The agreements require compensation to be paid by the Company, typically, by a combination of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">fees
                                            comprising amounts due initially on entering into the agreements and additional amounts due
                                            either on specified timelines or defined services to be provided;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">milestone
                                            payments that are dependent on products developed under the agreements proceeding toward
                                            specified plans of clinical trials and commercial development; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">royalty
                                            payments calculated as a percentage of net sales, commencing on commercial sale of any product
                                            candidates developed from the technologies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Milestone and royalty related amounts
that may come due under various agreements are dependent on, among other factors, preclinical safety and efficacy, clinical trials, regulatory
approvals and, ultimately, the successful development and commercial launch of a new drug, the outcomes and timings of which are uncertain.
Amounts due per the various agreements for milestone payments will accrue once the occurrence of a milestone is likely. Amounts due as
royalty payments will accrue as commercial revenues from the product are earned. Through December&nbsp;31, 2021, no events have occurred
that require accrual of any milestone or royalty related amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>UBC and the Vancouver
Coastal Health Authority Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In April 2016, the Company entered into a three-year, CRA
with the UBC and the Vancouver Coastal Health Authority. The agreement was amended various times through September 2019. Refer to Note
15 Related Party Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>UBC Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In February&nbsp;2009, the Company
entered into an agreement with UBC to further the development and commercialization of certain technology developed, in part, by the
Company&rsquo;s Chief Scientific Officer. The agreement was amended and restated in October 2015. Under the amended and restated agreement,
the Company is committed to make royalty payments based on revenue earned from the licensed technology. An annual license fee is payable
over the term of the agreement. The agreement remains effective unless terminated under the provisions of the agreement. Through December&nbsp;31,
2021 no accruals for royalty payments have been made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>University Health Network Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In April&nbsp;2006, an additional amendments
through November&nbsp;2013, the Company entered into an agreement with the University Health Network, Toronto, to license certain technology
and related intellectual property. Under the agreement, the Company is committed to make milestone payments of up to C$635,000 based
on the successful outcomes of clinical and regulatory outcomes, buyout payments and royalty payments based on revenue earned from the
licensed technology. As of December&nbsp;31, 2021 and 2020, no accruals for any milestones or royalty payments have been made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 154; Options: NewSection; Value: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Indemnification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In the ordinary course of business,
the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify,
hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit
losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement.
The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The
Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company
has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors
and officers against liabilities that may arise by reason of their status or service as directors or officers. The Company currently
has directors&#8217; and officers&#8217; insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Leases</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During the years ended December&nbsp;31,
2021 and 2020, the Company made short-term lease payments in the amount of $20,806 and $19,071, respectively, and are included in general
and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss. The Company&rsquo;s commitment
for future payments under its lease agreements is C$8,765 for the year ended December 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>17.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>NET
                                            LOSS PER SHARE</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The following table sets forth the computation of basic
and diluted net loss per share attributable to common shareholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Years
    Ended December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: -12pt; padding-left: 12pt">Numerator:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 68%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 0.5in">Net
    loss attributable to common shareholders</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 13%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9,790,106</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 13%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,250,280</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: -12pt; padding-left: 12pt">Denominator:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 0.5in"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Weighted-average
                                            shares outstanding used in computing net loss per share attributable to common shareholders,
                                            basic and diluted</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,785,617</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,759,997</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 12pt">Net
    loss per share attributable to common shareholders, basic and diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1.69</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.89</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following outstanding potentially
dilutive common shares equivalents were excluded from the computation of diluted net loss per share for the periods presented because
including them would have been antidilutive:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>December&nbsp;31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2021</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2020</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 68%; padding-left: 9.35pt; text-indent: -9.35pt"><FONT STYLE="font-size: 10pt">Options issued and outstanding
    under stock option plan</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 13%; text-align: right"><FONT STYLE="font-size: 10pt">738,037</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 13%; text-align: right"><FONT STYLE="font-size: 10pt">646,195</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9.35pt; text-indent: -9.35pt"><FONT STYLE="font-size: 10pt">Warrants</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,560,688</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">619,429</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9.35pt; text-indent: -9.35pt"><FONT STYLE="font-size: 10pt">Convertible debt</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,166,667</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9.35pt; text-indent: -9.35pt"><FONT STYLE="font-size: 10pt">Special warrants</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">540,653</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9.35pt; text-indent: -9.35pt"><FONT STYLE="font-size: 10pt">Deferred share units</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,061</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,061</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">3,466,353</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">1,087,338</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 155; Value: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>18.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>Subsequent
                                            events</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In January 2022, the UBC CRA was amended,
and funding was increased to C$5,030,000 for an additional two years. This amendment, along with the November 2021 amendment extends
the project for an additional three years, effective January 1, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 156; Value: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="y_001"></A>ProMIS
Neurosciences&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Condensed Consolidated Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in US dollars, except share and
per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Current assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-size: 10pt; padding-left: 9pt">Cash</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">13,754,211</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">16,943,905</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Short-term investments</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">33,693</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">33,248</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Prepaid expenses and other current assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">622,540</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">737,316</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Total current assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">14,410,444</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">17,714,469</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Property and equipment, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,015</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,671</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Intangible assets, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">26,648</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">27,614</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">14,442,107</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">17,746,754</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Liabilities and Shareholders' Equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Current liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Accounts payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">644,548</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">408,981</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Accrued liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">745,273</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">520,093</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Total current liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,389,821</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">929,074</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Convertible debt, net of issuance costs and debt discount</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,049,151</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,906,057</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Derivative liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,633,811</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,379,878</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Warrant liability</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,631,405</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,871,687</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,704,188</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">12,086,696</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Commitments and contingencies (Note 13)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Shareholders' equity:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 9pt">Common shares, no par value, unlimited shares authorized, 7,195,526 shares issued
    and outstanding as of March&nbsp;31, 2022 and December 31, 2021</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Additional paid-in capital</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">68,164,043</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">68,039,178</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Accumulated other comprehensive loss</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(140,078</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(187,919</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Accumulated deficit</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(64,286,046</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(62,191,201</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total shareholders' equity</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,737,919</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,660,058</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and shareholders&rsquo; equity</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">14,442,107</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">17,746,754</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these unaudited condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 157; Options: NewSection; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="y_002"></A>ProMIS
Neurosciences&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Condensed Consolidated Statements of Operations
and Comprehensive Loss</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in US dollars, except share and
per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended
    March&nbsp;31,</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2022</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2021</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Operating expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; font-size: 10pt; text-align: left; padding-left: 9pt">Research and development</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1,902,832</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">219,592</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">General and administrative</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,035,686</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">348,377</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Total operating expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,938,518</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">567,969</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Loss from operations</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,938,518</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(567,969</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Change in fair value of financial instruments</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,980,672</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(5,537,565</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Interest expense on convertible debt</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(147,773</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,719</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Other income/(expense)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,774</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,058</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Net loss</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,094,845</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(6,109,311</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Other comprehensive gain /(loss)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Foreign currency translation adjustment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">47,841</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(53,375</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Comprehensive loss</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(2,047,004</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(6,162,686</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Net loss per share, basic and diluted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.29</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1.26</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Weighted-average shares outstanding of common shares, basic
    and diluted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">7,195,526</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4,901,606</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these unaudited condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 158; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="y_003"></A>ProMIS
Neurosciences&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Condensed Consolidated Statements of Changes
in Shareholders&rsquo; Equity (Deficit)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in US dollars, except share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Common Shares</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Shares</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Additional <BR>
    Paid-in <BR>
    Capital</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Accumulated <BR>
    Other <BR>
    Comprehensive <BR>
    Income (Loss)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Accumulated <BR>
    Deficit</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt">Balance, January&nbsp;1, 2021</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 10pt">4,828,846</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 10pt">51,655,168</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 10pt">(50,731</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 10pt">(52,401,095</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 10pt">(796,658</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Conversion of special warrants</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">270,326</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Share-based compensation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">78,676</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">78,676</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Foreign currency translation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(53,375</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(53,375</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Net loss</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(6,109,311</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(6,109,311</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Balance, March&nbsp;31, 2021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">5,099,172</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">51,733,844</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(104,106</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(58,510,406</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(6,880,668</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Common Shares</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Shares</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Additional <BR>
    Paid-in <BR>
    Capital</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Accumulated <BR>
    Other <BR>
    Comprehensive <BR>
    Income (Loss)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Accumulated <BR>
    Deficit</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt">Balance, January&nbsp;1, 2022</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 10pt">7,195,526</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 10pt">68,039,178</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 10pt">(187,919</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 10pt">(62,191,201</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 10pt">5,660,058</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Share-based compensation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">124,865</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">124,865</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Foreign currency translation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">47,841</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">47,841</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Net loss</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(2,094,845</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(2,094,845</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Balance, March&nbsp;31, 2022</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">7,195,526</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">68,164,043</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(140,078</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(64,286,046</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">3,737,919</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these unaudited condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 159; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="y_004"></A>ProMIS
Neurosciences&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Condensed Consolidated Statements of Cash
Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in US dollars)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended
    March&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Cash flows from operating activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; font-size: 10pt; text-align: left">Net loss</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(2,094,845</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(6,109,311</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Share-based compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">124,865</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">78,676</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Foreign currency exchange (gain)/loss</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(114,706</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">73,165</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Change in fair value of derivative liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,736,109</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,537,565</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Change in fair value of warrant liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(244,563</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Depreciation of property and equipment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,780</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,727</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Amortization of debt discount and issuance costs</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">130,563</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Amortization of intangible assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,317</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,317</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Changes in operating assets and liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Prepaid expenses and other current assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">122,907</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(210,774</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Accounts payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">226,866</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(199,497</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Accrued liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">215,157</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">65,978</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Deferred compensation</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(461</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 27pt">Net cash used in operating activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3,366,768</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(752,615</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Cash flows from investing activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Purchase of property and equipment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,057</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other investing activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,058</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 27pt">Net cash (used in) provided by investing
    activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,057</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,058</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Cash flows from financing activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Proceeds from convertible debt</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,875,184</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 27pt">Net cash provided by financing activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,875,184</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Effect of exchange rates on cash</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">179,131</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">54,175</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Net decrease/(increase) in cash</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,189,694</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,178,802</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Cash at beginning of period</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">16,943,905</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">806,887</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Cash at end of period</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">13,754,211</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">6,985,689</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Supplemental disclosure of cash flow information</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Cash paid for interest on convertible debt</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">70,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these unaudited condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 160; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="y_005"></A>ProMIS
Neurosciences&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Unaudited Condensed Consolidated
Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in US dollars, except share and
per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>DESCRIPTION OF BUSINESS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Business Description</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">ProMIS Neurosciences&nbsp;Inc. (the
 &ldquo;<B>Company</B>&rdquo; or &ldquo;<B>ProMIS</B>&rdquo;) is applying its patented technology platform to build a portfolio of antibody
therapies, therapeutic vaccines, and other antibody-based therapies in neurodegenerative diseases and other misfolded protein diseases,
including Alzheimer&rsquo;s disease multiple system atrophy, and amyotrophic lateral sclerosis. The Company also plans to investigate
additional synucleinopathies, including Parkinson&rsquo;s disease and dementia with Lewy bodies, frontotemporal lobar degeneration, progressive
supranuclear palsy, corticobasal degeneration and schizophrenia. These diseases share a common biologic cause &ndash; misfolded versions
of proteins that otherwise perform a normal function, become toxic and kill neurons, resulting in disease. ProMIS&rsquo; technology platform
is an example of the advances in drug discovery enabled by computational power, in silico discovery, and/or artificial intelligence.
ProMIS believes this platform provides a potential advantage by selectively targeting the toxic misfolded proteins with therapeutics
or detecting them with diagnostics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company was incorporated on
January 23, 2004 under the Canada Business Corporations Act and is located at 1920 Yonge Street, Toronto, Ontario. The Company&rsquo;s
common shares are traded on the Toronto Stock Exchange (&ldquo;<B>TSX</B>&rdquo;) under the symbol PMN and on the OTCQB Venture Market
under the symbol ARFXD. The Company has a wholly-owned U.S. subsidiary, ProMIS Neurosciences (US) Inc. (&ldquo;<B>ProMIS USA</B>&rdquo;),
which was incorporated in January&nbsp;2016 in the State of Delaware. As of March 31, 2022, ProMIS USA has had no material activity and
has no material financial impact on the Company&rsquo;s unaudited condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The success of the Company is dependent
on obtaining the necessary regulatory approvals of its product candidates, marketing its products and achieving profitable operations.
The continuation of the research and development activities and the commercialization of its products, if approved, are dependent on
the Company&rsquo;s ability to successfully complete these activities and to obtain additional financing through a combination of financing
activities and operations. It is not possible to predict either the outcome of future research and development or commercialization programs,
or the Company&rsquo;s ability to fund these programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>COVID-19</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Impacts resulting from the COVID-19
pandemic have resulted in a widespread health crisis that has already adversely affected the economies and financial markets of many
countries around the world. The international response to the spread of COVID-19 has led to significant restrictions on travel; temporary
business closures; quarantines; global stock market and financial market volatility; a general reduction in consumer activity; operating,
supply chain and project development delays and disruptions; and declining trade and market sentiment; all of which have and could further
affect the world economy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The extent to which the novel coronavirus
may impact the Company&rsquo;s business, preclinical research and development activities will depend on future developments which are
highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, travel restrictions and social distancing
in Canada, the United States and other countries, business closures or business disruptions and the effectiveness of actions taken by
governments around the globe to contain and treat the disease. International scientific conferences at which the Company has been invited
to present have been postponed, cancelled or will be held online instead, which diminishes exposure and the opportunity to meet with
collaborators and potential partners. These scientific conferences have started to be held in person with an option to attend online.
Vendors performing work for the Company have remained open, although they have indicated that their timelines are now somewhat longer.
The current global uncertainty and its effect on the local and global economies may also have an adverse effect on the Company&rsquo;s
ability to secure additional financing to continue its research and development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 161; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Liquidity Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The accompanying unaudited condensed
consolidated financial statements were prepared on a going concern basis, which assumes that the Company will continue its operations
for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. To
date, the Company has not generated revenues from its activities. The Company had a net loss of $2.1 million, for the three months ended
March&nbsp;31, 2022 and an accumulated deficit of $64.3 million as of March&nbsp;31, 2022. Available funds are expected to be sufficient to fund the Company&rsquo;s operating expenses for at least 12 months from
the date these unaudited condensed consolidated financial statements are issued. However, additional funding will be necessary to fund
future research, pre-clinical and clinical activities. The Company will seek additional funding through public financings, debt financings,
collaboration agreements, strategic alliances and licensing agreements. Although the Company has been successful in raising capital in
the past, there is no assurance of success in obtaining such additional financing on terms acceptable to us, if at all, and there is
no assurance that the Company will be able to enter into collaborations or other arrangements. If the Company is unable to obtain funding,
it could force delays, reduce or eliminate research and development programs, product portfolio expansion or commercialization efforts,
which could adversely affect future business prospects, and the ability to continue operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company may continue to incur
net losses for at least the next several years as the Company advances its product candidates. The Company is actively pursuing additional
financing to further develop certain of the Company&rsquo;s scientific initiatives, but there is no assurance these initiatives will
be successful, timely or sufficient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>2.</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>BASIS OF PRESENTATION AND Summary of Significant Accounting Policies</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Basis of Presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The accompanying unaudited interim
condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the
related notes thereto for the year ended December 31, 2021, which are included in this Registration Statement. Furthermore, the Company&rsquo;s
significant accounting policies are disclosed in the audited consolidated financial statements for the years ended December
31, 2021 and 2020, included in this Registration Statement. Since the date of those audited consolidated financial statements, there
have been no changes to the Company&rsquo;s significant accounting policies, except as noted below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The accompanying unaudited condensed
consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States
of America (&ldquo;<B>GAAP</B>&rdquo;) for interim financial information. Accordingly, certain information and footnote disclosures normally
included in financial statements prepared in accordance with GAAP have been condensed or omitted. Any reference in these notes to applicable
guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&ldquo;<B>ASC</B>&rdquo;) and
as amended by Accounting Standards Updates (&ldquo;<B>ASU</B>&rdquo;) of the Financial Accounting Standards Board (&ldquo;<B>FASB</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In the opinion of management, the
accompanying unaudited condensed consolidated financial statements for the periods presented reflect all adjustments, consisting of only
normal recurring adjustments, necessary to fairly present the Company's financial position, results of operations, and cash flows. The
December 31, 2021 condensed balance sheet was derived from audited financial statements, but does not include all GAAP disclosures. The
unaudited condensed financial statements for the interim periods are not necessarily indicative of results for the full year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On June 21, 2022, the directors
of the Company authorized a reverse share split of the issued and outstanding Common Shares in a ratio of 60:1, effective June 28, 2022
(the &ldquo;<B>Reverse Share Split</B>&rdquo;). All information included in these unaudited condensed consolidated financial statements
has been adjusted, on a retrospective basis, to reflect the Reverse Share Split<FONT STYLE="background-color: white">, unless otherwise
stated.</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 162; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Principles of Consolidation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The accompanying unaudited condensed
consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and
transactions have been eliminated in consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Use of Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The preparation of financial statements
in conformity with GAAP requires management to make certain estimates, judgements and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made
in the accompanying unaudited condensed consolidated financial statements include, but are not limited to, the accrual for research and
development expenses, the valuation of share-based compensation, and the valuation of warrant liabilities and embedded derivative liabilities.
Actual results could differ from those estimates, and such differences could be material to the unaudited condensed consolidated financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Segment Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Operating segments are identified
as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating
decision maker (&ldquo;<B>CODM</B>&rdquo;), or decision-making group, in making decisions on how to allocate resources and assess performance.
The Company has one operating segment and its Chief Executive Officer and Executive Chairman of the Board of Directors collectively serve
as the CODM. Substantially all of the Company&rsquo;s assets are located in Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Foreign Currency</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Comprehensive loss is defined as
a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. The reporting currency
of the Company is the United States dollar (&ldquo;<B>US$</B>&rdquo;) and the functional currency of the Company is the Canadian dollar
(&ldquo;<B>C$</B>&rdquo;). The assets and liabilities of the Company are translated to US$ at exchange rates in effect at the balance
sheet date. All income statement accounts are translated at average exchange rates. Resulting foreign currency translation adjustments
are recorded directly in accumulated other comprehensive income (loss) as a separate component of shareholders&rsquo; equity (deficit).
Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional
currency are included in general and administrative expenses in the accompanying unaudited condensed consolidated statements of operations
and comprehensive loss when realized and are not material for the three months ended March 31, 2022 and 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Emerging Growth Company Status</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company is an Emerging Growth
Company, as defined in Section&nbsp;2(a)&nbsp;of the Securities Act of 1933, as modified by the Jumpstart Our Business Startups Act of
2012 (&ldquo;<B>JOBS&nbsp;Act</B>&rdquo;). Under the JOBS&nbsp;Act, emerging growth companies can delay adopting new or revised accounting
standards issued subsequent to the enactment of the JOBS&nbsp;Act, until such time as those standards apply to private companies. The
Company has elected to use this extended transition period for complying with new or revised accounting standards that have different
effective dates for public and private companies until the earlier of the date that it (i)&nbsp;is no longer an emerging growth company
or (ii)&nbsp;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS&nbsp;Act. As a result, these
unaudited condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting
pronouncements as of public company effective dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 163; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Recent Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In February&nbsp;2016, the FASB
issued ASU No.&nbsp;2016-02, <I>Leases</I> (&ldquo;<B>Topic 842</B>&rdquo;), which requires lessees to recognize the following for all
leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee&rsquo;s obligation to
make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents
the lessee&rsquo;s right to use, or control the use of, a specified asset for the lease term. In July&nbsp;2018, the FASB issued ASU
2018-11, <I>Leases </I>(&ldquo;<B>Topic 842</B>&rdquo;) <I>Targeted Improvements</I>, to amend certain aspects of Topic 842. These amendments
provide entities with an additional (and optional) transition method to adopt Topic 842. Under this transition method, an entity initially
applies the transition requirements in Topic 842 at that Topic&rsquo;s effective date with the effects of initially applying Topic 842
recognized as a cumulative effect adjustment to the opening balance of retained earnings (or other components of equity or net assets,
as appropriate) in the period of adoption. On April&nbsp;8, 2020, the FASB changed the effective date of this standard applicable to
the Company as an emerging growth company to January&nbsp;1, 2022. The Company adopted this standard as of January 1, 2022 with no material
impact on the unaudited condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In December 2019, the FASB issued
ASU No 2019-12, <I>Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</I> (&ldquo;<B>Topic 740</B>&rdquo;), as part
of its simplification initiative to reduce the cost and complexity in accounting for income taxes. The amendments in ASU 2019-12 removes
certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim
period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also amends other aspects of the guidance
to help simplify and promote consistent application of GAAP. The guidance is effective for interim and annual periods beginning after
December 15, 2020, with early adoption permitted. For emerging growth companies, the standard is effective for fiscal years beginning
after December 15, 2021. The Company adopted this standard as of January 1, 2022 with no material impact on the unaudited condensed consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In August&nbsp;2020, the FASB issued
ASU No.&nbsp;2020-06, <I>Debt&mdash;Debt with Conversion and Other Options (</I>&ldquo;<B>Subtopic 470-20</B>&nbsp;&rdquo;<I>) and Derivatives
and Hedging Contracts in Entity s Own Equity (</I>&ldquo;<B>Subtopic 815-40</B>&nbsp;&rdquo;<I>): Accounting for Convertible Instruments
and Contracts in an Entity&rsquo;s Own Equity</I>. ASU 2020-06 will simplify the accounting for convertible instruments by reducing the
number of accounting models for convertible debt instruments and convertible preferred shares. Limiting the accounting models results
in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments
that continue to be subject to separation models are (i)&nbsp;those with embedded conversion features that are not clearly and closely
related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative
accounting and (ii)&nbsp;convertible debt instruments issued with substantial premiums for which the premiums are recorded as additional
paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity&rsquo;s own equity
to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective for the Company for fiscal years beginning
after December&nbsp;15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December&nbsp;15, 2020, including
interim periods within those fiscal years. The Company is currently evaluating the potential impact adopting ASU 2020-06 will have on
the Company&rsquo;s consolidated financial statements and related disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 164; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>FAIR VALUE MEASUREMENTS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following are the major categories
of assets measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 94%; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">As of March&nbsp;31,
    2022</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 1</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 2</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 3</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 13.7pt">Short-term investments</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right">33,693</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right">33,693</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 27.35pt">Total assets measured at fair value</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">33,693</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">33,693</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;Liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 13.7pt">Derivative liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3,633,811</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3,633,811</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 13.7pt">Warrant liability</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,631,405</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,631,405</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 27.35pt">Total liabilities measured at fair
    value</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,265,216</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,265,216</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 94%; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">As of December&nbsp;31,
    2021</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 1</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 2</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 3</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 13.7pt">Short-term investments</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right">33,248</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right">33,248</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 27.35pt">Total assets measured at fair value</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">33,248</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">33,248</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;Liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 13.7pt">Derivative liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">5,379,878</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">5,379,878</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 13.7pt">Warrant liability</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,871,687</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,871,687</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 27.35pt">Total liabilities measured at fair
    value</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">7,251,565</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">7,251,565</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No transfers between levels have occurred in
either reporting period presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>4.</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>PREPAID EXPENSES AND OTHER CURRENT ASSETS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Prepaid expenses and other current assets consist of
the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 94%; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-size: 10pt; text-align: left">Upfront research payments</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">237,371</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">554,878</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Goods and services tax receivable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">100,783</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">48,690</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Insurance</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">24,285</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">32,853</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Dues and subscriptions</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">21,142</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Consultants</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">90,773</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">69,915</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">License fee</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">54,783</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">19,754</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Deposits</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">15,722</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,839</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Deferred financing costs</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">71,069</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Miscellaneous</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,612</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,387</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">622,540</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">737,316</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>5.</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>PROPERTY AND EQUIPMENT</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Property and equipment, net, consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 94%; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-size: 10pt; text-align: left">Laboratory equipment</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">67,294</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">66,403</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Computer equipment</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19,980</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">17,657</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Total property and equipment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">87,274</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">84,060</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(82,259</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(79,389</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Property and equipment, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,015</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4,671</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Depreciation expense was $1,780
and $10,727 for the three months ended March 31, 2022 and 2021, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 165; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>6.</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Intangible assets</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company has intangible assets
consisting of acquired rights and patents with finite lives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In March&nbsp;2012, the Company
acquired rights to a certain patented technology that it had licensed from its Chief Scientific Officer for C$100,000. The Company is
amortizing this asset over its expected useful life of 15 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 94%; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-size: 10pt; text-align: left">Intangible assets</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">80,074</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">79,015</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less: accumulated amortization</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(53,426</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(51,401</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Intangible assets, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">26,648</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">27,614</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Amortization expense was $1,317
and $1,317 for the three months ended March 31, 2022 and 2021, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of March&nbsp;31, 2022, the estimated
expected amortization expense related to the Company&rsquo;s intangible assets for each year through the year ended 2026 is $5,342 with
the remaining $1,272 to be expensed during the year ended 2027.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>7.</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>ACCRUED LIABILITIES</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Accrued liabilities consist of the
following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 94%; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">March
    &nbsp;31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-size: 10pt">Legal</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">178,481</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">171,777</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Accounting</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">113,870</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">123,026</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Project work completed</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">352,903</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">106,845</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Accrued interest</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,729</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">54,398</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Annual meeting</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">32,648</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">21,479</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Other</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">65,642</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">42,568</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Accrued liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">745,273</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">520,093</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>8.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>CONVERTIBLE DEBT</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In March&nbsp;2021, the Company
completed a $7.0 million private placement of the Debentures. The Company allocated $3,567,442 of proceeds to the Debenture. The Company incurred $48,220 of issuance costs in connection with the private placement of which $24,575 was allocated to
the Debentures and amortized over the life of the Debenture. The Debentures are convertible into common shares at the option of the
holder at any time and from time to time at a conversion price of $6.00 and accrue interest at 1% per annum, which is payable
annually. At the Company&rsquo;s election, accrued interest may be paid in cash or common shares (such number of shares determined
by dividing the interest due by the 5-day volume-weighted average price (&ldquo;<B>VWAP</B>&rdquo;) of the common shares). The
Debentures mature on March&nbsp;22, 2026. Prior to the maturity date, the Company is entitled to convert the Debentures at the
conversion price upon raising an aggregate of $50 million in equity and/or debt. On the maturity date, the Company may redeem the
outstanding principal amount of the Debentures in either cash or common shares (at the then 5-day VWAP less a 10% discount) or a
combination thereof. The Company recognized $17,210 of interest expense on the convertible debt and an additional $130,563 of
interest expense relating to the amortization of the debt discount related to the derivative liability and issuance costs allocated
to the Debentures for the three months ended March 31, 2022. The Company made interest payments of $70,000 in the three months
ended, March 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 166; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The conversion feature has been
recognized as a derivative liability recorded as a discount to the Debenture, adjusted to fair value each reporting period
and being recorded in the condensed consolidated statements of operations and comprehensive loss. The derivative liability has been valued
at $3,432,558 at issuance date using a scenario-based valuation method using a Monte Carlo model, volatility of 101.43%, a risk-free
interest rate of 0.15% and a selected debt yield of 15.96%. The derivative liability at March 31, 2022 has been valued at $3,633,811
using a scenario-based valuation method using a Monte Carlo simulation model, volatility of 87.00%, a risk-free interest rate of 2.41%
and a selected debt yield of 20.61%. The total liability of the Debenture and the derivative liability at March 31, 2022 was $7,682,962.
The portion of issuance costs allocated to the conversion feature of $23,645 were expensed when incurred in 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 94%; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31, <BR>
    2022</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; font-size: 10pt">Balance at December 31, 2021</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">5,379,878</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Change in fair value of the derivative liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,736,109</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Foreign exchange gain</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(9,958</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 9pt">Balance at March 31, 2022</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,633,811</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 94%; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">December
    31,<BR>
    2021</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Balance at December 31, 2020</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 87%; font-size: 10pt; text-align: left">Derivative liability at issuance</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">3,432,558</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Change in fair value of the derivative liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,936,191</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Foreign exchange loss</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11,129</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 9pt">Balance at December 31, 2021</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,379,878</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>9.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>COMMON SHARES</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company has authorized an unlimited
number of both common and preferred shares. As of March 31, 2022 and December 31, 2021, the Company has 7,195,526 issued and outstanding
common shares and no preferred shares as of March 31, 2022 and December&nbsp;31, 2021. The common shares have no par value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Common shares reserved for future
issuance consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 94%; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>March&nbsp;31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>December 31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2021</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 74%"><FONT STYLE="font-size: 10pt">Warrants</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">1,560,588</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">1,560,588</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Convertible debt</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,166,667</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,166,667</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Options issued and outstanding under stock option plan</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">847,004</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">738,037</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Deferred share units</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,061</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,061</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Common shares available for grant under stock option plan</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">172,831</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">281,798</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total common shares reserved for future issuance</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">3,748,151</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">3,748,151</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The rights of the common shares
are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Voting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">Subject to any special voting
rights or restrictions, holders of common shares entitled to vote shall have one vote per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Dividends</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company&rsquo;s board of directors
may from time to time declare and authorize payment of dividends, if any, as they may deem advisable and need not give notice of such
declaration to any shareholder. Subject to the rights of common shareholders, if any, holding shares with specific rights as to dividends,
all dividends on common shares shall be declared and paid according to the number of such shares held and paid in Canadian dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 167; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Liquidation Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In the event of the liquidation,
dissolution or winding-up of the Company or any other distribution of the Company&rsquo;s assets for the purpose of winding up the Company&rsquo;s
affairs, after the payment of dividends declared but unpaid, the holders of Common Shares shall be entitled <I>pari passu</I> to receive
any remaining property of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Equity Transactions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In August&nbsp;2021, the Company
announced the closing of a public offering of 2,096,354 common share units at a price of US$9.60 per unit for gross proceeds of $20,125,000.
The Company incurred $3,067,604 of share issuance costs in conjunction with the public offering. Each common share unit (&ldquo;<B>Unit</B>&rdquo;)
consisted of one common share and one-quarter common share purchase warrant. Each whole warrant entitles the holder thereof to purchase
one quarter common share at an exercise price of $12.60 per share at any time for five years. The warrants contain an acceleration clause
allowing the Company to accelerate the expiry date of the warrants to 30 days following a time period during which the common share VWAP
exceeds a TSX trading price of $37.80 for ten consecutive trading days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company determined the allocation
of the US$9.60 Unit issue price to the common shares and the one-quarter common share purchase warrants based on the relative fair values
of the warrants, with the residual charged to equity. The common shares were allocated gross proceeds of $15,868,381 and share issue
costs of $1,665,099. The common share warrants are accounted for as a warrant liability since the exercise price is in US$ while the
Company&rsquo;s functional currency is C$. The initial balance was calculated using the assumptions below resulting an allocation of
gross proceeds of $2,739,221. Due to the existence of the acceleration option, the Company determined it was appropriate to fair value
the warrants using a Monte Carlo Simulation model (&ldquo;<B>Monte Carlo</B>&rdquo;). The common shares issued were allocated a price
of US$8.28 per share and the quarter common share purchase warrants were allocated a price of US$1.32. Assumptions used to determine
the value of the common share warrants were: an average risk-free interest rate of 0.84%; annual volatility of 95.6%; and expected life
of 5.0 years. The issuance costs allocated to the warrants based on the relative fair values of the warrants amounted to $444,558 and
were charged to general and administrative expense in the condensed consolidated statements of operations and comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of March 31, 2022, the fair value
of the warrants was calculated using the Monte Carlo model with the following parameters: risk free interest rate of 2.39%; annual volatility
of 94.00%; and expected life of 4.4 years. The balance as of March 31, 2022 was $1,631,405.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 94%; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31,<BR> 2022</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; font-size: 10pt">Balance at December 31, 2021</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1,871,687</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Change in fair value of the warrant liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(244,563</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Foreign exchange loss</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,281</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 9pt">&nbsp;Balance at March 31, 2022</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,631,405</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 94%; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31,<BR>
    2021</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Balance at December 31, 2020</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 87%; font-size: 10pt; text-align: left">Warrant liability at issuance</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">2,739,221</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Change in fair value of the warrant liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(840,555</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Foreign exchange gain</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(26,979</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 9pt">&nbsp;Balance at December 31, 2021</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,871,687</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 168; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Related to the sale of the Units, the Company paid certain
intermediaries $1,408,750 and issued 146,744 compensation warrants. The compensation warrants are exercisable at any time for five years
at an exercise price of USD$9.60 and do not have an acceleration clause. The compensation warrants have been issued as consideration
for services provided by the intermediaries. The Company used a Black Scholes calculation to determine the fair value of the compensation
warrants at the issuance date. The fair value of $957,947 was recorded to additional paid-in capital. Significant assumption used in
the Black Scholes calculation included risk free interest rate of 1.21%; historical volatility of 95.6%; and a 5.0 year expiry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>10.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Warrants</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In March&nbsp;2021, the Special
Warrants issued by the Company in connection with the November&nbsp;2020 financing, automatically converted into 270,326 common shares
and 270,326 common share warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of March&nbsp;31, 2022, outstanding
common share warrants and exercise prices denominated in C$ unless otherwise noted, related to unit offerings are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exercise<BR>
    Price $</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number of <BR>
    Warrants</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Expiry date</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 31%; text-align: right"><FONT STYLE="font-size: 10pt">18.00</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 31%; text-align: right"><FONT STYLE="font-size: 10pt">81,009</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: right"><FONT STYLE="font-size: 10pt">August&nbsp;2022</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">17.10</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">21,083</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">August&nbsp;2022</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">28.80</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100,073</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">April&nbsp;2023</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">28.80</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">139,659</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">January&nbsp;2024</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">18.00</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">68,334</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">June&nbsp;2024</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">18.00</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">150,818</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">November&nbsp;2024</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">18.00</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">49,167</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">December&nbsp;2024</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12.00</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">279,613</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">November&nbsp;2025</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">USD12.60</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">524,088</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">August 2026</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">USD9.60</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">146,744</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">August 2026</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">1,560,588</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>11.</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>SHARE-BASED COMPENSATION</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>2007 Stock Option Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company maintains the 2007 Stock
Option Plan (<B>&ldquo;2007 Option Plan&rdquo;</B>). In June&nbsp;2015, the 2007 Option Plan was amended from a fixed option plan to
a rolling share option plan pursuant to which the Company is authorized to grant options of up to 20% of its issued and outstanding common
shares. Share options granted vest at various rates and have a term not exceeding ten years. As of March 31, 2022 and December&nbsp;31,
2021, the Company had 172,831 and 281,798 options, respectively, available for grant under the 2007 Option Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following table summarizes the
activity of the share options under the 2007 Option Plan for the three months ended March&nbsp;31, 2022. All amounts are denominated
in C$, except year and share amounts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 94%; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number of<BR>
    Share Options</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Weighted<BR>
 Average<BR>
    Exercise<BR>
    Price Per Share</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Weighted Average<BR>
    Remaining<BR>
    Contractual<BR>
    Term (years)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Aggregate<BR>
    Intrinsic<BR>
    Value</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 48%"><FONT STYLE="font-size: 10pt">Outstanding as of December&nbsp;31, 2021</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">738,037</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">8.40</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">5.1</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">2,231,293</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">120,833</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8.40</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6.0</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Forfeited</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(12,016</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">6.60</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Outstanding as of March&nbsp;31, 2022</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">874,004</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">8.40</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">5.6</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">1,720,258</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Vested and exercisable as of March&nbsp;31, 2022</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">652,195</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">7.80</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">4.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">1,720,258</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 169; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The aggregate intrinsic value of
options outstanding, exercisable, and vested and exercisable is calculated as the difference between the exercise price of the underlying
options, and the fair value of the Company&rsquo;s common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During the three months ended March
31, 2022 and 2021, the Company granted share options with a grant date fair value of C$796,967 and C$162,796 respectively. During the
three months ended March&nbsp;31, 2022 there were no options exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The fair value of the share options
granted was estimated using Black Scholes with the following assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 94%; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended
    March&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-size: 10pt; text-indent: -9.35pt; padding-left: 9.35pt">Weighted average fair value of common shares</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">C$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">6.60</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">C$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">6.60</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -9.35pt; padding-left: 9.35pt">Expected volatility</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">99.6</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">89</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -9.35pt; padding-left: 9.35pt">Risk-free interest rate</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.81</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.99</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -9.35pt; padding-left: 9.35pt">Expected dividend yield</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -9.35pt; padding-left: 9.35pt">Expected term (years)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6.0</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5.2</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Expected volatility is based on
historical volatility of our shares over the expected life of the option, as our options are not readily tradable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>DSU Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company has a deferred share
unit plan (&ldquo;<B>DSU Plan</B>&rdquo;) for senior officers. Under the DSU Plan, rights to the Company&rsquo;s common shares may be
awarded on a deferred payment basis up to a maximum of 16,666 common share units. Each common share unit will fully vest upon cessation
of employment with the Company and then can be redeemed for one common share of the Company by the unitholder. The Company has 1,061
units outstanding as of March&nbsp;31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">S<B>hare-based Payment Expense</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following table summarizes total
share-based compensation included in the Company&rsquo;s accompanying condensed consolidated statements of operations and comprehensive
loss:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 94%; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended
    March&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-size: 10pt; text-align: left">Research and development</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">62,062</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">28,403</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">62,803</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">50,273</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total share-based compensation</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">124,865</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">78,676</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of March&nbsp;31, 2022, there
was $1,094,922 of unrecognized share-based compensation related to options outstanding, which were expected to be recognized over weighted-average
remaining service period of 3.2 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 170; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>12.</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Related party transactions</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During the three months ended March
31, 2022 and 2021, the Company paid $205,699 and $62,491, respectively, for consulting services to a firm specializing in finance and
strategic support for life science companies. The Chief Financial Officer of the Company is a managing director of the consulting firm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In April&nbsp;2016, the Company
entered into a three-year, collaborative research agreement (&ldquo;<B>CRA</B>&rdquo;) with the University of British Columbia (&ldquo;<B>UBC</B>&rdquo;)
and the Vancouver Coastal Health Authority in the amount of C$787,500, with the Company&rsquo;s Chief Scientific Officer, as principal
investigator at the UBC. In March&nbsp;2018, the CRA was amended and funding was increased to C$892,500 over three years. In July&nbsp;2018,
the total funding commitment to UBC increased to C$1,130,000 over the period of the agreement. In February&nbsp;2019, the CRA was amended,
and funding was increased to C$2,130,000 for an additional two-year period. In September&nbsp;2019, the CRA was amended, and funding
was increased to C$2,630,000 for an additional one- year period. In November 2021, the CRA was amended for an additional grant of C$800,000
effective January 1, 2022, for the 2022 calendar year for total funding of C$3,430,000. During the three months ended March 31, 2022
and 2021, the Company incurred costs of $98,690 and $98,712, respectively, and are included in research and development expenses in the
accompanying condensed consolidated statements of operations and comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>13.</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Commitments and contingencies</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Research, Development and License
Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company enters into research,
development and license agreements with various parties in the ordinary course of business where the Company receives research services
and rights to proprietary technologies. The agreements require compensation to be paid by the Company, typically, by a combination of
the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">fees comprising amounts due initially on entering into the agreements
    and additional amounts due either on specified timelines or defined services to be provided;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">milestone payments that are dependent on products developed under
    the agreements proceeding toward specified plans of clinical trials and commercial development; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">royalty payments calculated as a percentage of net sales, commencing
    on commercial sale of any product candidates developed from the technologies.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Milestone and royalty related amounts
that may come due under various agreements are dependent on, among other factors, preclinical safety and efficacy, clinical trials, regulatory
approvals and, ultimately, the successful development and commercial launch of a new drug, the outcomes and timings of which are uncertain.
Amounts due per the various agreements for milestone payments will accrue once the occurrence of a milestone is likely. Amounts due as
royalty payments will accrue as commercial revenues from the product are earned. Through March&nbsp;31, 2022, no events have occurred
that require accrual of any milestone or royalty related amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>UBC and the Vancouver
Coastal Health Authority Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In April 2016, the Company entered into a three-year,
CRA with the UBC and the Vancouver Coastal Health Authority. The agreement was amended various times through September 2019. In January
2022, the UBC CRA was amended, and funding was increased to C$5,030,000 for an additional two years. This amendment, along with the November
2021 amendment extends the project for an additional three years, effective January 1, 2022. Refer to Note 12 Related Party Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 171; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>UBC Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In February&nbsp;2009, the Company
entered into an agreement with UBC to further the development and commercialization of certain technology developed, in part, by the
Company&rsquo;s Chief Scientific Officer. The agreement was amended and restated in October 2015. Under the amended and restated agreement,
the Company is committed to make royalty payments based on revenue earned from the licensed technology. An annual license fee is payable
over the term of the agreement. The agreement remains effective unless terminated under the provisions of the agreement. Through March&nbsp;31,
2022 no accruals for royalty payments have been made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>University Health Network Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In April&nbsp;2006, an additional
amendments through November&nbsp;2013, the Company entered into an agreement with the University Health Network, Toronto, to license
certain technology and related intellectual property. Under the agreement, the Company is committed to make milestone payments of up
to C$635,000 based on the successful outcomes of clinical and regulatory outcomes, buyout payments and royalty payments based on revenue
earned from the licensed technology. As of March&nbsp;31, 2022 and December 31, 2021, no accruals for any milestones or royalty payments
have been made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Indemnification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In the ordinary course of business,
the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify,
hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit
losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement.
The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The
Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company
has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors
and officers against liabilities that may arise by reason of their status or service as directors or officers. The Company currently
has directors&rsquo; and officers&rsquo; insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Leases</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During the three months ended March&nbsp;31,
2022 and 2021, the Company made short-term lease payments in the amount of $10,598 and $5,385, respectively, and are included in general
and administrative expenses in the accompanying condensed consolidated statements of operations and comprehensive loss. The Company&rsquo;s
commitment for future payments under its lease agreements is C$15,312 for the remainder of the year ended 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 172; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>14.</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>NET LOSS PER SHARE</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The following table sets forth the computation of basic
and diluted net loss per share attributable to common shareholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 94%; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended
    March&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-indent: -12pt; padding-left: 12pt">Numerator:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 0.5in">Net
    loss attributable to common shareholders</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right">2,094,845</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right">6,109,311</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-indent: -12pt; padding-left: 12pt">Denominator:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Weighted-average shares outstanding used in computing net
    loss per share attributable to common shareholders, basic and diluted</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">7,195,526</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4,901,606</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 12pt">Net loss per share
    attributable to common shareholders, basic and diluted</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.29</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1.26</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following outstanding potentially
dilutive common shares equivalents were excluded from the computation of diluted net loss per share for the periods presented because
including them would have been antidilutive:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 94%; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>March&nbsp;31,</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2022</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2021</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 74%; padding-left: 9.35pt; text-indent: -9.35pt"><FONT STYLE="font-size: 10pt">Options issued and outstanding
    under stock option plan</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">847,004</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">738,037</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9.35pt; text-indent: -9.35pt"><FONT STYLE="font-size: 10pt">Warrants</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,560,588</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">889,754</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9.35pt; text-indent: -9.35pt"><FONT STYLE="font-size: 10pt">Convertible debt</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,166,667</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,166,667</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9.35pt; text-indent: -9.35pt"><FONT STYLE="font-size: 10pt">Deferred share units</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,061</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,061</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Total</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">3,575,320</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">2,795,519</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>15.</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Subsequent events</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><U>Series 1 Preferred Shares</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On June 17, 2022, the directors
of the Company authorized the issuance of 70,000,000 Series 1 Preferred Shares (&ldquo;Preferred Shares&rdquo;) with the following
preferences, privileges and rights:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Dividends</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">If the Company declares, pays or sets aside any dividends on shares
of any other class or series of capital stock the holders of the Preferred Shares shall receive a dividend on each outstanding share of
Preferred Share in an amount equal to that dividend per share of the Preferred Share as would equal the product of the dividend payable
as if all shares of such series had been converted into common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Liquidation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In the event of any voluntary or
involuntary liquidation, dissolution or winding up of the Company, the holders of the Preferred Shares shall be entitled to be paid out
of the assets of the Company available for distribution to the shareholders an amount per share equal to $6.00, plus any dividends declared
but not paid. If, upon any such liquidation event, the assets available for distribution to the shareholders are insufficient to pay
the holders of the Preferred Shares, the holders of the Preferred Shares shall share ratably in any distribution of the assets available
for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon
such distribution if all amounts payable on or with respect to such shares were paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 173; Options: NewSection; Value: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Voting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Preferred Shares do not confer
any voting rights or privileges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Redemption</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Preferred Shares are not subject
to mandatory redemption or other redemption provisions for which the events resulting in redemption are not within the Company&rsquo;s
control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Optional Conversion</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Preferred Shares are convertible,
at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder
thereof, into such number of fully paid and non-assessable common shares as is determined by dividing $6.00 by the applicable conversion
price in effect at the time of conversion. The Conversion Price shall initially be equal to $6.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Mandatory Conversion </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">All outstanding Preferred Shares
shall automatically convert into common shares, at the effective conversion rate upon the closing of one or more sales of equity securities
resulting in at least $30 million of gross proceeds to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><U>Amendment to the Debentures</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On June 17, 2022, the Company amended
the conversion feature of the Debentures. Previously, the Debentures were convertible into common shares at the option of the holder
at any time and from time to time at a conversion price of $6.00. Following the amendment, the Debentures became convertible into Series
1 Preferred Shares at the option of the holder at any time and from time to time at a conversion price of $6.00. No other
terms of the Debentures were amended. The modification of the Debentures was determined to be non-substantial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Conversion of the Debentures</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Between June 17, 2022 and June
19, 2022, the Company received notices of conversion from the holders of the Company&rsquo;s Debentures, requesting conversions in
the aggregate of $7 million, representing the entirety of the outstanding balance thereof. In satisfaction of the notices of
conversion, the Company issued, in the aggregate, 70,000,000 Preferred Shares to the Debenture holders in accordance with the terms
of the Debentures and made cash payments to settle accrued interest through the conversion dates in the amount of $17,069.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company recognized the redemption as an extinguishment of the outstanding debt and the related derivative, which required a remeasurement
of the derivative liability as of June 19, 2022. As of June 19, 2022, the Company recognized a gain on the change in fair value of the
derivative liability of $892,753</FONT>. The extinguishment of the convertible notes was accounted for as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>June
    19, 2022</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carrying value of convertible
    notes net of issuance costs and debt discount (includes amortization of debt discount of $117,212 from April 1, 2022 to June 19,
    2022)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,166,363</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative liability
    remeasured as of June 19, 2022</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,741,058</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total liabilities extinguished on conversion</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,907,421</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional paid-in-capital</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,600,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain
    on extinguishment of convertible notes and derivative liability</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,307,421</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Debenture modification costs estimated
to be approximately $65,000 will be expensed during the period incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 174; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Appendix A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ProMIS Neurosciences Inc. Patent Portfolio
Summary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border: black 1pt solid; vertical-align: bottom; width: 30%; padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Patent or Publication Number<BR>
    Type of IP / Jurisdiction/Filing Date</U></B></P></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; width: 32%; padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Title
    / Inventor(s) / Assignee (s)</U></B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; width: 24%; padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Status
    / Patent Term / <BR>
    Comments</U></B></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-bottom: 8pt; vertical-align: top; width: 14%; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Ownership<BR>
    Status</U></B></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3004593</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility-
    </B></FONT>COMPUTER IMPLEMENTED METHODS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Canada</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SYSTEMS AND METHODS FOR PREDICTING MISFOLDED PROTEIN EPITOPES
    BY COLLECTIVE COORDINATE BIASING</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven Samuel Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PENDING</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051306</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">US 2018-0330045 A1</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility-
    </B></FONT>COMPUTER IMPLEMENTED METHODS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SYSTEMS AND METHODS FOR PREDICTING MISFOLDED PROTEIN EPITOPES
    BY COLLECTIVE COORDINATE BIASING</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven Samuel Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PENDING</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051306</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3374906</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EP16863269.3</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility&ndash;
    </B></FONT>COMPUTER IMPLEMENTED METHODS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Belgium</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SYSTEMS AND METHODS FOR PREDICTING MISFOLDED PROTEIN EPITOPES
    BY COLLECTIVE COORDINATE BIASING</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven Samuel Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ISSUED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on EP 16863269.3, which is a National Phase of PCT/CA2016/051306</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2036-11-09</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3374906</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EP16863269.3</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    - </B></FONT>COMPUTER IMPLEMENTED METHODS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Denmark</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SYSTEMS AND METHODS FOR PREDICTING MISFOLDED PROTEIN EPITOPES
    BY COLLECTIVE COORDINATE BIASING</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven Samuel Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ISSUED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on EP 16863269.3, which is a National Phase of PCT/CA2016/051306</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2036-11-09</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;3374906</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>COMPUTER IMPLEMENTED METHODS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>France </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SYSTEMS AND METHODS FOR PREDICTING MISFOLDED PROTEIN EPITOPES
    BY COLLECTIVE COORDINATE BIASING</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven Samuel Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ISSUED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on EP 16863269.3, which is a National Phase of PCT/CA2016/051306</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2036-11-09</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 175 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3374906</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>COMPUTER IMPLEMENTED METHODS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Germany</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SYSTEMS AND METHODS FOR PREDICTING MISFOLDED PROTEIN EPITOPES
    BY COLLECTIVE COORDINATE BIASING</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven Samuel Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ISSUED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on EP 16863269.3, which is a National Phase of PCT/CA2016/051306</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2036-11-09</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 14%; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3374906</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>COMPUTER IMPLEMENTED METHODS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Switzerland</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SYSTEMS AND METHODS FOR PREDICTING MISFOLDED PROTEIN EPITOPES
    BY COLLECTIVE COORDINATE BIASING</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven Samuel Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ISSUED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on EP 16863269.3, which is a National Phase of PCT/CA2016/051306</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2036-11-09</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3374906</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>COMPUTER IMPLEMENTED METHODS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United Kingdom</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SYSTEMS AND METHODS FOR PREDICTING MISFOLDED PROTEIN EPITOPES
    BY COLLECTIVE COORDINATE BIASING</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven Samuel Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ISSUED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on EP 16863269.3, which is a National Phase of PCT/CA2016/051306</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2036-11-09</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;1259338</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>COMPUTER IMPLEMENTED METHODS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Hong Kong</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SYSTEMS AND METHODS FOR PREDICTING MISFOLDED PROTEIN EPITOPES
    BY COLLECTIVE COORDINATE BIASING</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven Samuel Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on CN Publication No. 108475298A</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">201817021051</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    - </B></FONT>COMPUTER IMPLEMENTED METHODS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>India</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SYSTEMS AND METHODS FOR PREDICTING MISFOLDED PROTEIN EPITOPES
    BY COLLECTIVE COORDINATE BIASING</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven Samuel Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PENDING</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051306</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 176 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">6952351</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Utility &ndash; </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">COMPUTER IMPLEMENTED METHODS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Japan</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SYSTEMS AND METHODS FOR PREDICTING MISFOLDED PROTEIN EPITOPES
    BY COLLECTIVE COORDINATE BIASING</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven Samuel Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ISSUED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051306</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2036-11-09</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 14%; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10-2018-7015912</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>COMPUTER IMPLEMENTED METHODS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>South Korea</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SYSTEMS AND METHODS FOR PREDICTING MISFOLDED PROTEIN EPITOPES
    BY COLLECTIVE COORDINATE BIASING</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven Samuel Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PENDING</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051306</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">108475298A</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>COMPUTER IMPLEMENTED METHODS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>China</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SYSTEMS AND METHODS FOR PREDICTING MISFOLDED PROTEIN EPITOPES
    BY COLLECTIVE COORDINATE BIASING</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven Samuel Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PENDING</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on CN Publication No. 108475298A</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3142040</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>COMPUTER IMPLEMENTED METHODS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Canada</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2020-05-27</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CONFORMATION-SPECIFIC EPITOPES IN TAU, ANTIBODIES THERETO
    AND METHODS RELATED THEREOF </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PENDING</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2020/050722</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">17/614487</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*not yet published</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>IMMUNOGENS, ANTIBODIES, METHOD OF DETECTING OR TREATING A TAUOPATHY</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2020-05-27</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CONFORMATION-SPECIFIC EPITOPES IN TAU, ANTIBODIES THERETO
    AND METHODS RELATED THEREOF </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PENDING</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2020/050722</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 177 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2020284288</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>IMMUNOGENS, ANTIBODIES, METHOD OF DETECTING OR TREATING A TAUOPATHY</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Australia</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2020-05-27</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CONFORMATION-SPECIFIC EPITOPES IN TAU, ANTIBODIES THERETO
    AND METHODS RELATED THEREOF </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PENDING</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2020/050722</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 14%; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">114174515A</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>IMMUNOGENS, ANTIBODIES, METHOD OF DETECTING OR TREATING A TAUOPATHY</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>China</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2020-05-27</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CONFORMATION-SPECIFIC EPITOPES IN TAU, ANTIBODIES THERETO
    AND METHODS RELATED THEREOF </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2020/050722</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3976793</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>IMMUNOGENS, ANTIBODIES, METHOD OF DETECTING OR</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Europe</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2020-05-27</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CONFORMATION-SPECIFIC EPITOPES IN TAU, ANTIBODIES THERETO
    AND METHODS RELATED THEREOF </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2020/050722</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TREATING A TAUOPATHY</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;202147059454</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>IMMUNOGENS, ANTIBODIES, METHOD OF DETECTING OR TREATING A TAUOPATHY</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>India</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2020-05-27</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CONFORMATION-SPECIFIC EPITOPES IN TAU, ANTIBODIES THERETO
    AND METHODS RELATED THEREOF </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PENDING</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2020/050722</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 178 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2021-570226</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>IMMUNOGENS, ANTIBODIES, METHOD OF DETECTING OR TREATING A TAUOPATHY</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Japan</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2020-05-27</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CONFORMATION-SPECIFIC
                                            EPITOPES IN TAU, ANTIBODIES THERETO AND METHODS RELATED THEREOF </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PENDING</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2020/050722</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 14%; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10-2022-0034733</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
 &ndash; </B></FONT>IMMUNOGENS, ANTIBODIES, METHOD OF DETECTING OR TREATING A TAUOPATHY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>South Korea</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">2020-05-27</P>
</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CONFORMATION-SPECIFIC
                                            EPITOPES IN TAU, ANTIBODIES THERETO AND METHODS RELATED THEREOF </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven Plotkin</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">PROMIS NEUROSCIENCES INC.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2020/050722</P>
</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt"><P STYLE="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt">Co-Owned
                                            and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3148562</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash;</B></FONT> IMMUNOGENS, ANTIBODIES, METHOD OF DETECTING OR TREATING A SYNUCLEINOPATHY</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Canada</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2019-10-07</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CONFORMATION-SPECIFIC
                                            EPITOPES IN ALPHA-SYNUCLEIN, ANTIBODIES THERETO AND METHODS RELATED THEREOF </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Xubiao Peng</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PENDING</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2019/051434</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">17/283292</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*not yet published</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>IMMUNOGENS, ANTIBODIES, METHOD OF DETECTING OR TREATING A SYNUCLEINOPATHY</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2019-10-07</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CONFORMATION-SPECIFIC
                                            EPITOPES IN ALPHA-SYNUCLEIN, ANTIBODIES THERETO AND METHODS RELATED THEREOF </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Xubiao Peng</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PENDING</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2019/051434</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2019356804</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>IMMUNOGENS, ANTIBODIES, METHOD OF DETECTING OR TREATING A SYNUCLEINOPATHY</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Australia</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2019-10-07</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CONFORMATION-SPECIFIC
                                            EPITOPES IN ALPHA-SYNUCLEIN, ANTIBODIES THERETO AND METHODS RELATED THEREOF </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Xubiao Peng</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PENDING</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2019/051434</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3861015</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>IMMUNOGENS, ANTIBODIES, METHOD OF DETECTING OR TREATING A SYNUCLEINOPATHY</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Europe</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2019-10-07</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CONFORMATION-SPECIFIC
                                            EPITOPES IN ALPHA-SYNUCLEIN, ANTIBODIES THERETO AND METHODS RELATED THEREOF </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Xubiao Peng</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2019/051434</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 179 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">202127020718</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>IMMUNOGENS, ANTIBODIES, METHOD OF DETECTING OR TREATING A SYNUCLEINOPATHY</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>India</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2019-10-07</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CONFORMATION-SPECIFIC
                                            EPITOPES IN ALPHA-SYNUCLEIN, ANTIBODIES THERETO AND METHODS RELATED THEREOF </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Xubiao Peng</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PENDING</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2019/051434</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 14%; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2021-516452</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>IMMUNOGENS, ANTIBODIES, METHOD OF DETECTING OR TREATING A SYNUCLEINOPATHY</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Japan</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2019-10-07</P></TD>
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CONFORMATION-SPECIFIC
                                            EPITOPES IN ALPHA-SYNUCLEIN, ANTIBODIES THERETO AND METHODS RELATED THEREOF </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Xubiao Peng</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PENDING</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2019/051434</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">62022047684.5</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>IMMUNOGENS, ANTIBODIES, METHOD OF DETECTING OR TREATING A SYNUCLEINOPATHY</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Hong Kong</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2018-05-30</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CONFORMATION-SPECIFIC
                                            EPITOPES IN ALPHA-SYNUCLEIN, ANTIBODIES THERETO AND METHODS RELATED THEREOF </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Xubiao Peng</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PENDING</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on EP Publication No. 3861015</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3064785</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>IMMUNOGENS, ANTIBODIES, METHOD OF DETECTING TDP-43</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Canada</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2018-05-30</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EPITOPES
                                            IN THE RNA RECOGNITION MOTIF 1 (RRM1) OF TDP-43 AND MISFOLDING-SELECTIVE ANTIBODIES THERETO
                                            </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Xubiao Peng</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pending</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2018/050634</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">11214613</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2022-01-04</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>ANTIBODIES, METHOD OF DETECTING TDP-43</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2018-05-30</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EPITOPES
                                            IN THE RNA RECOGNITION MOTIF 1 (RRM1) OF TDP-43 AND MISFOLDING-SELECTIVE ANTIBODIES THERETO
                                            </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Xubiao Peng</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ISSUED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2018/050634</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2038-05-30</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">US-2022-0162293-A1</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>TDP-43 IMMUNOGENS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2021-12-03</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2018-05-30</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EPITOPES
                                            IN THE RNA RECOGNITION MOTIF 1 (RRM1) OF TDP-43 AND MISFOLDING-SELECTIVE ANTIBODIES THERETO
                                            </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Xubiao Peng</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Divisional of 16/616832</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-bottom: Black 1pt solid; border-right: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 180 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: black 1pt solid; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3634987</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash;</B></FONT> IMMUNOGENS, ANTIBODIES, METHOD OF DETECTING TDP-43</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Europe</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2018-05-30</P></TD>
    <TD STYLE="border-top: black 1pt solid; width: 32%; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EPITOPES IN THE RNA RECOGNITION MOTIF 1 (RRM1) OF TDP-43
    AND MISFOLDING-SELECTIVE ANTIBODIES THERETO </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Xubiao Peng</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-top: black 1pt solid; width: 24%; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2018/050634</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; width: 14%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">62020014330.8</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash;</B></FONT> IMMUNOGENS, ANTIBODIES, METHOD OF DETECTING TDP-43</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> Hong Kong</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2018-05-30</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EPITOPES IN THE RNA RECOGNITION MOTIF 1 (RRM1) OF TDP-43
    AND MISFOLDING-SELECTIVE ANTIBODIES THERETO </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Xubiao Peng</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pending</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on EP Publication No. 3634987</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2019-565224</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>IMMUNOGENS, ANTIBODIES, METHOD OF DETECTING TDP-43</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Japan</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2018-05-30</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EPITOPES IN THE RNA RECOGNITION MOTIF 1 (RRM1) OF TDP-43
    AND MISFOLDING-SELECTIVE ANTIBODIES THERETO </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Xubiao Peng</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pending</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2018/050634</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3123116</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>ANTIBODIES, IMMUNOGENS AND METHODS OF TREATMENT AND DETECTION OF MISFOLDED TDP-43</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Canada</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2019-12-16</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ANTIBODIES TO MISFOLDED TDP-43 AND METHODS OF USE </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pending</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2019/051823</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 181 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">US
                                            2022-0056118 A1</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>ANTIBODIES, IMMUNOGENS AND METHODS OF TREATMENT AND DETECTION OF MISFOLDED TDP-43</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2019-12-16</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ANTIBODIES
                                            TO MISFOLDED TDP-43 AND METHODS OF USE </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2019/051823</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-top: Black 1pt solid; border-right: black 1pt solid; width: 14%; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;2019399680</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash;</B></FONT> ANTIBODIES, IMMUNOGENS AND METHODS OF TREATMENT AND DETECTION OF MISFOLDED TDP-43</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Australia</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2019-12-16</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ANTIBODIES
                                            TO MISFOLDED TDP-43 AND METHODS OF USE </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pending</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2019/051823</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3894433</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>ANTIBODIES, IMMUNOGENS AND METHODS OF TREATMENT AND DETECTION OF MISFOLDED TDP-43</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Europe</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2019-12-16</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ANTIBODIES
                                            TO MISFOLDED TDP-43 AND METHODS OF USE </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2019/051823</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">40060768A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
 &ndash; </B></FONT>ANTIBODIES, IMMUNOGENS AND METHODS OF TREATMENT AND DETECTION OF MISFOLDED TDP-43</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hong Kong</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">2019-12-16</P>
</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ANTIBODIES
                                            TO MISFOLDED TDP-43 AND METHODS OF USE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">PROMIS NEUROSCIENCES INC.</P>
</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Based on EP&nbsp;Publication No. 3894433</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">Co-Owned
                                            and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">202127031355</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    - </B></FONT>ANTIBODIES, IMMUNOGENS AND METHODS OF TREATMENT AND DETECTION OF MISFOLDED TDP-43</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>India</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2019-12-16</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ANTIBODIES
                                            TO MISFOLDED TDP-43 AND METHODS OF USE </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pending</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2019/051823</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2021-533492</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    - </B></FONT>ANTIBODIES, IMMUNOGENS AND METHODS OF TREATMENT AND DETECTION OF MISFOLDED TDP-43</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Japan</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2019-12-16</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ANTIBODIES
                                            TO MISFOLDED TDP-43 AND METHODS OF USE </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pending</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2019/051823</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 182 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>WO 2021/217267</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    </B></FONT>TDP-43 NUCLEIC ACIDS AND METHODS OF TREATMENT</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PCT</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2021-04-29</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SINGLE CHAIN ANTIBODIES AND INTRABODIES TO MISFOLDED TDP-43
    AND METHODS OF USE</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Beibei Zhao</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Published</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-top: Black 1pt solid; border-right: black 1pt solid; width: 14%; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>WO 2021/207854</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    - </B></FONT>ANTI-SENSE OLIGONUCLEOTIDES AND COMPOSITIONS AND METHODS OF TREATMENT</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PCT</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2021-04-16</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>COMPOSITIONS AND METHODS FOR INHIBITING TDP-43 AND FUS AGGREGATION</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Beibei Zhao</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ching-Chung Hsueh</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Catherine M. Cowan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Published</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2009301580</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>METHODS FOR PREDICTING AND MAKING IMMUNOGENS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Australia</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2009-10-06</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>METHODS AND SYSTEMS FOR PREDICTING MISFOLDED PROTEIN EPITOPES</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">William C. Guest</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issued</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2009/001413</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2029-10-06</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2,743,361</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>METHODS FOR PREDICTING AND MAKING IMMUNOGENS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Canada</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2009-10-06</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>METHODS AND SYSTEMS FOR PREDICTING MISFOLDED PROTEIN EPITOPES</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">William C. Guest</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issued</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2009/001413</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2029-10-06</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 183 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2342220</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>METHODS FOR PREDICTING AND MAKING IMMUNOGENS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Germany</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;2009-10-06</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>METHODS AND SYSTEMS FOR PREDICTING MISFOLDED PROTEIN EPITOPES</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">William C. Guest</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Granted</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on EP 09818707.3, which is a National Phase of PCT/CA2009/001413</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2029-10-06</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-top: Black 1pt solid; border-right: black 1pt solid; width: 14%; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;2342220</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>METHODS FOR PREDICTING AND MAKING IMMUNOGENS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Denmark</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2009-10-06</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>METHODS AND SYSTEMS FOR PREDICTING MISFOLDED PROTEIN EPITOPES</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">William C. Guest</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Granted</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on EP 09818707.3, which is a National Phase of PCT/CA2009/001413</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2029-10-06</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2342220</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>METHODS FOR PREDICTING AND MAKING IMMUNOGENS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>France</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2009-10-06</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>METHODS AND SYSTEMS FOR PREDICTING MISFOLDED PROTEIN EPITOPES</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">William C. Guest</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Granted</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on EP 09818707.3, which is a National Phase of PCT/CA2009/001413</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2029-10-06</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2342220</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>METHODS FOR PREDICTING AND MAKING IMMUNOGENS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United Kingdom</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2009-10-06</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>METHODS AND SYSTEMS FOR PREDICTING MISFOLDED PROTEIN EPITOPES</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">William C. Guest</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Granted</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on EP 09818707.3, which is a National Phase of PCT/CA2009/001413</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2029-10-06</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2342220</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>METHODS FOR PREDICTING AND MAKING IMMUNOGENS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Netherlands</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2009-10-06</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>METHODS AND SYSTEMS FOR PREDICTING MISFOLDED PROTEIN EPITOPES</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">William C. Guest</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Granted</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on EP 09818707.3, which is a National Phase of PCT/CA2009/001413</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2029-10-06</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 184 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5898495</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash;</B></FONT> METHODS FOR PREDICTING AND MAKING IMMUNOGENS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Japan</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2009-10-06</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>METHODS
                                            AND SYSTEMS FOR PREDICTING MISFOLDED PROTEIN EPITOPES</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">William C. Guest</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issued</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2009/001413</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2029-10-06</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: Black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10,475,525</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>METHODS FOR PREDICTING AND MAKING IMMUNOGENS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-05-12</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>METHODS
                                            AND SYSTEMS FOR PREDICTING MISFOLDED PROTEIN EPITOPES</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">William C. Guest</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issued</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Divisional of 12/574637 ( now abandoned)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated term expiration: 2030-09-05</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3004498</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Utility &ndash; IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING
    OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Canada</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">2018-12-06</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AMYLOID
                                            BETA EPITOPES AND ANTIBODIES THERETO</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pending</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051305</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10759837</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>A-BETA ANTIBODIES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2018-12-06</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ANTI-AMYLOID
                                            BETA ANTIBODIES BINDING TO A CYCLIC AMYLOID BETA PEPTIDE</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issued</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051305</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated term expiration: 2036-11-09</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Terminal Disclaimer: US 10,751,382</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">US
                                            2021-0087243 A1</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash;</B></FONT> IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-09-11</P></TD>
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ANTI-AMYLOID
                                            BETA ANTIBODIES BINDING TO A CYCLIC AMYLOID BETA PEPTIDE</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Continuation of 15/774,778</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; width: 30%; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 32%; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 24%; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 14%; padding-left: 5.4pt">&nbsp;</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 185 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: black 1pt solid; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016353553</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    - </B></FONT>IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Australia</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-top: black 1pt solid; width: 32%; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AMYLOID BETA EPITOPES AND ANTIBODIES THERETO</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-top: black 1pt solid; width: 24%; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ISSUED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051305</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; width: 14%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2022202549</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    </B></FONT>IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Australia</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2016-11-09</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AMYLOID BETA EPITOPES AND ANTIBODIES THERETO</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pending</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Divisional of AU 2016353553</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>108350053A</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    </B></FONT>IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>China</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AMYLOID BETA EPITOPES AND ANTIBODIES THERETO</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051305</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3374383</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    </B></FONT>IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Europe</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AMYLOID BETA EPITOPES AND ANTIBODIES THERETO</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051305</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 186 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1259324&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    </B></FONT>IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Hong Kong</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AMYLOID BETA EPITOPES AND ANTIBODIES THERETO</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on CN Publication No. 108350053A</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 14%; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">201817020841</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    </B></FONT> IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>India</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AMYLOID BETA EPITOPES AND ANTIBODIES THERETO</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pending</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051305</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;2018-522803</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    </B></FONT>IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Japan</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AMYLOID BETA EPITOPES AND ANTIBODIES THERETO</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pending</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051305</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10-2018-0094876</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>South Korea</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AMYLOID BETA EPITOPES AND ANTIBODIES THERETO</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051305</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3004482</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Canada</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATIONALLY-SELECTIVE
    ANTIBODIES THERETO </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pending</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051300</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 187 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10772969</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    </B></FONT>IMMUNOGENS, METHODS OF DETECTING A-BETA DISEASES AND MAKING A-BETA ANTIBODIES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATIONALLY-SELECTIVE
    ANTIBODIES THERETO </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issued</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051300</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated term expiration: 2036-11-09</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Terminal Disclaimer: US10,751,382</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 14%; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">US 2021-0154315 A1</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    </B></FONT>IMMUNOGENS, METHODS OF DETECTING A-BETA DISEASES AND MAKING A-BETA ANTIBODIES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09&nbsp;</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATIONALLY-SELECTIVE
    ANTIBODIES THERETO </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Continuation of 15/774,805</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016353552</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    </B></FONT> IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Australia</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATIONALLY-SELECTIVE
    ANTIBODIES THERETO </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ISSUED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051300</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2022202256</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    - </B></FONT>ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Australia</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;2016-11-09</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATIONALLY-SELECTIVE
    ANTIBODIES THERETO </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pending</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Divisional of AU 2016353552</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 188 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">108350051A1</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>China</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATIONALLY-SELECTIVE
    ANTIBODIES THERETO </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051300</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 14%; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3374379</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    </B></FONT> IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Europe</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATIONALLY-SELECTIVE
    ANTIBODIES THERETO </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051300</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1259325</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    - </B></FONT>IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Hong Kong</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATIONALLY-SELECTIVE
    ANTIBODIES THERETO </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on CN Publication No. 108350051A1</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">201817020836A</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>India</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATIONALLY-SELECTIVE
    ANTIBODIES THERETO </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051300</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2018-522707</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Japan</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATIONALLY-SELECTIVE
    ANTIBODIES THERETO </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ALLOWED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051300</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 189 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10-2018-0088828</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Utility &ndash; </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA
    DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>South Korea</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATIONALLY-SELECTIVE
    ANTIBODIES THERETO </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051300</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 14%; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3004494</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES <B>Canada</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EPITOPES IN AMYLOID BETA MID-REGION AND CONFORMATIONALLLY-SELECTIVE
    ANTIBODIES THERETO </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pending</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051303</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10774120</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash;</B></FONT> A-BETA ANTIBODIES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EPITOPES IN AMYLOID BETA MID-REGION AND CONFORMATIONALLLY-SELECTIVE
    ANTIBODIES THERETO </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issued</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051303</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated term expiration: 2036-11-09</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Terminal Disclaimer: 10,751,382</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">US 2021-0087244 A1</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>IMMUNOGENS, METHODS OF TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT>2016-11-09</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EPITOPES IN AMYLOID BETA MID-REGION AND CONFORMATIONALLLY-SELECTIVE
    ANTIBODIES THERETO </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Continuation of 15/774,707</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 190 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016354688</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash;</B></FONT> IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Australia</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EPITOPES IN AMYLOID BETA MID-REGION AND CONFORMATIONALLLY-SELECTIVE
    ANTIBODIES THERETO </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issued</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051303</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-top: Black 1pt solid; border-right: black 1pt solid; width: 14%; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;2022201737</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES <B>Australia</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EPITOPES IN AMYLOID BETA MID-REGION AND CONFORMATIONALLLY-SELECTIVE
    ANTIBODIES THERETO </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pending</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Divisional of AU 2016354688</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">108350052A</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    - </B></FONT>IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>China</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EPITOPES IN AMYLOID BETA MID-REGION AND CONFORMATIONALLLY-SELECTIVE
    ANTIBODIES THERETO </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051303</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3374381</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    - </B></FONT>IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Europe</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EPITOPES IN AMYLOID BETA MID-REGION AND CONFORMATIONALLLY-SELECTIVE
    ANTIBODIES THERETO </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051303</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1259326</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    - </B></FONT>IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Hong Kong</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EPITOPES IN AMYLOID BETA MID-REGION AND CONFORMATIONALLLY-SELECTIVE
    ANTIBODIES THERETO </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on CN Publication No. 108350052A</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 191 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">201817020839</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>India</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EPITOPES IN AMYLOID BETA MID-REGION AND CONFORMATIONALLLY-SELECTIVE
    ANTIBODIES THERETO </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051303</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-top: Black 1pt solid; border-right: black 1pt solid; width: 14%; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;2018-523030</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Japan</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EPITOPES IN AMYLOID BETA MID-REGION AND CONFORMATIONALLLY-SELECTIVE
    ANTIBODIES THERETO </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pending</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051303</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA
    DISEASES</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10-2018-7015909</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>IMMUNOGENS, ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>South Korea</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016-11-09</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EPITOPES IN AMYLOID BETA MID-REGION AND CONFORMATIONALLLY-SELECTIVE
    ANTIBODIES THERETO </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pending</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2016/051303</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3031135</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    - </B></FONT>ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Canada</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2017-07-18</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ANTIBODIES TO AMYLOID BETA </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Judith Maxwell Silverman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ebrima Gibbs</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pending</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2017/050866</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 192 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">US 2020-0172602 A1</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2020-06-04</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>METHODS OF INHIBITING AND A-BETA AND TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2017-07-18</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>METHODS OF REDUCING TOXICITY INDUCED BY AMYLOID BETA (A-BETA) OLIGOMERS USING ANTIBODIES SPECIFIC TO A-BETA OLIGOMERS</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Judith Maxwell Silverman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ebrima Gibbs</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ALLOWED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2017/050866</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-top: Black 1pt solid; border-right: black 1pt solid; width: 14%; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;2017299858</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    - </B></FONT>ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Australia</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2017-07-18</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ANTIBODIES TO AMYLOID BETA </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Judith Maxwell Silverman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ebrima Gibbs</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pending</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2017/050866</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>109476729A</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>China</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2017-07-18</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ANTIBODIES TO AMYLOID BETA </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Judith Maxwell Silverman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ebrima Gibbs</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2017/050866</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>3484919</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Europe</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2017-07-18</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ANTIBODIES TO AMYLOID BETA </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Judith Maxwell Silverman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ebrima Gibbs</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2017/050866</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 193 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">40008189A</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash;</B></FONT> ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Hong Kong</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2017-07-18</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ANTIBODIES TO AMYLOID BETA </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Judith Maxwell Silverman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ebrima Gibbs</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on EP Publication No. 3484919</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-top: Black 1pt solid; border-right: black 1pt solid; width: 14%; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;201917005362</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>India</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2017-07-18</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ANTIBODIES TO AMYLOID BETA </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Judith Maxwell Silverman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ebrima Gibbs</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2017/050866</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2019-501965</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Japan</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2017-07-18</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ANTIBODIES TO AMYLOID BETA </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Judith Maxwell Silverman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ebrima Gibbs</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pending</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2017/050866</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10-2019-0028495</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>South Korea</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2017-07-18</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ANTIBODIES TO AMYLOID BETA </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Judith Maxwell Silverman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ebrima Gibbs</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2017/050866</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ANTIBODIES, METHODS OF DETECTING OR TREATING A-BETA DISEASES</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 194 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3070085</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>ANTIBODIES, COMPOSITIONS AND METHODS OF DETECTING OR TREATING A-BETA OLIBOMER DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Canada</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2018-07-18</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ANTIBODIES TO AMYLOID BETA </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Judith Maxwell Silverman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ebrima Gibbs</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pending</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2018/050875</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ANTIBODIES, COMPOSITIONS AND METHODS OF DETECTING OR TREATING
    A-BETA OLIBOMER DISEASES</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-top: Black 1pt solid; border-right: black 1pt solid; width: 14%; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;US 2020-0181247 A1</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>ANTIBODIES, COMPOSITIONS AND METHODS OF DETECTING OR TREATING A-BETA OLIBOMER DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2018-07-18</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ANTIBODIES TO AMYLOID BETA </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Judith Maxwell Silverman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ebrima Gibbs</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2018/050875</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>3574020</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>ANTIBODIES, COMPOSITIONS AND METHODS OF DETECTING OR TREATING A-BETA OLIBOMER DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Europe</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2018-07-18</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ANTIBODIES TO AMYLOID BETA </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Judith Maxwell Silverman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ebrima Gibbs</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2018/050875</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">40017344A</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash;</B></FONT> ANTIBODIES, COMPOSITIONS AND METHODS OF DETECTING OR TREATING A-BETA OLIBOMER DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Hong Kong</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2018-07-18</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ANTIBODIES TO AMYLOID BETA </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Judith Maxwell Silverman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ebrima Gibbs</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on EP Publication No. 3574020</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 195 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2020-502655</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    - </B></FONT>ANTIBODIES, COMPOSITIONS AND METHODS OF DETECTING OR TREATING A-BETA OLIBOMER DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Japan</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2018-07-18</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ANTIBODIES TO AMYLOID BETA </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Judith Maxwell Silverman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ebrima Gibbs</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pending</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2018/050875</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-top: Black 1pt solid; border-right: black 1pt solid; width: 14%; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;10751382</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>A-BETA ANTIBODIES AND COMPOSITIONS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2018-10-01</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING A-BETA
    OLIGOMER-ASSOCIATED AND/OR -INDUCED DISEASES AND CONDITIONS </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issued</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Continuation of 15/808842 (abandoned) which is a CIP of PCT/CA2017/050866
    and PCT/2016/051305 and PCT/2016/051303 and PCT/2016/051300</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated term expiration: 2036-11-09</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Terminal Disclaimer: US 10,774,120 and US 10,759,837</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">US 2021-0038678 A1</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>IMMUNOGEN COMPOSITIONS AND METHOD OF TREATING A-BETA OLIGOMER DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2020-08-21</P></TD>
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING A-BETA
    OLIGOMER-ASSOCIATED AND/OR -INDUCED DISEASES AND CONDITIONS </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven S. Plotkin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Judith Maxwell Silverman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ebrima Gibbs</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PUBLISHED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Continuation of 16/148601</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 196 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>WO 2021/195770</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>ANTIBODIES TO, METHODS OF DETECTING OR TREATING A-BETA OLIGOMER DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PCT</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2021-03-31</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ANTIBODIES TO MISFOLDED AMYLOID BETA</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Johanne Kaplan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ebrima Gibbs</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Published</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-top: Black 1pt solid; border-right: black 1pt solid; width: 14%; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;10,053,510</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>ANTIBODIES, PHARMACUETICAL COMPOSITIONS AND METHODS OF DETECTING MISFOLDED FasR</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2014-05-26</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>FasR ANTIBODIES FOR DIAGNOSTIC AND THERAPEUTIC USE</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Marni Diane Uger</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Veronica Ciolfi</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE UNIVERSITY OF BRITISH COLUMBIA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issued</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT2014/000457</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated term expiration: 2034-07-03</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Patent Term Adjustment: 38 days</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2642848</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility-
    </B></FONT>USE FOR TREATING A SOD1 MEDIATED NEURODEGENERATIVE CONDITION</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Canada</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2007-03-05</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>METHODS AND COMPOSITIONS TO TREAT AND DETECT MISFOLDED-SOD1
    MEDIATED DISEASES </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Avijit Chakrabartty</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joachim Berhhard Ostermann</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rishi Rakhit</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">UNIVERSITY HEALTH NETWORK</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ISSUED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2007/000346</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2027-03-05</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">7977314</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>METHODS OF ALS TREATMENT</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2007-03-05</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>METHODS AND COMPOSITIONS TO TREAT AND DETECT MISFOLDED-SOD1
    MEDIATED DISEASES </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ISSUED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Continuation in part of</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">11/565,967 (USP779469) and 11/367609 (USP 7439324)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">and US filing corresponding to PCT/CA2007/000346</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2028-01-22</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Patent Term Adjustment: 690 days</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Owned</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-left: 5.4pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 197 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: black 1pt solid; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;7887803</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>METHOD OF ALS TREATMENT</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2007-09-05</P></TD>
    <TD STYLE="border-top: black 1pt solid; width: 32%; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>METHODS AND COMPOSITIONS TO TREAT AND DETECT MISFOLDED-SOD1
    MEDIATED DISEASES </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-top: black 1pt solid; width: 24%; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ISSUED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Continuation in Part of 11/682,217 and 11/565967 (USP779469)
    and 11/367609 (USP 7439324)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2027-02-23</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Patent Term Adjustment: 357 days</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; width: 14%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Owned</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8709422</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>METHOD OF ALS TREATMENT</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2010-12-24</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>METHODS AND COMPOSITIONS TO TREAT AND DETECT MISFOLDED-SOD1
    MEDIATED DISEASES </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Avijit Chakrabartty</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joachim Berhhard Ostermann</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rishi Rakhit</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ISSUED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Continuation of 11/850,502</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2026-03-03</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Terminal Disclaimer US 8,778,885</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Patent Term Adjustment: 95 days</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Owned</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">9637552</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    </B></FONT>METHOD OF TREATING SOD-1 NEURODEGENERATIVE DISEASE</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2014-06-10</P></TD>
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>METHODS AND COMPOSITIONS TO TREAT AND DETECT MISFOLDED-SOD1
    MEDIATED DISEASES </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Avijit Chakrabartty</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joachim Berhhard Ostermann</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rishi Rakhit</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ISSUED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Continuation of 13/155939 (USP 8778885)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2024-08-20</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Terminal Disclaimers: US 7,763,710; US 8,075,891; US 7,439,324;
    US 8,513,387; US 7,977,314; US8,778,885; US7,887,803; and 8,709,422</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Owned</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;5823663</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS FOR TREATING SOD-1 NEURODEGENERATIVE DISEASE</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Japan</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2007-03-05</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>METHODS AND COMPOSITIONS TO TREAT AND DETECT MISFOLDED-SOD1
    MEDIATED DISEASES </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Avijit Chakrabartty</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joachim Berhhard Ostermann</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rishi Rakhit</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">UNIVERSITY HEALTH NETWORK</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ISSUED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2007/000346</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2027-03-05</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 198 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2514823</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>ANTIBODIES AND IMMUNOGENS FOR TREATING ALS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United Kingdom</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2007-03-05</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>METHODS AND COMPOSITIONS TO TREAT AND DETECT MISFOLDED-SOD1
    MEDIATED DISEASES </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Avijit Chakrabartty</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joachim Berhhard Ostermann</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rishi Rakhit</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">UNIVERSITY HEALTH NETWORK</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issued</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on EP 07710682.1 which is a National Phase of PCT/CA2007/000346</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2027-03-05</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 14%; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2514823</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>ANTIBODIES AND IMMUNOGENS FOR TREATING ALS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Germany</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2007-03-05</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>METHODS AND COMPOSITIONS TO TREAT AND DETECT MISFOLDED-SOD1
    MEDIATED DISEASES </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Avijit Chakrabartty</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joachim Berhhard Ostermann</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rishi Rakhit</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">UNIVERSITY HEALTH NETWORK</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issued</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on EP 07710682.1 which is a National Phase of PCT/CA2007/000346</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2027-03-05</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2514823</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>ANTIBODIES AND IMMUNOGENS FOR TREATING ALS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>France</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2007-03-05</P></TD>
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>METHODS AND COMPOSITIONS TO TREAT AND DETECT MISFOLDED-SOD1
    MEDIATED DISEASES </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Avijit Chakrabartty</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joachim Berhhard Ostermann</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rishi Rakhit</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">UNIVERSITY HEALTH NETWORK</P></TD>
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issued</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on EP 07710682.1 which is a National Phase of PCT/CA2007/000346</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2027-03-05</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned and Exclusively licensed</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;2536305</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>SOD1 IMMUNOGEN, ANTIBODY, COMPOSITION, METHOD OF MAKING AND DETECTION AGENT</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Canada</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2004-08-20</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SOD-1 EPITOPES AND ANTIBODIES</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Marty Letho</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ISSUED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PCT/CA2004/001503</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2024-08-20</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Owned</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">7439324</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>SOD-1 IMMUNOGEN COMPOSISITON</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2006-03-03</P></TD>
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ALS-SPECIFIC PEPTIDE COMPOSITION</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issued</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CIP of PCT/CA2004/001503</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated term expiration: 2024-12-11</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Patent Term Adjustment: 113 days</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Owned</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 199 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8,075,891</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>SOD-1 ANTIBODIES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2010-06-02</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ANTIBODIES THAT BIND ALS SPECIFIC EPITOPES AND METHODS OF
    MAKING</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issued</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Continuation of 12/236,731 (USP7763710)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated term expiration: 2024-08-20</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 14%; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Owned</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">9,523,697</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>METHODS FOR DETECTING A-BETA <B></B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2020-10-22</P></TD>
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>DETECTION OF PATHOGENIC ABETA USING AN EPITOPE PROTECTION
    ASSAY</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Marty Lehto</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issued</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Continuation of</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10/568,729 (Abandoned), which is a National Phase of PCT/CA2004/001503)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated term expiration: 2025-06-14</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Patent Term Adjustment: 298 days</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Owned</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;9,625,476</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>ALS DIAGNOSTIC METHODS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2014-07-31</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>METHODS OF DIAGNOSING ALS</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issued</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Continuation of 13/313,869 (USP 8828389)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2024-08-20</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Terminal disclaimer US 8,075,891; US 8,778,885; and US 8,828,389)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Owned</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5357111</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>SOD-1 IMMUNOGENS AND ANTIBODIES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Japan</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2010-07-05</P></TD>
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EPITOPE PROTECTION ASSAY AND METHOD FOR DETECTING PROTEIN
    CONFORMATIONS</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Marty Lehto</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issued</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Divisional of</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2006-523496</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2024-08-20</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Owned</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-bottom: Black 1pt solid; border-right: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 200 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 30%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8,513,387</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>SOD1 ANTIBODY AND METHODS OF MAKING</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2010-21-07</P></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 32%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Methods and Compositions for Detecting Amyotrophic Lateral
    Sclerosis</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Avijit Chakrabartty</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rishi Rakhit</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 24%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issued</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Continuation of 11/565967 (USP7794692)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2027-07-12</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Terminal Disclaimer: US 7,794,692)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Patent term adjustments: 224 days)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-top: black 1pt solid; border-right: black 1pt solid; width: 14%; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Owned</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;2,877,505</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>PRION PROTEIN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND USES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Canada</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2013-06-11</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ANTIBODIES AND CONJUGATES THAT TARGET MISFOLDED PRION PROTEIN</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Marni Diane Uger</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Viengthong Chai</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Veronica Ciolfi</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Wah Yau Wong</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Heman Lap-Man Chao</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Baomin Tian</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">HELIX BIOPHARMA CORP.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issued</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2013/000569</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2033-06-11</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">6430373</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>PRION PROTEIN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND USES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Japan</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2013-06-11</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ANTIBODIES AND CONJUGATES THAT TARGET MISFOLDED PRION PROTEIN</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Marni Diane Uger</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Viengthong Chai</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Veronica Ciolfi</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Wah Yau Wong</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Heman Lap-Man Chao</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Baomin Tian</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">HELIX BIOPHARMA CORP.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issued</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2013/000569</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2033-06-11</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">9,296,819</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Utility
    &ndash; </B></FONT>PRION ANTIBODY, COMPOSITION, METHODS OF DETECTING AND TREATING PRION DISEASES</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2014-12-12</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ANTIBODIES AND CONJUGATES THAT TARGET MISFOLDED PRION PROTEIN</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Marni Diane Uger</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Viengthong Chai</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Veronica Ciolfi</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neil R. Cashman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Wah Yau Wong</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Heman Lap-Man Chao</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Baomin Tian</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">HELIX BIOPHARMA CORP.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS NEUROSCIENCES INC.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issued</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Phase of PCT/CA2013/000569</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calculated Term Expiration: 2033-06-11</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Co-Owned</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 201 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section&nbsp;12 of the Securities Exchange Act of 1934, the registrant has duly caused this amended Registration
Statement to be signed on its behalf by the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROMIS
    NEUROSCIENCES INC.</B></FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">/s/ Eugene Williams</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: Eugene Williams</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chairman and
    Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: July 1, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 202; Options: NewSection; Value: 123 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXHIBIT&nbsp;INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
<TD STYLE="border-bottom: Black 1pt solid; text-align: justify; vertical-align: top; width: 10%; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
<TD STYLE="width: 2%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; width: 88%; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
of Exhibit</B></FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1#</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex3-1d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.1#</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex3-1d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate
of Amendment to the Articles dated July 8, 2015</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex3-1d2.htm" STYLE="-sec-extract: exhibit">3.1.2#</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex3-1d2.htm" STYLE="-sec-extract: exhibit">Certificate
of Amendment to the Articles dated June 17, 2022</A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922076352/tm229830d7_ex3-1d3.htm" STYLE="-sec-extract: exhibit">3.1.3#</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922076352/tm229830d7_ex3-1d3.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment to the Articles dated June 21, 2022</A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex3-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2#</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex3-2.htm" STYLE="-sec-extract: exhibit">Amended
and Restated By-law No. 1</A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex3-2d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.1#</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex3-2d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By-law
No.&nbsp;2</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex4-1.htm" STYLE="-sec-extract: exhibit">4.1#</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex4-1.htm" STYLE="-sec-extract: exhibit">Form
of Amended and Restated Unsecured Convertible Debenture dated June 17, 2022.</A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1#+</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint
Venture Agreement dated July&nbsp;7, 2020 by and between ProMIS Neurosciences Inc. and BC Neuroimmunology Lab Inc.</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2#+</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint
Venture Agreement dated July&nbsp;8, 2020 by and between ProMIS Neurosciences Inc. and BC Neuroimmunology Lab Inc.</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3#+</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborative
Research Agreement by and between The University of British Columbia and Provincial Health Services Authority (on behalf of Children&#8217;s&nbsp;&amp;
Women&#8217;s Health Centre of British Columbia Branch, a public hospital) and ProMIS Neurosciences Inc. effective April&nbsp;1, 2016.</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-3d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3.1#+</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-3d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
No.&nbsp;1 dated February&nbsp;13, 2017 to the Collaborative Research Agreement by and between The University of British Columbia and
Provincial Health Services Authority (on behalf of Children&#8217;s&nbsp;&amp; Women&#8217;s Health Centre of British Columbia Branch,
a public hospital) and ProMIS Neurosciences Inc. effective April&nbsp;1, 2016.</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-3d2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3.2#+</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-3d2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
No.&nbsp;2 dated July&nbsp;5, 2018 to the Collaborative Research Agreement by and between The University of British Columbia and Provincial
Health Services Authority (on behalf of Children&#8217;s&nbsp;&amp; Women&#8217;s Health Centre of British Columbia Branch, a public
hospital) and ProMIS Neurosciences Inc. effective April&nbsp;1, 2016.</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-3d3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3.3#+</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-3d3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
No.&nbsp;3 dated February&nbsp;13, 2019 to the Collaborative Research Agreement by and between The University of British Columbia and
Provincial Health Services Authority (on behalf of Children&#8217;s&nbsp;&amp; Women&#8217;s Health Centre of British Columbia Branch,
a public hospital) and ProMIS Neurosciences Inc. effective April&nbsp;1, 2016.</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-3d4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3.4#+</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-3d4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
No.&nbsp;4 dated September&nbsp;9, 2019 to the Collaborative Research Agreement by and between The University of British Columbia and
Provincial Health Services Authority (on behalf of Children&#8217;s&nbsp;&amp; Women&#8217;s Health Centre of British Columbia Branch,
a public hospital) and ProMIS Neurosciences Inc. effective April&nbsp;1, 2016.</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4#+</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended
and Restated License Agreement dated October&nbsp;6, 2015 by and between The University of British Columbia and ProMIS Neurosciences
Inc. </FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5#+</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
Agreement dated August&nbsp;3, 2006 by and between Amorfix Life Sciences Ltd. and an Affiliate of Biogen Idec Inc.</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6#+</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusive
License Agreement dated July&nbsp;14, 2010 by and between Amorfix Life Sciences Ltd. and Biogen Idec MA Inc.</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7#+</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
Agreement dated April&nbsp;4, 2006 by and between University Health Network and Amorfix Life Sciences Inc.</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-7d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7.1#</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-7d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
dated July&nbsp;13, 2006 to the License Agreement dated April&nbsp;4, 2006 by and between University Health Network and Amorfix Life
Sciences Inc.</FONT></A></TD></TR>
</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 203; Value: 123 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 10%; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-7d2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7.2#+</FONT></A></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 88%; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-7d2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
    No.&nbsp;2 dated July&nbsp;11, 2007 to the License Agreement dated April&nbsp;4, 2006 by and between University Health Network and
    Amorfix Life Sciences Ltd.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-7d3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7.3#+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-7d3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
    No.&nbsp;3 dated November&nbsp;4, 2013 to the to the License Agreement dated April&nbsp;4, 2006 by and between University Health
    Network and Amorfix Life Sciences Ltd.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-8.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8#&#8224;+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-8.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting
    Agreement dated April&nbsp;1, 2021 by and between Elliot Paul Goldstein, MD and ProMIS Neurosciences Inc.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-8.htm" STYLE="-sec-extract: exhibit">10.8.1#&dagger;+</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-8.htm" STYLE="-sec-extract: exhibit">Consulting Agreement dated October 1, 2021 by and
    between Elliot Goldstein, MD and ProMIS Neurosciences Inc.</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-9.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9#&#8224;+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-9.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advisory
    Consulting Agreement dated May&nbsp;26, 2021 by and between ProMIS Neurosciences Inc. and David Wishart.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10#&#8224;+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting
    and Advisory Agreement dated March&nbsp;1, 2005 by and between Amorfix Life Sciences Ltd. And Neil Cashman.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-11.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11#&#8224;+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-11.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting
    Agreement dated June&nbsp;29, 2015 by and between Amorfix Life Sciences Ltd. and Virtua, LLC.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-12.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12#&#8224;+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-12.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting
    Agreement dated October&nbsp;17, 2016 by and between ProMIS Neurosciences&nbsp;Inc. and Danforth Advisors, LLC.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-12d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12.1#&#8224;+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-12d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
    No.&nbsp;1 dated March&nbsp;27, 2017 to Consulting Agreement dated October&nbsp;17, 2016 by and between ProMIS Neurosciences&nbsp;Inc.
    and Danforth Advisors, LLC.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-12d2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12.2#&#8224;</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-12d2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
    No.&nbsp;2 dated December&nbsp;12, 2017 to Consulting Agreement dated October&nbsp;17, 2016 by and between ProMIS Neurosciences&nbsp;Inc.
    and Danforth Advisors, LLC.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-12d3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12.3#&#8224;</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-12d3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
    No.&nbsp;3 dated August&nbsp;28, 2018 to Consulting Agreement dated October&nbsp;17, 2016 by and between ProMIS Neurosciences&nbsp;Inc.
    and Danforth Advisors, LLC.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-12d4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12.4#&#8224;+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-12d4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
    No.&nbsp;4 dated March&nbsp;27, 2017 to Consulting Agreement dated October&nbsp;17, 2016 by and between ProMIS Neurosciences&nbsp;Inc.
    and Danforth Advisors, LLC.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-13.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13#</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-13.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of
    Finder&#8217;s Warrant Certificate dated April&nbsp;30, 2018.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-14.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14#</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-14.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of
    Non-US Warrant Certificate dated April&nbsp;30, 2018.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-15.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15#</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-15.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of
    Employee Stock Option Commitment.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-16.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16#+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-16.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of
    Unit Subscription Agreement for Non-U.S. Subscribers dated February&nbsp;25, 2020.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-17.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17#+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-17.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of
    Unit Subscription Agreement for Non-U.S. Subscribers dated June&nbsp;17, 2019. </FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-18.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18#+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-18.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of
    Unit Subscription Agreement for U.S. Subscribers dated November&nbsp;27, 2018.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-19.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19#+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-19.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of
    Unit Subscription Agreement for U.S. Subscribers dated October&nbsp;21, 2019. </FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-20.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20#+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-20.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of
    Unit Subscription Agreement for U.S. Subscribers dated April&nbsp;13, 2018.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-21.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21#+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-21.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of
    Unit Subscription Agreement for Non-U.S. Subscribers dated April&nbsp;13, 2018.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-22.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22#+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-22.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of
    Unit Subscription Agreement for Non-U.S. Subscribers dated November&nbsp;27, 2018.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-23.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23#+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-23.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of
    Unit Subscription Agreement for Non-U.S. Subscribers dated October&nbsp;21, 2019.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-24.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24#+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-24.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of
    Finder&#8217;s Warrant Certificate dated November&nbsp;2020.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-25.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25#+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-25.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of
    Non-U.S. Finder&#8217;s Warrant Certificate dated January&nbsp;2019.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-26.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26#+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-26.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of
    Non-U.S. Warrant Certificate dated January&nbsp;2019.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-27.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27#+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-27.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of
    Non-U.S. Warrant Certificate dated June&nbsp;2019.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-28.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28#+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-28.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of
    U.S. Warrant Certificate dated January&nbsp;2019.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-29.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29#+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-29.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of
    U.S. Warrant Certificate dated November&nbsp;2020.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-30.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30#</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-30.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of
    Special Warrant Certificate dated November&nbsp;4, 2020.</FONT></A></TD></TR>
</TABLE>

<P STYLE="margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 204; Value: 123 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify; width: 10%"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-31.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31#</FONT></A></TD>
<TD STYLE="width: 2%">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify; width: 88%"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-31.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of
U.S. Special Warrant Certificate dated November&nbsp;4, 2020.</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-32.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32#+</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-32.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of
Warrant Certificate dated November&nbsp;2020.</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-33.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33#+</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-33.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technology
License Agreement dated February&nbsp;1, 2006 by and between Dr.&nbsp;Neil Roy Cashman and Amorfix Life Sciences Ltd.</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-34.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34#+</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-34.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Service
Agreement dated September&nbsp;1, 2020 by and between The University of Saskatchewan and ProMIS Neurosciences&nbsp;Inc.</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-35d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35#+</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-35d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignment
Agreement dated February&nbsp;18, 2005 by and between Neil R. Cashman and Marty Lehto and the Governing Council of the University of
Toronto and Amorfix Life Sciences Ltd.</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-35d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35.1#</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-35d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
Agreement dated April 1, 2005 to the Assignment Agreement dated February 18, 2005 by and between Neil R. Cashman and Marty Lehto and
the Governing Council of the University of Toronto and Amorfix Life Sciences Ltd.</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-36.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.36#&dagger;+</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-36.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
Employment Agreement of Eugene Williams dated December&nbsp;31, 2021.</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-37.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.37#&dagger;+</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-37.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
Employment Agreement of Gavin Malenfant dated December&nbsp;31, 2021.</FONT></A></TD></TR>
</TABLE>

<P STYLE="margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
<TD STYLE="vertical-align: top; width: 10%; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-38.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.38#&dagger;</FONT></A></TD>
<TD STYLE="width: 2%">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; width: 88%; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-38.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProMIS
Neruosciences Inc. 2015 Stock Option Plan.</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-39.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.39#&dagger;</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-39.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amorfix
Life Sciences Ltd. Deferred Share Unit Plan for Canadian Senior Officers.</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-40.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.40#</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-40.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
of Non-U.S. Finder&rsquo;s Warrant Certificate dated November 2019.</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.41#</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-41.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
of Non-U.S. Warrant Certificate dated November 2019.</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-42.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.42#</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-42.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
of U.S. Warrant Certificate dated November 2019.</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-43.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.43#</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-43.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
of Non-U.S. Warrant Certificate dated November 2020.</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-44.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.44#</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-44.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
of Broker Warrant dated August 2021.</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-45.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.45#</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-45.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
of Non-U.S. Warrant Certificate dated August 2021.</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-46.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.46#</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-46.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
of U.S. Warrant Certificate dated August 2021.</FONT></A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-47.htm" STYLE="-sec-extract: exhibit">10.47#&dagger;+</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-47.htm" STYLE="-sec-extract: exhibit">Consulting Agreement
dated April 1, 2022 by and between ProMIS Neurosciences Inc. and Larry Altstiel.</A></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm229830d8_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1*</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm229830d8_ex99-1.htm" STYLE="-sec-extract: exhibit">Press Release of ProMIS Neurosciences, Inc. dated June 22, 2022.</A></TD></TR>
</TABLE>

<P STYLE="margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">*</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Filed herewith.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">#</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Previously filed.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates a
    management contract or compensatory plan or arrangement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 97%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain identified
    information has been excluded from the exhibit pursuant to Item 601(a)(6)&nbsp;and/or Item 601(b)(10)(iv)&nbsp;of Regulation S-K.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 205; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm229830d8_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Exhibit 99.1</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0"><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 24pt"></FONT></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 70%; padding-right: 265.45pt; padding-bottom: 36.3pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 22, 2022</FONT></TD>
    <TD STYLE="width: 30%; padding-top: 0.75pt; padding-bottom: 0.7pt; font-size: 10pt; text-align: right"><IMG SRC="image_001.jpg" ALT="">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0"><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 24pt"></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0"><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0"><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 24pt">ProMIS Neurosciences Announces Debt Amendment
and Conversion</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 22, 2022 (GLOBE
NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (&ldquo;ProMIS&rdquo; or the &ldquo;Company&rdquo;), a biotechnology
company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated
in the development of neurodegenerative diseases, is pleased to announce that it has entered into debenture amendments with seven (7)
creditors to settle an aggregate of US$7,000,000 of indebtedness via the issuance of 70,000,000 Series 1 Preferred Shares (&quot;Series
1 Shares&quot;) of the Company at US$0.10 per share. The debenture amendments allow for the settlement of indebtedness under the amended
debentures in Series 1 Shares in lieu of Common Shares at the option of the holder. The Series 1 Shares are convertible into Common Shares
at a ratio of 1:1 in accordance with their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This transaction will allow the Company to conserve
its cash on hand and is an important step in the Company&rsquo;s efforts to meet the minimum initial listing requirements of a major North
American stock exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transaction is subject to acceptance of the
TSX. The shares to be issued have not and will not be registered under the US Securities Act of 1933, as amended, or any state securities
laws. The rights and privileges of the Series 1 Shares are fully described on the Company&rsquo;s website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following unaudited pro forma balance sheet
presents the Company&rsquo;s financial position as of March 31, 2022 after giving effect to the impact of the June 19, 2022 debt conversion
as though it had occurred on March 31, 2022. This unaudited pro forma balance sheet should be read along with the Company&rsquo;s audited
financial statements for the year ended December 31, 2021, and the unaudited information presented in its quarterly financial statements
for the three months ended March 31, 2022 which are available on SEDAR. The unaudited pro forma balance sheet is provided for informational
purposes only and is not necessarily indicative of the financial position that would have occurred had the transaction been completed
as of the dates set forth, nor is it indicative of the future financial position of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ProMIS Neurosciences Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a development stage company)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PRO FORMA BALANCE SHEET<BR>
(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>all $ in Canadian dollars</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>March 31,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>2022</B>&nbsp;</P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Pro forma <BR> adjustments <BR> attributable <BR> to <BR> conversion <BR> of <BR> convertible <BR> notes</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>March 31,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>2022</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Adjusted</B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">$</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">$</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">$</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ASSETS</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Current assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; font: 10pt Times New Roman, Times, Serif; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">17,177,02</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">(22,104</TD><TD STYLE="white-space: nowrap; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)<I>a</I></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">17,154,92</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Short-term investments</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">42,078</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">42,078</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Tax credits receivable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">125,862</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">125,862</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Prepaid expenses, deposits and deferred charges</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">651,600</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">651,600</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17,996,565</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(22,104</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17,974,461</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Property and equipment, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,263</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,263</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Technology rights, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">33,280</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">33,280</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><B>Total assets</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,036,108</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(22,104</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">18,014,004</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>LIABILITIES AND SHAREHOLDERS' EQUITY</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Current Liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Accounts payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">804,946</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">804,946</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Accrued liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">930,739</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22,104</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)<I>a</I></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">908,635</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,735,685</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(22,104</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,713,581</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Convertible debentures</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,056,806</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,056,806</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">)<I>b</I></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Derivative liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,538,106</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,538,106</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">)<I>c</I></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Warrant liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,037,389</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,037,389</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total Liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13,367,986</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(9,617,016</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,750,970</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Shareholders' Equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Common Shares</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">72,045,506</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">72,045,506</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Series 1 Preferred Shares</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,000,000</FONT></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><I>d</I></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Other equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9,019,103</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9,019,103</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Contributed surplus</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9,715,259</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9,715,259</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(86,111,746</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,594,912</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><I>e</I></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(83,516,834</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total shareholders' equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,668,122</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,594,912</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,263,034</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total liabilities and shareholders' equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">18,036,108</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(22,104</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">18,014,004</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><I>a</I></TD><TD STYLE="text-align: justify"><I>Cash settlement of accrued interest through June 19, 2022
of $22,104.</I></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><I>b</I></TD><TD STYLE="text-align: justify"><I>The pro forma net adjustment of $5,056,806 includes an increase
to the carrying value of the convertible debt for interest expense and amortization of debt discount through June 19, 2022 of $145,214
and the extinguishment of the carrying value of the debt as of June 19, 2022 of $5,202,020.</I></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><I>c</I></TD><TD STYLE="text-align: justify"><I>The pro forma net adjustment of $4,538,106 includes a decrease
in the fair value of the derivative liability of $1,144,651 from a final mark to fair value on the conversion date and the extinguishment
of the remaining derivative liability of $3,393,455.</I></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><I>d</I></TD><TD STYLE="text-align: justify"><I>Fair value of no-par value Series 1 Preferred Shares issued
of $7,000,000 (70 million shares at $0.10 per share).</I></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><I>e</I></TD><TD STYLE="text-align: justify"><I>The pro forma net adjustment of $2,594,912 includes a gain
on extinguishment of the convertible debt and derivative liability of $1,595,475 and gain on the change in fair value of the derivative
liability of $1,144,651 offset by $145,214 of interest expense.</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0.2in; text-indent: -0.2in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0.2in; text-indent: -0.2in"><I></I></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0.2in"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0.2in; text-indent: -0.2in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About ProMIS Neurosciences Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ProMIS Neurosciences Inc. is a development stage
biotechnology Corporation focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated
in the development and progression of neurodegenerative diseases, in particular Alzheimer&rsquo;s disease (AD), amyotrophic lateral sclerosis
(ALS) and multiple system atrophy (MSA). The Corporation&rsquo;s proprietary target discovery engine is based on the use of two complementary
techniques. The Corporation applies its thermodynamic, computational discovery platform - ProMISTM and Collective Coordinates - to predict
novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, ProMIS is
developing novel antibody therapeutics for AD, ALS and MSA. ProMIS is headquartered in Toronto, Ontario, Canada with offices in Cambridge,
Massachusetts, U.S.A. ProMIS is listed on the Toronto Stock Exchange (TSX) under symbol PMN, and on the OTCQB Venture Market under symbol
ARFXF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Visit
us at</B></FONT> <FONT STYLE="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Blue"><B>www.promisneurosciences.com</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #0000EE"><B>,</B></FONT><B>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">follow us on</FONT></B> <FONT STYLE="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Blue"><B>Twitter</B></FONT>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>and</B></FONT> <FONT STYLE="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Blue"><B>LinkedIn</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For Investor Relations please contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Alpine Equity Advisors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nicholas Rigopulos, President</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: underline; color: Blue">nick@alpineequityadv.com</FONT><BR>
Tel. 617 901-0785</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The TSX has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release. Certain information in this news release constitutes forward-looking statements
and forward-looking information (collectively, &quot;forward-looking information&quot;) within the meaning of applicable securities laws.
In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology
such as &quot;plans&quot;, &quot;targets&quot;, &quot;expects&quot; or &quot;does not expect&quot;, &quot;is expected&quot;, &quot;an
opportunity exists&quot;, &quot;is positioned&quot;, &quot;estimates&quot;, &quot;intends&quot;, &quot;assumes&quot;, &quot;anticipates&quot;
or &quot;does not anticipate&quot; or &quot;believes&quot;, or variations of such words and phrases or state that certain actions, events
or results &quot;may&quot;, &quot;could&quot;, &quot;would&quot;, &quot;might&quot;, &quot;will&quot; or &quot;will be taken&quot;, &quot;occur&quot;
or &quot;be achieved&quot;. In addition, any statements that refer to expectations, projections or other characterizations of future events
or circumstances contain forward-looking information. Specifically, this news release contains forward-looking information relating to
the potential listing of the Company&rsquo;s shares on a stock exchange in the United States. Forward-looking information is necessarily
based on a number of opinions, assumptions and estimates. Important factors that could cause actual results and financial condition to
differ materially from those indicated in the forward-looking information include, among others, the factors discussed throughout the
 &quot;Risk Factors&quot; section of the Company's most recently filed annual information form available on <FONT STYLE="text-decoration: underline; color: Blue">www.SEDAR.com</FONT>.
Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information,
whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">##</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Source: ProMIS Neurosciences Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm229830d4_1012b-img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm229830d4_1012b-img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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MWES*=@VPHN9 PV\XR ;'_$5=^VY_T5#1_P#PD=)_^1Z/^(J[]MS_ **AH_\
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MXBKOVW/^BH:/_P"$CI/_ ,CT?\15W[;G_14-'_\ "1TG_P"1Z_.JB@#]%?\
MB*N_;<_Z*AH__A(Z3_\ (]>QZ%_P<I_M?WO_  3]\4^.Y/B-I1\3:9\0M&T&
MWN?^$7TP*EG<:;JL\J;/(V$F2VA.XC(VD X)S^0]?1'AC_E$[XX_[*UX=_\
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M::FD.GF+[=]IL TSQ+#YT99][+C<20%R?#M%_82^.'B3XEZIX+T_X-?%6_\
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MQ%7?MN?]%0T?_P )'2?_ )'K\ZJ* /T5_P"(J[]MS_HJ&C_^$CI/_P CT?\
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M@]\4?V/4\?\ PCU'7M-\:-\3O&E[INR_>^D8:I9-!=P+J-O<J9)&EV3,XE3
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M*_!G[0AO4\<^"]667^S]4AN);B0*DL;+/$\7VF94=6Z2-D$[2O:6_P#P7?\
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MDQ^,O"WB(?$'QN/$'@;3H-(\-ZH-=NOMGAZR@#B&ULYM^^WAC$CA(XRJJ';
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MO_2J.@#UC_@L/_RE>_:1_P"RE:__ .G":OF^OI#_ (+#_P#*5[]I'_LI6O\
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M>TC(9@3R>.E &U^TO_P3*^ /P/\ VK]*^ 6B_%#XQ^,?BOI/BBQ\/^*(]*\
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MB!AMRO.#ZUZIIW_!?S7=2U'XV6_BWX0> _&OA;XS^,X/'EQH5_J&HVT&FZI
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MM^,6F?%ZY\4+I,-\(/"NN3^'YKF=%6&\N($C,S0$,2R)([0DL%/F02C! #,
M?SB?\.!OVN/^B13?^%'I'_R51_PX&_:X_P"B13?^%'I'_P E5_2%X.^,7A?X
M@^+_ !)H&BZYI^IZSX/GBMM:LX)-TNFR2H7C60=BR@X_W6'4$5TM '\S'_#@
M;]KC_HD4W_A1Z1_\E4?\.!OVN/\ HD4W_A1Z1_\ )5?TSUSGAOXJ:3XJ^(GB
M7PO:/.VK>$UM'U!6B*HHN49XMK?Q?*C9]* /YN_^' W[7'_1(IO_  H](_\
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MM;?#CX$>*(=&\7>*].T+4I[/^T1#<+)\EMO9/.=E4JD>Y6&YB!P: /YWO^'
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MC!XAOO&/AV6^UK2;:ZDL+^=[FW,L7VL[',<BY7)P<BN _P"' W[7'_1(IO\
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MX6>+?@#JF@^()M!_9YT#6[]]4GMW:#Q+&MG.GAJWB?DS/'!*)9<<K/8Q=2Q
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MQ7#!M2>T2YV*)UW2JC7)1]L:L/T0HH _.WQAX)/BWX,^"?$/BOQ7XX\0^$=
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M_C5<Q_PDL'_/'4__  77'_Q%'_"2P?\ /'4__!=<?_$4?7N/OY,1_P""Y?\
MR(?4/#W^?#?^#(__ "1T_P#PL_QG_P!#GKW_ 'S;?_&JJZWXV\5>(]&N]/O?
M%VN3V=_"]O/$1;@21NI5ER(L\@D<5A?\)+!_SQU/_P %UQ_\13+CQ;:6D#RR
MIJ$<4:EW=["<*@')).S@4?7N/OY,1_X+E_\ (A]0\/?Y\-_X,C_\D:/P[OM;
M^$_@+1O#'A[Q+K6F:#X>LHM.TZT3R&6VMXD"1H"T98@* ,DD\=:V?^%G^,_^
MASU[_OFV_P#C5<CIGCG3];TZ"\LVO+NTNHUEAGALIY(YD89#*P3!!'((J?\
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M *(M\//_  3Q?X4?\.K_ -G'_HBWP\_\$\7^% %ZBJ/_  ZO_9Q_Z(M\//\
MP3Q?X4?\.K_V<?\ HBWP\_\ !/%_A0!P'[:G_)F_Q:_[$S6/_2&:NS^''_)/
M-!_[!UO_ .BEK@/VT?\ @F=^S_X3_8[^+&J:;\(/ 5EJ.F^#=8N[6YATJ-9+
M>6.RF9'4XX96 (/J*[+X<_\ !+G]G:^^'NA3S?!GX?233:=;N[MI$1+L8U))
MX]: .GHJC_PZO_9Q_P"B+?#S_P $\7^%'_#J_P#9Q_Z(M\//_!/%_A0!>HJC
M_P .K_V<?^B+?#S_ ,$\7^%'_#J_]G'_ *(M\//_  3Q?X4 7J*H_P##J_\
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M[JUT*^FAE328PT3K;N58''!! - '"_\ !,?_ )1T? O_ +$31O\ TBBKW.O
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M_HBWP\_\$\7^% %ZBJ/_  ZO_9Q_Z(M\//\ P3Q?X4?\.K_V<?\ HBWP\_\
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M %%%% !1110 5X)_P31_Y--M_P#L:_%?_J2:G7O=>"?\$T?^33;?_L:_%?\
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MH_\ *#_\K*/^%)>.O^CA?C1_Y0?_ )64 ?7M%?(7_"DO'7_1POQH_P#*#_\
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MU6:6+1?#:Z797IOK8P82$3/Y7E@@Y+2%\<D=:9\)_P!C/_A5Y^!/_%1_;O\
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M&+MV<DF>E_\ #:&H_P#0FQ?^#D?_ !FC_AM#4?\ H38O_!R/_C->345_.O\
MQ%S.OY*?_@,O_DC^EO\ B#>1?SU/_ H__(GK/_#:&H_]";%_X.1_\9H_X;0U
M'_H38O\ P<C_ .,UY-11_P 1<SK^2G_X#+_Y(/\ B#>1?SU/_ H__(GK/_#:
M&H_]";%_X.1_\9H_X;0U'_H38O\ P<C_ .,UY-11_P 1<SK^2G_X#+_Y(/\
MB#>1?SU/_ H__(GK/_#:&H_]";%_X.1_\9H_X;0U'_H38O\ P<C_ .,UY-11
M_P 1<SK^2G_X#+_Y(/\ B#>1?SU/_ H__(GK/_#:&H_]";%_X.1_\9K'^(7[
M5&I^-_ .N:*OA.&W;5]/GLA*=7W"(R1LF['DC.-V<5Y]11_Q%S.OY*?_ (#+
M_P"2#_B#>1?SU/\ P*/_ ,B;G[+/QJU;]G3]FOP%X!F\.6^JR^#- LM%>]34
M_*6Z-O D1D"&(E0VW.,G&>M=[_PVAJ/_ $)L7_@Y'_QFO)J*/^(N9U_)3_\
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MV,WB;_T_ZC7ME>)_\$]O^38X/^QF\3?^G_4: /;**** "BBB@ HHHH ****
M"O&?V>?^3E?C]_V,6E_^F+3Z]FKQG]GG_DY7X_?]C%I?_IBT^@#V:BBB@ HH
MHH **** "BBB@ KR[]JC_D&?#7_LK'@3_P!2C3*]1KR[]JC_ )!GPU_[*QX$
M_P#4HTR@#](:*** /SI_X+'?\I"OV,?^OWQ7_P"DEC7HU=3_ ,%"?^">/B']
MLOXN_"'QKX7^(>E> ]8^$LNJRP)J/AA]<@U$WT=M&=RI>6I38L#=&.XR#IM^
M;D_^'?7[0/\ T7SX7_\ AI;O_P"7U #Z*9_P[Z_:!_Z+Y\+_ /PTMW_\OJ/^
M'?7[0/\ T7SX7_\ AI;O_P"7U #Z*9_P[Z_:!_Z+Y\+_ /PTMW_\OJ/^'?7[
M0/\ T7SX7_\ AI;O_P"7U #Z*9_P[Z_:!_Z+Y\+_ /PTMW_\OJ/^'?7[0/\
MT7SX7_\ AI;O_P"7U #Z*9_P[Z_:!_Z+Y\+_ /PTMW_\OJ/^'?7[0/\ T7SX
M7_\ AI;O_P"7U #Z*9_P[Z_:!_Z+Y\+_ /PTMW_\OJ/^'?7[0/\ T7SX7_\
MAI;O_P"7U #Z*9_P[Z_:!_Z+Y\+_ /PTMW_\OJ/^'?7[0/\ T7SX7_\ AI;O
M_P"7U #Z*9_P[Z_:!_Z+Y\+_ /PTMW_\OJ/^'?7[0/\ T7SX7_\ AI;O_P"7
MU #Z*9_P[Z_:!_Z+Y\+_ /PTMW_\OJ/^'?7[0/\ T7SX7_\ AI;O_P"7U #Z
M*9_P[Z_:!_Z+Y\+_ /PTMW_\OJ/^'?7[0/\ T7SX7_\ AI;O_P"7U #Z*9_P
M[Z_:!_Z+Y\+_ /PTMW_\OJ/^'?7[0/\ T7SX7_\ AI;O_P"7U #Z*9_P[Z_:
M!_Z+Y\+_ /PTMW_\OJ/^'?7[0/\ T7SX7_\ AI;O_P"7U 'FO[:G_)F_Q:_[
M$S6/_2&:NS^''_)/-!_[!UO_ .BEJ+XG?\$O/CK\5_AMXA\+:C^T!\-H]/\
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M_P#X:6[_ /E]0 ^BF?\ #OK]H'_HOGPO_P##2W?_ ,OJ/^'?7[0/_1?/A?\
M^&EN_P#Y?4 /KYU^,GPXTOXI?M]>$M,U=)WM1\/=8G'DSO"ZNNJ:3M(92#WK
MZ'_X=]?M _\ 1?/A?_X:6[_^7U<Q>?\ !*+XX7OQHT_QRW[0/PZ_M?3=%NM"
MBC'PGNO(,%Q/;SNQ']N9WAK:/!SC!;@\8 \T<M_PQUX,]->_\'%S_P#%T?\
M#'7@STU[_P '%S_\77J'_#OK]H'_ *+Y\+__  TMW_\ +ZC_ (=]?M _]%\^
M%_\ X:6[_P#E]7+]1PO_ #ZC_P" K_([/[1QG_/Z?_@4O\SR_P#X8Z\&>FO?
M^#BY_P#BZ/\ ACKP9Z:]_P"#BY_^+KU#_AWU^T#_ -%\^%__ (:6[_\ E]1_
MP[Z_:!_Z+Y\+_P#PTMW_ /+ZCZCA?^?4?_ 5_D']HXS_ )_3_P# I?YGE_\
MPQUX,]->_P#!Q<__ !='_#'7@STU[_P<7/\ \77J'_#OK]H'_HOGPO\ _#2W
M?_R^H_X=]?M _P#1?/A?_P"&EN__ )?4?4<+_P ^H_\ @*_R#^T<9_S^G_X%
M+_,\O_X8Z\&>FO?^#BY_^+H_X8Z\&>FO?^#BY_\ BZ]0_P"'?7[0/_1?/A?_
M .&EN_\ Y?4?\.^OV@?^B^?"_P#\-+=__+ZCZCA?^?4?_ 5_D']HXS_G]/\
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M_%T?\,=>#/37O_!Q<_\ Q=>H?\.^OV@?^B^?"_\ \-+=_P#R^H_X=]?M _\
M1?/A?_X:6[_^7U'U'"_\^H_^ K_(/[1QG_/Z?_@4O\SY.\2_!ZZ7X]:GX/\
M"B7;1K!;3M/>327$6G1NIW2.S')R1\J Y8^@!(^D/A=\+M,^$OAA=-TU68LW
MFW-S+@S7DI',CGN>.!T      K=A_P""=WQ[MYY94^._PJ26<@RNOPBN@TA
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M0/\ T7SX7_\ AI;O_P"7U #Z*9_P[Z_:!_Z+Y\+_ /PTMW_\OJ/^'?7[0/\
MT7SX7_\ AI;O_P"7U #Z*9_P[Z_:!_Z+Y\+_ /PTMW_\OJ/^'?7[0/\ T7SX
M7_\ AI;O_P"7U #Z*9_P[Z_:!_Z+Y\+_ /PTMW_\OJ/^'?7[0/\ T7SX7_\
MAI;O_P"7U #Z\N_:H_Y!GPU_[*QX$_\ 4HTRO3O^'?7[0/\ T7SX7_\ AI;O
M_P"7U4[_ /X)B?%_QKXE\(/XJ^./@34-#\->*]$\47%GIWPSN+&YO3INHV]^
ML"SOK,JQ[VMPA<QO@,3M/2@#[?HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
>*** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm229830d4_1012b-img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm229830d4_1012b-img02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" #J LT# 2(  A$! Q$!_\0
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MS=VT:2K$B2,2L$T;EDN 3CRV5D4T >1_\14G[<7_ $5VP_\ "0T;_P"1:/\
MB*D_;B_Z*[8?^$AHW_R+7PK\6_#GASPE\0]1T_PEXEE\7^'K<QBTU>33'TUK
MP&-6?-N[,R;7++RQSMSWQ7-T ?H=_P 14G[<7_17;#_PD-&_^1:]0/\ P<N?
MME#]BX>+_P#A:=E_;Y\:G1_M/_"*Z3C[+]A$VS9]FV_?YSC/;.*_*&O;3_RC
MC7_LI!_]-@H ^H?^(J3]N+_HKMA_X2&C?_(M'_$5)^W%_P!%=L/_  D-&_\
MD6OSQK]QO^"''_!._P"'7[1/_!-OX9>(;OX3_!3QMXJ\5?&&Y\.^(+OQS>W-
MM>2Z#'9-<7$>F>3*KR7R+$7CC5'RJRDJ "Z@'R/_ ,14G[<7_17;#_PD-&_^
M1:/^(J3]N+_HKMA_X2&C?_(M6O%7_!'3P!\0O&6L^.[/XJZ;\'/@_P"/?BQJ
M7P^^%]KKVC:A?:EJ!BN6C5ITPLEM;HVV(R3GS%(_>*IR3]!Z7_P0YU+XE?\
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M[D+#O5\,RM)APH^0D@&O_P 14G[<7_17;#_PD-&_^1:/^(J3]N+_ **[8?\
MA(:-_P#(M3>'/^"%/@_Q)INA7T'[3_@N2QUGXCGX1>9%X2U5G/BC,.VVB4H/
M,MMLH8W+F-0 ,*Q.!S_[''_!"CQ'^UG\6/&GP_'B[5-)\8^#/&FI>"+K[#X#
MUC6=#M[FS^7S[O5((_L]I#+*'1=Y+C9N955E) -K_B*D_;B_Z*[8?^$AHW_R
M+1_Q%2?MQ?\ 17;#_P )#1O_ )%K@_V[/@SX?^'/_!)_]BO6K/PWH>E>*_$;
M^/(?$.I6ME%'>:N]IKD<, N)D&Z;RDRB;R=JG"X%?9_QR_X)3>#/C[^R/^R/
M\*OA--\./#5[XB\!W7Q4\9^-]2\*/#JSV$$3M<7D]\A>=H%:=(ULP""WE-N4
M)P ?-G_$5)^W%_T5VP_\)#1O_D6C_B*D_;B_Z*[8?^$AHW_R+5_X,?\ !O5<
M_M*ZY\+;WX?_ !O\(:[X"^+6C^(-0TKQ'<Z-=V#6-QH^P7-M=VLGSQ@L_$BL
M_"LVW&W=SWP;_P""+?@GXR>$8/%%G^TKX77P?KGQ5A^$GAK5H_"6I2_\)!J<
M]C9W4,BQ':\,1-TT;&7;M,!.3N H TO^(J3]N+_HKMA_X2&C?_(M'_$5)^W%
M_P!%=L/_  D-&_\ D6O,/VW?^"4D/[(?P!UGQUI7Q7\.?$-/!_Q'E^%GB>ST
M_2;RR_LO68[6:Y98I)U7[1$!!*A<*OS+P&!S7R!0!^N6G_\ !R7^V)/_ ,$_
M-7\=-\4+(^)[7XA6.@Q7?_"+:3A;.33;R=X_+^S;.9(HSNQNXQG!(KQO_B*D
M_;B_Z*[8?^$AHW_R+7SQI/\ RB>U_P#[*UIG_IGU"OGB@#]#O^(J3]N+_HKM
MA_X2&C?_ "+1_P 14G[<7_17;#_PD-&_^1:_/&OO#_@C!\/O VH?";]JCQYX
MP^'G@[XD7WPL^'(U_0M/\303SZ>ET+R--SI#+$Y!4D'#@^] &]_Q%2?MQ?\
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MO_&GP<\4:AIFK:UX,G@CEO=.+_9[J.>VANH74. P)BGC)4CY6R,G&2 ?5?\
MQ%2?MQ?]%=L/_"0T;_Y%H_XBI/VXO^BNV'_A(:-_\BU^>-% 'ZV?M;_\'*'[
M8WPL_P"%9?V)\4;*T_X2/P#I6N:AGPMI,GG7<_F^9)\UL=N=J_*N%&.!7D/_
M !%2?MQ?]%=L/_"0T;_Y%KYP_;Y_YHM_V2K0_P#VO7@% 'Z'?\14G[<7_17;
M#_PD-&_^1:/^(J3]N+_HKMA_X2&C?_(M?GC10!^AW_$5)^W%_P!%=L/_  D-
M&_\ D6C_ (BI/VXO^BNV'_A(:-_\BU^>-% 'Z'?\14G[<7_17;#_ ,)#1O\
MY%H_XBI/VXO^BNV'_A(:-_\ (M?GC10!^AW_ !%2?MQ?]%=L/_"0T;_Y%KU3
M]FS_ (.6?VR?B%X.^+UWJWQ2LKF?PKX'DUG3&'A724^SW0U/3K<.0ML W[NX
ME&&R/FSC(!'Y.U[E^QO_ ,D]_: _[)G+_P"GK2* /IS_ (BI/VXO^BNV'_A(
M:-_\BT?\14G[<7_17;#_ ,)#1O\ Y%K\\:* /T._XBI/VXO^BNV'_A(:-_\
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M0!^5/_!ZM_RE-\ _]DJT[_T[ZQ7Y 5^O_P#P>K?\I3? /_9*M._].^L5^0%
M!7=?LQ?M!:U^R?\ M$>"OB9X<M],N]>\":S;:Y80:C&\EI--!()$654='*$J
M,A74XZ$5PM?3GPV_X(V_M+?&#X*6GQ$\-?"W4=6\(:CHDOB*QOHM2L0VHV<3
MS)*;>%IQ-/*AMY"T$:-*J[&*!9(RP!Z1^S__ ,%^/BW^SWK/CV\L_!WPF\0'
MQ[\1;CXI/#K>CWD\>BZY.Q+36@2[C(094*DQEV[%(.[+'A)_^"G/B#XP>(O"
MVD>/K#1+/P=;?&2Z^+6JS:+8N;]+F_G@:]BB$TKQ-$J1$Q1NI.3AW<=,?2?^
M"1/[1NO_ +,6D_&2P^&&IWWPXU]K&/3=5MK^SE:_DO+_ /L^VCBMUF-P\CW1
M6/8(]PWHQ 5E8]A+_P $*OVD?"_QO^'/@OQ=X*M?"G_"RO$0\,V6JS:]IEYI
M]G=JIDFBN)K>Y=(ITA2206\C++)Y95$9N* /KS_@IS_P6*^#'Q*U&U^)GPOU
M&WU+XZ>%?B-'XG\":UI6AZMIL.C:9N:6:'4H[^\EAGFE?8&%M"D9VGA02I^,
M?$__  5L\13_ +1OP\^*7A#X2? ?X6>*/AUKTGB* ^#O#$UC#K-RYC++>"2X
MD=XL(0(XVC51+(5"LV1N>+O^"#'[2.F_M(>./ASX?\(Z9XKG\#3A;K5K3Q)I
M4&FO#+=3V]JS3RW2Q0S3M;N5M9'6X'1HP:Q?#O\ P2I\;^(?V?S<+X7\;6_Q
M:D^,<'PCAT"ZBL+73_MTMDUPMO)+-<I-'<EU."8O(V#)E!.* / ?V@OC!'\?
M/C!K7BZ+PEX.\"IK+QN-"\*V4EEI%ALB2/$$4DDCJ&V;VR[9=V/? XRO>?VJ
M_P#@F1\<_P!B+X?Z%XH^*'@*Z\+:'XBO'TZSN'U&SNBETD8D:VGC@FD>VF"'
M=Y<ZH^ >/E./!J "O;3_ ,HXU_[*0?\ TV"O$J]M/_*.-?\ LI!_]-@H \2K
MZ3^&/_!5#XG?!S]EWX??"GP['X=T[2?AI\1XOBAHNJQV\_\ :BZK'$T2I(_G
M>4UOM8Y01!CW?'%?-E% 'WOIG_!PW\6$\1:_>:Q\-_@3XLL]4\:2_$'2M,UW
MPQ<7EGX2UN49EN].!NA)&7DS*5E>5?,9F !)K"\&_P#!?_\ :%\"Z-HJ6>H>
M&6UK1OB;??%7^W9=.=K^^U2]M;BTN8)AY@@-H\-U,OE)$K ,-K@  ?$M=+\'
MO@]XH_: ^)VB^#/!6A:CXE\4^(KD6FG:981&6>ZD.3@#L  6+' 55)) !- '
MH_[8_P"VD/VP;S195^$OP7^%8T>2[G=/ 'AQ])&I27+1,[7+232O($,7[M P
M2/?)M4;C7K7A'_@MO\4?!WP/T7PM%X3^%-UXI\+^$9? FA?$6Y\/R-XQT/19
M$DB%I;W8F$2!(99(D?R3(B2, V236_\ !G_@@A\<I?VUO@[\,?BIX2N_ ^B?
M%'6VL?[:MM7TV^MU@MR6OEBN(9Y(/M4<:28@9O,++@1L1MJK\8?^"5=EXI_X
M+,?\,L_"V;5]#BO=872+2\\6ZYIFI31*L!GDNI)[$I P,2M(L"XF&1$5,HVD
M ^>/CW^UWXE_:*^%/PI\'ZY9Z);Z9\']"F\/:+)90R)/<V\MU+=,UP6D96DW
MRL 45!M X)R3Z5X._P""L?Q'\$^*OAGJ]KI'@R2X^%/P]U#X:Z0DMG<F.XTZ
M]CO8Y99P)P6N +Z7:R%$!2/*'#;OJ#PU_P &W?C?Q'^RU\8#IUM?>(OCG\//
MB/:>$M-TS3/$>DC0K[3I84D^TRRN^V.5O,7:KW$;*66-H_,.VOECX3_\$=_V
MD_C9\2O&WA'P_P#"S57UWX=ZBFD>(8K^_LM,AL+R0XCMO/N9HX9)9."B1NS.
M&4J"&!(!V_PI_P""Y/Q4^$GPG\,:':>$?A+J7B[P-X9G\'>&/B'J/AZ2;Q=X
M>TJ19$6VMKH3K$!%'-(D;-"S(KL ?F;/$6?_  51^(=CXS_9PUQ-)\'_ &O]
ME^""W\*H;2X\N_6&[^U+]N'GYD)?Y3Y1B^7I@_-7E_@W]D;XC^/?VFX/@UIW
MA/4/^%G3ZK)H:^'[MH[.Y6]0L'A<S,B(P*M]Y@..M>J^//\ @C;^TK\,_'OP
M\\,:W\+[ZRUOXJWDVG>&;?\ M6PE%[=P@&6VDD2<I;3H#S%<-&XP?EX. "IX
M0_X*B?$#P7X<T#3+72O"#P>'/C /C9;-+:7!>36ML*^0^)P#9X@3Y !)RW[W
MICVCX$_\'%/QF^ NLZO?VO@SX/Z_=ZCX^U3XBV<FLZ)>3'0]1U*427:6OEW:
M?N6(P/-\R1!]V0$ CA;3_@@G^UK=?$74_"K?""\L]9T:PL=2OEOM=TNSMK:*
M]9UM5:YEN5@$TC(P$&_S01@H,BK7PZ_X(=?&CQU^S#\:OB'=VFF>&=0^!VMI
MH6M>&M;O[;3]0DE$2S7!!FE15$<3QNN?]?OQ#YC B@#Q;X\?ML>*_P!H;]GO
MX6_#76['0+?0OA'-KDVCSV4$J7=PVK7HO;G[0S2,C!9  FQ$PO#;CS7LW@?_
M (+B_&?X<>+?@QJ^CVO@FV;X)^#9? -A:/IDL]IXBTB7'FV^I123,)@^%SY?
ME#Y%( (S7!_%O_@DS^T1\"?V>%^*GBSX8ZOH_@@06EU<7;W=K)<Z=#='%O+=
M6:2M=6J2'A6GB122!G) KUCXN_\ !"?XS:E^U)\2?!?PB\#^)O$N@?#S5[#1
MKR\\1:CHVE75E<7=C'=Q+<D7K6Z!]Q".LK(=T2DK)((Z +&B_P#!P+\7_!OQ
M)\'ZSX9\&_!_PCX?\ Z!J^@:!X.T30;BT\/Z<FJ "\N1$+GSGN'*JV]YF ()
MV_,V?$_@K_P49\<? CX$^"?A[H^F^%Y]%\!?%2W^+VGS7=K.]S-JT%O!;I#*
MRS*IM=ENA**JODM^\ P!Y%\6?A3XB^!7Q-U[P;XNTFZT+Q/X8OI=-U33[D#S
M+2XB8HZ'!(."."I((P02"#7/4 >]_&[_ (**>-_CY\'/'O@?6--\+V^D?$3X
MI3_%S4I+.VG2X@U:6"Y@:&%FF95M=MU)A&5GRJ_O."#X)110!]#Z3_RB>U__
M +*UIG_IGU"OGBOH?2?^43VO_P#96M,_],^H5\\4 %?0/[!__!1+Q)^P+_PL
M"WT?P=\/O'6C_$S0QX>UW2?%]E=75E<6HE67 6WN(&!+*,Y8C';O7KEE_P $
M9O$WQ:_8T_9>\:_"K^UO&WQ&_:&E\5@^&=UM:Q6B:)<2HQAEE= Q:&%W*L02
M1M4$D ^:?$'_ ()"?M'?"[XM?#WP-K/POU2'Q1\59YK7PO:6]_9W:ZG-"VVX
MB,L,SQ0R0G_6I,R-$.7"CF@#JYO^"U'Q4A_:?^'_ ,2]-T#X;Z!;_"O1]3T/
MPEX,TC19+'PMH4&HVEQ:W;16L<P?S9!<O(TC2EFD6,L650M7?!/_  7$^+/P
M@_9@T;X7?#WPY\,/AO9:;>:'J%WK?AW0I(-6URYTB:*>TGNVDF>!I#-#')*Z
M0HTS [RP9@WO6D?\&]-QX2\._LSZ/X^M_'NE?$?XS>*/$6C:UI6A:AHVK)%;
M6%H;BUDL7\Z.V9FVGS"]VRX#  ,NP_'?@S_@E[\<?B1^S2WQBT+P-/=_#=_M
M#6FJ3ZI86MQJ$=O,(9I(+.2<7,ZI(P5FBC=5;(W<&@#TKXE_\%K?&OC[XW^%
M/B7IOPG^ '@CXA>&?%L'C6?Q%X<\(O;:AK^H1JX;[9))<2%HI3(SR1Q>6'<A
MS\X##3^,'_!=+QQ\<?$?P_N-?^$/P N-$^'-_J^I:?X=/AR\ETJ[FU*&.*=K
MA9+QY796C66.19%DCDP0^%15Y_Q!_P $+OVE_A_XJ\$6/BWP##X<L/'/B:V\
M)VVJ/K^EW=K87\WS"&Z:"Y<6SA,MLFV$XP,D@5Z%\8O^"%'BG]F?PY^TLGC2
M;5M5U7X(V.E:AI%YX7N-*OM-U&WO+VZM!+>H;P7-MN:V.V)8GF')=%787 *7
MBC_@X<^,WQ'\=>-+[QEX/^#OCCPGXYT?3-$O?!.N^')KGP]:P:<TK69@07"W
M*21M/,P<SLQ+\D[4V_'7QT^++?'3XM:WXL;PYX3\(_VU,)1H_AC3%TW2=/ 1
M4$=O "=BX4'DDDDDDDDU[?\ &O\ X(U_M,?L[?"J+QIXR^%.K:-X>::SM[B8
MW]E//IDEV56V6\MXIFGL_,9T4?:$C^9E'4@58_:&_P""*_[3_P"RKX#N_$OC
MKX2ZMH^CV&J0:-<RPZA8W\EO<SR>5 'BMYY)%CEDPD<I7RY&90KDL,@'RW17
MM'[8'_!/CXN_L%7FAV_Q7\*P^%Y_$7V@642:S8:BY>#RC-'(+6>4PR()X28Y
M=C_O!Q7B] 'O_P"WS_S1;_LE6A_^UZ]]_9N^!/[.'PH_X)6^&OCC\8OAQXX^
M(6J>*/B=?>"Y!H?B[^Q3IEI#807(FCC-O*LS@L_RL4SN'S #%>!?M\_\T6_[
M)5H?_M>O3_V9O^"E_P +?A_^PQI/P-^+/P!O/BUH^@>-[GQO8W-OX]F\/(9I
MK6&V,$T<5I([H%C8DK*A._MC) /4_P!H_P#X(W:+\"!^TM9>';'6/'UIX4TW
MP5KG@/6Y-9BTV>PM/$-^D,"7EJ8RMS,WFK"=KQJI0R<!MJ^0:W_P1'^+VE?M
M1:9\';?6OA?JWCR>/49M9LK+Q3"R^$([""*>YDU1F"_9HQ',I5_F63:X0L5-
M;?C;_@M9K_Q@T[]HF'QKX(T_5U^/7_"*VD5O8:G)IUGX6T[0=1CNH+&!%1G=
M&AC$&X2(ZDF3+,<5[7XS_P"#E&/7OB7\.KZV^!T-[X8\(Z)KGAO6K7Q/XVNM
M?U[Q+IFJQ"*:R;6)($N(H8P%V!EE8%1EB>: /E?P9_P2D\:>/+[QG=Z=XZ^#
MS^!_ 4%A)K/CEO%D:^&X);XE;:V6XV;VN&*N#$(]R;<MM!4G4^*'_!%7XY?"
M?2?$EQ>Z?X>U"?PQXNT?P=<6>F:H+R>YGU>"*?3;J#8NR6UN%F14D#9WY4J"
M#CK/AQ_P51^%7@7PS\2OAO+^S;!=_ /XA/I5\O@^'QW=P:IIVHZ?N*7G]K&!
MVD:7S'$B&!5V[ H3:2WH/[/_ /P</:E\'OVX/B#\4=7^$NC^)O!7C#2]%T[3
M/ 1UM[>ST!]#DMFT2X6Y:"1YI;3[.WS%%+M,[97A: .2\)_\&XW[1WC#Q/K>
MEP1>!+>32O$MSX0M)KG7A%#KNIVZ;IX+0E,L(V_=F201Q^8"@8L"*X[P+_P1
M#^,/BOX0:=XUU;5_ACX&TK4_$MSX0@@\4^*8=-O'U6WOOL4]JL)!:1TDWLWE
M[@(XW8].?8?V9O\ @XP\5_#;]GV;P'\1?#?CCQD8_%>H^+;36?"?Q0U3P)J#
MSW\\ES=P7CV*L;J%[B620 E&4N<,.,?-7[3/_!0V]_:1_9*^&WPQN?#]S97G
M@#Q/XC\3RZ]/K<M_<:M+J]S'<%7$J>8&C*',KRR/(6W'!SD M?M _P#!)CXN
M_LN_#+XG>+/&]KH>B:7\*_&</@/41+?$RZEJ<L*W")9KL_>I]F=)]Q*_NW!Q
MGBN8_8W_ .2>_M ?]DSE_P#3UI%?57_!<?\ X*@_\-H? _\ 9V\$V?B+1]?U
M#2?"5GXF^(=]I+,8=5\4RVL5F6N&*KON8+6UC5F VJ;B15+!17RK^QO_ ,D]
M_: _[)G+_P"GK2* /#:**V?AY\/M;^+7CW1O"_AK3+O6O$/B*]ATW3;"U3?-
M>7$KA(XD'=F9@!]: +WP5^*VH_ CXR>$O'&D0V=QJW@W6K/7;**\1GMY9[6=
M)XUD565BA9 & 921G!'6NVG_ &S_ !3<?MY/^T.;'0?^$U?Q\?B*;,02_P!E
M_P!H'4?[0\KR_,\W[/YO&WS=^SC?GYJ^L_@'_P $'_$NB>&_VA/^%\Z?K/@W
M6OAC\)=8\?\ AN'0_$&E:A!?7EBQC,-T]NURNQ9%*O$&CE![K63^T3_P0&^,
M-E^T5XG\)_!WP/XS\5:+X0LM'GU:Y\17FBZ;<Z=)J%M)/&TOEWTD*PD12'S/
M,PF )"I*[@#S'X+?\%>OB%\'_&OQJOKKPI\,O'/AOX_:J^M>+_"/BG19;[0K
MF[-U+=1RQ(LZ31-%)-)L*S9'RDEF16'B_P :OVE=;^,/Q#\1ZW:Z?H7@+3O$
MLBO/X;\'VS:3H-N%A2'9%:JY4 J@W;BQ9BQ8DDFO=)/^"4WB_P  ?LZ_M$ZO
MX\\,^/-!^(GP)UC0-(N-'@@L)K**74[A8T%P_P!H$[;T=&A:UBF5]Z$D*P:H
M_$O_  0R_:F\'^,_#GA[4OA=]EUOQ4\L=E9-XDT@RPM%;&ZD%T!='[&1 #)_
MI/E\"@#Y+HK] _V4?^"''B6[^,WQ@\&?'_2/$_@34/!GP/UKXK>&VTC4K"ZM
M]7DM)+=+=OM$8N()[5C+)O$3AOE&'7O^?E 'K'[!G_)\OP8_['K1/_3A!7#_
M !7_ .2I>)?^PK=?^CFKN/V#/^3Y?@Q_V/6B?^G""N'^*_\ R5+Q+_V%;K_T
M<U '/T5]'_\ !)+]B#3/^"CW_!0CX??!C6=<O_#6F^,CJ/G:E90I-/;_ &73
M;J\&U7^4[FMPIST#$]J^\/V9O^#>#X0?M-?$OX%^(?#GQ(^)&H?![XPW7B71
MI+>_TZSTCQ/I^H:3;W;AD*FZMY8'DM6!(&5  SN?Y #\@**^G?%G_!&K]I;P
M+\8_!7@+5OA?>67B?XAV=Y?Z! ^KZ>;>^BLU+7>;D3FWB: #]ZDLB/'D!@"1
MF'4O^"/G[1ND_M"6'POG^&\P\7ZIH+^*;55UG3GTV32DSOOO[16X-D(%(VF0
MSA0Q52<L 0#YHHKZE^'7_!%C]IOXK^/O%WAK0OA?<W>J>!;^'2M8,FM:;;VD
M5Y-&DL-M%<RW"P7$SQR1NJ022,0ZD#YAGQ+PC\(+>Q^/J>"OB1J\WPQAT_4I
M=.\0WNH:5/=3Z"T)99E:UC'FO*K(4$?RY<@,R#+  X>BOIS_ (*]?L(:-_P3
M=_;?UOX5:!XAU+Q1I>EZ;IU_%J-_;I!/+]JM(YR"B$@8+X'/:OF.@ HHHH ]
M[_89_P""B_CS]@:]\6P>&K/PKXG\*>/]/&E^*/"?BK33J6A>((%+&/SX Z-N
MC+,4='5EW-S@D'KO%W_!6WQIK_@;XE>%])\ _"#P3X:^)NG:!I=WI?AGPZ^F
MVVEPZ-J3:E;&W"S$M))<.WFRW!FD=6QN7"D?6_QL_P"#?#X:>'_AWXWT[PA\
M5/&TGQ1^'WP>MOC+J%KK6@VR:!?:<\3/);174<WF1SCRWV[X]I^7DC<R>;_\
M%?O^"!/C/]A?QGXC\1?#/P[XM\2_!7PQHFF:C?:_JVI6$]];R7$:"5S!%Y4Q
MMUF;;YJP%%P0SDJ30!X3^T'_ ,%:OB3^TEI?Q&M-<TCP7:1_$[X@67Q'U4V%
MG<H8-1M+>2WCB@WSOMMRDA+*VYR0,.!D'<\>_P#!;3XS>-?$&L:Q;1^$O#FL
MZM\6K7XS+?:58SK+8ZW;V<EI''$)9I$-H8Y&W12*Y8]7VDJ>/^+O_!)']H;X
M%_!>U^(/B/X<W$/A6ZEL8#<66KZ?J5Q:R7H'V1;BUMIY+BW,I957SHTRS*OW
MB!6GXS_X(Q?M,> OBWX-\"7_ ,,+F3Q9X^>]CT;3K'6=-OW=K)(GNUG:"X=+
M4PK/$9!<-'L#C..: /4/#W_!P'\1?!WQ1UOQ)HGPA_9WT*W\5:5J.E^(=&TS
MPG<6ECX@-_/!/<7-T\=V+IYB]O'MQ.J1_-M1=QSQOQ]_X+4_%+]HGQ#\4M1U
M?P]\.].?XM^"M,\!ZM#I>FW,$-G86$T4T+6J&X81RDQ*&+;DVDA47@CQ/]J_
M]BOXG_L/>-[#P]\4/"L_AG4=7L$U/3V%W;WUIJ-JY(6:"YMI)()DR",H[8/!
MQ7T9KW_!.#X/^.?^"8/Q%^._PQ^)OCG6M8^$&IZ/IGB*S\0>&(=+T[5I-0E2
M+&G.EQ+(PC:3)\T*Q5"2B[EH ^(**** "BBOT(_X)Q_\$G_A-^U#^Q#IWQ9^
M)7CSXA^&[CQ'\8+;X0Z39^&M%M=11+NZM+6:WN9Q++&WE[[AE;R]S *N%;)P
M ?GO17ZK_%?_ (-D_&.E?LU>)_\ A74FJ_$OXQ>$OC%<^ KN&VU*PT[1)](3
M3DN8KH"Y*&.Y:6:",H;AAND\M59AN/R'\%O^"./[27[0FAZW?>%/AE=WW_"/
M:O?:!>6=QJ^GV.H?VA8KNN[6*TN)X[B>6(?>2*-SG(ZC% 'S)17N.E_\$WOC
M1J_[*-S\;H_!GE_#2U6=SJEQJUC;SRI!<"UFDBLY)ENI4CG81L\<3*K @G@X
MV?CO_P $FOVA_P!F7X%#XD^.?AEJN@>#T-LMU=27EI-/I9N0/L_VRUCE:XL_
M,W*%^T1QY+*.K $ ^=:*^UO^"1W_  3<^'G_  46\0OX6\0^)?BKH7BK5+R>
MTL+KP_X/CU'P_H4,5KY_VS5;V2>/RHF;<H5%)'EY+#>M?&>MZ:-&UF[LQ<6U
MX+6=X1<6[;H9]K$;T.!E3C(..A% %6OZU?\ @TS_ .4*?@3_ +#>M?\ I?+7
M\E5?UJ_\&F?_ "A3\"?]AO6O_2^6@#\J?^#U;_E*;X!_[)5IW_IWUBOR K]^
MO^"PG_!.SQK_ ,%Q?VW?$7CGP]JOA;P%9?":2Y^%;VVHW$]Y+J<FG7]W.;T%
M(5$:R"]4>7\Q4H?F.:^7/^(4+XI_]%/\ ?\ @/=__$4 ?E17[+^"?^"@7P-_
M8@_9R_8D^)NN)XZ\4?%WX7_#C7F\,Z3H-Y8R:')=7=S?VHBU4.XGM]IDWYB5
MF=2 5PO/G_\ Q"A?%/\ Z*?X _\  >[_ /B*/^(4+XI_]%/\ ?\ @/=__$4
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MK]5_^(4+XI_]%/\  '_@/=__ !%'_$*%\4_^BG^ /_ >[_\ B* /RHKVT_\
M*.-?^RD'_P!-@K[J_P"(4+XI_P#13_ '_@/=_P#Q%6_^(>WXI'0?^%(?\)UX
M!R+C_A.?[2\N[[K]B\C;L]MV: /R=HK]5_\ B%"^*?\ T4_P!_X#W?\ \11_
MQ"A?%/\ Z*?X _\  >[_ /B* /RHKZ/_ ."3'[=-I_P3>_;W\#_%W4M!G\2Z
M5X>-W;7]A;2B*Y>WNK2:UD>%SP)468LN2 =NTE=V1]D?\0H7Q3_Z*?X _P#
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M;T7$D8V2K# 9'C#D%I,*<#.O_P 0H7Q3_P"BG^ /_ >[_P#B*/\ B%"^*?\
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M^V]\-?BS-I)UVU\$:S'?75@K!7N8"K1RK&QX$GENQ0GHP4U]W?\ $*%\4_\
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MB)X\U+0- T/Q;KD&HO;/!,(;+-I=7%N;8#S;C#2!VW=3GB/^(4+XI_\ 13_
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MVX4 $$@L0#TRBBB@ HHHH *\H'_)\9_[$4?^G UZO7E _P"3XS_V(H_].!H
MXO\ ;+_:\\2?L^?$K0="T"V\#F.\\+ZWXHNY_$VIR:?"Z:=)8I]FCE16"O)]
ML)#,K >7T-;G@G_@H'\.?$OAF*[U*_U#P[?6^@V>OZU97VEW8'AV.YLX;R.*
M[G$7DQR%)E55+@R.&1 SJRCJO&_[.&D?$#]HCPE\0=3\B[F\(:+J6DVMC<6B
M31E[R>QF^T!FY1X_L048'25N1CGG/B3^QAIGQ-T_XIV]UKFHVG_"S+W3-1$M
MM$@DTBXT^*V%O)'NW*^);6.0AA@\KTYH SO&?_!1?X>^%_"EOJMK'XOU8GQ!
M8^'[S38/"FJKJVG27>XQ2RV#6WVI8V56*,8L2D;4+,0#VNF_M4^"-6^(D/A:
M'4=2_M::9;0-)HM]%9I<M#YXM'NFA%NEUY?S&W:02CH4SQ7":O\ L3ZAXCUO
M7/$^H>,TF\=ZSJ.A7RZA'HPCT^V31YI9;6 6GG%V1FN+DR$S[B9CM9 JJ'^"
MOV#M"\&_'N^\<FV\#ZG>:EJ[:]-=7O@ZVEUJVNWB".+?4-^^.(N"X5D=UW,H
MD"X  );+_@H-\/?#7@S1[OQ;X@M+/4;_ $9->N!I6FZE?6=M8M++%]K:3[,K
M16RM"^^698UCP"Y4,I/I?Q7^-_AKX*Z1IMYX@O+J-=9O!8:?!8Z=<ZE=W\YB
MDFV0V]M')+(1%%+(=J':D;L<!2:\=;_@G=IS_"[Q-X8_X2>]\KQ+\-9OAP\_
MV-=T$4C7C&Z W<N/M9^3./D'/-=[^T%^SA_PO+X+V_@S[?IEM;1QI$UQ?:3]
MN:,K&42>#$D;07,;$/'*K91E!P>E &PG[27@MXXC_;.UI]<;PW'$]G.DSZ@L
M)N#"(R@?_4*9=V-GEC?NV\UYIK__  4U^%D'P:\1^,M!O]9\2VWA_0H?$:VM
MKH6H13ZG8RLJ1SVPD@!GBWNJO)&&2$Y\PIM.,[P/^QUJNG?MG7GBK4-0U6[\
M)Z)X5L[73'OKF*>75==D@:RN]3D"_,)5L;:UAW,!O\^7 P*)_P#@F_IEQ\,?
M#_AK_A*M11/#_P *'^%D5REHF^2(BSQ>D$D!P;-3Y?(.\\\4 2C_ (*">'_#
MW[07B/2O$$NMZ7X3A\)Z%KNG-/X3U6*\M6NKO5X;J:]C,'F6D"+9VV7N4B1-
MQ+-AA7IVJ?M4>!-%^)P\(7.M21ZQ]LCTUW&GW36$%Y)&)([22]$9M8[ET9&6
M%Y1(P=,*=RYYKQ'^R9/XZ3XF7&M^)%FU3XH>![7P7?S6>G?9X;18#JN+B*-I
M7.3_ &HWR,YQY(^8[CC$LO\ @GUX9T?]H76O'MM9>"[JYU[78O$DLNK>$;6_
MU;3[Q(H8_P#1+]F#PQEH5D"E'979RCJ"  #?3]LCPWXS\,>&M9\)7T5UI6O^
M(=/T>*\U;3-3T^"_BNMVR6R=K4BY#@9CD7]PW>5:['X,_'SPO^T#H4NJ>$[N
M_P!0TQ"ICO)M*N[.WO4;)66WDGB1;B%L'$L)=#V8UY3X:_8$M]&O%N&US3K'
M'B;2_$WV+0M#&F::;BR>9VD%MYTBK/<&;]]*I ?RH_D!!)[3]G+]FH? 36_$
M]^+[27;Q,T$DUGHVC_V1IR2QF8O=?9Q+(OVF8R_O9%VA_*C^0$$D ]4HHHH
M**** "BBB@#Q/4O^4C6C?]DWO_\ TYV5>V5XGJ7_ "D:T;_LF]__ .G.RKVR
M@ JGXA\1:?X1T&]U75;ZSTS2]-@>ZN[R[F6&"UB12SR2.Q"JBJ"2Q(  )-7*
M\;_;-B\2^*?"WA?PAX7T1=5NO%GB&VCOI[N*;^S=/LK7=?3&ZDC4[(YOLRVP
M!Y9KH =\ 'I-M\2?#MYIF@7L.OZ++9^*V1-$G2^B:+6&>%[A!;,&Q,6ACDE
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M2UJG5S_@F3_R<)^TG_V,&B?^F2UH \-_9,_Y*)^T3_V6?Q+_ .C8J]FKP_\
M95_8W^'W[0/Q(_:)UGQ5I>JWNHV_QF\2V<;VVOZC8((EEB<#9;SQH3ND;YB,
M\@9P ![%_P .Q/@Q_P!"_P"(?_"QUK_Y+H O451_X=B?!C_H7_$/_A8ZU_\
M)='_  [$^#'_ $+_ (A_\+'6O_DN@"]15'_AV)\&/^A?\0_^%CK7_P ET?\
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MOB.E:E)@%KHE3NC7YEP>",X)!T,3V>BJ/_#L3X,?]"_XA_\ "QUK_P"2Z/\
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M.M?_ "71_P .Q/@Q_P!"_P"(?_"QUK_Y+H O451_X=B?!C_H7_$/_A8ZU_\
M)='_  [$^#'_ $+_ (A_\+'6O_DN@"]15'_AV)\&/^A?\0_^%CK7_P ET?\
M#L3X,?\ 0O\ B'_PL=:_^2Z /-K_ /Y/CTK_ +$6]_\ 3A:5ZO7CE_\ \$YO
MA&G[<&E:2-#U[[#)X&O;MD_X2S5]QD6_M$!W_:MV,,?ESCOC(%>J_P##L3X,
M?]"_XA_\+'6O_DN@"]15'_AV)\&/^A?\0_\ A8ZU_P#)='_#L3X,?]"_XA_\
M+'6O_DN@"]15'_AV)\&/^A?\0_\ A8ZU_P#)='_#L3X,?]"_XA_\+'6O_DN@
M"]15'_AV)\&/^A?\0_\ A8ZU_P#)='_#L3X,?]"_XA_\+'6O_DN@"]7B:?\
M*1J3_LFZ?^G-J]>_X=B?!C_H7_$/_A8ZU_\ )=>*I_P3N^$Q_P""BTNB?V'K
MO]FCX<)?>7_PE>K[_-_M-DSYGVK?C;_#NV]\9YH ]XHJC_P[$^#'_0O^(?\
MPL=:_P#DNC_AV)\&/^A?\0_^%CK7_P ET 7J*H_\.Q/@Q_T+_B'_ ,+'6O\
MY+H_X=B?!C_H7_$/_A8ZU_\ )= %ZBJ/_#L3X,?]"_XA_P#"QUK_ .2Z/^'8
MGP8_Z%_Q#_X6.M?_ "70!>HJC_P[$^#'_0O^(?\ PL=:_P#DNC_AV)\&/^A?
M\0_^%CK7_P ET 7JN?\ !,G_ ).$_:3_ .Q@T3_TR6M8O_#L3X,?]"_XA_\
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MER!Q3S\+/#!\=_\ "4?\(YH/_"3>7Y/]K_V?%]OV8QM\_;YFW'&,XQ0!\_\
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M._/R[WZ<DNW<_4.$/#.6>X#Z\L3[/WFK<G-M;KSQ[]C[Z_X;'^%?_10/"O\
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M'Q3^'<\EC+Y]L\FI0LUO)L9-Z$_=;8[KD<X=AT)H ^2/'?@CQ%^R#8>$=?\
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M*\3_ .'D/P%_Z*YX#_\ !M%_C1_P\A^ O_17/ ?_ (-HO\: /;**\3_X>0_
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M'D/P%_Z*YX#_ /!M%_C1_P /(?@+_P!%<\!_^#:+_&@#VRBO$_\ AY#\!?\
MHKG@/_P;1?XT?\/(?@+_ -%<\!_^#:+_ !H ]LHKQ/\ X>0_ 7_HKG@/_P &
MT7^-'_#R'X"_]%<\!_\ @VB_QH ]LHKQ/_AY#\!?^BN> _\ P;1?XT?\/(?@
M+_T5SP'_ .#:+_&@"SJ/_*0/1_\ LGM__P"G*SKV.OCN_P#^"@7P2?\ ;DTK
M5!\4O!1TY/ M[:M<_P!IQ^6LK:A:,$SG[Q56./0&O6/^'D/P%_Z*YX#_ /!M
M%_C0![917B?_  \A^ O_ $5SP'_X-HO\:/\ AY#\!?\ HKG@/_P;1?XT >V4
M5XG_ ,/(?@+_ -%<\!_^#:+_ !H_X>0_ 7_HKG@/_P &T7^- 'ME%>)_\/(?
M@+_T5SP'_P"#:+_&C_AY#\!?^BN> _\ P;1?XT >V5X)'_RE!E_[):G_ *=G
MJ_\ \/(?@+_T5SP'_P"#:+_&O$D_;[^"H_X*.2ZS_P +0\%_V4?ANEE]K_M.
M/RO/_M1G\O=G&[;SCTH ^V:*\3_X>0_ 7_HKG@/_ ,&T7^-'_#R'X"_]%<\!
M_P#@VB_QH ]LHKQ/_AY#\!?^BN> _P#P;1?XT?\ #R'X"_\ 17/ ?_@VB_QH
M ]LHKQ/_ (>0_ 7_ **YX#_\&T7^-'_#R'X"_P#17/ ?_@VB_P : /;**\3_
M .'D/P%_Z*YX#_\ !M%_C1_P\A^ O_17/ ?_ (-HO\: /;*\\_87_P"3L_VF
M?^P[H/\ Z8[6N6_X>0_ 7_HKG@/_ ,&T7^-6/^"9?Q8\-?&?]HG]I37/"FN:
M;XATB?7]$2.\L9Q-"Y71;96 8<<,"/PH \-_9,_Y*)^T3_V6?Q+_ .C8J[;4
MOV@/!.C_ !,A\&W/BC1H?%,Y15TQKE?M :12T:E?X6902JG!8#(!KB?V3/\
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M 0&1P&1N>58 @\$ T 3T444 %%%% !7E _Y/C/\ V(H_].!KU>O*!_R?&?\
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MP53,*]!QA"UT_BM_-OK%=>V^JNU])T4B.)$#*05(R"#P12U].?)A7D?[4/\
MR.GP8_['V/\ ]-6IUZY7D?[4/_(Z?!C_ +'V/_TU:G0!ZY1110 4444 %%%%
M !1110!YS^V%_P FD?%+_L4-6_\ 2*:NL^''_)/-!_[!UO\ ^BEKD_VPO^32
M/BE_V*&K?^D4U=9\./\ DGF@_P#8.M__ $4M &U1110 4444 %%%% !1110!
MY1?_ /)\>E?]B+>_^G"TKU>O*+__ )/CTK_L1;W_ -.%I7J] !1110 4444
M%%%% !7B:?\ *1J3_LFZ?^G-J]LKQ-/^4C4G_9-T_P#3FU 'ME%%% !1110
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M:K&=Y=D:EVW[A0!]'5#J.HV^D:?/=W<\-K:VL;3333.$CA11EF9CP  "23P
M*^5;#]CI_AYXYU76O#]MXQCFT/XA:.WAV)_$-]<6UIH\D.FC4?+BDF9#&[S:
MB9-P))'^PF/)="_9:^)_Q"\._$#1/%MGXPE\5:IH'B:PU.7:RZ-XGEN3(=/)
MN7U%T(4^281%;1F%-\3;%W!@#]![>XCN[=)8G26*50Z.ARKJ>00>XKG_  '\
M4M)^(^K>)[+3'F>?PAJYT341)&4"W(MK>Y(4_P 2^7<Q<^I([5\*>.?A1XPO
M/AYX<L/"7PH\<>'FT3PE:MH,K37<EW:ZNMS<M=*RKJ<4%H4*Q2B5XYC.DVP!
MA&L1Z/4O@/XS@_:^\1ZEHOA'QY8Z]J?Q6TW7K3Q/'JAAT)?#\=GIT6HQ2Q>>
M%8RI!<1;#"6=WA8,1%F, ^V?&7BNT\!^#]5US4"ZV&C6<U]<E%W,(HD+O@=S
MM4\4SPYXUTSQ9+-'8W2336L<,D\71X1*@DCW#ME2#7P=X%^ WQ4N=,6"X\.^
M/[3QC'X:\26GQ#U74]8-QI?C"YGM94LULHC<.K;KADDAVQIY$*M$VTMM/=?'
MKX5>,;S3_$!;2/'=]9IJ.A7-E8:3%]IMM1\G298I(+J);JWD-MY[*6\J0$3)
M"Q!56H ^S*S-!\%:-X51ETS2=,TY7N;B\86MJD(:>XD,L\IV@?/)(S.[=69B
M2237QY\<?V8_&GQ0T?Q!XA?3_&FB>,K:U\(KHR:1XHO,Z5()HAJBP2+*%E98
MFD225P2ZJ#DU[?\ L>_#'5?@_>_%/09XM8@\,V_C-I?"J:A>RWFW3I-*TV1_
M*DE=W,?VUKW@MPV\#C% 'L]%%% !1110!XGJ7_*1K1O^R;W_ /Z<[*O;*\3U
M+_E(UHW_ &3>_P#_ $YV5>V4 %%%% !7R?\ M0_L^_$SXL_$;XA>,?#EQHUI
M=^$]*L+'PAI^I:5)<OJ5S9RP:RTL,ZW,:PK<7:6MLY:.3_CQSC'7ZPHH ^8O
M"WC2\@\:?%*R\1?"OXAZAIWQ+DM-12WM]-22!X)- L8)K664RHJ2B2*6(@D
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MA_\ R97U710!\J?\)7\6?^B#^+/_  HM#_\ DRC_ (2OXL_]$'\6?^%%H?\
M\F5]5T4 ?*G_  E?Q9_Z(/XL_P#"BT/_ .3*/^$K^+/_ $0?Q9_X46A__)E?
M5=% 'RI_PE?Q9_Z(/XL_\*+0_P#Y,H_X2OXL_P#1!_%G_A1:'_\ )E?5=% '
MYX:AXE^)I_X*#:0Y^"_B87X^'E\JV/\ ;VC^8T7]I6>9=_VK9@-A<;MWS# P
M":]D_P"$K^+/_1!_%G_A1:'_ /)E=AJG_*4'0_\ LENH_P#IVL:][H ^5/\
MA*_BS_T0?Q9_X46A_P#R91_PE?Q9_P"B#^+/_"BT/_Y,KZKHH ^5/^$K^+/_
M $0?Q9_X46A__)E'_"5_%G_H@_BS_P *+0__ ),KZKHH ^5/^$K^+/\ T0?Q
M9_X46A__ "91_P )7\6?^B#^+/\ PHM#_P#DROJNB@#Y4_X2OXL_]$'\6?\
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M&_HI S@'(] !S3MI?^OZ_KJ'6Q\J?\)7\6?^B#^+/_"BT/\ ^3*/^$K^+/\
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MT/\ ^3*^JZ* /@.^\3_%#_AM/2W/P4\3B\_X0F\5;3^W]&WM']NM<R;OM>S
M.!C.?FZ8S7J/_"5_%G_H@_BS_P *+0__ ),KTC4?^4@>C_\ 9/;_ /\ 3E9U
M['0!\J?\)7\6?^B#^+/_  HM#_\ DRC_ (2OXL_]$'\6?^%%H?\ \F5]5T4
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M>(?$WA_QU_:7B#P^VO>-D\-M-=V.F/9V\4VF3+-(4BWNR([!MB[V*YY8G)H
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MK8ZIJ2W8^SV<MU+'%;;FZ;)7EC"2#*-NR&(R:^4?V8/^"<'Q*\9_LM^"M/\
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MVBBBB@ HHHH **** "BBB@#R_P#;=_Y,O^+O_8E:S_Z0S5V?PO\ ^29^'?\
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MEE-9WTES))'!;SQP3&X0PQDW"OY7V=657W%11T?]AKQGH_@WXL>!(_%WA8^
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MZG:ZA]A^'_AGP:WDQLNZ72OM_F3#/\,GVQ=HZC8<]:\[_M+X]?\ 14? ?_A
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M;_M+X]?]%1\!_P#A R__ "QH_M+X]?\ 14? ?_A R_\ RQH ZG5/^4H.A_\
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MJ2BOEO\ M+X]?]%1\!_^$#+_ /+&C^TOCU_T5'P'_P"$#+_\L: /J2BOEO\
MM+X]?]%1\!_^$#+_ /+&C^TOCU_T5'P'_P"$#+_\L: /5/VW?^3+_B[_ -B5
MK/\ Z0S5V?PO_P"29^'?^P9;?^BEKXV_:VU#XX-^RI\31??$KP1<V1\)ZK]H
MAB\#21/+']CEW*K_ -H-M)&0&VG&<X/2NJ^'NH_'<> =#\KXG^!4B_L^WV*W
M@.1BJ^6N 3_:(S]<4 ?7E%?+?]I?'K_HJ/@/_P (&7_Y8T?VE\>O^BH^ _\
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ML))2H=@%#J5PW3Z]^VAX2\/^'Y;V2#6)I;:^URRGLH8HFNK?^R8KB6YF=?,
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M;>\M;6^AO+>SLC<M<13P7CM!$H#?ZR)I'*,"D8VN>LTC_@GSX=TG2?AQH_\
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M/7O^^;;_ .-5Y'_$4N'_ .>7_@#/9_XA+Q'_ "0_\#7^1]>T5\A?\+/\9_\
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M_P#T4M &U1110 4444 %%%% !1110!Y1?_\ )\>E?]B+>_\ IPM*]7KRB_\
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M-1\)75G!?";P3J6KZKIA>Y+!)]3>=[HN/X@6N)-H_AR/2O2J "BBB@ HHHH
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M&A/EKN?Y9"%R0#V;PS^T?X2UKP-X7US4=6L/"X\7V\=QIUEK5_;6]U-O (0
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MFKK/AQ_R3S0?^P=;_P#HI:Y/]L+_ )-(^*7_ &*&K?\ I%-76?#C_DGF@_\
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MV/\ AMCX=?\ 03UO_P )K4__ )'H_P"&V/AU_P!!/6__  FM3_\ D>OTGHH
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MZ_2>B@#\V/\ AMCX=?\ 03UO_P )K4__ )'H_P"&V/AU_P!!/6__  FM3_\
MD>OTGHH _("^_:C\'2?MS:7XB$WB Z+#X$O-->[_ .$:U+8MP^H6LBQ_\>^<
ME$8].U>L?\-L?#K_ *">M_\ A-:G_P#(]?I/10!^;'_#;'PZ_P"@GK?_ (36
MI_\ R/1_PVQ\.O\ H)ZW_P"$UJ?_ ,CU^D]% 'YL?\-L?#K_ *">M_\ A-:G
M_P#(]'_#;'PZ_P"@GK?_ (36I_\ R/7Z3T4 ?FQ_PVQ\.O\ H)ZW_P"$UJ?_
M ,CT?\-L?#K_ *">M_\ A-:G_P#(]?I/10!^;'_#;'PZ_P"@GK?_ (36I_\
MR/1_PVQ\.O\ H)ZW_P"$UJ?_ ,CU^D]% 'YL?\-L?#K_ *">M_\ A-:G_P#(
M]'_#;'PZ_P"@GK?_ (36I_\ R/7Z3T4 ?D+^RY^U-X-\'?\ "Q?[3G\06?\
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M@C_CW]:_3RB@#\V/^&V/AU_T$];_ /":U/\ ^1Z/^&V/AU_T$];_ /":U/\
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MK?\ X36I_P#R/7Z3T4 ?FQ_PVQ\.O^@GK?\ X36I_P#R/1_PVQ\.O^@GK?\
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K\5OVA=>TV/4?[)U/Q!I!M+BZT^>S%P$TBWC<H)D1B ZLI..HK[6HH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tm229830d4_1012b-img03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm229830d4_1012b-img03.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #8 I@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH CF4-#*I) :.121G(!4@D8*G//&"#GH0>:_(WQ?<_MD^*_P#@HU\?_ W[
M._[0_P (/A=X'\*?L2?L,>+[[PG\>?@;\4OVC_#4WB#QW\<_^"AVE7OB7P1H
M7@?]K#]FO1?A[XAU/3/ >BZ/\1-8F@\<:G\1M*\.?#R$ZOX='@F"2?\ 7.0@
M1R$D !&))Z !2<GKP.O2OS+T[6+K0O\ @HY^W5KNE^'=4\::EI7_  3I_P""
M>NL:3X0T*XT.UUSQ7J&E_'?_ (*M7D'AW19_%&M>&O#,.JZQ+$FGZ;-XC\1^
M']"2\N8&U?6]+T\7-] 2E&-+$5:EU1PM"IBYM7_Y<IMZ[:17-U=DW;34]G.I
MRPC[)U)UL/1P:KU%0P_U_$UZ6'P_M,0VO9INHE=RC%+WG**4I1Z(?#O_ (*D
MJZ1I^V#^P4B>8F'3_@FS^T2(>6 !8_\ #UXEQUR%<'&0I&,UH_\ "N/^"I7_
M $>5^P'_ .*U_P!H_P#^FR5^"/[&'_!7;]MKXT_\% /AY^SOXUATC7_ ?BCX
MD^,O"^I^%=(\"^#M(\6:-IND:/XJNX=:U#63XFT/28K;PO8:'-XHUV'3-3U'
M4]8L](NHO"FF^)KA[6RNOU6_X*9?%7]I;5-<^'/P$_8R\*?&_P =_$W0-,O_
M -I/QW#^S_XP^#?A35]+T'P4L]A\"O _Q U#XJ_M ? UX_A7\9_BS;W$GC2S
MT"_U;4/'7P\^&GQ'\):=;275VT1^8X5XPRGC3 XC,<JYN7"XN>!Q*DGS*O3C
MSQ>JNU*G=Q=VG9M65K_NOCQ]'CC_ .CKQ7E'"7B'+AEYQG_"^4\7X7_5GB*/
M$%&&6YM%JA',)JG0G@,8I)<N&E14:M!K$4:M>G[Z^ES\-_\ @J201_PV3^P&
M<@C _P"":_[1V3GL/^-L9Z_0_0]*9_PK?_@J3NV_\-C_ + N0O!_X=K_ +1A
MQ@="/^'KY/;!(8#V'2ORD^*?[3'_  3E^*7@OQW\8]3_ &^O$/P9_:.\5PZ%
MKNA? Z?_ (*O?M$_ [7O"$%QI/AE+7PQ+^RIX2_:Q\!^"O#5YI.C7+7]WINC
M?#[3FN]2_MC6K>&XF0ZO=8ES\3O^"0G_  TGH^A1_P#!5_5A\))?@CXDU?4E
M'_!?S]K?^S1\1K+X@Z!8:#%)XK'[?TTO]JR>&KO61%X>&NQ"YC!U<Z66LW\K
MZF-/GDGVT6NNOS_#]#\'Q-X5*%!J[J58O9Z<K4;WVW:LV['ZZK\./^"I Y'[
M9'[ GS.!_P HV/VC#R3UX_X*P#C.#MY/3YAS4K?#;_@J7M./VQ_V W.#A&_X
M)L?M'HK\?=9_^'L$FP-T+>7)M!SL?&T_G/\ \$R?B1^Q?XQT_P#8PO\ X7_M
M[^)?V@/VJ?$_PU\/ZI\7_AOK'_!4GX^?M/:I>-=?!76KSQQJGBK]FGQM^TE\
M1_!>@3:9XRM;>:\NV^'NF:CX&\0/IUJM_H\LQT:\_H<K2M!PY=;W4FO1-+^O
M*SZ@ZG-BL72O?V$Z4&[6OS4G*Z\M-'UUL?EAX*_9_P#^"I/A'Q)\3_$?_#>G
M[(OB?_A:WCNQ\>G2_&O_  3W_:/U[1OAX;/X7_#/X7Q>$?A3I1_X*C6;>!_
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M_P"&]/V1?$__  M;QW8^/3I?C7_@GO\ M'Z]HWP\-G\+_AG\+XO"/PITH_\
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M/_%:W[1__P!-CK] Z* /S\_X5M_P5+_Z/)_8$_\ %:W[1_\ ]-CH_P"%;?\
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M?1VU/6****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4R6+WA8,R>MTI^RYY^S[^]Z]/P"G[7DC[3M[G?EZ_CL%%%%26%%%% !1110
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MQ?'&"^K<)^'6:2G3H8?AVMQ?QI@92R^O1>(\V\%?MG>*9O!6GGX1_P#!.?\
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MGB?XG_"WQE>?M1_L[^#[&]UO6O@Y\9?%44?QF\"Z!%&Z6$/PM^-5Y%/<^/\
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M @^_M5FJ"2=?>X0?FV"/P_QYJ_7Z?&#A3IP_E4E]TG?\S]AI6G%UE_R^;?\
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M\.Q'4_%D&C1^%OA?X?C.UM?^)WC"]D\#_#C0D<GYKC7?&>J:=:1EL(KR(20
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M3ZR?R-3O]QO]UOY&H.\GUD_D:PK?"O\ K[A?_4B)-3>'IB/_ %'/Y(OV^O\
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MA>*7_8?P'_[\Y_+-_P '<_\ REE^#?\ VCI^&W_K2?[2]?S%U_3I_P '<_\
MREE^#?\ VCI^&W_K2?[2]?S%U_K-^Q__ .4-LM_[.?XE_P#JTR8_K7Q!_P"2
MAJ?]@V'_ /2 K_40_P"#83_E"#^Q3_U\?M.?^M>_'JO\N^O]1#_@V$_Y0@_L
M4_\ 7Q^TY_ZU[\>J_D;]N;\/T8/^QIXI?^J/(#Z#PQ_YFWI2_P#3<C]]1U3_
M *ZM_-*MU4'5/^NK?S2K=?X T_BE_AC_ .G,2?IT/X=/_"_S84445J4%%%%
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M 4445904444 %%%% !37^XW^ZW\C3J:_W&_W6_D: /S_ /\ @FI_R;O\1/\
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M>" PQDX/!_#/(XJ6I]WECRWMRKO_ %L='NZ<N_VO7S^04444""BBB@ HHHH
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M/QYXL3]O222\DUF+]HK5](\2:K<Z3H)D7PD6\,?'O6+;]D#[*?%4%KX>FO\
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M3E]9KNKA\+3@OXL,36J;X$_/'_@H5X<T7]J*Q^'O["-G;ZA+J?QV\5:5XO\
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M44 %-?[C?[K?R-.IK_=;_=;IMST/3=\O_?7R^O&: /S_ /\ @FI_R;O\1/\
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MLY_!7_Z\+_T]3)G\%7UPWYY@?RB?\%=/^4X__!4#Z_L<_P#K(/PSKX@K[?\
M^"NG_*<?_@J!]?V.?_60?AG7Q!7\&^.7_)S<_P#^P?)__5; _P POI'_ /)Y
M>+?^O/#G_K-Y8*O4?4?SK^Z#_@V(_P"4(O[%_P#U^_M,?^M<?':OX7UZCZC^
M=?W0?\&Q'_*$7]B__K]_:8_]:X^.U?I/T<O]RXY_P9)_Z>JG[3]#OX?$?_NS
M/_4OB(_?./\ @_X!_P"TZN53C_@_X!_[3JY7]7/XI_\ 7R?YH_M2G_#A_AA_
MZ9H#7^XW^ZW\C4'>3ZR?R-3O]QO]UOY&H.\GUD_D:PK?"O\ K[A?_4B)-3>'
MIB/_ %'/Y(OV^O\ E8L\/_\ :&'P_P#^MP>-Z^AJ^>?V^O\ E8L\/_\ :&'P
M_P#^MP>-Z^AJ_O#Z/G_)M\+_ -CSB#_U-I'^;7TJO^3N8C_LE^%O_43,!&Z'
MZ'^5>Q_\&PG_ "@\_8G_ .O[]J'_ -;!_:!KQQNA^A_E7L?_  ;"?\H//V)_
M^O[]J'_UL']H&OS_ .DWMPK_ ->LT_\ 3V"/U'Z'?\#C_P#[".%__2\Q/Q!_
MX+Z_\IP?AU_VBE\!_P#K7_QIKX#K[\_X+Z_\IP?AU_VBE\!_^M?_ !IKX#K_
M $E_9^_\HZX#_LM^./\ U99>?R5].3_D^N(_[([A7_TSFP5_5K_P;&?\H0/V
M)_\ KY_:9_\ 6P_C[7\I5?U:_P#!L9_RA _8G_Z^?VF?_6P_C[7\^?M,_B\*
M/^P+C7_WDG[3^SV_A>*7_8?P'_[\Y_+-_P '<_\ REE^#?\ VCI^&W_K2?[2
M]?S%U_3I_P '<_\ REE^#?\ VCI^&W_K2?[2]?S%U_K-^Q__ .4-LM_[.?XE
M_P#JTR8_K7Q!_P"2AJ?]@V'_ /2 K_40_P"#83_E"#^Q3_U\?M.?^M>_'JO\
MN^O]1#_@V$_Y0@_L4_\ 7Q^TY_ZU[\>J_D;]N;\/T8/^QIXI?^J/(#Z#PQ_Y
MFWI2_P#3<C]]1U3_ *ZM_-*MU4'5/^NK?S2K=?X T_BE_AC_ .G,2?IT/X=/
M_"_S84445J4%%%% !1110 C=#]#_ "I@QO&/3IZ<?X8HF8+%*QW86-V.Q"[X
M"DG8BJY=N/E0(Y8X 5B<'\QOV_OVSOBM^RMJ?[*FC?#3]GKXK?&S5/CQ\=3X
M$\16GPPL_A1K%U:>&?"GPU\5_%#Q?HFFV_Q5^-'P>L+/Q-XE\.^%M7D\*WNH
M31:'!:>%O%TWB.]T75Y/!&D^-N;$RY?8+^?$4X_*]_S+C"\92_E37WJY^FZ]
MC_M+_7_&IJ^"_P#@G9^TA\1?VMOV1?@A^T%\3/A[KGPV\4?%3PY%XV&AZY%X
M;M5FT'7-2U&]\,:UHD/A_P 5>.;5?#^O>%+C3;K1%O;W2O%#6:7#^)M#\,W\
ML=DWWI774HNC5J*33;Y+M;>[&W779]3&%15.:WV)6^]7_0****DL_-O_ (*E
M6_A>Z_8F^*FG>+/$?Q3\)IJE_P#"S3_#E_\  FW\+S_%NY^)=]\7O L'PRT'
MX>1>.9+;P38>(/$/Q.D\+:38ZSXSOK/POIES?QZCXCO(M(M+EQYO_P $M_'?
MQ[U[PY\9/ O[4/CG]H[6_C_\./&WA.#QEX"_:0TG]E"'Q)\.]'\3^$8]3\-R
M^'O$O['>G:9\)?%_A7QI86U]K,4PU+6O$NE:O:W,6LH)4W3^V_\ !1N;P[%^
MQS\=+?Q=/X/@\.:OX;@T;68OB)\ ?B'^U5X/O--U3Q+X8L+^TUC]GKX4WVD?
M$KX@R7-K)<PV.D^"-6TYK&X=/&-Y?VT&G2SP?"W_  0LNH[7X9?M">&= \)>
M"=-\":)\5_#<OAKX@> _V0_C_P#LCV'Q1U;7?A]H^I^+]6\2>%OVD_&'C#XL
M>+/%7A:^AM?!,OB_Q!>PV"^'M%\*:5I0FAC"A9?;VV>O33%8+\<)+K=NUG;9
M:6NWN9YC?V&2Z/\ W?%VOL_]II7<?=6G>\I^\M%!>Z_WHHHHI+>7JOR+6R]%
M^05^?GPZ_P"4I_[8O_9@7_!-G_UHG_@JK7Z!U^?GPZ_Y2G_MB_\ 9@7_  39
M_P#6B?\ @JK5#/T#HHHH **** "BBB@ HHHH *1@2K ':2" PZ@D8!_ \TM%
M '->)?#OAKQEH&J>&?&&@Z'XD\,Z[8WFGZYX<\26%GJFC:OIMU%);7]CJVF:
MA#<6.HZ;>6LDUO?V=Y;RVMS:RRP7*2PR/&W-?#KX4_#3X0>'K?P9\(OA_P"!
MOAEX-L;M[F#P;X \(^'O!7AJSN;F17N+V'1?#VD6=J+VX;+RW2)&)F4,\GRE
MJ]*HH **** "BBB@"*89AF&,YBD&!U.4(QS@?G7SC^TU\;;3]G7X'>//BB;
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M+V.QTKQ?IFGPVVJV<.G:GXA\+_VYH-IX@EO-3M]&N;Y-4%AK#6JV-Q\R7O\
MP3=_X5]\6M ^+?[,GQGUGX:7VE^#O#'AKQ!X;^.*?&[]J_0/$\GP[\0V.M_#
M76-.C\9?M$^%_%7A%/!NDW?BOPO;>'O!^MV'AM[;QA/%_8A6+[/+^HB3)*Z2
M02ILD:VPC@?=\X,^W/ >2,2;2.000.2*VEV\X&#W_P#K?Y]*^OIM4_:.@VJ=
M6-'#58MM*+RVD\#&"BU]F*E&]W>RVM<_FRKB?[0K5,3&.'HT)XS'XVAA\.DU
M&6;8N>9U\1*7Q...J8B->BI?#2II123=_P D_CI_P36U;]JJP^*?B+]HOXNZ
M#=_&OQ5\%7^"GPY^(?P0\&_&WX)>%/AQX4N)O%-_J:Z_\-K/]J[Q7IWQ<@US
MQ%XBMM9U#1_%WB2ST&[L_#&@:9J^E/8F[BGW/"_[ GQ*\.?M7_#_ /:%N?CY
MX-\<>$/A;X-\,?#/X4?##XM?![XG_$C6_A5X-L+.TL?'MS\-_B5K7[3EM]E^
M)?CJVM[N#4/C#XQ^'WC'Q+'IUW!H<_\ :>@6R:=<?J>2@/0Y![>OYTI88X;!
M],?_ %NOXXHHU*>&]I3I6BZ\N>>SO)1<+WM=>Z[:/5;WT*J/VW(I*_)%Q6VU
M[OH+M4=OU/\ C3JB#,2.>X[#_"I:MWZW\KDJ"ALK7U"BBBD,**** "FO]QO]
MUOY&G4U_N-_NM_(T ?G_ /\ !-3_ )-W^(G_ &D _P""L/\ Z]+_ &S*_0*O
MS]_X)J?\F[_$3_M(!_P5A_\ 7I?[9E?H%0 C=#]#_*HG&Z+''.1\PW+SN'S+
MD;AZC(R.,BI6Z'Z'^502EE@9E5W8*Y5(_+$C, Q"QF5DB#L<!?-98]Q&]@N2
M)E\+]/\ (3/GC]I?Q=XB\#_!SQ/XD\)Z_K/AGQ7#=>'[3PS>:/X @^*.I2^(
MM?\ $NE:/HNA_P#"%7/B'PE9:_9Z[JM];Z3<)<>+_"4%I:733R^)=%CC;4+;
MYJ_9!^.W[:WC+7[/P7^UA^SAX%^'UW=6-]JUKXF^'OQ#T?5?$GA^RMVD?1/^
M%V?!O2_$_P 5?#WP;UGQ?C4;?0]/\%?M*?M'P75]HFLPW_B>."*2_L_'/^"K
MOPY\-_$[P1X*T7QG\+M ^)6C: EUXVBN-:LK6\7P5KWA?XB?"K6M!\7Z9-J7
M@3QNVJ1?:X8O#>J^&Y[270M8M?$J:;K%M=63%&V_^"56@Z1I7@GXK2Z1X,\*
M>%)[GQYI)U&;PUX&\.>!1K:1:$GD3WJ>'_AKX$BU-[55Q"3;R>61(!);K*ZS
MO!_P<0^TXK_RDQ8Q6>$\Z4W_ .58K]/Q/UK;H?H?Y5&PP%'U_7]:=*,QR#.,
MHXSO:/&5//F)\Z?[Z_,OWEY K\./VM/V'/!'Q:^/?QT^*7PT_96^&?AOXX_#
M;]E+XB>.? G[0^E_ [PKH'Q5^+'[4?Q;\ ?$+X7_  TME^-FE^']#U_QA+\(
M/"WA,:CJ/ANX\1WCZ#XA\=^ =4=8H?"WA)4B57EG"G;X[R^YV-*=+G:E>W+&
MU_*R>VFK_KN?N!<?\>TO_7.7_P! :OP#_P"#7W_E!C^P_P#]<?VD_P#UKGX_
MU)^SC\ _$GB+X6?M4>&/^"<DOC7_ ()A>&?&_A;]E^P^%/C3QG^PKJ?@7_A$
M/C%X/NM<U#]H;Q)I7[+'[0WP[^$,GB^7Q]\/X_ _@#Q3X\U?3QIVM>+DU;QM
MHVK^(;CPHKW=3_@V(>*3_@AW^Q"V2Y)_:.^8)]E,:G]KKX_21Y\ID"1RF..'
MRX-]K(T?V$J55\76IJ$*O][#J3:6FM>FK/S]/G:Z.:,^?ZW'_GW5PL/PS%W_
M  \WZ*U_Y2_^"NG_ "G'_P""H'U_8Y_]9!^&=?$%?;__  5T_P"4X_\ P5 ^
MO['/_K(/PSKX@K^"O'+_ ).;G_\ V#Y/_P"JV!_F-](__D\O%O\ UYX<_P#6
M;RP5>H^H_G7]T'_!L1_RA%_8O_Z_?VF/_6N/CM7\+Z]1]1_.O[H/^#8C_E"+
M^Q?_ -?O[3'_ *UQ\=J_2?HY?[EQS_@R3_T]5/VGZ'?P^(__ '9G_J7Q$?OG
M'_!_P#_VG5RJ<?\ !_P#_P!IU<K^KG\4_P#KY/\ -']J4_X</\,/_3- :_W&
M_P!UOY&H.\GUD_D:G?[C?[K?R-0=Y/K)_(UA6^%?]?<+_P"I$2:F\/3$?^HY
M_)%^WU_RL6>'_P#M##X?_P#6X/&]?0U?//[?7_*Q9X?_ .T,/A__ -;@\;U]
M#5_>'T?/^3;X7_L><0?^IM(_S:^E5_R=S$?]DOPM_P"HF8"-T/T/\J]C_P"#
M83_E!Y^Q/_U_?M0_^M@_M UXXW0_0_RKV/\ X-A/^4'G[$__ %_?M0_^M@_M
M U^?_2;VX5_Z]9I_Z>P1^H_0[_@<?_\ 81PO_P"EYB?B#_P7U_Y3@_#K_M%+
MX#_]:_\ C37P'7WY_P %]?\ E.#\.O\ M%+X#_\ 6O\ XTU\!U_I+^S]_P"4
M=<!_V6_''_JRR\_DKZ<G_)]<1_V1W"O_ *9S8*_JU_X-C/\ E"!^Q/\ ]?/[
M3/\ ZV'\?:_E*K^K7_@V,_Y0@?L3_P#7S^TS_P"MA_'VOY\_:9_%X4?]@7&O
M_O)/VG]GM_"\4O\ L/X#_P#?G/Y9O^#N?_E++\&_^T=/PV_]:3_:7K^8NOZ=
M/^#N?_E++\&_^T=/PV_]:3_:7K^8NO\ 6;]C_P#\H;9;_P!G/\2__5IDQ_6O
MB#_R4-3_ +!L/_Z0%?ZB'_!L)_RA!_8I_P"OC]IS_P!:]^/5?Y=]?ZB'_!L)
M_P H0?V*?^OC]IS_ -:]^/5?R-^W-^'Z,'_8T\4O_5'D!]!X8_\ ,V]*7_IN
M1^^HZI_UU;^:5;JH.J?]=6_FE6Z_P!I_%+_#'_TYB3].A_#I_P"%_FPHHHK4
MH**** #I33AAR>.N:5NA^A_E4;9$1(5G(5F"(5#O@$A%+,BAFX +,J@X)8#D
M14;C%RBKRT2^;2 9*J^3,0I?$;_*%#EL(?E"' <GH%)PQX) -?@7^WC\0O\
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M7\:^./$5_;^&? '@;1PWWM5\6^+]5T?P]IXP?]*OXW(*JP/'_L>_!'7?@?\
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M4/\ ZV#^T#7Y_P#2;VX5_P"O6:?^GL$?J/T._P"!Q_\ ]A'"_P#Z7F)^(/\
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MU)P2DG&ZZK_@G=^Q[J7[%'P:O?A+K?CFY^)>LW_CG6?&NI>-GU#Q>]GXAO\
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M^.F^(/Q"O_B;XHT#XG)XKUHKK7@O_A$_AG\'6\":!%+X?UH?$>6Y;Q%!^I=
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M (.9?^4R/PN]_P#@FA\/B/H?VG/C_7XFU^V?_!S-_P ID/A9[_\ !,SX>?\
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M/^NB_P#H9JQ44OX4/^W_ /TMC?\ $J?]P_\ TEA7Y^?#K_E*?^V+_P!F!?\
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MC[7\^?M,_B\*/^P+C7_WDG[3^SV_A>*7_8?P'_[\Y_+-_P '<_\ REE^#?\
MVCI^&W_K2?[2]?S%U_3I_P '<_\ REE^#?\ VCI^&W_K2?[2]?S%U_K-^Q__
M .4-LM_[.?XE_P#JTR8_K7Q!_P"2AJ?]@V'_ /2 K_4+_P"#87_E!]^Q)G/_
M !]?M.=,DX/[87Q\)^[R2?;GTYK_ "]*_P!0S_@V%&/^"'_[$G.?]-_::_3]
ML3X]C^E?R+^W-]I&/T9)K^&L9XK*?K_8W#4ORL>SX<?PL]_PY;_ZDR/R6_X+
M%?#GX>_%#_@O)X-T#XF>"?!?C[0['_@D5X4UFPT#QOX=T;Q9H4>L_P##8_Q8
MT&._&G:Y%+;+?0Z#J&I+&RQ2L))'B>":-G4^'?\ #&O[)'_1L'[-O_AB_AG_
M /,W7U+_ ,%5QC_@O[X.QC_E#UX3 S[?MF_$KK[5FY/JGYFOXI^B_P ,9!F?
MA+@L3F&19+FE9\2<5)5<SRC)\QJTXK,Z-X4JF8Y1F-2G3E*]24*=2G"51N<H
M2G[Y_I%X(Y=E^-X'C4Q>79!C)PSK-H1GG%.$JT(^UP\N2C*5.4G2YFY23D[5
M&[63/FT?L;_LDH0Z_LP_LWJRD,&3X&_#Y'4J<AD>P\/P7RL",JUG-#=J0#;R
MQS!''[M_\&QLCO\ \$1_V+6W/(?MO[3JL))'<H8OVO?CW;K&2V]8$@ME06]L
MIPR *-NTL_Y;J3N7E.HZ$YZU^I7_  ;#?\H/OV+/^O[]J'_UL#]H*OR_Z7V3
MY7DSX I97E.5Y5"O+B6K6IY7EN6Y;"M.&$P=*%2M#+<MRZ%6<(2<(SJPJSC!
MN$9PBW%_#_2&P6#P3X5C@\%D^"C4_MB<XY/",*=24:%."E7Y80;J*,G&%[_N
MV]C\:_\ @M]_RG:\ _\ :)7PG_ZV-\6:^4Z^K/\ @M]_RG:\ _\ :)7PG_ZV
M-\6:^4Z_M+Z"_P#R8/ ?]E9Q9_ZF8$_B;B/_ )'%7_L RK_U%JB-T/T/\J_H
M\_X-@O\ E!I^Q#_O_M0?^MB?'ZOYPVZ'Z'^5?T>?\&P7_*#3]B'_ '_VH/\
MUL3X_5^%_M&?X?A7Z<8?^H^4GI<,[8G_ +"<O_\ 3\C^=C_@YE_Y3'_"G_M&
M7X!_]:?_ &@J_$NOVT_X.9?^4Q_PI_[1E^ ?_6G_ -H*OQ+K_0W]EY_RBSA?
M^SD>(7_JPR8_T?\ H^_\FXH_]E%Q)_ZF80*_O<_X-B_^4)/[%_\ V$/VH/\
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MO'N<]:&Z'Z'^51,Q$,AP6VH_ +ACA<@ QJ\@/4 QJSCC8K, *Z)>[&4_Y?\
MA_T/GY:SC#HTW]SM^0[8,Y[#UQS^O\Q3B%(&3@=N0/\ ZU?E]^WS^VK\1OV7
M-8^&VC_"3X?Z-\3M:BT_Q!\:OCSIFHG5GE\%?LJ_#*[T&R^*OC.RN-%US39+
M7Q?>W?B'1=-\ 7VL:-JNEK_8GBZ6^TZ^BMC;GLOB;^T%^U+'JWCW5_@#\&?@
M+\2/A7X-TO3K]?&/C?\ : \:?#[Q3X@2Z\ Z'\1KB]T?PIH_P+^(&FZGX=@T
MSQ?IVG:1?2^/- +:NDY>*UM S0\T:OMZ5:O;_=YJDW;3WH\]FUUMKZ;=;;QP
M[A6I459>WIRJ1=]U&7)UM:[/T0   '&.V?7_ !I:_';X0?MZ_&?]I3XU?&+X
M:? [X??#VQ\)Z+^SQX=^)7P/\6?%;4?$<6D^//'&H^/M9\ >,]>O]7\.KK-U
M=?"CP_KECKNA:0=&\.Z;?^)I?"QU+P_?IX1\6Z!>I[Y^R)^UI/\ &'X:_'WQ
MS\4O%WPQ;P7\"_BWXY^'S?M!>&[35OAC\'/'/A/P5X:T/Q!XA\?Z3#XY\=>.
MH_#6@>&-6U7Q+X6U[6'^(NKV+IX5GU4ZM8[1I]IU*GR0A/\ Y^QY_P!%==--
MNYG>U2K3>]*2B_-M7/T-/0YZ=Z0$'I7Q_P#LQ?MC?L]_M;:1XLU#X,?$CP[X
MJU?P=XE\7Z#XA\+V7BKP)JGBNV@\,^+]4\+6?C:;1_"?B'Q%?Z?X.\>1:5%K
M'@'5M1NK6/6_!VH:->M%:O<%8_S9\"?\%)_C/K'Q6MO!\GB_]F/XAZC<_M>?
M&7]FS7OV<OAEX;\8VO[1/@/X>_#W4?'&CZ3\?_$%_>?'#Q#/<^%K2#PIHVL^
M+8-;^$_A6.73]4G31/%6G.T5W;D$ZM:-!6O.+DK[:22+<'[&I7TM3E&+_P"W
MTVNM^C\O,_>5F4 @^AS^6?\ /!Q41:,8YSSD>_,G';'\7/Z"OYDO"'_!9O\
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M67B*3PA;^,XO"EU;>*M2\/3S+KVFZ+&FM6\3&*.XE]T_X;Y_8>_Z/._9(_\
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MRA"<J<Y1C+\)O^#N@!?^"L7P80'&W_@G7\-#D<XV_M*_M+DGUZ_UK^8_>?\
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M>5YEFD*,^9<\85IT)2A!SC&4$YKT^&L-7A'$NM%QE[? \MU;3VSOT7FMGO\
M(_)W_@YE '_!9/X6 #/_ !K)^'BX]C^U!^T/Q]221Z^E?B;L'_/$_D?\*_4/
M_@X/_:7_ &<?CG_P5=^&OQ"^"WQ^^"'Q=^'5A_P3T\(>#-8\=_"_XI>"_B/X
M3T[Q/H_[0WQI\0:CX7N?$O@C6==T33_$^GZ3KFE:WJ-A>ZE:7,6CZI'-(8!/
M;RS?D3_PLGX0?]%*\$_^%1IG_P O:_O_ /9M\:<&9%]%_*\)G/%V0Y3C7Q[Q
M_*I1S7.LERRO4<<QR>+J4Z.99UE=6=*SA%5*=&I3YGR^T4ER'^@7@)G&6X3P
M[HT<;F.18.HN(.(W&GFN?9#E5:4?KN&CSTZ.:5%6J4W*#3J4TH*=X-N:T[,H
M "?*(QWP>/?IVK^]K_@V+Q_PY%_8P'_46_:</_FXO[0F?U-?Y^:_$?X1NRI'
M\1_!LDC$*D<7BG3EED=CA4C:/5;N19&8A49+2Z<,05MYB!&W]I?_  ;R_P#!
M0/\ 83^"?_!(+]D[X7?&K]M/]D?X1?$GPWJ/Q_?Q'X#^)G[27P8^'?C;PXFN
M?M0_''Q/ID^N>%/%7C#0];TFVU/0=7T34K*[-F9KN#6+:[5 &\\_S=^U?XJX
M;XCH>"U+(,^RG/51_P!>E7JY3F>69I3PTYT^')0I5IY7FF:PHU*D(NI"%:=&
M<Z<93A"<(RG'X/Z1V.P.88O@5X'&Y3C%3K9Y&H\IS;*<WA3<L+2FE7GE,Y0H
MS<8RE"G62G."E.#<(M']6\753UPS >V74?UHKYM^!/[6/[+O[2[Z\G[-G[2/
MP$_:%/A"3P\GC-O@?\6_ 'Q33PI)XEGURY\/Q^+#X UWQ&_AVYUV#P_XANM(
M&K26R:K+H6KK%Y:VUPQ*_P @9*I&K4A/[+M'IISU4]'JFN5)IZIZ-)H_F&C_
M  :-_P#GS3\K?'IKYW^\^GZ***1H(>A^AIA"E0<D8XZ9/KC^O7%/;[K?0_RJ
MK.I:W=07!:.491G1QE<?(T:O(K?W616=6P55F %#LDYOI?UT5]_D*3:BW'5W
M22\V.8(48$]F&2%(!P>2K'!QW#'!Z'BOSR^'B(__  5$_;$6)1(?^&"/^";I
M1D"P@2#]H?\ X*I99=B#'0 [48G@;G.-GC/_  4=_;B^+G[)GB7X5Z'\*/#W
MP\OX]7\"?&;XV^.[SXB:)K5^OB'P#\#-:^"FG7OPA^'YT[XB> 8/#?Q0\>P_
M%RY?PCXVUF+QMIGA'7/#^GV6I_"OQ);^+VUG2OQ2^"?_  66^)6M?\%!/B%X
M]7]FW6/'@^*_P^^'/P"N_ WPVT7QEJOQ%E\'_L\^*OVHOB'X+USPOX1NH&U*
M37_$C_'K6U\8:7KD1N=+T7P^E_IRO>6NLK7SF=<891PWA,-C<XE.%+&YMALF
MP*C"=1RS+$4U5HW48OEBH27-)V2C-_%-QB?M?A3]';Q3\;\)QKB^!,DR3,\-
MP!PM0XPXIK9YQ%D?#E##\/U\QQ>72^I5\YGAX8S'RKX&K*C@HX_*Z=1PA[3,
M,.ZD.;^P*.2WD\MS'$Q-ZJQH+60J)T9,R1^9:R2!P2I,N( #@^:H&1JO- 9'
M38"XC8M(#&"!M.>0=XP.YZ=QQBOX]/VWO^"VO[;/AW6O#7AKPI\ M>_9.MHM
M0@U]8_C5X*\<Q>+O%MKX6\56NJVFIVMMXL\#?#FUM?"VLVMLFAZ_I.GVGB&2
M[LIKV*#6XVFCQQWCS_@I)^W;\0O@#K'BC7?"/_!1/3+CQ%\,=0UBS\;?"_\
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MEO\ KMBL-4BYT\=#A7/\+E^/P624N7ZQE\L5E>!=2DJ=:BL70:Q4OK*OT"_
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M%G5@G@\NSC"4,?.I@\1@U*&"I8=9'F5Z4.:GC:44Z+^5H>"?T;<O\./$3/\
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M!IFJR1F0Q1)/^3'["VN?$KX%? /0O#NO_L-V/@GXA:S97LGB5_BY_P $Q/\
M@JE\<OC(K3ZNTL,/BGXK_!K]A7PMX<F^S0*9M"T[1[O5ET=5L_+\3F1!<+\:
M_P#!+KXB_M!_!S]J+]I'Q=;_ +"?Q#^#<O@'6;CP3X6US7_V./\ @IC\6K7P
M;8ZSH/A;6_\ A5OC#P1\)_AW\7/$?AOQC?\ P^U[X?\ QBTVS\:>&?#^H)IG
MC$3WOB*;2O$WABQB].'@YXOX]U:L,^\',FRW@JA[7Q0E+Q X;S"IRMQ^OQPE
M\/3P59O,J=2$:>18WB'#5(2>)>(45"I+R<%COH-972\:\%7P/CCQ1[6EBX>
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MZU+XAZS9Z/K7A-?'WP].D^%YO#/ACTW_ (*D_M:_\%+7^"7@_P &_L4>-?\
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M,:U6I1DTO98:IC$WLW2DXJ*_O2:=DM7LM[/TT_ ;_@A):?'35_V>_%?[&O\
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M$HO^"6RH7_X=J_L"MA"Y _8V_9T?)4$\(OPY,CMQ@ #<3P.<&MB+X0>/(?\
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MK>\*EU=NS55I:=+K7SU8U_O.*_Q4;?\ @D_-3QM_P3,_X)3^!?!GBKQM>_\
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M)X5LA//XQ70=>N-.T74/L%_^"3__  2T5&8?\$T_V!,JK,/^,-/V<Y.0"?\
M5Q_#CS'_ -R/YV^ZOS$5HZ?\)?&\'_!1)?CE!X8C3X477['W_"KH_$MMJ/A^
M.UM_'[?&JX\;MI*:/'JZ:]//JF@:A=:M>ZI#H-QI/FVL:2ZPMS(L;?>E%#^!
M0NVY6Q'-=WM+^T,RTW=K+ETZ>::9$74E6Q+J-M>TPZIMRYO<679<M[O[2EZ;
M;IGS-\"_V3?V6_V9FUY_V:_V;?@'^SQ_PF#^'7\9I\#/A)X!^%<?BJ7PW-K]
MKX??Q</A_H7AN3Q%=Z%!K_B*TTDZM%<QZ5-KVLE/-6XG4%?3-%:&@4444 %-
M?=L?:<-M;:00"&P<'+*ZC![LC =U8<%U% 'CGQ%^#GPI^,'_  B3_%3X9?#_
M .(MY\-_%6G?$'P#/XZ\&:-XT3P7X\T*&2#2_%OA&X\0:'-#X>\4Z+<^7>:/
MK>B_9M5T_4+>&^LWMY[>-D_G\_9 \#^ A_P5F^+?A.T^%/PIT=_ \GQ_UN3P
M)X>^$7PYTB^^ FC>$+_X%^'/V?/B?;^,](\/:/X_M9OVGO"_Q,^-FHZC8^*?
M$'C#PCXP_P"$5;5OAHFC+X*\?6R?TRMT/T/\JH9?S\ 2$9&"!)MX[_ZT+CMG
MR_;%8_5Z,L70Q<\+&M5P\*BIU/=YZ7,^9<O-_>]]=FKJS=UZV7\0\0Y+A,RP
MF0Y[GN1QSB@L%FKR//\ B#(?[2RYJ2K9=F3R#.\D>9Y=64YJOEN93S#+:ZDU
M7RZNI24O'/B)\#/A)\4Y]*N_B!\,OA_XWNM)N)%L+GQMX%\->)YH%DG$KPVK
MZ[!)+!;LYR8TWAB6D$;2.S-W&G>"O#.G>&T\'V_AW1K3PM%IL>BP^%[?2-/B
M\,1V"DDV<>@VBBRALF4E3:F-+8)A"A5FW]A+D-&<L/WBCY2P)&X9.%=!M.3R
MP88X*D<&7Y?]K]*Z(S7*Y*DZ*O*4ERQO-W3<G*.KV2O)MM6Z+3SWC,P>#I9;
M'&8VME^&4XX+!5\?CL1@<LA5FZN)I9;@<1C:^!RRGBL1*>+Q5++,%EU/$XN4
ML7B88G%REB7QWA[P'X.\)7%S/X6\(>&?#4M\\)NI_#NA:7H\ERL; E;C[';Q
M;TR"NT \?,,.%8=O461E0!P"!D]?\^W3V%2U"KJO=J_N/EU^]=7LEZ=D8K2,
M(_RJWKK?Y",,@CU!'YBJ\RML.U5+!"55V*(S@'"LX20JI/#,$<J#N"-C:;!X
M!/H#0,, 2!^/-9UE[2/LOYO>^2T''W9>T[)Q^]\WZ'X6_L2_'?QMXF_X*;?M
MQ_"36?B+IWC/PZ=>\6^/5\-?"ZP^'.CZ%\.M5\$7_P +/@IHNF_M0^#[[]C?
MX,_'CP[^T%XJ\#Z)X9O_ (8^-?$'[0_QT\$_%_X,>&+R_P# C:9X"^'_ (7E
M;]TZ0KD@^AI:W;7)2BO^7<.3UL[WV_S\S&"_>5I_\_)J7W1Y?Z_ ****DU"C
MZ444 <]XLMO$%[X;UZS\*ZII^A^(KO1M4MM#UK5M'?Q#IFCZO/8SQ:9JFHZ!
M%JNA2ZY8:?>O#=WFCPZYHTNIV\,EE'JNG-.+R'^6WX ?ML?M-M\7OV,K'5/B
M+H6E^(_VC[OX5^(_B'H>B_"/X.>&;W]M_P :^(/CU\5OV>OCUXW\23:=X*A\
M<ZAXB_92_9H^ 'P/U!]1^'7B#1;CPSX4@\.R?%2+7O J:!IWAG^J^;B&4^D<
MG_H)K-N%#0W*X7#)(,.N],-,F=ZDJ&7GYE+*",@D9S54N>%>-=->SA"49Q:O
M=MIWMMHGIYF&*;^KU5WPN81[6<\+25[^7+HMM7JM26,<\]I!^?VF,5HUXK\8
M/C7\'OV?_!]]\1?CC\7/AS\%/A[8ZG8:=?>.OBMX[\+_  ]\)V6IZM>11:=I
MMQXD\9WUCHL6H:A,0NF:>MS&]W,OE0*W*UYU\'?VT/V/_P!H36++0?@-^U-^
MS?\ &S7KY]>ET[2?@W\=OAE\2=8N+#P@WAM?%-Q;Z=X6\0W=R=-\.7/B7P_:
M:NUI;7"V]CX@\/7LS)_PD=LSPJM*LY2IN]FE)^=KKUTN=#3O4;35Z]6UU;:.
M&_S/J^BBJ>HWEGIVGW^H:A<6]I86-E=7E]=W4]M;6MM9VT$D]S<7-S>/%:6]
MO#"CR33W4D=M%&K23ND2LP8BTY8(Y0 N%8J&)"E@#M#$ D G&2 2!T!K@/B#
M;^)[WP=XKM_!.NZ=X8\5-H>I?V!XDU?1$\0Z;H]^UE*+;4)M)>]T^+4X;.8)
M<2V4M[;1W2Q?9I)X4D,T7%>&?C[\#O&GA;Q9X\\&?&CX3>,/!'@*T_M3QOXM
M\+_$;P?XB\*^$=.7PII?CA;_ ,0^(=(\07&D^'-/;P9K_A_QG;W&H2&W'@N_
ML]9;-OKL,K^KZ5J5CK%I9:MI5Y::GIFI6UM=V6J6%S:WUEJEG<QI+:7MAJ&G
MR/;W=E+&RO%,H*30,'!$;;FSK4?;TW#S4ON_KY$RE[.5&M:ZC7A':Z=U>WX'
M\O7[)G[9OQ^U3XX?\$U[CQ)\5M(F3]L+]G[]GGXI?M _#;X:^&_A-\,_B[\=
MOC;XY\!>(O#FO_M(?$[PUXD_8HU6T^,/PN\&>!_AC\)_A_XNU_X!_M4?#;QG
M\&TT7PMH?C7PO_PC\G@SP]?_ -4E54''TE3'YXJU71.:<:5-)7HP<');R=TT
MWYVTW=UN54?/BL55M9594Y**M:-J;C962T_K;1%%%%9@%1NK88QE5?:VTLI9
M0^TA25#1EAG!9=Z$C(#KG(>W0_0_RI$.1]#BIY[34?YHM_<[$S@I1YNL6K?F
M?#G[?7Q@T7]GG]DGXP?%_7?C[;?LM:/X*T/3;S5/C;+X/\.?$75_"D-QK.A:
M.]KX7\*>,;J+PCK_ ,1?$374/@[P+=>*=,\7>';#Q-J6F7>N^&?$FG0W>A7_
M .)'[!_[9W[3&I_M(?LG?!S4/C)\,?%/ACXGW-[XEU_X<?![P_\ L[>(?"7Q
MB\%?$WP7^TS\:/B]^UCKGQ"^ 7@QO#.K_$SPG\?M#\'^ OCG\1/@3XJM/V;=
M4^.7B[QCIEQIFLZ[\4/"WB73?ZF'7)'N0#_3_/M3E4+[GUI8-QPU3%3<8S]H
M_ADM%>G)<W7X;IJVMUN+$KVTL,]5[.$U>ZUO-2[>7FK-Z+JW:0%/OD_B1_AS
M[U)32V"!CKC]:=1%\TIRW4G%_=&Q2CRI+IT^_P#S"BBBK&-8$JP7[Q4@?,5Y
MP<?, Q7G^(*Q'7!Z5^?_ /P4?^.^C?LX?LD_$CXM:]^T:O[+FG^&QX+:7XLV
MO@KP7XS\2(FM>,=)L+CPMX"\._$R['PYMOB/\0HY'\)>#?$OQ!T+Q+X+^'VN
MZM'XS\7^&M>\/Z3J%A)^@5! /4 _6L:])5H<C[I_<73J>QFI]M/ZT?Y>C3/Y
MC?V"?VJ_CS=_M>_LX?!/Q5\>OA3\2_"7Q'^#UGXY\3?#7]DW4O@>G@Z3XG>,
M_!/C3XW_ !D_:K^*^B:/^R#HUOX^^'WQG^*WB'4D7]H']EG]KYOA-JOQ[U6#
M1==^'&J>(/%GBVTM_P"G*D..,]<\?7_/6EKI=12A2@E9T8<C?65VFF]%K96Z
MG/"ER5*]33]_.,[)62M'E_7\@HHHJ#4**** "BBB@ HHHH **** "BBB@ HH
MHH *1CA6.TO@$[1MRW'W1N*KD]!N95R>2!DTM% 'Y7_MH?M1_P#!2#X'_%7P
M_P"&?V.O^"5K?MR_#74/ &E>(==^+B_MQ? 7]F@:!X[N]>\1:5J?P^'@3XJ>
M%]:\4ZP-,\-Z-X3\1-XTL[Y='OU\:-HGF+<>&;BY7Y,_X>&_\%TVQ_QSNX]S
M_P %;_V/?Z^$C_*OZ ) &CD4X(9&!! ((*D'(8$$>Q!!Z$$5^??_  41_:9\
M7_LK_ +1_B3X2^(7P,^$5WK'QM^!?PUU3XJ?M'Z/K/B#X._#WPG\4OB1H7@S
MQ3XR\96.G?%GX'V\<?A/2]7N-;C:X^*GA^T,5C)]JN;6W?S878FI+V=*57^5
MJ/WZ]-?D? 1_X*&_\%TL$'_@W=X((./^"M_['W3OT\)_T^E(O_!0O_@NB,;?
M^#=W/_>6[]C[\\GPD,GWSG\*^>/C-_P6&_:H^&'AF>[^"^N_LA?M]:+X=^-?
MP"T6]_:+_9O\&^-=$^"_C;P?XU\/_M%^//CA\$_!>B:7^T_\8M-O?V@_AC\.
M?@G:ZUHUWI?Q?^(6G0CXA>#(?'GP^T+56@GN/7?V^/\ @KE\<_@#\9_%/A7]
MFSPI\%?B'\(/!7[#7Q]_:(U'XB>/K#Q3J,FJ_''PS\)M8^,WP@\#Z->^&?&W
M@JQF\*3?#J/P[XD\;Z7+I#^(+C0?%FC0:=X@L+N7[8UPC4G>--)W:W_KL7"-
M:;I<J7LZU.523UWB^77RMWUL=8?^"AO_  73ZG_@W<Z9_P"<M_['OX_\RG1_
MP\-_X+I#_G7=''/_ "EN_8^]\=/"7'.<'V/..3['X2_X*&_&#XM^$_V7-(^&
M_P ._ACX2_: ^(WCCXQ_!/XY_"'XNZSXS\GX-_'?X8_LY^./B7I^@OXBT);G
MQ.OA/6O$&A:+K]IXS_X0?6[GQ5\&_%%CXEM-/TZ?58-3CM?"K]M_X_:]X#_:
M^_LO2/@_^V%X_P#V7/%&B^#K+QO^S.;7X-_!CQCXNUWPU<^)/'7@CQ/!XZ^-
M7QUA\#ZS^S]>P):?&S4_#_Q#^*.J-!*-*\(>$E^(KZQX(ARKT:V&DE.$7*=*
M=:TG*ZC#&95@D]K)2J9M!*\DV[\L9*,K<^'Q%'$3Q%.FW?#552J:?:</:6WU
MM'?33K;KXB?^"AW_  71QS_P;O #&<_\/;OV/C@ #_J4CQP.W<>G"#_@H?\
M\%T/^E=X?C_P5N_8_P#]K _Y%+IG=CM\IQ[]KX8_;B_:\^.7PP^!&J?!6V^
M7@KQ_JO_  3Q^%?[>WQL@^)?PQ^)WC'PKJ]_\5]*NKO2O@[\-;/0_C#X"U#X
M<R:IJ?A?QO?'QSXXUWXHQ:#90>&[.V\(Z\-1FU6T]>\.?\%=_P!B/6_%_P "
M?@_K7[17P1\#?&#X\?!VW^)<'A[7_C+\*/L_PZ\1:SIWPPU+PW\*_'^E7?Q%
M\,>--)^)WCA_C-H>H_#/PU#X;?4/'OAWPWXIU>QU"S:SMGN)C&HW)>R3<7:2
MA>:5JW$E"2<HII:\,5VKVYE"ZWL:U;PY;+F4H59W2;:]C7RNBWRIW:2S6%[*
M33?PZ-KYL'_!0_\ X+H'&/\ @W>')X_XVW?L?=?E_P"I1XXV^G7V.''_ (*&
M_P#!=/O_ ,&[G_G6[]CT_P#NIFOI;P_^VS\4M1_9]^'\^K:?\/M!_:CD_:)O
M_P!FGXKZ)?Z)XTT[X<^$O$/PF\0:CXB^.OCO2_#IUW4_$L/A$? #P+XL^,?P
MP:]\8W^D:SH?B'P"]_XBUFWOWT^;SCXL_P#!7+0- ^"[_$'P'\%OC/X/UG6K
M/X4_$[X%1?&OP-IDUA^T;\ _&/[0GP>^%_C/QU\)_"/PX^)NI^-[2>R\*?%[
M2-2\(^$_B_I/PP\=6UQKG@_6+[P%<^'YI)Y[C0<X\TH*+3A%Q^U'VF$P&-3E
M'5QYH9C"4;I<RE=72N%&]6O&@DO?A5G&2UC)4L;F&!;C+:4>;+I+F6CW75'F
M'_#PW_@NGM(_XAWR@P?G7_@K;^Q^S+P?F5%\'3LS#J%6"8L>!%)G8?TR_8H^
M,/[5?QJ^&&O>+/VP/V+V_8=^)UA\0-5\/:'\(5_:)^&/[2Y\1^!+/P_X>U/2
MO'Z>/?A5I6@>&-)&I>(=:\6^&SX-U&*75].'@O\ MZ<NOB2T=.C_ &<?VF]&
M_:(D^(VF3?"_XK_!3XC_  <\>VOP^^)7PF^,MEX$7Q=X2U:^\(>'/'GA[4HM
M2^%'Q ^+/PS\0Z+XE\'>,])U#2_$?@KXAZ_ISQSW&E:S/IVM6%QHT/U=1[-4
M]+6OK]VGD._OU(?\^Y*/WJY^5_[:'[4?_!1_X'_%7P_X8_8Z_P""5K?MR_#7
M4/ &E>(==^+@_;B^ O[- T#QW=Z]XBTK4_A\/ GQ4\+ZWXIU@:9X;T;PGXB?
MQI9WRZ/?KXT;1/,6X\,W%ROR;_P\+_X+I?\ 2NZO_BV_]C[_ .9*OW_D7='(
MO]Y'7D CE2.0RNIZ]&1@>ZL.#^=O_!0?]IWQ7^RW\*?ACXM\.?%']GWX(1^.
M/CS\/OA7XD^,_P"TWHNL>)/@S\+_  MXBT[7Y=1\1^(]+T[XP_L\6OVL:MI-
MMHE@][\3?"=MOOLS66IB*2W7*M6]A#G[R4>O7T'[-5.E[:?KV/A!O^"A?_!=
M'O\ \&[H /!(_P""MW['IP.YQ_PB)/Y4W_AX9_P70+9_XAWP21]W_A[;^Q^"
M1GKG_A$!Z8/.>*^=/B]_P64_:4^$]GX&O? 6K?LG_MD_#6U_:9^&/@;Q]^U9
M\"O"WCSP[\#_ (C?!"[^#WQ]^.W[2UC\%K72_P!H#XVQQ?''X!>!/A$E_J4U
MO\7/B5X&*:K;)!X6M]8:ZT'PIZI^W?\ \%:_VAO@%^TG\<_A9^SIX#^"WBOX
M?_"+]C+XD?$[3/%_CS3/&.J_VY^TEX+N?@KX@L_A_+<^%O'/A71T^'>F_#7]
MH#X3Z_J312P:X]]XQ*6MW"(4CEZ*U#$TL/'$TX)PG@,VQ[DY?9RG"8;%U4[[
M6AB8WT6CWT:+I4U&I45K?[-.6S>BGNMMNF]GOH=N?^"AG_!<\?\ .N_W#'/_
M  5M_8_'.>@_XI 9YXS[\GBG_P##PW_@ND/^==T<<_\ *6[]C[WQT\)<<YP?
M8\XY/T/X;_;Y^)WQE'[/?A_X.^ ? 7AGXJ?$G0_VF/"GQ5^%OQFU3Q#:7OP6
M_:4_9[\.>&H[[X8>+/$/AJ236M,\.Z7XLU2[FO/$UGX%\0WWC[P!?>%_%GA7
M2]/T/Q =9&+\*OVW_C]KW@/]K[^R](^#_P"V%X__ &7/%&B^#K+QO^S.;7X-
M_!CQCXNUWPU<^)/'7@CQ/!XZ^-7QUA\#ZS^S]>P):?&S4_#_ ,0_BCJC02C2
MO"'A)?B*^L>"(<*RKTJV)HU*<54PU;$4IPFVIP5#$</X>+DK.*4Y<04W"7/[
MZ?-!246S.C%?5Z#_ )O:[7>T[M:N[M?MIK<\2_X>&_\ !=(\?\0[HYZ?\;;O
MV/NG'_4I=.G7U'IP?\/#O^"Z8_YUW/R_X*W_ +'W]/"==IX7_;C_ &O?CA\,
M?@/JWP4MO@%X*^(&J?\ !/+X5?M[_&N#XE_#'XG>,O"NKW_Q6TNYO-)^#OPU
ML]#^,/@+4/AS)JFI^%_&]\?'/CC7?BC%H-E!X;L[;PCKPU&;5;3V_P )_P#!
M8+]A'4_'/[/WPB\5?M%?!+P3\4_CG\(['XGS>&=;^-WP>MHOA[K&KZ=\*-7T
M/X3>/+'5_'V@^+-!^*7CO_A<&EW_ ,,="D\'7UQX[\/^&?%6LVUTJZ?']HUI
M4YRNI146G.Z@U*WL\9F>"=WY3RNHEW23M[R2J*YZT:*N^:$I[?RNW^7G?2S/
MES_AX;_P73/_ #KNX^O_  5O_8]_D?"1/Z4#_@H9_P %TP>/^#=W_P ZW_L>
MC_W4@?P/Y5]7C]N7Q9:?ML:[\']2\,^&8OV=[^S\??";X>?$"(>)(_&GB+]K
M?X+_  _T3XU^//AM<W<=W=Z//X5U#X3>)O$<GA<6>DWFH#Q=\)/B/;"&[:."
M$<9\5/VZ/VVO@)\)K'XY?&']CG]F9?AUJMGI=GIEE\&?VW?BK\0/BA)XH\6:
M5>)\-?#%KX6\6_L$_"SP;>2>(_';>'_"&OWL_P 1;*P\&QZW)JDZ^(;&RFCN
M)K-TJE.D_P#EXG);=)<H)ZUJ=OX4U'IUA=?TCP,_\%#?^"Z(RS?\&[P"CEO^
M-N'['JX Y)W?\(B=O&<L3@=<U]V_L+_M#_MR_'>3XD-^VA_P3S/[!B^$9?"%
MK\,T3]K/X/?M2I\5I?$-SXG?QM$9?A-H5E/X#'P^;P_X<V6NL3-!KD?B@V\7
ME)X;NI1BV/QA_;&^!WQ3^"NF_M07?[.GQ&^'W[0_Q1@^$>DW?P!^'_Q2^&VO
M_ +QQJOAOQMXM\.Z'XHN_B-\4OBW;_'/PCXAB\*0^&)?'OAWP[^S]J&E:O\
MV1KNH?#3^P?$<B^#_P!,*TE3Y%%_SIR^YV?X_P"9G!ZS]5^3"BBBH+"BBB@
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M?M$_ V3X\>'OAMX>C\4'PI'X!^/?P3^-;7)T-M<.J+\%?B'H'Q!/A>.R&N:
M+(^)7T/^REUMQX@CTQ;M[U]%U5(DM)"BFMTN[_X!%=<V'G!_"VF_DDOU,/\
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AT#X _#^U\3:K<ZY+X#OKA?"ND^$_T3HHJC(**** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm229830d4_1012b-img04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm229830d4_1012b-img04.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #E ?L# 2(  A$! Q$!_\0
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M2N3USN?)S[T[);L=D3?\)=X9_P"ABTG_ ,#8_P#XJC_A+O#/_0Q:3_X&Q_\
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M!*J2,_E7 /\ $75!X>TJY6UL_P"T+BX*72%6V)'E1E1NSDB2/J>]=S)HL/\
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M(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6TEM=01SP2J5DBE0,K@]00>"*IQ:!HT%JMK#I-A';K&T0B2V0($8@LN ,8)
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M,^$AJDU]#=W$,JVLL.]6=+0=0"/]5\W]*ZG5Y-FF3KLE(D1D+1X&S*GYB<C
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M8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\
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MDOW=@*Q2-D@@X)'&3ZUW%%"T!ZE/5=.CU;3I;*622(/M(DBQO1E(967((R"
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M:WE]Y[O^M66]Y?\ @+_S/+Z]]^$G_)-=-_Z[7?\ Z4RUR7_"C[[_ *&FW_\
M!6W_ ,?KT?P?X>;PKX7M=&:[%VT#2L9A%Y88O(TGW<G&-V.IZ5UX/#SI2;D?
M.\19QA<?2IPH-W3;=U;I8W****[SY,**** "BBB@ HHHH **** .6C_Y*K/_
M -@2/_T>]=37+1_\E5G_ .P)'_Z/>NIJI=/0;"BBBI$%>$V_^H6O=J\)M_\
M4+7M9-\<_1&578[+X<_\AC5/^O>'_P!"DKT2O._AS_R&-4_Z]X?_ $*2O1*X
MLQ_WF?\ 70N'PH\"TO\ Y!-E_P!<$_\ 017;_#I/,U+74W,NZWMAN4X(YGY%
M<1I?_()LO^N"?^@BNY^&W_(6UK_KA:_^A35[>8_[H_D9P^-_,ZS^P7_Z#.J_
M]_E_^)JG<^%99[ZVG&KWVV+.6=P7'3[I &/UKI**^<5::V?Y?Y%.E![K\_\
M,Y7QVNWPW$NXMBYB&3U/6N KT#Q]_P B]'_U]1_S->?U\UFO\9>A]/E'\!^I
MZ=X/_P"12T[_ *Y?U-<G\0_^0[8_]>S_ /H0KK/!_P#R*6G?]<OZFN3^(?\
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M %%%% !115>^O[/3+.2\O[N"TM8\;YIY!&BY( RQX&20/QH Q_'?_)//$O\
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M_P 51_PG?@__ *&O0_\ P8P__%5T%%(9S_\ PG?@_P#Z&O0__!C#_P#%4?\
M"=^#_P#H:]#_ /!C#_\ %5G:MX]329M7MIK ?:[*XMXH(C/@7"S8VOG;\H&'
MSP<;#5:[\>>';.\MM5LXYKJ:_FM["=TAF#B+$KQ.L>S,BDE\%1\V3R<4;@;7
M_"=^#_\ H:]#_P#!C#_\51_PG?@__H:]#_\ !C#_ /%5JZ;J5IK&G0W]A-YU
MM,-R/M*YYQR" 0<@C!&:MT <_P#\)WX/_P"AKT/_ ,&,/_Q5'_"=^#_^AKT/
M_P &,/\ \57056U&[^P:9=WFSS/L\+R[,XW;03C/;I2;25V-*[LC(_X3OP?_
M -#7H?\ X,8?_BJ/^$[\'_\ 0UZ'_P"#&'_XJN*E^,DD6@R:DFB6EZP@AF6+
M3]3\\(9'"^7(?*&R0;L[<'.#3M4^-%O8W>H);:)+>6UI#;RK,D^#-YA0%5&S
MJOF#OR>.*JSV)NCL_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\
MBJYFU\?6MOIFKSZ#I$4^FV,OVF2XDOQ&A$ZFX=R6!()=R H!Y./E'36G\?06
M^I6EO)IEW'#-ILNH/-*-NP(BN4 Q\YPW)!P#QR<X3TW_ *W?Z,:UT7];?YHT
M/^$[\'_]#7H?_@QA_P#BJ/\ A._!_P#T->A_^#&'_P"*I/"_B:37_M45S8"R
MN8%BD,:S>:ICE3>AW;5YQD$8X(ZD<UT--JVXDT]CG_\ A._!_P#T->A_^#&'
M_P"*H_X3OP?_ -#7H?\ X,8?_BJZ"JVH7L.FZ=<WUPP6&VB:60GLJC)_E4MV
M5V4E=V1D?\)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5<Q_PG
ML.M^#K]-6T,6T\TJ6$NGS7FU2D\8*L\H4%%*,<D#(P<9-:.E^.KW7DMX](T6
M&:Z-O]IG6:]\N-$WLB['$;%]Q1BORJ,<DCI5--$W1K?\)WX/_P"AKT/_ ,&,
M/_Q5'_"=^#_^AKT/_P &,/\ \56AH>L0:]HMKJ=NDD<<ZYV2##(02"I]P01^
M%:%)JPSG_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJZ"N2\7
M>-/^$7U+3++RM._TY)F\_4-0^R11^6%XW;'R3NX^E*XTKEW_ (3OP?\ ]#7H
M?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJN2/Q@2.>[BGT&>$PZ6M]%OE.99#C
M$.-G!.1@\Y]*H3_%W3-1L9HM3T-HVBL8=6MXVNB%EE0B98]P488% 1USM/'8
MNPOZ_K[SO/\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJI0^-)
MO^$B_LJ[T=X@]J]U"89Q/*T:[?F:-1E0Q.%Y).#D"LK_ (6<SZ);W\6B-YKI
M>3RV\ER%,<-L^USD*07/&%X'7YN,EV_K\/T!*^QT7_"=^#_^AKT/_P &,/\
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M# ."<#CTJW139)$AB>61PD:*69F.  .I- ',3M]I^*%I&HR+/2I)'/93)(H
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M *%?5O\ O[:?_'Z/[:U#_H5]6_[^VG_Q^CE86-FBL4ZWJ&#CPOJQ/;,MK_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
2*** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm229830d4_1012b-img05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm229830d4_1012b-img05.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #) HH# 2(  A$! Q$!_\0
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M(?,M)[ZUC=IK-+R..0PB<*)/))CW8S799'J.1D>X&,GZ<C\QZU_%#XT^'?\
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M\*ZQ#XUOIXX_!LVE:9876N^,/$-CIT*7<.L:-)I.B73/*9I;6*%W/4_LX_\
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M7P?X5^)_@K7O%;)+,/"&F^(-/N_$40M$2:]SID<SWC26L;!YXUC(B&2_RC(
M/<J*J6LWG!FR3NVL"0JG!R=I0$LI7.&W>W/<VZ "BBB@ HHHH XSXA>$] \=
M^#?$/@SQ7I5GKOA?Q/I=WHGB'1K^ 7-GJ>D:C"]K>V4\7!:.>&1D)4ADSN4@
M@&OSF\'?\$C/V#?!6H7M_8_ 33O$%U=>"-<^'BWGC7Q%XF\6S:-X/\364^G:
MOX8\/1ZUJ=U'HNF7&FW=S:AM+%O);V\DD<3*217ZED C!_D#_/(_2C ]!^5
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M<>?9+87&G7<LGD0)&RR!U\UYMH4%2:_$+]@C_@LW^T!^UO\ M*?M0_"/P/\
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MSGC-9CZO<B**9+FR&,I*K31,AV'!D617V?.<A5)R>&Z#!_B4^,'[6'Q7NO\
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MGQ.NOCE\8O'.@?%+QCX8?]E'X/?LT^+O!?@/2]7DL-)\6^(?'_C<IXIEUC3
MHM]=_P"$GT:,>&["*Z9U>[66*$+*P)^O/V]OVL/CK\%'^'VB?!O3M!&N:_\
M#WQ_\4M<F\1O!%;6VA?#/P]:^(M6TA \4Q%YJD+S6L$@ $#LK."%(H _40W<
MJ$*6(+2%=\L0"$(Q!"L&7YY% ,:DL23P,,!4C32.VV.XPKC)E*I^[9,$QB,
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M;F=]5S*_H[V#^MOR_7NM#GM3MGG,0#LH!);&<;" .AX8Y.03GH,CYC7X%_\
M!;7]DWP5X@_9J^*O[1>DZ_JOP_\ $?A;PK(_Q..A:K-H>E?%'PI8W44MKX>\
M5K:HSW+^>L<5K>*!<P;L!]B[:_H(NBB@.?F8#"@]"69>NWKCKC@>]?-?[47P
M%F_:3^#'C3X.1>*+'PC9^-=+DTW4=4O_  EH7C>T-M(X=UE\/>(H9=*N\.N5
M%S$Z*0KA=RUV9-CL3EV>Y1BUF^9\/4)YAA\+BLRR:&'JXSZC]<RW$XSF6)R_
M,Z+HUL!A,QP,\/7P5?#58XQ^TI<[A6I>CE&+>78N5>/L)T:WLUB\-B:4,3A<
M53I\_MZ>(PM>-2A4A*,\--1G3:C6HTJ\5&K34W_'7_P;I:'^RG\6?$'BJ75K
MJ_\ #_QG7PYX@TJ6.?XLZO9ZY/"-8TW4+"7P[ID,EE<2+;V8@B65;J<R^4Z3
M6\B.XK^K?Q#X>_:0^"QLM5^%/B.?XT^&WU&,:WX,^(UU:P^)M/TYP!<W>A^(
M;2"V>[EB10MKIUS QD<CS+D')K\VOV:/^#?KX&? RQU[2?%7Q,N/'VEW]A?)
MH.J:#\//"7PQ^(7A7Q'/JD&J6GB+2?B)X12#Q,TFF30N+/3)[M]+162-[9X8
M4BKU[7_ O[<7[!>EW'B?X>?$C4_VT/V?]$CN+[7? ?QCO0?C9X=TZ"-I[J]\
M.^.=/M(SKCPHC)%8:E83[SY$$(C+23C[_P 7\O\ #GC3Q"XXSKPOXJS#)\AS
M?.JN-X?PG%=/#9'#+LMJTL&J.49=G-'+<)E.3PP^(I8J6&PF?9-*E7EC)4GF
MM.-6E5I54R;"YW.%# YC@\#G->DE+"44L'CL;C93EKE\L5#^R\?BZZ<+8>O/
M UW.')1]M*5.+_2#P;^U3\-O$6J0>'O$,VI?#KQ?YB6]SX<\>:;>>'6CNV.Q
M;6SU6^BCT;4YICAXH[#4+J0HP)0'<!]'#5(WQ)%LDB==T4JD/'.<9_=.A8-P
M>H./0D=?S4_9T_;;_96_;EM==\#6^FM!XY\/6UO;^,?A9\2-+ALM5TJ[NH&>
MXL+*:X\VRUB:P4,EW<:!<W!AZ,4<[1[C+^SQK'AN26[^!WQ>\<?#5+!1-%X)
MU867CGX<7TQ3]Q:RZ+X@0:YIVG*Y ^R^']?T-7&09.>/QW%X/B3()U<+F."Q
M&/K<KJ2YIX7*L5&A*ES4:F5T)+$9;F=":A>.*P./KT*TI.5)Q;<8>9B<-F.5
M5JF&S+!XJC/#OV,Z>-H3PV-A*$5%_6Z%6,.2NY*4IQBXP7-'DJ3BXM_78U"1
MIUC"+M9 V23SD [5(R.!USCV&.:LM=G<R*HRHR,G /"DC]<>GO7Y_P#C[]IW
MXC?L[>'KS4_CI\,H-1%O9RIHOC#X:S:A?^$];O(HC]GM]8TAK:YUOPS<W3(6
M:%!K%C9D_-J,F,GX>_8P_P""SS?M5?'U_@[XB^#OA;X7>'X=&US69?&U[\29
M;P&#2-D<*06-YX=TR)IIYY$CFBDO4>!<DAL;1\]B>/.&\KQ^7Y5FN8U<'F.9
MXBEA\%@J^!Q&&Q:E5BO9TL7&<JE-UW*,E*I"<*,[Q<8Q^UPXG-LLPU7"T,1B
M5AZ^/E##X6G*,G*=:7,X\ON23D_[\HP5K<W?]W_M$W)**HVDCD<M@GGJ0!@>
M^._!IGVN7_IG^=>/7GQX^"6G*'F^*G@/<O(C;Q5I =L=0B"Y+/(3PJJ"2<=2
M<5Y]K?[9O[/.@N\=UXXBNFC5F8:79W.I@[?F(5K*.16.,@!<DC&!GBO?QV99
M=0K^SJ9BL/+EC)QJ8BEA;\VW+&=*M*IYRNN5^[KN=3JX7#6IUL1*4VG)2FH0
M=KVMHK;^F^G5GU%]KD!Y"$=P#SC!HEO9$C#",$DD\'@* 3DG/'3GD#WQS7YT
M^)?^"IG[)7AD.-0U/XDW 4/F32_A3XYU6,%<@D/9:/*,X&?QP,58T7_@I)\#
MO%<-M%X+\*_%WQ'-J%N\UFO_  KS6]($L0C8%I#K=O9)"%'593&Q'&!G-<=3
MB3)<%"C4KYMAG">)Y/WF)J5U-*C5DXQ>%P,K)./,U-13MI+9/-8N@ZUZ;52E
M'#U)R7,G[\&G]G5>ZFNSV>I]IO\ %?P$MZFGQ^,_"37KW"VSVIU_3A<K.SB/
M[,+?[093<M*2@BV!LCISBO3%.0#Q@@$$=#GGCV_G7\7_ (?_ ."@'C[Q?_P4
M'\&Z</A/\']-T:/XDWWPRM8-0\)WT.JSZ9XE\2:5<W.O:K'%K9ME\76ITN&+
M3+OR'CMTEO496$ZE?[.H9,QQ_* /+7@=!\@. .P[ <8KY_@'C[+N-HYZL#7A
M5EE&9SPU24%B%'V55U'A^5XBA13C:C4Y>52=K\R3Y;^9DV=T,Y6*]C3G!X2M
M[*;DFN9RYVFKO5+DDKKHEW1/12 @Y(_SQ_G_ #FEK]%3NM[_ "MV?X7]>Y[8
M'\>O;\N?;G-8,BQ/>3')#[-C-A=SQ!VW L>#$IW*5.,C/(Y-;U<=XC?5[33-
M;O=$LK+4M>2QNUT/3[^XDMK#4-2%L\FGVMW-"DTEG;37FR.YG6.9TC=I-A*A
M2P/XP_&'QV\!?L]?MR>-OAI\,?V\?VA=$\->)?VEWUO7O W@S]F?PMK_ ,+(
M/%?B_P 2I!J7ANX^(6J64MT-/N]3CNM,NM2^V>7;W$%RD4B-"RC^V&P8-96K
M*VX&W@(;8$W9B0[MJ_*-V<X7Y1G X K^-'Q)^Q[\>?BA\2?"=[\4O@E^Q-\&
M/BIXE_:'\0ZZ]BW[5'Q4?3M>TFT\9+JEY;7GPWL&M]-UB[62Z_M&UT?^U;**
M34;VY9M-A::2-?[*=(@>VTVSMY'5W@MXH6,9!B!B18RL. #Y*E<0ARSB,+O9
MFRQ );BU,\B/YK*$93@ 9 4-]QNJEB1NZA@H4CFHGL,@;9=I^4.VT L$.4&5
MVG[_ "1GG..YSH$ YST(P1GC'/Y9SR?IZ4M &2^EAWRUQ-M(*NN[!E!R=SLN
M&+(6(C.0$7@#O7YY?M(6[0?MN?\ !/J%Y7DQK'QW <X#%/\ A7,NP,V,EE4@
M9!&XC+ FOTC]??\ PQQ^7YYK\YOVFO\ D^/_ ()]?]A?XZ_^JXDH _1&W3:&
M/&#M X^; &?G;^(_-U^OK5BHH?NGZC_T!:EH ****32:L_SM^* C9"QSO(&,
M  # ]3]3QSV[5!/$Q0 .3\V>0#CJ>._Y'/I5ND;'&[ID?G_]?WI33<'%*+NK
M6DE);K=2C)/;JGZ#3>VG?5)_C:_RO]Q@W]E'):S12!98I8VCGBEC6598I-RL
MC(P(92IVLI&TJ2"#7XM_M2_L\?%[]E6R^(7QT_9$O;^Y^'VO+JDWQ<_9S-M!
M?^&$MM;MI;;Q'\1/ VER20_9]6TV*0:S+H-G+!9Z@\-R@1#,17[>R0I*.N#D
M$,N"01GG!!!]P>#^>?-/BHFHV/PX\:7&B^'H_&6M0>&]8?1_!TDMO:6_BG43
M9RBRT.>:Z9;>%=3G*6DDDDD42K*6=E0$UV9;C\1@)8BG"GA\?3S"B\)C<KQ\
MHRR[,\/4:B\+BZ=6G6HTX23FHXJ%.-?"J4ZE"M"\J9WY5C*N!Q+Y'S8?&<F&
MQ^&G"%>CC,'.K!UJ-6A64Z,I<CJNC6485L+4E[7#U:,XOF_B3_X)<Q_#[XY?
M\%#=>\+Q>-M3U1;-M5U:.WT[PM=>#=:5[NWO+C77:YMM;BN-'OM'U$11$6J7
M2R* DB^4"#_5=XD\._M+_"&&'6/@[XVE^,FFV]_'!JO@;XIR6::E)"98U$NC
M>)K.VM)8I;:VW>1:3P2FXF""2=22:_F8_8W_ ."37[8'@S]O'Q=^T-JWA#XT
M_LR6GBO5?%'B31?''ASQG\--<L/ .H:_/>7DNG:EX86741X@\--++!9_V/+:
M.\UGO N[>79(/WN\7?M(?M7?L?:7<>)_VJ_ ?ACXZ_!S1I(/[4^,?[/ND:IH
MWC7P]:RW%O;6^L^./A-JMWJRW]M(I-Q<7?A+6;J>"19 -)CA(>ONO%?PGX+P
M'''#\?"WB;@G-:,N%<BKT>'>$,LP7 F'?$N:\(X.>;Y)/ X>K6X>XRS?+,Z>
M)D\UQ./HXZKBHPJ3PT(S]E#IX@R;AB@ZU+A6-;+,-B\:Z[7^L>5YAB)U?[:J
MU)T\-CH9?2PM&BLNITJ3RK$8?Z]2H*<)8VOB:D*Q]M^&OVK_  !=26ND>.HM
M4^%OBIS'!=:)XXTV[TB"*^9EC6.+6WC;1)4N9F*V@6_,DP9!L#,!7T;%K4=S
M#%=6K0SV]P$:.:&19X61D!&)86DC)!/.UF&WG.>*\.^'OQ&^"?[3/PXTGQEX
M/O- ^(?@SQ-I*7*1SQVUU*D4Z[WM-5TJY#W%AJ4 8K<6US%%<V\@(948 #BY
M?V<U\+RR77P/^)/BCX12$^:_AVV:U\4?#V[<9>&(^%=>2<:; 'W&Y'AV]TB>
M4EQ+<%B"/Q^O'/<!B*V7U,/^^PDZL,93S)5:&;X:M"<*3I/+ZD,/1Q,?:7I^
MTC6IT*+O*G6Q/+!5?GY2K8:4JE9.M"2:BX645[LK/ENW=/6S:ORK9'UI%>&1
M<, &(P%Y7G)PH+ 9!4<GU]C4GVEE!WJ%.,C)..YXQSUX&>O:OAWQ?\?/BY\!
MM(U#6_C;X"L?%7A+2K.>X;XF?"L7DEI;?9X6DC;Q/X*OFO-8TN.ZG$<2'0[G
M7C&C-(YC"8/Y)^&_^"_,NN_$CPOX%NO@KX$@T[Q%XSTGPK-XBB^)7B&2ULK?
M5-5ATY;M[>X\!VSK<)#-]H,%PT%O&T;I+=(H#CQ<ZX^X<X>6"AQ!BJF55LVQ
MD\NP%)4:E><\3&K&@W&5.+C%>TG%<TY<BNG+E29YN.SG*\!6P4<5C71=91]V
M4)\U9R:C%65.44W*<;>\E=[JUS^D?[5<9.%CP<=6/;CLIZCCZ@T?:[C^Y&1U
MR&/3MU4=?KC\J\+UC]I+X%:)9RWEY\3?!TB01H\]MIVN6&I7P=D!(AL[622>
M4G/"H@()SM' /SAXE_X*8_LI>%BPU#6/'UVL992VC?#7QAK"XCY8[K'2I003
MG!'!!/;!7U99QED)<DLUIJ:BKQECJ$9JZ5KKZH_>>FB;LWKHKOUG5PT9<L\1
M*,M/=DX*5I*\7;EZIJV[ZVTU_0Q;ABJE@NX@$C(  [GKU!R,$@>X)Q2^><#
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MW85"@<@@DY+*2< \Y&>#_6J1L+A6=EF7) 4?*V!ABWJ<9# #T''.*VJ  .@
M^E1*+E&I'GFE4CRRY9R36J=X/7V<M+.44FTVGH3RK7M*-2,M7JJOL^?KHW[*
M%I+56=M&T8BZ?*K*/-4YWLP9>78[L D<J .I!ZGC!JDVC&2.XBF\H[PP.5:4
M&-UVOE9,J3@M@;<$]<C)KJ*C< <  %N,@9_,<9_$_3G%34I*JGS).;NN?134
M6DI)-)1E%I:PJ0JPT^%WL.483G[24(2J*3G&I*"=2#:2<J<URN#2BK./O*WN
MRB[-?GK\>_\ @G;\!/C&T?B6QT?_ (5M\3+&62;2?B1\/C)X=UVSNY7$SR7
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M-:W&G)8O86I,99_O#_0OTP :?9$(L>^U@D*+NVJTD2NP7>2VT,QP&)(&,\T
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M+%:B-\3O'"RN8XC)A?F(-?1EE?VVHVMM=VS1RV]Q EQ"XX$D3KOB=0O\+##
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M0U+P5J&F1V;RVMU?_P"@W37^C2EC#+:M&\CQL&/AGCS_ ((W_#?XI?#7Q?\
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M $$4^J]M*DD0*L#L)C;MAD."OU' )Z'J."*GR/4?F* %HI,CU'YBC(]1^8H
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MJZG/.#\-Y"/H3QP?7'7% 'Z,0_=/U'_H"U+44/*9]Q_Z M2T %%%% !1110
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M+<AY(S@*RD$<<'>N_"&DZC<R75WI6D-+).SR2?V?9M+,,<"69H6:1@ ""S9
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MGK%I[WB]'\UM=;.Q^<5]^WK\6;/XI>&_@]=_\$_OV@4\>^*O!?B+X@:)I?\
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MQ'_T6.#_ ,)KQ1_\J*4?\%1/V(S_ ,UDMP "Q)\->*<*J@EF/_$HZ  D]^.
M37VV^AZ)&-TF@:4JYP"=.L#EN2  +<G)(P/>O/\ XF>//@Q\&O"-_P"/OBEK
MW@+X?^#M*,'V_P 2^+7TC1]%@-Q.EM#"]Y<Q1QM/<32I%#"A:221@J(QXH ^
M68/^"JO["5U=7MC:?'72KJ^TY()+^RM]#\22W=G'= M;/<VZZ2985G56:(R*
MH=58KD U:_X>B?L1CC_A<D!QT/\ PC7BGITZG2.2<9SZ$9&:T_V=?A]\,_$/
MQ6^,W[4'PY\=^ ?B=\//VA]/\ 1^%+CPDNFZMHMBO@.SU72K\Q:G:^?:33W=
MU<LDJ((FAEMGCF3>AQ]F?\(_H_\ T+VE_P#@OT__ .,?3\J /B#_ (>B_L1_
M]%C@_P#":\4?_*BC_AZ+^Q'_ -%C@_\ ":\4?_*BOM_^P-'_ .A>TO\ \%^G
M_P#QBD;0=&4%FT#2@H!W$Z?I^ ..2?(XQCKV]10!\1#_ (*B?L1L0H^,<!)(
M '_"->*.I]_[(Q_AWJB__!5;]@^'48=(E^.^DIJ=RDLEK8OHGB07=U'!_KGM
MX#I/FS)%D!V1#MR-QYS7U_XRU[X8_#[PSK7C+QM>>#O"/A7P[9O?ZYXC\1)I
M>F:-I-G'C=<W][<Q1PPP;BBAG<!C(BKDN ?C7PWI/P,_:4^/OPX_::^"OQ:^
M%?Q#\(?"OPKXJ\,ZS8>")M%\26EU>>*XK>.VGN;[2I)K>U:T-N\ACN8Q*5RR
MD!: -C_AZ+^Q'W^,D'_A->*?_E0:/^'HO[$?_18X/_":\4?_ "HK[>70=&90
MPT#26# ,&73]/VD$9!7]R< YX&3@<4O]@:/_ -"]I?\ X+]/_P#C% 'Q!_P]
M%_8C_P"BQP?^$UXH_P#E10?^"HG[$1'_ "62#G(_Y%KQ3QGO_P @C_Z]?;_]
M@:/G'_"/Z7GK_P @_3^^<?\ +#V-59]/\,6J3276D:3 EO'YT[2:99*L<2@L
M[D_9L$1HK.^/NH-YPO- 'P3-_P %2_V%].N;*PN/CQI,-UJMQ.EK;7&B>(X+
MJY,2B1TMH)-*628QI('?RD<JOS,,<UH#_@IG^Q3$&C?XT6P(D! _X1OQ0?EX
MY)&CGU[''4CL0HTKX)_M;?%;X+?&3X+?%3X8^,-&_9V\8>.;/Q=I/A=M*UF:
MXU34M/\ ^$?DTK4EM&SIMWI]W;RDI?0GS"K&+)P:^[O[ T@\OH.CODXW1Z=8
M["I/ &8"21P">_(Z5K[:?]W6S;LKMJZ3ZZI::=/O(J0=6.(A4G.4,2X.4'RI
M0]FHI>RM%."?*F]6[WUU/AY/^"H/[$B;@?C-;MEB0?\ A&O%)X],_P!C@G(Z
M>F?K4R_\%/\ ]B9\&/XPP,&;#D>&?%1$8 ^](1H^$4@8#$XSZX(K[<_L#1_^
MA>TO_P %^G__ !BJDWAW3?,/E:!I7[Q >=.L-JLAVX+>3CHV[&T@XQUK(O\
M2R^Y)?HBWX1\6Z!XZ\-Z-XM\+WPU/0-?L8M1TJ^6*6$7-I<*)(9/*G2.6/<C
M A)$5P.HR#7252LK=;2%8 JJJD[%1%CC50HX2- $C4<@*H5>.!BKM !1110
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M>]^+VB:-HL^I:?K?@?XDW%S=R:%XMU[PO>+=V'A#Q=?Z6=:TRV<21SK+Y>P
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MXF\!"RUX:GJ7PN^&DMC%I-@_@#7W$T$]_P");75=3@T/4;NPCD&8W0 ^\/\
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MNY%Q+<72VR^48K=+B>XG2W5%EED<,3]#0 ^4H+.2.[J%;&<X(  Z<9';OD4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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>%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm229830d4_1012b-img06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm229830d4_1012b-img06.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "A L<# 2(  A$! Q$!_\0
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M5S_B'_D.>$_^PK)_Z175 '04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %4;C1=*O(Y([G3+*=))1,ZRP*P:0
M  .01RV .>O J]10!1.BZ49KJ8Z99F6[3R[AS NZ9,8VN<?,,=C6/XQM+:Q^
M&?B&UM+>*WMX](NECBB0(B#RFX ' KIJY_QW_P D\\2_]@JZ_P#134 =!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7&_\+$LCXP'AY+&=G%Q]GDF\Q,*W\)VYW$$ANV<+GI782;O*?8,OM.T9QS]
M:\9T6WUFV^(<%KJWB&PFD:\$\EM_:=O]HW;.%*"$.V,D8#*".PS1'6202TBV
MCVBN7UGP+8ZU#?Q2:AJ%NE_=1W4X@:/#%$50I#(P*?*"00<D>G%=17+R>/=)
M\J[:VBN[QH+Q;)8X$7,\K('_ '99@"-I)R2!P?:@:N1:A\/]/U?"ZIJ6J7L0
M7Y899D"))LV>:H51M;&>!A,\[<U<@\$Z"+%+;4+"WU9EEDF,^HV\<SEY""[?
M= &<#H .!Z5F?\+0\/E&F"WAM1%N%R(QL:3RQ)Y0&[=OV$'&,=LYKH]%UB'6
M[%KF*&>W9)7AE@G"AXG4X*G:2/R)'-/7^OZ_K[B=+_U_7]>IF>!H(;7PW);V
M\4<,$6IZ@D<<:A511>3   <  <8KI*Y_P;_R [G_ +"NI?\ I;-704AA1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <YXM\7
MVWA*VMI)[:6X>Y9DC1'5<L!P,L1U) XR><] :T]$U6/6]%M=2CC:);A-VQB"
M5.<$9'!Y'4=:X#XG7DMAJ-C>S:CJEE9P$!1$EF8I)&#<@SL/F '.<]1CN:[3
MP>T#^$-+:VEGEA: %'G9&<CW*$K_ -\\>E$=4V$M&D7-7UK3]"LQ=:C.8HF<
M1KLC:1F8]E506)X)X'0$UGMXU\.).L+:I$"T'V@/M;R]A0N,OC:#M!;:3G S
MBK/B*UU*]TF2VTQ;5WE^26.XEDA#QD$$+)'\R-R#G!Z8[Y'GMU\*M5N[#^S)
M=1L_LKQH[SHI5Q,ELT 4(!MV<@YR#P1CG-"\_P"OZ_X!5E_7]?UN=LGCGPY(
M+4C4&!N7,:*]O*K*00OSJ5S&,LHRV!\P]13O$/\ R'/"?_85D_\ 2*ZKCS\.
M]<FOKB^EN-/2;4FV7L:RNRPH'B(,9*#<<18P0OWNO'/0:OIUU;^+/#-S+K-]
M=0R:K+MM9D@$<6;2Y(VE(U?@<#<QX/.3S3=K&:;ZG84444B@HHHH **** "B
ML?7O%&E^&VLEU*9XS>S>3#M0L"W'7'3KUH/B&&Y<QZ5;S:BX_P"6D(VPCG',
MI^4].0NX^U;+#U7%3Y79]>GW["NC8J*YNK>SA::ZGB@B7J\KA5'XFLM;/6[T
M WNH1V2$ F&P7<P/<&5QR/HBFI;;P[I5M,LYM1/<KG%Q=,9I1DY.&<D@>PP.
MGI1R4X_%*_I_F[+\PNR/_A)+*4E;&&[OR%W VL#&-A[2'"'_ +ZH%UK]RP\K
M3;2TC*YW7-P7<'TV(,?^/UL44>T@OAC]^O\ D@LS'&F:M.J?:]=D1@<L+*V2
M)6]OGWG'T/:N.^(=SJ/@VQLM6T:&34;A[E89$O'N)P"1\C*JR!5YX^[R6'IS
MZ35'4=%TK6/+_M/3+*]\K/E_:8%DV9QG&X'&<#\A71A<6J=:,ZL;QZI)*_ET
M_,4HW6A9M3,;2$W#(TYC7S&1"JEL<D DD#/;)^IJ6HX((K:"."")(H8E"1QQ
MJ%5% P  .  .U25Q2:;;104444@"BBB@ HHHH **** ,+Q9XJM/".E)?WD4L
MJ/)Y86,@'.UFZD@=%/U. .M3^&]=3Q%HL>H+;O;DN\;Q,X?:R,5.&'!&1UKD
M?BE/-;06-RU]J5G9VTJR2-;K:F*1CD*"9V W \]Q[9P1N_#Z>WN?!UK/;7%S
M<1R/*WF7#Q,Q)=L_ZHE ,] O2B.J;'+2QT]%%% @KG_'?_)//$O_ &"KK_T4
MU=!7/^._^2>>)?\ L%77_HIJ .@HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@!KL4C9@I8@$[5ZGVKS'39+B#QI%=W5
MKX@TJVO[PLL5U9V9@,K+]TNA:09QUSU^M>G.H>-D)(# C*G!'XUYS81>%;+Q
MA#9M+X@NKJVG"0RWMW//;K,01QN8C<.1DC&3C.:(_$@?PL](KDM1\%O=W-[>
M6^I+!=RZA'?P.]OO6)DB$15EW#<",]UZ^W/6U4U'5=.TBV%SJ=_:V4!8*);F
M98UW'H,L0,\&D--]#@5^$-HEJ;%=5D%B%\Q$\@;UN/)$7F;MV",+G;MZD\]J
MZ.R\'0I8>5J%_>S7+W$MS+-974]DKO(03\L<@X   !+8Y]36BGB?P_)-'"FN
MZ8TLL7G1HMW&6>/!.\#/*X!.>G!J]9WMKJ-K'=65S#<VT@RDT$@=&'L1P:IM
MO^OZ_I>1.E[F%X&A6V\-R0(9"D>IZ@BF21G8@7DPY9B2Q]R23WKI*Y_P;_R
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ME'H*=XA_Y#GA/_L*R?\ I%=4W:QFD^IT%%%%(HBN;F&SMI+FXD6.&-=S.QX
MK)L[6;5IX]2U*%HXT.ZTLW_Y9^CN.[^@_A^N33(!_P )#J(NWYTNTD(MT[7$
MJGF0^JJ1A?4@M_=-;U=#_<KE7Q/?R\O7O]W<6X4445SC"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** .(^*;PIX43SM/N+S=/M7[/(R/&2C
MC(*@GYAE.F#OYXJ_\/<_\(?;;K9H'$LH<M([^:V]LR;G 8[CSSZU3^)EK!=^
M';99W@.R[1E@GM)+I9SM8;/*C(9SSGVVY[5H^!4MX_"-HEL+-8P7&VSMGMT0
M[SE?+<EE8'((/?-..TAR^R='1112$%<_X[_Y)YXE_P"P5=?^BFKH*Y_QW_R3
MSQ+_ -@JZ_\ 134 =!1110 4444 %%%% !1110 4444 %,EECAB:65U2-1EF
M8X 'N:H3:KOF:VTZ WDZG#L&VQ1'_;?U]AD\CC'-)%I)EF6XU*8W<RG*)C;%
M&?\ 93N>.K9/IC-3S7V-E2Y5>H[>77[NGJ_N8W[==ZB=NFQB.#O=SJ<'_<3@
MM]3@>FZGIH=J(9%E>XEGE4+)=&9DF;!S]]""HSV7 ]JTJ*.7OJ#K-:4]%^/S
M?]+R*FFZ;;:39K:68E6!<;5DF>3:    7)(  ' XJW113225D9RE*<G*3NV%
M%%%,D**** "BBB@ HHHH *\:OK\Z9\1IKNY:]-C%J.YM/BL+N2+.S'V@.N4+
M9_A"]??FO9:\C&]_BRSR:M=F)+X"([)?+!((:/.[;U54Z;?^!&B/QK^OZ_KJ
M$O@9ZTC!T5USAAD9&*=110 4444 <_X-_P"0'<_]A74O_2V:N@KG_!O_ " [
MG_L*ZE_Z6S5T% !1110 4444 %%%% !13)6*0NXZJI(S7%'QEJ(^$\7BKR;7
M[<\"2&/:WE9+A3QNSC!]:/\ @?CH']?J=Q16'K^L7-@VFV5BL/V[4IS!"\X)
MCCPC.S, 06P%Z9&2>HK%E\7ZE9:D_A^XCLY=9-Q!#!.B.D#K*KMO*%F(*B-_
MEW'.!R,\"5P.VHK T?5[YM;O=#U4VTEW;01W*W%M&T<<D;EA]QF8J04/\1SP
M?:I)/%.GE)TM!-=7T:LR6*QF.:4#NJN%RN?X_N^] &W17/>$]?N-9\+C5=4C
M@M95EG658V.R,1R,O4]>%Y/\JK^%/%-SXBO-:$UH+>VM)8Q:@@B1XV0,&;)X
M)SD#C (SS0]'8#J:*XZ+XEZ%)9V5V\=Y#!=VMQ=*\D:_(D)P^X!CR3T SGVJ
M7_A-?M$[6-OIUU:Z@KVV8;U4^Y*QY&QSDA$<]>./<!V ZRBN)7XG:8UL+C^R
M]5$;6;7RDQQ<P*VUW_UG\)Z@\G^$-6QX?UZ76=3UJ$B+[/9SQ);N@(+(\*29
M;)ZY8],<468;&]1112 **** .$^)EY#:6VEDS0VER\[B&\FU(V2Q?(=P+@$G
M<.,8Q^0K7\":KI6J^$[)M*>'RH4$<D45P)S$_<,W4D]<GDYR:QOBC<WEMIVF
MBVOH;59;@Q.7(W?,,97*L>!D\8YP<X!KH/!RG_A$].D>6&:22$.TL)4A_3)4
M ,<8!..2*([/U"6Z-VBHYYXK:"2>>5(H8U+/)(P55 ZDD]!5=M6TU+Q;-M0M
M%NFB\X0F90YC_O[<YV^_2@"Y7/\ B'_D.>$_^PK)_P"D5U5Z/Q#HDL5K+'K&
MGO'=N8[9UN4(F8=50Y^8^PJCXA_Y#GA/_L*R?^D5U0!T%8^MR2W3PZ-;.R27
M8)FD7(,4 ^\0>S'(4?4G^&M9W6.-I'8*B@EF)P !WK(T"/[0DVM2H1-J&UD#
M+AD@&?*0@\C@EB#T9VK:E[J=1]-O7I]V_P!PGV-6"&*V@C@@C6.*-0B(HP%4
M#  J2BBL6[ZL84444 %%%% !1110 45C:-KW]KW^M6WV;RO[,N_LN[?N\SY%
M?=C Q][&.>E5=-\76]WX*?Q-=P&UMXTE>2,/O($;,O!P,D[?UH_K[PZV.CHK
ME7\7S:6\3>(=.CTZWN(I)8)8KKSON(7*R#8NUMH)P"PX(STS+:^)[P7FG)JF
ME)96^J';9R)<^:^[87"RKM 0E0>C,.,9'%.S"_4Z6BJIU*Q6]>R-[;BZ2/S6
M@,J[U3^\5SD#WK(\6>++?PM:6\C0-=7%Q,D<<"-M.TLJLY.#A1N'XD#O2 Z&
MBN9B\7K)XB73S:*+1[I[&.Z\[+-.D>]E*;>%P",[LY'3O5JX\7Z':ZI+ILUX
MRW,,D<4H\B0I&T@R@9]NU=V1C)Y/'6C>WF!N45A?\)CH7V_[$+UC,97A7]Q)
ML9T4LZA]NTE0IS@\'@\\54M_'VB&&$7LSVMTXB$D/DR.(GD0.B%PNW)!X]3P
M.>* .HHKGK;Q=9W^M:;8V*&:&]AN)#,VZ-HFA959&C900<MR#@C'2NAHL 44
M44 <;\2;J"TT"U>4QQ2M>(L%U+>_9%MWVM\YD )' 88P<[L'BG_#G5]+U+PV
M(=/FMWGMY7%RD5Y]I.\NV9"_4AR"P) R#4/Q0O+RP\*"XL[NWMBLXWM, <C:
MV, JV<'!( R0#BKW@&-E\+0O+<PW4ADD7SHV5B5#L%#,H&6 X/'6G':0Y?9.
MGK/U;6K'18H9+UYAY\GE1)!;R3N[8+8"1JS'A2>G:M"N=\8:%/KVFI;0V&D7
MA!;*ZDA/EY4@/&P!VL"<].>F5ZU+!6ZCSXU\/K)=QO?E&M(S),'@D7 & 0,K
M\S LH*C)!(! )JIXIU*TU;X7>(KVRE,D#Z5=@$HR$$1N""K $$$$$$ @BN53
MX8ZPMN;9]2MIEM1)+:SR.^^>5Y8I3YHQ\HS%C(+$ALXXP;>O>$!:?#;Q#<:C
M/<_;_L5_<NEIJ%PD 9_,DV[%95<#=C++\P'(QQ565OZ_K^O,7;^OZ_KL>DT4
M44@"BBB@ HHHH **H:QJL>C6)NY8))8PP5A&\:D>_P [*#Z8!SSTJAI^IWGB
M.QBNK*-]/L9AE99=C3.,=54$JOU;)X/R]ZES2?+U-XX>I*G[5Z1O:_G^?X&E
M>ZG;V3K$Q:6Y<$QV\0W2./4#TZ<G '<U6%G>ZC\VH2?9[?/%K YRP_VWX)X_
MA&!VRPJY9V%M8HP@3#.<O(Q+.Y]68\DU9HLWN'M(P_AK7N]_EV_%^@R&&*WA
M6*&-(XT&%1%  'L!3Z*IQ:K93ZM<Z7'-NO;:-)98]I&U7R%.<8.=IZ'M5&+;
M>K+E%4['5;+4OM7V2?S/LD[6\_RE=DBXR.0,]1R.*IV7BG1]1O$M;:Z=GDSY
M3O!(D<V!D^7(RA9, 9^4F@1L45CVWBG1KN_6SANV,DC%(G,$BQ2L,Y5)2NQR
M,'A23P?2MB@ HK.U;7-/T.*)[^9U\UBL:10O*[X&3A$!8@ 9)QP.M7+:Y@O+
M6*ZMI4E@F0/'(AR&4C((- $M%%0+>0-?262R9N(XUE9,'A6) .>G)4_E0!/1
M574=1M=)TZXU"^E\JUMT+RR;2VU1WP 2?PJRK!E##H1D4 +1110!%<R^1:RS
M8SY:%L>N!FO'/"&OZ?XE\:6M[-%X6BU-]D[W,4I\Z3?'D1)&6YD7E6?VZ>GM
M! (((R#VJNEA9Q.'CM($<<AEC (_2A:.X/56+%171N!:RFU6-KC:?+$I(7/;
M) )Q4M%)[ >2Q>,_$7E:7)+?*9$A@DFC2! +MI+LPL.F5"J,C;@Y(R36GX3\
M:WLC2RZQ-=W<4UK#<JEK8/,UN[O*#'MA0MM C'+9.<Y/(%=S_8NE;[5_[,LM
M]H2;9O(7,)/4IQ\N?:I+33;&P>=[.RMK9KA_,F:&)4,C_P!YL#D^YJD[;_U_
M7]=0>W]?U_7H8O@:9;GPW).@D"2:GJ#J)(V1@#>3'E6 *GV(!'>NDKG_  ;_
M ,@.Y_["NI?^ELU=!2 **** "BBB@ HHHH :ZAT9#T8$'%<?'\/($\-OX>;Q
M!K$FEF(1) PMOW8#!@0PA#9!'<FNRHH P'\,&XM%BO=:U*[FBE$UM<R"!)+9
MP",IY<:@\$Y#!@<TT>#[%K>;S[F\N+V:9)VU!W43ATX0C:H4 #/RA<<G(.3G
MH:* .<\.^$(/#FH7EW%?W=Y)>*HE>[VE@5+$!=H557YC\H4#O71T44 8%OX1
ML;:QM[$7%V]I%//-) [J8[CS2Y9)5VX=,N<#V'6G:)X0T3P]J&H7FEV,%L]\
M5WI%$B*@48VJ%48!ZD<\G-;M% '"S?##3ELFBMKNXD\JVNK>U@NBIAB6?DJ0
MBJY (X^;(]>E/\->#-0MM6DU?7KSSKS9$B*DXE'R(Z[BWE1\XD; "C'<DFNW
MHII@]3DA\/-(%DEK]HO?+73)=,!WIGRI&#,?N_>R.#T]JU]&\/VFAR7DEM),
MYNVC9_-8'!2-8QC '91^.:UJ*+L HHHI %%%% 'FOQ!U6UN=8BTB?2KZX%OY
M9%Q8W@AF$DV\(BJ>&4^6=Q) '![<=OX=M&L/#UC;/;K;M'&-T2S&;:>IRYY8
M\\GN<U6U;P;X;UV\^V:KHME>7.T)YLT09MHZ#/XFM6RLK;3K*&SLX$@MH5VQ
MQ(,*H] *%HK ]7<R/&>CG7O"&J:?'"9YY+:00Q^9L#2;3MSR!UQUX_*N#\3^
M!?$&KW-[;6L"HER%F6\:5 $VVC0^21G=DL<Y (P3SVKUJBA:.Z*4FCR!O!OB
M.?4KB^_LLQ+J+;!"TT6; "2!MYPQ!R(F/R$G.WCJ1U^KPZPGBSPR]Y?6,UB=
M5E\F&&S>.1/]$N=NYS*P; R#A1D\\=*["N?\0_\ (<\)_P#85D_](KJG?2Q"
MBD3^(/\ 3$M='"[A?R%9QP0(%&9,CT(PG_;05%:>+M*N_%MWX8A,W]HVD?F2
M*8\(%PIX/_ Q4]A_IFNZA>D'9!MLX2<8./F=A]68*<]XZT5L[5+IKI;:%;AA
MAI0@#D>YZ]A74Y4X1]G--Z:6=O>=G=][+2PM=T34445R%!1110 4444 %%%%
M '+V'AS5]+UW4[RSU>Q^QZC=BZF@FL':1?D5"JR"8 <+U*GKWJKI7@N^L_#\
MOAV^U6SN]&ECFC:-+!XY\2%C_K/-9>"W]SM7944!UN<K)X0FU22)?$&HQZA;
MV\4D5O%';>3]]"A:0[FW-M)&0%')XZ8JQ>#M677=*O;O7A>V>G,##:-!Y?(1
MD\QFW-EP&[!5/IGFNTHIW=[A;2Q6N=.L;S9]JL[>?9()4\V)6VN.C#(X(QUK
M \5^!M/\4J99)KFVO"L:">*XE4;%D#[2BNJG.#R>0<'L*ZBBD!R]MX-2VUZ.
M]%YNLX;E[V*V:,EQ.\?ELQD+<K@DXQG)SN/2LBX\&:CJWB3Q%]JF6VTB_N+2
M4@('>=8E!(4AOD^90"2#D=,=:[^BCMY?\#_)!_7]?>>5KX,U^\U*/3)8OL>D
M6UY>313'9("DRN" P<.QS(3@HFWGEL GIK[P.+N^N;A;_P M9M1M+X)Y.=H@
M"C9G=SG;U[>AKKJ*:=K>7_ _R0/6_G_P?\V<EH_@C^R=<BU+^T?-\N:]E\OR
M=N?M#J^,[C]W;CISGM76T44NE@>KN%%%% 'E?Q<UV&WEM=*NC9K;^6)R);DP
M32%G\K$;YPN%=BQ(8;<\=ZZ_P%!%;^$+417UI>[VDD:XM)C*C,7)/SDDL0>"
M>Y'0=*WYK2VN&#3V\4I P"Z!L?G3XHHX8Q'%&L:#HJC %$=$T#UL/HHHH *Y
M_P =_P#)//$O_8*NO_135T%<_P"._P#DGGB7_L%77_HIJ .@HHHH ***YN7Q
MC"GB%M"CTN^DOQR &AVE><,3YF0,#/(SC''.*F4U'<VHX>I6NJ:O97?DN^Z.
MD) !). *RSJ<MXQCTJ)9@#AKJ3B%?IW<_3CW%)_9<M^1)JT@D3J+2(D0C_>[
MR?CQT^7-:@ 50J@  8 ':C5^0_W=/^\_P_X/X+U.?U/18I-.F6[MKW5Y[A3$
M[1M&K(K9SL#,JH.W')XSGK4G@VPDTKPM9:?-9S6LENFUTE=&W.?F9@58C:69
ML9P?:MVBDJ:4N9%RQ=25'V,MKWZ]K;;;>044459RA7&/%JVE?$'5=4CT&]O[
M.\L[:&.2UEMQM9#(6R))4/\ $.@-=G10M'<.EC@](L=7M)/$6F7&B:@D.J7\
M\L5]#-;[(XY%"AB/-W@C'930-%UC4]/T'1;G3FL$TIXWFO1-&R2;(RH\D*Q;
MDGG<JX&>M=Y11;2W]:;!UO\ UKN>9-IGB6.Q\.^'I-&QI^FSVIGU&.5&SY3#
M#(@8N0V!G*KMYY8=/1KRT2^M7MY))T1^&,$K1/CV92&'U!!J>BFVWN'6YPOB
MGPQJ$\.GB)]2U:""65I(UNDAN%#1E$"2 Q_*"QSELL.I;I6?XHT^YM?"W@G3
M]1@AN[B+4;6*>&(*J2$1L"H!P,=L<#Z"O2J*7EYW \-U:Q?0(_(UNUC\BZM;
M[^S+"65%%@SMF,*Q.POM.T+&689PH(R:ZF/PIJ%_9:*]U8!U2\M#-%(5^6WC
MMRIW GGYV;CKSTKTFB@'O<\8F\ ^((]"CM[32U2>2RU"WN LT8+!I ;="=W(
M"_='1>G%>R1*5B13U"@&GT4[Z6![W"BBBD 4444 %%%% !12$A5)/0<US/A;
MQ?\ \)+/-&;'[,OD)=6[";S/-A=G56/ VME#\O/4<T+4.ER?P;_R [G_ +"N
MI?\ I;-705P?A/Q-#%?ZGH M+F6:WOKZ9GC4,"&NG;IG/\8'X5U3ZLP1BFG7
MS,!P/* S^9J(U(R5TR5)/8TJ*YK0O$U_JEI)+=>'[VV=7VA0!R, Y^;:?TK1
M.JW>?ET'46'8[[<9_.7-)5(M<R_)_P"0*2:N:E%9BZG>N<#0KY/=Y(/Z2&G?
M;KX\#2)P?]J:/'_H54I)CNC1HK/^UZC_ - O_P F%I/M.JGIIL&/>[Y_] IW
M"YHT5FM<:SC]WIMGG_;O6 _2,T@FUTD Z?IR#U%\[?IY0_G2YO)_<%S3HK.W
MZS_S[V'_ '_?_P"(I<ZP>2MBOMES^N!3N%S0HK.VZR>?.L%]O*=OUW"D,>M$
M86ZT]3ZFV=L?AY@_G1?R"YI45E^1KW_02TW_ ,%[_P#QZGBVU? W:E;9[XLR
M!_Z'24F^C_KYA?R-&BL_[)J1ZZHN?]FW 'ZDT?8M0/!U5@/]F! ?US3OY!<T
M**SOL%]_T&+C_OU%_P#$U3U+0M0OK":"/Q%?1/(, A(@HY_V4#?DU2Y-+17^
MX&WV-VBJ>E6<MAI5M:3W#7,L2!6F;.7/KR35RJ6JU&%%%%, HHHH **** "N
M8\7W<=A>^&[R8XB@U&61S["QNB:/%/C >&[F"%;'[43!)=SDS>7Y<$94,P^4
M[F^<87C.#R*XSXI^.M"M9M%MH+M+VXLM2\^Y@MI%?:BQR1O&YS\K'?C!YZUU
M8/"U,56C3IJ]_P!-R924=STG0K-['1;:&95$Y4R3[1@&5R7<_BS,:T:YJV^(
M'A*>UAE?Q-HL+NBLT;ZA$&0D9P?FZBI?^$[\'_\ 0UZ'_P"#&'_XJL*CDYMR
MWNQHZ"BN?_X3OP?_ -#7H?\ X,8?_BJ/^$[\'_\ 0UZ'_P"#&'_XJH&=!17/
M_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 50!T%%<__ ,)W
MX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5 '045S_\ PG?@_P#Z
M&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\
M&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\
MQ5'_  G?@_\ Z&O0_P#P8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\
M"=^#_P#H:]#_ /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_
M .AKT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0
M_P#P8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%5T% !1110 4444 %%%%
M!7/^._\ DGGB7_L%77_HIJL>*=7FT/P_/?6\:23AHXHA("5#.ZH"V.< MD_2
MN.USQE97GP[UNQU2_L8M8F@N[$6T4@5I3N>$2)&S%MN02>N &Y.*3:2;>R+A
M3G4E&$%=R=EZGI-9^J:WIVBK$;^Y$1F;;$NTLSMZ  $D\BO,;OXGW&ORFQTZ
M_P!.\.E#YHN]2NT02*.-F"I&26S]%-=(NI_#Z802ZCXET.]O(RKFXFU.)FWC
MN/F  SV  ]JRC5]HOW?W]#T*N 6$DEC'9]8JSDNU^BOZM[Z(Z7R]0U//G%["
MU/\ RS1AYSCW8<)]!D^XZ5FVW@:QL_$0UNWO;V.Y!(V#RMFTG)4C9D@],YW>
M^>:G_P"$[\'_ /0UZ'_X,8?_ (JC_A._!_\ T->A_P#@QA_^*JW3B]7J<T<9
M5IIQIOE35FEV\[WN=!17/_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"AKT/_
M ,&,/_Q56<IT%%<__P )WX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P_
M_%4 =!17/_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 '04
M5S__  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#_P#!C#_\50!T%%<__P )
MWX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P__%4 =!17/_\ "=^#_P#H
M:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 '045S__  G?@_\ Z&O0_P#P
M8P__ !5'_"=^#_\ H:]#_P#!C#_\50!T%%<__P )WX/_ .AKT/\ \&,/_P 5
M1_PG?@__ *&O0_\ P8P__%4 =!17/_\ "=^#_P#H:]#_ /!C#_\ %5L6-_9Z
MG9QWEA=P7=K)G9-!()$;!(.&'!P01^% %BBBB@ HHHH ****  C(P>E<K9?#
M[P]9I.MU:KJ4#;1'%J,<<R0(A<JJ KP!YC\G)YZUU51SQ":"2(D@.I7([9&*
M3NKM#WT9YQX=\(>!_$/A[5+&+3=*EDDGNP;J"P5)(HII9&B,;/&#\L;*%8 K
M\O!(%='<?#KP?<3VDO\ PCFE1?9I3+LBL8567*,FUQM^9?GW8_O*I[5!X(\+
M7_AU9CJ$MN[BUM[*+R&9@T<(8!VRHPS;CD<@8ZFNOJI))Z$JYR]O\.O!]O/=
MR_\ ".:5+]IE$NR6QA98L(J;4&WY5^3=C^\S'O5>'X7^#X;72X/[#L9/[/V_
MO'M(2]SB)H_WQV?/G=N/3YE![5V%%(9RZ?#KP>FHS7G_  CFE-YL4<7DM8PF
M--A<[E7;PQWX)[A5]*K_ /"K_!_V'[+_ &'8_P#'W]J\W[)#YG^N\WR\[/\
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MF(J\?[SY.5^;<%Z[E4]J[NN.\1>#9=7O-3FM6M;<7FG?9]VTAC,) X9L#D<
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M; 7>T]P96&,D_* HR>N:Z^AVLA=6%%%%(84444 %%%% !1110 4444 %%%%
M&1K>L3:;)8VMG:+=7U]*8X(Y)?*0;5+,S/M8@ #LI.2.*A?Q39V,=M'K*MI]
M[,NYX #,(ANV[F= 55">C-MZ]CQ5O5]%BU=;=C<7%K<VLGFV]S;E=\3$%3@,
M&4@@D$$$<UDW?@;3[T)Y][J+DPB"Z9Y5<W<8<OMD+*3C<3]S;C.!QQ0O,'Y$
MW_"<^'?.NHC?LK6WF>9NMY0"8V".%)7#D,0,+D\CU%.'C;P\5MF^WG_2"P4?
M9Y,IAMA\P;<QX8A?GV\\53N?A[I%T@62:[X>XD4AU^5II5E+#Y>JLB[?US27
M7P]TJ_NK*[OKFZO;JU+9FO$AN#*"VX@B2,JHST\L)CH,4+I<<O(6]^(N@6UC
M>SP2W%U):@YBCM907Q((FVDKA@'."5SC\15B+QWH$VF7&HQR7[6EM(8YI/[+
MNOD89W9'EYPN#D]!WQ4$OP_TJ6V:#[3>J#%/$&5TROFS"8D?+U#*,=L=0:AN
M?AQIMWH,>D7&HZE) )YIY69HB9VE)+AU\O9C+9&%!4X((HZ"ZDD/Q TJ:_G@
M)\B""Y:!Y[E9(U8+#YI9#L*G@'@L..>Z@VG\=>'H[9)WNYP'E,(B^Q3^;O"%
M\&/9O'RC=R.1R*HO\-M&E5HI[B^FMF;<;=W3:6,'D$Y"AN4P>O4 C'(-J#P-
MI\5Q'=2WE]<W:RM*UQ*T8:0F$P@,%0# 1N, <\G/--VZ"5^I<O\ Q/96<6E3
M1L)XM2?]U(K<>6(VD9^F2 J].^15.W\>:'?26@L;Q'$\BC]_'+"VQHW=74-'
M\P(0\G"\'YLC!9J/A$MI6B6>G3X_LI#"AG;[\9A:(Y*CKR#T[=JS]%^&EE:V
M6G-JEW=7=];00Q.3(ICPD3Q^6OR E/WCGGYN1D]J';6W]=AKI<UT\=>'9+4W
M$=]*ZAP@C6TF,C97<"L83<RE<MN (P,YQ3KCQSX<M9HXY-0)\P1E9(X))(_G
M&4&]5*@D<@$YQS51? 5JEM!&NLZOYUKA;:<RQEH$V%-B*4V8*G!)4L>"3D U
MA7GPUN&UF""PN(;;P^K6[O"LA#YB0H#M*'<Q&!NWJ!CE2>:3\A*]M3J8_&NA
MRVEC=B:[6UOF"6\[V%PD;%B N6* +DD8+8!SQFJ]K\1/"]Y-'%#J$NZ5T1"]
MG.BG>Q53ED VE@5#=,\9S5>\^'&DWJ:5'+>:AY6F0PQ0Q[XRI\H@HYRAPW&"
M5VY!P:2/X;Z/%!%"MS?[8XH(E)D3.(IC,O\ #UW'!]O3K3TOY#Z>9(GQ%T*.
MZEMKR:6"99FC0);RRAE$C1JQ94VJ69& !.3CC.:CF^(-EYY:U@^T6"QVTK7.
M\H5669HCE&7(*LO(.#UZ8YD_X5[I.Z-OM%[N06PSO3YC!*95)^7J68[O7MBJ
M\OP\M8+26#3[F;_27B6<W#@CREN&G8+M4<DNR\\8QZ<BMI?^MO\ @@^MCM:*
M**0!1110 4444 %%%% !1110 4444 %%%% %35=1@TC2;O4KG=Y%K"TTFT9.
M%&3CWXK*@\175K9RW>OZ:NG0#887@G-SYN_@(%50_F9Q\H4@Y&":V;VS@U"Q
MGLKJ,26\\;1R(?XE(P16"W@V&6T:&YUC5KAU>-[>:65"UL8SE"BA F1ZLK$]
MR:$#V'CQUX<-Q! +]B\X0KBVEPNYS&-YVX0[U*X;!!X/-*WCCPZK7"F_8O P
M0JMO*6D);9B,!<R_,"OR;N1BJD7P]TB%)0L]X6F\II7+KEWCG:?>?EQEG8YQ
MQC@ 5'<_#C2KNQEL9[R_>S,GF06SM&T5NV\N=L;(5;DG_6!^#@<4WY _(OCQ
MQX=:[@MEOV:2=8V3;;RE?WA(3+;<*25( )!R,=:JZ3\0=%U5(%1-02YFB>9;
M?^S[AV$:LR[CM0CG;^? R:=#X"TF *(WF0*;4[8EBC7-N[.IVH@499CNP![8
MJ.'X?Z?!%=)'J.IKY]JUJK+*BM#&9#)\A"#D,QQG/'!S0[=!*Y%=_$C1XY?+
MMEFD'V6>X:6:WGB2,Q,%9)/W99#DG.5XXX^89T[GQIH%D]TES?F/[*CO*WD2
M%/D&7"MMPS*.JJ21W%8\?PNT:&S>VBO+^..2.XBD\LQ+O6;:7&!'@?,@8;0,
M'VXJU>_#O2+_ .TI+<7HMYC,RP*R!(9)1B21/ESN()ZD@9. *-- U-"7Q;I8
M\.ZCK4$CRP6"OYJ-$T3AE&=I5P""<C&1W!JG<^/M%MH[J*2Y6.]MD?S(Y8Y5
MB61(_,:/S1&02%YX!.,D U/J'A."XT/7K"WGE635BTK.YXCD**@(P!P-BGOW
MK"C^&XU&?59-<OIBEW<R3Q6]K*/+0O (B_S)G>!O Y*\@XS1I<:Z7.A/C/08
M[F6VFU!(Y88S)(6C<(,*&8!RH5F 8$J#NP1Q3)/''A^*T6Y>[F"EV0Q_8YO-
M0JNYM\>S>@"D$E@!@@]Q5>7P'ILQNXWO-0^QW66DLUF"Q&0J%,G"@EOE!P25
M!&0,UC:]\/KV2))=&OR^HR/-]KN[R14EF62,1D96(J  J?*$&<<,IR2GMH$?
M,Z&W\;Z%>074]I->7$5KM\UH-.N) -P##&V,Y.""0,X!YQ5=OB+X7$RQ#4)9
M&9$=3%93NK;TWJ 50@L5Y"]>.E5;?X<Z?'X=_LA[Z]VO,D\S(4P[")8RI5E*
ME"%^ZP/UZ4ZP^&VC:<+<0W%\1;RPRH&D0\QQ-$H/R]-K'/O^5.5KNPHZI7W)
MYOB!HMO.&DE=K*6*%K>X@BDF,S2*[A0B(6&$3=D^M17/Q!TZ6.W_ +%4:C)-
M,(@C%X ,PO*C LGS*VS (XY//&*+#X=:1I]G9VT5S?.MK.)T:1T+$B#R #A>
MFWGZ_E3(OAWI]@D$UA<7375I#"EN)I%V$Q121INPF>DISCT&/0DK:V*6ZN=-
MI.I0ZQH]GJ5OGR;J%9DSU 89Q5RL_0=+71- T_2U?>+2W2'?_>*@ FM"G*W,
M[;$K;4****D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/ %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm229830d4_1012b-img07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm229830d4_1012b-img07.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" #; AX# 2(  A$! Q$!_\0
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M1MXQNO#,OB1-#\VXCB\P6$7S3N=^U005!8,P(4@_D5'^VG^QUXH\50ZQ>_\
M!4;]M&;Q3</DFPDU2PTAYV) VZ<NB?9UCR?]7T]QV /WGHKS+]E+X=_$#X7_
M  T?2_B%\2E^*]^MTTNGZ])H$.C7;V;*OEQ7,<#&*253NS*B1!@1E 02?3:
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M\(/$'AF/S/MMAHGPTU'1[^XS&PC\NZEUVZCCQ(48[H'W*K*-I8.H![!1110
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M_I=PJS7'S _O95#OU8 DUT=?/X_;)^(I'_)IWQ__ /!OX(_^:&OH"@ HHHH
M**** "BBB@ HHHH *SO%OC#2? /AVZU?7=4T[1=)LE#W-[?W*6UO;J2%!>1R
M%49(')ZD5HUS7QD^&-M\:OA3XA\(WM_J.FV'B6PETR[N+ Q"X6"52DBH94=
M60LN2I(#$C!P0 9?PY_:6\!_%C1=1O\ 0O%.DW4&CI--J"RR_9I;"**>XMWF
MFBE"O'%YMK<*LC*$?R7*L0,TSX9?M/?#_P",GB"\TKPQXMT;5]1LY)(S;PS8
M>X$<5M*\L ;'GPJEY;$S1;X_WZ#=DXKQ_P#X)R?\$N?!_P#P3-^$/B+P?X U
M?5K.P\27D]]*D0#16D[R2B.>$7!GD\U;<V\+>9(\3?9$<1(SR;\C_@GE_P $
M@?A]_P $V_B5X[\2^!]2UDS^/;HRZA#,^Y+M L1C,Y<N3,DWVJ0/!Y$9^V.K
M1$1Q; #ZSHHHH **** ./^/WP5\)?M%_!?Q)X(\=Z3;ZYX0\26+V>JV,Q8+/
M">3RI#*00&#*0P*@@@@5^%'[&W[*G[/GC'P5I'B'X3?\$Y?BQ\9/!]GJ\ZZ7
MXV\3>,;6WFU=H+IE,CVQG2)HD=2H7RRK*F&#'=7] =W&)K612[1!D(+JV"G'
M4'L:_ #X<Z7^S3\)OB3)H7A7]H;_ (*?>%OA7)XNGTM_B%I6N?8OAL^L2W3+
M*ANXK49,ER2K2>5ABQ8MM)>@#]_K+_CSBQ%Y(V#]WC'E\?=_"LGXE0>(;KX>
MZW'X2N-)M/%,EC,NDSZI$\ME#=%"(GF1"':,/@L%() (!%:]I&(;6-0[2A4
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M&92 ?6\4JS1JZ,&1@&5E.00>XIU-B4QQJ"Q<@ %FQEO<XXIU !1110 4444
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M;R"XU75;O5+A 5NU'EK/>2J@QD(J!F9@6/8?\1*_[;'_ $*G[+7_ (+->_\
MDV@#^@NBOA[_ (((_P#!2'XB_P#!3G]E3QOXQ^)VE>"](\1^$_']_P"$5B\+
MVUS!920VUG8S!R+B:9RYDN9!G<!M"?*""3]PT ?B;_P=L_\ )QG['?\ W.O_
M *2Z57YRU^C7_!VS_P G&?L=_P#<Z_\ I+I5?G+0 4444 >S_P#!(;_E.O\
MLN?]S7_ZC]W7],M?S-?\$AO^4Z_[+G_<U_\ J/W=?TRT %%> ?\ !6#_ )19
M_M*_]DJ\4?\ IHNJ_E*^&'[*O@+Q%\-?#VH7F@^==WVF6UQ/)]MN%WR/$K,<
M"0 9)/ &* /ZM/\ AVG\.O\ H8_C_P#^'V\;_P#RVKR#_@GM^Q+X8^./[ WP
M/\:^*?&/Q_U3Q-XP\ :#K>KWG_"\/&<'VN\N=.@FGE\N/5%C3=([':BJHS@
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MCSJ5A\0_$/A_2-#;QE:>'4L_#D&J:DEK<QW=V'26*)8;>%(QR4D4@[4-:_\
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MO%'_ *:+JOYC/@M_R1SPG_V!K/\ ]$)0!TU%%% !7[F?\&N/_*"CX&_]Q_\
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M"]O[8?PL\:?$+7=/\-_LU37?Q*U^+Q'J:7&GZVT<%Q'I6GZ6JPA;M2L?D:;
MQ#%CO>0[MI55[#_B)7_;8_Z%3]EK_P %FO?_ ";0!_0717YN?\$!_P#@K9\8
M/^"F/C;XXZ#\6]%^&VDW?PN&@_87\(6=[!'<?V@E\\GFFYN)BVT6T6W:$P2^
M=V1C](Z /AK_ (+K_P#).OV=O^R[>&O_ $7>ULUC?\%U_P#DG7[.W_9=O#7_
M *+O:V: "BBB@#Y__;G_ .1__9E_[+MX5_\ 1LU?J97Y9_MS_P#(_P#[,O\
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MTVPT;2-,A6VL[&QMTM[:TB486..- %10.   !7PA_P &N/\ R@H^!G_<?_\
M4@U.OO\ KX _X-<?^4%'P,_[C_\ ZD&IT ??]?R!?\'1W_*=?XY_]P#_ -1_
M3*_K]K^0+_@Z._Y3K_'/_N ?^H_IE 'P!1110 5^_P!_P8Q_\W1?]RI_[FJ_
M &OW^_X,8_\ FZ+_ +E3_P!S5 '[_4444 %%%% !1110 4444 ?R@_&/_D^K
M]JC_ ++=XM_].#U1J]\8_P#D^K]JC_LMWBW_ -.#U1H **** /US_P"#1/\
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M_9V_[+MX:_\ 1=[6S6-_P77_ .2=?L[?]EV\-?\ HN]K9H **** /G_]N?\
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M0==L: *N6)8X')8GJ:Z2@ HHHH _E!^,?_)]7[5'_9;O%O\ Z<'JC5[XQ_\
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M^B[VMFL;_@NO_P DZ_9V_P"R[>&O_1=[6S0 4444 ?/_ .W/_P C_P#LR_\
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M/4?BGK5IXI\&^ -'\$P>?_9&K:5XRN]2U6^Q,H@^T6,FEV\5OOAW.^R[FV.
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MU8N@,9=5$D9;]6: "BBB@"&_E,%C,XB,Q2-F$8_Y:8'3\:_%W]EG_@F;J_\
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M/I2TB?<'TI: /YF_^"OG_*=?]J'Z>%/_ %'[2O%Z]H_X*^?\IU_VH?IX4_\
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M /\ AH?_ +KH ^@/^"L'_*+/]I7_ +)5XH_]-%U7\QGP6_Y(YX3_ .P-9_\
MHA*_:/\ ;<_X+%:K^TG^QA\7?AUH7[&?[=]KK?C[P5K/AS3Y[_X2.EK#<7EC
M-;Q-*R7+L(P\BEBJ,0 <*3Q7X\?#W]GSX]^$_ .AZ5<?LL_M0O<:;I\%I*T?
MPUU$HS1QJI*DH#C(XR!0!:HIOBSP1\8/ 7A;4M=UW]FK]I71=$T6TEO]0U"_
M^'E[;6MA;Q(7EFEE<!8XT169F8@* 22 */"?@CXP>/O"NFZ[H7[-7[2NM:)K
M5I%?Z?J%A\/+VYM;^WE0/%-%*@*21NC*RLI(8$$$@T .K]S/^#7'_E!1\#?^
MX_\ ^I!J5?B#_P *<^.O_1J_[4O_ (;34/\ XFOT?_X(S?\ !1[Q5_P3M_X)
ML_#CX.^-?V._VW]4\3>$/[3^V76B?">:>PE^TZI>7D?EO+-%(<1W" YC7Y@P
M&1@D _9^OY]/^#EC_E-?X3_[(C:?^G[4:_0S_A_I_P!65_M__P#AH?\ [KK\
MN/\ @KOX^^*O[??_  4-T3XM>#OV2_VO=-\.:;\.H/",MMK/POO(;UKM-3N[
MLNJ1&5/*\N= "7#;@WRXP2 ?/-%7O^%.?'7_ *-7_:E_\-IJ'_Q-<_\ 9/B7
M_P +3_X0;_AGS]H7_A-O[*_MW_A'O^$%NO[5_L[SO(^V?9O];]G\[]WYNW9O
M^7.>* -*OL#_ (-J/^4V/BO_ +(C>?\ I^TZODW_ (4Y\=?^C5_VI?\ PVFH
M?_$U[Q_P2)\??%7]@3_@H?K?Q:\8_LE_M>ZEX<U+X=3^$8K;1OA?>37JW<FI
M6EV'9)3$GE>7 X)#EMQ7Y<9( /Z1J^ ?^#HO_E!3\<_IH/\ ZD&FTG_#_3_J
MRO\ ;_\ _#0__==?,'_!9?\ X*0>*?\ @HC_ ,$V?B1\'?!7['?[;^E^)O&'
M]F?8KK6_A/-#81?9M4M+R3S'BFED&8[=P-L;?,5!P,D 'YHT5>_X4Y\=?^C5
M_P!J7_PVFH?_ !-<_P#%&T^)?P.\"7WBGQK^SY^T-X/\,Z7Y?VW5];\"W6GV
M%IYDBQ1^9/+MC3=(Z(-Q&6=0.2!0!I5YI^V%_P FY^(O^W;_ -*8J]9_X4Y\
M=?\ HU?]J7_PVFH?_$UR'QY_9=_:!^*/PHU70M/_ &6_VG(;N^\GRWN/AMJ2
MQC9,CG)6,GHI[=<4 ?UV)]P?2EK\_P!?^"^>%_Y,K_;_ /\ PT/_ -UTO_#_
M $_ZLK_;_P#_  T/_P!UT ?DU_P5\_Y3K_M0_3PI_P"H_:5XO7IW[=ME\9/V
MG_\ @I/\9?C%H'[*/[65IX9^(8T3^S;74/AC?1W\'V+2X+27SD3?&N9(V*[9
M&RI!.#Q7G_\ PISXZ_\ 1J_[4O\ X;34/_B: *-%9OAVT^)?B_QWXB\+:3^S
MY^T+J?B;PA]F_M[2+3P+=37^B?:8S+;?:H%S)!YL8+Q^8%WJ"5R.:Z#_ (4Y
M\=?^C5_VI?\ PVFH?_$T ?H7_P &D_\ R<?^V']/!?\ Z3:I7[9U_/C_ ,$.
M/VB/B/\ \$SOBS\>M>\=_LC?MD:M:?%$>'_[*30?A9=3R6_]GPWJ3>>)GA"[
MC<IMV%\@-G;@9_0__A_I_P!65_M__P#AH?\ [KH VO\ @NO_ ,DZ_9V_[+MX
M:_\ 1=[6S7Q[_P %)O\ @IIXE_;%\*?"FQ\,_L<_MQ6,O@;XE:1XQOSJGPGE
MB6:SM$N%DCB\N>0F4^:NT,%4X.6'>_\ \/2?$/\ T9Q^W+_X::7_ ./T ?6=
M%?%GC_\ X+16_P *!HO_  E/[+O[8OAK_A)-5@T+2/[5^&XL_P"U-0GW>19P
M>9<KYMQ)M;9$F7;:< X-=!_P])\0_P#1G'[<O_AII?\ X_0!V?[<_P#R/_[,
MO_9=O"O_ *-FK]3*_#']I#]M_P ;?&#Q/\'[W3/V/_VU8(OA_P#$K1?&.HBZ
M^%4ZM-9V3R-*D.V5MTI#C:&VJ><L*^S_ /A_I_U97^W_ /\ AH?_ +KH ^_Z
M*^ /^'^G_5E?[?\ _P"&A_\ NNOOX'(H 6BBB@ HHHH **** "BBB@ KG?BY
M\6/#WP(^%_B#QGXMU2#1?#/A:PFU/5+^8$I:V\2%W<@ DX / !)/ !)KHJ\9
M_P""AO[,E]^V7^Q'\3/AAI>H6^E:KXQT.:QL+NYW>1#<\/%YNWYO+,B*' !^
M4MP>A *'P:_;=NOC'=W,(^"_QK\-M)HKZ]HLFLZ38QVWB* 8VI#<17DD-M.^
MY"L%^]K(0V2H"N5X#]D;]L7PM\:OVE?BK%H'[.'C[P%XLTK4+?2?B)XHU"U\
M+PL]Y:V"36D%Y-9ZG-<WA2VF18F5)4C$FW<@#8] _9C^,7Q<\;:SIVB^+_@?
M>_#K1M)T=8]0UC4_%.FW1N[]=J".PMK%YS);$!V\VX>V=1L'DL2=O(_L8?LZ
M^,OA/\>_VKM:\0:/]@TSXE>.HM9\-S?:X)?[1M%T6QMC)M1V:/\ ?0R+MD"M
M\N<8() /6OV1?VH- _;0_9R\+_$[PO::Q8:#XM@DN+.WU6*.*\C5)I(B)%CD
MD0'=&W1SP1]*](KXS_X(X:)\3?V=OV2_AY\&_B!\%?'OA#4/"6G745YXAN=5
M\/W>C2N;F65%C^RZG-=DLL@P3;* 0<D<$_9E !7 P?M5_"^Y^(]UX.C^)'@*
M3Q=8WD>G7.AKX@M#J5O<R*S1P/;^9YBR.J,50KN(4D#@UWU?EW\!?V!OBY\-
M?C]\"=/UKX6'5M,^$7Q3\6^)M3\<_P!LZ85UJTUE+TV]['%Y_P!J,B--$)T>
M)"#&GEB5<E #]'_BS\9_!_P$\&3>(_'7BOPUX+\/6[K%+JFO:G!IUE$['"JT
MTS*@)/ !/-<1XT^)WP'^,NFZ+>^(O$/PD\56?ANWA^(VD3ZC?Z??1Z5#;EA%
MKUNSLPB2(LX6\3 0EL.,FOGC_@I#^R!\6_VB/AMH_P#:4UQXVOO"_C6W\0^&
M;KX7/%X+\4>$4C2=%G1M5O;JQU.4"1$='>Q4J9&4[MJ5\7?M*?LJ?$BP^#O[
M+OPQ\52>!-)^,7Q&U;5_A_XF\/Z+:V-C>7?@W4KPWEQ>3V.G_P"CB2(6L;W$
MMOF!99Y/WC;RQ /UO\6_M@?"7P#X@L-)UWXH_#K1=5U6*VN+*SO_ !)9VUQ>
M1W+,ML\<;R!G65E81E00Y4A<XKE?CC^W+IGPF^-5O\.-!\$>/?BCX\;1CXBO
M-&\)Q6'F:3IWFF)+BXFOKNU@7S)%=4C$C2OL8JA )KXZ_P""FO\ P3>^)/Q]
M^)O[0%]X*\"VFK6/BKX/Z!X1\+R?;K& RWMKK;W4ULGFRJT06$1MN?:AVJ Q
M88KV[Q1\*OB9^R[^WAXG^+OA+X<:I\6/#WQ*\%Z5H6IZ9HVKZ;8ZIHFHZ:UQ
MY+XO[BW@DM94N"&993(C)D1N#0!]&?LW?M&>%?VK_@WI'CKP;=SW>AZOYJ*+
MFW>VN;6:*1H9H)H7 :.6.5'1D89!4]1@UW5?/7_!,K]F3Q)^RW^S5<:=XS.G
M)XO\6^)M8\8:S::?.9[33;C4;V2Y-K%*54R+$KHA<@;F#$<8KZ%H ^?_ -I?
MXH?%/_AJ?X<_#3X::]X \+_\)1X5\1^)]2U+Q/X6N_$'_(-N]"MHH(8K?4;'
M9O\ [6D9G9W_ -4@"C)-'_"N?VIO^BR? #_PS>K_ /S3T?$;_E*;\&_^R5>/
M/_3OX,KZ H ^7_ '[,'Q]^%']M?\(MX^_9@\-?\ "2ZK/KNK_P!E? K4;/\
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MR5[]Y1:1^@7_  KG]J;_ *+)\ /_  S>K_\ S3T?\*Y_:F_Z+)\ /_#-ZO\
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M #3U] 44 ?/_ /PKG]J;_HLGP _\,WJ__P T]'_"N?VIO^BR? #_ ,,WJ_\
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4* "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm229830d4_1012b-img08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm229830d4_1012b-img08.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" #F 7(# 2(  A$! Q$!_\0
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M6MM=L\%WX;\,W.@6L=OL0+&T$]_>NT@<2$R"500RC8"I9NPH **** "BBB@
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M'1W_ "@H^.?_ ' /_4@TROO^O@#_ (.CO^4%'QS_ .X!_P"I!IE '\@5%%%
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M@1\<= _:/^%6D>,O#$EY/H>N0+<6LMQ:O 9%(!RNX8=>>)(RT;8RKL.:Z^@
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MEH7P.^%GB7QKXIOO[+\,^#]*NM;U>\\F2?[)9VT+S3R^7&K2/MC1FVHK,<8
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M_7VI0 5XM_P;G_\ (C_M=?\ 9SGC+_T7I]>TUXM_P;G_ /(C_M=?]G.>,O\
MT7I] 'Z*U_+GXA_Y/0_:M_[+KXN_]+C7]1E?RY^(?^3T/VK?^RZ^+O\ TN-
M&A1110!]N_\ !JS_ ,G9_MF_]R1_Z1ZG7[/U^,'_  :L_P#)V?[9O_<D?^D>
MIU^S] 'XA?$O_E.Q^VO]/ O_ *CZUZ#7GWQ+_P"4['[:_P!/ O\ ZCZUZ#6T
M=@"LW_@F%_RL.ZM_V;K-_P"I+;5I5F_\$PO^5AW5O^S=9O\ U);:E/8#]CJ_
M!+_@X5_Y3D^&/^R%6O\ Z?[^OWMK\$O^#A7_ )3D^&/^R%6O_I_OZR ^<***
M* .__P""9W_*=7]E#Z^+O_4?N:_H]K^<+_@F=_RG5_90^OB[_P!1^YK^CV@
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M_=HN4X;<2Q/Z&5\F?\%R_P#E%I\4/^X3_P"G>RH _>.O@#_@Z._Y04?'/_N
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M[^L@/G"BBB@#O_\ @F=_RG5_90^OB[_U'[FOZ/:_G"_X)G?\IU?V4/KXN_\
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M O\ ZCZUZ#6T=@"LW_@F%_RL.ZM_V;K-_P"I+;5I5F_\$PO^5AW5O^S=9O\
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M^&<TOAN]>RU:TN99X+F*5Y)+>1+:0Q.(OG#QDA021]*_\/\ 3_JRO]O_ /\
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M;W?B73[ZWU_[=//-:1Y$=M''\CNSAEDX* ?-0!_+C_PZ=_:F_P"C:?C_ /\
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M_M#[5<:1\*[F6SD^T:C=72;&EDC<X29 <H/F#8R,$^R>/_\ @M[9?"C^Q?\
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MAIIRW?9XS@VX-N]N:_?FDJ:N^]Y0<Y]^:R/9/^";G[:/C']JK7_$%KXY\1>
M-)\4Z-"6UCX:0^&-0T3Q5X&F9D>)+MKN\D^W0-#(NV[AMH(96PT98,57ZUKX
M0^"?Q0^&GPM^-O\ PL3Q#XC_ &P?BCXMM="?PWIM]XI^ WB&,Z38231SS11#
M3O#5H',DD,)9YO-;]TNTKEMWM_\ P\L^'7_0N?'_ /\ #$^-_P#Y4TW;DBEO
M;7[WWUVMNVUM>5KNM>>3Z7T^Y?K?HK[V5['T!17S_P#\/+/AU_T+GQ__ /#$
M^-__ )4T?\/+/AU_T+GQ_P#_  Q/C?\ ^5-2,^@**^?_ /AY9\.O^A<^/_\
MX8GQO_\ *FC_ (>6?#K_ *%SX_\ _AB?&_\ \J: %_X*P?\ *+/]I7_LE7BC
M_P!-%U7OPZ5\0_\ !0C]MKPQ\<?V!OCAX*\+^#OC_JGB;QAX U[1-(L_^%'^
M,X/M=Y<Z=<0P1>9)I:QIND=1N=E49R2!DU]O#I0 M%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tm229830d4_1012b-img09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm229830d4_1012b-img09.jpg
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M\BNOO%(=X^HH97]/+_6>4JCW%.'\_3VPL[.SN+BXNKJ*YT^M5@LK"=,'KTN
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M\5+O89"+>@^H]X2H]X2H]S0:8N]!9>'_H4FHS9RBWA/$E 0,\F**%U.\F)*
M05Y,\5+O89"+>@^H]X2H]X2H]S1*Z3U?_>I7JQDE6I^[4^\)8DH"!GDQQ8LI
M7DQ)P" OIGBI]S#(1;T'U'M"U'M"U'L:J?=T8>ES%&!KR(TI7DQ)P" OIG@Q
MQ8LI"1CDQ10O]1X&N:CW@'I/B'I/B'I/H_3>\_.?_WQG8 L+"_WO3KTGB"D)
M&.3%%"^F>#$E 8.\F.*EWL,@%_4>4.\)4>\)4>]II-[3A:7/48"M(3>F>#$E
M 8.\F.+%%"^F)&"0%U.\U'L8Y*+> ^H](>H](>H]C=1[NK#T.0JP->3&%"^F
M)&"0%U.\F.+%E 0,\F**EWH/@US4>T"])T2])T2]IY%Z3Q>6/D<!MH;<F.+%
ME 0,\F**%U.\F)* 05Y,\5+O89"+>@^H]X2H]X2H]S12[^G"TN<HP-:0&U.\
MF)* 05Y,\6**%U,2,,B+*5[J/0QR4>\!]9X0]9X0]9Y&ZCU=6/H<!=@:<F.*
M%U,2,,B+*5Y,\6)* @9Y,<5+O8=!+NH]H-X3HMX3HM[32+VG"TN?HP!;0VY,
M\6)* @9Y,<6+*5Y,2< @+Z9XJ?<PR$6]!]1[0M1[0M1[&JGW=&'I<Q1@:\B-
M*5Y,2< @+Z9X,<6+*0D8Y,44+_4>!KFH]X!Z3XAZ3XAZ3R/UGBXL?8X"; VY
M,<6+*0D8Y,44+Z9X,24!@[R8XJ7>PR 7]1Y0[PE1[PE1[VFDWM.%I<]1@*TA
M-Z9X,24!@[R8XL44+Z8D8) 74[S4>QCDHMX#ZCTAZCTAZCV-U'NZL/0Y"K U
MY,84+Z8D8) 74[R8XL64! SR8HJ7>@^#7-1[0+TG1+TG1+VGD7I/%Y8^1P&V
MAMR8XL64! SR8HH74[R8DH!!7DSQ4N]AD(MZ#ZCWA*CWA*CW-%+OZ<+2YRC
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M:&B])W1^3R+,F!R-PWCO'?3?YVA,IJ:F$O>II!COO</8?X'A>EZO\)))9><
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M#RA>O;VGOL>G3Y_BU^O=WU/OK"JU]W D_7QXH[/!5Q;??O+D[44,;GS(*_'
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C(C(IU'M$1$1D,OSE+_\?TWX_+S7;55X     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tm229830d4_1012b-img10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm229830d4_1012b-img10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" &  LH# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_***\V_;
M N?$%K^R]X^_X1/Q/H_@SQ5/H=S;Z)KNJW<=I9:5?2(4MYI99(Y411*R<F.3
M_<;[I&!Z1GFEK\O/B?\ MI^-;;P)XJ:R\>>)=#U;X<>%_%FIZ.K:U9:E;^,O
M$^EZC9VT=I#=);0C4+16FBMO(6*-S+J$D<B">&,Q_I=-XBEBUN6S73;Z01QB
M59@T(CE!X(7,@;@XSE1U&,T :M%4/[8G_P"@9>_]]P__ !RC^V)_^@9>_P#?
M</\ \<H OT5F-XBE2[2$Z;?;Y$9U&^'HI4'_ ):?[0J3^V)_^@9>_P#?</\
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M#_\ '* +]%4/[8G_ .@9>_\ ?</_ ,<H_MB?_H&7O_?</_QR@"_15#^V)_\
MH&7O_?</_P <H_M>?_H&7O\ WW#_ /'* +]%0:;?#4["&X5619XUD"MC*@C.
M#C(S^-3T %%%% !1110 4444 %%%% !1110 4444 %%%(QP/QH 6BOAGQI^V
M+\8O ?CW5_!_BEX_"?B;Q1XOCTKPFD_A^WDL_P"P)_$\6FIJL%Q%>S>;,EE<
MV>8KJ. BXO8F\IXPR5] _LB_'G4_B9\$K6]\5$7.O6?B3Q#X5GNK#3I5AOY-
M(UF^TS[447>(//6R\W86P#(54G H ]EHJA_PD4/_ #ROO_ .7_XFC_A(8/\
MGE??^ <O_P 30!?HK.D\3VT3*&2^!=MJ_P"AS<G!/]WV-._X2&#_ )Y7W_@'
M+_\ $T 7Z*H?\)#!_P \K[_P#E_^)H_X2&#_ )Y7W_@'+_\ $T 7Z*H?\)#!
M_P \K[_P#E_^)H_X2&#_ )Y7W_@'+_\ $T 7Z*H?\)#!_P \K[_P#E_^)H_X
M2&#_ )Y7W_@'+_\ $T 7Z*H?\)#!_P \K[_P#E_^)H_X2&#_ )Y7W_@'+_\
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M_"0P?\\K[_P#E_\ B: +]%4/^$A@_P">5]_X!R__ !-'_"0P?\\K[_P#E_\
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MXKW!9WM98([BX,31?N)<JH(-><_LY_\ !>[XO>/_ (1ZUKWBOPM\/+2:[O\
MPMIOAFXL--O4L[BYN_\ A'WU:"XWW;D2"'7!); ,ORV\N[S/+;/JL'Q;_9WT
M[QGX7\3-^SU\;8=7\$:KK>NZ/J%UX$\2@:9=:PTCZE-NDAVXE,CL0_R1YR@3
M QS.B^+OV-_#WPFMO ]K\$_BS%X9M/$6G>*X;/\ LC7',6IZ?;6]K:7 E,QD
M^2"U@39NV.$)96+,2\+FF'@[UE)Z17P3MI)7^SORWUO[TK)V15?.<+*3]FII
M<S:O3J)VUM'X=OA6WNKFM=V/N/\ :N_;!TO]E#_A#[>Y\*>,/&>L>.]2GTG1
M]+\.16;7-Q/#97%\X+75Q;Q*/)M93EI!R .]?/.M_P#!<KP)>_LV>/O&]EX9
M\4^$9] \":=XV\/OXTBL[.Q\00ZI)-;:<P>"ZE,2&\C\J43^2R [AE/GI/B/
M_P %+OV>_BEXF\*:KXKT+Q1'J_@>^FU/15U,?V5/8SS6D]G)(8)+B)G#6]S,
M@\Q&7Y]R_, P\UTO]H/]B+PU>>$;B30[O2!X$LM'T[1IKCQ"ZVUC;:5/-<:>
MDC&_\N00S3RN/.W%V9=V\J@&:S/#MVFY<K:7P3T5G=K1:WY;:VMS;.S&\ZPD
M5S+FNEUA.SES+1^[I%QNN]WV(_A-_P %ZM3UZ+PW=S>%+'XH:=IGAKQC>>-I
MOAJEO="*[T"_LH6O;*2ZU".$Z?):W+3A?,EF?S8 A8Y#>_\ [./[9_Q!^+O[
M?FM> 94\">(/AR/ ]MXPCO\ 0K&\AO?"\MW< 6%C?332E+B6YM ]R D%NT84
M@JPVR/\ -/Q;^+?[ WQR^)_B/QIKB6$OB+Q;'-#K5]8_%*'1VU".:WMK:>)X
MK?68E,<T%G;)*@7;*L8#ALMGI/V>/VN_V'OV3_'FL^(? 7C?2_#EWKUU<7VH
M:<WQQLYM*EN)]OF2G3)]=:TCDPB*"(%:-4"KM Q6U/-</[KJ)W2=_=E9M\WD
MM%>+B]URVU4M,IYMAM5!RLVK7A/9<O\ =WTDGT?-?1K7])<52T;_ (^+_P#Z
M^3_Z E?+^D_\%K?V;]<G\FU^*7@&XN-N\Q1>--"E90.OW;XCC/4'%>\_ KXN
MZ'\<O ,?BKPU>6^I:'K$\CVEU;W,-S%.$/EL5DA=XV&Y&&58],'!! JACJ-:
M7+3>OHU^:.G#9EA\1+DI.[]&OS2.UHHHKK.X**** "BBB@ HHHH *XG]HGX\
MZ%^S)\&=<\<^)6NO['T&)'E2V16FGDDD2*&)-S*BM)+)&@:1TC7?N=T0,X[:
MD9=WX4 ?G;I?_!7/Q[XT^"FO>+]%@^%LK_#71O&?BKQ=;V$]QK%IJ%IH>NSV
M,.GV%RDL6R:>S@,WVJ2-US) RV^R7"_>TGB*S@\9RV[38F@M09%VGY0S9'.,
M<X->;^)_V ?A/XQBLDO_  Q+)%8WVJZAY4>K7L,=XVJ:B=3U"&Y5)@+FUGO,
M2O;3;X"55?+"C;7JHX\2@9S_ **?_0Z '?\ "1V?_/;_ ,=/^%'_  D=G_SV
M_P#'3_A5ZB@#$G\06A\1VI\[C[-/_"?[\/M5W_A([/\ Y[?^.G_"BX_Y&2T_
MZ]I__0H:O4 4?^$CL_\ GM_XZ?\ "C_A([/_ )[?^.G_  J]10!1_P"$CL_^
M>W_CI_PH/B.R _U__CI_PJ36];M/#>CW6H:A=6]E8V,+W%S<W$JQ16\2*6=W
M=B JJ 222  "37R_XP^,OB/]J;1K:\TO5/$7PX^$>H7!MK.^L(7A\8?$3DC9
MIT;+OT^Q=5)%UC[3+&S2Q&SC2.ZEBI5A3BYU'9(SJUH4H.I5=DMVST[XN_MG
M>#?A=XGE\-6AUCQKXZ1(W_X1/PM9'4]7A63!C>Y0$16,+C[L][)!"<']Y7EN
MN_M"?&CXE:C<6.CP>#_ +*0C:=9Q-XP\06X)R1=2++:Z9ILX7^%IKU,]/,'%
M=]\(/V;(_"?@U-!TW1K/X;^#3,]R^@Z'*4U'4IGP9+F_OT;?)/(?FD96:61\
MM)<2[F%>P>&/#&G^#]%@T_2[*VT^QMQMBM[>)8XT'LH'_P"NN+VF(KO]TN2/
M=K5^D>GK+7^Z><JN*Q#_ '*]G#O)>\_2+V]9:]X'S/X?_8GN_'[?;/BI\8?B
M[XKD?.W2[/Q3-H5G"A_Y9R?V/'8)< >K1+Z'=RQ[7PS^PG^SWX3<O:?"/X9_
M:67;+=S^&;:YO)^G,D\L;2R'@<NQ/%>YT5TT</&FM&V^[=W_ %Y*R71';A\-
M&C&R;;[MW?\ P/162Z)'D9_9*^!I'/PK^&)_[E2S_P#C-4=0_8C_ &?-6G\R
MZ^#GPDN9 H0-+X,L'(4$D#)AZ9)./<U[516[UT9T/71GAW_#"'[.FW'_  I3
MX.X]/^$)T_\ ^,4C_L'?LYOU^"?P</;GP1I__P 8KW*BIY(]B>2/8\#_ .'>
MG[-&P+_PHWX-;%Z+_P (588'_D&JNL?\$]?V:H; M'\#/@TK;T&1X*L!P77/
M_+'TKZ&JCXA/_$K/_72/_P!&+4^QI_RK[C/ZO2_E7W'A[_\ !/']FMMOE_!;
MX4VK*20UIX5M;9N>OS1QJ2.G'L/2HI_^"='[-UT1YGP@^'<A7.TOH<;8_-:^
M@Z*EX>D]XK[D)X6@]X+[D?.__#MO]FC'_)&_AMTQ_P @"+_XFHIO^";/[/#R
M$Q^ -,M$_AAL[F\M8(QZ)%'(J*/95'.3WKZ-HH^K4?Y%]R%]4H?R+[D?.'_#
MM?\ 9[_Z$F'_ ,&FH_\ QZF3_P#!-/\ 9\GA9!X-:'<,;X-:U.&1?=72<,I]
MP0:^DJ*/JU%_87W('@Z#T<%]R/F@_P#!,SX"$?\ ($\2?^%IK_\ \ETX_P#!
M-'X#F,I_9'B@QDABA\;>("I(Z$C[9BOI6BL_J.&6BIQ^Y&?]G81;4H_^ K_(
M^9_^'9_P-5F,5IXZL_,7:ZV?Q$\36RR#G[PCOE#=3U]:A7_@F!\"TDW"/XD
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M+^^$G'_4T6G_ ,74G_#V+]EG_HY;X ?^'#TC_P"2* /H"BOG_P#X>Q?LL_\
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MIX/_ !X6?_?E?\*^7/\ AA;XMQ 11_M!:_*F[FXGM[_S57G *)J"HS'CYAM
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M3CO^8].3VLOY'^'^8_;3_D?_ )+_ )GU!_PCNG_\^-G_ -^%_P */^$=T_\
MY\;/_OPO^%?.=E^S1^T?8:.(!^T[87=TA;_2KOX8V!+ \KN6*XC7@YZ8R !C
M.6*V/[.7[2JV\HNOVE_#TDI&(7@^%MM&J'(^\&O6W<9Z$<D>F#7._P"5_A_F
M5[27\K_#_,^B?"JB/PQIRJ  +6(  8 ^05?K&^'UO=6?@71H;ZYCOKV.P@2X
MN8X/(6XD$:AG$>YM@8Y.W<<9QDXS6S6AJ%%%% !1110 4444 %%%% !1110
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MUN+'%A9#-Q@_N%Y^1_:KG_"-:=_T#[+_ +\+_A2ZM_Q\V'_7S_[(]6WDV=J
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M4?V%%_STO/\ P*E_^*H N;>*"H-4_P"PHO\ GI>?^!4O_P 51_847_/2\_\
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M1X%^I?"WPRT+P-X:T_1M#T^/1=&TFW2TL=/T]WM;2QA10J1111D)&BJ %50
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M "233O$GB;3_  ?X=OM6U6^M-,TO3+:2[O+R[E6&WM(8U+/)([$*J*H)+$@
M DU\L_$OXLW?CS4_#&MZMX?DUG6/$,\D_P +/AI=2?9I-7EA\MAK^K[E)MK>
MW\R.8[T?[&DD1\N;4)K:V3HJ5&O=CO\ UJ==2JT^2&LG_5W_ %J1_'_XP/\
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M.U?AJ7YO?BS@]1_PM;Q1C_TX5:K57_R[:^:$XP7VCW#PP?\ BF]/_P"O:/\
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M2;"1< W\P-[.I)@6%?(NSC/%SG-T<*KM;M_#'U[O^ZOFU=7]%4TES5-OQ?\
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M?1?WI?\ :H ZBBL+_A9_AH?\S#H?_@?%_P#%4?\ "T?#/_0Q:%_X'Q?_ !5
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MRC'X/^&)\8O-6MTEUFXCY&^WTV"8K;%D8,LE]=38(*S::I^4>B_!O]A_P?\
M!C7[#7H8F\2^,M.MWM8/%'B)!?ZO;Q.,2QV[_+%90R=6@LHH(">?+%>Q@8KQ
MGXM_\%$?@C\$-?;1O$'Q.\(Q^(Q)Y2Z!87HU/6YG[K'I]KYET[<=%B)KHP^"
MIPE>G&\GUU;^]W=O+8B=5M6;T/6Q:7H_Y>X/_ ?_ .RI#;WH_P"7N'_P'_\
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M> ?#W@HP>']9O]7N1?W[7UE>1+ (HTN8WCA W^9M,69(Y%DD5SL!#\A\+?\
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M;_X)$?LV^%&B:T^ /P(,L#[XYKGP'97,RMNW B27<V0>ASQ@8Z5ZYX"_9_\
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M/%/A?3?&_AN_T;6=/LM6TC5K:2ROK&]@6>VO8)%*212QN"KHZLRLK @@D$4
M?G-XR_;;^+DG[)?P_P#&(\=7&C>(M-_9[D^*\ZV^EV"Q^.=:B%C_ *++'+"^
MRV9I1&T=J8I,ZC'MD5EC-?H=)J;6_BN0-9WWE16P43+%OCD);.%(R<C'.0.H
MZURVC_LD_"SP]H7A[2]/^&OP_L=,\(ZB=8T*SM_#MG%!HM\6+&ZM46,+!,68
MDR1A7R2<UZ$J[0/:@"E_;T?_ #[WW_@,_P#A1_;T?_/O??\ @,_^%7J1C@4
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M10!1_MZ/_GWOO_ 9_P#"C^WH_P#GWOO_  &?_"KU% %'^WH_^?>^_P# 9_\
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MBW&P"%[D+YK1XBC^4MC]VG'RC'4@8I:* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $(R: ,"
MEHH **** "BBB@ HHHH **** .?^+/Q B^$_PL\2^*9[2ZOX/#6E76JR6UL
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MFE_X2/3_ /G^L_\ O\O^- %VBJ7_  DFG_\ /]9_]_E_QH_X233_ /G^L_\
MO\O^- %VBJ7_  DFG_\ /]9_]_E_QH_X233_ /G^L_\ O\O^- %VBJ7_  DF
MG_\ /]9_]_E_QH_X233_ /G^L_\ O\O^- %VBJ7_  DFG_\ /]9_]_E_QH_X
M233_ /G^L_\ O\O^- %VBJ7_  DFG_\ /]9_]_E_QH_X233_ /G^L_\ O\O^
M- %VBJ7_  DFG_\ /]9_]_E_QH_X233_ /G^L_\ O\O^- %VBJ7_  DFG_\
M/]9_]_E_QI&\3:;&I8ZA9  9),Z@#]: +U%4O^$CT_\ Y_K/_O\ +_C1_P )
M)I__ #_6?_?Y?\: +M%4O^$DT_\ Y_K/_O\ +_C1_P ))I__ #_6?_?Y?\:
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M_D;.G/>GQ_L<_M%VTC,OQQ^&TKOC=(W@WQ2K'VP/%F/R J%5QK_Y=1_\#?\
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MBHZ]I/AG1;GQY"UOX<EGM6ME>*P+I;W]Z;.(74EM"(DDF^=&56/L_B/]CO\
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MZ*36ZU/T,_X?D_LX?]!_XC_^&G\6_P#RLH_X?D_LX?\ 0?\ B/\ ^&G\6_\
MRLK\\Z*K_B'.&_Y_2^Y$_P#$0,1_SZ7WL_0S_A^3^SA_T'_B/_X:?Q;_ /*R
MC_A^3^SA_P!!_P"(_P#X:?Q;_P#*ROSSHH_XASAO^?TON0?\1 Q'_/I?>S]
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M4U2Y\.3:Q'IM_)I%M,+>:^6W<VT4A&0C28VAB.@)S1XC\*:IX/O([?5M-O\
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MK:YT2PN%(9(](T!'EA1XVY2:07-X,_/<LJC;U/PF\"P? 3P]=>!?!EQ'XO\
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M((4?WUH TJ*.E% !1110 4444 %%%% !1110 5^,O[6?_*1[]I7_ +&_2?\
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M)SM(/S&O-J[/Q9\<]8\9_"W2/"5Y%8G3]%NYKRWF5'^T,9,Y1F+$%5SA1M!
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M?[0__"^/#_CJPO?#6K^$/$O@>_&CZUI&H3V]P]O+)8VU]$R2P2/'(C07<7S
M\.)%_@R0#UJBBB@"AXH_Y%G4?^O67_T U?JAXH_Y%G4?^O67_P! -7Z $9MH
MKXR^"'CC4_VG_P!H'Q/\3='GB-UK,5UX1\!W!'FQ>'?"]M=^7>ZR4.5:;4]1
MMB81]R6WL-.? V39]%_X*@?&K5?A+^RCJ.F>&+JZM?'/Q*O[7P+X7:T)%W'?
M:BQB>X@[>;;6HNKL9X_T0YKO_P!F7X :9^SS\*M,T+3K*ULFMK2WMWBML^3;
M1P0I!;VL6>?(@ACCAC']V/)^9F)\[%SG4FL+2TOK)]H]EYRV79)O=*_E8V=2
MM46"HNUU>4ETCV3_ )I--+LE)[I7ZOP#X#T_X>^'H=.TZ)HX4=I79W,DMS*Y
M+22R.>7D=B69CR236]MP: .*6NZG3C3@H05DMDNAZ-*E"E!4Z:M%:)+H@HHI
M"<59H+6+\0?B/X?^$O@Z_P#$7BK7='\,^']*02WNJ:M>QV5E9H2%W232,J(,
MD#)(Y(KYE_:,_P""HUEHWQ,O_AA\%/#-_P#&CXJ:=(UMJMOI,<DFB>$90=NW
M4KU%,:3 Y M@P?<H$SVJ,)AQ_A/_ ()P^//VC/$UAXL^/?B6/4M6M;N&[M[5
M<SRZ8%D61H["-'%GI ;#1%H4NK\Q,ZMJ<JL%3"==)\L%S/R_5[+\_(YJF)2?
M)37-+LOU>R_/LF>W_P##T']FHC/_  T1\"\>O_">:5_\?J2R_P""F?[.&IWW
MV:V_:"^"%Q<XW>5%XZTMWQZ[1/GL?RK0/[!'P>G8M>_#[0=;<]7UF-]48\8Z
MW+2'@<#T&0,9J#4/^"=WP*U>R^SW?PA^'=Y&6#N;C0K>5YC_ --'92T@]0Y(
M(XZ4N;$?RK_P)_\ R(N;$_R1_P# G_\ (DX_X*$? 1NGQP^$!^GC+3O_ (]0
M/^"@_P !#_S7#X0?^%EIW_QZLV[_ ."9W[.U\!O^!/PC4JH0,GA*QC8*. -R
MQ@XQP1T()!X-!_X)E_LY#_F@?P<_\(W3_P#XU1>O_*OO?_R(<V)_EC_X$_\
MY$TO^'A/P$'_ #7'X/\ _A9:=_\ 'JHZ_P#\%#_@ =+N(C\=/@V))(F"JWC7
M35W<>\U-B_X)H_L[1LA'P%^#H,;;E_XHW3_E/K_JO85T7AK]DSX6_"/0+]?"
MWPU\ ^'%ECD=QIGAZTM [%3DG9&,YR:N#JW]Y+[_ /@(T@ZS?OI)>3;_ $1E
MK_P4-^ 3IN7XY?!XKZCQGIN/_1U*O_!0KX!L./CC\'S]/&6G?_'J-7_X)\?
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MBZGVDOO_ . 7%U;>\E][_P CL%_:P^%S=/B5X /_ ',-G_\ '*4_M7?"\?\
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MJNKAWRR4JF^B?-)*+\[0::\XV/I:..P,:,:.(5XRC#;=<O,Y>C<_PE?4[/\
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MB/@6Q]!X]TK_ ./TA_X*A_LS@X_X:)^!>1U'_">Z5Q_Y'IW0'M'_  C>G?\
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M_P O*/\ AU[\7?\ HM/PX_\ #8WO_P O*]G\<?M>>)[^?X36OP\\#Z1KM_\
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M(+3P!XMMGC?X1>*TN7:74/#3*R0'3A+)&!"V^1$*1EHP[*98PWL7_#=7@_\
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M)&!V6PF+&]N9&P0(UG F/'DX.P>A' *E>59J%_G)_+\KV5MC!U^;2&OY??\
MY7/0_&7[4/A#P?X@N=$COKO7_$5J0LVCZ%92ZI>P,WW5E2!6$&>QF*+@$D@
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MAM-?DC\*/%.N?&CX&_L[_"'PCJ5[IGB?XB6_B#XAC5+:7;<>';?7=0U2236
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MJ\8__+2CZM4\OZ^0>VB?5M%?*7_#"O@__H:?CO\ ^'J\8_\ RTH_X85\'_\
M0T_'?_P]7C'_ .6E'U:IY?U\@]M$^K:*^4O^&%?!_P#T-/QW_P##U>,?_EI1
M_P ,*^#_ /H:?CO_ .'J\8__ "TH^K5/+^OD'MHGU;17RE_PPKX/_P"AI^._
M_AZO&/\ \M*/^&%?!_\ T-/QW_\ #U>,?_EI1]6J>7]?(/;1.V_X):_\HROV
M=?\ LF/AK_TU6U>[U^>'_!/']C+PKXI_8"^!VIW'B3XT03ZC\/\ 0;J6.Q^+
MOBNQM8V?3H&*Q00ZBD4,8)^6.-%1!@*H  KV+_AA7P?_ -#3\=__  ]7C'_Y
M:5,<--Q3T_KY#=:-SZMHKY2_X85\'_\ 0T_'?_P]7C'_ .6E'_#"O@__ *&G
MX[_^'J\8_P#RTJOJU3R_KY"]M$^K:*^4O^&%?!__ $-/QW_\/5XQ_P#EI1_P
MPKX/_P"AI^.__AZO&/\ \M*/JU3R_KY![:)]6T5\I?\ #"O@_P#Z&GX[_P#A
MZO&/_P M*/\ AA7P?_T-/QW_ /#U>,?_ ):4?5JGE_7R#VT3ZMHKY2_X85\'
M_P#0T_'?_P /5XQ_^6E'_#"O@_\ Z&GX[_\ AZO&/_RTH^K5/+^OD'MHG;?#
M_P#Y2;_%O_LF'@C_ -.OBZO=Z_/#P7^QEX5N/V_OB5IA\2?&@6]I\/O"5TDB
M?%WQ6ET[2ZCXF5E><:B)9(P(5*1NY2,M(R*IED+>Q?\ #"O@_P#Z&GX[_P#A
MZO&/_P M*F.&J6Z?U\ANM$^K:*^4O^&%?!__ $-/QW_\/5XQ_P#EI1_PPKX/
M_P"AI^.__AZO&/\ \M*KZM4\OZ^0O;1/JVBOE+_AA7P?_P!#3\=__#U>,?\
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MO\CYU@^'?[7\#Y/Q:_9UF&,8?X5ZO^?&OBK4WA/]KBWBA$?C[]G.Y?'[UV\
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M\%ZE\<;WXIZ?\76LX97NO$,O@NQT*.YA^UQ3K,?[%\L67VA1&G^D"5HS'B0
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M_P!-EO7E/[%&C^*OV:?CQI7P\^)T6M:GXQ\5^'KW4K+Q%'\4-<\5Z?JRVEQ
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MXT6ROA:Z;=120WCR-,L:K+.7VHI261X@(U*QJV6/2>/_ /E(Y\*/^R<>,_\
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M,_\ IJMJ^@*^3/<"BBB@ K+\9W:V7A>]=A(5\HK\D32')X'"@G&3R<8 R20
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MDX '%=3_ ,,B?M(?]%L^"/\ X9_5/_FEKZTHH^M55HI![&'8^2_^&1/VD/\
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M]%L^"/\ X9_5/_FEKZTHH^MUOY@]A3['R7_PR)^TA_T6SX(_^&?U3_YI:/\
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MRQO@!DA$HB#  $1@@ 8% =3TS[%>_P#/\/\ OP/\:/L5[_S_  _[\#_&KU%
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!",TM%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
B%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tm229830d4_1012b-img11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm229830d4_1012b-img11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "; >H# 2(  A$! Q$!_\0
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M,F!@LPX-=)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M._%_4/$*:#JVJ?"IOBKI.M:+9ZS\.?"RZYHW]D6MQ;ZJLUWINH64JRRP6EU
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MFTDM-$[:I[/H]U<^^A_P58_X*6Y^;]O#]K 8SDCXY?$'!QGUUP\=#_GF0?\
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M\?VL#G&<?'+X@\9Y_P"@[Z=Z^0M&T_P_J$2PR+-%>(J[U9R59A@,P& <$C<
M.<$>M;S^&-'CVL8C)@%,"783Q\K%B&QC@[3^=??<-?12X\XOR##<3\.YSP;G
M&2U\-];G6R[/EB,3@WR\T\OS##5:&'J8?&45_%A)74E*-NIR5<[H8:K[*I2J
M\S?(KPT;TM*+<E=.^ZOTT/J!?^"J_P#P4LPY_P"&\/VKL \?\7R^(/?@YQKH
MY!Y'OSC'7Z6_:R_X*;?\%#?"WQ+\.Z=X:_;8_:@T*PN/@K\!=7GLM/\ C;\0
MHH)M6UOX0>#M6UK474Z\V;K4]5O+J_NWSA[FXE<  X'X_P"HVBVL]Q'&<(K@
M!<AL88@#<.N!GZGH*^F?VSQGXL^%_P#L@G[.//3K\$? Y!^G>OYTSK)\9D&<
M8[)\PA!8C!5ZU&HZ<E."E0FX/EE%M6;3LM=CUJ<U5@JD=(NS2ZZW=K>6SW/2
M_P#AZU_P4N/_ #?A^U=_X?+X@_\ R]IY_P""K'_!2T $_MX_M7>__%\OB"><
M'H/[=_/GCIGD5\!! "N<^W'7K[_D<'I]*V/L<BVZ7+VY$6]5#NF48L&(Z[1G
M ...OUKQ*DU![:7?Z_Y';A\+/$PJ2IZJ"N]'9*Z5WIHM>K7D?<X_X*K?\%+C
M_P WX?M8?^'R^(/]-<H3_@JQ_P %*]^)/V\?VL-IS]WXY?$'/0X_YCO7/]?:
MOA]D62, Q1H 1\R  YZXQCH>3VS]*I201IEMA+#.>.G(],_R'?'7G)5TVU[W
M;1JZ?E?3RN=M;+:E"G&LH1GR)3<6G[Z2O:U];VZM7OHS[QC_ ."K'_!28DE_
MV\?VLB < +\<_'^2.^2=<QW'3_#+U_X*I_\ !2K.'_;N_:U )[?'+Q_]W&1G
M.M]>W('TKX.2"..-I2F6/"@'/TQZ_CC\:Z'3);)[*_2\L7>[D3;8O&PP&VD#
M<N#RIQG#=\8J:E=P7/:3A=*[ENTTG9*VBO[SOMKLF*EE=.=2G2Q&)J4L1B8\
M]'#T82J24;-VY81DUK9?:6N[/L\?\%6/^"DYVH?VZOVKBR CY?CE\0!O+9VL
MW_$^P'0<#;M' )!YRY_^"IW_  4QC4.?V[_VL I()'_"\_B 6VM@@Y&N  \^
MAR:^%-/LI%O%-S"ZP^;&KG86"K+T9>S8QD<C)Z$'-=SK5SH5KITUO8VJ27%R
MD<+-<Q-OMS& 'GB?< /-(+;-AVJ<;B <U5Q,(SC&ERS3:UNGOVL^VO\ 5CT<
MNX?IXK!8_&8K$2PL\/";AAZL:D)WBG91@X)MR=DNVNC/JMO^"J__  4L#,#^
MW?\ M8@9( _X7GX_./0$_P!N\_7CG% _X*K_ /!2K;G_ (;Q_:PS_P!ES^(&
M.>G!US/Z_A7Q$MI;NA"D2,% SM !('7J<YXYZ?RK/33Y99 BQA06PK-R2=QP
MH RS$]>0,Y^E*.)A+F<N:"@_>;T36NR>NJ7]6.#$957PRPTJ<5B_KG+"C&%Y
MR4Y1BUL[<RYDK;WO=:,^_K;_ (*G?\%)1$9;W]N_]K)HY5DC3R_CI\0 T<R*
MDBL<ZV000=I!SQTP>0V3_@J5_P %+(HXI9OV[_VLE657VD?'+X@9W DKG.MG
M(/? [ CW^0)/ >NZ=I%IJ]YIMQ]ANI66WDE1HHV>'RII@FY5#9B( (!YP.N<
M=OXL3PEJWA;PJF@V5Q;:W"]]'K@N@J03KB+[&;0J6+E3YXE#(@&4PS;J\Z><
M4X5H*DXUJ-:K.$ZB:<:"A%N*TUC*5G>6L7RZ'UU#P[S&. XBJ9I2Q>3YOEV3
M93F&69-CJ=6EBLYAC:BYL;ED)4XJ6'E"5[S?O1IU.2+:1] _\/4_^"ELR*T?
M[=G[5R%0%;'QT^()#$#!;!UTD$\$\@<D 5$/^"JW_!2M3\_[=W[66X'D'XY^
M/\8.1VUS/7!SG';J*^+VM;>&*%%LYHYAEII  591D%0,D\L!SMQSV-9E]"J1
M).4V&3K$1AEP<Y/4G..O!SC\?1>(I^TBJ=15(2Y;:KFNTVUHVFDUY:;V/EJ^
M4*G3FI8A2K4=*DZ%&M'#*5ES8>52=.,?K%"7[O$1N[5-+NQ^O7AC_@II_P %
M#;G]DKXQ>*;G]M?]J";Q+I/QJ^#&C:5KLGQM^(1U'3])U;PQ\5KC5M.MICK_
M ,EMJ-SI6FSW:%"7EL;=@5"$5\SI_P %5?\ @I61&6_;Q_:P^9E! ^.7Q!Z$
M\X']N=<=.O/;GCS/PF=W[%OQQ('!^/OP)(_'PG\9B!@>WTKY5AMG,L>&(Q(B
MC Y!/ QU!(.#D]#C'-=$ZD6KI*GU;VT2Z7NG>_X:W/'IPFW*$XJ\ZD<-2ELG
M4J/EIS3ONVV_))71]^O_ ,%3O^"EZ-S^W=^UIL>,R1,/CA\026&<9_Y#G3((
MSCMT]5D_X*E_\%-(VQ_PW9^UD5]?^%Y_$#_Y>>X]/\/$-=^&\%C\-? GBVRU
MVUU&]U1]4L=8T&"*9=3\/-9W.V"35,PF$)>Q'SX/)DD<*"' (Q7FEKI4]Y,M
MNN^6662WB@2)?,:268@/ \:-YPN4. (HXY<GC<O?S8YGA9QK2IUXS^KR=*I:
M47>:W5DW9JU[/75Z.SM\]A<\PF(H5L3"K&<<%F.897BZ>JG'$Y?6=&JFI*+^
M*+::CRSC>4)2CJOKD_\ !4K_ (*:Y&W]NS]K'![GXY_$#TST_MS_ #^@<?\
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M8/\ PO3Q^H[]O[;8GM@G'TQ52X_X*??\%.+>R>ZD_;F_:VC6.18GD;XY^/\
M8K,"1P-:R%(7&3GL,9KS"X+&':)?+620L&.PJNW/RL1%P&W>F1@]2#63K6EZ
MCJFBZEING6XNC?O!F7$9@@V_*525DC)FD.,;0&VD\,"2.'Q1^CKD7!W"F*S;
MA[B*=;,LEE4EG4.(J7U7#9E1G5E4IPRF:;HY;B:&'E3I/ZW7?MZD'*%O:)*L
M@SNMG&81R[#X6IBL1BKJC"G%R<+)\SLK[6;[+2^YZK%_P50_X*63,JC]N_\
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M+NG3_D2-#K^=958TMZ?M+NVE].M_F5*^T=T]>G?OZ'\A_P"V)_R=A^T=R/\
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M[]&5E4NDG"/)LK-[NRUNGH^RJ7#22_:)9<!F:,@$Y/+$\'N,$$X)QC\_I_\
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M[J&@7/F:=?6CWEB+)U2*]B:S+17,KV\KH8;BV=2I@G:*;S%V*O0CMM%\5?\
M"IO&OAWXCQ:;:>);32WM[?5].OAY$-Y;SL MS=JJ7"FX3EFC^?.  ^3Q\:ZW
MXMU'Q!K\_B"XDFCUJZGNKW5=5+L;C4]0GG>\FN[H#:#<7-P[>8Z[5RV=HZUV
M \9:CX@\*:I9W<\(DMGM2B22)')=>6<N,,P:3:2<;<DXX.,5]%BO';A#B;Z.
M>>^%/B=PS3Q>=5,@PW">24LDI3KY5[657#XC"YIEU15)U\)4PN*PU/#4L;1K
M*KB<%4JO$485*LN7X_"Y1C,+G6$S7"S6'I2IU:E2I\4%*,HM3=-KE<5'1:ZW
MMT/U_P#BWX"\*OXGL?%OA3XM?#[XHZ1\0?#T'C**3PJUT)/#-UX@AL-5U/3M
M0T*_*RZ7JFD3WDMA=64-U=7<9@NMD4IC*5\>^(-,32M4@N/M<[>0#Y=RL$K1
MK,K9EM+A<*YFB<!<$ '!/&<5\O?#'XF:S\,M8M]7TV.&^LG<6^L:%?6[#3-0
MTYI5:XLKQLI(]O>JI4M#+'=1$AEG#@D_J':_%?\ 8&\0?L[:OXUU0_%/PQ^U
M.?%UQ+H/@K2]4LKCP;:Z+:6N=)O&N[KPA=K)%+<J@N()-4^U2*<O(#EJX<@^
MDE@^#.#>&>!>.>'.,N(WA*& R?+L)P3P%3Q=>EA*N%Q&&H9?B*>"Q>#HY5@\
M5'#X6.8\29AA<?#!5(SQ,\-&K5;/TGB"GEN,X5AG.7YKB,1Q-3QO+)X.N\-/
M 4:-&%6%:A[%8B,)5ZS="7M(MU(QY;1U9PFM?MG^)O!'P:U']F#Q)8:EX@^'
M^H:KIWB_3;N6,VM]IMWJ4)GNHX;65IHK.V-U)<+&OF&:YPLXC E"C\^OB/XJ
MT3Q):7LWAN#4GMQ:*KVVIQ1K)9".1C*ZF.1@4.]2K%4)&<CI7TI^T?\ 'SQ9
M^U9XS\/^+/&NC^%]/O\ P_X:\/>"I)O".EQZ#:ZEI>BV:Q66I:M;"25K[7(H
MDAA-]O!P@"1JBA1X#J^G6NF>'M:MS^\NI-*N%\UU#2B,;Y/+DE _>$1JS[NN
M"J<8%?B7A%]'_"\0Y'Q)XA_5?^(;?VN\\SC.>$WQ ^):&+SZACL[ES87-L%A
M:&45Z6%P>$R^=;ZO3P,J=>IB*3P\Y*<G>:>//&6=<.Y/PMQ3# 8R&%P]+#8?
M'O*<%0S6<*4G"DL3C\-[!XJ;4DISJX9U)I+FFW&[^5'7RR5)R.H/8AEW?U/\
MJ_N _9Q_Y-Y^ W_9&/A=_P"H/H=?Q!2C.$SD@8)Z=%(Q[_IT!]S_ &^_LX?\
MF\? ;_LC'PN_]0?0J\# X/#>WJTFI8N,<-AJG/2FX)3J7Y]HSNM%%)[-7ZV7
MQ\)<UY6M=WM]]OO/Y%_VOT+_ +67[1!&"K?&GXA;NV,^)[_ YZCKT'ZUQ4-H
ML4+(D2;3R =I+IZ[NVX>X//..<]Q^USG_AJ[]HKC!7XT>/P?8_\ "3:AZD]^
MY[_2N1AB$@4^8 /*0DE@0..0>W)_QK^U?H393A,QGQY4JX.&+QF'>48'#QC6
MP="DJ6.HX^=:=\<G[T)X>FJ3C-1C%M34M&OFN(JDXNG&,K1YZEVE)MVY;?#Z
MN[[6:.,\2V2[(6BB$3'G''.,CJ&P<D>O'ZG T^Q:^GAMA(0&<*V#V[EN<GH2
M1DCC Y&:W?%-Z@>.U20,T/RLRE2/F.1G'3()XXQ[FH/"]U;6]XKS*&#;@KLP
M^5B.#D\8SSG [9ZU\SQ=DW"N>_2#CDN(JX!9'5Q^18#/Z$ZU%PH5,/[&GG,7
M4H6P\JM'&+$4?:I2I-1;=W[SZ,-/%0RQ3>D_9_NKWLUR^YS.6NJY6]M=['8R
M>$M.6%(023@YD!_CQDKTR.,'..<G)ZYY>TM8M+UAK>9P4"NJ9!;'(VX(SSVZ
M'GKQ7HRWB1(S2#<I<B,@Y!X'*L"001QGI@#H.GF6NWH35/-B9=Z,68JP88.-
MH()(R.X'MU-?TEX[\,>%' F3\%<8</8/AC!9WE/$F JX/^RJC=>GDM*7LH2J
M4(XA\\I4:+JRDTX\\YR5DXI>/EM;%XJ=>A5E4DY0GS1E\,:G:*=VE>RWV;3[
MG;&:*([E52=C;PW! ."6YSDC'3KU]:X#7+X22R"-\*3C@$8YQD#_  ].>]++
MK]Q,A4!5.#\P/;D$'V/7\,BN;GE>4LYZ$C@]3VS@]O\ /?G^?/&GQSR[B/*J
MV5</UU0P>.<*E6-&%6E-8B='DQ%6+]K9.M/E<GR/FY8M61ZF7Y6L/4]I54O:
MJZ:E).+BG>"2M?:]]=ABJ 6"N3G^(C//!]>G)QP>:<J':[%N-P!!&<].G!P2
M/?&.W6FJ"4XZ]3GZ@=\_3I_C4D:NP,0!W.P*X7@].>F.>@_6OY'IX3$U)X:A
M[&6,I5</45&G5E4?/CIRDZ33IRA/VLI2C&-I7:LFFSZ!\C<N=VBDKV2NK=KK
M;?\ -=CK=)\-3WULMQ))&+<D$9R6] ,$$D@X!/\ 2IM0\/E<FRD8%3\T9105
M[$Y)VX[=?P[UU>BSE-,BMB@63 R1QR.O4CTZ9XQG)J[^ZCP93&?.R3R"?Q&>
M#Z\<YQ7^GV0?1V\-LP\.N&,-7HM9EFN1Y=F.<X[,,5"GCL!GJHPDZ.78N-.C
M6H4L/*K-*E5E6DU)>TE*R:^,JYGB%C*JBXRIPJ.--*,FG"4K7G!RLY:?%%(\
MG;3[[#;X_F4;2<Y;C /.XJ,XYQCUSCKTGALPQ27 E0&50!\P)&><].IZ]\?@
M>.@OT@B5I%9%4$DKA3GGMV/L>:P=.>$:D5'RB7+<_*I)/'/3\1QSWS7Y?D_A
M?E7A9XF\,8[#9I@\37K9O+#5GF^*IXZ$\/B,+B:<,4JEH5?K$8\E.+E5]C&,
M;^QYG<[*N*GBL'73A&/+#F3IIJ3::NM6U9:NUDUN3>(0_P!@E8+MC8*%'7@O
M@\>@Y]_4FO</VRT\SXM^%@O+CX!?LW[1Z_\ %D? OKCD8..1[5XQXH,8TOY,
M?>4$#J/WHQQZ'@].G2O9?VS3L^+/A5P?G'P&_9P _O$?\*/\#'ICH?7U]N*_
M"OI<4IX?Q6J4EBY8NG4X;R/&4)1E3GAXK&X98BJJ?LU%*E&I+]TKN48NTI2/
M1X;DOJL95(S4/K25H_'RQE9ZOFUT=[KL>,Z'X5O;S29+Z*UMY6MYX682W%M&
M?*Q(S\22+NR5 *@,3GIWK#U.V>*Y9S;QP RA%,;J0@R<LVTD$ #L#CL>U1V6
MM7\-IY:S.L9_@5\%N?XE[DYXR#WQBJ,][+<DAPZX.\,QX;/&!SUPW8=L#G-?
MR135>-:;DH2CSRYE)R:L[JR2:LM;_+K8_:L7B>')9=@Z-"CC%C)4J:3J0I.F
MZD8Q=Y?N-;\LK\\GM'E[&I<7R+;BTMYFC0A7EV[OFD4$ YP#T8\ ^F3QBLB-
M5F95;C:')W,P+ *V7W9_@QOP>3MP,DBJC%U/(*Y'&X'U//UX/_UZ6*5E?/JC
MJ,^KH4&>.N3V.[\S750IQA-<BC%N=[Z63;LW=ZNR>EV]=3P,PQ,<PQ-*KBY5
M.2C%0A0IU*E+#QC&*47[.$TF[Q5T[KWI75VK?1/[/5UIVG?%30K*^GA,&J-=
M:5)([2*8?[3LVMK:[,F-J^3/(."0> 6P@)KFM=T6^L]?\1:1#;7%W-::O=P3
M7"D%D_?LRKOW8"M&RL&W<[CSUKS[PWJ<V@:_I.L.Y\RTO+>X8AE5C%#(&95)
MR P&2/?(SV'V'#IOA^74CKNKZ=>YOI8M7N'>\N[-=<LY=L@ BB@E6.,1@Q^>
MG##Y@:^1SBK#*LP>,DYU85Z-.FE))TY5L-6E*/,H<LVW&=FHRY91M>.B:_HK
MPRP-?COPWH<&RG1PV=\,<?9[G,O9RC3EE_"O&?"V'H9B\)*O[6,)T\VRRA]7
MKSC*O2YJM)UI<].*^6I3K&BC[;&LFDWT8,IEAE$,@$A^5HIHP91N7!P 5/7T
MKA[NYNKZYGN[ZZ:YGG.^2:>220R%G.YR^&)//S$XSU'M]3?M-3>'=3\1V&I>
M"](FLO#?]E6T!\N)TBDNHT4%@[<,%Y+9.2>3C-?)+2.0RE<?,5R> >< */;N
M<X_.O<X?Q<,PRW#X^I0IPJ5[?N_>O1A=IPDY2]IS*VL79Q24;6B[?E7C!PY4
MX"XWSC@./$,>(LOR/$>SJ<19/5Q<.&>)\QG1I36<9#A(NGAU&I.JH5L6J+EB
M9T,1[>52+=TF6(3M^]5H@6VE=Q7@Y7;N&<#L6 ([\XKHM#TN[U1)XK8QL8T:
M1P\T4 \H9&?WK(&(]%R>1C/&>>6S>65(X@[,3@+@D'/8<9(QT^F3V-=+%87-
MG$Y$ZP2C 9%F57>,J&V$$@DY/ZXQR*]7$R3LJ;2<6K-)V7*W9^K22=GJ?G^2
MX/%_6*V*JTY-.#IR@[1I2TLWRIJ*>[LK15[122BEF6L'E3*'F2&.,R%9)5\Y
M&4DJ (@KA3N!VMP<=>,&KLE[,B)"+^9K<2[A%Y]RD1X'S^2$,9 SQ_%Q]W'6
MK(H#$KA4;[B;MS*.<Y.?E);<2" >?<56E0OC&2%!+=]H^7!..>N.IK)<M:;E
M6497M;W8WCYQNF[^NE]FD=TJ=7"4:E+".I0524HU9T<3BJ<JU"3;>'<:>(A"
M%)ZI2A#VEFKZFA/?[[?[*LQF"S>;N,8522N"5)"N< X)(!/<=*QY9-\9) !&
M#QD]2,].N"?US4R)L+;P0 H))!&,D<DGD#ISP#WILB*8V*_-D$ #)S@Y.,$\
M#K^N:V5*$9)4I2E%).\I*][>\DH\JMV7+]^ISUZ^*KTI.I73E"G[)4JS<G"C
M37+32E*]6?NMVG.;E+>2OO\ 3_@WC]B_XXY) /Q]^!'/L?"GQEZ#L<9'_P!8
M5YK83PPZ7;(L865XD"MV P/FQV 'I@\=J]+\(_\ )EGQQ*_='Q\^!'/09/A+
MXS;1GIDD9 [XZ8KPR&^?R+6-\H4APV<@J&10IVGG).,#@'IUZXX^E3J4HNM!
M3E&[C&5[/16;LTW+?9[=+O7\[SW"+$THP<^:-.K*JH0G:$JCLFG\3>D4FDU=
M?CT=T\<;K)-+&$9>I4DGIDG )''L?Q&<X%U=6]W/'"D@\J&+RK*-6F50^3F>
M3*X+\D?-M.,#!QBJ%S=B<B,S\IZMGVY Y /MG\1URR##(0)%9I#F)LJ!'SSN
M8< GCJ.Q[$US83#<M.4Y.2Y;>RIMWC"]T^5--I6MUVM<X<+@73@ZUGAY\L53
M5)MP:5_>M4YW==TUI)JVJMVL%G916879DF0DDCOU...YR<^_I71>"A!8^+_#
M][<I(;!M62)+60$B1)0T,I 4$JK.S@9P>A[UP\&J*8T,O[R:-AA8CN4XP"6*
MY(SC.<8/.*D@UFZ&H1S1.5:WN/.M462,^4X<ME5SN4 DXR>/7@5@\+CJ\<<Z
M53D@J-ZG--1;IWFHJFFFI.,FI/LDTMT<^(I8S$87,Z,ZV(E"KAU%2YXKD4G5
MC=/DM"SE%J26C6K:W]NT[X+^+OB!XZD\'^!_#]YK&L7NH32:?I]LBB22$.PW
M0KN5Y$CS\[CY%P26 Z7OVE?@-\0OV;O$.A^ _BCHZZ5K^JZ#9>)5MTNX;MHM
M.O9[JTA5Y;:6=!(LUC.)(P^Y&7#!6R*]6^$OQ4\5^#?$>F?$;POK46CZ]I$$
M-S:Z@!9"ZTU#_HUW%)%=_NM2BU">-V,$0>XMP?,P%8&J_P"W!^T!XS_:<\>:
M!\1O&<&D1:EIWA'3?#X2P1;2*XM[&YOK@3K#N#2274]Y-<RX!Q),T2@*@ ^"
MI9KQA'CG)LNIQRNMPC1R[,*F,Q=\3_:U+-*5##RRUT7&HL*Z,J\JZJQG1FVD
MKJ/N\WYE3S7C^'B+PSE,UD>(X IY!G#S#$RGBWQ#3SJCA<'+*)4)PK0PD:7U
MAXI5_P!S*I9IMP7+S_"$YME+O;S+'D@+N5W,H&XMP1E0N1R0N=W' (&7=$%+
M=%D+D,V\ , N[&[ (R-V#P"02,'/2CRYMQ8)M5W/R!LE /[PP2H.>"=N<$<X
M(J]';,Q3;LQ_$9, C/'RENX_'UY[_KM3$U7RRE-NI5BU7J72=>*2<(U%&*IV
M@XIQ=.$'=:M]?V]U:5*-.SFI6?M:KJSG4K)IVC6DYR4U&5FERV3BK=SHO#=G
M:7%E(K(1YC[7<G.X8)QMZ_> .0H].E=$^DV4%LS[B)1E<(&#A",##!2<>H!Y
MY& .N3HGV>R20%LLSDD C8/<9[CCGOD\<5JW.H _\LRR$$$+T[<YP,=L^G;O
M7S.+E5^LIQJ57%34G#G<8M)W<6TN9)IZV=]%8^<Q=2O4Q4)TZD_8JI"4Z?.X
MJ4(R3<7;6SBK.UM-M],2:VMQ9[H+N%[A&+?9_*E68C/>5HUC((P<!QD=*O::
M%2XE:Y?RT$2;I+HO*F=O"JB*S+DGY1@@,!DCC(+6*>1!$S*LK*"44R,H8X9@
MHZLHYVXP>@'(I]Y#!NGBANAC]WMDN,0%]JACM#$<[2IQU^8=B#76\PJ3IQC[
M'#JM!J-/%0P\:=2G#:4:E*DE0Q+E=WJ8B#J]>;HNAXJM4H5\-*O4E2KU,34:
MY:=Z3Q7LU4]G)1<DDJ<5&\ELW)-[4]2$:V=SY9R)+;YSCG Z9&,]>ASGVSS7
MI'PI(/P<_:.YX_X1+PEGKT_X3?1#]>A^I^M>0WURQ@D0993;;=X)(/7/(.#]
M?\CUSX4?\D;_ &C_ /L4O"/_ *FVAUVX!-0=^^W;3MT_I'I9725*G))RDE+[
M33Z6Z)?H?1'A:'PU'\.?#,%YJ$ZZH-'T^<&WTN%V*O;PNL+3&8!M@^3<X48P
M2 ,UPWC8Z<OV>XNKQWL[A0S&YB1&D:(>6BB&!I1&%"!1@D.!GN:YOP[KL5KX
M?T>.21RRZ78CRY.'8+;1@B)6P64?PE<CUR":X?Q7K)\0M#;6!9K>#> &D D5
M@W[P.,@J%?<%!'3'8U_HOQQQ7PKDWA'F-6EF*GF6;Y7E^7Y/PRW"6:5JN:9#
MD^ Q]>>%C351T,,Z-6MA)QC:G.<9U'44DG&(C7S"KAX2RS+*.'PU5S]MA:=:
M-:3C)VE4E*O.+<K<TVH)<SE:VB4\>J0:YK%AI,CP?V7!(X@M=KFUF*J'5G55
MR)6)*DL!\JJ">*]IM8--&DQH$N$N0P$=ND?[N-$)!5>,!" ,<@8[\BOENQAO
M=*N0_P AG#B:&0L&V!6!8$DX&X+M ."<]S@#VVS\=6=S#%([?8YS%L1"F5X
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M9045)MKW+O:ZV.5TA)-/O1%(7BMVC!W29P9L84< L<C!R,@<#.0170>(E1]
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MQ=(0I.?E"D-PQZ%1@&F2([!5MMVP_(%QAB0?F+\C<"&&T'ISTKT_Q'>Z+?\
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MUD!@ R1R17-2>*+*X\JVL=(N)KF=REG'&[R7#LO"_+&'V[G[[&Y/ XP?O_\
M9.U7XS_LR>+M)^/_ ("T/^Q_B)I-NS^&=?U31Y]6CT%]0LKD?VGI<'FQV\US
M:BXA7%UITX75/L$3?)(ZM^;>-WB5/Q(X K<%\#9IP_CZ^,J599=G/$N,P>59
M++,,1CXUI?O<1./$#JXN:J5,'@<)@5C:L*;C*E2K3IQ?TO!/"G$->I7>5Y7C
M<=A,)A*N88]T</6GR0H1^'6FH^TG3;<%*2CI>4DDCXUU[PKXX^'OBJ_\/^-/
M!&M?#S6=!U Z'K?AO4-%U#2Y+&]L&:&YBN8-8:[N%D\R!_.4%&+%LX!Q6AI
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MRVD]K&=+UC299H8UN[5DE@OHU9XC?V[HML0QW5F_MRZ/^SUXAUJ'Q[^R_P"
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M*;A4E*%.,).2;:?O1=YQLI7T5M_X%X]S;,>*N+N,N+,;E]#*\3Q7Q!G/$E?
M99.K5RC"5LZQ^*Q[PN J5G&HL+05:%*E2JPC4IQ@U-7D?1WA/G]B[XY_W?\
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M58?!T54HPKX6EA^;&XC$NM35)T'3G&4;RC^,>H/%#*1+)YK!W25XW80<[4R
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M:Q/>ZC!:P6=A9:GJ<3!))[F#3(;6W>-1'Y<44"0P!"0(QG-?8_2I^A10XO\
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MZ^/EA\0J5=59+!4\)F,:U>IR]A/;V<]O;ZA<&&&82O)+;@NZR LJLX9AAB%
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M6:W=^&Y=/2.RV->JVT,H*L0"!N8X _S^-?Z\WB3_ ((Z?\$P_$/B;7-?UO\
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M[>72Q_DJ3^(M!G@DB-T&+H0 %).2,@8'N.XKAK'^R3>LFH3O!!EW5\%N #L
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MX.% .#C@\GTZ=_RK0_MNWN_+2[AC41PB,2!2&)7H21],?2O]>;_ARW_P2O\
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M[57M79MB,IC*%7X&&VC*[@>0<'KT)/;(_P!?QO\ @BU_P2NP?^,'_@C]X?\
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MU"WF65+C:T6TQE(E0J5.004"X(/(/4'!'3-?Z_O_  Y9_P""5O\ T8_\$?\
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M'YE^4=LYV]SV_.HKSQ!J>H/!-<7):6WB6",B,?ZM7:09P,'#.P_^MU_U^?\
MARS_ ,$K?^C'_@C_ ."C5?\ Y;T?\.6?^"5O_1C_ ,$?_!1JO_RWJU0HIWC"
M$7W4%L;1P^'B[JE#_P  7]?\,C_($CU_58R/W_ _O1*V,9Z94XSD@XQG/M3)
M=9OI@V^12<#&(0.><\A1[=:_U_O^'+/_  2M_P"C'_@C_P""C5?_ );T?\.6
M?^"5O_1C_P $?_!1JO\ \MZ;I0?1+TC_ ,$KV5#_ )]P_P# $?X_*:G>IT<D
M=>5!(/'.=H].GN:L+KFIA67SC@_P[!@GU/!Z8!Z^U?Z_W_#EG_@E;_T8_P#!
M'_P4:K_\MZ<G_!%G_@E;N'_&#_P1[_\ ,(U7T/\ U%Z?LX?RQ_\  ?\ @@Z5
M%)OV<=%?X(]%Z'^/T=6OW.6E/ R/DZD<@''/)_"JYN[AVW.S$Y&3CCJ,\!?3
MZ],<U_L)_P##EG_@E;_T8_\ !'_P4:K_ /+>D;_@BU_P2N )'[#_ ,$?_!/J
MOK_V%Z/9Q_EC_P" D)4[K]W'MLNOR/\ '^AU:^M&G6SNI(1<0SVDK*Q'F6DH
M'^CL.C1DYR#W(/I7O?PH/_%G/VCPSIO7PCX2RK.H)*^-M$R$!PS8."57.!R>
M!Q_K!-_P1:_X)7 D#]B#X(@<?\PC5?0?]1>MO3?^"-O_  2]LK#6;*U_8I^"
ML-KJEE;0:A"NCZF5NH8KV"YCCD+:J6VK/#%(-K*2R $D$@U3C"GM"+>NMDKZ
M-*^GG_5S;V=&*<Z<%!JU[):NSMJK/37<_P A"T\?>(+.U@LXM0MXH(+>.W5#
M86LA$<48C52[1,6("C+$Y..??'E\5ZOO,J7,4C.2Q46L,:H<X#*J(J@MC)VJ
M,G)/J?\ 7M7_ ((M?\$KN?\ C"#X(]5'_((U7U_["]/'_!%G_@E;DC_AA_X(
MXP/^81JOO_U%_85]1GO'7&'$\,+A\_XJXBSO#8.C1P^%PV:YE7Q5##X?#TJ6
M'H4*-.4N6%*C1P]&C3@E:-*C2BM(F%/#QI2<HV3;NTE%)MWD]4D]Y/\ IG^1
M#9_$'Q/9#S(+^-&5CLS96[NF\@[DD>(LC1M'&R$$%6Y&"37HNJ_M(_%K7[JW
MO-=\::GK-U!;Q6D4FLI;:C#;010K;Q_9H)K=DA,42*H* $[1G.*_UE6_X(M?
M\$KMQ_XP@^"7_@HU7T_["] _X(M_\$KB&/\ PQ!\$>W_ #"-5]?^PO73@.-N
M+LJP]"CE/%O$N54,/34*&%R_-<7AL-AX)R:IT:5.NHQ@I2G-1Y;*52;MJ9XC
M X7%24J]"G4DM>:5.$FWW;E%OMUZ'^1FWQ0\7+*LJ7T!;DD_V?8A"Y=F9UC\
MC:K-E=QP&8CYCP +8^,/C@ (NJPQKD,W_$NL""58,IVK;#)# 'G/&/7G_6_/
M_!%K_@E<>O[$'P1/_<(U7_Y;T[_ARU_P2NV_\F0?!'[W_0(U7T_["]>F_%KQ
M0<*E)^(G&,J5:')5C+/<P?M(-<KC-/$-25M+2NK%K!X2-N2C"+5DFH03T7DE
MVT7^1_D3ZCX^\0ZUJD>LZE=6UWJ42>7&[:;IXCV9W?-"+81N1R065B#SG!K5
MC^*GBN(^9]MM Y&TJ=(L"H !51M-KMX'7&#[CM_KB'_@BU_P2NX_XP@^"7W,
M_P#((U7K@_\ 48H?_@BU_P $K@0!^Q!\$NG_ $"-5]3_ -1BO-P'B1QMPU4J
MU\CXMXIR_%8FH\17Q."SJ>$G4J3C&$I3_<UISDU"-YNHKI)<JM=Q5P=&LN6K
M&,TG=*48RTZ+5;>7XL_R-9_BAXFN$,,US8R1,<X.CZ<2I./FRUJ2 "3^7OFJ
M0^)'B2(&.*;3S'W']C:9DY''(M 0>,Y^G2O]=4?\$6O^"5W_ $9!\$NA_P"8
M1JW8'_J,4K?\$6O^"5P8X_8@^"7;_F$:KZ#_ *C%;S\6/$G,L2L9C>.N+ZN(
MIIP]K5S[%5JDE)\S]Z"H+5K7GC-]FEH:4\-1I14(0BHI;**2^Y;'^1+)\0_$
M\R^5)>VIC;(8#3+'IGK_ ,>_4\_Y%8DWB75W)!NPR$DE/LT07!)X "8 ([
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12.VW5?DS2#Y-G9;?F^Z/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tm229830d4_1012b-img12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm229830d4_1012b-img12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $W NX# 2(  A$! Q$!_\0
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M2T'3+W3+.ZT=["3P]/#>Q2Z;^H5 !1110 4444 %%%% !1110 4444 %%%%
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MXG_V+_P@;>*/[4LIRWA :[_PD:6(34&TX6<B3'W@2$L5"/P,Y(P.F1UY^;!
M/3(()!P#_&!^U1^T!\:/'GQ6M/"^J_\ !0OQ'^R)%\2_^#?/]F3XH:I\:M:\
M8^*])^'_ (7^+7CS]HO1M+U7XD:_I_@N>V?PA?\ CXWK^#-7^)_A?3[#Q%X;
MTG6Y'TO4["&W3;\D>,?VI_AUXN_85^'>KZ1\3?"7P ^&_P"S+^TK^TM:?$?]
MFKQO_P %*/VV+C]FC_@I7_PK/X=>'CKUW^R+^W@OC*?X[7NG>$-8>V\3?"_X
M90Z_>^#=7^)EPFG6FF>,)K]Y-3 /[@M:_:.^'.@_M#^"?V8-0B\:?\+2\?\
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M\<-77X&:M^Q=X]\;?&GXB?M-?ME_M/?LN_#/QU^W7K.J:5XNU?2?B/\ M0_
MZSUKQ]J/B+X;:?J&M0?"?X=>*=>LO"EQIUDUPJ0W-M96MU_3]_P2?U+Q_JW_
M  3U_9BO?B;^T=X;_:Y\6GP-=6ES^T=X4O?%FJZ1\5M.TSQ)KFF:+XA&N^.-
M(T'Q5XEOH])L[/3-3\3ZSI%E=^([^PN-9<7!O?MEP ?H?1110 4444 %%%%
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M21R*'CD1U_9R*NCHRNCJ2K*0RD@@UT/_  734#_@D%_P418##-^R[\102.I
MLX!C/IC@^HP#G K]._!3-)X-\)22.[N_AG06=W=F=V;2K5F=V)+,S$DLS$LQ
M))))H _*0_\ !=+_ ()[X.-8_:KSU_Y1[_MZG@<DX_X9P';/?CK7UU^R1^WG
M^S1^V\/B:O[/?B_Q9KFH_!O7/#7A[XE^&_'?P@^+OP7\7>$]1\9^&H/&'A(Z
MEX2^,?@CP-XC^P^(_#5Q'K&CZC#ILME>V3)/',8IK=YOLBOQ?_8* _X>M_\
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MD^KW?P%^+]S;"[BM$TGX6:I\--6FT[2KS4(="U'4;JVTIZ$?MV"#T(/T(/\
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MX_X*'A">/V:_&!("@\F2P..1R&QP>I!W#!P3VWP__P""B_[.VC>!/ ^EW?\
MPGIN=/\ !7A&RN#%X+NGB,UMX>L(Y2KK<(9 &!56&4 4,H )SX&>\5<.\,QP
MD\_SG+\ICCI5*>#ECL0L/'$U*,83KPI2FI)RI0J1G-.46HR6[=CDQF88++XT
MY8[%8?"JK*48.O5C34G%<S24KRE:+3;C&2NUJD[GZ=[E]1^8K\=?V"_^4D'_
M  6L_P"RS_LB?^LJ^':]]/\ P4H_9N( "_$' )R/^$*NB6ZX(!O,X'MC\<U\
MC_\ !,#XA^'OBO\ MU_\%C_'WA,WQT'7OC7^R@;(:C8G3;\BP_9AT"TF\^T=
MY'0.\;>6Q8.5VM@$BL,EXUX4XCQ-;!Y%G^5YMBJ%-UJE# XNGB*D**G"DZLX
MP2<::J3A!R>G-*,=V9X3-LKQ\Y4\#F&%Q=2,>>4*%55)1AS*/,THQM'F:5[O
M5I'[C44@&U0.@4 <9QP/?)_/)I:^H7]?K^)Z 4444 %%%% !1110 4444 %&
M1ZT5&P&X$GH,8'/4DY/MQZ'//I4R;2NE=W6GJTOR;?R _*+_ (+I_P#*(#_@
MHA_V:]\1?_2.WK]./!! \%^$,D#_ (I?P_U/_4)M*_,7_@N<A_X=!?\ !1(!
MN1^RY\1,@D 86P@)YP3G"G:N,,S$$C.:]K\+?MZ?LQ67A;PO:3?$"X6:V\,Z
M!%*L?AG6V0.FCV994;[ PR"Q& VWGB0J 3XF;\2Y#P_3H5<]SC+,GABJE:GA
MI9EC:&"A7E0Y74C2E7E%5)0A.,YQC=QC*+>C3.3%8[!X)0>+Q6'PJJ2E&F\1
M6I45-Q5Y*+JU*:DTFFU%NR:;W1][[E]1^8K\8/V"B/\ AZW_ ,%X.1_R5_\
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MIVB#Q9I_B(WFI1:WXTTCQ;IYN]3U&[DT)[O4KBX7]G:* /RP_8%_X);^#O\
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MXRWGC+7_ !S/X2UBZD^%#Z5-\+VU;Q'>HND6.D67BZ.P6TC?QLLJ/(?V$HH
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M4?\ 0OXV_P#"2I_\P!_Q&KA/_H0^#?\ X;JW_P!%QPJS?\%D5 7^R?V%N!C
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MA8XBIAXR]M7I1PT)5H^M_P#!<GG_ ()#?\%$B1\G_#+WQ%![Y LHPW!]0#W
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MM_:7]/@;_P!_?B#_ (5[M10!X3M_:7]/@;_W]^(/^%&W]I?T^!O_ ']^(/\
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MM0NRJJHSL<,7!^4*8Y0OY26GPU_X+8>-]/U+3?&7[67_  3;^ ANXA:VFM?
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M%/BA;^$/!WPPN?B-<:1XT_9/TCQUX.\+31^)?CYX<^%_A)O$_BFV\1>%=3\
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M0![K163/KFE6[%)KZWBD ^[)(JGH#Z].14'_  D>C?\ 02M/^^S0!NT5A?\
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M3H.C'+Z+3UA.&"KU$E'WH--KR<1FV.Q-U.JX1=_=IW@K/H^5IM6=K-]#Y?\
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M;Y+S5H4\MJ12KX53OA<53E5Q,Z]5KEA.I.I45*IB9RJ7K03E)4E*I!01]/\
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ML?'Q/CCPP(O ]^;DV:V7C!FU3/AF[-Y#):K!K?V*83P_9UC::/RU_.C]BO\
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M=:E'$TOQM^)]RFR^TWPU>:=<*8IXSOM;R=0Y:-BLB2*G[DG]I+X/#KXAUO\
M\-]\1O\ YDZ /=**\*_X:3^#O_0PZW_X;[XC?_,G1_PTG\'?^AAUO_PWWQ&_
M^9.@#W6BO"O^&D_@[_T,.M_^&^^(W_S)T?\ #2?P=_Z&'6__  WWQ&_^9.@#
MW6BO"O\ AI/X._\ 0PZW_P"&^^(W_P R='_#2?P=_P"AAUO_ ,-]\1O_ )DZ
M /=:*\*_X:3^#O\ T,.M_P#AOOB-_P#,G1_PTG\'?^AAUO\ \-]\1O\ YDZ
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M?_,G1_PTG\'?^AAUO_PWWQ&_^9.@#W6BO"O^&D_@[_T,.M_^&^^(W_S)T?\
M#2?P=_Z&'6__  WWQ&_^9.@#W6BO%]-_:#^%&KZEIVD:?KNL2W^JZA9:98Q2
M^!O'UI%)>:A<Q6=K'+=W?AB"TM8WGFC62YNYX+6W0F:YFAA1Y%]C652Q7D8]
M>O&,\#.,9QS^&: ):CFP(W)&0!R.#QD9^]QC&<DX '.1C(DIK*KJ589!QD?0
MY'X@@$'J#R.: /P>_P""LNL?#?X5_%#X?_&+XQZW^SQXJ\)^)_V/OVPOV>?
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M< N,Y8KG8=PP&RNXX!W!@" 0*.YYY.2QSP,@AF((. I+!F*?(6VXJ>B@"O\
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MZ'-)WL[6OTNKJ_2ZZH/0XOQSX)\'?$KP9XG^'OQ$\,:'XV\#>-M#U7POXO\
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M51M'JW_?;_\ Q5.HH ;M'JW_ 'V__P 51M'JW_?;_P#Q5.HH ;M'JW_?;_\
MQ5&T>K?]]O\ _%4ZB@!NT>K?]]O_ /%4;1ZM_P!]O_\ %4ZB@!NT>K?]]O\
M_%4;1ZM_WV__ ,53JBFFC@0R2ND<:\LSG  ]CT_.@!^T>K?]]O\ _%4;1ZM_
MWV__ ,57/-XM\.QL4?5K0.O##S!P1U[\?X4W_A,/#?\ T%K3_OX* .CVCU;_
M +[?_P"*HVCU;_OM_P#XJN<_X3#PW_T%K3_OX*?'XIT*=MMOJ5M*V0,*X)!.
M>^<#Z&@#H-H]6_[[?_XJC:/5O^^W_P#BJ:CB0*RL"I.,\?-QD$?A@X^H[5)0
M W:/5O\ OM__ (JC:/5O^^W_ /BJ=10 W:/5O^^W_P#BJ-H]6_[[?_XJG44
M,* @C+<C'WF/Z$D'W!!!'!!!(,<4 C.=Q8XQW'4Y))R68ELG+LVW)"[03F>B
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:[%?73:HOS1\%]"_:-;X=^)GTWXK? ^UL$^+G[2$=S;ZA^SUX_U2YEU.W_:
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M\ ?_ !&?XB__ $65 'T%17S[_P (]^U/_P!%C^ /_B,_Q%_^BRH_X1[]J?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ@ HHI"<#.,].F/7D\D# ')YZ ]>E "T4Q'#@D C!P<XR".Q )QQ@\]B#3Z
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M+&S_ &J?C/!:65C;0V=G:P1>-M56*WMK6V2*"W@B4!(X88TC10%50 !7YYT
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MMS\)/@_;(\C_  J^&V$0R'/@;PR,A%9WP1I9)(523\N$ +,3D*0#I/\ A/O
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M_P!#KX2_\*/1_P#Y,H_X3[P)_P!#KX2_\*/1_P#Y,K$_X4W\(?\ HE7PW_\
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M>]N5BMD96D6NT\*?\@.T^LO_ *,-?#7_  58_P"4<7[=X[']B[]JW([$?\*
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M5_B2Y6F[*-F^[LDS^NXYR2%;'T]^F >W_P"K/&89;BWB!,LJPC^](ZIT//\
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M0!CPW^UE^TUH**HZ;4TWXIHHRVT@!2NY 2AX-;]C^PUX+\-WMOJOP_\ C_\
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M@VSG&HZA=7LD#VMO<W26.DQ2L9+W5K"VBGG3Z#^'GB#6/$W@7P?XE\3^&)O
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MM;:,M-<3PPQR-7Z)6G^KD_Z^KS_TKFKY7_;H_P"31/VDO^R"_&;_ -5KXFH
M_P +HXXQZ<\CDY/L",=,')XR#M( 2BB@ KU'X'2I!\:_@_-()FCA^*7P_E=;
M>WN+NX9(_%FD.P@M;2.:ZN9BH(BM[:*6XF?;'#&\C*I\NKU7X$_\EO\ @W_V
M57X>?^I=H] '^X/H/[0W@*TT^VCE\._'K<OF*0O[*G[4F,-(71N/@XRM\J;E
M?.$WE&=V.X_%G_!3SX[>"/$'_!/']N32[+0/C9!<7O[''[4EG'-JG[,O[2>C
M:;!)=? ?X@6\<]]J^L?"2QT?2K*)Y%>[O]5OK33[.V$MU>31VT,KK^IGA3_D
M!VGUE_\ 1C5\-?\ !5C_ )1Q_MW?]F7_ +5O_J@/B+0!_B)-C"X_N]R#@]^0
M!WR0.< X)W!J92GHOT_J:2@ KZ>_8CNH[']L_P#9%O9DNI(;/]I_X!74L=C8
M7^JWTD=O\5O"<TB6>EZ5:WNIZE=,J%;>PTVSN[^\F*6]G:W%Q)'$_P PU]3_
M +"__)[7['7_ &=/^SY_ZMKPC0!_ME>%/COX)OUT#0K;0?C7#?:C<V&E6TFJ
M?LS_ +26AZ9%=:E=Q6T$FI:]K7PIT[1]%TU))T:\UK6+RQTK2[82W^I7=M9V
M\\\?OD4;%]SAAA67G'7*G@9. <9(7<I;=^\8!:R?#/\ R";'_K@?_0EKH: /
MCK_@H*ZK^P-^W#YD;2QK^R!^TL[Q@C=*H^"_C4M&,<9< A<=">237\CW[(7_
M  6%_:YTCX%?L]?\$J?ACXB^"6A?M0^$/A?X2\/6'[<_CB^A\8?# ?!]OA)\
M./&O@[PU\&_AE?W-J?BU^V#\/_#/Q+T#P5XD^&6O7MOX.\+ZKX0BUC5M.\7Z
M1JEUIFG?UO\ _!0%;[_A@O\ ;=_LRPN]6U%OV0OVE/L.DV$;27NIWI^"_C7[
M)86D: N]U>3^7;6Z("7FD10I8U_*3^S;^R?^S+XS_P"">W[-WP-U_P  >$OB
M%\)M6^#_ ,,OB,T[Q0VNJM\0/&?A6Q\4^(?B1X=\7^&WT_7O#OQ&MO$.NZI9
M6OC7PYJEAXCM[>R&ERW4EDUW8W/Y=XE\>4.!LFPE5T<6L1FV*KY=2QN'PU/%
MSRWV&7QQ=3,XX*M-0QE3#3KT94L#+$47BN2JHUHJC.1\_P 09N\HH4N1RC+%
M.=*%54E5]A+EUJJ$Y0IU'23YHTJDHQJOW>9.R/9O ?['OPF\.>-9OBU\1Y_%
M_P"TW^T1=2+<:Y^T7^T]K)^+'Q7FOD2:WE3PJFM0'PC\*M AAD.GZ?X6^&_A
M[PY9V.D6]GI=[<ZO):6]_']8"-YR!(7D\H;$65_,6)4PGDQKA'C2,*J1H6+)
M&D9554@G\]K'X<?MP?LY"*S^$?Q*T7]M'X4VKF/3OAQ^TYK<W@O]H;PO81HH
MMM*\._M":-IM_HWQ,@M+:$I:0_%3PW;^(+JXECBG\56>EVYB793_ (*._!GP
M!);:9^U9\._CI^Q=J\TMO:)J/QV^&>NZA\)-0O[A]L%KX?\ CU\-++QE\-==
M(+1P2W<FHV"6^P)=S6\L-S%!_'6:Y3Q3Q7C*V:X?B"?&[YI<M; XF-7'TJ<V
MZB]ODF(J8;,<!6=->SQ%/"X*I04U&G0]I#]Y+\QQ%#'9AB)5_K4\SJ2;Y5"K
M.IB:<7KKAZDJ-2FG\+IQA4IQ_P"7<IVC?] X-/#8V+D=LEN>",,7+G<=N"<C
ML0%*G.U:Z*SE3L..PZC/3 SD8(R2,;B,\\8'+?"CXF_"GXSV3ZG\&/BA\,/C
M'80A&N+_ .$OQ"\(?$FWM@S%$:\/@O6M;GLM\@*(+V*V=RK X=75?>=-LD1C
M'+%(K19$JO&ZM$0<'S(F7?N!!S'A711N< <UXU/)986JJ.88:OEM9Z.EF%.M
M@ZLI7U<:6+HX6<NOO*$H[KG;5G%+!M2]G5C*G)/554Z;O>UK553E>[;TB^U]
M#C;?PQ(X&(CC(QG'0GJ>.AS@YP1G&>F-2/P?*Q_U/UPN<$\<;0<<]R2-H8\X
MS7M6CV5D2@EV#LPZ$D ';R/F#K]T-M))+ $#=7K.CZ+X=F0?:+B.++8+90D+
MP5/)4Y)W!L;N@.>2*^OR[A2CB[>SG%II-M-2B_247)+2_57WU/;H9/2K))2L
M^ED[/SORI::=7V]?CR7P9*G)@8<#KQZ9'*D]QS^7'3,N/"SQL<QG ';MQG'W
M.O7'?MU%?;FJZ%X;@5_L]S!* "68&,,%!PY*E\$JOS'.!A<XX./)M9L+&/<?
MD7(7Y6P!N)*KM8#85)#*&!.\JRH&*L \PX3HX6,I3DFTM]H]?M248Z><]NPJ
M^3TJ2=YJZ[NWXM6_\F^1\OW.ALA?Y.!A><YW8ZCIQ^!Y] :PI]/V9(RK$-_>
M&&!R,GIG&W:>V #N ->X7]LDC,(HC*78A8XU$DI8XV*8U9G#2@,(E =Y6&V,
M.R.B>#_%?XD_"SX,:>NL?&;XG?#/X.:7,)#;ZA\5OB!X1^'-O>",NLWV)_%^
MLZ,U_)$X1)8[%;B2,N ZJ9$!^2JY+*O4G2P5&MB*B=N3!T:V+J7TLN3"4<5)
MO5=.JU/'JX1)N--.HT[?N_WC^ZDJLO*W)>^W8K;)8&9HI98S('5G1BLC*YD4
MQ;T"?NG4DL6R[;G3E0&/RC\0_P!C[X0^-/%J_%7P>GBW]G;]H.T)DT/]I#]F
M3Q'-\&_C-I-\\0M8WU/5?#MO'HWQ%TZ6%SINJ^&_B/HGB;3KVQO=4M+==*N[
MI+RUX&Y_X*0? KQI=WFD_LP>#?C=^VEK-E>3Z?<S_LY_#+7[OX::=?VT<326
M_B#XY>.K3PE\*M B9IXX8[Y]<U"T+8V32++;-/@R^!_V\OVB'^R_%'QSX=_8
M<^$]]%(FH^!_V<]>@^(7[3WB#3)XF6XTB_\ CUJVEP^$?A#=7%I<+%=WOPJT
M#6_$&CZC DVB>+)K69&7U,LRGB;A?%4\VGG=+@CV3C+ZWC<96P68XFG[E9K#
M9+@,5BLRQC4&W*GB<OI0G-.E5>']I45,P^'QF"K*O'$PP$KQM4E.K0E)2<7:
M."HN=:M)77,YTJ:E)-3Y>:7*SX_?\%AOVS(/A_\ %+_@E3\2?%_P&\4?M:?&
M32])^#G@O]OWP[J47PV^%_@;P-\2?#?C!O%6I?M+?#G1KV:+X-_M5:CX/\&^
M*;#X2>!O"FJ)X6\=>-=<T75-,T70]+T"[T'Q!_3S_P $T'M[G_@G7^PR\%NU
MI:7'[*GP.\BP;<&M[:;X=:&8K5B22)((RD9+#@HRY8Y*_P S7Q?_ &1?V8O"
M'[#W[0OP TWP+X:\ _![6/AAX[\3^+]1N)/[3UBX\3Z+H-]XLMOBOXQ\;>*K
MG4=<\2^-]#\1:'IWB:+Q=XEU*ZO+6XTV)+5[#2K:"TC_ *8_^":D^J3?\$Z/
MV)9M2TY]'U6;]E/X*W4VEWS>5]FNI?A_HDJQW1CC22&#>0[>5&FRW?"H[!<?
MV-X8<>PXVRK'R]GB/K&28["X#%XZ='#8=YFZF%JU*69O#X:4\+@98GZG6JU,
M)"MBG1B\(YXFI+&)4?T_(,W>;8:K)1E[7"R6'=1R5/ZRTXQ55J*FZ//))SBX
MR<8.6LG)GYN_MW_\$/?AK\7)?&'QI_9[\>:K\,?BU/!J?B/5]"^)_BO7O%WP
MG\5W4'FZG=/<:YK6I7GC/X:^>Z,TT^A^(7\&Z?:Q,+?PMI&Z75HOH/X3?\$D
M/^"?GQ%^%GPW^(%S\)_BSH]QXY\!^$/%\^D1_MD?M6ZK'I<WB3P]IVL2:?'J
MFF_'1M-U..S:[-M'J6G,UAJ"1+>6;M;SQFOS5_X*SZ!_P5$D@U*_^,&I:5KO
M[&=IJ4-]XITK]G>'Q):^%].\(Q7T%SJ+_'BTL9(?BAK.A6NDO<QZG<6]\O@L
MVL4UU)HNFWL=M>U^R'AFP_X*9S^'="F\+^+_ -A*3PW)HVE2>'WT_P /_&::
MP.B2:=:RZ2;&2VU/[+)9MI[VSVKVH%N\#1F#,6VOU[_B*?%>>4J?#F+Q.<O!
M\*RG0RZMB%2A6E1Q33E3H2A3IU:N BZ<9T7BI3E3JN?U><J4VC[_ #CZ-_!'
M"V5Y)QW0S_@7,<?XAO'5\QP.69C5Q&#RJOECH_NL>ZM#GI\0UXXJ53'488;!
MTHX.-&7/F$E]9H\W_P .7O\ @GO_ -$W^+O_ (EQ^UU_\_*C_AR[_P $]_\
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M:AK5_KMWJGB./P]<C3]*\*Z/X?T?[0/_  4V_9B#;A9?M!G!Y _9;_:"QD
MJV/AUGIGH1@\8/ KW?\ 9L_93^'O[*7AWQAX#^$MUK6G?#'Q!XWU3Q[X?\!Z
MKJ%YK6G?#W4/$%I91>(M"\'ZAJ%W<:C;^#[_ %'3U\066A7\E[)I&LZGK\MK
MJ#6>IQ65C])&SC 8G#'!(R@.3V+Y)+N!P&R#W Z"C+\)F%'!86&,KX:IBH4(
M4\1)892YIPJ5G*2GSQ<^=.,TW%2O4NU&2G$]KB[-N!\PXESO&\/<-X_"9#BL
MQJ8C*,(LTI8!X/+YPPRP^#>#A@<4L/+"QC4HS@L?C8SG2G66)K+&25/\^?\
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M%%% !7JOP)_Y+?\ !O\ [*K\//\ U+M'KRJO5?@3S\;_ (-@=?\ A:OP\_\
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M[\/=)^&WBV6_-P+DZE<>+_A9%X+\2WFJ/.JR/J5_JEU?N5 >Y==^[!L_V#_
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M3]-TK3+6*UTW3K&T@6.*SL[&T@@M+>&*-(H((%B0"-%V?A;_ ,%/?VV+_P"
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M>H6VIV0G@/AL": W-K&)XMR-)$717C9@Z_L?^U)_P4=T[PU^R1X,^-?[&O\
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M_#VCW5YHWA;3(\AI]:\6:TFG>&]$MD_>7>K:I9VD(\V=<?EWXO\ ^"@/Q_\
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M5JFM5=7M=7TU*^_Y.SW3W7I]UUU9^=/[2W[%.L?M2?M0? KXB>._'_C/PO\
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MT[]DO]JK1/\ @I;\.?B_H7P*'@;X-_#GXQVWA.Q\>_#[Q3\.(?"VN_LN:-\
M)/AUX/A\9R:AX\'QA\2Z_9ZMHOARQUCPC=>#;7PEX=GLK?5-).N3J-;E\)_9
M._X)Y?M-_!/P3\"YKGX/?%'PKXCUO_@G?^T[\'?VE4\"_&'P3I7C:]^)^IZO
M=0_!7PKH.N:SX[NO#.F>-+30H[#_ (5YXHM4/A'P7?-'<ZQJ6FQ2ZPPXUP=D
M\<%'$5.,<JC6JY=3QE/#P>#KSI5O;XMU,)B94\?2C#$/ T,/6A2A&4_KF)6
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?C^&_C;1M#N-/^)?CGQAK'@+XBKHWA#3[73)K"Z\!Z]HWB&]TG6I=+L+R_\
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MZE*([/3HVFN;J2)8YF/Y%Z9^S]\>Y_\ @C'^TC\!F^&/B>S^*5^OQ[\/>"/
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M#WCS5;J&P^'FBPV5O8^";JQD\.:9I>C06'VF;RWPK\ ?V[?A5\)U/@*]^/\
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M,Q&88?*JF)P^+RO"9EEF(Q.,P.4X>M6I8AYG#^F=7VLQSG<1P1E5;!&PD+N
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#Q;Q;\%? WC'XK?#?XR:Y!J;^-?A=X*^+'@+PI-9ZB]KIJ:!\:I
M?AZ_C:+4-/\ )=;R\GE^&GA?^R;KS(CIHM[T ,MX0OR/X<_X)@_LQ^$F\#P^
M')_B]IWA[P1=_LVZ^/"%I\5O$-KX.\7>,_V2/$_AGQ)\"/'7COP_!Y-MXG\1
M^#T\':%H<T-T(O#FOZ5IFA76NZ!J/B3PGX-\0^&2B@#T+7_V"OV<_%7[+]M^
MR7K^B>)K_P""UOXN3QO!9OXJU"W\11ZX_P 3;OXIR,OB&S6"]-A=^);^^L;W
M3R@M[WPWJ-YH-W')8W%P).TG_97^',7QM_X7MX+\2?$KX9>*-:3PA%\0O#?P
MW\8W'ASX=?%T?#>T71_!DWQ*\$S6-]I>HZEH&C6\'A5M?T ^'?$6N>#=*T'P
M?XDU77/"WASPYI.EE% 'CVJ?\$X_@AK,NHZOXE\:?'3Q3\4Y_%OPO\9^%_CA
MXB^)LVK_ !>^'5U\%]3\37OPUT_P5XENM%.F6^BZ!%XX\;:/J-IK^A>([SQG
MI7C+7K?QW>>)GN$NK?VWXT?LQ^ _C1XR\#?$V7Q!\2?AC\6?AUI?B#PWX=^)
MWP=\9W'@CQA)X&\97FCW_C+X;^)&>UU7P]XN\%>(=2\-:%JK:3XET'56T+Q!
MHEAXF\(WWAKQ%#'JU%% &#IW['GPZTCQ/\2M>T3QC\8=&\*_%N'QU>>._A'I
M_P 0[MOA)K'BOXE:5<:-XW\>VGA:^LKJ\T3Q3XE6\NM9U2WT;5M-\)7/C"ZO
M_&TWAA_%VIZGK=[YQ_P[N^"FF:'XJTCP?XO^./P]'C?X?_!/X1^+M1\!?$V;
M0M6U[X<? 'P!XO\ A?X,\(WU\^DW9&GZAX2\;Z[%XBO+6&'6)=5.G^(=$U'1
M==TG3KV HH W-(_8;^'J?!CQY^S_ .,?$'BW7OA3XG^)GPT\8>"/!&FZYJ>D
M^'O@SX"^ LGP<M?@5\'OA5I]Q>:I'X5\$>$K3X&^"=3U[3[$V\'BKQGK?Q"\
M57T<6H>+[Z<8/@+]CB[M?B=^V#\;_'GB>'PI\5OVH=2\*^%+?Q3\![O5_!6N
M^ /@W\)#JEO\)X;?7]4;5&U+XDWD6HWWB/X@ZTVE'0]3O;V+PM'I5_X=T>V6
M_** )])_X)Z_!;PO=>&];\!^,?CE\.OB1I;>,V\5?%OP3\5=3T[XB?%RS^(O
MB^7XB^,K/XPWM[8:AX=\<0:MXX?4?$^B7$WANSU3X<:AK/B>V^%M[X'TOQKX
MPLM=]]^*/[.7PK^,WBSX2>+OB1HLOB:\^#C?$>#PWIFHSI>>'-5@^+/PSUGX
M3^-M+\8Z)=P3V_BC3-9\$^)=6L);.]9(#<7!FG69"8R44 ?.5I_P34_9IM_"
M6N^"M5?XK>+M/UKPU\.?AYX>O?&_Q1\1^+O$'PW^$OPF^(GA[XH>!/A'\.=:
MUN2\N-!\#Z5XM\,:#=ZU+>/JGC'QO:Z+H=KXY\5^)_\ A&_#)TC[H\9>"?!G
MQ%\*>(_ ?Q!\(^&/'?@;QCHNI>'/%W@SQEH&E>)_"GBGP]K-M)9ZQH/B/P[K
M=I?:/KFBZM9S2VNI:7J=G=6-];2R074$L3LI**-]];6:OK9IIJU[VLTFK6LT
MFK-)HNULVO1M?DS(LOA1\+=-\9:;\1M.^&O@"P^(6C^ T^%FD>.[+P=X=M?&
M6E?#&/5;778_ASIOB>#3H];L? ::Y96>LIX0M;Z+P^NJVEKJ*Z>+RWBF3S3X
M=_L@_LF?"#XE>)OC/\)OV7OV=OA?\8?&MOK-IXQ^*_P[^"?PU\$_$KQ;:^(]
M6LM>\0VWB;QUX:\,Z9XHUZWU[7=.T_6M9AU75;J/5-6L++4;Y9[RU@FC**++
MFY[+G][W[+G]]\T_>^+WY-RG[WO2;E+F;;:LK-65FHIJRLU!<L$U:S4(I1BF
MFHQ245%)(^A_+3GY$YQGY1SCIGCMV]*< !T 'TXHHI66]E>R5[*]ELMMET6R
MZ)#"BBBF 4444 (55OO*&QTR <?G3##$PPT4;#)."BD9/4X(ZG)SZT44TVMF
MUZ-K\F@WWUM=*_125I6[73:=K73:=TVAJV]N@8)!"@8AF"Q(H9AT+849([$Y
M(IWE1;MWEQ[L8W;%W8R3C.,XR2<9ZDGN:**')N]VW?>[;OMO=N^RWOLNRM"I
M4HI1C2IQBFFHQITXQ33DTU&-.*33E)II)IRDTTY2<@0Q#=B*,;\[\(HW9&#N
MX^;(X.<\<=*411#.(XQD '"*,@= <#D#MZ4447;W;?75M[;;M[=.W2PU&*5E
M&*2;:2C%).7Q-)12O+[3M>7VG(!&@Z(@X"\*!\HZ#IT'8=!2>3#G/E1YSG/E
MKG.%&<XSG"J,]<*OH,%%):7MI=W=M+ON[6N_-W?F/E5FK*S5FK*S5[V:M9J^
MMFFKZVOJ!AA( ,41 ((!C7 (.01QP022".A.:#%$3DQQD@Y!**2".AY'4>M%
M%#UWUNN5WUO'?E=[W5];.ZOK8&D]&DU=RLTFN9M-RLTUS-I-R^)M)MMI-'E1
M9W>7'NQC.Q<XYXSC..3Q[GUKG?%'@WPIXW\/:OX1\:>&O#WC#PIK]A-I>N^&
M/%6AZ7X@\.ZWIMP%$^G:OHNK6MWINI6,X1!-:7EM-!*$4/&P4444-*2<9)2C
M).,HR2:<9)J46G=.,DVI1:<9)M---IU3E*C5A7HRE1KTJL*U.O1;I5J=:G.-
M2G6IUJ3I5J=:G4A"I3K4ZL*M.I"%2%6%2$:D>7^&7P9^#WP7T.3PK\'?A5\-
M?A/X8EN[C4)O#?PT\">&/ >@RZA<!8[B^DT?PMI6E:=)=S*JI-=/;&>554.[
M <>DF"!@5:&)E8[F!C0@MG.X@C!.><GG/-%%32A"A"-.C"%&G!*,*=&$*-.$
M4VU&$*,*4(13E)J,(1BG*344Y2;TQ=>OF%>KBL?7K8_$XB3E7Q..K5L;B:\I
M1C"4J^(QE7&8BO*4(0A*5>O6E*$(0E)PA"$%\F+C]U'P-H^1>%!R%'' !YP.
M,\UFZOH^CZ[IFI:'K6E:;K.C:M8W>FZOH^JV-MJ&F:IIM] ]M?:?J%A=Q36=
M[97MM/+;W=I=12V]S!-)%/')&[J2BFTI)J2333BTTFG&2:E%IIIQDI24HM.,
ME)IQ:;3RC[DE.'N3C.-2,X>Y.-2#3A4C.')-5(.,7":FIP<8N,XN*:9H?A[0
M/#6CZ9X?\.Z)I&@:#HMA::7HVB:+IMEI>D:1IFGPI;6&FZ9IMC!!96%A8V\<
M=O:6=I#%;VT*+%#&D:JHU5BB0 +'&H'("HJ@'.<@ #'))X[G/6BBE&,81C"$
M8PA",80A",80C""2C",(1C",(I)1A&$8122C"*22JI.=:I4JUISK5:M1U:M6
MM.=:K5JRE.<JM6K5G5J5:LIU*DY5:M2I4E.I4G*I*4YRG)1115$A1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
*1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tm229830d4_1012b-img13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm229830d4_1012b-img13.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #) E@# 2(  A$! Q$!_\0
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M!\.W&N65SXWD\.ZGXF6#Q%=P21KH6D?V9H]\[:E<"6(3*B-&%W.OT_7Y/_\
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M5OQV_94AT#QKX@\*)K?Q%USX SZ+;>+/&O@;2M-U:YO;_P *7/\ ;-M-%#-
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MXG@U76+'3K?2],@L[6\B@AT^SB1+>/U*F 4444 %%%% !114;R;3C /RYR6
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M1110 4444 %%%% 'Y:_\%#_^"P_[$W_!+K6/A7HG[7/BWQQX9OOC+IWB[5?
MZ>$/AWK_ (WBN[/P3=:%9:^;^;14==.E@N?$FEK!'-EKA9)'3Y8V-?G'_P 1
M;_\ P1@_Z*K\:/\ PP7CO_Y'K\+_ /@^,_Y*9_P3H_[$7]I7_P!2#X+U_![0
M!_K)?\1;_P#P1@_Z*K\:/_#!>.__ )'H_P"(M_\ X(P?]%5^-'_A@O'?_P C
MU_DVT4 ?ZR7_ !%O_P#!&#_HJOQH_P##!>.__D>C_B+?_P"",/\ T5;XS_\
MA@O'?I[P#_$]!DD5_DW 9SVP,_J/\^OUZ4E '^LE_P 1;_\ P1@_Z*M\:/\
MPP7CS_XQ1_Q%O_\ !&#_ **K\:/_  P7CO\ ^1Z_R<@$*J20"<YXS@]/N].F
M#WZDC!IIVC&&#9Y(VXQSTYZ\ >W) H*<6K.ZU2>C5]>EM[G^L?\ \1;_ /P1
M@_Z*K\:/_#!>._\ Y'IA_P"#MS_@B^26_P"%K_&G)X_Y('X[X''3_1^.,_\
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M'EBY2E)I.*;/ZCXK^C7X;\.\#9/GF$\0)9[G:AGSS^A@IQAA*=? QP<LKPN
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MGZK-?^%]7%QHLV;VQBB@ENA&EW;!_P#&GA_UL7./WB<^GS#GBOZK/^#LL?\
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MC5-UJ56>&]E*7^J\G_!V[_P1@08'Q6^-.  !GX!>/,X48'/D$G/7DY_E3_\
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MP7K^#VO[PO\ @^,_Y*9_P3H_[$7]I7_U(/@O7\'M !1110 4444 +^7Z=_\
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M3G!++]X&N:)S[#M_+^GYUV'B:6<W6Z?)#8>W:1/+9D(PK-N)RBKC: 0"I7
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MHRY9I*<>:,9<LHWC%W2****9(^/_ %D?^^O_ *$*_JN_X.S0?^&J/^"?&/\
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M$=E:1\O8?#B".\\17;W?EP2ZDNFV8C=9I&7XL'4?4=>GXU]'7WB?7V_9YM/
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M#MC'T/6OY[-,U5],$B[ XN-C;@6RI0DC:01SR0?0Y //'])_QT2SD_X-R/\
M@F&E[$CQM^U]^UFL?F(KA7-P0'!8-M 7.3E5(X;CI^ _B3P_H4\B65NEM:2B
M(-#>10&,EV)_=3HH"'YC@MMWA<,KC!6O[1\(/HT\?Y]X6TO'GP^X[X8P&;X#
M-,VR7"\,8VI+"YQ5QL<=6R2EA:&+KR>7P_MC#0Q=3"UL5&EAHS5##3Q>&Q.)
MHU(_/8_.,)2QW]EXO"UI4YPIU765G3Y;*;;BGS6IMQ3M=[OE:3,B#QU9)%9-
M=B>Z,4A,MM'@ !,;<,02&SW/ &[[W!'&>(/$\^M2X,,=M:I([I!'G>Y)X,[
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MD85K#7#:'KVJZU:SWE\EK?W"7J:KI\6J:5<7MG(;<7-]/>^<DUJA22.VCF6
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M'/.#UZ?-D=:A(P?7I^HS72RIIGG7BB9GM0%,7*QR)(Q(^52"T@Y(8YY4 G/
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M#6[F.4B"32/#<<US8Z9=)\RQ[[ZYFDMWS'--(TJ@M''7RO$GA7P3XN9GX?\
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M>AX( P,\<>I'8_A7TYK.IL-.AMIE@N[14EA(@@+@%5B^9UD&Z/:"$+<9"HP
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M YP.#R#17ZK&TDI)III-.ZLTU=-7WW/P)QE%N,HM2BW&2;46FM&FGV9^LO\
MP=Y?L'_MC_MF_$']A:__ &5OV<?BE\=['P#X.^/=EXRO/AUX=EUVW\-W?B'6
M_A5-HMMJLD4BBUFU*'1]3EM5< 2I97!4GRG"_P <?_#C/_@KW_TCS_::_P#"
M NO_ (_7^TK;?=;Z0_\ HB*K- C_ !8?^'&?_!7O_I'G^TU_X0%U_P#'Z/\
MAQG_ ,%>_P#I'G^TU_X0%U_\?K_:>HH _P 6'_AQG_P5[_Z1Y_M-?^$!=?\
MQ^C_ (<9_P#!7O\ Z1Y_M-?^$!=?_'Z_VGJ* /\ %A_X<9_\%>_^D>?[37_A
M 77_ ,?J6+_@AM_P5W1@7_X)X_M-L/F! \ 76<%2!C,^,@G(/8@&O]IFBAJZ
M:[Z#3<6I*UXM-75U==T]&NZ>C/\ %DD_X(:_\%>68E/^">?[3@0G@-X N20.
M>"1-SC-,_P"'&?\ P5[_ .D>?[37_A 77_Q^O]IZBA:*W_#@W=MZ:N^BLM>R
MZ>A_BQC_ ((:?\%>\$?\.]/VF^>G_% 76/?/[_\ #\^M)_PXS_X*]G_G'I^T
MSZ\^ +GG)ZX,_7_]?O7^T[10%]O+_.Y_BQ_\.-/^"O8 _P"->G[37!W?\B!<
MX_2;CWY[?D\_\$./^"OA7:?^">G[3>,<K_P@%UM)&0I/^D#HI8#N.V<\?[3-
M%*RWMJM@4FDTFTI;I-J_K9J_]:'^+'_PXS_X*]X)_P"'>G[37./^9 N>>>X\
M_(Z>GIT! +?^'&?_  5Z_P"D>G[37_AO[K_X_7^T]13$?XL/_#C3_@KW_P!(
M]/VFN?\ J0+KM_VV]_QY]*<?^"&O_!7LDX_X)Z?M-#)S_P D_NOI_P ]^./3
M^5?[3E%'2W_#_P##!_7W;'^+*O\ P0V_X*]#K_P3R_::([_\4!<YZ'&!YV.,
M DX/3!ZBE_X<;_\ !7K/_*//]II@0 =WP_N0<]2<B?()./F## R.17^TS11L
M^FGEZ;][65K[/6P?\#\+V_-^;TUT1_C?>&_^"3G_  6Q\,Z5)H5M^P1^TY<:
M295N(+*\^'<MP+:Z1-@D@G^TI-$"%&$WLN%78JX!-X_\$D_^"PEX&GU+_@G3
M^TZ=1)B07-KX$N#&\$:;?+E@GNB""V678ZI\Q4*HP*_V+Y?NC_>7^=./WE_X
M%_*O(JY!D]6I.O++\-&M6ES5*M*FJ-2<EJW*5-*,N=V=2]/]Y:/.Y637Z)@?
M%_Q*P6"PF4T^,<\Q&6Y71C0R_ 9CC*F98/!T'&:IT\-1QCJU*$:"G46'4,7R
MX95*D</"C3G.E+_&?O\ _@C3_P %@[C[0(/^">G[4$$=R6,L9\ S%&4D87:M
MUA %7K\Q!SG(88Y&;_@A_P#\%>Y RC_@GG^TX$_@4^ +HD$G/)^T>^"!T!YZ
M5_M(45W4<'AZ"4:5-02MMJ]$DFW:[:2WWU9\MF?$>=9Q4=3,<?5Q,OWME)M0
M@JU256K&G!2Y*<)U)N;A!*/,D[:)'^+*O_!#;_@KR)$<_P#!//\ :;VJZ9Q\
M/[K<<$$G'GC\\A1W(K^C_P#X.1/^"<O_  4(_:6_:._8E\2?LY?LF_&WXK>'
M_ O_  3F^"GPW\9:QX,\+/JUAX>\>Z5X]^*VH:]X-U66"YS:Z_I5EJ.AW=]:
M.NT0:C9M#+-NE$7^BW5>/_7R_P#7./\ ]'75;RC&<7&45*+5G%JZ:\T>%.$9
MQ<)Q4HR5G&23379IZ,_Q;YO^"'7_  5_GE>:3_@GO^TVTC\L[> ;D$DX!R3/
MC&>G?')Z<20?\$.O^"O,1^;_ ()Y?M-$<]/ %SE>I8C-QSV R>>>?7_:4HH<
M8M.%DHI)66FEM-MK=!.$7'DLE&R225DDE9)6M:W0_P 6NZ_X(=_\%>[AE(_X
M)Z?M.;50 !O -R<G)^;B<X)&T8R<8JJ?^"&G_!7L_P#.//\ ::[?\R!==AC_
M )[U_M/44XI12BM$NGW_ .;'&*BE&*LDK+^NK?5G^+#_ ,.,_P#@KW_TCS_:
M:_\ " NO_C]'_#C/_@KW_P!(\_VFO_" NO\ X_7^T]13*/\ %A_X<9_\%>_^
MD>?[37_A 77_ ,?H_P"'&?\ P5[_ .D>?[37_A 77_Q^O]IZB@#_ !8?^'&?
M_!7O_I'G^TU_X0%U_P#'Z/\ AQG_ ,%>_P#I'G^TU_X0%U_\?K_:>HH _P 6
M'_AQG_P5[_Z1Y_M-?^$!=?\ Q^M"W_X(>_\ !7E%V2_\$\_VG"JC"!/A_/\
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MA&$7*5E=J,8IMJ\FKR<I-R9Z1C'1*T(J,=$DM%I=I*[ZN[LKG^+#_P .,_\
M@KW_ -(]/VFO_" NO_C].'_!#7_@KTK _P##O/\ ::.#G/\ P@%V2??'VCKW
MQZ\5_M.45S)N+4D[.+33\TTU^*7]:H_(_P :/P]_P1C_ ."NFGV\EA??\$[?
MVFVM67,<D7P_F6028*GS2URI96Y. <@[3G:<UTC?\$:/^"KQ5&_X=Z?M2LKJ
ML<T,G@&0EH@!B,G^T/G3  52H4=,';7^QNW0_0_RI!]X_C_)*_H[A3Z5?BUP
MGDN$R'"XGA[-<#@,-2P&#>>\/X3,:]# X7$?6<-@I5%5PL<3@Z$Y5Z<*&,I8
MF-3#XFOA\5+%TYI+QJV0Y?7K2KN%6G4FVY.C5<$W;65N5N,G9>]&47IHUL?X
MO=U_P0]_X*V2WUY);?\ !.S]IU+25YA;0MX"GS"KL=F3]JVDIDX&<?@2:RG_
M ."&?_!7@.P3_@GI^TWL!.,^ +C.T="=MRRYQG.&(SP#7^TT.K?7^@I:_GO,
M,;5S+,,=F->&'I5L=B\5C*M'!8>G@\%2J8O$U\54IX3!4/W&$PU.>)G3P^'H
MI4J%"%&C32ITJ<8^M"*C%).3M%1O*3E)J/NIRD]92M'63U>MS_%B_P"'&G_!
M7KO_ ,$]/VF^O./ %T>#_P!M^O)Z^O;FE_X<:?\ !7K/_*//]IK''_,@7)[@
M]YR.G)Z?,2,8XK_:<HKE3:V;7]?-?@6?XL?_  XU_P""O6"/^'>7[30R<Y_X
M0"Z)P,X'^O'L/IG\7?\ #C;_ (*]!<?\.\OVFL9;KX N3[C_ );9 SCU[X.2
M:_VFJ*:G)7M975G[J>ET[>6JUMZ;"M^#O_7Z=NQ_C<_!_P#X)1?\%S?@'XXT
M7XD?"#]BC]K7P)XRT"^M]1TW5M%\#SIMN[99DB:[LKB2>PU"-(KFYB6.]M9X
MU2XEV!&<D_;6H? /_@X%\7/-:_$C_@GG\>/%FBZF477K+3_A=<^%;C4E-W!>
MW%R+C2;SR(K^6Y@%QYWV5HQ.=\<49 Q_JV45\AG_  +P7Q5C:>8\0\*9!FV:
M8>A3PU#-L9EF'J9M0H0G*O2I4,R@J.-IPHUI2K4HRKUU2K/VM%49N;J=4,9B
MJ=)X>&(JJ@Y.;H<S=%RDN63]G*\%SQ]V:BHQFM)PGHU_D/\ C_\ X)H?\%=?
M&[W*Q?\ !-;]JG3K9-6O]2TJ1O"#S:G:6]W+OAL[K4#.EQ?I!EFWMY;-*=^1
MDY^<]?\ ^",/_!8?7;A[JX_X)Z_M.-</+YHN6\ W F*['4K(5NB7)\QQEW9F
M!SGG _V;**]#*N',ER>G3AEV"6'A"*Y$ZE2HXJ23:YY^\^9Q3G=VG*\I1NVW
MVXG/,UQ</9U\7.4'*G-QCS17/2A"%.:;J3DI15.+5I)<R<E%.3/\^7_@U)_X
M)U?MU?LA?M]_&+X@_M/?LK?&/X(^"-<_9?\ $WA?2O%GC_PQ)HFB7OB.Z^(W
MPYU&UT."ZFG8RZG=66G:C=P011N?L]C<-(R9C\TK_04E^]'_ +R_^C(Z*]U*
5RLMD>3)RDW)R=VVV]&VWJV[]3__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tm229830d4_1012b-img14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm229830d4_1012b-img14.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $! 7P# 2(  A$! Q$!_\0
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MU7P^-1ET/4@FHZ;;WESH]S<V,%_%;7?V&2WEN+6VFD>%/Y+OC]X1^$?[8O\
MP5%^,$7COP9K7COX??&?_@W(M?'HT#XAO=:7X^U6W/BWPM\4_!:^+;CPG)HN
MIVGC#3_$FE^'M8UBVT26PB7Q!I\@AMQ; VQ_-[_@GCXI_96_X)9_ +_@EE_P
M5Y^%TFA:AX/\3?#_ .//[*?_  5%MOAEXQO/B1XDTSQSX[L?$GCSX"W/C/PE
M#XK\0/X"\87?B3X?^$[*71HM&\.P)HLUI?W>G(=3BO& /]',D $D@  DDG
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M6HIK'A76?&^N:EX2N=2\6:KX;U>"VU/0=0UZYOKW1K^&.^TRXM;N-)5^I**
M/,O#'P9^$O@KQE\0?B)X.^%GPW\)>/\ XMSZ3<_%;QSX9\#^%] \8_$VXT"U
MN-/T&;XA^)M)TJSUKQK+H>GW=W9:/)XDO=4?3;:YGM[1X8I75_);S]AW]B_4
M_AG??!/5/V0OV7-0^#&I^-)?B1J/PBO?V?OA-=_#&^^(EPLHN/'MYX"N/"4G
MA:Z\:3_:;A9O%-QI4NN2K--OOCYK@_4]% 'RC\(/V$?V(?V>?&"_$/\ 9_\
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M;::&5@#^QV(L=VY@V&."  .IX !. !C&>2,-_%4M-7H?]Y__ $-J=0 4444
M%%%% !1110 4444 %%%% #7^ZW./E/.<8X/.>,?7(Q7\]_\ P<&?L=?MF?M
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MMXPH -ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:7N_^!/U=K.3O9-I*+;:M;71<LM=KV=KZ*]G97N]W9?,_ET_X=X?\',&<?\
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MM.#7YUQ_CL;@8Y8\'C,5A75>+C4^KXBK14U"-*47)4Y1YFG)I-WT=K'[4?\
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M0]606&K6GGRV$=O<F>QFNK6X_D-K]NO^#<7_ )31_L5_]=OVC/\ UD;X^U^
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M77_7O-_Z+:O\.W3O^/.R_P"O>#_T6M?[Q_L//^1[](S_ +%'AA_ZM^+S\O\
M$GX,H_QXW_TW1+5%%%?]"</A7HORB?D[_P OR044450!1110 4444 %?MU_P
M;B_\IH_V*_\ KM^T9_ZR-\?:_$6OVZ_X-Q?^4T?[%?\ UV_:,_\ 61OC[7\U
M?3,_Y1(^DS_V8OQ-_P#66Q9[/#O_ "/\F_[&>"_]/Q/]4X?='^\_\Q4J=#]?
MZ"HA]T?[S_S%2IT/U_H*_P"):EU_P0_.1_1SW^;_ "D/HHHK884444 %%%%
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MC_,O_)O_ )6*Z_F7WO\ ^0-*BLW^TD_YY-_WT/\ "C^TD_YY-_WT/\*.:/\
M,O\ R;_Y6%U_,OO?_P @:5%9O]I)_P \F_[Z'^%']I)_SR;_ +Z'^%'-'^9?
M^3?_ "L+K^9?>_\ Y TJ*S?[23_GDW_?0_PH_M)/^>;#W+# ^O%/FC_,O_)O
M_E8[K^9?C_\ (&E16<=2AW;4'F,>FUE*GZ,N[.>V ?R.:LQW D*KL92W4'JH
MVELL, A<@J"0 3@=>*+IMQO[RW34DUUNU*,=/.^^F]D'5+JW)6:DG[JO*ZE"
M+25MWHWHFWH6****8!1110 4444 %%%% !1110 4444 %%%% !1110 R3[N
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MGX%_^92OFS:W_/0_]\K_ (4;6_YZ'_OE?\*_GG_B._C1_P!';\3/_$WXH_\
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MX%?#+Q;XMU1];\2:WX?2^U;5'MK.T>[NA+<0M)-!I]O:6<<NS;N$%O#$V<A
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M\07=E97D6G07EI:0PV47]C[@E>#CD>G?C!!X()(!!Z^QY'\5?[1'@ZP\/?\
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M ?U'7?\ QZ77?_1YO_1;5_AWV"D65FW!7[- =P.0/W:YR>V.A/0'@D' /^D
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M\'_J+Q#=_P"RT?+_ &NGMIY'Y>45^H?_  XL_P""V?\ TCK^(_\ X</X-?\
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M^3J8*NG7H-8G+,7!*J^9JFIV4:D&_N[<?[A_7_"C<?[A_7_"OA+;_P %XO\
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M&C%4X1:G.3C>\$VW=?UNT5_+3_P]+_X.&?\ I !;_P#B6?@7_P"*H_X>E_\
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MS<>.]!_8I^)?QM30O$%M+J/A_1_C/\,/AKKNJ>(O"WB?2-)U+3=0;2]+\?\
MAV]L=0TR#4=*U&72S$B7&GS7"21<]6M&EA\=B&W*E@%AY8A27-5C#$^WC3J4
MDVX5XNK2J49*/L_9XF,,-4<9U*<Y:4J52M7P.'2C[7,:SI4-E!3A.A&4*M>2
M<*,7'$4ZM-S:E*'UFI"%6-&LZ?Z[;P,%@0#CVX8@ ]./F90?3(H#H6QGMG&>
M>3@#IZ\'C\*_"G]@/_@J-\6OVDOV'_VB_%?QO\*>!/A[^V]^R]\*]2\;^/\
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M(14YJM6C5G5YE1I.E347%0Y98SZU3DI4X0O.%*I*G[+WO:R<:EW549/\V/\
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MUSP;^S]^S1H=]%XL:S>\,L^EV/Q)^/?B[Q[K.K:5#-]EGN_"FD7\D0N"6/\
M0!7SE^R?^S?X*_9!_9L^"O[,?PYN+V\\(?!/X=^'_ >DZGJD4$6K:[+I-JBZ
MCXBU?[*%MVU?Q!J<E]K>HE-Y:_U"=VEFD)E;Z-H **** "BBB@ HHHH *8>A
M^C_SHHI/9B>Z]?T8WLOT?^1IS=&^B_S-%%)[?]O+_P!*0E\7R?YCFZ'Z'^5(
M?O+_ ,"_E111U^?^8NB_P/\ )!W_ .!?^R4@Z/\ 5OY444EU]'_Z4BGT]?\
M,5>W^ZO]:/X_^ _UHHI]?E_[>)?U]R$/1/JO\J7^/_@/]:**%U^?_I3#_/\
M^1'4445104UN_P#NM_2BBD]F)[KU_1C1]Y/]T?R-(/N-]?\ "BBA_P"7YH.B
M_KN.[O\ 0?R-#]!]?Z&BBCHOE^@/=?/\@7HOU/\ )J3_ ..444Q/I_B_S''H
M_P"/_H(I&Z-]1_):**G[7R_R$MOG'\HCEZ#Z#^5+115%A1110 4444 %%%%
B!1110 4444 %%%% !3'ZCZ-_*BB@!QZ?BO\ ,4M%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>tm229830d4_1012b-img15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm229830d4_1012b-img15.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #C PP# 2(  A$! Q$!_\0
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MFMTTTU=)ZII-:23U2T:Z-7ZVBC_/Y45V""BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBDR,@=S_]?_"@!:*"<4=: \@HHHH **** "BBB@ HHHH
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MSC36ZL'2_3:_GN?LSYB9QG)R!P"<$] V!\I]FP1WIY.!GG\ 2?R&37SMX_\
MVDOA7\$_ACX(^*/Q_P!;7X):3XSN_!_A^'3/&44MYJ6D^.?&5JLVF^ [P>%X
MM;MI_$CWPFT9$T^2YLM0U6%(=-N)Y+NV6;R#P%_P4J_8?^)_BOP;X%\%_'S1
M-2\6>/?&6L_#;P]HM]X8\?\ ARXC^)6@RZQ'??#3Q)+XE\)Z/;>"/B/,F@:O
M>:1X!\:S^'_%_B#2[3^U] T;4M+GMKR9 ?<OF)@D-G )^4%L@<$#:#N.2!M7
M+9(&.1E0RDX!SQGC.,'ISTYZCU'(R.:_-O1O^"C_ ,/M9_;VG_89C^'OBR%I
MK?QIH>@?'0ZAH<_PY\2_%[X=>"/"WQ&\<?!FPL89'UL>+_#?@;Q0FOW\DZ+:
MXT;4[-2;FU=%YSX>_P#!3OX33?M._M'_ +./QIU+PW\*M2^%?Q^\$? OX7ZN
M4\7ZK8>/-1\=>!=%\5:./%_B*#PY+X-^'VM:QJVI2Z%X9T[Q'XATT>)+F!8-
M)>ZO95MB-I;Z ?J0S!1EC@9 R>@STR>P]SQ2*RMG:P..H!Y&"5((Z@AE8$'N
M".H-?//PQ_:K^ 7QJ\<^-_AO\+_'\'B_Q7\.]8\1^'_$\=GX=\6VOA^/7O!N
ML+X>\8:/H7C34M LO!GC#4O".O.NC>++/P;K^O7/AO47%GK$=C<$)7R9\*/^
M"F/P9A^$G@WQG^TE\0OA1X)\:?$+QA^T!H7@KPS\';GXI_%NQ\76'P!\;)X8
M\5Q^%8(/AMI_C#7O%/AS3+_0[_QGX>TSPM<2:7-)K,^ER:MHFA:GJ]N6=K]%
MK?R[CLWT/TZ+ <$\X+8]AU/^>O..AI-P]^3C[IQG..N,#GW_ $-?F-\<?^"E
M?PQ^&7C3]A+4/"M[X;\?_ /]LB3XL74?Q7T$^+/$FI6.C^ ?AROC;P[-X$\%
M^#_#VO>)/&FL^)M1<Z)+H%EI#:U9%+EFL?,L[V.WI_$G_@HMH%HWPW\7_ ;6
M_@=\6O@_\3OV3?VB?VD/!VN3>./%>E^-_&MW\&/#B:WIMAX.\-6G@VZTJ[\-
M3W"7&G>.+W7M=T#Q%X7OD%C%X?O;Z.ZM[<N%GV?W'ZBEE&<D#')^G'/TYY/0
M<Y/!HWKG&X9/0=2>0"0.I )Y(X'.2,''Y'^ _P#@JC\,_BI^R!KWQ?\  OB/
MX567[1'A3]E#PM^TMXD^$WQ U7XB^"_A_I6G^(='$EQJUMXZNO 5SJ7C/X8:
M-XAMM4\,ZKX_^&^B^-[&PU.P&G7(CU">&VE].^ /_!1GX:_&_P#:8\4?LG#P
MWXIL?B3X0^%/PA^(UQXJT;PM\0-6^&'B6\^(_@_5_%FK6.A>*[GP/866C:1X
M?L]+(T7Q-XROM LO&POM/@\*B_U&.^T^ "SU=G9;OMZGZ24SS$P#N !( SD<
ML 0.>Y# XZXSZ''SI!^UM^SQ<_&^\_9QL_B/9WOQ?TR:WL-3\.6&@>++S1]*
MUJZTA]?M/"NJ>.K709?A]I?C2ZT.*76+7P1?^*;;Q;<:7%+?PZ*]K%)*OR'\
M??\ @JE^SKX!^#/Q_P#&?P8\;^&OBO\ $GX.?#_XE>,?#WA*^L?''ACP7\2;
MOX4:Y'X=\;:;X$^)=]X7M_!WQ#A\*:R\FG^)9OAIKGBU]%EAG>\CBM[>>6,$
M?J/YB9(W $8R#D,,D@94@'YB#MX^;!VYP:4,I(&1D@D \%@N,E0>64;ERPR.
M1SR*_/;]FW]L[7_CG^T;^T?\$M;\#:1X;T7X$?!?]DCXK6/B'2=4U;6-4U^Z
M_:-\!^+O&.O:1<:3_9\?D0>%9?#4-EI$EBUW=ZQ'=N9K>&55A;B/@7_P5B_9
M;^+OPK^(_P 8/$E_XJ^#WAKX;?&G4O@C<P^.O!'Q#2]\6>)SXRN/ W@VS\!V
MUOX+CNO''BCQOJD6=-^'7@^T\0>/=)5S#K^@Z=-$RJ#L^S/U"H_S_GT_&O$O
MA7^T=\$/C3\.M6^+/PX^(NAZUX \.WGB;3O%FNZ@M_X4E\$:GX+EN8O%VD^/
MM$\7V>@^(/ >K>&OLD\VMZ7XPTK1-0TZT$=]=6\=G-#/)Y7X;_;U_9*\8?"O
MQE\:](^,6GV_PQ\ 1:%>>)/$_B/POX[\&JVF>*8_,\(:OX=TCQ?X7T/7O&FA
M>-I!)9>!M=\&:7K^C^-M5M;[1_"M]J^J6%[9VX(^P"R@@$@$@D#O@8R<?W1D
M9;H,C)&10&##(.1P<X.#GT/0^^.AX.#7Y>>(_P#@I7X$U?XY_L@?#'X(PZ5\
M1?#?[0GCC]I;P!\1-5\06GC;X?\ C;X3^(O@%\$+_P"+\&C:I\//&'AK0?%&
MF:SKDEO96TEEXLTG1)%T2^MM;TL7EO=6\DOT+^P7^TIK7[7_ .R;\(/VC?$7
MA72O!.L_$S2]<O[[PQHNI7FL:9I3Z/XLU_PW'':ZE?VME=W2SPZ/'=,TUM$8
MY)WC 94#L#L[7MIW/K^BBB@04444 -=MJEL9QT'J2< 9/ R2,D\ <D@ TWS.
MORL% !+$$8&.3@C/'<#G\.:>Q &3TROIW8 =>O/8?,>B@M@5_(7^PS\*?V@_
MBW\;+KXJ_![X??$?PM>?!W_@IO\ MJ:_\;OVO/$7Q;\%?\(1XK^!>@:[XATJ
M#]FO1_A_9?%?Q-\4_&>J7NJW&E26=AXK^$_@[X<>&K6U?4M/\8WMPJ:?="U5
M^GW?@]0/Z[_.7L"> 1C'\2Y //'4 YP.<YP#3A)DL,'Y1GCYL\D< 9SD@@>I
M! Z''\V?PR_;<_;/N?\ @EQ^S;^U7XM^.&E:Q\4OVPOC/\)/A=>>.Q\+OAEI
MWP\_9E\$^)OBCXA^&]]X\T/0(=(TN'7_ !-JFE:187^J77Q&U?Q!X.M?'.IJ
M-(\/Z-X8A70KGY/_ &V_B)\=?VEM$\._LE>/?C1X@\9Z+\/?^"U7P*_9=\$_
MM)>#Y;+X9>*/B3X>\?\ [.7Q&\:ZCH/BA?A/IW@_P9J/B/X6>)=>T_PUK5SX
M4T'1] U2:PLTO='37-*U&>4&E?1']?BR;B0 3@D$]@0<$'C (Y)Y[8ZD90R<
MC",<@X(!Q@#(YQW&,#KDXQD&OXL/%O[2/QG_ &OO&7[#_P 2?$FN^/O"-G^Q
M5^V1^P5^QK\2;9M8UWPG8^/_ -JWQ)\;EL?V@;V^M;>[L9_%FB6_A/P9X/@M
M)M0LY]'OI?%&J):)<">8CUKPSX*^,OQF^$?Q_P#$'@OXG_"CQTGP*_X*X?\
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M? ?]M#]JFV\=?#CPSK_Q^\.?M):5\=O^"7_Q)_;8\1ZO:>!/AIX;'[,WQ/\
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MU'Q,NFVFHH ?K#13-QR1@<9/WO3_ (#QG]*4,2<8';OGJ,^G\OK1_G;KVO\
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M%[PCXK\7MX9L9;:&]\1Q^'M"\77NKMHME-=VL-WJ*V;6UK-=6RSO&9 *I?\
M"TO^"9!T'QMXJ;XX_LN/X9^&AT9?B)XBB^._A"30_ ;>(M<F\,Z!'XPU1/&K
M6/AV;6O$<,F@:9#JEQ;2W^M*VG6R2W0\N@#\C-(TWX$>%?V"/V#?@)X?_:F^
M"US\>OV%OB+\+_BWH8O]%^,^F_!7XD>)O FKZ_+K'A_6=4TSX92^*="T[6]*
M\2ZA/I_BN/P3KVH:1KL45S-X<U**YN6KSF;X;_ OQIX_\)_&;XC_ +37[/T'
MC3QS_P %%[W]M#]H7P#X>T?XT:IX#TCX=6WP4N?@/X>^%'PV\177PA\.:IXZ
M\1)X5M-.UGQ)XQ\6>$?AY;Z[KVM:\1I-K'86=SJ?[PQZU_P3YD^&>B_&E/B+
M^SXWP>\2:K)H7ASXK+\8/#__  KG7M;A;45ET?2?&I\6CP[?:K&VD:JKZ=:Z
MC->!M.OE6)FM)PF'<?$'_@FI:_":V^/5Q\9/V98?@=>:[?>%[7XP2_'#PJGP
MSN/$NE7UWIFJ>'8?&Y\8_P#"-R:[INHV-[87VDKJ1O[2\M+JVN;>*6"10"C=
M*VU]'Z:?Y'\__P 'OV>?@=\,]'^']QKO[;OPT^('COP/_P %#/V<OCM8>)]?
MT3XP@:+^QE^RQIGC31/@]\!= B3X8F&+Q/X<L/&VN7)B-I9Z1J6HZO>W&K^*
MM0F@M[E^XA\-_!C2_P!DSXK?LS^*?$?[ '[4FC_%'X]_M0_&"'0?CK9?M)>%
MM/\ A[JOQBU_6-4^&WC[P9X[\-? OQIXITKQSX+M=8N+;5;?PMH7@GQ-:W)>
M\\&_&30YF62/]P?B-\2O^"9OP@TGP1KWQ7^-G[+GPTT+XEZ$/%'PZUKQ[\>?
M!_A+2?'?ALM8HOB#PAJ&N^-+&U\1Z(\FJ:;%'JVD27=C)+?VD:S^9<VZR]'K
M.M?\$^/#GCCX?_#+Q!\1OV?-#^(WQ8MM&O/A=X"U?XP:!IWC'XC6GB)'ET&Y
M\#^&KOQ7#K/BJ'6X8Y)='DT2SO5U)4=K0RHN^GKU?XW_ %95]+=.GEZ'Y)?$
MA?@!KO[$7[$7[*.E_MP^&/B%XL_95^*7[,GC#Q5\5?BIX7^*=G>>/M"^!NLV
MM_K*6MMIO@SQ3>VVI7=C NF^%['4[^[6WL[6P@UGQ%<SQ3W]QYWJNC?!UKKQ
M_J6D_M5_ Q[WQ#_P6'T[_@H]H-OJ&B_&N*T3X;Z7X!\.^&(/!.K/!\+KE[?Q
MY-JVBRW$HT^";01I\P,NMW4DMQ:O]L:=^VS^PK\3_@;^UO\ %/\ 9O\  GPW
M^*'C']DOQ5XQ\*:[\-_'W[1/PB^".G>+XO!VNZ5H4GQ!M/B?KWQ(\1>#/!OP
M?\1W&H7(\*?$7QV^@VFJW.EWEA+IME=&)7^P=2\7?\$_?"7BCP!\-?B5X\_9
MV^&_QB^(^@^$M=\,_"3Q-\<?"EIXVUN/QD9K70QX:T>?Q=;:CXIL=5U>SU/2
M-!U?1;&>P\17>FW0TEY]C*B%:UVWH?@,OP4\$:5\//A;\0-'_P""FEGJG[5'
MPZ_;'LOVUSX(\0>!?#UK^R_=?$_7_'UX_P 4;*S\<:%^QK:_M9C2_%?P:UK6
M/A^EOK?Q1US0;BZCTI[_ ,*_V18:?9:7W/Q:\/>!/B3\4?VC]-A_:N_9RT_X
M"_M4?MB_L_\ [2/CC6?[*_: MOC1X"\*? :T\%WB^&/!MA:?#%_"NN^*/&6M
M>#X+.'7;_P 1^&K3P1I<\NHVUMXGU&2&TLOW-\'>*O\ @G5\1?'\'PH^'OQ2
M_9R\=_%"ZT[6M7M?AUX/^,_AOQ+XXNM+\.7*6?B"_MO"VC>+[W6[BUT*ZEC@
MUF6"QD&FR.$N_*<JIO\ Q.U;_@GW\%/%7ACP+\8OB'\ /A5XU\;-:+X.\(_$
M;XNZ#X+\2^*3?ZI!HED= T3Q%XLT[4=66\UBZM=*M'LK>9+C4KB&QC8W,B1E
M-)Z/U_K[@/RF_92\9?!#]G_]K[XK_&6R_:2^%7PL^!/CY/BEK'B3X)_"+Q=^
MUEXN^'OQE^+?Q&^(5OXK3X]WWP/^*OABY^'G[,?CJ#1;1=.\4:+\&M>\7Z9X
MUUB_U'5;[5;"&063>+?L^^%?@K\)/'7[%_BK7_VLO@IJ5G^S7XR_X*2^)?%E
MOI&A?&1[K6[7]LV_CN?AY;>'#>_"RU$D_AB$,GC3^U+FPC20*VD-KAPT?Z1?
M$_X^_LO^#?V\?A#^P7X7^'/P4USX@^-_ U_\1?'NI>-OV@)_A]J7A#1UU#3+
M+P]X0\#^"['PUXZU3XC?%KQ797UQXGT7P/KU_P#"[2KGPE8RZS;>,;IW-E'E
M>#?VCOA+XR_:DUK]D6/_ ()I_M:Z#\4?"F@>$/'/C>]UWQ5^Q>WA'P9\,/'/
MB/6O#'AWXFZMJ6@?MU:[JVI^';B_\/ZI/<:%X2T+Q)\1K*RBAEN? T<UY:03
MM2NY1OV37X^7W]@/A;X!:;\"_A/9_P#!+>VUS]JOX,:D?V&-<_:5U/XD_P!E
MZ!\8G3Q5!\9_#.OZ)X:7P+]L^&5L99](N-6@FU?^W!H210Q2"Q>^8)&WB?PP
M^$?PG\#> ?@3X3O_ -KSX$7%]\+?V>/^"A/P@URYT_1?C<MKJ&O_ +77B;Q'
MKG@'4])+_"FVD72/#,.L6\7BPRP6%U#/',=$L]3B5!)^D_@O]N+]C'Q-JVAW
MOB;]D/\ :%^%'P5\4?'_ %W]E_P[^T[\0K?X/W7P0N_C9I/B^]\ Z7X5UJ+X
M;?M'_$3XQ^ M/\8>,++^P?#'B_XC_"'PAX.>^O-.CUO7M$^WVOF'@S]N7]BG
MQ7\4O^$"U+]DO]H3P)X'G_:I^(7[%NF?M!>++#X4W?P>U7]HCX=WEY97G@Q+
M#P/^T/XS^->CV'B)[)G\,>+?%/P<T#PG<K/;0ZMK.C7<IME5K<J[?Y/_ #'=
M]W][_P S\QK?X8>$/%?@BZ\+_$C]K?\ 9ETZ]^%W_!,?6O\ @GM\"KOP#H_[
M0C6/C35O%]_HMWXF^*WQ>L];^%L+^$=,M;3PCX9T_0O _AJ7XAS)J$VN>)+G
MQ.DSZ;H]K]R?L[_%/X,?L^_M:7_QBMOVB_@IXL^&GQ._98_9Q^"7Q/CN$^,N
MB^.O!?C/]G+PKXGT33M3\!Z*GP:U?0O'/A;QG=:S9_;CX@\5^ -4\/0B]O(+
M'79A!9/^F?[2_P#PRC^RE\%O&7QR^)OPZN;SPYX0M;;R?#GA/[3JOC?QCK^H
MW,=AHG@SP1HNH^)-&L];\6>(M2GM]-T+3)=5L8[V[F ENK:!7G'R5JW[5_[*
M5O\ L9^#OVXO#'[&'[27Q"^%'B3X:>*OC)XCT'PGI/PNM/&GPN^%_@BTN[KQ
M7XI\?3^-_P!H3P=\.)[O2A:B.V\#_#_XB^//B5XC\V:Z\*>#-=T_2/$-[H["
M[LUW_P"!_D>*_ ?XV?"WX#?';]IE-'_::^!?B#]G?]IGXQ^)/CMK7BS5="^,
M]I\??"6M^*_!MGX:U7X?Z+X<T[X9P^#M0T^UO].L+_P]\2-3\?M=Z)I,,VAO
M\--2EN4UBU_*_0?V4?@#H_[.>K_LW:G\:_A#XRU7P3\-?C%\//@3^T5XH_;&
M_P""F6KV&D2^.9-5T[2?%5Q^P[XH\#^+OV;OA;K7B/PQ?16/Q M_AOXDOM%L
M]7DU+4O#.EO:7B:7!_3Y.W[$.F?!/PQ^T7XLN_A]\//@MXM\*>$?&>E_$#XF
M>)KCX>:!!HGCJQL-0\,/J]]XMUG2;?1KO4H=3LHH[#4I;>[%W-]D\DSJR#*U
MWQ-_P3O\+_"3PW\??$OQ._9T\/\ P+\9"R/A#XR:S\9_#6G?"[Q2-1>X2R/A
MWQ[=^+H?"NLB\-K<?9?[.U6X,Q@N 50V\NT$? 7[*WQ7_9L^!'[47[2GQR\3
M_M-?#35_#7QH^"G[&OPT\.Z3H7A_XK/KNEZS^SCX"\7>%/%U]K2:A\/[&P73
M-;OO$-K<>&VL;V[NGM8+@ZG;:?,(XG^+8=$\ ^&]'TFQ\,_M,_L[ZU>? 3_@
MHAJG[>'[/=QXCU+]H/2K/XE6OC?5?%"^-_A9\:-/TWX%:M'\-[W3=!\67Y\'
M_$#P>_Q8']LVEO)J7@Z&UNK_ ,[]E-<^//\ P2A\,>%_!'C?Q)^TC^Q_H'@S
MXEV6JZE\.O%FL_M&^ M-\-^/-.T/6(- UF_\':U>>.X=.\26>E:W=6VD:C=:
M1<7<%GJES;V$TBW,R(?1_!VK?\$_/B'XPOOAYX!^(?[/WC;Q]IFEZAK>I>"O
M"7Q?T#Q'XKT[1M*73WU/5;_0-(\67FJ66GZ>FJZ:][>7-M%!:I?V;3.@N(\@
M:]_Q/RS^'-_^RQ>_LV_MW?#GXP?M8>!/#/Q0_P""@OC?XO\ CKXAWOPD\,?%
M'6/!7PFE^(WA>R\#Z#H'@R]\2>"/"6K^.%T'0M)L+_Q#XDU70/!-_P"+]9O]
M7+:7HT0MIZ\S^+'C?P=^T=^PQX<_9H^+/[4G[,?@;QQ\'=3_ &=[WX7R_"'4
M?VH-*\,>/KC]G>YL;IKCX@_$#P_X%^%_Q#^&&G?$62QMK&TT3X4:1>:Y\'KJ
MQD\0:-\0?'EQJ=KHWA[]?O!7C?\ X)N_$OPSX]\8?#[XN_LT>.O"/PNL&U#X
MG^)_"'QO\*^)/#GP_P!,,5R[7WC36M)\97-CX8T]HK2Z=;[6I;*W=+>=HW81
M.5ZFS_X*0?\ !/6YT67Q#9_MU?LA7>@6VO6OA*?6H?VDOA'/I=OXHO+.2_L_
M#MU?CQC)!;:]<V-M<WD6E3.+YK6&2<Q;59B"?9GX-?#CP_\ LS:!^T3^SG^T
M(WQ9^#?PQUKX:_$OX^>,_C)]N_:Q_;V_;7\7_%:'XD?LN'X > =5M_B1^U)\
M*[+Q7IFJ^&;EK6QO_#@N(]"@\*:9:75A?WFJ.VFP_M+_ ,$H/"&B_#?]A+X+
M?"_1OB+X/^*A^'">+O#&K>,_ </B6#PM?ZO)XRUWQ!/;Z:OB[0O#>NL+.UUV
MS@N'NM(MT-RLHA:6,+(W9^+_ /@HC^RSX'_:W\&_L8^*OB)HN@_%3QY\)F^+
M7A[6]4\5_#[3? T]M/XATK1-#\"R7]]XTMO$S_$;Q9:ZHGBCPKX>M?"ES9ZW
MX2L]1U>VU@&%+>7TGPO^VC^R!XR\&>/?B-X1_:I_9V\5?#[X6I;2_$SQQH'Q
MI^'.K^$?AY%>.L=K)XU\1V'B*?2O#$5U(R16LFN7=DMS*RI&26&0J[M;H?3E
M%<=\/_B'X"^*_@_0OB'\,/&GA7XB> O%%J]]X:\:>"=?TOQ1X6U^RCN)K.6Z
MTC7M%N;S2]0@BO+>YM)9+2ZF2*YMYH)"LT4D:=C0(0G )] 3W[?3)_($UQGB
MOXB^!/ ;>'$\<^-?"'@J3QEXGT[P5X/C\6^)M$\.-XK\8ZPEP^D^$O#:ZQ?6
M3:[XGU1+2Y;3]!TL76J7HM[C[-:RBWF*=I7\>WQG_:,^)OQ[^-_[/NJ_%[X_
MW,WC3X=_\%TH?A1HW[%K>%_A/IEE\)OA=\-4US1OAIXPCN--\#Z9\:VU7QGI
ML^EZ[=>,/'WCCQ#X'\5M\0+;3_"6@Z5]ET>2,] /[ )'8I(IW)E64NAPZ9 4
M.APV6&6*;5<EE V@G;7Y_>'OV [#P?8WNG>%/VK?VO?#%EJ>JZEKVKVWAOQE
M\(- M]7\1:S.+G6_$.M6NB_!"RMM1U[7;PFZUS6;R">_U.XD>YOKB=B7'Y)_
MLN?MX_MV?%KXMZ+XQU?XC^&([1/B-^U?HWQH_9L\>^,_V4-'TKP!\/OASX=^
M)\_P^7X6_!WPEX>M/VWV^)'A;Q%X.\$W?BJW\>^*O%NB^*O!NJ^,M:L=)L8)
M_"^H:/\ +^B_\% ?V]=;_8[^.'[6?A#]LOQ_(WAS]G+]F#6['PW\0OA[^Q ^
MB>#_ -HSXO\ QF\-:9\0D\+^"/ GPL/Q&N_@OHWA75H/#?@]/B-XJCUT0WMQ
M%?ZYJOBJ(ZKI K]=']X=+_/^O,_?@_\ !.3P:/ \_P +S^T;^TZ/AA/87&D3
M_#%M9^!Y^',FE7=PUW<Z7)X$/P*;PJ^FW%U/)=7%E+I)M)[B5[FXC>>5G;E;
M[_@GG\%?A?\ #_2TU']I?XW?#KX5?!Z^G^(>AVUWK_[.G@WX<_";4]%_M+4;
MOQ_H=O)\"],\+^ -3TD:KK-W/XNTM-(O;%M3U2XEU&$W]]-)\0_\%2/VO?C/
M^Q5\._#OPO\ !?[5OQMNOCKX:_9W^*OQ[3Q]J7A_]B?PG;_$>?POXHTJPLK+
MQK=?$[X7V/AGQGIVFW?B"/1=+^#O[/'PW\/_ !9NO#MM;:[K?C2:XBGU+5/!
MO^"C/[6?Q@^(&C_&[X0>-/VA7_9W^&>I?\$>;?\ :"\'>$-*\+_"F\L?VM/C
M+\2SKNC>._!DFH?$'P9XD\8ZIHG@S2[31=&M_!/P5\2>"/%]O-X^&OZSK<]B
MNBPP@/2U^NQ^MNB_L ?#7Q1H6EZ]X>_:C_:'\1^&?$'B72?B]HVLZ+XJ^ >L
M:'KOC$M;ZOH?Q8TK4+'X'W&GZIXND9+/5=,^(%M/+KVZ.WO;+6<QQ2CA?BS_
M ,$Y/V9M)^'OB+5?CQ^T1\1M/^$^F>(-1^)'B^]^,&H_LNP?#6P\6ZY=+!K/
MC_Q--XW^ B^%K?Q/K-U=QP:GXQU8IK>JSSQ)=:G-)*I;\D;K_@HM\3_A,O[
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MNJZ6^_\ X /RV/T_\0_\$Q?AAXLU_4/%/B[XX?M ^*_%.J:/9Z!J_BKQ1)\
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MO%GA?QYXU^//[1GC3QUX'GL[KP3XX\87/P'\4>,_!=S87_\ :EE<>$/%>O\
MP"O_ !#X9GL]3"ZE:2Z%J-A-:WZK?6S17:K,?SW^/_['7['.N_\ !<C]DC1]
M?_92_9@U>T^)_P"R7^UQ\6OB'INL_ CX3:E%\0?BCH/Q%^#3:/\ $WQ?;7_A
M2<^*?B!H9U#43I7C764O?$FE1ZIJ\=IJELFJ:A'>?GE^T5X=_9<M=+_X+2>.
M[6R^%VC_ /!0SP?^UXT7[$WC;P+!X5T[]LW2/BV? GPVB^&>A?!K7/#@@^,A
MT/4_$N[3M>\-:)<2^$M4\,3^*K7Q%H]WHDNNV\K7O*ZTVWTW _H.UC_@F/\
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MIX7\;^*/ E@T=_I.C>/=&NX;#XIZ#!>Z-J>C^+M"TG7M.^S?V6?VCHOV??\
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MY-\9OA#\-?CY\,O'?P:^,?@O1/B'\+OB/X>O?"_C7P7XAM#=Z1KVB:@J;XW
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M+EU\7OVD=6_:!\,?M'?M ?$K6?"GA?XJ^*/"WPWU?X)Z=\*_#O@"QU"?X;_
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M=^'FK7B>.=0?Q9J">(/%_BO3='T^QT>PT[3+G4;OV3]I[Q;\)?!?P:\1:_\
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M_P 0OV9/B=\3?VZY/A5^WE_P2Z\<>"O^"@7[/GPU^!.L^+OB9^W3\#]!UO\
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M;6-!\2W'PK\77MG\3="^%.L:OJ]Q9P23V7P_EFN?"4VJZ';7&DQWL^_\IO\
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MO@KID&L?\%D?@AJ>AWGAWX4^,]*\7Z5IGPWU?P=\./AW=_"/4_!OB'3QXD\
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M[.5O;+VW+SWDQZMOO-MKR49)-:)*3E+WFE?V<8T4_9VC%U%%%6,*8R*QRW8
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MUHIIJ3Y6T_M0C+F4N:*M>=.2Y7+EO)\R3NKR5[M<MGZJ_P"&S_#0_GV\'?\
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M1CTP2 /P'%25_9:U2?=)_@N]G]^O?6YX84444P"BBB@ HHHH **** "BBB@
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MX"_]2K2:_P!ZK R3Z]?PH \$_P"%/_$/_HZKX\_^$Y^S!_\ 0XT?\*?^(?\
MT=5\>?\ PG/V8/\ Z'&O>Z* /!/^%/\ Q#_Z.J^//_A.?LP?_0XT?\*?^(?_
M $=5\>?_  G/V8/_ *'&O>Z* /!/^%/_ !#_ .CJOCS_ .$Y^S!_]#C1_P *
M?^(?_1U7QY_\)S]F#_Z'&O>Z* /!/^%/_$/_ *.J^//_ (3G[,'_ -#C1_PI
M_P"(?_1U7QY_\)S]F#_Z'&O>Z* /!/\ A3_Q#_Z.J^//_A.?LP?_ $.-'_"G
M_B'_ -'5?'G_ ,)S]F#_ .AQKWNB@#P3_A3_ ,0_^CJOCS_X3G[,'_T.-'_"
MG_B'_P!'5?'G_P )S]F#_P"AQKWNB@#P3_A3_P 0_P#HZKX\_P#A.?LP?_0X
MT?\ "G_B'_T=5\>?_"<_9@_^AQKWNB@#P3_A3_Q#_P"CJOCS_P"$Y^S!_P#0
MXT?\*?\ B'_T=5\>?_"<_9@_^AQKWNB@#P3_ (4_\0_^CJOCS_X3G[,'_P!#
MC1_PI_XA_P#1U7QY_P#"<_9@_P#H<:][HH \ E^$'Q&"-L_:K^/*L05##PW^
MR\2I8$!@'_9R52RL05#94M@,"I./=[<N%5'E:9DCC5I'$8=V"J/-<1QPH'E;
M>7$<21!E(1(MI2IR 1@\C_)I BKDJ ,\G' YZ\=!G&3@<G)ZDT .HHHH ***
M* $/0_0U^8W_  4)^'W[8WCWQ-^S7'^R/\1/$OPPDTF__:*F^)GB?3]'OO%O
MAD:5J/[//CC2_ ^E>)?!-M\4/A=%K5_J7Q"FT2'P/JUWJFI?\(AXP_LW7X+2
M'[.9H_TZHP/04 ?BA^Q;>?\ !0C1?C=\.8_CM\'_ (Q+\(=3^ /A[X+>(/&G
MC+XS^&?$*:1\0/AW\.?#'B:P^(VL_#$ZUJWB&#5O&GCN'XP^'?$OQ(DUC5M7
M\03^(/A;I-^CZ3HMO>6/*Z'X#_X*5&3]F;3K;XC?M!^$O#FD?#_P=X<^+>AI
M<?![Q,=8UOQMXM^+^G^/_$GB[QE\0_#GCGX@MXF\!^&C\/=7\,7NB>*X-,TZ
MX-B]YIGB*V-WIT7[L8'H/R_SZ"C ]!Z=.WI0!_*%_P $V/!O_!;KPM^S+\2_
M@Y\;]1^.O@B#P=X.^$/PT^$.O^,+/X!:K\7_  E<Z/\ %G1?"^LW_P /;U?
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M0W6I:QK.KZE<V>CZ#H&CV=_KGB'7+_3M#T/3M0U?4;&RN #LZ_F\_P""H_\
MP7&\&?L#_MY?LA?LY:SKGB_PGX7O?$GC;7_VE_#J_!#Q+XYUWXG_  QUSX/W
M^H_ YO@3JVE:/J*:[J_B/XV6@^%]U::1=6=_IWBR*>U\3-HOA<#Q,/T[_P"'
MH'[*'>R_:V4]U;_@G5_P4-1@<9PRM^RV&5AT96 93E6 (('AOQ+_ &K/^";7
MQB^(GP7^+'Q0^#O[0'CKXC_LZ^)M:\8?!'QAXC_X)J_\%![_ %GX;^(_$&B2
MZ!J^J^'9W_9;\M+BZLI(;A(KR*\MK36=-T/Q)900>(?#^AZIIX![/<_&S]I_
MQ7\2OCUX!\/CP#\"&T#P9X0\7?!:[_:!^ GBKQ'HVH>%O*M9_B!\4]2\6_#7
M]J.UTWQ[HUA>RW?A ?"76M*_9R^*'@_5K!_%.L-XC\&ZAH=]J_,?&+]JO]H_
MX4_L[_L\ZW9_#"T^(OQS^)GAO0/$_P 5M6\ ^!=,?P5\*/!&F:3I6N_$[XIR
M_!?XC_M)_"WQGXAT?0['4K:U_P"%8^$?C/XP^(VBW.HR7-A#\0(- N8=6\WT
M/]JK_@G?X?UCXLZ_:>#OVR=2UGXW)>VWQ'OO%7[%/_!5#QL^I:5J4$MO?>&]
M 3QE\!=>B\!^#[I+B>6;P;X 3PQX5:[FEO/['%W))<,OQ(_:J_X)V_%N[T^]
M^(/@O]L+7[C2O%NC>-=,D3]B#_@J3HWV'6]#TJ'1+6VMHO#_ , M*AB\,:AI
M<$=GXF\%+&/!GC&,,_B[P_KD\DLT@!UGPU_;9^+/AC7;GPO^V1I_P+_9MO->
M_:!;PW\._%'C7QSX'\'>%?$OP0\16%M#\)[G2I3\=/B -9^*7QV\;Z?XN\*_
M!;P[K^J?#CX@>.-$\"?$/QMK7P&\"3>!G\'>)_U4!!. 03SP",\'!_(\'WXK
M\;/B+^TE_P $U_BQ;_9?'_PU_:PU^)OB5I/Q<E<?L)_\%0=(N;CQSH?A9_!&
MG75W=Z'^S[IUY>^'3X,EN?"NH> [JXD\!ZMX=N[[1-6\-7UAJ-Y!+]#+_P %
M/?V4E8$VO[6IZYS_ ,$Z_P#@H8"0<XS_ ,8M^N, 8QR/FXH _0ZBO)O@Q\;/
M OQ]\'-X\^'</Q @\/+J]_H>/B3\'OB]\$?$#WVFQVTEU)#X.^-?@;X?>,)]
M+(NXDM=<AT*31+^9+J"PU"YGLKR.W]9H **** "BBB@ HHHH *0]#C@X.">@
M^M+4-P)#!,(51Y3%)Y22,R1O)L.Q'=<LJ,V%=E&X*21R*-]'LP,G5=,TG6-/
MU+2=5M+'5-*U.SN+74M+U.VMM2TR]L[A&AN+:]T^Z$EK>6TT999K:XBDBEC)
M1D.2I_F8_:C^#GQ3_8B_X*$_L^^$?^"6GB[1?A$OQX^&7[1WQO\ C%^QIKD]
MY<?LK_$K6OACK'@[5(=5G\+L+NU_9_OOBAJWC'4_!DWQ)^'UOH]I9^*;WP_K
M-]H.JV6F:OI]W]Z7W[,W_!6_XU7NLZA\3/\ @H5\-?V5M"O-3GN?#WP^_9)_
M9T\/>,M;T+1MTD%MINL_%CX\W_B Z]J@MO)N9M1LO NEVJ7;S0Q6;P(KR>._
M#_\ X(^?'CX">(/B5\2?@S_P41^)OBOXQ?%6[&J>/OB#^U%\'? /QTUSQQ=0
M//<Z;X>U7Q5%J7ACQ3X8^'^D7EW=S:'X#\"7>@^#?#9NG?1_#L4T<3+^>^)U
M7Q!7 O$?_$*:?#N)X^E@94.&/]9L?+ </8;,Y5J+AB<XQ-/!YE.IA*%&G5]I
MA:6$=2L\2H^VIJFYPZ<)]6^L4OKDYTZ"FG5<(J4O9]6D_)IWUMO9Z)_IK^R+
M^U[\*/VPOAK/X_\ AM/JVD:UX9UJ^\#_ !A^$/C*QET#XJ_ GXKZ,8T\2_##
MXI^$+PIJ?A[Q)ID[B6PN'@DT3Q3H;Z=XM\*ZEJOAO6]+U._^M8F0DG<N2JX
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MAJ[L_P!B:?3OV^?C#J=P-!\(^&_V>=:MO&?P=TW7)HIMVK?%[]HK0EU+X/\
MP\\'>'&DANO$<=QXKO/&D\;QV.@^%M4NYBMO^JY]GN4<.Y1C,ZXBS'+\BR3
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M&59XNA0:KPE4AR585I2]V,Z;YKTXV?-HKZ.^G]D7_$3]_P $AO\ HL?Q+_\
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MZ<TOFIUYQSSC/0D$^N 01D=Z_%W1?AK^V#\(+.U7X)_MS?$[Q18::I$'@O\
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M@X.3G&<]LT\,&&0<C_)_D:_-0_M2_ME>.=,CO?AU^QQ\/_A0;P1);Z?^U_\
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M=:CKNDM\-_BI\2=#U6R\.:I\._B+''JDO@_P?J$+7T]SH/C:'S6TK5KFQO\
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M,N5CWMLR06<_-0!-1110 4444 (>AQUP??\ 3(S^8^M?GA\>?V]HO@=^UO\
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MI'10P[Q$FO;8>A!7YJE>3C&-DVKN,*DM6DKJF[7Z:V_HR627^ZQZ$M@L.Y(
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M2@TG6G\-SZ'XA\1Q"^U+^S+%[2[NM2NK$V=U<?Z.7&U26R%P3C'R_*.1VX)
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M#>C7K7$-O%XY^/7B+X4_#BRE8SZOXTTS3[>ZNX/[MQV;9=E>!Q69YAC\)E^
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M==\*:U=F.-?M<6F>"O!>G^>K26EC:V[BS3] ?V3OA1XI^"7[-7P+^$GCJ_\
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MGA;5'^,T5EXJ2XN/%5]XF\6VFM:+X/T7PXG@2[U _P!K1?#W_!/W_@@KX_\
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MU/P:_P"S>OVG/_5C?LE5]"U\]>)_^3J?@U_V;U^TY_ZL;]DJ@#_(;_X."_\
ME,S_ ,% /^RTP_\ J#^$:_'"OV/_ .#@O_E,S_P4 _[+3#_Z@_A&OQPH ].^
M"?\ R6;X1_\ 93O 7_J5:37^]+/_ *F7_<;^5?X+7P3_ .2S?"/_ +*=X"_]
M2K2:_P!Z6?\ U,O^XW\J /\ &A_X.#O^4R/[='_91?"'_JI/AY7XU5^RO_!P
M=_RF1_;H_P"RB^$/_52?#ROQJH _>K_@V+_Y3C?L/_\ 73]H_P#]9'^/=?[
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MNA/;YQ_]*B0G[I_WD_F:_P M;_@Y8_Y3(?M0?]B]^S[_ .L\_#"O]2D_=/\
MO+_,U_EK?\'+'_*9#]J#_L7OV??_ %GGX85_JO\ L9?^4O<S_P"S'\=_^KG@
M,^&\0O\ DGX_]C+"?^F\4?A!1117_5 ?B(4C=#]#_*EI&Z'Z&N3'?P)>D_\
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M#/J?]A[G]KCX.*22#'\2L@G/7X6^,%."<D9!(.",@\]L?TC11H2HQP 2 ,@
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MMZA\6OVK[WQ'K.E_M6?\%,?BEK6OF_\ C!XW\,?$BP.D:MH'PV^+.OQ7UO\
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M8VFFZ;IUI;6&G:?801V]C96%G;1V=G9VD$4<4<5M:6L,5O;1I'&D<$:1HB(
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MXLV^GWFJ22W7AOX3>&=-GMO#]C]!?"__ (*O?L7_ !#\3VG@#Q#\0/$W[/\
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M^]^8KE;='^RMBYSM&<YSCOQS_P".C\@*^>_$X'_#4_P;7''_  SU^TV,=O\
MDHW[)5 '^0-_P7L.NM_P5_\ V\6\3KHR>(#\9(/[37P])?R:*)SX)\*8_L]]
M5CAU%X?+"9:YB5O,WX^0H3^0U?L?_P '!?\ RF9_X* ?]EIA_P#4'\(U^.%
M'I?P8\W_ (7!\*?L_E?:?^%E>!/L_GEQ;^?_ ,)3I?E_:#$&F$.['F&)6D"Y
MV@L0*_W+9Y_VG,2 6GP$* $?/J7Q%Z$\[C'I)W84-G;]PXR<9K_#5^"?_)9O
MA'_V4[P%_P"I5I-?[TEPH,,N0#^[<<C/##!&#V(X/J..E '^,;_P7S_M\_\
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M-\+9;G;:F9E_UBM<D_::_LV99;3X!A&DL]P.I?$4@DW4"H<)I8=AO"Y5/F9
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M_9W430E#,;@76V7.SR5.&Q_?? TC "7;O$:%]F[87(P_EE@"T>1N0GY@K@.
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MS!+"5JM6C!8BEB)5*2BY1="C4A;W_=2Y9-R=[J,7+X5*2_Q2LO\ \^M[_P"
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MV9U:\30-*\":'XI\-IX]_:/\(#0I-*>Q_:2T7QO\1O GCVYNWU3PKJFA(/\
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M(>0>_!]L_CVH 7(]:^>O$Y_XRH^#1Z_\8]?M.=.?^:C?LE5H_$/X@^-?"OQ
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M%;:QO9FFTR6=9;6!8Q#-$K'>&KXF_P"(*G]OG_HY3]F3IG[WC_IZ_P#(N=*
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M)O\ _@C-_P")E?#3_P":.@_\$"_A6.?^'WW_  1G..R_ME?#/<?9=WB55)]
MS*"<991R #^A+_@Q]_Y))_P4!_[*;\!O_43^)U?W;Y'K_G_)%?RE?\&Y_P#P
M3>^-G_!-GX)_&[Q%X5^(_P"S-^V7\/\ ]I[Q/X%\5^!OBA\!/C5'=^ /[/\
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M_B5^TY^SUXV\??$&+X<>!M5TOP'!\5M<TKP_\2_B'%I=WXN^*EYXQ\?:S?\
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MTUR4TU[-*-DB%Z<'2C*<^6CA\/&524JC='#)<B]I-N<V^9OFFW.3UFW+G;_
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MHH **** /#?VC?@GI?[1GP8^(WP0USQM\3/AYHGQ,\/-X7UGQ=\'?&,WP_\
MB1I6DW5W;3ZG%X9\8PV6J2:)+K-C;S:%J-Q!I[W)T34M7M[6:WGN_.3\]OA_
M^S+_ ,$EO^"-O@K2=9^'7PC^"7[-MUKUW>Z%X;\2-I&H^/OVAOB/JMU:K+=>
M&/#7BSQ _C7XZ^/Y&M8Y[D>'=(UF[T?1+>2\N6L]+LI+JZB_3/XK^(O%GA#X
M>^-_%/@3X=ZK\7/&GAWPOK.M^$OA9H?B#PKX2U;XB^)=-T^:XT7P=8^*?'.L
MZ!X/\//K>HI:V4NN>)-6M-)TV*8W%PSK$\4G\_7P4_X(\?M!?M4?&CQ%^UO_
M ,%D_BKX<^)GC?6V%IX _9'^ .O:UI_P'^%?PTEGAU+3/A?XT\;SZ1X;\:^.
M]-T^X<1>*?!?AJ\TKX>>+M=M-0UGQK>?%);^PEL9E>VEGJD[W>CE%2M%6YFH
MN3BFU'F4')V0='Y+;OY+S/&? WQF_:2_;D^-W[4/C;]CGP5KOPZ\7_M%>._
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MX\J"2>*&R\-:#%/_ &MXM\1>'?#]M?:O:?D%^T-=_$/XV"\_:E_X*0ZQX9^
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M36K8BL^:K6J3J3DW>\I2?Y)126R222LD,"E1VP,]0.-W!P1V'I]!C@5^8O\
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MY:Z9IMS:^&++48Y;B3[O )VEA\P)Z8XZC)Y[C'3N>@&<?V&>&.HHHH ****
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MC./V O\ Q9;^T5_]*=H_X6)_P5-_Z,X_8"_\66_M%?\ TIV@L_0&@Y[=??\
MS^G?U%?G]_PL3_@J;_T9Q^P%_P"++?VBO_I3M'_"Q/\ @J;W_8X_8"."#_RD
MM_:*Z@Y'_.)WU% $/_!,OG]FKQ:1@#_AN#_@J+E02<?\;-/VN<CY\MA3@8 4
M*1@?* H_0>OD#]AKX-?$[X%?L_Q>"_C%;^!+#XBZ[\;?VLOC-XCTCX9^+=?\
M?>"?#S?M'?M7_&O]H72/"VB>-_%/@'X5Z]XJ7PKH/Q1TSP[J.O7WPW\''5=6
MTR^N[?1K2T>W5_K^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (I$+]/\ 9(ST
MWK(CJV.N4* @9PW0BG"-%& H QC';@D_S.:?10 5\K?MC?M.>"OV//V;_BQ^
MT;XZC>_T7X9>&WO[/P_;7=I9W_C'Q=JU[:Z!X$\#:9>7TUM9VNK>,O&.J:+X
M;L)KR:*WM'U(SW$D=O%)-']4U\S?M/\ [(7[/W[9WP]T_P"$W[37PYTWXL?#
M33O'/A+XBKX*UK5?$%AH&I>)_!-T]YX>?Q%8:%J>EQ>)M%@GED-]X9U[^T?#
MNL(5BU33+F(*BQ-2?+:4H6DFY0BI235TK1YHWUE=W?+RQ<6FIN4"_P#7^9_/
M!^R!^SY^TI^W)XX^('[3A\0ZK\(9?BDT^E^/OV\+V#2?%7QC\86'F-;:E\ _
M^"<VB^(+/4_"7P5_9'^'D[R>#]/_ &@;S3=4UWXZZM9ZUX_\(:;JMG?:7XO'
M+^'/$GC?XJ?M(?LC_L+_ !_\1GQR?V?/^"H/Q=\%>/=8UI$GU?XN>#_V=O@M
M<_M%_LDZSX_3[/:V>K:YJ6@>,?!-_P")+V"V-GK?C'X<7>N310SW;AOZO=)\
M,Z3X?TC2M"T+2]*T;1= TNRT;0]$T;3K32M(TC2-+LTL-,TG1]-LHHK+2=-L
M+"*&PLK&PA@M;6SB6WAC2,)L_G?_ &O/V1_C%X/_ ."R'[#'[1OPJ\":WXK^
M"?QI^->C^)/CGJ^@6%Y=1_"/XJ_"[X&?%#P##XU\2FU@DCLO#'Q,^&OB'1_"
MEQ=W\T-E;^(/#.GQ%C=WEI'/^!9Y]'_@3,.(N#>,)\/X/..,>%/$?+./EQ=G
MU:6-XGQN(H9;Q)D^)I5\VJTIU8Y?1PF=8*IEV082. X>RN>2Y8LLR:AB<''.
M,;Z=+-<72H8C#J:5*KAIT.2*Y5*,YTINZ22Y[PMSM-N*:<K<L5_1=!$7YP@W
MF1V* C+,3YA&2<,\BEB3PJ;(QDC?5K[/R6Y#$8)5R."<E?=<*@ )(&Y@NT40
M* 0!C"E@,YSRTI! P/O* WN"#VQ5NOWC#Q4:=-."4U%*3C9KFLKZVB[M\TGS
M*Z<Y7;;9YTFG*5MN:5M$KIN]]/7\.A4%NVW:" N2!CJ!MP#D=3NPQ&1EAZ9!
MDCA5&W 8))SU.>6P23DDX(R22> ,X%3T5T$B#/.?7CZ8']<TM%% #,<M^GN2
M!G^0].IY]/YI/^"Z\<-Q^T!^POX8OX+IHOC%9?$+X'>'IX4**_B7Q?\ '/\
M93\07FG"0X'VB\\"^#_&4JQ1#SY;2VNRH9$D:OZ7J^5OVE?V/?@_^U;J7P%U
M?XK6FLR:G^S;\=_"/[1/PMU#0-1@TV[T_P"('@^SU/3;6'4FN]/U.'4/#>JZ
M9JUY8:WI*PVTEW"\<D-Y:W,,4R\>,P5#'X>>&Q%*%2C4J4JDH5$G>5"M2KTV
MKIK^)0A)=4[/H&O-S)V:5M/ZZGU+'&B ;$5<?( H  5/E4#'  4  #I^=24U
M00,'!.23CIDDG^M.KL6B26B2LEV7;Y;?( HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH 9*2(Y".H1R. >0I(X.0?H>*A( )QD;A<%N3S@
M@#OP .@& "20,DDE% $V!O''\)/_ 'S@#\@S#\?88?110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
6%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>tm229830d4_1012b-img16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm229830d4_1012b-img16.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $? :4# 2(  A$! Q$!_\0
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M\!^%_@K\6O"?PJA\>>+?"GPF\0:AX>\0?$:74?#>J>)/B'X.L?$6GV/AS_A
MAKEGHUZU_/:ZG87D<]NL?K7@%_VB/^"@/[;?[ %C\4_VG_VJ?@!H7B/_ ()0
M_"[]J+XP?#OX"?%R[^$UM\0?B=IWQF6]L1XATV&&]T?3;+7Y+.6/QTOAK0M'
MU/6?"LUMX8&N6.@-]EN-H1E+!QQTG!4E1C5KW4I3A&7#&?\ %,I6BVFIX;A[
M$4U]J-6I2BU)S44ZR5+$/"R:2<X4V^63TGB.'J#2LE=I<0<RY6[QA*[A>Z_K
M5N-H3"QLQ9BQ(49&(I" K,CQ+YA00,TAC4"1CYBMMW?/OP%_:7^"_P"TNOQ5
MU3X,>)]1\4V?P;^,7Q)_9V^)$]_X-\;>$%T+XN?"2_L],\<>$;;_ (3/0/#
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M7X8?$'XZ?ME?'7PQ\>K+Q-^TO\8OBS^WGK_A[Q;?>/+'3O"_[8&@7/A_P7\
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M\6OVG/'.D7FA^+-&^ ?A6QM[>QU;6+VTLM$\+?\ "V/C=KVH76K:1###\/\
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M$MYH+Z^MM5;X?SSK?71#RU^O/_!3+QCX'^(?Q\_X(IZ=\)/%'AKQA^T+8_\
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M  B\732Z(EWX7\50>%/!.E^$=1B;2=5A:WO]#U".RGC;3+^V>*>TN!%,A6(
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M)W"ORC7_ ((Z_MX.RNG@CP/#@*=@^)FD(JX !"C?*#G))^8@MDC&0!^CLO\
MP;G?L$*01\0OVZU4C[O_  VU\>&;MT UPX/J"6[XZ8J0?\&YW[ SH"/B!^W8
MQ ^Z?VV_CNN,^SZ\N.>>GKZ&OY^XW^C=X:\?<0U^*LYI9M#&8JG&&,66XUX>
M-:5.+C&52G*A/WE%R<G%.4Y-2E)I*)_,'B!]$;PI\2N,>(..>)Y\;/.\]K82
M6,JX;.J-# *E@L%# 4J6%P];*\Q4(\D(2?NJ?,I.-2,92C+B/^"=W_!//]K+
M]G3]IFT^*?Q3\,>&K#PK:> /&/AF6>R\9:=K]Y+=ZU-I#68AM+!#<*BI9W.V
M3&49AP2PK]M](_9^^$VC_%S6_P!HK3_ >GP_&CQ/\-] ^%.O>/9;C7)]=U#X
M;^%=2U'7-#\)M!)?O86EEI^K:SK&IVJZ;I5K>RWUZ3<W#.3G\@?^(<_]@0#8
MWQ!_;KZ?=_X;;^/!7Z$C7PN._>GK_P &Y7[ F!_Q</\ ;K& , ?MM_'; ]A_
MQ/QC'T%?HGAUX=Y!X7\.OACAJ6:/*YX^OF48YEB5B)1K8F,8U%!QITHQ^&.B
MIQTW4GJ?KOA7X6\.^#W"L.#>%*^<U,DCCL1F5&EF^,P^,G3KXOE55PJ8?+,N
MU;@K>T4YQBY13Y6FOTU^*'[%'[+_ ,:K_P".U]\4?@GHGC#4/VEOASX3^#OQ
MVN;V]\5Z?%\2?A[X#U#5=8\!^&]=72-;L(/LGAJ^U_6)+76=+ALM8M#=36W]
MHW-N8:\[_90_X)>_L$?L1^)->\;_ +*_[*?PN^#'C;Q+I\.E:OXIT2SUK5/$
MC:5F1I]+L=>\3:MXAU#1[*8.?M=KHMW86M_(L9ODG$<6SX/_ .(<K]@7_HHG
M[=?_ (FW\=O_ )H/8?E2_P#$.5^P)_T43]NOG_J]OX[?K_Q4'\Z^\C*<;\FE
MTT^FCW6ZWZVW6]S]$G&$N53[II=VK-='MNNSVMT_5WX\_LO_  ._:@\(:?X&
M_:&^$'A?XO\ @K2?&.A>.;#P;XTMY=0\/CQ+X8EM[O0M4FTVWN8+2_DTYY+N
M*.SU2"YTV\:,QWEO+:&WA7\^_P!IO]FW_@GA_P $WO\ @G3^U-K]A^Q=X(D_
M9K\$1)\=OB+\%OAQ#+X?O?B!KGAS7=(O]*NY-8N]6BNOM>BZH+.^T*"XU:/2
MM$MK1K33["SMU6!O)O\ B'+_ &!>O_"Q/V[,_P#9[?QVS_ZD%8/B'_@VS_X)
MW^)=#U;P_P"(?$O[;?B70M7M&T_5]!UK]LWXTZIH^KV,CHTEAJ&G:EK-Q87]
MHS+'<-;W=O+"\D49*G&*RAR4Y3<?BJ64M^[:U[7;?8UE*?+&4G+EI7<-=$VK
M-I7WLDKVOM?8_2'Q[^R9^R!^WOX._9V^*O[1'[-7@7XIW'A?1_!?Q/\ A7!\
M2M$76=0\#7/B'1-+\2V>G736MU]@UFWL6EM8-3TS4VU7P[?7=LS7-I<!PS;?
M@G]@/]D3X;Z[\$/$'@+X"^%_#.I_LV:S\7->^!MSIL_B:%?AEK'QSFCN/BO-
MX5T^XUVXTZ&R\; "/4=/NHKG3[,H%T2STI4.?S7M?^#<'_@G_96EK96GCW]N
M:WM+*VM[.TMH/VU_CC;P6]I:PI!;6\%O#KD<%O!!#''%#!!''##&B1Q1I&JJ
M+0_X-R?V!<?\E$_;JYZ_\9N?'7_YH1^M)6HN4G)KVGZ._2_?J1=2_>?SZ7VO
M9M^N[>_KW;_1C3/^"??[(NG_  I^#WP.M?@+X7LOA1\ _C9I_P"T?\(/!EMJ
M'BQ-)\!?'+1/%NO>.M(^(VE,?$7]J3ZS%XN\;^*_$3VFHZGJFBM>W\Z2V;E8
MBGM?QP^ GPA_:0^&/B?X0_'/X7^%_BO\-?&UD]KXD\%^,].6^T6_B0SS:;//
M"?\ 3+75;5Y-D>K:3<6NL6DC><MVA2,I^/G_ !#D_L"_]%$_;J_\3<^.O_S0
MTG_$.5^P)_T43]NO_P 3;^.W_P T%5=5GS<S;@V]W]K??5WMYC]/ZTM^6GII
MMH?KA^S]^S3\#?V4OAEHWP;_ &<_A)X2^#WPST22>?3_  ?X+TL6-B\\Y626
M\U"]DN+G4]1U>9PIN=8U>^O-1NF'[V5CC;]#U^!/_$.3^P*?^:B?MU_C^VY\
M=?Z^(*3_ (AROV!/^BB?MU_^)M_';_YH*:FI>ZOL:/1[OY*[=O/H!^^]%?@.
MW_!N5^P)M;_BX?[=1P"<-^VW\=@#@'J1K[''KA6/H">*_.+_ ((^_P#!+WX"
M?$O]H/\ ;H\?^,_B+^UEK6L?L)_\%;_B+\+O@)8WW[4OQ9O?#EEX'^ Q^&7C
MCP!I?C/0;W7+RQ\=+_;-W/#X@.O"636]'NCI]X0B/O8']BM%%% 'YV_M;?$7
M_@H#I?B33_A]^PW^SI\)/&.NWVAZ5K.M?'C]IOXF:OX;^"7@]KW6M2LKSPGI
M?@OX<V6I_%?QUXKCL=#L]0U)3<>$/"EG#J?A]_[9O)+[Q#%I'S!H'BG_ (+S
M?"O5[#5_B=\,?^">G[4G@)I9IO$'A;X->*?BY\ OBYIT.T^7!X*U#XA)\0/A
M]XD>W&98[7Q$/#DMTZFW-];JZSIXW_P5!_9?_P""#?QR_:&\,>)O^"GOQ;^"
MW@S]H'3?A!X>T/PSI7Q'_;.\3_ #6F^$<?C+QEK6B:G8>$-&^+_A&QOM+U'Q
M=K_C:QM]9N=.GO+NTMI[*"]:W\.QFW^*_P!BC1/^">7[/?\ P5$_99^"_P#P
M1M_:'U#XA_"CXC_#']H#Q/\ MF?![X7_ +1WQ!_:.^ _AWPOH/@VWF^&OQ3U
M_5?$WC'QAX=\*_$&?XB7&@^'8UTOQ%'XA-I=/:3Z%#!<![E8)JO6G03MR1G)
MRE[M->S4KI36EU*+@U>ZJ+D<5+W5&-:]@K6UG&&EFW-S4.75M7YDX\J5^;W;
M<Z<5_5GX;U.]UO0=!UF\\-:SX<U#4=(TW4;KPWXA^P#7=!OKZQM[J\T;57T>
M[U#P_!J>G2S/;W\VCZEJ6E3W44T=C=2QA7/;444RPHHHH P?%7_(L>(_^P#K
M'_ION*_$7_@VE_Y0B_L%_P#8H_&'_P!:,^+]?MUXJ_Y%CQ'_ -@'6/\ TWW%
M?B+_ ,&TO_*$7]@O_L4?C!_ZT9\7Z /W8HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@!K_=;_=/\C7X(?\ !#K_ )*/_P %M/\ M-;^
MUC_ZB/PFK][W^XW^ZW\C7X(?\$.O^2C_ /!;3_M-;^UC_P"HC\)J /WQHHHH
M _FR_P""D_Q6_:!\8_M@3? ?]EC]D/\ X)T_&?Q1^S]^R1IO[7?QQ\??MU^!
M=:\3ZWK'PLUGXB>-O!^C?!SX,:IX1\,:D_A[Q;XGN/ _C;4GU'Q4\_AF-M5:
M9H;!XI5O_0?^"8W[0OQQ_:Z\2_#KXX?LU_L4?![]A'_@FIKO@Z/Q!J]UK?AK
MP[X6^._[37CS5/!UJMC-\/\ PC\/?#>BZ#X9^#?PW\87FKZ6/'7BN$:U\4[+
M3;#5_"HT32]0U#38?G+_ (*YZ1^RO\/?VR_"'Q+^('_!4_XO_L"_%;]HO]FC
M1?V<-<\$_"WX6^$_B5I.M_!/P9XX\<>(W\6?$'4->\,^*I?AGX/3Q7\0M;T&
M7Q?>'PMIHO[":VCU!I8+UTY/_@CSXT^%.C_M&?#O]G'X3?\ !4[]LGXZ> /@
M[\,?%VC?"#]G[XY_LX>$OA5\%OBS\+OAU;WWPTM==^#'Q1;PKI^K_$O1_A_J
M4=KJ5KK6D>(]035+2WM;R9;BQ+SI654Y>PE.$E*?U6:BY0J5(*4*'%M.K=0G
M*%U3_L? X64X2_LC-,HS#.9K.J-'$XG#XYAS4Z='VLHWYX^\G*G%POPK0A:5
M3EYG'.UG.(E.,H4_9YCA).*>-H5,1_6+1114FP4444 8/BK_ )%CQ'_V =8_
M]-]Q7XB_\&TO_*$7]@O_ +%'XP?^M&?%^OVZ\5?\BQXC_P"P#K'_ *;[BOQ%
M_P"#:7_E"+^P7_V*/Q@_]:,^+] '[L4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%1O+$AVNZJVTMAB =H#,3] J.3[*3VH_K[D
MV_N2;?DF]DVC_)OY)-M^B2;;Z)-NR3:DHJI-?V5N&,]U!"%4.S22*BJA65PQ
M9B %V0RMDG 6-V/ )KD;/XG_  VU"'[19?$#P7=0AVC,L/B?1702( 60D7OW
ME#*2.HR/6L9XC#TITZ=2O0IU*L:DZ5.I6HTYU84G&-6=.%2K"=2-*4X*I*G&
M<:;G!5)0<HJ7-6QN#PU2E2Q.,PF'JUX5*E"GB,5A:%2O3HN,:TZ-.OB:,ZT*
M4IPC5G2C4C3<X*I*#E%2[FBN0_X6#X"_Z'?PA_X4NC?_ ";2_P#"P? 7'_%;
M^$.<X_XJ71N<=<?Z;V[TI8K#15Y8G#17>6(P\5]\J\5^(EC\#)VCCL#)]HXW
M!R?;:.+;WTVW.NHKD8OB!X$N+E;.V\:>%;J\:*2=+.U\0:5<W;PPJ7EE2V@N
MY)WCC16>1DC(15+,0 373VUS!>01W-K*D\$H+1RQL&1P&*DJPX.&4@^X(K:#
MC4@ZM.4:E)5'2=2G*-2FJL4G*DZE.4X*K%-.5-S52*:<H133>]&K2Q%.5;#U
M:6(HPJNA.K0JTJ]*%=0C4=&=2A4K4XUE3G"HZ4IQJJG*,W34)1E*>BBBF6%%
M%% !1110 4444 %%%% !1110 4444 -?[C?[K?R-?@A_P0Z_Y*/_ ,%M/^TU
MO[6/_J(_":OWO?[C?[K?R-?@A_P0Z_Y*/_P6T_[36_M8_P#J(_":@#]\:***
M /YD/^"AG@3]KKPI^WS^T'\5?@U^PAX]_:_^&_[0G_!+SP[^R)#X@\*^)? F
MBZ=X!\>0?&KX\^(]?M-8M/&5Y;OJVF3:9X@\):E=6^GJMT1]@.\RQ!$\Y_8%
M^'O[=/B/X^?\$A?"WQH_8$^)O[.?@;_@GU^S-\3?@YX]^*_BOQ=\/]8\-^+=
M7U#]GRP^&6A7'A[3/#>J7NOVL.LZSH$%Q>KJD,+-/=0WTI$@.W]G/VL_V"]$
M_:;UFT^(_@_]H+]HG]E/X[:/X;7P?I/QC_9[^(%[H.H?\(^MYK=[#I'B;P9J
MO]J>"/%&G1:IKNLZE')J>C1:EY<UJ/[21X8Q'\O>#_\ @E+\;]9URVN?VH?^
M"J_[;_[2/@"&$P3_  GM=1\#_!+P5XAA:XCEB7Q?<_#'0]-\3:T@,1@N;<ZQ
M9VDL$DD$B*6W+&75I82FZ>D&Z<J3YN9/E='/VH[QVI<38J;4D[)<Z?)&;>6.
MI4\5"#4>>$)*<90O*/-&612;;5X:1X=PZ7*DVI.]Y2@U^VBW$+XV2*^0"-IW
M AE#JV1D;70AD;.UUY4D5-7&^&_#%EX.T/1/"WAK3TTWP[X;TK3] T+38YII
M4L=)T>VALM,MHY+F6>5H;:TC$0>[ENKF0H"\A/S5V72KVU>B6K?9+5FH45%Y
M\).!(N<,W?D(0'(.,$*2 V,[20#@D5$]]:(2KSHI&!@Y&2?-^53C#.HAE>1%
MR\<:&215CPQ2E%\UI)\C:G9I\K7(VI:^ZTJE-M.S7/"Z]Z-W9]G]S_R,OQ5_
MR+'B/_L ZQ_Z;[BOQ%_X-I?^4(O[!?\ V*/Q@_\ 6C/B_7[:^*IXAX8\2;I%
M4+H&M,68[5"IIL[.2[84!5(8DG  )Z*V/Q*_X-ICC_@B)^P63G'_  B7Q?7.
M">6_:-^+X4<#O@\] .20*=FM]!--;Z>I^[%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !6/J'_'Q'_P!<9/\ TGO*V*R+T W.3V@&
M/QBU $?EBHF[.'FZB^_"XO\ R$W9/SIUU]^%Q6OX''?$)6;P;XL?'%OX,\03
M#GE6&C:BI 4\$.I*D_>';@FO\\[2K:WCTW3U:STH9L;)@+FUBDGYM8=YDEE:
M9YF:3>YE+@,7P$7;S_H:^/<'P/XRR<Y\)>)XR2#@(-#U(@GV!QQS]*_SRK*3
M.GZ=N2,D:?9C+9SQ HS]#VK^ ?IMU<12J^'-!54J,X<5S:YDKRCB<EY=54IO
MW;R5N;KJGT_R\_:,5<51Q'A'1A52I2PW&<W%SY?>CBL@<=54IRT4I67-;5^Z
M[Z7_ ";7_GTT/_P"MO\ XBG>1:F)Q]BT,MO4J!9VX8C!Y4[ ,#&2.>_:J^]?
M^></ZU,@!C+GR5PX3;\W\0.#P#]>O;@YP*_@YU*O+-J<'RQ;:G4;NM%:*^MW
M<VVE%*[>MDV?YGQK5%*+JUZL%&I3:^KU9N<I<_PR7UU>XU=N[M=+U/OC_@EM
M$C_MZ_L[01VVFPB35_B<QF@M+>&["V_P(^+%U!%'<QIOAM_[1CM)[@,,F))
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MY>_\%7OVB/BG^RU^Q#\1OBU\)O%&B_#?Q38>._@EX+U'XM^)?#4WC7PW\%/
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M4?;8C)ITO:_5JM3V?M(PG*'/;FC&35[,_P =?VJWA?XE^&F8>"=+Q&\/>-N
MJN;8/CV65T^,^%L[X9GF4<#C.&Z>-> CG."P;Q:PE2K2AB?8*?L)U*<:O(YQ
M3EJ0?ZIO^NB_^@O4=2#_ %3?]=%_]!>OX?AM/_N%_P"GHG^2%/XH_P#7RC_Z
M=1]^?\$M/^3^OV>?^PM\4O\ UG_XL5_;'IW_ !YQ?67_ -'25_$Y_P $M/\
MD_K]GG_L+?%+_P!9_P#BQ7]L>G?\><7UE_\ 1TE?Z??0P_Y-?FO_ &76<_\
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M.XT.6X+8OE#>.?L[_L#_ +7%U^U/\+/VL_V\OVQ_#'[1OB_X"^%?B-H/P'\
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M]_UD7_7NG_HV:OROQ0^/(O\ KWCO_2,*?\3O^EH_\E7]"?\ [%OTA/\ UHN
M2G4@_P!4W_71?_07J.I!_JF_ZZ+_ .@O7Y=#:?\ W"_]/1/^/FG\4?\ KY1_
M].H^_/\ @EI_R?U^SS_V%OBE_P"L_P#Q8K^V/3O^/.+ZR_\ HZ2OXG/^"6G_
M "?U^SS_ -A;XI?^L_\ Q8K^V/3O^/.+ZR_^CI*_T^^AA_R:_-?^RZSG_P!9
MSA8_V0_9[_\ )EN(O^SF9Q_ZRO"A=HHHK^OC^[0HHHH **** "BBB@ HHHH
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M_P!@3XVZ5^TE)\<+GX7^(;KP!X=OO#?[-NO/X;^./Q,\5:_\2/!>D_#KX7>
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M /).M+_Z_P#6O_3G<5^?-G]Y/^OD_P#H:5^@WP/_ .2=:7_U_P"M?^G.XK_
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M?/>^";Z]FEB!MA97MG&K?:$G _6+_A_#\)1,&/[/?Q3S"CPEV\4^"-[EF1E
M;[4$9 (R3@ [B,?+FOY2/@L ?A388X U/42V>7.-7U? !Z!>=V/4D#BO3&9
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M\IA\2?\ 9B.._P#UK> #UNBBBO\ B_77T?Z'_6YF'^[2_P"W_P#U'Q1-:?\
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MLA^SW_Y,MQ%_V<S./_65X4+M%%%?U\?W:%%%% !1110 4444 %%%% !1110
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M;]MSQ1\0?V_-.^#/P;^(WA#X\>+OA1_P6/L/B3^T.-)M_!T/[4'AO]ICXG?
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MQ_\ E$K^W?\ ]D/U'_T_^'J_R4Q]Z3\?_1AK_6L_X+C_ /*)7]N__LA^H_\
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MQVU*QM]4^%L_Q*/PIU[P5,G@33KC4?A;)8:=X/B\6VTK0^-K:]FU2:'39S*
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MC_R5?T)_^Q;](3_UHN 2G4@_U3?]=%_]!>HZD'^J;_KHO_H+U^70VG_W"_\
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M$/\ X-J/^4(7[!O_ &)_QB_]:+^+])[/T?Y,3V?H_P F>[?\%Q_^42O[=_\
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M_P"DR/\ 6?%?P)^M+_U(PY]Q_!3_ ))19?\ 83U+_P!.VK5Z2_6X_P"OB/\
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MTK]!O@?_ ,DZTO\ Z_\ 6O\ TYW%?GS9_>3_ *^3_P"AI7Z#? __ ))UI?\
MU_ZU_P"G.XK_  +_ -(3_P"4+N$?^S[<"_\ K,<='^V7["C_ )3#XD_[,1QW
M_P"M;P >MT445_Q?KKZ/]#_K<S#_ ':7_;__ *CXHFM/^/VT_P"NT?\ Z.BK
M]+KW_61?]>Z?^C9J_-&T_P"/VT_Z[1_^CHJ_2Z]_UD7_ %[I_P"C9J_*_%#X
M\B_Z]X[_ -(PI_Q._P"EH_\ )5_0G_[%OTA/_6BX!*=2#_5-_P!=%_\ 07J.
MI!_JF_ZZ+_Z"]?ET-I_]PO\ T]$_X^:?Q1_Z^4?_ $ZC[\_X):?\G]?L\_\
M86^*7_K/_P 6*_MCT[_CSB^LO_HZ2OXG/^"6G_)_7[//_86^*7_K/_Q8K^V/
M3O\ CSB^LO\ Z.DK_3[Z&'_)K\U_[+K.?_6<X6/]D/V>_P#R9;B+_LYF<?\
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M\*LL"&40G4]45MP._?\ VQJ^T#'  48;@DG!!XP?2V*'[1AP,W$95L9!7;<
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MREQ::629%*]])*63Y/57*_M/DDF]K7MYEVOY3_\ @[\_Y1O_  !_[/L^'?\
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MIS4.;5RY7?"DIPBW4:NKNZDY*RNT[M)NR2O=+5/H?R0?\%//^"V/[*W[4W[
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MO_X;?'^T\(>"8/"NL_ ?]JY[U+^6ZWP?LT_%F:-/-N9[J3RI$\/?O59[MQD
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M!X?[1T3P_8:9>^3)_8P#Q?:K:4QL.J[2"17H,?\ P<8?L)1YQ\*_V^#G@_\
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MR?$WPOXMB\7^)?!_QB^-'Q1\?VVOWZ> /!^M>&X8+77]:\5>'+&&WNTN)8=
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MUCPCX;DTC5[.32]8\-RS1VZW3)<QW-JRB0NY0;U,C_C^WP4^-JG;_P ,U_M
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M?JSADV74J64492G3J2BXYC3^L8A^SG%4XP<54E:G'^.37O@%X._91_X)@?\
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MSP6LTWP\LX+7X;W]Q8:7<:AX2NI]*TV2U^@?VG/V1/V>/VQ_@AXJ_9Q_:/\
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-WHBBBBD4%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>tm229830d4_1012b-img17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm229830d4_1012b-img17.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" %3 FL# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_*^+M?\
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MI7QV+IQPM5T,10<9+=-M'Z;EV:8#'X>.+P4E4IRV<977]>6ZZGAO_#ZW3_\
MHV?]KS_PW:__ "31_P /K=/_ .C9_P!KS_PW:_\ R37N5%<WM\/_ ,^O_)F=
MO-2_E_$\-_X?6Z?_ -&S_M>?^&[7_P"2:/\ A];I_P#T;/\ M>?^&[7_ .2:
M]RHH]OA_^?7_ ),PYJ7\OXGAO_#ZW3_^C9_VO/\ PW:__)-'_#ZW3_\ HV?]
MKS_PW:__ "37N5%'M\/_ ,^O_)F'-2_E_$\-_P"'UNG_ /1L_P"UY_X;M?\
MY)H_X?6Z?_T;/^UY_P"&[7_Y)KW*BCV^'_Y]?^3,.:E_+^)X;_P^MT__ *-G
M_:\_\-VO_P DT?\ #ZW3_P#HV?\ :\_\-VO_ ,DU[E11[?#_ //K_P F8<U+
M^7\3PW_A];I__1L_[7G_ (;M?_DFC_A];I__ $;/^UY_X;M?_DFO<J*/;X?_
M )]?^3,.:E_+^)X;_P /K=/_ .C9_P!KS_PW:_\ R31_P^MT_P#Z-G_:\_\
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M&S_M>?\ ANU_^2:]RHH]OA_^?7_DS#FI?R_B>&_\/K=/_P"C9_VO/_#=K_\
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MB>&_\/K=/_Z-G_:\_P##=K_\DT?\/K=/_P"C9_VO/_#=K_\ )->Y44>WP_\
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M)EU5S>0Z+!^[TRSF93]GBXRV%XWR$;FZ]EW,$%>I_P#!8G_DQ#5/^QO\&_\
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M"@&=VY0H)RH&)%P2=P7R_$C TL3E,<?)?O*;2OWC+=??9K>VMMV?2>!>;XC
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M"6KSVT2A=Y8S)F/:%Y)W<8.<8(%'1+_7_'6GO<Z%H>L:Q:)(86FL;*6YC1\
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M^"]#U?3-'^&_@+2=-\0PK;ZK:6?A^T@@U.(9PDZ+&%E4;C@.".3ZUWU?)_\
MP_#_ &7?^BG_ /EN:M_\BUUTH8FM=TE*6U[7?I?]#6"JS^"[/<+?]D_X66?@
M>X\,1?#3P!%X:N[I;Z?24\/6BV,UPH"K,T(CV-(   Q&<#K6KHGP(\#^&M/L
M+33O!GA33[72K[^U+*&VTBWBCL[O9Y?VB-50!)=GR[UPV.,XKYZ_X?A_LN_]
M%/\ _+<U;_Y%H_X?A_LN_P#13_\ RW-6_P#D6M_J>8/>G/[I%^PKM6<7]SZG
MT9'\'/",4,,:^%?#BQVVJMKL*C3(0(M18L3>*-O%P2S$RCY_F//)KYZ\)_\
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M:M_\BU=2CF4X\DH3MO\ "_/R\W]["=+$3^*+^Y]=_P CT_XC?L'?"[Q[X/\
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MV222**W\S4-2N=1DCBBSY<:-<22%$7).U2!DDXR<U\B?\+:_ZK_^W-_XC_\
M_@;1_P +:_ZK_P#MS?\ B/\ _P#@;6LIN4G/J]62DDE'HC[&N_ACHUWX5BT;
MR;NWL8)OM$7V6^GMIHI-Y<LLT;K(N2S9PW(8@\'%4-#^!'A;PWK6FW]CILEO
M-I,4<-JBWD_D1[(WB5S"7\MI!&[KYC*7(/+=*^2/^%M?]5__ &YO_$?_ /\
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ML;9;.VNX[*)9[>!00L2.%W*@#, H. &/'-0M(\O]=?ZUOT>Y4E=MKL_OZ/\
MJWXGE&O?M#^*+#X?>%=?6#0K2WGT(:WKKFUGO8K?Y4/E[8I/M$$1_>?Z1Y$Z
MKL.Y!WYS_@H&1/X^_9M*G(;XFSD$<Y_XI+Q&:]RUSX1^%/$]OIT.I>&/#VH1
M:0NRP2YTV&5;)?E.(@RD(,HGW<?<7T%>(?\ !0.-I/B#^S>$5G(^)ERQ"C.
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M'?>)7LYK?688=1NM.DF2*VNI0JK<6TR+]HAA9@@90VUB/H/Q;9@HW'7C_/\
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M<'&M%6?+MY+YW[^5]CY$_8M_:K^+WQ!^*'P=N_&OB?P[K&A?%[PIJ-\-(L-
M%C_8\U@T8$PG,KO*\PD^<$*BX^1!UK[@KG=#^$/A/PQ)HS:;X7\.Z>WAR"6U
MTEK;388CI<4N/,C@VJ/*1]HW*F V!G.*Z*IQN(IUI\U./*M>W\TFMNT6E\C"
M33=UY?E8****XR0KRC]O#_DQWXR_]B+K?_IOGKU>O*/V\/\ DQWXR_\ 8BZW
M_P"F^>M\-_&AZK\RZ?QH^NZ***P, K\]_P#@F1_R,/[4/_9?O%?_ *%;5^A%
M?GO_ ,$R/^1A_:A_[+]XK_\ 0K:NVA_N]7_MW\SHI?PY_(^I****XC,****
M"BBB@ HHHH **** "BBB@ HHHH **** /#/^"G__ "C2_:'_ .R9>)/_ $U7
M->YUY3^W?\-=:^,W[#WQE\'^&K+^TO$7BOP-K>C:5:>='#]JN[BPGAACWR,J
M+ND=1N=@HSDD#FL+_AX=X!_Z 'QS_P##*^,O_E70!Z5J_@FZO_C/H/B))+<6
M6EZ/J.GRHS'S6DN)K)T*C&-H%L^<D')7 .3CYU\+?L:>/O"7Q&\4>*K>T^'Z
MW^I:C::C#9V]TEC;ZA+;W_VC?-)!IB2H71WYF-Y(K#'FN')'H'_#P[P#_P!
M#XY_^&5\9?\ RKH_X>'> ?\ H ?'/_PROC+_ .5=$?=E&<=XWM\W?\PE:4'3
M>SW-[X;?LSZ?:_"G2-+\4VEO+K5LQN;F?3-0N8@LYR,Q2J8Y H4)V7E%;&X
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MNMDDKZV/*S3-\7F#7UBHK+9+1?=W\V?1=%?.G_"J_P!O;_GM^R'_ -]^(O\
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M^(O_ (FC_A5?[>W_ #V_9#_[[\1?_$T?4O\ IY'[P]E_>7WGT717SI_PJO\
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MI?\ R17T;10!\Y?\.EOV??\ H0/_ "N:E_\ )%'_  Z6_9]_Z$#_ ,KFI?\
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M"!_Y7-2_^2*/^'2W[/O_ $('_E<U+_Y(KZ&_M*W_ .>\/_?8H_M*W_Y[P_\
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M/_?8H_M*W_Y[P_\ ?8H#0^>?^'2W[/O_ $('_E<U+_Y(H_X=+?L^_P#0@?\
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M_ATM^S[_ -"!_P"5S4O_ )(H_P"'2W[/O_0@?^5S4O\ Y(KZ&_M*W_Y[P_\
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M,#FM%5:3IS?++:Z2L_D?+<8XROA<M=7#RY976J(?^(B?XS?]"=\)/_!3??\
MR97ZY_LV>-9?C'^SIX!\7:G9:=!J7BKPYIVL7<=K"5@CFN+6.5UC#%F"!G(
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M7_Y^9OR3_P")H^RO_P _,WY)_P#$U/10!!]E?_GYF_)/_B:/LK_\_,WY)_\
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M=<?*I;^51_;T_NS?]^7_ ,*GHI%D'V]/[LW_ 'Y?_"C[>G]V;_OR_P#A4]%
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MOT^OVIK\1^E%_P EU4_Z]4_R9]3P'_R*E_BD0?;T_NS?]^7_ ,*/MZ?W9O\
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MZ?\ XFD63T5!YEQ_SRA_[^G_ .)H\RX_YY0_]_3_ /$T 3T5!YEQ_P \H?\
MOZ?_ (FCS+C_ )Y0_P#?T_\ Q- $]%0>9<?\\H?^_I_^)H\RX_YY0_\ ?T__
M !- $]%0>9<?\\H?^_I_^)H\RX_YY0_]_3_\30!/14'F7'_/*'_OZ?\ XFCS
M+C_GE#_W]/\ \30!/7XK?\''/_)[WA;_ +$:T_\ 2_4*_:+S+C_GE#_W]/\
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MQ> H5(8N'*VU;5/IY-D]%1Q-*6^=(U&.JN3_ $%25_-Y]L>,?"S_ )3(2_\
M9&6_]/B5]EU\:?"S_E,A+_V1EO\ T^)7V700]PHHHH$%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?$_PI_P"4F?[4
MG_<I_P#IJ:O=*\+^%/\ RDS_ &I/^Y3_ /34U>Z4%K8^:?C%\=_ _B'6[V*\
MO/V?]<FDAN-'OK?7/B.MN/LRSAT1X?LDJ[RR!F! ,;K@,V-U>K?LP6^DV_P7
MTS^Q#HC6$TUS.'TCQ'-XBM99'N)'D<7TRK),S.6+%AD,67G&:YK]I?4O'R:]
M;Q^&M5UO0]&L;%=0NIM'T6/4;R](NX4GB7S89D!2W9Y$C6,R2-]W(1E/4_LU
MZMK>M?"2SF\0W>M:AJ*W-W%]MU;3!IEU>Q+<2+%*UL(XC#NC"$*R!@,9SU)2
M_A_UW?YN[^]A4^+Y_P#MO^5E?T1WE%%% PHHHH **** "BBB@ HKA=7_ &FO
MA_H_PT\<^,/^$NT._P##OPS^WKXJN],N1J/]A26$1FO()TM][K/#&,M#M\P9
M VY(!P_V=_VQ_!_[1'V72XI_^$4\?MIB:SJ'P_UZ_L8_%N@6C^68I+[3X+B9
M[;?'-;OM<AE%Q$KA')0 'JU%%% !1110 45\I?&3_@L9\)?@5^UKJGPFU^S\
M<Q?\(M_9L?BSQE'H;-X2\$S:BNZPBU.^+#[-Y^Z$+*4,(,Z[I%V3>5]6T %%
M%% !117F_P"U5^UW\-_V(_A)-XY^*?BJQ\(^&(KJ*R%U<1RSR7%Q*2$AAAB5
MY9I" S%8T8A(Y'("(S  ](HKS?\ 95_:[^&_[;GPDA\<_"SQ58^+O#$MU+9&
MZMXY8)+>XB(#PS0RJDL,@!5@LB*2DD;@%'5CZ10 4444 %%>;_M=_M%0?LG_
M +-_BOQ]+I-]XANM$M532]%LHII+G7M2GE2VL-/B$,4L@DN;N:"!6$;;3,&(
MP#7C7P5_X*!7?PW\:^%O '[3>N?"GX;_ !A^+&IS77@KP7H6HW-]-::8\<7V
M:UU"Z=?)^W>?]HMQ(IC@NI(@MOO8,H /JVBBB@ HHHH **^)_CW_ ,%Q/AO^
MS5_P40_X4CXNTV^TWPQ96NG6>M_$!VE32?#.NZ@DMQ9:;?;X5CBCFM(O.%RL
MS*-S!E5(IY8OMB@ HHHH ***^?O^"EG[9.I?L5_LWQZOX6T:Q\3_ !)\9Z[8
M>#/ >A7LKPVVL:[?R^7;Q2RC"I&BK+,WF21*X@,?FQLZL #Z!HKY$_X)+?\
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MQ+8?#;48GU+1_B;X&(>#4]/LIHX!8^?8374,D$,:RRRP:NLA:YDGN(;KW/\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^)_A3_RDS_:D_P"Y3_\
M34U>Z5X7\*?^4F?[4G_<I_\ IJ:O=*"UL>*_M(?#%O'/Q$T2ZUKP'J/Q*\)V
M=C,J:1;75H([6^9@HN)H+JXAAE_=,ZHV6:,[B -VX=A^SAX9U?P?\)K*PUF&
M^M)HKBZ:UM+V^^W75C:-<2-;02S[W\QXX3&A(=P-N-S8W'YW^,?A_P ,?$SX
MKZ]I]U\++;PK807TD=_XC_X57=:]K6MR!D+2VSK836J1O\X\Z1IW8?\ +)#A
MJ^BOV<O!GA?X??!K1M'\&Z=J>E>';)9%M;?4;.ZM+E29&+L\=RJS LY9OF4
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M\2/A;^T!X/UV?7['XG:?K+PZ#JWP[EN;*Y@NM5MI^-7NXI@MD;.S@MK.6?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#QCX6?\ID)?^R,M_Z?$K[+KX4\/?%+0OA__P %LO#.DZO??9-0
M\<?"Z71-$B\F23[;>)?7%^T654A,6MC=2;G*K^ZVYW,JM]UT$/<****!!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWWKG_P 31_PJO]LC_GM^S-_WWKG_ ,30%SVBBO%_^%5_MD?\]OV9O^^]<_\
MB:/^%5_MD?\ /;]F;_OO7/\ XF@+GM%%>+_\*K_;(_Y[?LS?]]ZY_P#$T?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>tm229830d4_1012b-img18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm229830d4_1012b-img18.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $Z ?8# 2(  A$! Q$!_\0
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MFBDE>3>H4*!EF)X  X/:OGS_ (:.\7_] W0_^_$O_P =H_X:.\7_ /0-T/\
M[\2__':!'T%)X0T=Y;:1$O('MH$MHS;:A<0_NT^ZK;'&X#)^]FIK+PSI=AJ
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M#P%J,5G+92ZL\%HUK]C:%+BXN4E3*Y?;*Y6(E0RA%!"[OO,.!WJJ%4*H  &
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M/-0QQ-=1I(UJF6(6$E<H 6)'<<>@H N6]_K&HZS<FS-C'IMG<BVDCFB8RS$
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M:[_V[_\ HB.OKN."&*25XXD1Y6WR,J@%VP!D^IP /H!7R+\;!_Q=[7?^W?\
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MU85MZE3U/0U7Q@D&B(JJ6ZZA1115&05T'CO_ )*%XE_["MU_Z-:N?KH/'?\
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MVMCWIB.R-N4X/M244K"LA6.YBQQR<\4E%%,9TOP^M9KCX@>'FC0D1ZG;.Q]
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M/C;_ ,E>UW_MW_\ 1$=?7]8]]X3\-ZG>27E_X?TJ[NI,;YI[..1VP !EB,G
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MM<NA1]E'EN?$%%?;_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\
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2 .)HK54\-973^3(5!I63/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>tm229830d4_1012b-img19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm229830d4_1012b-img19.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %[ @,# 2(  A$! Q$!_\0
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M_P#"G/[-_;'_ .%H?V7_ ,)-_P (5_P[:_X*._\ "0?\(G_;/_"*?\)AY?\
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M!5?^$Z_:0DT/Q3\+A<^%OAGX9?XH>+7UCP_#X.\)SQ1?/YM\([KXD_M%3?\
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MS1#XI<_&FS^%]I\:KCP:N@^*5E7X7OXG_P"$+'BH^*'T%O#$A;Q$K:&=$7Q
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MX@\+(/AR_A;X;_$7XFI\-?"?A+5W\3^"O@Z?!WBIHO"_]1_[).J^/M=_9E^
M6J_%KQ]\,_BM\1;_ .$G@F]\8_$_X.^)#XM^&/Q#\1/X:TY=5\>_#[Q9_8?A
M=M<\.>*)V?7;76H_#F@0.NL*MO"D2J& /IJBBB@ HHHH **** "BBB@ HHHH
M **\[U?Q9J&G:E-:Q1V/D0@?-<,R$\#^Z1C'^''KE_\ "9ZQ_P \K'_OS+_\
M577' 8F24DE:236VS2:_!H#U+;_M+^=&W_:7\Z\L_P"$RU?_ )Y67_?J?_XN
MC_A,M7_YY67_ 'ZG_P#BZ?\ 9^*[+\#3D?<]3V_[2_G1M_VE_.O+/^$RU?\
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M^I__ (NC_A,M7_YY67_?J?\ ^+H_L_%=E^ <C[FE\0/"B^._ _BWP./$FO\
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MDS:5J=@Y0!T$MM/+&60@D.4#'[M?GZG_  4Q_9U'@CQSX[O=>\4:)9?#?0?
MOBW7_#^O?##QIH7B^^\*^/\ 6-&\+^$]?\->&=3CW>+=&UC7]8&C/J^@D"W;
M:)4,80UUGCS]OOX%?#_X;_!OXH:]XO2/PC^T)/H-K\+[S2?#?B/5+[5_^$IT
M_3-234M5TN&!GT#1[ :IIJ^(Y->,7_"-+JD2S3/&HD3PGG.1+#_6)<09!&"E
MR.4Z_+&'/761IRC)1FN:I-15H?"TK*@XRG]G'PE\4)XC*\+2\.^*,1/.^(ZO
M#6&C0X<SRNZW$-+AR?$U2E2E0=6,U'ANE4XAE*,Y)9%"<G:I3K8>C\ZZO_P1
MH^"OCWX:>#O@E\;OVB/VIOCE\&?A'X \2?#;X"?"_P <2_LW^%= ^!5GJW@!
MOAEH_BCPCJ7P1_9L^%_B?QKK_A7P$=2T'PH?CAXG^*?A*2'5II_&'A+Q1XD"
MWB?57P<_8NM?A=\78_CY\2/C_P#M!_M/_%C2/AEJ7P@\$>*_C,GP!T"+X=?#
MC6]=TCQAXM\->%O"W[-'P&^ 'AO6#XJUGP?X0O+_ %GQ1X8\6>*+8:#HEMX6
MN/#T,WB-;VMH_P"W+\(]4N_#VEZ;J=]<Z]XE^.>O_L^67AD>$_$\OBBT^)GA
M6+6=6\6:9J>G!=^E:)H6AZ)<>)W\37!?PZ?#,VDRBXV3Q[OJ/_A,]6(!\NQ*
MD<'RIN1U_O\ )_6O6R]4LPO_ &?CUFJ6MU4C-:ZZM*/*W9W4K2T=TGM\[F7#
MW$.1Q;SK ?V4DY*[NKV:BVO=7-&\HI3AS4Y*2<:DXR4GZIM_VE_.C;_M+^=>
M6?\ "9:O_P \K+_OU/\ _%T?\)EJ_P#SRLO^_4__ ,77=_9^*[+\#Q^1]SU/
M;_M+^=&W_:7\Z\L_X3+5_P#GE9?]^I__ (NC_A,M7_YY67_?J?\ ^+H_L_%=
ME^ <C[GJ>W_:7\Z-O^TOYUY9_P )EJ__ #RLO^_4_P#\71_PF6K_ //*R_[]
M3_\ Q=']GXKLOP#D?<]3V_[2_G1M_P!I?SKRS_A,M7_YY67_ 'ZG_P#BZ/\
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M<XRE'V?+1J.4XOE3_P!%HL0P&TD'J>P_SQ^OI2D*,M@9[D 9-?P:?L)?MO\
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M_P#22S]O[_Q,C]HW_P">!7WW]L2[+[Y?Y'Z-[=_RG^S917^,G_P]=_X*D_\
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ME?\ !4".1(;G_@I+^WDLC_(TS?MB_M%NQ0D!MP/CII$&!S&) K ;3N!J<_\
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MP,^O''/;B@\ X&<#@#O@=!_(5_E>?LO?\%)?VT/%DOB?X:_$?_@H-^VGX?\
M$7C*]TKP[H'Q&US]JO\ :0UJQ\#+J>L:*SWSZ7JWQ8_L&)E92&U\XDA\,'Q
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MR?,'Q8Y9MP\[J5GROXHN3_"%KWNNCU?3#\2:%;C39-1M#%:3V#HK88EKO>0
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MQE\E_$$V\NN06-E/?2W,%L+361<C3C86^H!G$@T@J#&-$0E"-^W* X_ASN>
M/BQ-X*633=5\)^"O%NG27*3W5OXF\/F[OA$NGII8T[3M8Q%KNDPC3%38%E3R
MY8TD(W(&;#\1/>0:I>27L/D7,!.;<YP#Q]>,8.>U<;?PQ PZE=9G^W=?J#C^
M?'Z]Z[<+1PV.RZ.%Q,;^['9O5N-VU*+@T]79Q=UM=M7/1PF$PV/RV.6XF&D4
MH[R5Y):M2@Z<HR5[Q::<5;635W^\WPF_:R\#?$_P7X4TWX;?!OP+X+^)/@#P
M-KGAS6/%-QJFF7^KZ=X8CLG&M>(?!&D:Q8VZ^)O&GB/P[NT(MXU?4$;=K"1;
M)/$@DMOQX^+GCW4_C9\5O$/C2==:GU?Q)XCU.XE.H7)OM4OH]0U"Y%B/-@#%
M]4(%@9GW*9-;U%F!C4 C>^'_ (X\/_"WP]X\NX-.;4-:\2>#=>\/Z5-]I./#
M]YJV=).J+@8R'SP=H.[@] ?G[3KK6;$M<V5S/;SQ>0\$\.1>(US*4B1&XVF1
MAEQT&[@BOC>">!\MR#/>),TR[ 5(1E)4L+[>5656-&<ZE?B",95:E5QP_M:O
MN*FH0C-U)^S:<ZD_SWPU\,,FX6XDXISC(LLFE-TX<.3XBJ5JTVL34J<2\24Y
MU*U6O4?#KQ<[4Z2Y%&*DHQ;DJC]#\,I)KWAJ_P!!?1](-KH]Q?\ BNYU$6I_
MX2"/3]*TQEU+2VU?JNC,$+HA0AO$4D;J<2UYEK=I+IVI^3,5$I@LYKAHKO[6
MMQOC!W>86VAMO1<D#'<$&K]IXMUBWMIM,,D-Q:W-TMU=P&.-7N6_BS>JAG'H
M#N(Z]3Q7L'P#^#VA_'/XB6_@(^-?#OPV;5?[3&E>(?B!JET-!-Z(/,TG0YI=
M%T25X]4UV58M(CD:)+<W$@+A$(CK[FI6>44,RS/,)..617.W&,I\L(J\IM1C
M*=XV<WRPDU%-I>ZVOTNK6HY#0S/.LS;6503J/E4Y\E-)2J3<81E-J*7M)<L9
M.R;44HMKP_0_"NLZ[;:U>Z59SW%GH&G'5-;N(0-MG8%@-S9XQGCGN#D@#GG3
M&R2A0?F/4^N,#MQZ^O7\![MXL\+R_#7QCXN\#7.MQ3RZ!J&N^#;W4?"CZA?:
M!K]]I>J/I6HW\;R'P^[Z'(L<K*\D>65$=XF#D#Q*X1UNI$4AV!PK<X_H>/K[
M"O1PF(==/$1:Y&KINWWMVZ]>BNE:Z=O5P.+^O)XG_F ?(Z;5[6E'FW=M7=.]
ME92Y7JI%W2+NSM-1M+B]L_[0LX+E)KJR^U/:_:K1&1GLO- 9H]X!):,.WS':
M#C-2>(=6EU[5;O5IH;.":^N'N9[?3[46EE S\8CB481223U/+$EB3BN>3.3@
M_7/.>O\ GJ*'SD9/TQQCI_GJ:Z/8KVWUBVNWR;NU:]M7;6W1+9'1[&/M_;_:
MM;KM>[6]K-VZ7T2O9'TYX&L;F\\/:1#X/TCQ!J7BW7_$EUH,NHP-I>HZ;9:!
MLA_=,I237/"6KP:QJ7]KIKI9(BA0H"BNK^Z:3X,3Q'\5?"GPK\8:IJ/@?P/>
M^.?#GA%O%?B6ZL/[&T'PF=0CTE?$<^J/MBV1:4QUN5HF_P"$<($LB8B9"WP3
M;74]M)+]DDGC7@,Y!\Q03CY <DL>@/')'7I7T]\-OBAX<3PAXP\'_$*QOM1U
M"^TB2U\+:]=7#74NG2#R)-+TUE#-Y<>3JJ(2V<:F2P!4D_&<09;CG06)PRYK
M=?>]NN9I>VBK<DYT(OW:<M)12?-%NY^?\7Y+G:P[QN50]M)RY6J<)/B##RG.
M27$5)RDZ4_\ 5Z$W*,)**BH1=.\G.W]1'[-GA*T_:!_:]_8]UG5/BKX UV3]
MF#]M[]FOP[X5D^'FBK8Z7XS\*^%/BE\.K_0-3U/4]&UO7?[3UJ]71#K>UW*Z
M#XDUG67GF:)A%%_';XJD8>)_$P)(/_"0:L4+?P^7J4I!^A&"OM^%?O/_ ,$C
M[C3_  G^UY^Q5'\//B=;:Y=^-?VK/V:K/Q9X4@N]0O-9M+-/CW\.(GW^%=;T
M:/\ >+I<?[S6?#@\1-X:57>2>%B&K\&_%AD?Q9XBSL &O:H@;!P-M_*JEAD9
M)! /J<]L5\SX/9%B^&<OXGR*.8RKY'1XC4^&X2X<_P!772BJ4%BO^W)8MXBM
M=.3C[9*<I2YI2^&\ ^$\7P3E_%7"[S&69Y'E7$L7PK!\+2X6=.A.A3_UB3IN
M*4U5XH5:O%PE.F_K$G3?)*#?%T445^N'[\%%6I;8QQB0G@G '^?_ -7O56@#
M4:>9S_K9.6F)"+D;Y>NPXY#\DC)(/?C%=CX1F\/#Q!HD'BK^T5T"34K3^W[?
M3)%CO&L8V!,FG._W+D1IB-BP <IGG!')YD+2F* JD12X96P-B[OF( )!5\$=
M0<Y)!K[3_96^#5WXS\2Z=\0/$6G6]CX(\*:NFI3:A?6TAM-<U'3)(UCT@#'E
MM#$V#K9\QL#=O4' ?P>(,YRW)LES#-<RE[.-%.2<)1513E%N$8Q2?-4J3<(P
MC&\G)III1DW^O>"GAGQAXL>*?!?!'!.5QSO.LYS^E>%>E4J</4N'J-2$^(L_
MXC=XJ'#6&H0E4XAG.5.+H\U+F]K5I)_/5W86]KKNM;(KRVM9]2EFLX-0V_;1
MHBWA33=Y0E/.!XG*?*9 Q7*X-0Y()P?;/M^->I?&3Q1;>,OB#XHU:P$]Q:ZA
M?,EHTY/F6]KN<Z:6;)&%4",*.!M8#Y37EGF3IF&6(9SM7OGDY/(Z#ISS[>O'
M@J^(Q-#+,7B8>S3A!>SZ1LK66B=K;*W5OM;ZWB+)\KX:XEXFRG*LSCG>49)Q
M/Q1%<4)**:@Y1C)*+FHPFDIPCS2482@FV[F>+*TD! B(G-SC&>,=2,=/\]B>
M<O4(OLTLQCB@\HD_9V@/!)(P>I/3KGZ"NDK U26&+]S_ (8]_P QZ>OY]V';
M=KMOUU[GQV<8;"X;"WV?=)>G5?/IK;L<\)1&_P"[B)Q_Q\"YYR2>_/''YYK4
MMA-<P3WD4/\ Q[_\?7?()_/IZ\CT[F>6'"8CBP1WM[L\=^F,\\#IZ\5#>+%/
M"(U/S*>/7/\ GUKMNGT[:[_\.?*_5\5AM5KIHMON?3SWWN54\4:K!*9(I3$W
MD?9M@Z%.A7!'7/..,'\:=%?SD_O!^Y)_X^)^3GT4#)Q[=QT[FF#21ME+?N95
MY GX^TY/.W(X(/.>03WSD4RVE\R0<>N6R<6N#@'V';CGU]:JV'=WRO3=]%OO
MK_3T.?ZQFE_]JS.2OKJ^9+OVVLNB?;2[-R:Z@33H8H_WLY8D]3C)Y '4XZ X
MZBN<0E&+9Z^^..W_ -?KFFR_NN)>O7./U_GGI_.EDZS>;#C'3MS_ )[\BML/
MA_Z_K^OU>/Q_UBWDK)?A^B*,49\_S1P,YQ[\?_K_ ,XKM+37KFQ;"96*XMQ^
MX/3:1T(['.3ZUS,.4\Z4G$_KTQD\_P"3^M4F!5HAYI&"1SV'^?\ /2C$4%B7
M9KIM^"U,,!F&*R7_ &K"-I[W3Z)VZ^JNMMCK_P"U)KF3SKJ809/_ "\9/Y<C
M/\\YQ7WC^R;)#+^RC_P5D\N7.?V-_@SP> ?^-DW["Q_$=\BOS@9\GRAT'^<9
MQQUZY],&OT+_ &/YC_PRA_P5CB&?^3,/@P?KC_@I/^PIQC\NU&'P][V_X;M_
M7_#M8C.<5BL*XXO>WXO2W;_(_.&BBBMSYX**** "BBB@#V;PU;Z!=V>N:7?Z
M;K=]XHU2QTZW\(/ITD30+KL]\_GB]428-I>0%C'/ A?(9)##L!/U=\6/!.H?
M"V*U\/>*9+VPUK3?"_A^WCTJW;3X[JSOY; C2].U1]*UMTCA+J0S/N<;<NA*
MG/K?[*GP*O?!OA7Q-XT\;:JG@W6?$?A?4X--DNF-OK&@>'SL<WT4;1JBZOX@
M/R^&$!=9F<,/W84MX_\ %[Q&OB6SQIFF744EM=7T>M:]>Z@;RRU9-5"JHTI5
M9]J@:41@-(V-6"X QC\2QW%$<YXM64Y4_:9;DE:;Q>)YW*%2M4A%J-.HU[/E
MI)RIM4W4J2G>24:/)-_:^/WA]G_AWBOH]97GZITLXXAX5XDXJXGX2I<*^SXE
MX7X7XDXFC0X2J<5<15*M2<.)>*J5+B6I'#/AI\14N&I<-1<(JHI1^9=)U/4M
M!EL=8\FVG-O=BZ^S:E;?;M.O/[)XQK&DYP>#SD >I%?>'[+G[6?@+X?^)+BV
M\=?!/P3K5MK7@[7_  M-J.G0OH<FCMJZ)#H_B6.Q \3:&FL^&M60$:U_PC7_
M  D;)J?/SJE?$4LO]J#^R ?^/<X^TX_X_1S[$?ET]NYX;L-(N;F<7/VC_0",
M7/K[\_\ ZNO->_Q#D^5Y_EF:8+-Z<W&4)1:I5*M.=I_ U*G./,U.S49<R<E9
MVO8_,N-.%>%..<BS;"YW@:M%R7++V=2I3YHZ:2=.I!M)I-7>Z3NM;_H7^U]\
M=]4N/!G@_P"'T?ABS\+>!?$T%EK_ (9^'?@#6/[7\+:%HFEKK&B:4\_B6?3K
MC6]8\8:QK>H:V_BEKE0%W%_#*)%XC2&#\O=&NY/#.JZ=JZ6VE:G"-4\S3WU.
MW_XDU\#(F[^U=+<C=I!W;B 02NXGC(KT/XW?$&W\<>+=&DTG3FTBU\/>%=.\
M/Q6W4F73!NU*1CTW2.93S@XSD9(KS)/$^LV\UC)&WDC3KHW5I#/F]L[8Y)&$
M<YP.-V%)XZYKNX.X<AD'#E+"X?+XQ==2K8CFJ3LZM2563YY3=:<I-."E4G.M
M)N4I5).4I-_)^&_!3X?X2RW"X3+O9K.:E6KQ%3O*]ZM1R;_B5)>U<53]I.=:
MI)N,KUI-\[[GQAX?FTM;W5#';0+=0KKK0VUUIEDMFNKD#22-)4%BIZ@(I;:1
MCID^1KJMPUJEEYDA9)<G!.60'..0,@YY_#IBNCOM:C\0W<$NK03B^^U%;JXL
M9UM!=6!'S#:X9=P/?&1UXY%?1GC;]GF#P+\$/ OQPTSXA?#WQ;8^.)#I#^$=
M(U'4[SQ7X.\21Z?_ &EJ>G^*-*ET"/2/^))I4VGM(Z3R12MK,(C13$2GO?6:
M.4T\NP^:R?\ :.:3482M*4'5DI3C!3C"RYX)R3J\BFHZ7G>"^OIYV^&8Y?EF
M:9FU/-VN'(M*<E*R=J3M%Q5U"3@ZDHQFZ<TI-II_-_B#P]JGA2^^P:W"VFWA
MM++4Q;7$!5BNIJKY( W*%3!'&,*P R#CE[^6.20&//E;L><00<8]!T).01R:
MZ[Q'>&_AAOTO[[46$%C;'^T%VN&'1 6)_M<!AMRH&W@L&517GY)( SQ].G4?
MRKUL&J[PZEB-VES65E=7^%.\DK-=6^E^K]O 8[$XC+?JN)M?2[VM:_1[6^_S
M=F=DNNQ1^'#HBZ7;QM)JHU#4M2QNN[P1J4TS35D!9=*$2_VDS*!OD$N\C8AW
M6O -GI]]XHT:UU.WU"^TZZN8[2[M=+U#3+'4+M'("V.FOJX,8=BT<8+-\Q?
MP0I/"9W,,]R!CVJTX: QR1^F.>X[=S^8]?P-2I)T6E9<[DM7ULN_33OII\L7
M@D\/F"P[WT;>KULKN_:R6CTM96/M_3KWQM'X:O/$L6F^*GMI]6DT;3/*MWL[
MZ+1C(HU>^&FJ&42LK:3HA=R8OE,9?>0M?HY^Q1JUW\-?A?X@\>Z7\8/AE8>)
MOC#\1G^#GB[X?^+M'TSQ+XPT+P)_9]KK8^(6BZ>NO>&=LJ:L'T.,(8_#K/'L
M\P8&W\0_"GB35?"FNVU_<F]O-/2]M8-<TL73#^T;:(I(UADX#;HE(C+8 X;
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MVN]?=2TNY2:LE?OJW9)-O3RCS?G$4OY8/'O[_G[X[B(>0",R9FSTP?Q[=?\
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M'>OIC61HGB#P5X<U0W$=AKFJZ:ECJTDUP+.VMY].$=@K#'#9VJX4D?.1G !
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MY=FL<7X+\=/*8<9\,<RX5_U:A"/#?$\N5N]6G[T=5R2YE*TTJD.)G3=G[/\
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M^"3P^%(_:Y_9%FU?SH_B[%_P41_8)C\&37/VXV4OA2;XZZ4GCU6^QI_8BO\
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M1I[=-GKIU:;[6^15BU[RKCSO]3U[$?K_ )YKTKP?XW6VE6(3$'D0?OP!G.
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M[=.?UZUSG[GS._3_ #[9_3;6K:Q32R>3_H_Y_3K_ /JZ]:RQ/Z_Y'K9?B/\
MF$*:&><G=$8B>YZG\.OOCCWQS7J/@;4;>6V?0;Z1!:3723W$ZVRWE[;,GWSI
MY+K]]?O , PZG!->9W6H0M;7-O%B64$@SC/^D^F0?7ZYS[U+X,CO+O49+6'S
MYC+;+;\DYMCNR..1@$8ZCC/K6&84/K.6MUVX.#;5KZ6>B3?:Z:Z_>>QPCFRR
M?C#*_J?_  M_VS[KC_B3BX65EK9)NVBU37Q'N_A'P_XHTFXN=$MKO2H-'U";
M,=C/J*"RU34"XT\N^GC5@=,;#MB5GDV)E _E*HKO?&&B_P!A>"=1EN;:*"^U
M:2T744LSDDF_5OWBZE('&!AAEQM8#=\NX54\._#CPY:BXO-2N-2U#4Y)MTLI
MN!;6;'(X+*J*.F6?"@ D\XK.\2P7<FEZI9F6]NK<75C<V[W%TUY=!L83+A3E
MUR693M'W1W./S?$9E3Q^;4^2LY.G.BZK]@Z2J/634&ZSO:3NKJZ:]V%]%_:6
M3\+8KA+PXS3!XS*GS9WPKQ1'A?\ XRB/%#X7YXRE9)<,04&[NWLZDN5\T;2<
MN9?.-R";< >O_LHK]*_^"?7BG_A"O@Y_P4M\9>7/(-#_ &2/@W):&$_+=:@W
M_!0O]C2$#IG"B3' Z#@$FOS5G\N&.XB?((&21U&2 3GC!S^'%?=W[(PDA_92
M_P""HM^D/D%_V1/@XGGCU3_@I%^PO(>3_LJ_&.W3%?I*H8?,,++"XEV3BX76
MNC3DU;;11NM_Q/XMIYMF7#V>Y7Q!D+2S?(Y4^*KO[,N%:E.4&]'_ ,O%3:NM
M=%U1X)\4/C#J_CKQ%/K'CR)[F^206\%K]K(#6NF (#_:8W=DVI@$GDY&X*O"
M:G\8?%5UIMGH.AS1>%/#,%G>6H\.^'M^GV=W'?7Y=EU<LJZMKFII"!'_ &QX
MBN?$,YV01Q%(E(KR#4KLW-QEMQYY'L/UY]R>2!DU&MJ7"E5FQ@?*G '7@C@_
M7H1CH:Y\OR++<!A,!A5E\*<(+W*=FZ>MH_NX3E)72O[SN[R;OJV_D.-\SS_Q
M-XHS/BKC[,Y<:9U*3E.<K-2E=OFMRV;VU>NEU)+0O)JEZ(C&MY<20L"9UGG)
M#=^@Z#MGKZC/7ZV^!NO7,-SIGBKP?:0S>+O FH^']>AM?$&G:5K>@M>Z20YU
M'5])UH,NLAF W*5*X."O<?']GI=Q?7\%G'YGS'G;UX_D.E?4'POU8_#CQ4WA
M1=,LKJ7Q1<^'])\1W5QI3G6]*T+6-F5TAW.$=X]4TQ\GPVS.Z*BQJN*X^*,/
M0Q.6SP^%UJJ/M(IJ*IM*_.JB2BO9R@Y1M>+DY))KG/SKBRAESPO]EXG+=5=M
MJZLDFG9JVFK3N_>YFKI2L[GQ0^/7Q2U.X\=Z/XWU675YO&FH#4O$\^H6]AJ%
M]K]\9](UD:JVKMYDA)DT]6)4MNWDX))"_+L6O3QM@=2>WK^O]>>V>GK/QD\/
MW6@>-/%&AV>I:9JFF6.ID6MU;W'R7M@"PTG4P1SRA7)[9((P0:\,>W:&4&3
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MQ5Q-7M4DYKAQ59>UCPQPSS.37"M.+?\ JQ'GORRE)\M1LHVMU-:R^=#-B?\
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M_=YH+AF=YM1M+F]W>TI-0DO._BK&\)TS3XV*+I4=];P1F$!@7U&=GR&!W%F
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MNE-I&E::M_N).AVND"Q@_L1#L6* %!"58-X7MX<]X^_KWY]NW\L9Q7JOPO\
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M? O]JWQ/\ _!GCOPGX5\,^#[G5?&=SIFHV'C76-%%YXY\!ZUHUSYVF:_\/\
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MED.]2'Z$$$-C%>E^ +BQ\.7T.LWL2:C;M;7L-_;3VE]=:A!/\YTQF*0AO,(
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MVEZIH;:3K+C6F+!UUK8T>54GRS5]&>2$WT>IP7$\3M T4RM:WZ@C=IC!>I4
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MM[-+&(V/ [Y.?_K54II-N[T\O+7_ #^8TFW=Z>7EK_G\S[H_X)C,P_X*2_\
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MFV4DX)[\\$ 9Y/6DO6N+P,]SB8)<9/)&<8SCW)Y^OKQ6WHDL.IN]M*/]%D)
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M5^]+)^)_]9;M)MWDI_"ERW<H)M6:=N6UFT?(NJW\MS<B:7J6YR.@QG []?\
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M2NZM_P!FY_ G_P!-6LU_-@O4?4?SKX7,/^1AF/\ U]G^5,\ZK\;'O&T9PX_
M'K],C\ZCHHKS3(**** "BBB@ HHHH ZS0/,N=<TI$FAM9Y=5LV2XF;%O;D,&
M1G9MW *J3ZD'D$[J_4KXU?!%E\"I9Z[JUK-XK\.ZBMJ0;?4]8O$T+2?$+^$)
M]635#I!UM/!GA_6HS'#&=!B$[ZN4QX@'AU5U_P#)^TG^SW\,[JR ,,"(@'/;
MIP?PYYYZU]P>"M)N?%GA[P?=^,_&UAIOPSUCQ%_PAEKJ'B-=5US4/!4>G7VC
MW&L:KI6E1R*/[$C35-(/B+6(H&>033%?"[,D<<GP?&6&Q=3&\-YIA,R_LO\
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MF'^M$=%./$_#%23X6OM=M5&DXWLVHV6NGQ+^U3\+$T3PUX8\1QQ-$+-VT^^
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MYQD<6N224N=W23Y9-W<':5XQ;?>]B/P-X]L[!K?2$2.1EM2E]>3REF)8DJH
MP%!<Y).23C/-=WJGC758K.UT:Q#(^GW=]=7MQ;Y/]J6A==I49VY^4@9R&W L
M,CCQO2O .NS:A-J%JOFVHU6R@Q9P+=ALMPJX#%VP2-N1D].,U]E2:/H/A'3I
M]=\0-:3WMKH7APVVF6<_V:T%UI@BT:^L-4Y $NKZ3$TKRQN-S,PW88K7CY^L
MDPV94Y0C&O5K.RH15Y>VT37*X[R]O*R2:?*FGS*Z_2?"'!>*/$?"V;8/%YC+
M@K)\C2OQ.TH0CPNTW)IR:<HM<+-OEE.<M4VN>RH_"/X5:E?Z?JWB*[\5Z++X
M=%Y]@U^WAN=4:;3YGT_5=4*:GIK:,S/HIT;3&/F'Q([%8V+0@%BG3_"3]C+X
M>_$J3XS^*?%WQSA^%VF_#NZT*?2M#L_A_J&JZ_X]TWQ7ILNJPZCH&GZ3KWAI
MT@&D!9_#$21>((Y5E1V8*%?7?G?01KOBOQ7I^B^"O&LFC:SXGM]3CTB2&_U<
MZ;=E3'(=,F.A91B?[.VMKC:"V@1_+YCQQ>47]R^$'PIG\3^%?'?B[X=/H_C'
MXR:;8ZK+K?PR\--XSTFQTSPKINCZ;IVI>(SXET_Q#Y>L>9)J3>'_  [H<:3?
MV^DNOR,CO-;QW'EYV\]RG!YMBEQK/(IYQ3X:Y'2X<ITWAX.O&&(^L+B&G_JY
M3C*G&KAGQ'7<(4G4I2Y(3C&E6_Q*^E1E^9<*>)GB5F_#?'?^H^3YQ/A?_5Z=
M.'#W%+I48/A7FJU:O$L^)J48\34I2I1XGXEY%34E4?M*JIQ?":OX$^ FAZUI
MVG?!?P_\7_$6M0RZ@EY>^/H?#SWM[E@=*U+2?"?A+<^B,N?WBZ[XI\4QY.06
M X['XCZ[JUM8Z5K,OBS6/ASK.C)'X>/AK^TI!J&IZ$NE/IFL:II$Q1"/!NOC
M3M+/AK<74^(]7\0;2419&[C1/@QXI^&4WA^3QOX9UZZL-6UQ9M1MO#]JPOK:
M(G^RM4\,QZII@']L:RXU35-!&0F2Z@+A]M?'G[3E]KFJ:AI4WB.S>TU*(7<%
MKHXODN%6U@O1IMQJ,NC2+<:MI2ZU/IKF3SHM"23Q -:W1_O&B%Y'5PW$N?X&
MC1S+^UJ=.,E'B*56.*47)2C/V:J0473DXRYZBIQ<%*G/F?/"3_%N%YPX[XHP
M%##9H\]A%6?$RG3XD?O74HTX<LH2A4Y91J35-3IWA-.7/&3YB_\ B#>^(O%F
MMW^H->W,FJ7-C+%>7VM:9?6&EA3JP^P!](TG0M".ER^9(S'P]##;P^4@A60[
MHD[WPO:-K%BXC\N]7(N9D@ ^Z3SN..#S@9'J/I\V:-''INFB2YMI+2XO+QBD
MLZE2BEN#@@$8&">>,]<&O7?@QXAN/#?CS05ED,FD:O>6-A?":8;8#J3!9$8C
M!&$W,'(XVG.,8/WF?Y2XY=4EE453ED\$XQ44HS]BK\D;**CRJ,HJT;-Q:UYN
M9_Z^_1US+*.$)\#\+<0R;R7.9JGSQBU_JQ'B><:<)<G+K"7-%RT5HR;NXJ3/
MN?PIX%EO]&TR&:%IIC+:S7(N,C[4&)\Q>O<D[NY'T%?GE\>O!4WPX^(6N:9;
M1,(;N_35M-'8VD4JR1\D'Y2JJ#UQS7[6:2;..YN;.VC/F6L*M-(.N&#?Z!CC
ME=J@]R6 . !7R7^UQ\*U\66FD^*K*Q"WFDPFVU&^6Y+?:;($;"5X7: 0,J22
M!@C@U_/_ (;<?UL-QB\'F"<,ISJ-1I6?\5+VM)M6TAO%V7VD]C_8_P"FS]$+
M*^)/HV+-N"8_VUQCP)4I5(R3MS\-4T^&^)XPC:\I4XQ55R3:4HRM=IL_-3P_
MXCNDTBXLD6/%Q";:< $K<J<9!]<X!.W&"!]:Y+Q!8W-@Y@E(D>WD4\YP<8.!
MSV'ZCOFKUGI\]GK8TV0&-X+@VQ4]N>A_$'/)X(JUXL!CO9+7M"N[MT/7\?\
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M=^#/#UKI-M':V&N^-M7UF%;_ ,7MX\U+3)#JNG+XG1ED_L:/3Y3H*Z&N@^'
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M"DY4W[-\J4G3A=N[7-HY0Y6I.+OR\Q^7T'CS6]52::YO)X;?RB?*MV8 WVT
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M]!^OOCTK@_-/O_WT?\*_5,N_Y%65?+\V>+#X8_X5^2/P<_X*)_\ !?O]G?\
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MZF_XB^OV+?\ HU?]I_\ \&GPJ_\ E]7^?/E_0?Y_&C+^@_S^-/\ U@S+^?\
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M/]!C_B+]_8M_Z-3_ &G_ /P;_"K_ .7M0_\ $7W^Q?\ ]&L_M/\ _@V^%/\
M\OZ_S[<OZ#_/XT9?T'^?QH_U@S+^?\&+ZS6_G/\ 02_XB^_V+_\ HUG]I_\
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M\'6_[)=U:1WI_93_ &G$@D8J7EU7X6,A(X.&;75SSQT[=:NR_P#!U=^QY%%
MP_9R_:+N)1U@_M+X6[1^/]NXY[<\'IWK^#8LT9B1OW@A@\C_ %V0#DG*G' &
M[@?=Z')JI<ZA<!(8B#Z0 <'D\X]!TY..Q/H?/7'W%4G:.9M[V36MM7VZ+=^3
MZ'UB\..!<-A$L9E:<DDI/9-VC>R6BNV[)-I.R/[Q/^(L#]C\)YA_9B_:0!!Z
M?V[\*@!_Y7L].<=/Y5?T_P#X.J_V0=0#1+^S/^TE#,F/LYN=2^%A%UGIN(UW
M@G&!GGTK^#*VM6N%.!R2">?USQ@9]?PKJ]-T^YL@DDBF.&/B><CA<G\,D]
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MN5/V/[/"@F2,Q>9$,@PY(8#ZGG'3CV.:B&FW5ZT4<49%R&X,'+'('  Z_@>
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M'_!/T=O^&V?V5/\ U?/@05Y9INEVNH?$#Q"ESYL$"^*=>/[B$7A4'59?NJS
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MK1RY-M$MOE6;N<D$'+'N,9S]*_8>$J$<LRODPE1U6FVY:KWGNU]IW>M[)/\
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M,HMO632<7;HW%)M62R]8N/.$P$GE+(#C 6\"@X;K\HYXXY/Y@CR6-YHM0N;
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MX1<7OV>>:;-VP#(&W<!5*MC!QACD@]SO?$'7H[%(M' M[E-XNEE4EB,@YPS
M<8SG('4 >_C+,,9E^:U,HCEV^KN[75KW?YN[;=]$[,_1<1P=PQQ9X=97XA8O
MBEIQ?2,?M)+V?*N5QN]II-VB[VU1QFDF*]TJZC21XM0MIV:&40*+2X"C);G
M#JV,C:<@\CO7T/\ LVWDEU^RO_P4^MY)3(?^&5_@\KGR,G#?\%#_ -BU2<X
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MCBOZ*?B)I$OQ0L+'PQKFD#1? 4]M]KM=:T[4M*%\?$.?^@OK1&/^0L,C.?\
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M:(9K<8LQTR,$<#H0#SQM/%?75J^78S+?J_2E&.J=N5:)76S]ZUT];7=GK;\
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M7CSX[^$M.N_',KZM?>!BND1ZI)IXDNX[+5&+10ZSJYY:-6RGAU)&8K^\C3!
M!^3I4.]@.,.L?TXR?QYSSZC.15<"T,\RSAG*LIS^4'FV34_8U*D+N$_9-*,X
MW2E9P]G+76T;::);^&N7\299P3E&4<43A4SG(Z?^KU>=-R=.<J+DXR@Y)2Y9
M4G3T:O%WA]D^X?\ @FY'O_X*'_L#2_W?VT/V5&P>H,WQZ\&,WX888[?G7VYX
ME\8SW%^_V2^L3-?>(=5A>U>X170C57<7\@QC2T=VX+,CH%8JVP$CXD_X)LLR
M_P#!1+]@B#@C_AM#]ED'Z6WQX\&C.<>H7TYZ<BONW2_ *;X_$JZ+;Z+>6M_J
MTFKZ.+@M90$:D08%W$';&[O P4E3M#* ,K7Y_P"-BRZAEO"^*QBYI^TXA5&*
MV>E-)-<RNK/56:=_>5K'^Q/[,'"<9YGGWC#E7"5U"IPUPM/B*2;C*%*GQ)GJ
ME.#2<6U&4U*,FE*#DDI6LL?Q*)%^Q&Y>'!MD++ >;<Y;KG(9@,$X).:\IU"Z
MMH]UU=CRH_GGMYR#BY(P!8*>Y!! 4C(YYY%0^/M1U#0YGU75-2B6RD?.H64<
MBV=]!O;+#3K#.U@@(V8.Q<8;&W->/Z9X_P! U+4[ZROY+B&WNY?(L3<7/V2T
MM/[0D#*=1X90BQG,G(!V[F)7I^8</\.XN6%6+A^]A9.]%/W5O):K>+26BU]U
MVL]/[A\5_&3(,-Q1+A[%N.1YPZCBH\3S@U91M"4YPO93Y%NDX2?)LG>S\1/'
M%MX5T,R19O\ 5Y3B,0DBUM\GL%R J]U!&0"3DGGB/AC\0;KQ'']CU4QG4FS;
MV3K!Q/EMJ,K *QW'^++$$XR:YGQ!HM]KUK;6MW%-<3V]S=1(EI &\A6;.#?E
M3O)X8^9@ =B37MWA?X>V&B^%H4,=DVMZ<UW/:3HC&ZN+L% +&0J>%5@'PPX^
M8!R&Y_0:^'R#+,@>$Q2C+-*M5N-9<JDG%V5FI-0H^\E+F2C9.S:@F?QID^9>
M+/'_ (L/-\G?]B<'9#PNG+AB3<H2CRISB[*\^*&G-TWS22FHP<;/EETLH%PA
MM3*Q2VRT"M   1R,,3@DG'3.3U]:Y_47C:U:\RP5"MM-)YV2S9S@#^'"C< 5
M(8#TX,9\>)J^GPZ0VFM%=Z5.(+JY@MR'!)R4<C + @D#//KGDXEUJ4NM@?95
MM[:UMFS<F>7;<LPZ+DX!&>OR@GZU\YA\NQ.'E_M,?9I6;NUI?75\M[U;*VFK
M:UU/V;B#BG(<RP:>4YI_;;G%-)1<&Y;N+C/2/^J[3C+5OE6E[7.)U6(I+)=2
M!$N_M'[F6W&+3[( 00H Z!L8ZD G=\W%>:_$WQ9J#W<6D6&I%K=8;:,7%OOL
MEO$500[*""Q7)&9,GC)YXKW2VB:[M7CA8_9CN@,+#F GGO@9/)R,@X/3%>?^
M)_A=9:UYMY8WL=JD/[T)>3@39SC:@1<L?PY!^]BOO<BS'+Z&8Q_M2_[MM)[[
MZI/1JU]4MKWMO8_E?Q/X.XPS'A#,<-P8Y..<N$ZT(U>1U(4VY2BI/EBU*[3F
M^5VA&,VE='S3;WLMJERTB^:\[CS2P;') R022>!ZUZ]X2^'-U?/:ZKJQ+:?]
MG^T6T$4R@3KG&$.6P6/#$\@ @ &N+MO!.L7Q::-2]J[*7D\P,/E/(^]WZ'@?
MJ<_3>@6D>FPV^CVTGVNV@86XN5M]NXDX; YR1R1GG'3BOJ>)LX6&PM\L<5*;
MM+W4W&+C%-[64M'&T6[125U=H_!/!'PP6>9[?C7*ZJRC)HJ7#O-'DA.LZC:5
MHI^TI_#*3;LI):<HV^\#:'8F-M/#$) -WGD$PN#U&WKC.>AP3STJN=,N4+/#
M)Y,L!PUQ%.%M+C!]>@;&.A(/<*:Z&7SMT/VB-K6UR!.1.3TSV;G\"IQQTKE[
MW4XX7B\B2<B0^1#,WRD\@$<=!R!@' _'G\[HXC&XEWE/VDO7F2WTOS.][-M7
M>^Y_8.<9=POEE_JN6+(XV34(KV;TY4K+1Z>ZDW9)OE^%6/)-8\80VVJ*MPCM
M<27'G74\(&,.1U!^56+9V\XSZC./0$FM6MENH)3+"8?ESQN&,DX[<\_AGC(-
M<A<?#&XUS5)=0N=8C$$L^)G\J^NKE@#NW%?+!8].6E!//49KK=1MD6VM+6WM
MOLY1AF7<3DYP< 9''KC(]J^JQ[RRV7+!R]YJ]575N5)6NI6UNK*VBM:Q^$<*
MX?CK"XOB?%\094H93=/AI2BN>;3E!23A>ZE&SYI)-WMHM20332)#\T_[T9N
MX&+89Q@$#+<9.<^G/<8VI:?I\T1-W%GS?]&\\@YM\'.T'MD'G/.!WP<Q(VM"
M62SFB,TL1:<&"XR,*!NP>01@]>O7G-9_]OZ2OF_:+AAY<P,N#UR<!L @GN,=
M\].2*QP^%Q,9?[-KLVZ+6S>EG;1[;J^EFK[]V/SC*L3A'@\UE%-WC_QD_+'6
M/QI)OIJY:WBFVK6C;M? 7ANU@M(UMW+(9V6![T"U,Y^4"Q'SE3M/^T!\QQ@X
MPSQA! NHB2.6#'DC @!V6X .5]\<DD<<\<Y%>6:]XNN]-U$6NFRO':Z?O-C(
M<"[\L,&7E3DMG+<<+[9K=M]4OO%%O%=7<OE216RVZ^3  ;@#/#8PI/S8))Z
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MKWB'4_$5W-+/<2B-97,43LQ8L2<;5)PN.![\=,<TK.W%[)'IL*P^?)<!%GF
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M<W!=:@\4?G$&7)N=QGQ>D<>I8]?F'&[^532W4QF&V7$.?M'[\'_1\G.#V)'
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M_#J_^'>N:EJKZ%I6ZYU*[G\.>)+0WU\R_P!F:/HNX$CYE+:JP!Z$@X.00/Y
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MJ7+E$95TN6*C*-25Z4%?6K"-+9TW5FHS32^TG^2_[1<6L6O_  4C_P""5EG
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MV-LQ)@AC+,#D8Y+-EO=FQC..E58[^_OB/.!DCAF\^""]A:Y5L\'(((*D?>&
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M5XQE4BG-1FI\,:.,THVBO;8=0F\/^*KKQ&B_VM:ZO-=P1+<W.H$6<IR"Z8)
M/.W:Y(/\0!SGU6\T_2IY+7Q+-!%;WMQ,MA'91VQ-K/;_ &$[V)R=SMGYLY9]
M^\$$BO-?A)\3_"_B+1=0T;Q'I+3WVGVRW)N+>UM%LU7,>FB]R%$>TRE1E!AI
M3N#8^8>M:W+97XM+JV6X@-I9I]F@.;+[-G+8TX%N%./E(QN)88)P:_.<YEB\
M)FD<+B\NJTJT83H2K0:Y:]%V]@KQ4)6M?1NS5I27,VC^TO"Z/"^=<"/B'(.*
M.%<]RG.Y1XG7"S353A;BB524N*%.4X*7NU.9PBI.*O>SC\55M>NK8"&RE)BB
MF)MX?*W9+$Y/RCKQSDG).<$YSS?BJ[&KHAU1/ML,+>?<6ANF5;DGCAUR1QP2
M,L >,#)KJ(H18&%9UW8/_'O"#C)_BQGGZG\:J:W'Y\L-W8P>28$\H><,#<4(
M]CT)XYQ@ ]Z\#"RH8;%0E%6:=_;)\LFWUNM5;H]TWH^WZ9Q#ALUS+A_-,%BL
MS4E-14N%VDURR4O>4'>+4?=]V7NM*UK7/B[6-$\0WEM?ZO<V+_V%!J*VWG_:
M6 @8AB=/"]3E<#.. I P!BNQ\"W>H:1837#O:-I9O1F"0-;-; Y(;3]K#@DX
M8X^4 ?*?O5VD_AO4+:-Q>Q75SIGVBZEU&VL]5C5+BTCO%&TV2QLZDLK-DL<?
M+(%4+D>5>+]4OO"%W/;Z?J%MJ%K<6L9NX19V1L+:^D&6L%\W>I;1R<"1!Y32
M*H4*H.?V6AB(YWAUEF'5*SLFDERNR4;*STJNR>MFVKV;T/\ -/,,I?A=FL>-
M<9_K/!^^M9)U'.5VFE[JEPQI%.G^\FG:_(O9R?K6F:^-7OAI-MM74+UPMN9V
M%M<;B<X)!"@GGG//KDG/K?ASX1KK$,E[K5Q>O ;<&W:T+JH!_O9 (4#L ,Y.
M2HKX@\-^+;]M?M+ZYWO<1W.Z26\.]IQT RY/!&222>3C(YKZA^(7QN34-"TF
MUTQ;G3X]/@2W^S:7J!MI-1O$!SJ2,58HARH+*N<JH4KGCYK/LBSS#8K+L%E$
MHTH5(VJU7!5/9*[DN7X;IZ-JZ;6\K+3]S\(O&'PHSCA?BKBSQ.C_ &Y/($EP
MSPLVJ7^LSENYIR=-RI+FG*+5Y>ZH-WT^C_ =SI?PZT);G4X+2T"2,T=[9J,\
MY.+V_P!,.6*@998]KA<D 9%?!'QA\8V6N>)]1FT>28PBX*FXFG6[)R>,LGWS
MW[ #CKT]W\*_%CPSX@\/:]#XAN6M9)O#NH0:7YEL2+F^:PP%R,A-X#!6)Y++
MSD@'X]U*.RFOY$LHVXE8I$XPV"2<XZX!.,'G//O1P1P[4PF>9MFV;0KK-7?W
MFOW+46^6*=E9WU23DM->5KE:^E+XT83B+PR\,>!O#S,^%GP?R2J1C&,8\3TY
M1]V=/W.7WJDI>T5X*4HZJZ?,^9^S-L,F9?WLQ@R,'(P"0?4\C\*FV32 )Q')
M"S7&1P<CG.#DY P0/P/:G2GR)C&$.5&)@?7.2.G3\?IBK,EQ'&TT@E\\DX'^
M?0=\=O>OUV[_ *^[\C_.U8?"ZW:5OBW2>C;:>[W3NMFFK,DLKEXM0+)]YG9F
M(Z#YP 2?;CO]>E?JQ\%]+O[[]C3_ (*$C[-,TE]^S3\&P&P<$#]N;]DLXYY.
M3Q[DCG%?D_97!@U!Y"N)&.47'(P^!ST'0?3GTX_5K]FOQG>S?LJ?\%!O#4R?
MNK']E_X4ZMY@@.Y=G[<W[),6&; (S_:^[UP3@X ->;FL<6LSRK$X2%O91JJ3
M36O_ !C\XKK_ '>7_"V[WV_7_"W$9'B>%^/<GS;,FHYW",8)6M=<30;MK\7*
MFDG:*:LW=H_.O2/"5CI CO96&H7Q);R(L?9+<#@;V4?,3S\B@(.?QO76KW<;
M$*)DE$&1Y,XR<9'()SCGD<< >^(7E99/+0F7!(^T&8M]HR?O8/"]L<Y^M/ND
MM$DY^;)..@/OT^O'?G'3IXK<L3BD\6^;HM;V2Z+=6_J]]_IL+A<)EN5O!\._
M\(D=.:[UE)JSDY:2E+N^9*VR2L7=/U74+2;[:!'/<$[FFFB^V" C&&8%77*X
M&TD-M [9&/4O!DKWU]I-JL48M9VGMKUILA;FZ_M!]V2.1A/(5><C YP37E%A
M-#<,=AEC\@DB&;;<X/TPJ>HQMX.>N.>Z\.SR:5:?:X8&E7S]OD;6+*-N?MH
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M  NGYKO<[N&<0L-Q/E6*3DFIQ;<;MM\T6UKTEHGV5]--?K)M!U!F)&GN0?\
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M[L[C"Z\S>03/DX_BR./7 'X]:\997[?,'B<7)M-<L8)OE2LI7WTO):J*3O\
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M\]_^";?[!#39_P!8?V/_ -GO=T'.?^%>=??K1_PZ=_X)9?\ 2-/]@#_Q#?\
M9U_^=S6&':H;7?X_+I_6RL*A1]BFKMWMOY7_ ,_\K(_Q"R3'YL9[\?D>OY>W
MX^L5?[?/_#IW_@EE_P!(T_V /_$-_P!G7_YW-+_PZ?\ ^"6?_2-3]@'_ ,0W
M_9U_^=S6YN?XBD<A@:.6(XE4D^P[#\_:I9[^ZN$$4LI,8.0O;\<?G_3M7^W-
M_P .G_\ @EG_ -(U/V ?_$-_V=?_ )W-'_#I_P#X)9_](U/V ?\ Q#?]G7_Y
MW-!'(KW>KUU:OUNK:VTZ'^(+5J.4!#YF2,\>I_3![Y]OI7^W?_PZ=_X)9?\
M2-/]@#_Q#?\ 9U_^=S1_PZ=_X)9?](T_V /_ !#?]G7_ .=S06?X@U%?[?/_
M  Z=_P""67_2-/\ 8 _\0W_9U_\ G<T?\.G?^"67_2-/]@#_ ,0W_9U_^=S0
M!_B#45_M\_\ #IW_ ()9?](T_P!@#_Q#?]G7_P"=S1_PZ=_X)9?](T_V /\
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M^P1^QC:8('^C?LP_!2 XP#R8O!*$\G/-"?\ !-W_ ()Y7@S=_L*?L?7)R?\
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MCJX0]4D_9J^#;+QC^'_A#<?I6=/_ ,$PO^";"IE?^"??[$X/J/V6?@?ZJ/\
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I/7_L0:*YO]5,/WH?^$\'^/4^E?TF,8VW]6XIU;?_ "4RZN__ #X/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>tm229830d4_1012b-img20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm229830d4_1012b-img20.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #> <(# 2(  A$! Q$!_\0
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M"\#HBH 3N(''7C\:+6=@W/4O^&E;#_H6[G_P*7_XFC_AI2Q_Z%NX_P# I?\
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M316M_P (OX@_Z 6I_P#@))_A1_PB_B#_ * 6I_\ @))_A0!DT5K?\(OX@_Z
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M8T^Z67<($<$!PO(8<_A64GB.7PDGBSPY*@NYKB5X8[D-Q&P)5V'^\O%6M/\
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MT..?QKG?^$S^*'V,V_V._P!Q39Y_]FGSL?[^W.:YU8/& T.XT?\ LC4C9SW
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M.WP*QE6Y310N;?\ PLOXE_\ 0H:7_P"!2_\ QRC_ (67\2Q_S*&E_P#@4O\
M\<K+6 '_ /508/:N&>8\KM8U5'S-/_A9GQ*_Z%'2O_ M?_CE!^)OQ) R?"6D
M@>]VO_QRL9H>::8,]J%F/]T/8>9IM\6_'RDAO#FA@CL;]/\ X[2?\+=\>_\
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M]O\ K^O?_2J6M85%,B4;&_1116A)\W?'Z+/Q&L)/32D'_D66O,.U>J?'T?\
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MW.:&PLVYUVAAG Z9J1S$L.5/[P8P,?G2.C"-96.Y5/0GUK!^Z6F$(+3GRW*
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M&_()(]ZU$8R0LJK\_:IG'ET1JXK=EV-(=T@>1F&/E*]S2+%'Y<BNC>:3D5!
MLZQ^<N"4QD]@:M.UQ$J79==TA/3M6<HVZD,BFA$T:KL^9<[L^E."!0&V_*%
M^E/=9(Y=JL#Y@Z_6I#%+O>UW#<WRDTG/05A'DA=P5R%VX/N:CEB0W(\F3 V]
M:88I4$D"@%]XY],5)Y\:6_E[/WN>M/;X0)XE:TF:*)@Q(QGZTJGR/,CD4ER"
M!4.Z-;=9 _[TL<BI2SQA;IV#;STK.4[@TQJJACD:1L,HX%(YEFAWGE(Z&<//
MYDB[48U&JF>X>*)MJ,>,]*C63&D#.KB/:NW P33Y4$$@*.&.,YI4?_1C;[ 2
M#]ZK+6,9@C97RS=0.U:>QDH\S*<TM"M!)#YK?:0<D<8JQ%:/-$65@%4]":5+
M,1W49G7=G!Y]*NB)%8E.%)Z5O*A'E3CN92JHI2L(H0/+Y'5J;N";'5E=CSCT
MK2 S&5XVGKD55-K$LNY2 ?05DL/-WN2JL64Q-=27NY5\L>@Z5H,I'S.>?6@R
MI&2 H)JO)-)*/E''I7H0P:JM65K&,\0N@_[0N<+UJ-S([#%2) 7 ^4 U<CA"
MC#=:]>AA*5)WZG'.LY$-O'CDYKSO4FV_%WQ:?^H+;_\ MK7J C"]#FO*]9;;
M\5_%Y]-%MOYVE>Q0=[G'4V%60$]:L&4+'63!+D]:GEF(;9[9S71#>QQ%I)"S
MU9ZH<"J%J2[BM>&+*BLJO5'H8&24B@$.X\5.L56S;_-TI_E8KXW%WA4:/O,/
M47(B*&(L?04Z2(KRHR,U9B 5AD<5/=+@HL:\=:FCRR6J]/\ @C=9J2,[RB\K
M2/T5:4DI8)'$GS._]:O1VS"VNI3R@(&:9LVW-LBC"XR37?'#QY5-.X>U3=ET
M'&%GU)%<Y6)/N@^U5XO*6&[N%)+',?(ZX.<5,L@\^]N,YR-OT_SBHF#IIL.R
M,J93O QT]Z]"$'\-UT.=.VG]=QD@E%G!$D(5Y,29'(YXI)X':\2*6X4(A W#
MCBK,\,CWT<;/L2/.2IZCM598X':9YV\TXV_0\5JJ;7_#?BAQGI_74@CAC\QF
MFF+ *0IZ<]JK(+<12>9(=Y& 3ZU9,L0L3$4?#'<I8=AZ&HYE*QQ1&V9>=Z@]
M\UC4BVVO\NG]:G1"16_T?[*RN#YCGY7-+OA-J(&CVR,=P;')J><2>;';M"!(
MG3TYJ"5[B:?!B'FQ\ UC4CI=>N_]:&Z=]1TK0K L)B*2J<Y[M4,ODNJ,JE77
MJ.YJ599[J7S6AS*G!/L*7S"7\]8O][-<LH-Z6_'KV*CMKN0M!&<21L5!X8=Z
M@FM%B4!9P8WY'-:44I@F,XBW1M]XGM5::VB:38P(1N5:AP:CYE1F^:S**V\I
MF5!@N.AKHM)B+L6=</TSBLJ&TS-]XB1>03W%=1IMN5C7=U/.:RC'FE8\[-:R
MA2Y5U'& D8J[' @CV9"G%/:$@\#-)=((83(#R!7H\DK:'RLI;'*-I#+K!=FW
MACP2:]?\(\:')_V$+[_TJEKS:T7S6,C')SQ[5Z5X2_Y DO\ V$+[_P!*I:]'
M!SE*4D_(QQ;TBC<HHHKO.(\=^*?_ ".=F?\ IQ3_ -#DK)MP6AXK5^*Q \8V
M?_7BG_H<E8UE*"B@UP9BE4IJ/8Z*&@DD6"?7UJ)HU*!1R>]:9B5QGBFK D;_
M "$9([U\O4I\IZM*LD58 R_(BX]\5IQ"Z11.GR1C@L!555E9SL;:!UQ4ZF)$
M_>S$+GIU!/I7/\32.GF31+'9J+I?,N=R/\QVG(%2PQ0^=+YDC% "$QWIB30M
M RQQL7&,/G@>U+)++=(HC@VB-26([USSYF[ G<FB2#[,[NY\T ;14)F1$CDC
MES*S'</2ECNXYKI)&@VQJH& >M-#6\,S3RQGR23C'K247S:CMW9:4M L=QN!
M9R>#2I"8)A/*FXR GFJ]EY%Q(#(^Q<$C-:$ >[7*D%8P<9]!5^RT;>W4SDU$
MI+%&I8SJ1\I8 4D%N)+9Y7D^[]U?6KEPQN&5F4 !<<5'Y,8;YFVQL>1Z44J:
MG%W=F)UDD1M))=*D93"IQQ5FXMH@JF+*X R:@EF2*9TA;Y,\&FBY)^4G(INE
MS)<O0S=:_P )):,8791@Y&.:M>>(E5<9(JBTHP#TQS3/-).[/%;\O,[O8RE-
MO5F@LR,2226 QUI\<SK(#NVBL>!]S2L"3AL5;23D$YS7?&*AHT8MLU%<R99V
MSBH"X!P!SZU 9F;GD4TN0>*B6^NB$!!9]PS4T:X(QP:KM<K%]\X%/BO5=,B,
M^QKJC)1BFB&[E]20,G(/I3_/(/(JBMRQ89YIWG,>-OXUJI7,VK%PW2@X[UY?
MK9W?%'Q>WKHEM_.TKT8;5&XC)KS?63GXG>+CZZ);?SM*]3!R3;1SU5H9]N^V
MK6=V*H0\5>0YQ79LSA+=H-L@K>MUW8K!C^4@UM6,NX 5A7ON;X>?),U5@W+G
M%1/!C.:T;0 KS5@VH<YQQ7S^-H^U]Y'UF&Q2MJ9*6N%W-TH56,V[!('%:KP
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MXP<GO6<GRQ_X'X JEV.DMS')''YJR(_\([5)]D,EP+5W1FQ\K \"IK2SB=Y
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MTVD.$DBE.2#@>M=5X2_Y DO_ &$+[_TJEKF)2'E) XKI_"?_ "!9?^PA??\
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M'X?U%:FGZI:ZF@\MML@'S1-U'^(K2=R!P*YR_P!(-U<^;;)]GG!R&4X!/O\
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M4NK[6.VM1IUZ,L5@7I'647O'T>S7XCQ-;][ZP_\  R+_ .*I?/MO^?\ L/\
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M_"">$/\ H5-#_P#!=#_\31_P@GA#_H5-#_\ !=#_ /$T#=-'ES)#MXO+ _\
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?:6T>=D,$8C1<DDX4<#))/XU<8*+;$W<L44450C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>tm229830d4_1012b-img21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm229830d4_1012b-img21.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $^ =D# 2(  A$! Q$!_\0
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M4_#QG#R>)(1(L1;#?[SI_7H!P8_:_P#^"[$F=G[5_P#P5FY[#XX?MFG&._\
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M;_\ -!6OHW[5G_!>SQ-JEIH?AS]I;_@KGKFNZC<&STW0]$^,?[9NH:CJ%WD
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M_P""LW_A]?VR_P#Y?TO_  V7_P %TO\ H[7_ (*P_P#A]?VS_P#YHJ]RL_\
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M_@K><_WOC;^V;D>G_,PD]_4=J^G-#_X(M?'#X;_M1?M>_ T^/OA-K6N_L;?
M[3/CM/XFLFU<:?\ &!M7\ Z%\3/"'PM^'FD:]H/ASQ#I/Q7\4>!M6UUV\.>)
M/#*$2^$/$!5A%&GB0>H>(OV*+70OV:/ 7QN^*O[6?P4^!'B?XW> /&'Q"^ _
MP:U/0?BAKOCKQ[X?\)#7]&*ZL/!7@CQ-H?PPT/XBZYHVJ^'_ (3-XD\1^%HO
M%IFC5))/&B7"0_4Y3D^"S+"M?VE&.:MZ0Y>9:[:*,OF[)+KW/K\GX?PF8X7Z
MWBLS4;NRM'=VOND_.[?*N[[_  6_[7?_  7;0$/^U-_P5F'H%^-7[9H .3T
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M7\^N<]SU..*ZO3?$&DS ;(FLKX* MRQ)QJ'HOH.IX&/;)KSG5-4\P3Q>2/\
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MEZ?\!?KYZ/<R1J<^CR-%)#;8G'/V;K@_Y_"N<UBV\V ;!Y(SFUYZC//YCO\
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M=:_3LPH87#97_J]Y?+7UZ?+]4?JN84,+AL@ROA[R3]/GI^-M/G;PZ^TN;?\
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MQ_I5M<_F>_\ B.]$MU!;2>=]LN)S^'M[\_X=<8%>O_:&*WQ9ZV'SC%?\Q?\
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M./3WYJQ::+-=V\P^UF"#(NL7'M_4_P"%=&)(;&TFNX8+>$G&VXMCW.,=>/\
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MW_VG5/LGM>:C_D_@,=N#P\48?ZS_ &7A/Z_KT.'BC+_Z_K^NI\_O]W[F>?\
M6\\_TY^IJ&NDU2+R?];QS_Q[YZ$?D??CZ5SIP3P"JD\ Y.!Z^YK\S/R^:ZW_
M  _716\WJ?TQ_P#!N-_RF:_X)#_]D:_:W_\ 4%_;_K_6+K_)T_X-QO\ E,U_
MP2'_ .R-?M;_ /J"_M_U_K%USF9_GT?\'3DWV7]N?]J&?_K!I^SS^G_!9'X9
M?Y/;'O7\/<6H32Q^3GS_ /2OICO]/_K5_;__ ,'4/_)[W[47_:#7]GC_ -?(
M?#&OX<HI88O/A_<>3_S\\GG.?S)X_P#U5Y>/_P CR\?_ )'12^3Y?[K]_/\
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MWZ _S_*N\]$OQ10^7YWDW G/KG\_?_)/>K'E0R_OKK_7\_Z-WY//^>N:K_\
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MSP0"<D'FOL,GX?Q698J]U;KZ)._Y/\3[?(.'\5F.*^JX3U;>UDFVWTV7;O\
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MZ-F'B!BL3E?]DX0X[6;J:_N/.EF_SGCM5&+SHI)_;\.GO^74_G1%+YLF8O\
M]?3V[GKZ_P [WE>=GS.>/8_K^)_*ORL_)/\ :_+\0M?]*X]/P^OI_7/\KMK8
M?:I(/+Q/!_T\^G3_ #QVYYJQI<L/E_ZFWG_TO_CY_E]>U:HL+R_N/._Y=^?]
M&Z_CT_3TKU</A_K)W8?#A%:V<5S!"/M G^U<VUM]/I_A]?3H]4OY]+T_R?)_
M<?\ 'I=6USQ]C_Q^G7]*^A?@U\#/^$\_MS6/MGV&#P_I6HZM=7-M;?;]0L\=
M_P#/ZU\O>,I9KK6+_,W_ "]?\?'3[9[\]_\ /K7J_P"[87_9#U<1_LV%..EN
MOWO[K_P&]NV/7_/%7K#69HO^6UQ!_I6?7\>?\^E8E311?O/)_P"?COQ@_P">
MN/S]O#P^(Q6&/#P^(Q6&._EM8;^/SO)\_G_)_'U'IUKJK66\FMX+/GR/^)=_
MI/VKUY]NA_E[5RN@W7E6\$US#^XM_P#CZ_Z?/\__ *_8U369O+GGBA\B#_EU
MMOY?YQ^!S7U6'Q&%PV%^MGU7UC"X;"_6STW5=4TW[18S2S6^?^77_1>G^1C/
M7GMSBH+768=4^T0W,/D0$:<,_:O3/]!Q_.O"/[4F^SS^5@<?;..O&?\ .!UY
MHL+^:U\^'G_2/^?GMZ=1S[\5P_ZT8KS_ *^8_P#6?%>9]-:K=7D4GDZ+>^?;
MW%K_ ,@W_F']\^F*X[QEK.I2V\'G:;I^E6-O_P @NVT2V_X_/4\>WTQ5'01_
M:D<$WG>1G%I_I/'V/_#FL/5/L<N?-FMX/]*XMOM7MCI_D?RKZ/$9QBL3A?Z[
MGMXC.,5B<*>+Z['#Y8F)@^VL1FV'6T&<GKP3QQG//Z\Q]M/V7[)Y8Q][?GMG
MTQUS[X[]:Z;Q%BU064<WGC(R1Z?S/?\ '\37&?+GONQ^&W_'-?G6(_WE^I^9
M8G_>)/UU_P _EW3/Z8O^#<?_ )3-_P#!(?\ [(I^UO\ ^H-_P4"K_6/K_)T_
MX-QO^4S7_!(?_LC7[6__ *@O[?\ 7^L77.8'^>[_ ,'3O_)\?[4?_:"_]G;_
M -?)?#:OX<(1#^_\V'CCO_7K]/?L:_N:_P"#I0&3]N3]J()U_P"'%O[/1'T/
M_!9+X:$?I_/UK^%[]]SY7^?7KVZ=.<XKS,?_ !_^W4>5F'^\Q7]U_D:TO!GA
MBF_+T]^W\NG;-84O[W_VU'_UO\_6M;GR\^3_ -?7V;WS_DU>EL/]1>1>F#]I
M]O7Z=3_7OD</^[>IS?E?N^_Z?7_Z_P!..M$O[KG/Z_\ UO3]:U_LOE']U]GX
MXNA^O\\_3K]:YBFFE_U/?_./H>G(_$5A?OJKW_S++28G6$B(=>+DYXR<<>W?
M/Z5^B_[,/P;\*ZEHL/B[Q%]GU6XOB5MK:X&EBPM"#U*GGKQC QG'6OSF1V?R
M/W((M_\ IV!_7O\ 4^W85[%X<^/GCWPQIECH]I=F&QT^Z^U6WV;_ $'W[#OV
M&!7RO&.4YOGV1RRK*<U>33G)MR5W*6]]E?7>ZL[:;:'S7%.7YIF.5O!Y5F?+
MKMM;?37;6UOD>_\ [:7BC1]0\3Z5X6TP^?!H&F:=]JN>1G4?[*R?PSVZ?7&1
M\'RYEDF_Y89Z?AVZ?YQ^%;WB36M2\1ZQ>:C?S_Z;?[KJY^T\#DYY]S]/PK%<
M+#$OF=QG'3I^/^1^->IPSDZX<R+*\H5VDDVV]Y-WD^OVV_)I7W9W</Y=_8F5
M99E7:WXNW?I;>Y3B_P"/?\5_K259YMH_WIY[#_/?_/-3V%I-+Y\T1]_7KS^7
M].]>Z>N&?-_UO_/UZ?K_ )X^E9-W_K?SJ_=2@R_E_HWX>P';_P"L>]01?O9,
MR_N(/^?G!Z>Q_I_]>@Z"K5J*7S<\8Q1Y7[S''_@*/IZ_C]>.M3VMK^\\G_2#
M!ZVW?U^O^<\4%XG]?\B?4(O*C@)^OU/KQZ?K^8KG+^^_T@^5%TZ?_6ZYZ]^F
M:MZOJ!1Q:1QA1 3[]#U)[]^?UQ6#*YEA\P\'=M/U'7&<_P"0*ZL/A_ZV7_#:
M>FGWO 89Q7,UHU=?YZ%&60R.6/\ G^5?J%_P1=_Y2F_L/?\ 9;M,_P#35K5?
ME['Y>?WF?PSZ'TYZU^H7_!%W_E*;^P]_V6[3/_35K5=QZA\$VUL8SR<]OP]3
M[^E:EMB/F(>?Y&?])^TX_P#K8&:R[J$VIS(?.^T?EG/KS_B#5ZUM9O(\Z+GZ
MVW3KW_#_  XK[BAU^?Z'W^'Z^B_)&%J8,=Q@<XP?M R<_08[X_R:I0V,P/&.
M?Z>GH?KVQ7?6FEPW4<\UU#<?Z/\ ].OKP/P_SGURS8110'RO]?S_ *1SQ[?_
M %SZ=J/[/_YB_P /T_I'/B,OQ3_VM[?U_7](PK6+RNO?]<_Y^G-=':VOVK]]
M%%;P0?:OQ_KTQ^7Z02Q>3&89/W__ $\VWU_ ''?K_(5?BEFL<_N?)/V7[)C[
M2.>_;CD]>N..>E&'P_\ 7X?U\_-G1A\.?0'PB\%Z=XEUU3=7EP-,MKO3K4BW
M!S=G5F*G<.Q!!XQQR..E?67QB\0^'?!?PTF\,6=J(H;_ &FVMXAO!U", #5/
M[5)^=0JA1&."OR\*"1^?.D>-;WPS<&;3R)P!FV8YX!^GK^E2>*/'FO>,K>";
M6;RXG^S_ .B>HL_Z_P"?K7[?P_Q_D'#G!N:Y3E.5IYUGB:_UKMM?I_3VLV?N
MO#_B1D'#G!N:Y1A,K7]M9XFF[:I2Z)]+KS6R;/)+^7/^M]_ZGZ_IG'4<51\J
M:*/SC,>>/<_3_P"O^7%:UU;&648_?>?W[_\ Z_I]*KQ13?OX8H<_T[>H^GUY
MZ5^!8C#_ -?U_6OW?SKB,/\ [448I?-^O^1W_P _A7?V$LT6EY/[^#GM[_7_
M #CBN.M;6:6\_==N_P"?^>,_TK>O@+$P6<8;S[#*W G ^]QQCCCG''J._-;Y
M>_JOY_TO2[^\[LOTM\OT,C5/W=S/Y4/&>N#QZY'].XXS7+2NP[8_S_,]L\?7
MFNI^U?;[C^? Y/\ GOTX[U#+811>>/.@/7&.<?YXZ8Z=JPQ%\3^?]:HX,1A_
MK/:W]>GS,. $R#'H?U[_ *5ZI8W,,E@1'#<3G[-C'H1ZC]/KGI7(:3HEYJ-Q
MD0MY(/-S]GP/J<<^W^/%;FNR'P]:P6D1_P!(N;=;H]VM"QQQP<G@]OK6V7MX
M;#/%[12^;?Y;'=E[>&PSQ;M;\;_EWU.:U*^*0S22?\?!( _$_P"'YYZUQMU+
M]JESGI[C]?P_^M5NZU6XNX/)D.??\..G3]/Q[YWF'S <'GH>/K_/G].G-?.X
M_$/$XF_1_P!?KL?+XG'/$[K371^3U_3[ON9&,A1^?TSS7Z7_ +9$7_%W?ASG
M]P3^Q=_P3N_Y=?\ JP/]F/\ 3/?\<U^:@D)P>,'V-?I+^VS;3M\6OAT8SDG]
MB3_@F^;:WSU)_8#_ &8R3ZG/7MFC#_I^A.&MTMMKWV/FN+R8O]5-Y_\ I7.>
MOIZ]/TKE?$<4T5SQ^_S_ -//K^?;U]ZW-+^VRV_G10YQC_CVM?Y_3_.!@C5M
M=+AO_/ANIO\ EZQ_QZXYXS^7MGW]^[ZOBL2=_P!7Q6)PIYS%:S?O_P!S_G./
M?_/YU/%:_P!>G\^?R.?P/:NQ&C7EK@Q#_KUZ?Z9WX]P*)8IK6W\F4^1]H]O;
M\OJ,_K7/]0_JYA]7Q7UHHZ7:PR_\>L/GP?7_ (\SW_SW_&OJC]GCX+3?&3Q[
MI7A2*:W@L;?.K:I<\_VA9Z=_:O?CMWZ>]?+VC70L(K?]S<3>O^?\\=<BO</A
M5\:=8^#?B"#7O#D-OY]OI?\ I7VG&+S/K^OO^'7UL/\ 5<,>YA_]F/Z%/C)X
M-^$O[+7[*?Q-TW1M-M[&^\0:#J.DZ#<ZE:Z4/$&L>(O^)U_8_P#Q-]$Z<]?I
MQGFOY9M>\DW'[W]_.;H_:[G\^/\ /;MZ_8GQD_:Y^(?QS\+Z'H/BV;SX/#__
M !Z@W7]H?;/[8_S_ $XQ7R#JD4PD@O)<&"X_X]?]%Y^@Q_/&/6M^(,1_:6%#
MB#$?6<*<[Y7[R#IQ]?Q^OOZ4DO\ K/\ GO/T^GZ\<=3^-7Y;7'^JX'^>Q]>O
M^14$44WVC]U_Y+<?GV_+^E?+'RQV.@RS6NGSS2_:/L,X%W_GK_GK65K,4,4?
M[KTX_P!%Z'I[8''0&KUU"=+T^"SEXO[@?U_#ZX_EWP[J_P#M5QY/N/KU_P Y
MSW^@KV\1_NOU3[CV\P_W7ZH<K*1%'^.?I_GUY^E3Q2P^?^7^>WY=L_GN2Z-_
MTVMX+?I_I./_ -7_ .KBH+72[VZN/)M?^/C_ /7^'X=>WT\/ZOBOZ1X?U?%?
MTCT;098?[/GY\^>W_P"G7VP,YSU_SGMP&J:S##%^\_<?9_\ CU_T7_/'OTX[
M5U5_GP1H_G77[^?4.;7_ *=/7_'^G.*\?FUR;4LV4L/^OXMAR,'G/;G.#STS
MWZ5[F(Q'U;"_UT/<Q&)^K87ZI_7]?TC(O]4^U2>:/ZC/M_G/Y=,&K,O^O/F]
M/;IC\>/7IW]Z)8O*D_=YX]^_IS_GIUYKYP^</Z9/^#<;_E,U_P $A_\ LC7[
M6_\ Z@O[?]?ZQ=?Y.'_!N/\ \IF_^"0__9%/VM__ %!O^"@5?ZQ] '^?3_P=
M+ R_MT?M1","8G_@A;^SR0,]!_P^2^&I!S[@@_B:_AFD,TAF/D^1!.1:?\>N
M#D'/!^O<=NV:_N9_X.G+K[+^W'^U#,#_ *C_ ((:?L\$<^O_  61^&1_/FOX
M;K'Q TEQ#/%+]AFS@L,[>_?T]SCO7#CD[1:3TU[VZK;T/,Q]W9I/2W^9[O\
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M_P#UO7CM5 +%YV#-+_\ P7X]OTY]J27]['!Y7_Z^WY=?;GOTJ>67'_MUW/\
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M?/)%CAE.3T.#C)[GZ@UKZU<S0:>D)GNH$^TWIN/FR<$#8 >>V,+T[8/2J?\
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MRSY?F=LX_7'K4=6N8O-$D7)X';'/X\'COWZ5Q'&?TQ_\&XW_ "F:_P""0_\
MV1K]K?\ ]07]O^O]8NO\G3_@W&_Y3-?\$A_^R-?M;_\ J"_M_P!?ZQ= '^>U
M_P '5O\ R>S^U7_V@L_9U_\ 7T'PNK^"_>?0?K_C7]Z/_!U5_P GN?M5_P#:
M"O\ 9U_]?0?#"OX*Z .ATW4I[>;$?H#S]?Z=L5U%M=8/[W/_ &[]?Q(_3_\
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M9?\ 5>N>GT_S]/RKLO"6LZE8^>;'/-KR>.G&<<^GT%>KP_G'U;%+ZWY[+O\
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M/_,X;GR_-\\_EWQ]/T]*/*AB\_D\# ]O_K=OPJ#RO*_UI/7N?\_X?TG\K]Y
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MP>@(^E56R_%8?#+%RTC^.O5_T_\ (Q^'^KX9=/NO;I?^F?'UA86<MQ ,_O\
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M+K/Q$T96'Q[;Q=\(VR_P7\#?$?6/B#\2/$<C^&/B;\5AXG\3:+\/6E\)>%%
M3PMN:_\ M<?#?0[/_@@!^U/=6M_?^!/V,QX<^&_Q?\)>#;;2+[Q?:^*?V;_V
ME]'^+FNKHND/X@\+"[U[Q/\ "[XB^$/$'A,Z_P")/"X_X2C5I<^*P(9''/\
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M_P"*YTG6?#PZ'&C C .3^.'_  C%KYD/)YQNY//H3SS^O^'#]?PJT>GY_EZ
M_K-O]J5G]Z\_Z_X!]/)^W[\=7.!X)_8PSZ#_ ()O?\$[Q^A_9D7_ /53_P#A
MO[XX[,?\(7^QK_XK=_X)X8_]9GSC'?I7RM<^&(1)_P ?8A]CSZ?X?B>O2LO[
M#Y5OG_E@?^?@?R  ]O\ ZU;MKM\O^#U ^N?^&_?CI_T)7[&'_BN#_@G?_P#0
MRT?\-^_'3_H2OV,/_%<'_!.__P"AEKXXNM,EB_?1?OX<\'G_ /5_^KM6/6P'
MW#_P\"^.O_0D_L8?^*WO^">/_P!#)4O_  \(^/?_ $*7[&__ (K?_P""=_\
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M>G7U^[OY'[*_\1#O_!8/_H[W_P P'^RU_P#..J4_\'#O_!8.3_6?M?@\8Y^
MW[+(_E\##^M?B=3TZGZ?U%;T.OI_D<1^V/\ Q$._\%@_^CO?_,!_LM?_ #CJ
M9_Q$-_\ !8+_ *.\?_PQG[-?_P Z&OQ6HKV+/O\ F*S[_F?M:?\ @X6_X+#
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M^_LK_B.?@4V/P_6O:/V@OVI_^"JO[1_[5\7A'X!_M*?M9:MXT\1?L=_LH?M
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M>%OCKX2^&GQ.^$?Q:^%W[/OB_P#8^^ _Q$3X&_#']H*R^"_[,7A'XH:%X@^
M7A5/A5XO_:1^!_A_QEXZF^$[?$3X;_%SQ$?$WAAXVU\#PEXH\5H)0,7X&?\
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M6KTUU#+<3^5^X@-U_P ?-S].N?QSUS7EXF[Q3[*WY6_$#5MO)B!\K]Q_HO\
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M'F3F4^1[XYZ\C\O:C>_]=;?T@+OF_9;C'^CS]?I@9[^G/U_$UN6O[W_4_O\
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M2PF-S'[\^O\ ];G_ #VJD<;P",Y7^IK^$<0\5EM[=&?4Q2;MZ_@;46J31?\
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MN@N/^/KGBS_'Z<>^<=JX,OOB?][TL[W5[IW36M]+/5;:]=K,R;J_FB,$,O\
MJ/M1N[7/Z\_Y^O:J4LVI>7!]F@,';_K\)JC+-_KH0/(&?_K?R_/-3_OO/)M8
M;B;_ $7BX^U'IWYQ@<@<9SD]*^B7R^?]+_/L<Y#)=3"":&8>3-]EY'3V(_Q_
M3BIK6Z$7^JAN/^GK_2O?)ST]OSXJ$"6ZE@F\L3"X('V>V!^WW?Y D^I !/L3
M6I:PP^7YV/\ CXNL?S]__P!?OP36(?EU?Y_>!U5K%,;.#S?L]O!W'/\ /CM_
MG&*X&6Q,MQ.#$8)O3MD^@]?\Y[#M[#_6?NIO(N/^/L?Z5P/;KQZ?C65Y7FW'
M[V;]_<8_X^LY&?K_ "[UPIO#7\_7^OOVL!1^RS2V<'VK_)&/\_EU&:Y:^ML9
MFB$_)'7G^6"#],]_P["Z_=1B&7_1_P#IU_3@_3\_QK*O[6&7_5?N(..GIGGG
MO_0\#-=N'W^?YL#G[*WFFD8Q\&& L>>QSQW]2?RS7:Z7YIM[C[5^_'_I8#VS
M[=.:Y6PB,4D^>@M22?P_/_\ 5^%;FER^;<#[4?W]O_A_3_/?#Q&OR^_=_AK^
M0$]U=?:OW,5E;_Z/_P >ML.H_7MQ2Z9)/<ZA!%?RG[/8Y^T0$$?9,'!(['GT
M)Z<]ZNQ0^5;_ .B_9_(U#^O\^?H?KS4$47V62>:U^SY/^B?YY_']*YKJS5O1
MO==_1;[*]^NZ R_$4D,<Y-K:3P3SD77VC/+9SPH YP/O'J,URUQ%-_K9!UP,
M_P OY^U=?+&;^XGEN?M$^?\ 2[7[-^?\QZ?C7*W\OFW!/E>1CW[8_P ]Z]"@
MU^*OYZK].@&?7ZC?\$7?^4IO[#W_ &6[3/\ TU:U7Y<U^HW_  1=_P"4IO[#
MW_9;M,_]-6M5L!^;NGZ?/J5U#:QMN)/!X.?KCL<=1QCTS7J%OIEGH\9BXGFS
M_P ? Z  <XR>![<]S[US_A&V$IO;Q1A;?)]NI7CKW!_J,<5<N[JZ^T .3"3C
MM_@.<^X_#KG_ $$\&N%\BX)\/<NXWQV7>USOCB<UPO5NY+AEQG).IS2=WSM.
M:D]6I+S/C\PKXG$XGZK'W4HQO>R;=M5;K9NVFBL6_M_E?N9(<]OS]\]^/\DU
MKZ68KG_51&"#\2.>OJ/Z$^F.<FVML_ZZ$3?:.!@8_3USW_QKU32]!^RVF8SP
M?;\P ,8Q7]E>#_ _&7&V??6_^9/D:_Z)6_\ 7R/G,WQ.&PV%TT;:Z_UKKN<3
M>61FES'$?+'/D9//4@#\SZ']:Z+PYX<AN8/]-M3]>1Q_GMR,_E6Y:VD4L_,/
M&>A]?I^78<Y[5M13?8/W,W[C'?\ 3\CZ?A7]3^'W@?POAL^_UAXL_P"%S)]N
MG]:?TCY;$YSB_JSPN%NG=.]W=>=[ZM[MWOHCGM0M8;:TF^S_ ,NW/ Q_GOFN
M.U.XBM--$?\ RWG((]L'I^1[>W6NQU6[AMS-G$Y'7'O]>WKWZY/->5W45W)<
MF:7]R.GV<<>W'///7WK\K\>,XPO#>*^J95E?_"QGB:MTX57Y?KT/6X?H?6-<
M2VTI)INUVTE;3K9W\OO1P<FDWU_=>3;QLP[*3P2,=<\X'X#ZY K5/@O4M@.Z
M'(Z'Y1CG'&!7J%J(=,3R(XO.GN/7V_+GD_0^E=+9Z'+>I#YH\F$X]/QXZ'GU
MZXYK^4N!OH4\(<65\VIXF7%F=\6R:<X1?+#AAK;G2TG;=<W-9WLE<^BQW$^(
MPSCI"*5[NR;?=VZWT5M%TN?,$]K/:&:.2,F8GOP>."/3/?\ $XK*&X*&QP3G
MCJ,DG\?TQCO7TOXH\)0SVMZ?)R1@VUP?Y=N",>XKYWDA:*3$D9VERHSGG X/
M/(_3O]*_B[Z2_P!'?B+P#XHR[*<UO+)\[A*?#,F[MTTUS.3ZZN+;U;N?49#G
M.&SG#<Z:BUH^VJOLMK6?IL5=TAXRWXC_ .M0 _KCZG/^-:$-C-=2F*WC,H/
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M1?:]_P (]_:G)\(Z1HH_XGFNX(.T;>G)'6OO?_@H_P#\$G?A]^QU\-X/B/\
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MG Q=_:!_;$_:=^.VN:KX;^+GQ1\3Z[I.@_VC:W6B6]T=/T"\ U7&=7TC0_\
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M0_/T_ 5>^T^:)S:C&>EL1_QYCU!QZ^YYR*/-_P! @$T,$&/^7G[5S>8'H.G
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M2_[<\5>.->\8>*O%7]@_VMJGB3Q9J>J^+?$&L#1SG_B<:OK?';1^,>N:\/\
ML@TO5)[R7_7V^E_:]+^TVO%GJ/Y\^^,]*]4^&EJ?[+@'A?4O%&DS_:OM>J7-
MM='_ )!W]E=>Q_IUKN+KPEH6J#[9XHU*W@GN/]+M;;1+72K#4+/_ *A/_8"]
M0.?KTK]I\+_!?Q&\2,5]4X(X7_X1_P#S5=3AS#$87#87*L7BSXTUF/7I=0S=
M?O\ ^T.?]&S?^O?T[<>I[]"*ZAM7^QQ3>?!_Q]_Z3=<6?OHW7]>M?37BCX?>
M&XO/ATOQ5J/G_P#$N^U:;<_\A#]3^59=UX7T&_DTJSBL[?\ X]?[)^T_9?\
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MK40RR'S3G' M\\''^?\ /2H)I89,^6.<^F#V' ]__K>M>7_S%?+]3@/ZR?\
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M&T\^#!^R_9CTP.>?;@9]<^N*^@I8O-\/_8XIM/\ /%UJ-I_QZ_\ 'GV'U_\
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MU]?\05/_  5-_P"B^?L ?^'3_:*_^A5IX_X,K/\ @J=W^/G_  3_ #_W5/\
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M2^,OV;;CQ*^BW#> HI[6#Q"INKN&=+V*/PU O_",Q\*G&CJI*7I_PR_4U/\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>tm229830d4_1012b-img22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm229830d4_1012b-img22.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %^ J0# 2(  A$! Q$!_\0
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M4_9TTY?A+X6T7P0/#FO^+=7_ .$OUSQ%/XE3XQ>)M$T3Q5<K\,(2R5\RS?\
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M4]QHQ^$&J:G\6T^%WAAO!NA>&XM5CF^*<W_")^(7M="TFXN$BDF9?#;?2?\
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M%U?PSXN\-0Q1>)_!\;KXK\50)X36*0^I_P##VWX"_!WX8_%CXG_M7?$OX?\
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M?@\1:%<.=+2'<?#TZ"#5(YXPSAD'XAZ5^PK\<M?\=?LM?&[XF:Q82?%/2_\
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MS]IO7/A?^UA^S%_P4+?2]+\!?&#2/!6D_#._75]'_9/\1:)H_COPTVB>+_\
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M)?%=IXS_ .%N^/\ X>:I^QIH$/P9U7]G/7VD^'$'PPT+Q_XA7]HCPKXGMOB
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M&TEVO"'_  4-^.=]XT^+/PUU+X+_  J\2_$V^_;V^*/[%W[,V@V'Q0\5^ O
M^KK\-O@*W[0.K:O\>/B'JW@+XD:]X/9? NCZOY7B'X=?#'Q</$/BO5_#?A*W
M\&P!Y/%<P!^S%%?E3K'_  4*\9:7H?B[Q/:_ ;2;_P /?!2WTVZ_:$N?^%QN
MVL^&8_\ A?WQ]_9M\0Q?!O0](^%?B;_A<^L>'_'/P'U[7X(/$TGP.D\1>$_$
M&@&WV^*HYO"%=5H?[=_B[Q2WQ$U#P;^S)\5/%'ACPO;_ !6'ACQ-I_AKXT.=
M;O?A#\6-#^$>N+JP_P"%%MX>V>(VFUKQ]X.\/?!/Q)\=_%_B;PCX-\0"'P>O
MC#9X7< _2RBO /A)\5==^*.G:%XBB\(V%OX:U7P_XCNM3\3Z3XKU&\TW1/&6
M@^+YO"&I> 'T7Q=X+^'/CU-;T9M+U=_%$GB/PCX9N_"?B+2]5\'W-LUW S)^
M1Q^/_P"V7;_M4?&/Q3X(^)WQC^)/PE^#?[6'Q0\!_%[X):W\'_@MH?[/GP[_
M &6?"'[+6D_$L^*?"?QOC^%OA7XDS_'0?%C4]$T#PUX=F^._Q/2=?$(7Q?\
M"CPMX1\WQ9X0 /WPHK\PY_VV/CU=^"/AUXCT+]F;P$/%/C;X+:_^T_JO@OQ;
M^TQ>Z"/"W[/FBP^!IGE/BS1/@3XKT#5_CEM^('DCX;(L'PLWZ-.Y_:'9##<5
M\MZ?_P %"_BQX.^,WQT^*GC#6HO$_P"R5\7O"'PZTG]B_P .:YI?A3PEXA\*
M?M,ZK^RU\ /C-X*^ ,@T;0/^$A\::[^UI)\==6G\&OKWBCQ&?"/B[X6Z]X1@
M"1>*/"L) /W@HK^=_P#9Y_:'_P""A?B+X6_![X8R_'GPQ\6OVF=7/_!7'X9?
M\)[XW^'7@7P'X ^)'Q4_99^-G_"L/@5JGB[1_ _@,CP5X>\-)PR>%QO\2(#-
MXL_X2:;9)7W5^QE\?HM*^!_QJ\2?M"_&S]H"]\6_ /4]5U;]H?2_VS/"G[./
MP[^)?[/L>F> ]%\8ZMI.LZW^S#\/OAG^S_XQ^'Q\,PP_$CPI\0/"[^+8YO#>
MOR+-XQD:,>'?#@!^FU%?@;\"/VFOVG/&OPB^,_@GXY_$7X@P_$SQ)\:_V/?&
MO@;Q+%\(]2_9]\8^ ?V:/VVOC-\,?AQ_PJC2(-;\ ^%YM=UKX*>(4^+_ ,/9
M/C':^'?$DTGAM?#'BZ3Q9+XO+O#]T_L5:S\6+?Q)^U=\)/C'XLU[Q)K'PU^.
MNG7?PZT?7=7L?'4?@WX-?$+X5>"=?\'>&M)^*PT#PSXD^)>CP>)8_B(8]?\
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MPK/'!(5E6W6-3%7LW[)_[5A_:0OOV@-(N?#G@S2%^!7Q-TGX?R>+_A]\3_\
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MPQ^&_"_[-_PJT!M ^!/[4Q_:M\':F/AW\%/@'\,OA+HNNGQV9= \3CPIX/\
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MK2X\8>(O%/B/Q& ?4=%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*[_X*+0?M?6/@'XA3_![P]\7M,_8=LI]6'A>T\'V?[,^M:6='^(OBW2/"_\
MPL ?$&7X@>)/V[5^&[OXE'PY/AG_ (4#\,EF:4&193SG[ 'BNT\2Q?\ !/;Q
M#X2UBX^*'B6[^&'[07A3XP>'H[7PSX=D_9ZTWQG_ &)\1_%_Q.UAM%T+PUXA
M,GQ-^+GPX\(>'4T'X@MXCG^*_P#PG4?Q;\$)%X3\*^)KB;]_:\M^%GPP\&_!
MKP#X3^%7PYT63PYX \"Z+I_A[PGHS:KJVMO8Z7IRN%C&LZWJVNZ]J_E[]N_7
M+B:<D+OG8XR ?CCK'[5W[1MW<_%;6OA#\8]5^(OB?0[?_@H_H/B_X.ZI\-/
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MXP7XB^*]9\:>+],\6:Q_9*3:[HMQK^NZJ/[#\0>?;A=L$BEU8R>^44 >)Q?
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M%^/OC%_C!X-^$F/$Z^*O"_[.?LQ?%SQ5^T=HMU\5/''P_P!;^&ECI^H:;%X
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MVD2%)?H$[< 8)!Z>WJ.F.W3Z].,_$_[7_C+]E3PAH7A"']IJ'1]<;4]2O/\
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M;UMUMZ['VO1117T9Z@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV9O"/;.KS7DXIZ[_ ,MT_(]GA[$/#XEX)WMJUZ_\-^2/TLHHHK];/MPHHHH
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MX_PZR-$^)7C7Q1)X8U=O$^A3>&_#"^&(])UR(#S4D%3FG%^5Y1FV69/B(O\
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M!;[-XCN'K?M/>,O$/P__ &<?V@/'?A/43IOBOP1\%_B?XM\,:H(=/O1INO\
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MK&D_#C3_ !-\^CZ\MR/#,OBN+Q%'H364\GB3^RO^$9&Q[Q98OY:?CA_P3_\
MC_XS\8>*_ 7[/GPM^%=MX6^"WP%\(>"/AO\ %OQ[\0O'O[/GB"^_:^'BCP5\
M?8OVD-(&C? OXX?\+J3X;Z_X1^$ \*Z!XD\4^&?"WA!3\7_A&OBN0CQ4OA;^
MBS_@KZ5C_8ZOKV^BFG\.V7Q>^#%WXP3[+]ML#X<C^(6C"9M9C& -'%R^EBX(
MX4F)3EB<YPY /J!7^BG"V6K$\,N:^*IQ/2<M_L0LEU2MSRZ*[?H?RMQ!F.*P
MO$T$DG%05KJZUUNM4[_-]>C:/P%^)OB3XG_%3Q#\6Y_!GPS^)4O[0OC#0/V
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M>+)1JW@'1E&LZIJ\B1R:WK3XW+XA>-'\6*1N56R!].U#%%#%'!#%%Y$%N/\
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M^2<5W?75N[_,_GE_9-_X).?M+?LH?L__ !*^"V@_$+X/:I8?M)?L>?$GX/\
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M7/\ &BR_:'O_ (R6T#MHFJ?$FSU*;P+%=OIFIIJ,GAH?#:36/A#HZB$S*O\
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MKU/ZBX>>4X?@?AB.:)2P$>&*;I137M;23UIMV<8MIJ4I7I<RE>$FFG[GX?\
M$&E^)M.MM3TB[2?2M2^U+:37$%U:/>&POWT[48OL&I1I-&(KB&:$J8<,RAX_
M,5D8_+_B_P 0:EK7[26O^%+JVCL]-^'7P9\%^(-#N;>0/>WMS\7/&WQ'TKQ-
M%JB!O+BA2+X*>$8_"H$,!,NI>(?,:8 3>'N3_:Q\,_ [P5\.OASXO\6?"/Q[
MXRUWX431^$/@/X4_9T_X3SPK\0-&U3Q/X=713X6\'W/PAU;P]-X)\+CP=H\O
M_"4227EKX6MO#.@1HL4\\?A_0+CYR^$?@+X_>#_CW!X^^*NH:[X+\ ?$OX>:
M[\/O!OP[^)/Q1T3XO_$>QU_PAXHG\5^%=#U'QWH_A+1;G59K7P7'XMUOPUX?
MO?B3\3?$Z^&)/'?BOQ9XMDD'BLQ?*<0YQF,,7@,DCE]2K*M-5'/AV=2I"G[G
MLZ;XAA*,(4X?ZQWBJ=+B2+=U5GS2<^7V>%LERWV./SS^T/9TU1XC4*?$+IQJ
MU)Q4)RH9 XSG+B%PX>:E)OARG3E+V]#FE*=+VOWE11161[I^8'_!3C_@H7J_
M_!.SPQ^SAXJMOA%X(\?>'/C[^TCX/_9SU3QO\3OC]IO[/OPR^$/B3XD:7K&J
MZ%X[^(WBW_A4WQ/V^!7T?2?%FO\ C#Q(WAI5\(^$]%>0!Y"D3^M?\$]/VT[+
M]O7]GNY^.NG>%?"/AFVM_BQ\5?A0D'@'XFCXK> _$T?P[\>:SX13Q]X2\6:W
MX&^&7B'5O!/B=-)3Q'X3'B3X9^&/%"^%]9POA9U"N^)_P4%_8K\2?MK>&?V8
MK+P7\7-!^#7B_P#9<_;,^$'[97@[6_%/PNO_ (L:#XB\2? O2?&IT/POJWA/
M2?BK\$_$$>@^(-?\61M.WACQ/%-+#HLEM%+";@^+$N?\$_/V.?&/[&?P\^+^
MC_$_X[6/[1/Q9^/GQ]\7_M%_%GXFZ+\"O 7[/6@>(O&?B[PG\,O!NLLOPD^&
M3GP]H>N2Z1\.M+\2^+O$"G_A)_%GBW7O$7B_Q?\ \5?XGKT6L%]13_Y><SOJ
M]8WT79)17EKT;>GFIXGZVUM&VS3;OWU6KOYR_!H^]****\X](\GO9WT#]IG]
MG'Q(!#>MXIMOC)\#S;NLEF;-/&/A#3OCA)XIB*JP\U!^S8=!7PZ\<BS#QB?$
MO_"51GP__P ([XC^[Y1A-O7='*#GCJL^/R)/OGOVKXQ\/>&[K7OVC?".O3?9
M)]&^&7PS\8W=QINH1&5AXQ^(VKZ)H/@_Q3HX5)(CKOASP=X$^*WAX>()O*\1
MP>%/B2?#TC[-=\5 _9TF#O/95/\ X]%*>?\ ..*^IX3HXB.&S#FT_P",AJRV
MWC"24GZ7:ZZ6?S^#XQK4/K>$P\6FXY%34M;M7EG<HQEHK2C!ZZ*ZG%OLM&BB
MBOKSYL**** "BBB@ HHHH **** "BBB@ HHHH **** .>U/2M+U^QFTS5]-L
M]1TZY0I<V5_;)>VLZGG#Q2AHVYSRR-SR%XS7F1^!GPZCA\G3](NM,MQR+?1?
M$?B70K0X]8](UBW0$<_Y S[0.#]X?D?Y8%+R?XQ^>/TKR,SRG+<PC'^T\LAF
MMEI[2$9QBNR4G&WW_+<ZL%F688)M87,:E--ZJ%2I3YGY\DE=_*[MO=7/#C\#
M/A]<J4FT_5[R!QAK35?%_C._LY3R</I^J:[/ V.NWRR.1R2#7=>'/!GA;P?#
M<P>'=!TG1Q<$FX&FZ9%9_:G"%0]\T00Z@XW'$DK,<$A"N<UV86-#QM''&23G
MZ'OCIS_*HG,A^ZT1Z\$#^?''YFLL%DF1Y2K95E60Y4N]+#TJ;LDK7E%1?375
M7VTNS:MFV<8ZA]6Q695IK?EG5JRBF]VHSG-)^=G]]FKU%%%>X>>4XR %VC:B
M9;OR>YZ9R?RKXF_;M_94'[7_ .SCXM^$>G2^']%\7-?V7BCP!XC\0VNHWUGH
M?B_1Y08Y6DTMO/T7_A(-!E\0>!)]>2#Q+_PCGA_Q!<7)\+^)X]_AB\]0_:9^
M.FE?LW?"'Q'\6]4T6Y\22:0VFZ;H'A.SU"VL+SQ%K^N:E%H^DZ>]]*C"WT>$
MZC)KWBW6_L_B!O"OA/1]?\5IX=ULZ%+!)X=^R?\ MT>#/VK=7UKP9:>"?$W@
M3Q[X;\,:?XLU'3;WR/$'A*[LO[3DTJY30_%>E&/,NC:L;"(R>)?#OA8^)S,[
M^"U\41>&/%Y\*^SE>5<24,)+BK*LNJ?V3DE6$98B$5*-&M>#ASW=K7E&+]V<
M%[11J-.II\WF&89%6Q4>%<SS""S/.:<N6CJG**3T71;:+>Z;3TU_'C5_VM?!
M&H_L_>/OAS\<=(\7^'?C?8Z5_P *'^(OP=M?[)L?B?XE\9>,=)_X0W5]6^&V
MDZV?FT$C5\_\)&."/^AJ_P"*5/BOV/\ 84^(W_">?LW^!M-O_L]CXJ^%]I_P
MJ?QEHG]EZK8:AX;U'PA_Q)M'TK6/[;Y_MW_A!?['_P"YK_X2#O\ \4I7[K:C
M\+/AMJWCC2?BAJWP^\#ZC\2=#TT:3X?\?W_A#1K[QWH&E2+JT9T;2?%LNCMK
M^C:(QUG6=T$-RD+C6=:#HHNI1+^4GQ:_9#^.?P#^+OQ%^,'[*/@5/CSX2^.G
MB?4/%7Q,^$GB'XD>&/ FN^'/BAJNHZSK.K>/_"GC'Q%HTFC-X),:MH;> FW^
M)6\4:V";A_"!8^%OTC+>-<OS&2P56G'(HN"?M(3YH>TOK#6"<(M:PE-MM^X[
M<O,_@LPX/S++D\7%O/'?X9*SMT>]F^C2TMJK[+Y-^,7PDT']J#]O+]DO]GWQ
MCH=]XA\!Z3X-^(?Q)^(-OI]MXJ46?A&33 D0UK5]#UWPV=$T'Q-XA\)Z+X=_
MX2/:V/%6M9*G_A)_"U?I[K/P@^"/_!.WX,_$SXW? 3]FV]\>>*O!VA:?'J>G
M>&+B;7_BOK?@"7Q3H\>JZ1IOBSQ!'XAU^;P]\._#SIX@B\-^;+ ?#W@[2+8,
M]U:6\@YW]@_]DGXB?"76_BW^T)\??^$.E^/?Q]N/#DESIF@V=A?CX7>"M%L$
M_LSX6KXKBV/JTT(32H?%7_".,?#OB"Y\'Z!<2>(O%K6T7B6Z]V^.?P3_ &@_
M&_B&'Q=\#OVO_%OP,OTNO#D&H^"O$'PL^%7Q>^$E_H.DIK+R);^%]6T?PK\0
M]&\1:]J>J+]H\21?%-H3#IGV0^&[@0^'Y?#GS?$W$4,SS3!95_:47D.30A3I
M1@\1'A^33<JLXJG'FA&;ERQE3@ZD8QYU*SA%_2\.\/QRW+%F>*RQ/.7K+2+:
MZ)*[^];-Z::GK'P@^.'P_P#C3\%? WQY\*:E;V?P\^('@C3_ (@6MWK%YI,<
MOA_3-4T^+5]4TOQ7)H^NZ[H&CZ[X6"ZCH'C1!KLT'AWQ/HVLVKS3HLN[\Z?$
MW_!1;XE_%O7/&_@K]BOX0:;J^D>$M3.FVW[3GQVDU73/V?O$<FF>+I=+UUOA
M'I/@P'Q)\<-'ET;3M6;PWXD\.^)?"?A*YEB,DOBI%E\-1>*_RM^'/[-?QH^,
MOQI_:V\'?M >)VG_ &9;[XOK=_$+P5\(+KQ7\-/A)^TS^TMX13^Q_%_CU]);
M7_%'B31-%\,ZY\OC ^'/%/ACPOXL^*_@SP""3XS^&;^%?"WZR:7I>FZ#I>E:
M#H.FZ?H>AZ/I>G:3H.B:;:_8-/T?3M'_ .0/I6D:/_S!-#]?_KU[^"X,R?*L
M1]=S"I3SNE)0E1IX=U(P=.=.G4C*I-JG.H_?<>1>SIN"A-\LYRI4O(S'B_,L
M1_LF$3R5J]Y3LW=76BU2VWM>]UJM7\Z>"/AA^UI*B:U\9_V__C_XK\82:EIU
MQ<0?#+3/A;\*_ 9TT:5HF=+?POI/@7Q5+(YQJY?Q+X>?PR[N-S^$F8DUV>I_
M![Q&JQOX+_:6_:[^'%S)C[;=Z9^TEX\^)37Q *KNTG]H;7?B=X?T7:.!_P (
MX?"^!D# Q7ME%?0J&#226%PB2227U7#:)*RM?#O9:;OU>M_G?K6,_P"AL_O?
M_P D?/7@3QC_ ,%"/V>]2\2W]K\6/!W[:GPV<W^K:'\-_C%;:;\)OBY:1B3Q
MCKVF>$?"'QN\#Z-XC\.:SK<[:IHIG\0_$;PPOA*X;0H_!_A=/AI"&\2-^AW[
M,O[;/PG_ &G$O-"MH-9^$OQFT"ZU*S\8_L\_%:Y\/Z!\7]*;2+'1'U+Q)I_A
M&/5[K6-=^'CG6-.C\-?$?0HCX7\1I*9X'1WQ'\[5XI\8_@XOQ/3PAX@\/^+M
M8^%OQ?\ ACKNH^+/@Y\8O"5MI=[XA\!>(_[+.C[E?62&UCP1XC.- ^+/P^\1
ME?"_BGPLH\)^,65@"/*S#AG*LVC+VD8Y#G%I-4[6HRE:32E""2@I.W-.G"\5
MKR2M9^YE_$.9Y=I-<RZ]_E??R5[/:Y^Z)V]3_(@_C^7&?PI5(Z#H/\_X_P#Z
ML5\*?L7?M(>+_CKH/CCPG\6/"-KX'^-WP4U[1_!7Q$TO1M3BU+PWXQ75/"^F
M:SX8^,W@S8#=:1X%^)B2ZQ+X=T"_>3Q'X5FTK6?"?B@&_P##TCU]R@D=/3%?
MD&-P6)P&)J83$QY9TGRS@]XO=;-IIQ:DFMU)6ZV_3L#B<-C\-'%89WC*]G;^
MOGZ$]%%%<QUA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $
M0&& ]N3]03Q^&*\?^-&G7=[\-_$;:; +W4-/BL=?MH#Q]JO?"^J:;K<:GT+/
MI*)@'DX KU[.'0=SCG\/3Z<?AFH,B59$/8Y7KSSV]^GTQ^7F8[+89CEV99;B
M9)0S2%2G.VMHSBHOUY>5/Y=]NC"8V6!Q^!Q44I.G4IU(IZ*3A44XW?1-II^O
MEK\76&HV>KVEG?V$OG6-];B[MKC.<@C.<?3VX(QD8-6^(Q[<_@!_^OG_ #FC
MXLT"?X7>(%M;AK$>!_$6H7R^'+['V'_A&-04-JH\.:JP6*%M'DVZN_AA(@?*
M?]R05$3&ZC"522.G'?O_ )[_ )>O^;7%'#^:<)9]FF59J[PT=XNZ=UI):[2W
M3[/?1I?T#A,7A<7A8XO"-++91ER\RUC:S<9622E"_)-?S1YDN6492EHHHKY\
M[PHHK,U35-.T:PGU+5+RWL;&V_X^;FY.% [ ^N<'&1T/''0$W8Q=>T%?&=UH
M/@8SK;IXJUFQMKDF[V7H\/Z/G6=8;3#RP55TD*7 *I_;&C$_PJ>;_P""@$FD
MW_PWE\'Z;\5_@'\"/B=XK^&WQC\/>&/BY^T-^SQJOQT\/Z?X!U7PYH^B?$WP
MAX4OF\>?"_0=!\:>*#K'@V:TT'Q!XF\5Q>,X]!N$'PC^)UGX8\0)X>^A?@YX
M7U$M-X_\0:;]BU+4=.31_#^EEW-[I7AZ68ZBTVKR>;"C:QK?E6$LEOB5O#HC
M2WB*RS^(&F^E3M(V^N&![\@<?RR?TK^]O!7@_$\)<,+$XU6S;.'SS;NN6,4^
M2ZWZN37:UU?W3\<XWS=8O-%E^%G%QRA<J<+2C*I*5ZC4E>Z3IQI1M*WN2M=-
M2?\ -+\:M,O-1_9(_:G^'6H?#GQGX,^+/QZ_X)-?LD_#[]E?X2^)!K&L?$^T
M^(@\)?&O1-&^"_A+5]>T+PMX@\0?%+X9_%36?"'B/Q<P\+^&/$_A5]:\.>-/
M&/A#PKL!7Z0\,Z'XN_9\_:O^%LOP!_:1^)GQBUS]HO\ :=:T_;3_ &6]:\(_
M"SQ7X4\ KI/P!U3P?XU^/<WBS1_A!X9_:!^"MMH.M_"'X<CPKK?Q*^*/BCX5
M?%9_%UOX9\&^%&E^)?A/Q1;_ +HT5^Q'Q9_/CH_Q:^%O@/XU_MAZ/X_^)GP]
M\%:O<?M1^+M6M]*\5>-/"NB7MS8?\*\^%^[4TTO6];C+HIT@A6,49( )1,[1
MZ!_PTA^SK_T7[X+_ /AT/ /_ ,OZ_<81(_WD4XZG'UZ^OIT_+N&)$^ZBC/0X
M_P X]#Q^?;[RGQS"&$IT?[(I2Y*<(<_M9)ODA"'-R^STOR<V^E^R/@'P57>)
M<_[4G9MNW+KK=V^+SM<_#G_AI#]G7_HOWP7_ /#H> ?_ )?T?\-(?LZ_]%^^
M"_\ X=#P#_\ +^OW"\L?\\U_[[7_ !H\L?\ /-?^^U_QK?\ XB'A?^A3/_Q(
MZW_R O\ 4?$?]#27_@'_  3\/?\ AI#]G7_HOWP7_P##H> ?_E_1_P -(?LZ
M_P#1?O@O_P"'0\ __+^OW"\L?\\U_P"^U_QH\L?\\U_[[7_&C_B(>%_Z%,__
M !(ZW_R ?ZCXC_H:2_\  /\ @GX]_P#!)ZZM=3^&/[9?BOP:=$UR\\0?MK?'
M6Z\/ZW#=1-H6OV+^&_!6L>$7.J:2&WZ$RZL'!",R)J4VS+N%.7X/_;2_: ?3
MOC]X"N/B=^RO\;OB9X9^-G[-/P4^%7QV^$WPK^*/A3X)VGC7]I%] TAM'\7_
M  TU?]HWXDZUXY'P4B4^.?%4OPY^.WACP]\3K/5H_!$=Q\,/&WAOQA=-^N.N
MZ=J&I:-?Z9IVN:OX3N]1L;NSM?$&@VN@7NM:!=2J\<>J:6GB/0_$F@?VG;LY
MD":WX<U_1'>*-9K::-F2X^2=6_8F\*^)-3\<^*?%'Q:^+OBOX@^,/^&?%M/B
M3J/_  IJV\7>!I?V;/B1KGQ>^%7_  B6F:%\(]!\!"*'QWXQ\6:[XGA\1^$_
M$R^(AJ[P2*(EBC@^+S7,'F.99EFM2/+*K*4W&[DHM\K<5*RTBDDKV26B6A]A
ME. 66Y9EV$6J@E%NWD]6K_AZW/B[X@_MU_M;_#[]GG]L35+?P7^SSXW^-W[#
MOQWT#X3?%?QY<K\1/AM\*/''A'7OA7\&_C7IOCSX=?!E/$7Q2\11ZNV@?&[1
M?AX/ASXA^/21KXMT+7/%2^-V1H?!B_JU\4/!:>-M)M(K:+3_ .W?#_B#2?%7
MAB\U*T/_ !+];TAY%G,&J):2W.BR>(M DUCP+/K,*ED\/>*-:ADBUV">?0KC
MY.\8?\$_/ 'C/X3_ !Y^$UY\7/C;I"?M.?$/4?B9\=_B)HDGP<'C_P"(GB,^
M&/ _@O2+=SX@^$GB+P'H>DZ+X)^'7@WP_;P>$O!_AW$6@1R2NQN]<$GW/H-A
M?:/I5EIM[KNM>*KRPMQ97/B'7+?1K36]6E3<W]I:F- T3PSH"NP(C=-#\/6T
M (1HXB3(#Y.(H8;$X;ZKB4K6::[WM_7W>9ZE&MB,/B5BL,]4XR36EG%W37S^
M]-KJ?*GA'Q%/X@TBWO-0TZX\/>(K>..W\3^%;F?3;V^\(^(')&J^%M7?1BRN
MWAT@G^WU+>&/%"E/%WA)F\'O&3UM==X[^&9UF^A\7^#IM.T7QS:6VFV$]]J6
MEE]-\6^&--U4:POA3Q3/"G]LB.$:GKQ\(ZRLUU_PA7BG7=4\4+X:\2VDGB'P
MEXE\)A^(FDV6I7WAWQQ:7_P\\2:1J,>GW5EXK@U&QT/7]V2FJ?#OQ=J[?\([
M\3M$;!U]3X;D;Q/X8&K:$OC+PIX5\8%O"Y_-<PPV)R=?5\1K![25K>5[:+[T
MGT?0_2\LQV$S:U6@_P!\E=Q;O)KO"[<IK1VY5*<=%*.G,_2****P/1"N=\4^
M)]'\&^']4\4>(KQK'1=!M3=:E<BTU;4 ,!B3I.DZ&&U_6-:8+QX?\.=<X4%L
M X_B+X@:)H4T^EVB7_BSQ8ESIT%OX#\&6O\ ;OBV[OM7.-(!TL$+HFB,SKCQ
M%XH;POX2\*\'Q?XN\+^#P67U7P?X"UB2YT[Q=XW M-2L+E;CPUX3TZ]TZ\L_
M#YFTH:2^K:KJW]D6\NL>,HK;5==TB5X;@^&EBU0QVUO<3(?$9VP^&Q68XKZK
MAM(K=]$]?DWW7WV6IQ9EC<+E^&]OF7+[1J\8W7-*.B;2^*$=;<[C9/5*;7(+
M\&? 'B+P[:>(/$/C6<W7BSQOKYU.YTRWN%.E^#_#NDAM)\'^"=(>(K@Z'H:K
MK_BJ1[JXAN?B;KGCSQ!X56T\*7?ASPMX>^B\C&1R,$_E0<=#CGU.*7C'M^F*
M_0\#@<-E^&6%PJ2C%;:=O+S=_P"M/S3&8S$8[$2Q.(=W)MMMMMMV6[OHDE%:
MZ))=VRBBBN\YPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M"$]%_$_F?_K4X'EBH[?A[\<=>OKQ^%(PP5'8 9^@SG^M?''[9G[1EE^S3\$-
M?\6K=72^+/$+ZEX(^%UM;Z>-4\_XEZOX;\1ZKH4NJ HVDQZ!X<AT;5_$OB>?
M6G1&\/>'M42QB\0>*9M"\.:]I@<!B,;BL%E^#3E.I.-*,4FW.3:A3C9=VW)O
MHHR?2SXL?F&&R_#2Q6*?+"*;OIIU>OW*W=H_'[_@J)^T?/\ $7XJ6GP:\-^)
MM#U#X7_!]TO]=&G6VDWR7OQE1M;T;69=7U;S9G?_ (5WH>K+X?3P[H-UX?>+
MQ/K7CX>,G$OASP\_AO\ 2_\ X)Q?L_7/P9^ -GK/BOPX?#GQ*^*MP/&7BBTU
M/2X[#Q1H^A%I(?!_A36'DB7Q #H6C3?VU-X>\02ROX6\4^+?$MM&J2&96_#S
M]B?X*V'QY_:1\"^ M96_O_#6E0^(/B3XYW:E*U]JWAWP@=&:1FUC5HY/[9_X
M2/QKXM\*>'_%7F;/$\OAK6=<@,B-*OBROZU!$$);/ 18\ =   ,?7:.WUK]N
M\5ZV$X0R+AOPOR>/-.A%8OBN27+&KBY\[IIVD[MI.<HR5HKV$4Y)*WXWX:4,
M7Q9GF9^(6;13A-^RX86GN4&FI2VOVBK:N\GZW:***_#3]Q(U' ))&"3_ "']
M*^&OV_\ Q_XB\$_LN?$73/ OBX>#OBC\67T3X)_"36+?5Y=$UVW^(7Q<U>/P
M5I.J:/JFBR)K]L_A/2-2U3X@SZUX9CD\1^%?"W@WQ#XQCY\.S[/N=N%/H!^G
M2OQ\_P""FVO:K>?$O_@GO\/)M!U*U\)^(/VD/$OQ U/XE%6_X1WPUXD^&WP<
M\<'PAX$U5GCM](.O?$S_ (2[6#X7\_Q$P)\&:VUOX2\4*99/#WM<+X".9<1Y
M5@Y6<)UH*2ERM.$>>K*/++27-&DURV;=[)-I(\C/<1]5R3,\4MXP>W=M)?\
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MH\21BKWDK<JM&R/T'@BNVLPPBWIU$U=O[2:?7\O4NT445\ ?;A1110 4444
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M:;H^G/JVIRD9&=EO$S[ 1OP5R&P0 ?'/Q[_;C^"O[.'Q%\,_#;XAQ>+)M?\
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M0 5FWEG9:E:3:??6EO>6-[;F"XMIX/MEG=6C @QNI!C965N ^>H(#?*U:5%
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M%)_$?Q*;PE\+OBB]MXUMW\->+O#/A/Q3X8 /V)\7>,/!_@#PYJWB_P =>*]
M\$>%](MQ>:UXL\7:[I6@>'M)5=MB9M4UG69(]#TI3(T<3NTT<9D)#KR1)VM?
MS^:W^SW\:XEL_BM)'^UY'^U#XD_8+_8U\+:9J6@?&S]H\>$[CXP^$M6\>1_'
M+2_%_A+1OBG'\'O^$W\.:!K.DZZI^(_A9$D\4ZQXA\6^#I;GQIXB\62R_/\
M\:?@)^VK?:I\8_'7@!?V[H?VT=8^-W[;=OJ?BW1OV@?C+H?[.%U^R.OP7_:&
MC_99TGX;^$M#\>O^SZ#&?%_P@7X3>'O#/A8?'WPG^T$WB#Q?XS?PP1XK\5H
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MC+\2?$GPR\5? ,ZKH+_LT>+?%8^)WQ>\->% #]+J*** "BBB@ HHHH ****
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M-+^ _P 4O@[H_A;1=4U7R[B:2V7XA:?(NMZ[+YS0Z.YE+W3QLH!XO8?MC_\
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M+S3;'4/%_B!<Z?X0\":,^JE4C\0>+/$DFD^&_#"&3RY_$>L0H5 <(WR-X?\
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M+_AEX3\9>&_%?C?QAX:\,^(_#LTWTEG>/D(^O/\ ^O\ EW% #Z*** "BBB@
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M"'P0^)FIZ=X9\*>%?A5\9O%W@&_7P_\ &CXE>)-&^'/PZ\*^-_%7PQ\=^)O
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M/XC^,XG\7R+\0/B%KD:)HW@_5IKG7?#:>&7N/%$?AZ)89/"7_"41O\T?"/\
MX*:^+Y/#GP>^$/CW]GWXL>(/VK_B?^SK\'_BM\)=$EU_X+Z5H'[02>./!"MK
MGBO5?%N@^-'\+_!EK7QGX3\;>(_$WAZ>VGE\.?"PZ!XI\(^&O$WBZXNOA;X:
M )OVH?\ @F/\7_VK;WX>^,OB7^TUX,O/& ^'5_\ ";X_>'M/\ ?M=_#W]G_X
MS>#W\?ZKXOT/2O\ A2'[/_\ P4>^"-S&/#\6N:WX8GTGXT_$K]ICPSXDBUJY
M:?PS AEBF]>^$7_!.=_A1^T%X,^-\'Q>;6H?!_QL_;M^,<?A/_A7@T\7C?MJ
MZQX,U=O"YUI/'$D<7_"M7\(JG_"02>&I'\7C5Y,6WA4(PD^:/CM_P5.\>:O^
MS7^U=?? /X"_%/2?C[^SA\,?VC1\:Y[K7?@WJ&G?LU_$/X=>&?'.F:1J>D/K
MGB%]"^-D3^-](T7Q!X8CT'PX]K+\+(]9\6^+8+;Q@D?PC\5_;OP6_;Y^&/QG
M^,<?P \->$/BI_PM'1=2^/6@_$NPUG0/#&GZ=\+9_@/K/PQTO6-8\9:D/'$W
M_$F^)B_%_P"'GB#X1OX53Q4?%7A?6VN9(M ;PUXDBLP#\X/B[_P1N\6:1-^U
M7XO^&'Q4E^*VF>/O#W[;/Q'^#WP1^(>I_M/7_B;P?\;_ -JGX6_%'1M6C^'6
MMZY^W-X>_8^\'1W/CKXI>+(TUZ?]CF+Q+%X/\2WGA;Q%XW%W(_B]_J;X)_L%
M?&:!_P!F_P"(OQY^-?AO7?B)\$-9^!-UI?A_PI\'%\)K:_#KX&?!G]H#X;^%
MOA=XLU4?%KQ?HFN^.TU[]H_QIXA\6_&+PY!X5\)>*Y= T"/P?\(?!\&)1ZW\
M4_\ @H!X4^%OB;]H^Z\3_#GQ/IGP;_9)M?#VE?&CXSZQXT^%?A+P];?$'QMI
MWPNUWX?^$O"NE>,/'7AJ)]#N-#^+,,WB[XC_ !'\1?##PEX/NM%9'DO+2>;Q
M'X=\"\ ?\%@/A)\1K_X.V/A_PSHNMO\ %']HG4OV=+[XP^#/BOX9\<?L@Z/\
M0M(\*?"_QI#X2\)_M;>$=!N/A[XT\=?$?0?B3I.@?![P#X@B\'#XG?%GP;X_
M^$*^)O#7B[P[X9@\6 &[J/\ P3K^,Y^',?PR\,?M-^ ="T2Z\'?';]GW6M:O
MOV:-=UW7[O\ 99^.WBK1O%4GA?1GD_:/B\-Z;^T=X7*ZRG_#0DOA?Q%\+_%8
MU6.7Q=^S9,_AVV1O%O"W_!*+QIXWTC5_@9\5?B9-X7_8[\%?M >(OB#\/OA/
MIG@W3;SXP^(WT7X4_P#"G?AQXI7]H+1?'C^'M!\"_P!@ZLWB.3X=R_ Q/%D?
MBO1HT'C'PYX0(\(CZH\4?\%%]%\ >+[2P\1_L^?%>#X?^+/&OC[X1_!CQGI^
MM_"R\UOXN_';X9_%'Q;\-/%W@/1_!_\ PG8C\':+XAUO1_,\$_$+XC>)?"=I
MXE==<A\71>$'C\,R^+.<T3_@I)JFH>-/$_P U3]E'XH6/[8?A&__ +-UOX+:
M1\0_@WJ/@&VU34/A:?B]X+U3_A=FL>._#F@2>"_$OAK_ $:XF'AH^+?#/BBW
MUJ&7P7-:'POXC\4 'RO8_P#!&3X@Q?"KQCX'UO\ : ^"?COXF^)O%GP:U*P_
M: ^*7P?_ &^/BS\7O!EA\!]-\9'X<ZQ\./B!\3_^"L7BGXD_"SXK>&-:\:ZI
MXB\'_$+X(_$WX6^$O"JZQX^\,2?"KQ)!XL5_#'[-^.?@YH?Q,\#>'_!'C/Q9
M\7IH/#UUX<U@:_X ^,GQ.^!OC/6M6\)GS%OM:\7_   \0?#'Q!J^E^(97(\3
M^&?-7P=XD)3S?"1MUCCB_//P9_P5^_9_\81?$3Q/>^&?&/P^^'?@']D'P;^V
M =4^*UUX:\">-O'WPO\ &7A+1/&L/B7X1>'-6UT^ OB?X#\*KK<WP\^+'Q&\
M.?$I?#'PK^+.DVWA3QBR>%?$WA?Q=<_3G[&W[7_A+]L/X=^./&GA"_\ AEXD
MD^'WCZ]\$:[J/P$^-_AC]HGX2:MJ<?A_1?&FF#PA\;=!MO#.AZ_,/#GB_08_
M%^BS^'O#4OA'Q9!KOA=5\2>$8_#7C/Q> >D:?^S9X7D^,UI\>/&'C/XJ?$GQ
M[HMMJ5E\.]-\;>.M57X9_"S2]335H6_X0KX/^$%\,_"!O&J:5KFN>'/^%S^)
M_"'B?X]2^$]<UKP<WQ6E\%7 \-CX;^*7_!*GPG\3;SP#X@F^) T/XC?#O]N7
M7?VK]+\;V/@-KNYO?AKXR_:&\'_M(^+_ -G+5=-G\<0PG0O$7C+X:_#BXE\=
MQR2R0>*?!/A_Q8/"#I)X@\-W?%_L[?\ !3#XP_&#X8?!.VL?V:+_ ,=?M,_&
M'5?VAO$MU\//#_C/P#\.?!VA_ GX!?M)1_!WQ;X_/BG6?'GQ)!US0-(\6>$=
M \/> I)3<>,OBBOB")I_"G@MHO%EI]7?'K]N?P/\(?V4/AU^U0D_PDT/P]\5
MK/X>:KX+B_:6_: \ ?LH>#GTWXA>'7\<1Z3J_P 2?&G_  DOAV/QR/ T.IIX
M9\,^'H?$[^*O%L0MC<>'O!Z>)?&WAD ^1_B1_P $J?B-\7O#?A?X??$']ISP
M[<?#_P"#UG%X;_9GTWPI^SKJ6@^(_!?@T_&GX+_$W5!\>?&&M?'CQ1#\;/&<
M'A_X(^$_A[X6\1^%?#WP)A1]8\3>+O%OA+QA=7,-OX9^K]%_8;\/V_QH^./Q
MOU/XH?%"X\3?$KXS6WQC\!>&O"WQ-^/GPQ^'_A#4Q\!?@G\'HM(^)WP[^&?Q
MQ\,?#C]IG1I)/A#%XG:'XC^%&T"&#7M:\*I;Q7,GB3Q1XG\A\3?M9^-?%'Q%
M^#NM?#'Q-J&E_"KXOC_@G5XQT+1M3T'PK?ZJO@_]I7Q;^TP?%VFZG(I\0I#_
M ,))X=\(>$5D">("?##Z.TGA"?S6GDNO3OBQ^T3XT^%_[27Q!L-8T+XRZS\)
MOAG\%O@+XDTSPW\/[;X!W.F>.OB-\<_BE\8_AGHVC:D/&^N^'OB%#K/B/7=
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MH77Q0M3XC?\ !2Z7P!KOCG3=._97^-7B?1_#'@O]H#X@Z+XGM?%GP>LAXO\
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M[%Y/@[PF_AYAX@Z;X%_MZ^!OCY^T/K/P+\*>&-?\-?9?@5\//CUX;UKXDJ?
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MSJ2EM.\0^%-=TS7=#O  #^YU71I)H'(R-XC=PFY0W)"U^$D'_!,CXY6<VO\
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M?BIHO@Z6.Z98YM>\+Z!#XB:T8Q3O+$LD<GY;6O\ P3?_ &U?A#\'?V8?@?\
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MSE\'-7T?Q%X&\%>(I_&FDZ[XB\1'XA^/_BO\8_BU\3/$.O\ BSPR?!NJZO\
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MFT?3_P!G9O&1^$$0D_X2!FU1?#!\:>+0TVO/<+XGCUF4>+6\0&.)8]CQ_P#
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M?Q&\/?#>Q\3:]&KNVF:*^N:S FJ.(Y$><*DB^'H1-X@NE\B(NH!SOPX_8X^
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M]CGQMK/C+2?%>I^#/&?C#2=&T?XZ_!365U37;CXA"V'B+1X/$7A0Z]X8>W2
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MN?\ @GI\%)O@3\6?V>M/U;QOIGA?XJ?'WQ+^T?\ VZ;'X6:_JWP^^)^L^/\
M1OB;H@\':/XT^%_B?X>S:!X4US2-)A\,^&_B/\-_B/H1\,P2>%_%L7B>VE1)
M #K?"7[:_P -_&'CW2_AMI'ASQG9_$&71/&/B/QEX/US4?A78>(OAQX=^'?C
M_6OAIXTUG5]%D^*:MXQT?PQXTTHVWB;7?@RWQ3A@75O#(FD \3^&M_&^&O\
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MS?M!P>&_#8^#NM^%_"WQ$;X92^'/%_Q377/"D7_"-^%H/#7B_P 7 %7X&?\
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M_:#TKXI:S\)_ .H?&BS\+6_PKUCX6^&/@%\:OV<OBK\0?B5X?^,/Q6T7X->
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MD1>)CHDT"^(U@M$E29$Q!Y-I_P"R9^ROI'CGX9_$C3_V:?@+IWQ!^"'ABR\
M_!OQ]9_![P)9>,OA#X)L=.UO28O!_P -_%</AV/6O!/@V+2-<UFTM_#OAAM"
M\-0PZMK"(K-?S9U_VG^MSYC_ &:VVOR/(OVN/C=\;_AE>1:7\$;KX4Z??Z5^
MS[^T1^T3K^K_ !/\'^*_'=IK&F? /6?@P(/A[I6E^#O'WPWFT2;Q_HWQ&UN)
MOB \WBF/PK<:-H[OX*\5-*8J^'O&'_!3/XQ?##XN:Y^SM\0O#_PTF\<C]J3]
MGKX):;\6/"?P]^*NN>#O#_A[]I']FWXH?'OP>9/A!X?\0^)O'WCKQMX>U[X=
MO\'Q%X=\3^%H_%C:_H/C%HO"<A;PDO[0:]X-\*>)KF:?Q%X7T#7I9_#?B#P5
M-)K>AZ;J?VKPAXTFT<>+/#$QU6.9CX>\2-HFC'Q1H#9M?$7]D:+)<1RFTA1?
M._&_[-W[/7Q-TCQ]HGQ$^ GP7^(&B?%A/"</Q8T;QM\+? WBW3?B4O@"1'\%
M)\1=/US1KF#QG_PBJA1X47Q+'=)X9)#VL=NBF(=!D?F#!^W!^V+>VGC2'7OA
MU\)?A!>? ']GM?VB_B?I'Q \"_%36O$/Q6\'?\+Z_:"^&VBZ?X,TB+QSX3UO
MX*M\1_ OP/T;XDPGXAQ_%'Q+X*F\9#PAXK\&^)#$?%"YDO[:7QD\/6NI^$O@
MSI/@G0;I?%__  5%\>ZYJ_QJUWXR?':,:;^Q5\:M#T1-)T8:U\5_"WB'0_\
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M?@;PM82:QJ?PT&E:7\-]3U0)HT2ZGJWPZ71='?P;<2%I?"RZ/H<?A9H!#&
M?AY\4_V[M?\ CKX3^(W@?PU\1/#?CGPS877_  31^._PY^*/@/X/?&;]GO4;
MOP/\>?VU]&\'P:,_A3XG>./$GB'QQH>O>'_")\0)\1/#9\->%O%/A;7IO"#>
M%KAW:=_K#7/C5\6%U'3(O"OBC1="^&K> /\ @IWK_C'P'XANO'WBSQ;XRO\
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M'C+1M#3Q#_P@VA+HNCM:^&I;L^&(QI6A%(XTMHU3WB@ HHHH **** "BBB@
MHHHH **** *;ID*3@80H<XXW9'XCD$]OK7XU_LJ?$J_^*GBW]F7XE^"M3U;2
M? 7[0_PO^.?[5=UX6U2Z\'_9$\&_$OQ;X)^,'PXL-8T:82>//^$Y\*K\7?["
M;Q#\./$\GPKV#Q'_ ,)C'XL;Q/\ "E?"_P"JOQ%T2^\3>"?&'AG2KV/3M4\0
M^%/$N@V&IS+=!+.]U72WTR&_E^P%)0L#2I+NBVRIL'EX!*U_&O;:/X+\??\
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MD^'FO?M+>)_ OC#QPK:0/#O@WQ'\1O%C!?!VJP-XN\)^*/%B0^)_$GE_P/\
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MKX,2_LZ?$S1/ ?QR@UCXTCP]H_CS6O$O@;_A)?B7\,/BSXC\0^#/'*^+Y_\
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MM#_:1D_:ZUKQ!\2I1J_B+QOHOQ0_9C\.?#%_"OB'X?3?"/Q-X?M/"DWBK]H
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M7BS3/A3K/QU^'/AYO&L7B+3_ .QO"1_XISX6[5>7Q?X.\6S[CXLZ#XC?'?\
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M8^)O#:E5R-K/A/@S_@J+^P)\:OV]_'_[,2>(_C)X%\'?LD_#7XZ^'OC5\2?
M^D:%JI\2?%'3O"#Z/JOA#PWJVJ KX?UM)O)UY(9)8@OA=-;:2-/%,BH\?W;X
M1_9Z^"'PUDL_ OA'P/XN_:'\:ZRWB&R^)WBWQ#XCTMO"=[XRTGPKH2ZIXM_:
M,&C?\(U\'= UWQ,S>#S)X;^'?PJ;Q6C:Z?%?@OX0CP5#XIN?#O20_L/?LQ.#
M97W[ ?["D>ES6OVFY$'PP\ 7Q.H9&,:4_P !T5\ [MQ9FZC<6X/=A\!9=%:U
MFE:W?U_3IN? 9OGV68G&_7<)EDM;J2FT^9?9LK^[R[W2]Y.T[M7?YF?L$_L+
M7?[$WQ7_ &I1\/\ XC6VJ_LI_$WXB:=\2O@E\%O"?BGQ9X4U#X1>,M8TK'Q=
M\*E=&U_PUX=71/$>M'2-=\(^'$VIX3CT- $#!W?]/? OQ-URP2>T7Q0?B3IE
M_<_VMIEQX\)\(^+O"5D[!W\,:JGA#P.YU=?#LC,L>N2>'?#?BF*)8T\7/XG
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M !1110 4444 %%%% !1110 4444 %%%% $4B#80.Y[_C@?2OYV?VP/V;=0\
M?&34M;/P_P##$USXGG^,_BO]FC]KE_ASJGBKQ%^SI\4OBQ_:_B_6?#/B_P 5
M:'X=\0KX,\/^(O'6M^+-_B3Q#XB^%?@_Q1X6D^'OP> ^*7C+Q1XH!_HKX ]
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M]BC]H']F[XN_$CX/:-XJU_XT?LO_ +3?A^WU7PG\*_C7HGQ'U7QQ\$[7QYK
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MX(:AK_[3G[.6BWFLMXF_9C^,GBV0>$/BT?">G:1X'\52:-X_\0:ZNK:_X/\
M ?B/PU\3YO%?BN/79O,'PD^)WPMG;^MWXF?M/_\ !/CXBZ4?$OB7XS?!@ZQ?
M7'A^U\<^/-&^. _9V^*6D>$/",PUYDD\8?"_QSX<^(']K[%T36H_#Z^(_"OA
MGQ/%K7@5BTLDGA+POXEVLM5>^^KTTTY7ZVZ=->VO\N^+W$.6<6^(?$O%N5Y0
M\ARC/O\ C*90]U\DFVN*FY1M%I<5<SYU:_-&32E)QBGCT+XUU?X@^"-:^,WQ
M2\2_LP?#W5OA9X>^)$'B8>!+\^$?&WC/5/&OPY;P!\1/B-I.O^&OB'HFL_#4
MZY^SC^T.B_$?PWXL\3Q>$B?%/QD;Q0/B5X5\4>$_KC]IK5?A]\0K6?\ 9,\2
M:SX/U_7?VB-,LO!8^#^NW6CGQ'XS^%,FL-I?[1FHGPGJL40;P[X4^%$TFNIX
MC=)/#+^*%\.>%I7EG\5>&?#'BWS!O$/A#X__  $\6?!C]F?X87GCSX8^,/#&
MH_#R?QKX\TOQ98?#&9/%7A;6=(/Q UWQ7XSU_P *>//C3HC_ /$E\1R>*?AI
MXF^)7B7Q7))'"WC#PKXL<>)_#7V3\,/A78> ]9^(?B>ZU#4?$_CCXE>(=,U_
MQEXKU,,AO3HWA?1?!GA+2=&TL[D\'>'_  [H6C;X_#GAH0>&1XHUOQWXP>,>
M*O&'B:623\V/$-._8(_9MTK6/[2M-&^*5OI*Z_J7B&/X:']I7]I0_ 2TO=4U
M!=5;1M-_9UD^+<G[/VE^"!.Y8?#^+X9)X0*["?"Y!8R_9UI9V>GVL-I9V\%G
M8VMN(+:VM[<6EI:6B@$(J !%V@=%V#OL7YF-JB@"Q1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ;-J]_JVC>%(XR-$T7XBZ'H^D_%KPES*?#?B9-9FN9//D\+/XD^O_P#@I/\
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MX?#T,GAM9IO$L7\5G_!(G]HS6_BL?A__ ,$LO%OP3^&'Q.TRP^,WQ"_: O/
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MLOC9<:5\)]8OM-\$?L8C3?BCH@^+'A*3XD^*UU/2#\6?V9O@YXRA^&.MR/\
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M]KJS_;OU3QU\ K']FZ^\8Z1X%U2T2R^)VI?#FU_9IM8](\3:EXP\%'6M6^,
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MX)_%7X%66K?'KQEX=N_A_P#$OX:Z9X4UVR^%.B_!S6Y?"?B76M*T;Q%\3_\
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MLJ@)](\D>WYFI/)$HI?)'M^9J>@ HHHH **** "BBB@ HHHH **** "BBB@
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M2Z+X0\*>"O">D:!JDOAW6]#?7O#UOX;^'?@K1;CPMK37OA[5[/PEH3:E9O)
M0N='^RG^SW!J<^LW/PTTW4;_ %8:H4FUG5O$OB"*STZ^T7XE:3<:1IEEK&M7
M%IX?T)O#WQ<^)FC_ /",Z$EEX?%OXUUO%D#*C  Y[P=^W-^RS\0_@1X<_::^
M'?Q<TWXB?!+QEXQTWX?>%?''P]T'Q7X]7Q%XRUKQT?AKI/AG1]"\&:%XA\2:
MKK$OCE8_#R+!X?E;S)$<L4$DK>7^(/\ @IY^PEX5\ >'OB=XW_:$T#P;\/\
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M_#?Q*N==^)GQ4U^3XG>''TO5-%TK2?B?_:OCBX_X6C%X>\/ZUJ.D^%#\1?\
MA)?^$,@F4>&19% ];'B']E3X :GJ^I>(M1^'D%MJVMW%K;ZCJ?A_Q%XJ\.7U
MWJ$WQ9U+XP:+K$LGAS6="*Z]X<^+/B'5OB)X7\3;Y/$'@WQ)K.KW/A:]T\7'
MS 'C_P #_P!N+]F?]H#XI^$M"_9VU&/XDVGQ3^&GC3XBO\8O"WAK6+3P?JMA
M\-9?@V=/T9?&>M^&]"TCQUKK:+\=M)>VB\,>(O$C^$4CU>U\6V]FP<++KG_!
M0']GGPG*+[7-:UKPWX%33;77E\8^)?AY\:-*3Q#H2_#+XW_&*35_!FDR?"J;
MQ!XS1? _P.U_7H=<0P>%/$MK)]D\'^*O$_C&&W\'^(/;O O[./P7\"^-]0^)
M_A#P8EAX_N[/4=#O?&%_KWBC7M;N7UI/!>F>*;]Y/$NNZ\@UKQ='\-/AZOB[
MQ1D^(_&2^#?#3>,;[7VT.S%<M>_LB_LVZS:'0=<^%NGZ]I\FGDV5MXEUOQ3X
MHCTS0+CPKXS^&R^']'.N:[=-X?T&Q\!_$?QMX5\/>%]#%EX?\'Z3XMUZ#PS:
MV"3HE 'E\W_!3']AU?C?J?[-/_#0>E:C^T5X=M[2\U7X$:)X7^(.N_%NWCU;
M3=!UVSTR?X=:+X.D\5-X@@T'Q/H>LW/AV/0_^$CT1&O3<VRKH'B1;7JH?VV_
MA8/BOX=^&=[IGCC1H-?7XQ6UQXQ\6^#O%7A?2;7Q!\(?BI\%?@^^DQ1:SH:-
MK>C>(_$7QPT=T\4>'A-X:\*C1M;?QG/X:<ND?IFH_LV?![7]1\1>(9?#NL:3
M=>/-<TOQ?J[>&/'?COPC:WOBZRM]+GA\=#0_"/B+P_HNB?$-;70M/T__ (3[
M0[:W\:-;6Z*WB'#,HYCXC?LA? SXE>'?'NAZOX<U*UD^)/AOXE> M<\1:?X@
MU0^)]+T'XM7'@BP^)">$]5UN;7_^$9E\1ZA\/?!NO3'2(;1!XHT>/QD%3Q03
MJ! (M4_:B^ B7'PT\80-XA\0Z?\ $'X97OQ#^&WQ&T#X5^.O%.F:AX1\5^)O
MAKX3TG2=(U?1O#D^O)JWQ+UWQ7X*_P"$5\.P1^9XJ\K1YE0D>&#-SGQ;_;%T
M#P%X8\(>,_#7A/6_&_A?7K7XB:YXAENM#^*/A?4_"'ASX2:QH^B>/YM8T9?A
M1XFUSP_K6@ZSJMQ#<+\2(?A9X3\.3:/<#Q=XU\*)%YDOM>O? 'X4ZQI/A'2;
MGPM'8Z1X&\,-X/\ !=CX<U7Q!X-C\*^&H+KPAKFF:;H"^"]9\.1Z5'X;UCX>
M^$M:\*26L8NO">K>'M(NO"5UX=EM(Y4S[WX!?"GQ!H&@>%;K1-;ET?0)O&(M
M[6/QSX]TNYU:/7_$,-YX^TSQ=K6F^*$UKQWH/CO7XSK/C'1?'EWXIL?&EW))
M-XHAOF;90!R/QP_;)_9K_9T\._$;Q?\ '#XI:?\ "GP9\*+GP]8>/_'/B[0O
M%MCX$\.:EXQBT=O"NEKXO_X1W_A'-8U[7%\5:)*OA[0==N/$FW5$#P*$+1_/
ML'_!4W]EZ1=.\7#Q8K? K5_AUXT^*^G_ ![LH-8USP?=>#/"DW[,/]FZN-+T
M7P]-X@.A^(8/VH_"I76G@,'AB70M93Q?]AC4LOUWXL_9_P#A9X^O=:N_$'AR
MZO9?$6I>&?%FI-'XJ\8:3#;>+?"ITYO!_C?1++1]=M8?#OC_ $#^PM'-KX\\
M,/H'C*$:'H\,>O\ D6RI'B7/[,?P9UHQW4WAG5/[:E\-ZWH,_C*W\<>.]*^(
M-[X<\<-X%?Q1IFI_$'3/$<7CS4D\3K\)OA['XI%UXH;_ (2#^P87OW<[ED .
MK\1_ WX+>/\ Q]\._BYXX^#_ ,,/&/Q5^%(OV^%?Q1\6_#SPEXA^(OPY;6PD
M>M2> /%FM>'I_$?@N3Q!"BQ>)!X=N-!-PA,<Y<1B1?:*X?PEX7TKP-X?L/#F
M@6HL-"TBUGLM+TU+O4+N#2M/MKAPNFZ=_:-S>-!I-E!B+0M(S]CT&SCCTBPV
MZ<L:0]Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>tm229830d4_1012b-img23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm229830d4_1012b-img23.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '9 E,# 2(  A$! Q$!_\0
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M:-XD/PL^*2:9?^+?"N@Z_P"%?$VMZ-$RDMHWAWQ7X7F>1]S3LR9 !];>$?\
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M"GPF_8BN;Z)/VG/VM/C!\9/'>G_'/PU=^,=5^._Q3\,?"6'XW_'#POXST,>
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MCCP?\%O"GQ?UGQS\-I/ VA_$;7IPGC-_#7BWPQXD\4>%M"?PC;^)+9?$[^>
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M+PAXB\A9+AY!YD-NJ.]?744@E2*2(CRW4GGKCH,?0BOY%O\ @J1X4U#XX_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\(_$7]HG]IGXL?#3X7>(M(D7^R]7\&_"CXH_%GQ-\/=%UBW 6:%QX6D_L&9
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MA3Q]X,\2Z#(6>#Q#X7\2>'_$,2B1(Y0LC))]-44 ?BQ^TM_P2^^'7A7]A_\
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MB]@M-4DN(M.OG4YV+(VE:N(\EC(VFN4/R,:VJ "BBB@ HHHH **** "BBB@
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M47Q4T#4/"WB71]6;4HO#OPCU+2-<6Y^&/@>=QI</B+PMX5$?AB>/2="WJ?\
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M5\%-#\0ZG!#8ZCKVF?"7P)H/@?3=5U6)"((-5UR/1HKB>.',&^1A&?ER_O\
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 ?/G[2WP!\&?M1_ _P >? ;XA:MXVTKP-\1].T[1O%S^ /&.
MM> _%5WX?&LZ3JNI^&X_%6@ :_I>C>*(=,;P[XL6!XI+OPMK6M6C30AUDA_"
M[_@@KX&A\%_\$[?VX_AG\)M-;0;#P=^W;_P4&\"?"_0]/74[L:-IVBZO#H?@
MW3-(!8ZXPM_+T@QMS/(5#JJ228K^E2O*? WPI^&7PITK6]&^%WPW\!?#/1->
M\5^(/'>NZ;\._!OAGPKI_B3QKXLF;5/%GBC6-)T+28(]9\1>*6VR>)O$4R2>
M(]?N(WFG=F$<E '\-7_!-_XC_"'XA>(?^#9'X-_"'Q-X7\0_M*_ 'Q/^W9=?
MM/>"/">IZ<GQ#^%6@2>%O&P\8#XP:8CG7]!_X2G6=K1IXB2+_A*C'*ZO(TBA
M/ZWOCO\ \$Y?@Y^T%\9[/XT>*?&?Q8\.37MY\%K[XF_#GP=JO@2S\ ?&A_V=
M/B!J_P 3O@7'\1)=?\!>(OB-H</PV\=ZWJWB"&/X,?$OX5'Q--(8O&1\3P""
M"+Z:\'?LY?L_?#SXB^.?BU\/_@-\&? 'Q7^)[1_\+&^*'@SX9>!/"WQ"^(@7
M]Z7\9^,M%T2'Q%XR>.0*P;Q%=7# X9>F:]SH _'_ /X*"^+/VFO@G\0OV=/B
MI\)/B[^U0G@?QW^UA^Q9\'OB!X,\*:#^P/>?LR^ _!OQ%_:^_9]^#_C./XMC
MXI_#M/VQI=8^-7@CXK>)_#_@R;X#^*_%;>&/%L<7B3Q;_P *P\+0QW$W[ 5^
M&W_!87X26OB_Q1_P3R^*5[\.?'/B6]^$?[??[%ATWXC^'O!O['&M>!?A?)\0
M?V_OV+=#9?B%XQ^,NC7'[7?@E_%R*^@>#1^QA=6:^*->C-K^TJ)_A8MK:U^Y
M- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %?,%Q^U-\*+/X[>/?V=IYO&W_"P/AI\&[?XZ^,-GPS^(5QX4M/A\^J_V2C:
M5X]B\.R>'O&7B)AN<^!_#$WB#Q42[YMA(-L7IWCGX9>&?B)-IHUZ_P#B!8-I
M NULQX(^*_Q2^&@N1?["QU4?#+QOX6?6XQ]@VHNOM<1(2_E>7(T@;C?^&:OA
M_P#]#%\??_$L_P!J;_Y[] 'QQ:?\%9_V1+WX/?"CX[VI_:#MO WQJ^+=Y\'_
M  O;W7[+/[1J^*[#Q=HT4NK:I?\ B;P<GP\;Q'H'@F+1(TUR3Q3+ /#+VL_R
MW,KV_B.&T^F/AG^V'\'?BO\ M"_&;]F?PD/B-_PM3X$0V%QXZ;Q#\)OB9X5\
M"3PZI'IDD3^$?B-X@\/6W@+QGM&JZ86@\-^(KN9#,64>1YLR]?\ \,U?#_\
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MN5\&6S&YU>>!?"7B7Q9(?['M;641CQ#/KWA7JM?U+]HB+QE\+$\+^#?@S<>
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M9CEF:8=XG+<?#-(*I5I\T&FO:Y)-PJ*Z;7,JB:?]ZZ:332TZ***ZST0HHHH
M**** "BBB@ HHHH **** "OYPOVE/AI\4?\ @IU^U+^V/X6^$MOX%U/X5_LE
M?L\_%7]AKPCXC\:?$/Q3X%7P[^V3\?/"?@SQE\2?BIX(.B?"CXE'5M9^!_@I
MOAMX%;S7T!D\3:SXGBC+J(WC_H]HH _C5L_VJOV5_P!L'XZ_LS>)?^"P.H?#
M/PY\%/"/['OQ8^'6F>"/V@/%.GV?[.6E?\%#O@C\5/$'P9_:^3Q;'K<_AGP&
M?CFO@,Z+XA_9Y7Q%GQ-X7\)>,V\3^"EM?&-S$T78?L>6WAB#0?\ @D)#X(G^
M),_@@_\ !7__ (*7W7@R?XQ+X\3XFW?@U?"G[:H\''Q</B4J_$K_ (2!M!_L
M7S#\2F_X2MMJOXN/FF9C_7U7QI\3/V2/#_Q=_:=^ 7[3?C+XJ?%NZ/[-4GB?
M5/A=\#(C\-;/X(VGC_Q;X4\1^"-4^*>KA?A9%\8=4\</X,\7ZGH%NS?%0^$/
M#\,9%KX2A:Y\4OXC /YH/VE/CO\ ";X8?"__ (*F?L=^-/&&G:#^TKXP_P""
MP7P(^,7@WX-7%CJH\8^,/A7\2?C]^R-\3-"^*G@[2L@:OX$70/"&N#Q=\0"I
M\*^%?%>C#PCXR*_\)'X6'BSZ7_;.\7?$K]A7]I?]J;]F?X20ZT]Y_P %N;GP
M^/V3]3T32]2ETWX0?M<ZOIW@C]G_ /:/UK760 :#HJ?"[5M#_:&/B,819_!O
MB*,!F,;C^I.B@#^'C]M/XE?L'^#? 7QTLOA9\$/@)\%/VX_V=OVR_A9\+/AG
MXL\2?'?Q/XN_X*5:2GP'^(?PP\'Z/\4?"7A ^ ?$_P 1/AE^SAXF^%>CI)X/
M\.'XH>&?V>XOA9J44J^5-XEC\+O^_7[1W[%G[.?[8O[97QGT7]IKP##\9?!_
MAC]A_P"#EIH7@+QAJ6J7O@"P\0>,OB+^UQH\GCS_ (5V8X_#\OQ4\,:'NA\%
M?$HH?%_PNCUO7)?"$OAM_%+W,O[&T4 ?QS_#ZU^"'QB_8W_X-YOVGOVV_#/P
M?\=_V1\;M0^$OQ$_:"_:"\*^$/%LL?@W2?@C^UKX,^#_ (7^)/Q%\<Z%,CZ-
MXC^+&C_#9T/BOQ"J?\+6'ASQ<8Y?& RW]C%%% !1110 4444 %%%% !1110
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M%JBBBNT]8**** "BBB@#,-S"4BWC#2@E%"!\ D@$\\9((&<^O2G9W(XD?>@
M)0(5*#L0I&T>X[9/M7YS_P#!3#XP?'#X'?LT7OQ#^!=U;:1K%CXR\,Z;XN\1
MS:?IE]?^&?".K7<VF)J.D:=JIGTB^U"3Q;)X2T*1;C0?$*G0-2U=D@M78>)M
M"\]_X)0_%KX[?&+]GC6]8^-.IZ_XD_LOQ<-$\ ^-O$L5G:ZAK/AC2_#FA::Q
MAE&CQ3>+UT/6=.U;S?'6N7'B,^)_$;:T3KTZ:.%'AOB+ +B!<-)M9K[)XC5-
MQ5)._,I6?*^5)7MRMVBY<S43]0P_A!G^)\&<P\</[4X8?"E'BZ'!LN'GBHQX
MJEC)X=5^=8-Q2E24)*7+[5UG2<J\:7L(2F?K71117N'Y>%%%% '+)-=)))(B
MPBT1[>2$QX$OD!6>Y\TCYL@ ##G&\C:,'G\0/V4?VP_VCM-^.'[2.H?M/^"_
MCSX8^!&O#QS\3/"7BWQ[\*O'.G>%/A#I/P_L-1U6#P^GD>#5E31M9^&6DZ:Q
M@CD@5O%_AEPGAS7_ !M\1_$LS?N0L:[07:!7&U[W8V0P0<#"C;LS@NJ,03S@
M8&/YO/VU_'?QI\6?MUZ3XFL/V=?CA\2_V>/A9INE_"WQ1X=?X3?$7Q7\/OBE
MX9N]4.K?%C5M*\#ZQH6A:!J^J2ZVNFIX2G2/7_#GB?6_A3X&\4R>)D\-2^'W
M/XQXL9EC^'WP5Q/A,QXF:RGB:%&7#F"I*K0X@_UDB\*Y\31IPJ55P]PY"3Q%
M1PASQLG"2J\LC\"\<,YS/A=\"<5Y;F?%-\EXJA0GPO@*'M\-Q*N**;P;J\5P
MC1JUO]6>&(MXRI[%QJ1G:4)>U4#Z8_8&_P""@_Q@_::_:/\ B'H_BCP)XAN/
MA#KUH^C_  W\2:#X4\20^&_!=SX2U3QCXATV'XA&.'Q!I&C^+?&W@O6-.CU_
MQ!=>*/#WA_\ MSPCX?\ #/AWPY/=^(?M$G[;RG8Y*KPL4K@YSDG.?U_SS7DG
MP^^"7P@^$<FJS_"[X9?#[X<OKAL1KX\"^$/#WA8ZD+%YFL%U(:+IL"ZD83?Z
MEY,LX:2V74)U@V/+)(?6]GEJ?,.XJ)B#P?EQ@>N>1D?CS7VG >1\3</9!3PG
M%?$/]OYP^=SK*G&E3BYSE*,*<4W)QBGRQ;;]WEUFE&3^Z\.,BXMX9X8I95QI
MQ0N-,ZC7S^I5XE5".'4HU:TJE.DJ,6^6%*,E3BIMRBJ:AS2C&,I:E%%%?9GZ
M&%%%% !1110 4444 %%%% !1110!12'_ %;=PFPC(SR3C]#UZ<_ES/BGPKH/
MBW0-1\->)M#TGQ+X>U6V>SU/1-?TO3]<T/4K1]I:#5-,U)9H-1@+*I>*:.2)
MB%+*6&ZNMSW '(XQTYX_QK\0O^"[7_!1;XV_\$T/V4/AO\<O@)H'PP\4^+_&
M?[17A7X2ZIIOQ8T7Q)K^@V?AS6OAC\7?&$NHZ9IGA'QM\/=:EUN+6O 6DQPB
M3Q"8$M)]7_T9Y$CDB^BX!X#XD\4.->&O#KA"E3J\8\;XVEPQPOAY5J.'57%X
MKVSHQEB<2GA\.FZ-24JM=>RA&"<FEJ88C&QRS#3S&4I*.5P=233:<8Q45)IQ
M:E=*2LXM2O>S/VW4@@,PV^8"&'3!!^GKSC'%>;_$GP(?B7\//''P_G\3>+/!
M:>.?"'B'P;<>+?!&JZ;IGBSPV/%NG7&B3ZMX1UK5-#UN'2_$6C0ZG-+X;U>?
M0+B.UN5M[F2UD\M2?R/_ ."$_P#P48^-G_!2_P#92^(WQQ^/?A_X8>%O%W@[
M]HKQ5\)-+T[X3Z+XET'0+SPYHWPQ^$7C"+4=3TSQ=XV^(>MQZY+K7CW5TF$?
MB 0O9V^D8MTD>5YOVU=Y8X+CR8Q+,D)$4&0H9@"NWGL>,_3 ZBM./. .(?#'
MC/B?PYXSHPP_%_!F,Q'"_%.'A6HXB%/%T%2^L1CB,.OJ]9?OZ<U5H?NIJHY0
M=K,K!8^AF&&6+PLG*G**<'9J\7\.CN[6LO>M9+7L?.LW[-?@"/X7_ _X4>%;
MKQ%X#\*_L]Z_\*M4^%\WA&ZTC^V-$L?A&RZ)I7A)I_$&A>)G?P]XB\$?VK\.
M_%4C1IXLN/!^O^('M/%/ASQ:8O%$/AFN_P#!/?X>7WPU\ >!/!7Q<^.OPD\1
M_"G]HCXJ?M*_#3XR^!-7^%U_\3O"/Q!^,7B?XHZQXRT^"'XE?"GXE_";6_!6
MN:5\7O%_A=?#GBKX::ZL?AA]#EG$_C"V7Q++\;?L?_M%?&WQ=\<?A?X2_:#_
M &H?COX)_:5\::I\6;SXF_L-?M!_LU>$O@1\#_[!\'1^,TUO3/V)_BPG[-?A
M[Q+^T1-\,=:3X<:X/%'AC]K[X^^&/%/PGDU_Q5XM@\._\)-X<3PM[%^T#^U)
M\:_V?_C'^V_X9OM8FUG3!^R3\*_C)^QYHVH^'O#%IH-C\4]9\7^,_@;XP\)O
MK.F*WB#74E^*NL? 37&B\1*RVL7CN2VM7CBCW#YDU/K3PO\ L@?#KPAKO[,^
MN:=XF\=W]_\ LL?"'QG\%? O]NZII.H#Q!X;^(.D^!=*UK4_&:IH43:OKC0_
M#C1]ESH$GAE8Y)=9=U>*1+=9_P!GK]D?X=?LU:;\.M)\ ZGXWU.V^&OP7\/?
M S0I/%=_I%[+=^$-$\3:GXL34=7;2="\.K+K\NJ:K-')<1+!;B [(_#<;)Y\
MORE\#OVC?C#\7/CK^R)\,M-^(\FJZ5X+_9F^,'C/]LBY@\)>&57QS\6?!_CS
MP_\ LW:'I]_JVG:!]F\(,OQ:\,_'?Q(=$\'KX95Y_!)MB9/#%O)$/F74OVA/
MB#XL_:O_ &N/ /BK]LW_ (*6?"VQ^%W[1WAKX:?##P-^R5_P3\\-?M"_!'3/
M!6L?!/X)^+U7Q=\7/^'7G[32:3X@_P"$X\6>,Y?%47B#XZK_ ,(SX9?0WF7P
MVF54 _H HJ&+Y8XP9/.XQYQQ\W7GC/7H>3[FIJ "BBB@ HHHH **** "BBB@
M HHHH _)+_@JCI'BJ_\ !_[*NMZ9\*/A#XQ\,:'^WW_P3D?Q5\2O&?B[5=$^
M+?P?.L_\%(/V,HM"'P?\)#X4>+[?QF_Q U4R^'/'*:U\4O@:OA7PS;1WENGQ
M'>4>&$_6VOQU_P""M.I? B#2OV,K7X@?%67P?\;K[]O[]@/_ (4)\)_^&B/&
M'P[D^,,<'_!1O]C4_%=C^SUI'Q \-^&/VF%^'_@Y+?7U_P"$N^'?Q-7X0+=C
MQGX4D\*WETWB*7]BJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/X@30^(+GQ3<_P#"5^-/$5R/$2I<1P6_CFI?L+>+;7XF?&CXD_"3]NO]K_\
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M^PKR\')X\3ULQ6+S>4(4X)Q5",8M5?=]VJI)N4(\S4N5N-K)<BU/I.BBBO\
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MK&EZ/^SCKG[)OA?X?MX_7P)X^?X>I(?VFO\ A%?"7B24>,86\7QZ _A3Q/\
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MYXUJ+7_$DDLS^4]K&K&=?J&B@ HHHH **** /S^\6?\ !-;_ ()U^-_%&O\
MCGQO^P!^Q/XV\8>-]<U+Q5XT\6^+OV4O@/X@\7^+/$FNZK)J^O\ B;Q5KNK>
M 9=<UK7]=UC4)-9\2:QJTTTUQ<SR2W9>:26YDIS?\$H_^"7R([)_P34_8"+Y
M^0/^QS^SH!CO@GX?  ] !T./I7SE^UI_P60^ G[&WQT\0? _XJ?"7]H:]\1:
M'I^B:U;^(M!\)>"V\(^)=#U?18=6M]7\*7^N_$SPY<ZMI@U(ZGX;N=571K>
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M:!;/HWPN^#7[17P\^'7APM%I<,MW)X:\)Z,/$>MO=^*K_P"T>(]?O;Z;D_\
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M/$'F2>-!X4\,2+XC?]2Z_+'_ (*D?$KP]X8^%W[//P_U+3O'=[XD^*'[??\
MP363PY>^&_A5\4?%G@/33X._X*9_L;ZSJR?$/XK>$/!7B#X<_!UYX=L'A?\
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M"UMX<18=%NOA7]BS]E#XB?MB?&7PK:>(=%\8W?PBTZZLH_B%\07LK[4="L-
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MM;CPN]YH5Q\R?\$^-5\=_P#!3K1_"W[7?[8WP8^%L=U\ ?B*8/V1=6\(:?\
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MS'XP^#WPP\9ZG\3_ (]_#'XO>!O@-\#=;@_X2CQ=K_AGPY\1?B?XP)\0^"O
MWA;PMX4GGN_&(!]S_P#!2O\ Y-U^'7_:0#_@D[_Z],_8UK] *_%[_@IU\>M5
M\.R? CX!ZC\$/BG)IGCG]NS_ ()@WV@?'*;QS^R]I_PNN;_0?^"C/[)?B_7=
M*@\(ZQ^T5;?M-:]K&@I'I&C2IX9^ 7B:"VNM9T2XDN$\&1^(O%-I^ME_K>J6
M_BCP]H<7A7Q%?:7JVB:]JM_XTM9O"Z>$_#M]H^J>#M+TOPOK<<NO#QQ)KWBJ
M#Q+J^O\ A9_#_A/7_#,,'@GQ.OB_Q=X2N9?"%KXI -U,0(H9A'#_ ,L@R"(Q
M*"GEPJA))^Y\QY!ZDDY)0+%'OA5D$2_?B(SB/]X92Q P?,WX0@GMTV@5_-U^
MT5^W#_P4 ^'7[:.O^#?#OACQ1+\-=%^(>DR>'?A+I/@_PKXIB\=^ =/'A2-1
MHOC?3O!'B?77C^)$>J:3X@EDC?\ X2/X>/XO?PZPSH#,?Z&-/UG4[GQ-KFB7
M'A'7]/T_3M"\/:I:^,;F;PO)X5\07>LZIXQTW4O"FBPP:^WC>/7/"</AC2-:
M\42^(/">@^&IK7QKX83PAXM\6W4/B^S\*^/E6?X3-\7FN&PV^3SY9<KTE*-[
M2LTM8J,ETFI--QBIWE^G^)'@]Q+X79)P#GN?9CPOFN6^)O"D>*N'%PWQ)1XB
MJT,/)T$Z'$5.D^;#5O\ A>HOEY:E&2]K3A6G4P]2G3[B#'^PQ P" HQ^7M[C
MMQ3W903B/=ZXR3GZC_/6O$/#WQ83Q)X7_P"$C\.^!_$OB&ZB^(O_  @DWA[2
M/$?P>OM=_LL?$F/P8?B>^I:;\4G\$CP1_P (5,GQ]?0V\3+\5!\+98[;_A6'
M_"Y'C^$K_*/[8G_!33]D?]@GQ9X2\+?M<>-]:^#>D_$#0+K5_AEXTN?!7BSQ
MWX8^(EYHVL#2OB+X7TB+X5Z+\0O&N@:[\/(]6\ :_P")Y?B'X8\)^'/$-O\
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M^//VIOCWH?QP^(?B/XJ?#C]DNV^)>F_$KP%X/^&GP/T+_A=GQ$T;2M9T_P
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M2NKG75.C&P@N=.;0C!I\D:ZDNO+JNN#6;H6HA\/RP&/P]KC7=QH$\GAZ/Q$
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MOM?"P!VM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFX:=&K3?#<9Q:C14Y5/:<]D_:T\AU<%-2_.E/V//VSK?_@H:W[6EEXW^%O\
MPA%UXMBT2]T2^\6?$6XNKKX(B5-"G\-QZ)IW@[1=+366T.>;7="T)M>?PO:_
M$NPT?Q7>2^(F,A7]JC#&6E(=<M"J'C*QHFT 9QR>.Q./K4$3,%06YMQ*N#<;
M"2$7OP3MP<<E2?3C)JPDUN"VQ=WG+,ZCG!6+.1U[D'/)Z#KR3Z/#O!V6<,?V
MM'*4X1SKB*OQ)5BISFG5KNFZC]_2,9)<T5'W)+E=DKM]'!?!.1\"PXAAD\L^
M:S[B;%<58C_6#$SQ*?$/$34L1.BYI.$9SA!2IQ]R$EHW)<SUZ***^F/NPHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "OQ>_X)8?L=?&3X'_ +,G[9/PA_:+
M\$CX?ZE\</VU?VT_'WAVR_MSPAXM&L_"?XV^*-G@WQ>S^$M?\4:.IU_193<R
M^'O$T_\ PDL!C*>*;:)Y1'7[0T4 ?R*?L'?\$X/^"D'ACXU?\$S_ ((?M*?!
M;X=_#/\ 9F_X)":O^T'JO@S]HOPI\:O"GCB\_;!U#XGZ?K?A_P"'DOA;X5:5
MHL?C_P"%J>&='UE7\5+\11X=:\M_.>$&>-+:7^NNBB@#\"O^"N?[-?PNO/BK
M^P_^TOI?[/NHWGQ,T#]NK]@G3?%_Q\\%?!_]B.[@TG35_;W_ &1_"7A33/CG
M\5OC/X?'[8^CZ0T>LZUX=^$L?[(_B.-6NM;\0V?QGBF^%$R0O^^M?AM_P6%L
M?A;/XK_X)WZGXK\8?LBZ1\2+#]OG]BP?"+PG\9?AIX9\6?M6>-9=6_;\_8QA
M\:?\,9?$C6/BKX:\1?#"/PSHA37?VAO^$;^&7Q4_X3#X7OH?A>Z;X:PP_P#"
M3R?N30!R7B'0M'\4Z/J?A_7M/L-7T76=.OM)U;1]4M8]0L-4T[48GTW4].U+
M2YXO)U#2YX9G@N$F5XY8'*/^Y;Y\WP5X,\)_#_P]8^%/!7AK1?"'AK3A?C3/
M#GAC1].T+1-,&HWTFJ:@NFZ3I,<6CVWF:M?R32)%#&IN)+J0&1GD>3N#L9 <
MD#)]S_3V'3\.] V*A.21D>Q_K[CI^'>M+NUKO?:R[WW_ !WM?[Q_6Z_L?J]_
M^$_?EYG:Z32=MKV;5[7L][:$]%%%9B"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/[,OQ/;]G8>(#\5[6PT/4M 'A:/?K(TW2O$>BZAXG32HR)VU'5&\&IJ:1:%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5_ ?PK\5#P+XP"^ Q\.]=^)/B[QO;^$FM[CX=J\7]*(G$K_NI&SY*R%3U =
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?P_X4_X5C\.OBC]D\0>9)XT'A3PQ(OB-_P!2Z_/_ /X*5_\ )NOPZ_[2 ?\
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MRRC_ (;(_:*_Z1._M_\ _AQO^"67_P!,LK[_ ** /@#_ (;(_:*_Z1._M_\
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MK_I$[^W_ /\ AQO^"67_ -,LK[_HH ^ /^&R/VBO^D3O[?\ _P"'&_X)9?\
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MX6CF\51?:M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_A.-.&I:)'K&C>(='ABUW0Y&F\L>//AW-XK\'NZ1/%XH=W2-OTIK\?OV+/\
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MCIIE\)?$/2W\0JNDVY\3^&/B==PP^%DN!X3\*I<>(_%4OB@ ]8^+'PR^!_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
>*** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !# ,H# 2(  A$! Q$!_\0
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M5"[C/W7_ %V.JI,URK^.(3YDL&FWD]G&VUKE5^4>]8?C'5)+N?39M-NI1#/
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+ "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  X ) # 2(  A$! Q$!_\0
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?%)@444 &!1CFBB@ P*,"BB@!:*** $Q2@8HHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
